bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
Schaedel - Hirn - Verletzungen, Verletzungen, unfallchirurgischen, Patienten, Schaedel - Hirn - Trauma, SHT, Patienten, Commotio cerebri, Patienten, Therapie, Patienten, Haematomausraeumung, Blutungen, Drainage, Patienten, Diagnostik, Therapie, Verletzungen, Behandlung, Patienten, SHT, Krankenhaeusern, Roentgendiagnostik, SHT, Krankenhaus, SHT, lebensbedrohlichen, Blutungen, Druckentlastung, Blutmassen, Blutungen, hinteren Schaedelgrube, Hirnnervenverletzungen, Schaedelbasisverletzungen, Liquorfisteln, Literatur, Patienten, SHT	DerChirurg.60671107.ger.abstr_task2	Sentence: Zusammenfassung . Schaedel-Hirn-Verletzungen sind sowohl bei Polytraumen wie auch als isolierte Verletzungen sehr haeufig . In unserer Klinik der unfallchirurgischen Schwerpunktversorgung wurden in einem Zeitraum von 21 Monaten 489 Patienten mit einem Schaedel-Hirn-Trauma ( SHT ) behandelt . Dies entspricht 6,5 % aller stationaer behandelten Patienten . Waehrend bei Commotio cerebri ( CC 85,9 % , der Patienten ) immer eine konservative Therapie und komplikationsloser Verlauf festzustellen war , musste bei den 69 Patienten mit Contusio cerebri in 18 Faellen eine Craniotomie mit Haematomausraeumung bei sub- und epiduralen Blutungen und Drainage erfolgen . Bei zwei dieser Patienten war eine Revision wegen Nachblutung erforderlich . Eine Bildtelephonverbindung mit einem neurochirurgischen Zentrum wurde zweimal in Anspruch genommen . In vier Faellen mit Komplex-/Begleitverletzungen erfolgte die Verlegung in ein neurochirurgisches Zentrum . Die Letalitaet betrug 14,5 % . Es werden die Diagnostik und Therapie bei den einzelnen Verletzungen und die Voraussetzungen fuer die Behandlung von Patienten mit SHT in peripheren Krankenhaeusern dargestellt : Notarzt Notaufnahmemanagement , Neurologe , , Roentgendiagnostik mit CT , Operationsausstattung und qualifizierte Operateure . Falls diese Voraussetzungen gegeben sind , kann ein Grossteil auch schwerer SHT im peripheren Krankenhaus versorgt werden . Sind einige dieser Voraussetzungen nicht erfuellt , sollte bei jedem potentiell operationspflichtigen SHT die fruehzeitige Verlegung in ein Zentrum erfolgen . Nur bei akut lebensbedrohlichen Blutungen , bei denen aus zeitlichen Gruenden eine Verlegung nicht moeglich ist , muss auch in Kliniken der Grundversorgung ohne adaequate Voraussetzungen eine Craniotomie und Druckentlastung erfolgen . Bei Begleitverletzungen , wie intracerebrale Blutmassen , Ventrikeleinbruch , Blutungen in der hinteren Schaedelgrube , Hirnnervenverletzungen , Carotis- oder Sinus-cavernosus-Verletzung , Schaedelbasisverletzungen mit Liquorfisteln oder Pneumoencephalon sollen auch fuer Kliniken der Schwerpunktversorgung eine Indikation zur Verlegung in ein neurochirurgisches Zentrum sein . Diese Selektion ermoeglicht in peripheren Kliniken vergleichbare Behandlungsergebnisse , wie in der Literatur angegeben , und vermeidet die Ueberlastung neurochirurgischer Zentren mit Patienten nach SHT . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Zusammenfassung . Schaedel-Hirn-Verletzungen sind sowohl bei Polytraumen wie auch als isolierte Verletzungen sehr haeufig . In unserer Klinik der unfallchirurgischen Schwerpunktversorgung wurden in einem Zeitraum von 21 Monaten 489 Patienten mit einem Schaedel-Hirn-Trauma ( SHT ) behandelt . Dies entspricht 6,5 % aller stationaer behandelten Patienten . Waehrend bei Commotio cerebri ( CC 85,9 % , der Patienten ) immer eine konservative Therapie und komplikationsloser Verlauf festzustellen war , musste bei den 69 Patienten mit Contusio cerebri in 18 Faellen eine Craniotomie mit Haematomausraeumung bei sub- und epiduralen Blutungen und Drainage erfolgen . Bei zwei dieser Patienten war eine Revision wegen Nachblutung erforderlich . Eine Bildtelephonverbindung mit einem neurochirurgischen Zentrum wurde zweimal in Anspruch genommen . In vier Faellen mit Komplex-/Begleitverletzungen erfolgte die Verlegung in ein neurochirurgisches Zentrum . Die Letalitaet betrug 14,5 % . Es werden die Diagnostik und Therapie bei den einzelnen Verletzungen und die Voraussetzungen fuer die Behandlung von Patienten mit SHT in peripheren Krankenhaeusern dargestellt : Notarzt Notaufnahmemanagement , Neurologe , , Roentgendiagnostik mit CT , Operationsausstattung und qualifizierte Operateure . Falls diese Voraussetzungen gegeben sind , kann ein Grossteil auch schwerer SHT im peripheren Krankenhaus versorgt werden . Sind einige dieser Voraussetzungen nicht erfuellt , sollte bei jedem potentiell operationspflichtigen SHT die fruehzeitige Verlegung in ein Zentrum erfolgen . Nur bei akut lebensbedrohlichen Blutungen , bei denen aus zeitlichen Gruenden eine Verlegung nicht moeglich ist , muss auch in Kliniken der Grundversorgung ohne adaequate Voraussetzungen eine Craniotomie und Druckentlastung erfolgen . Bei Begleitverletzungen , wie intracerebrale Blutmassen , Ventrikeleinbruch , Blutungen in der hinteren Schaedelgrube , Hirnnervenverletzungen , Carotis- oder Sinus-cavernosus-Verletzung , Schaedelbasisverletzungen mit Liquorfisteln oder Pneumoencephalon sollen auch fuer Kliniken der Schwerpunktversorgung eine Indikation zur Verlegung in ein neurochirurgisches Zentrum sein . Diese Selektion ermoeglicht in peripheren Kliniken vergleichbare Behandlungsergebnisse , wie in der Literatur angegeben , und vermeidet die Ueberlastung neurochirurgischer Zentren mit Patienten nach SHT .	[ "Zusammenfassung", ".", "Schaedel", "-", "Hirn", "-", "Verletzungen", "sind", "sowohl", "bei", "Polytraumen", "wie", "auch", "als", "isolierte", "Verletzungen", "sehr", "haeufig", ".", "In", "unserer", "Klinik", "der", "unfallchirurgischen", "Schwerpunktversorgung", "wurden", "in", "einem", "Zeitraum", "von", "21", "Monaten", "489", "Patienten", "mit", "einem", "Schaedel", "-", "Hirn", "-", "Trauma", "(", "SHT", ")", "behandelt", ".", "Dies", "entspricht", "6,5", "%", "aller", "stationaer", "behandelten", "Patienten", ".", "Waehrend", "bei", "Commotio", "cerebri", "(", "CC", "85,9", "%", ",", "der", "Patienten", ")", "immer", "eine", "konservative", "Therapie", "und", "komplikationsloser", "Verlauf", "festzustellen", "war", ",", "musste", "bei", "den", "69", "Patienten", "mit", "Contusio", "cerebri", "in", "18", "Faellen", "eine", "Craniotomie", "mit", "Haematomausraeumung", "bei", "sub-", "und", "epiduralen", "Blutungen", "und", "Drainage", "erfolgen", ".", "Bei", "zwei", "dieser", "Patienten", "war", "eine", "Revision", "wegen", "Nachblutung", "erforderlich", ".", "Eine", "Bildtelephonverbindung", "mit", "einem", "neurochirurgischen", "Zentrum", "wurde", "zweimal", "in", "Anspruch", "genommen", ".", "In", "vier", "Faellen", "mit", "Komplex-/Begleitverletzungen", "erfolgte", "die", "Verlegung", "in", "ein", "neurochirurgisches", "Zentrum", ".", "Die", "Letalitaet", "betrug", "14,5", "%", ".", "Es", "werden", "die", "Diagnostik", "und", "Therapie", "bei", "den", "einzelnen", "Verletzungen", "und", "die", "Voraussetzungen", "fuer", "die", "Behandlung", "von", "Patienten", "mit", "SHT", "in", "peripheren", "Krankenhaeusern", "dargestellt", ":", "Notarzt", "Notaufnahmemanagement", ",", "Neurologe", ",", ",", "Roentgendiagnostik", "mit", "CT", ",", "Operationsausstattung", "und", "qualifizierte", "Operateure", ".", "Falls", "diese", "Voraussetzungen", "gegeben", "sind", ",", "kann", "ein", "Grossteil", "auch", "schwerer", "SHT", "im", "peripheren", "Krankenhaus", "versorgt", "werden", ".", "Sind", "einige", "dieser", "Voraussetzungen", "nicht", "erfuellt", ",", "sollte", "bei", "jedem", "potentiell", "operationspflichtigen", "SHT", "die", "fruehzeitige", "Verlegung", "in", "ein", "Zentrum", "erfolgen", ".", "Nur", "bei", "akut", "lebensbedrohlichen", "Blutungen", ",", "bei", "denen", "aus", "zeitlichen", "Gruenden", "eine", "Verlegung", "nicht", "moeglich", "ist", ",", "muss", "auch", "in", "Kliniken", "der", "Grundversorgung", "ohne", "adaequate", "Voraussetzungen", "eine", "Craniotomie", "und", "Druckentlastung", "erfolgen", ".", "Bei", "Begleitverletzungen", ",", "wie", "intracerebrale", "Blutmassen", ",", "Ventrikeleinbruch", ",", "Blutungen", "in", "der", "hinteren", "Schaedelgrube", ",", "Hirnnervenverletzungen", ",", "Carotis-", "oder", "Sinus", "-", "cavernosus", "-", "Verletzung", ",", "Schaedelbasisverletzungen", "mit", "Liquorfisteln", "oder", "Pneumoencephalon", "sollen", "auch", "fuer", "Kliniken", "der", "Schwerpunktversorgung", "eine", "Indikation", "zur", "Verlegung", "in", "ein", "neurochirurgisches", "Zentrum", "sein", ".", "Diese", "Selektion", "ermoeglicht", "in", "peripheren", "Kliniken", "vergleichbare", "Behandlungsergebnisse", ",", "wie", "in", "der", "Literatur", "angegeben", ",", "und", "vermeidet", "die", "Ueberlastung", "neurochirurgischer", "Zentren", "mit", "Patienten", "nach", "SHT", "." ]	[ "umlsterm" ]
plasma 6-keto - prostaglandin F1 alpha concentration is an outcome, serum HDL2 cholesterol concentration is an outcome, regular exercise is an intervention	68_task0	Sentence: The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, outcome	[ "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "B-intervention", "I-intervention", "O" ]	The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise .	[ "The", "increase", "in", "plasma", "6-keto", "-", "prostaglandin", "F1", "alpha", "concentration", "was", "associated", "with", "an", "increase", "in", "serum", "HDL2", "cholesterol", "concentration", "in", "the", "group", "taking", "regular", "exercise", "." ]	[ "outcome", "intervention" ]
plasma 6-keto - prostaglandin F1 alpha concentration is an outcome, serum HDL2 cholesterol concentration is an outcome, regular exercise is an intervention	68_task1	Sentence: The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise . Instructions: please typing these entity words according to sentence: plasma 6-keto - prostaglandin F1 alpha concentration, serum HDL2 cholesterol concentration, regular exercise Options: intervention, outcome	[ "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "B-intervention", "I-intervention", "O" ]	The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise .	[ "The", "increase", "in", "plasma", "6-keto", "-", "prostaglandin", "F1", "alpha", "concentration", "was", "associated", "with", "an", "increase", "in", "serum", "HDL2", "cholesterol", "concentration", "in", "the", "group", "taking", "regular", "exercise", "." ]	[ "outcome", "intervention" ]
plasma 6-keto - prostaglandin F1 alpha concentration, serum HDL2 cholesterol concentration, regular exercise	68_task2	Sentence: The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "B-intervention", "I-intervention", "O" ]	The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise .	[ "The", "increase", "in", "plasma", "6-keto", "-", "prostaglandin", "F1", "alpha", "concentration", "was", "associated", "with", "an", "increase", "in", "serum", "HDL2", "cholesterol", "concentration", "in", "the", "group", "taking", "regular", "exercise", "." ]	[ "outcome", "intervention" ]
miRNAs is a Non-Specific_miRNAs, RNU44 is a Genes/Proteins, RNU49 is a Genes/Proteins	9030_task0	Sentence: The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Genes/Proteins, Non-Specific_miRNAs	[ "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Genes/Proteins", "O", "B-Genes/Proteins", "O", "O", "O", "O" ]	The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls.	[ "The", "relative", "expression", "of", "miRNAs", "was", "measured", "by", "real", "-", "time", "PCR", "using", "RNU44", "and", "RNU49", "as", "endogenous", "controls", "." ]	[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species", "Specific_miRNAs", "Genes/Proteins" ]
miRNAs is a Non-Specific_miRNAs, RNU44 is a Genes/Proteins, RNU49 is a Genes/Proteins	9030_task1	Sentence: The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls. Instructions: please typing these entity words according to sentence: miRNAs, RNU44, RNU49 Options: Genes/Proteins, Non-Specific_miRNAs	[ "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Genes/Proteins", "O", "B-Genes/Proteins", "O", "O", "O", "O" ]	The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls.	[ "The", "relative", "expression", "of", "miRNAs", "was", "measured", "by", "real", "-", "time", "PCR", "using", "RNU44", "and", "RNU49", "as", "endogenous", "controls", "." ]	[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species", "Specific_miRNAs", "Genes/Proteins" ]
miRNAs, RNU44, RNU49	9030_task2	Sentence: The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Genes/Proteins", "O", "B-Genes/Proteins", "O", "O", "O", "O" ]	The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls.	[ "The", "relative", "expression", "of", "miRNAs", "was", "measured", "by", "real", "-", "time", "PCR", "using", "RNU44", "and", "RNU49", "as", "endogenous", "controls", "." ]	[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species", "Specific_miRNAs", "Genes/Proteins" ]
Children is a Participant_Age, with persistent conduct problems who dropout of treatment . is a Participant_Condition, Dropout is a Outcome_Other, dropout rate of children is a Outcome_Other, 32 is a Participant_Sample-size, CBT approach with conjoint family therapy and an eclectic approach . is a Intervention_Educational, overall dropout rate is a Outcome_Other, parental dissatisfaction with the treatment service is a Outcome_Other, naturalistic follow - up is a Intervention_Educational, Forty - six is a Participant_Sample-size, parental perception of a less organised treatment is a Outcome_Other	5953_task0	Sentence: Children with persistent conduct problems who dropout of treatment . Dropout of treatment is one of the key issues in outcome in a child and adolescent mental health service . We report two studies focusing on the treatment process and the dropout rate of children with persistent conduct problems presenting to a community mental health service , using a prospective design . The first study included 32 children and used a randomised controlled treatment design comparing a CBT approach with conjoint family therapy and an eclectic approach . The overall dropout rate was 36 % . Dropout occurred significantly less frequently in the CBT group . The dropout group was associated with mothers who were younger and less educated , a poorer rating by the clinicians at the last meeting , parental dissatisfaction with the treatment service and perception that the treatment was less organised and having less behavioural tasks . In the second study we used a naturalistic follow-up design . Forty-six children were included . The overall dropout rate was 48 % . Again , the children who defaulted were rated by clinicians as less likely to have improved and dropout was also significantly associated with parental perception of a less organised treatment . In both studies dropout usually occurred after assessment and at the early phase of treatment . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Participant_Age, Participant_Sample-size, Outcome_Other	[ "B-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Children with persistent conduct problems who dropout of treatment . Dropout of treatment is one of the key issues in outcome in a child and adolescent mental health service . We report two studies focusing on the treatment process and the dropout rate of children with persistent conduct problems presenting to a community mental health service , using a prospective design . The first study included 32 children and used a randomised controlled treatment design comparing a CBT approach with conjoint family therapy and an eclectic approach . The overall dropout rate was 36 % . Dropout occurred significantly less frequently in the CBT group . The dropout group was associated with mothers who were younger and less educated , a poorer rating by the clinicians at the last meeting , parental dissatisfaction with the treatment service and perception that the treatment was less organised and having less behavioural tasks . In the second study we used a naturalistic follow-up design . Forty-six children were included . The overall dropout rate was 48 % . Again , the children who defaulted were rated by clinicians as less likely to have improved and dropout was also significantly associated with parental perception of a less organised treatment . In both studies dropout usually occurred after assessment and at the early phase of treatment .	[ "Children", "with", "persistent", "conduct", "problems", "who", "dropout", "of", "treatment", ".", "Dropout", "of", "treatment", "is", "one", "of", "the", "key", "issues", "in", "outcome", "in", "a", "child", "and", "adolescent", "mental", "health", "service", ".", "We", "report", "two", "studies", "focusing", "on", "the", "treatment", "process", "and", "the", "dropout", "rate", "of", "children", "with", "persistent", "conduct", "problems", "presenting", "to", "a", "community", "mental", "health", "service", ",", "using", "a", "prospective", "design", ".", "The", "first", "study", "included", "32", "children", "and", "used", "a", "randomised", "controlled", "treatment", "design", "comparing", "a", "CBT", "approach", "with", "conjoint", "family", "therapy", "and", "an", "eclectic", "approach", ".", "The", "overall", "dropout", "rate", "was", "36", "%", ".", "Dropout", "occurred", "significantly", "less", "frequently", "in", "the", "CBT", "group", ".", "The", "dropout", "group", "was", "associated", "with", "mothers", "who", "were", "younger", "and", "less", "educated", ",", "a", "poorer", "rating", "by", "the", "clinicians", "at", "the", "last", "meeting", ",", "parental", "dissatisfaction", "with", "the", "treatment", "service", "and", "perception", "that", "the", "treatment", "was", "less", "organised", "and", "having", "less", "behavioural", "tasks", ".", "In", "the", "second", "study", "we", "used", "a", "naturalistic", "follow", "-", "up", "design", ".", "Forty", "-", "six", "children", "were", "included", ".", "The", "overall", "dropout", "rate", "was", "48", "%", ".", "Again", ",", "the", "children", "who", "defaulted", "were", "rated", "by", "clinicians", "as", "less", "likely", "to", "have", "improved", "and", "dropout", "was", "also", "significantly", "associated", "with", "parental", "perception", "of", "a", "less", "organised", "treatment", ".", "In", "both", "studies", "dropout", "usually", "occurred", "after", "assessment", "and", "at", "the", "early", "phase", "of", "treatment", "." ]	[ "Intervention_Educational", "Participant_Condition", "Outcome_Other", "Participant_Sample-size", "Participant_Age" ]
Children is a Participant_Age, with persistent conduct problems who dropout of treatment . is a Participant_Condition, Dropout is a Outcome_Other, dropout rate of children is a Outcome_Other, 32 is a Participant_Sample-size, CBT approach with conjoint family therapy and an eclectic approach . is a Intervention_Educational, overall dropout rate is a Outcome_Other, parental dissatisfaction with the treatment service is a Outcome_Other, naturalistic follow - up is a Intervention_Educational, Forty - six is a Participant_Sample-size, parental perception of a less organised treatment is a Outcome_Other	5953_task1	Sentence: Children with persistent conduct problems who dropout of treatment . Dropout of treatment is one of the key issues in outcome in a child and adolescent mental health service . We report two studies focusing on the treatment process and the dropout rate of children with persistent conduct problems presenting to a community mental health service , using a prospective design . The first study included 32 children and used a randomised controlled treatment design comparing a CBT approach with conjoint family therapy and an eclectic approach . The overall dropout rate was 36 % . Dropout occurred significantly less frequently in the CBT group . The dropout group was associated with mothers who were younger and less educated , a poorer rating by the clinicians at the last meeting , parental dissatisfaction with the treatment service and perception that the treatment was less organised and having less behavioural tasks . In the second study we used a naturalistic follow-up design . Forty-six children were included . The overall dropout rate was 48 % . Again , the children who defaulted were rated by clinicians as less likely to have improved and dropout was also significantly associated with parental perception of a less organised treatment . In both studies dropout usually occurred after assessment and at the early phase of treatment . Instructions: please typing these entity words according to sentence: Children, with persistent conduct problems who dropout of treatment ., Dropout, dropout rate of children, 32, CBT approach with conjoint family therapy and an eclectic approach ., overall dropout rate, parental dissatisfaction with the treatment service, naturalistic follow - up, Forty - six, parental perception of a less organised treatment Options: Participant_Condition, Intervention_Educational, Participant_Age, Participant_Sample-size, Outcome_Other	[ "B-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Children with persistent conduct problems who dropout of treatment . Dropout of treatment is one of the key issues in outcome in a child and adolescent mental health service . We report two studies focusing on the treatment process and the dropout rate of children with persistent conduct problems presenting to a community mental health service , using a prospective design . The first study included 32 children and used a randomised controlled treatment design comparing a CBT approach with conjoint family therapy and an eclectic approach . The overall dropout rate was 36 % . Dropout occurred significantly less frequently in the CBT group . The dropout group was associated with mothers who were younger and less educated , a poorer rating by the clinicians at the last meeting , parental dissatisfaction with the treatment service and perception that the treatment was less organised and having less behavioural tasks . In the second study we used a naturalistic follow-up design . Forty-six children were included . The overall dropout rate was 48 % . Again , the children who defaulted were rated by clinicians as less likely to have improved and dropout was also significantly associated with parental perception of a less organised treatment . In both studies dropout usually occurred after assessment and at the early phase of treatment .	[ "Children", "with", "persistent", "conduct", "problems", "who", "dropout", "of", "treatment", ".", "Dropout", "of", "treatment", "is", "one", "of", "the", "key", "issues", "in", "outcome", "in", "a", "child", "and", "adolescent", "mental", "health", "service", ".", "We", "report", "two", "studies", "focusing", "on", "the", "treatment", "process", "and", "the", "dropout", "rate", "of", "children", "with", "persistent", "conduct", "problems", "presenting", "to", "a", "community", "mental", "health", "service", ",", "using", "a", "prospective", "design", ".", "The", "first", "study", "included", "32", "children", "and", "used", "a", "randomised", "controlled", "treatment", "design", "comparing", "a", "CBT", "approach", "with", "conjoint", "family", "therapy", "and", "an", "eclectic", "approach", ".", "The", "overall", "dropout", "rate", "was", "36", "%", ".", "Dropout", "occurred", "significantly", "less", "frequently", "in", "the", "CBT", "group", ".", "The", "dropout", "group", "was", "associated", "with", "mothers", "who", "were", "younger", "and", "less", "educated", ",", "a", "poorer", "rating", "by", "the", "clinicians", "at", "the", "last", "meeting", ",", "parental", "dissatisfaction", "with", "the", "treatment", "service", "and", "perception", "that", "the", "treatment", "was", "less", "organised", "and", "having", "less", "behavioural", "tasks", ".", "In", "the", "second", "study", "we", "used", "a", "naturalistic", "follow", "-", "up", "design", ".", "Forty", "-", "six", "children", "were", "included", ".", "The", "overall", "dropout", "rate", "was", "48", "%", ".", "Again", ",", "the", "children", "who", "defaulted", "were", "rated", "by", "clinicians", "as", "less", "likely", "to", "have", "improved", "and", "dropout", "was", "also", "significantly", "associated", "with", "parental", "perception", "of", "a", "less", "organised", "treatment", ".", "In", "both", "studies", "dropout", "usually", "occurred", "after", "assessment", "and", "at", "the", "early", "phase", "of", "treatment", "." ]	[ "Intervention_Educational", "Participant_Condition", "Outcome_Other", "Participant_Sample-size", "Participant_Age" ]
Children, with persistent conduct problems who dropout of treatment ., Dropout, dropout rate of children, 32, CBT approach with conjoint family therapy and an eclectic approach ., overall dropout rate, parental dissatisfaction with the treatment service, naturalistic follow - up, Forty - six, parental perception of a less organised treatment	5953_task2	Sentence: Children with persistent conduct problems who dropout of treatment . Dropout of treatment is one of the key issues in outcome in a child and adolescent mental health service . We report two studies focusing on the treatment process and the dropout rate of children with persistent conduct problems presenting to a community mental health service , using a prospective design . The first study included 32 children and used a randomised controlled treatment design comparing a CBT approach with conjoint family therapy and an eclectic approach . The overall dropout rate was 36 % . Dropout occurred significantly less frequently in the CBT group . The dropout group was associated with mothers who were younger and less educated , a poorer rating by the clinicians at the last meeting , parental dissatisfaction with the treatment service and perception that the treatment was less organised and having less behavioural tasks . In the second study we used a naturalistic follow-up design . Forty-six children were included . The overall dropout rate was 48 % . Again , the children who defaulted were rated by clinicians as less likely to have improved and dropout was also significantly associated with parental perception of a less organised treatment . In both studies dropout usually occurred after assessment and at the early phase of treatment . Instructions: please extract entity words from the input sentence	[ "B-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Children with persistent conduct problems who dropout of treatment . Dropout of treatment is one of the key issues in outcome in a child and adolescent mental health service . We report two studies focusing on the treatment process and the dropout rate of children with persistent conduct problems presenting to a community mental health service , using a prospective design . The first study included 32 children and used a randomised controlled treatment design comparing a CBT approach with conjoint family therapy and an eclectic approach . The overall dropout rate was 36 % . Dropout occurred significantly less frequently in the CBT group . The dropout group was associated with mothers who were younger and less educated , a poorer rating by the clinicians at the last meeting , parental dissatisfaction with the treatment service and perception that the treatment was less organised and having less behavioural tasks . In the second study we used a naturalistic follow-up design . Forty-six children were included . The overall dropout rate was 48 % . Again , the children who defaulted were rated by clinicians as less likely to have improved and dropout was also significantly associated with parental perception of a less organised treatment . In both studies dropout usually occurred after assessment and at the early phase of treatment .	[ "Children", "with", "persistent", "conduct", "problems", "who", "dropout", "of", "treatment", ".", "Dropout", "of", "treatment", "is", "one", "of", "the", "key", "issues", "in", "outcome", "in", "a", "child", "and", "adolescent", "mental", "health", "service", ".", "We", "report", "two", "studies", "focusing", "on", "the", "treatment", "process", "and", "the", "dropout", "rate", "of", "children", "with", "persistent", "conduct", "problems", "presenting", "to", "a", "community", "mental", "health", "service", ",", "using", "a", "prospective", "design", ".", "The", "first", "study", "included", "32", "children", "and", "used", "a", "randomised", "controlled", "treatment", "design", "comparing", "a", "CBT", "approach", "with", "conjoint", "family", "therapy", "and", "an", "eclectic", "approach", ".", "The", "overall", "dropout", "rate", "was", "36", "%", ".", "Dropout", "occurred", "significantly", "less", "frequently", "in", "the", "CBT", "group", ".", "The", "dropout", "group", "was", "associated", "with", "mothers", "who", "were", "younger", "and", "less", "educated", ",", "a", "poorer", "rating", "by", "the", "clinicians", "at", "the", "last", "meeting", ",", "parental", "dissatisfaction", "with", "the", "treatment", "service", "and", "perception", "that", "the", "treatment", "was", "less", "organised", "and", "having", "less", "behavioural", "tasks", ".", "In", "the", "second", "study", "we", "used", "a", "naturalistic", "follow", "-", "up", "design", ".", "Forty", "-", "six", "children", "were", "included", ".", "The", "overall", "dropout", "rate", "was", "48", "%", ".", "Again", ",", "the", "children", "who", "defaulted", "were", "rated", "by", "clinicians", "as", "less", "likely", "to", "have", "improved", "and", "dropout", "was", "also", "significantly", "associated", "with", "parental", "perception", "of", "a", "less", "organised", "treatment", ".", "In", "both", "studies", "dropout", "usually", "occurred", "after", "assessment", "and", "at", "the", "early", "phase", "of", "treatment", "." ]	[ "Intervention_Educational", "Participant_Condition", "Outcome_Other", "Participant_Sample-size", "Participant_Age" ]
Ondansetron is an umlsterm, placebo is an umlsterm, postoperative nausea is an umlsterm, vomiting is an umlsterm, PONV is an umlsterm, antiemetics is an umlsterm, prophylaxis is an umlsterm, therapy is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, treatment is an umlsterm, PONV is an umlsterm, Methods is an umlsterm, double - blind study is an umlsterm, October is an umlsterm, ASA is an umlsterm, inpatients is an umlsterm, general anaesthesia is an umlsterm, intubation is an umlsterm, Patients is an umlsterm, emergency is an umlsterm, operation is an umlsterm, patient is an umlsterm, breast feeding is an umlsterm, allergies is an umlsterm, antihistamines is an umlsterm, drug addiction is an umlsterm, convulsions is an umlsterm, disease is an umlsterm, antiemetic is an umlsterm, medication is an umlsterm, All is an umlsterm, patients is an umlsterm, antiemetic is an umlsterm, emetic is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, nausea is an umlsterm, antiemetic is an umlsterm, emetic is an umlsterm, administration is an umlsterm, Patients is an umlsterm, premedication is an umlsterm, diazepam is an umlsterm, thiopental is an umlsterm, etomidate is an umlsterm, propofol is an umlsterm, Relaxation is an umlsterm, pancuronium is an umlsterm, atracurium is an umlsterm, succinylcholine is an umlsterm, relaxation is an umlsterm, glycopyrrolate is an umlsterm, intubation is an umlsterm, enflurane is an umlsterm, halothane is an umlsterm, isoflurane is an umlsterm, fentanyl is an umlsterm, evaluation is an umlsterm, Student 's is an umlsterm, Mann - Whitney U test is an umlsterm, test is an umlsterm, patients is an umlsterm, PONV is an umlsterm, operation is an umlsterm, emesis is an umlsterm, record is an umlsterm, medication is an umlsterm, patients is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, antiemetic is an umlsterm, patients is an umlsterm, Nausea is an umlsterm, emetic is an umlsterm, antiemetic is an umlsterm, medication is an umlsterm, medication is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, medication is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, patients is an umlsterm, medication is an umlsterm, emetic is an umlsterm, interviews is an umlsterm, linguistic is an umlsterm, Injection is an umlsterm, pain is an umlsterm, droperidol is an umlsterm, pruritus is an umlsterm, ondansetron is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, patients is an umlsterm, drug is an umlsterm, future is an umlsterm, PONV is an umlsterm, treatment is an umlsterm, Ondansetron is an umlsterm, droperidol is an umlsterm, postoperative is an umlsterm, antiemetic is an umlsterm, drugs is an umlsterm, methods is an umlsterm	DerAnaesthesist.40430504.eng.abstr_task0	Sentence: Introduction . Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting ( PONV ) , but it has not been proved to be superior to established antiemetics for prophylaxis or therapy . We compared ondansetron vs droperidol for the treatment of PONV . Methods . Our prospective , randomized double-blind study was performed between 15 October 1992 and July 1993 ; it included 271 gynaecological ASA I - III inpatients who had been operated on under general anaesthesia with intubation . Patients were excluded if : there was no informed consent ; it was an ambulatory or emergency operation ; the patient was pregnant or breast feeding ; allergies were being treated with antihistamines ; drug addiction was present or convulsions or Parkinson's disease ; any pre- or intraoperative antiemetic medication had been administered . All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously . The verbal nausea score ( 1=none, 2=mild, 3=moderate, 4=severe) was recorded every 30 min for 4 h , then before and 2 h after each antiemetic dose . All emetic episodes and the interval between administration and effect were also noted . Patients were interviewed 36 - 48 h postoperatively on subjective effects , side-effects and individual acceptance . After oral premedication with diazepam , anaesthesia was induced with thiopental , in a few cases with etomidate or propofol . Relaxation was achieved with pancuronium or atracurium and , when indicated , with succinylcholine . Muscular relaxation was antagonized with neostigmin and glycopyrrolate . Gastric content was aspirated once after intubation . Anaesthesia was maintained with nitrous oxide/oxygen , enflurane , halothane or isoflurane and fentanyl up to 0.3 mg . Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test . Categoric variables were examined by the 2 test . Significance was defined as P 0.05. Results . Of 271 patients , 100 ( 37% ) experienced PONV . The groups were statistically comparable with respect to demographic data , type and duration of operation , emesis record , perioperative uterotonic medication . Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h , the other patients up to 17 h after extubation . Nausea scores and emetic episodes were identical before antiemetic medication . The reduction of these parameters after medication was similar . Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group . In both groups the first medication failed in 4 cases during the initial 2 h . Twenty of the ondansetron and 16 of the droperidol patients needed a second dose ; among these 2 and 4 , respectively , a third ampoule . No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups . Onset and quality of emetic action were identical in both groups . It was not possible to evaluate 25 interviews due to linguistic or amnestic problems . Multiple side-effects were noted frequently . Injection pain was reported significantly more often in the droperidol , pruritus in the ondansetron group . Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment . Conclusions . Ondansetron ( 8 mg ) and droperidol ( 1.25 mg ) proved to be equally effective when used as a postoperative antiemetic . Both drugs showed similar side-effects . Due to differences in methods it was difficult to compare our results to those obtained in other studies . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Introduction . Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting ( PONV ) , but it has not been proved to be superior to established antiemetics for prophylaxis or therapy . We compared ondansetron vs droperidol for the treatment of PONV . Methods . Our prospective , randomized double-blind study was performed between 15 October 1992 and July 1993 ; it included 271 gynaecological ASA I - III inpatients who had been operated on under general anaesthesia with intubation . Patients were excluded if : there was no informed consent ; it was an ambulatory or emergency operation ; the patient was pregnant or breast feeding ; allergies were being treated with antihistamines ; drug addiction was present or convulsions or Parkinson's disease ; any pre- or intraoperative antiemetic medication had been administered . All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously . The verbal nausea score ( 1=none, 2=mild, 3=moderate, 4=severe) was recorded every 30 min for 4 h , then before and 2 h after each antiemetic dose . All emetic episodes and the interval between administration and effect were also noted . Patients were interviewed 36 - 48 h postoperatively on subjective effects , side-effects and individual acceptance . After oral premedication with diazepam , anaesthesia was induced with thiopental , in a few cases with etomidate or propofol . Relaxation was achieved with pancuronium or atracurium and , when indicated , with succinylcholine . Muscular relaxation was antagonized with neostigmin and glycopyrrolate . Gastric content was aspirated once after intubation . Anaesthesia was maintained with nitrous oxide/oxygen , enflurane , halothane or isoflurane and fentanyl up to 0.3 mg . Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test . Categoric variables were examined by the 2 test . Significance was defined as P 0.05. Results . Of 271 patients , 100 ( 37% ) experienced PONV . The groups were statistically comparable with respect to demographic data , type and duration of operation , emesis record , perioperative uterotonic medication . Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h , the other patients up to 17 h after extubation . Nausea scores and emetic episodes were identical before antiemetic medication . The reduction of these parameters after medication was similar . Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group . In both groups the first medication failed in 4 cases during the initial 2 h . Twenty of the ondansetron and 16 of the droperidol patients needed a second dose ; among these 2 and 4 , respectively , a third ampoule . No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups . Onset and quality of emetic action were identical in both groups . It was not possible to evaluate 25 interviews due to linguistic or amnestic problems . Multiple side-effects were noted frequently . Injection pain was reported significantly more often in the droperidol , pruritus in the ondansetron group . Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment . Conclusions . Ondansetron ( 8 mg ) and droperidol ( 1.25 mg ) proved to be equally effective when used as a postoperative antiemetic . Both drugs showed similar side-effects . Due to differences in methods it was difficult to compare our results to those obtained in other studies .	[ "Introduction", ".", "Ondansetron", "is", "more", "effective", "than", "a", "placebo", "in", "treating", "postoperative", "nausea", "and", "vomiting", "(", "PONV", ")", ",", "but", "it", "has", "not", "been", "proved", "to", "be", "superior", "to", "established", "antiemetics", "for", "prophylaxis", "or", "therapy", ".", "We", "compared", "ondansetron", "vs", "droperidol", "for", "the", "treatment", "of", "PONV", ".", "Methods", ".", "Our", "prospective", ",", "randomized", "double", "-", "blind", "study", "was", "performed", "between", "15", "October", "1992", "and", "July", "1993", ";", "it", "included", "271", "gynaecological", "ASA", "I", "-", "III", "inpatients", "who", "had", "been", "operated", "on", "under", "general", "anaesthesia", "with", "intubation", ".", "Patients", "were", "excluded", "if", ":", "there", "was", "no", "informed", "consent", ";", "it", "was", "an", "ambulatory", "or", "emergency", "operation", ";", "the", "patient", "was", "pregnant", "or", "breast", "feeding", ";", "allergies", "were", "being", "treated", "with", "antihistamines", ";", "drug", "addiction", "was", "present", "or", "convulsions", "or", "Parkinson", "'s", "disease", ";", "any", "pre-", "or", "intraoperative", "antiemetic", "medication", "had", "been", "administered", ".", "All", "patients", "wishing", "an", "antiemetic", "and", "/", "or", "suffering", "from", "at", "least", "one", "emetic", "episode", "during", "the", "first", "24", "h", "postoperatively", "received", "either", "8", "mg", "ondansetron", "or", "1.25", "mg", "droperidol", "from", "identical", "4", "ml", "ampoules", "intravenously", ".", "The", "verbal", "nausea", "score", "(", "1", "=", "none", ",", "2", "=", "mild", ",", "3", "=", "moderate", ",", "4", "=", "severe", ")", "was", "recorded", "every", "30", "min", "for", "4", "h", ",", "then", "before", "and", "2", "h", "after", "each", "antiemetic", "dose", ".", "All", "emetic", "episodes", "and", "the", "interval", "between", "administration", "and", "effect", "were", "also", "noted", ".", "Patients", "were", "interviewed", "36", "-", "48", "h", "postoperatively", "on", "subjective", "effects", ",", "side", "-", "effects", "and", "individual", "acceptance", ".", "After", "oral", "premedication", "with", "diazepam", ",", "anaesthesia", "was", "induced", "with", "thiopental", ",", "in", "a", "few", "cases", "with", "etomidate", "or", "propofol", ".", "Relaxation", "was", "achieved", "with", "pancuronium", "or", "atracurium", "and", ",", "when", "indicated", ",", "with", "succinylcholine", ".", "Muscular", "relaxation", "was", "antagonized", "with", "neostigmin", "and", "glycopyrrolate", ".", "Gastric", "content", "was", "aspirated", "once", "after", "intubation", ".", "Anaesthesia", "was", "maintained", "with", "nitrous", "oxide", "/", "oxygen", ",", "enflurane", ",", "halothane", "or", "isoflurane", "and", "fentanyl", "up", "to", "0.3", "mg", ".", "Statistical", "evaluation", "was", "performed", "by", "the", "unpaired", "Student", "'s", "t", "-", "test", "and", "the", "Mann", "-", "Whitney", "U", "test", ".", "Categoric", "variables", "were", "examined", "by", "the", "2", "test", ".", "Significance", "was", "defined", "as", "P", "0.05", ".", "Results", ".", "Of", "271", "patients", ",", "100", "(", "37", "%", ")", "experienced", "PONV", ".", "The", "groups", "were", "statistically", "comparable", "with", "respect", "to", "demographic", "data", ",", "type", "and", "duration", "of", "operation", ",", "emesis", "record", ",", "perioperative", "uterotonic", "medication", ".", "Twenty", "patients", "in", "the", "ondansetron", "group", "and", "27", "in", "the", "droperidol", "group", "received", "the", "first", "antiemetic", "within", "2", "h", ",", "the", "other", "patients", "up", "to", "17", "h", "after", "extubation", ".", "Nausea", "scores", "and", "emetic", "episodes", "were", "identical", "before", "antiemetic", "medication", ".", "The", "reduction", "of", "these", "parameters", "after", "medication", "was", "similar", ".", "Complete", "response", "over", "6", "h", "was", "60", "%", "in", "the", "ondansetron", "and", "68", "%", "in", "the", "droperidol", "group", ".", "In", "both", "groups", "the", "first", "medication", "failed", "in", "4", "cases", "during", "the", "initial", "2", "h", ".", "Twenty", "of", "the", "ondansetron", "and", "16", "of", "the", "droperidol", "patients", "needed", "a", "second", "dose", ";", "among", "these", "2", "and", "4", ",", "respectively", ",", "a", "third", "ampoule", ".", "No", "rescue", "medication", "was", "necessary", "over", "24", "h", "and", "a", "mean", "of", "1.4", "ampoules", "was", "administered", "in", "both", "groups", ".", "Onset", "and", "quality", "of", "emetic", "action", "were", "identical", "in", "both", "groups", ".", "It", "was", "not", "possible", "to", "evaluate", "25", "interviews", "due", "to", "linguistic", "or", "amnestic", "problems", ".", "Multiple", "side", "-", "effects", "were", "noted", "frequently", ".", "Injection", "pain", "was", "reported", "significantly", "more", "often", "in", "the", "droperidol", ",", "pruritus", "in", "the", "ondansetron", "group", ".", "Ninety", "-", "three", "percent", "of", "the", "ondansetron", "and", "85", "%", "of", "the", "droperidol", "patients", "opted", "for", "the", "same", "drug", "for", "future", "PONV", "treatment", ".", "Conclusions", ".", "Ondansetron", "(", "8", "mg", ")", "and", "droperidol", "(", "1.25", "mg", ")", "proved", "to", "be", "equally", "effective", "when", "used", "as", "a", "postoperative", "antiemetic", ".", "Both", "drugs", "showed", "similar", "side", "-", "effects", ".", "Due", "to", "differences", "in", "methods", "it", "was", "difficult", "to", "compare", "our", "results", "to", "those", "obtained", "in", "other", "studies", "." ]	[ "umlsterm" ]
Ondansetron is an umlsterm, placebo is an umlsterm, postoperative nausea is an umlsterm, vomiting is an umlsterm, PONV is an umlsterm, antiemetics is an umlsterm, prophylaxis is an umlsterm, therapy is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, treatment is an umlsterm, PONV is an umlsterm, Methods is an umlsterm, double - blind study is an umlsterm, October is an umlsterm, ASA is an umlsterm, inpatients is an umlsterm, general anaesthesia is an umlsterm, intubation is an umlsterm, Patients is an umlsterm, emergency is an umlsterm, operation is an umlsterm, patient is an umlsterm, breast feeding is an umlsterm, allergies is an umlsterm, antihistamines is an umlsterm, drug addiction is an umlsterm, convulsions is an umlsterm, disease is an umlsterm, antiemetic is an umlsterm, medication is an umlsterm, All is an umlsterm, patients is an umlsterm, antiemetic is an umlsterm, emetic is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, nausea is an umlsterm, antiemetic is an umlsterm, emetic is an umlsterm, administration is an umlsterm, Patients is an umlsterm, premedication is an umlsterm, diazepam is an umlsterm, thiopental is an umlsterm, etomidate is an umlsterm, propofol is an umlsterm, Relaxation is an umlsterm, pancuronium is an umlsterm, atracurium is an umlsterm, succinylcholine is an umlsterm, relaxation is an umlsterm, glycopyrrolate is an umlsterm, intubation is an umlsterm, enflurane is an umlsterm, halothane is an umlsterm, isoflurane is an umlsterm, fentanyl is an umlsterm, evaluation is an umlsterm, Student 's is an umlsterm, Mann - Whitney U test is an umlsterm, test is an umlsterm, patients is an umlsterm, PONV is an umlsterm, operation is an umlsterm, emesis is an umlsterm, record is an umlsterm, medication is an umlsterm, patients is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, antiemetic is an umlsterm, patients is an umlsterm, Nausea is an umlsterm, emetic is an umlsterm, antiemetic is an umlsterm, medication is an umlsterm, medication is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, medication is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, patients is an umlsterm, medication is an umlsterm, emetic is an umlsterm, interviews is an umlsterm, linguistic is an umlsterm, Injection is an umlsterm, pain is an umlsterm, droperidol is an umlsterm, pruritus is an umlsterm, ondansetron is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, patients is an umlsterm, drug is an umlsterm, future is an umlsterm, PONV is an umlsterm, treatment is an umlsterm, Ondansetron is an umlsterm, droperidol is an umlsterm, postoperative is an umlsterm, antiemetic is an umlsterm, drugs is an umlsterm, methods is an umlsterm	DerAnaesthesist.40430504.eng.abstr_task1	Sentence: Introduction . Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting ( PONV ) , but it has not been proved to be superior to established antiemetics for prophylaxis or therapy . We compared ondansetron vs droperidol for the treatment of PONV . Methods . Our prospective , randomized double-blind study was performed between 15 October 1992 and July 1993 ; it included 271 gynaecological ASA I - III inpatients who had been operated on under general anaesthesia with intubation . Patients were excluded if : there was no informed consent ; it was an ambulatory or emergency operation ; the patient was pregnant or breast feeding ; allergies were being treated with antihistamines ; drug addiction was present or convulsions or Parkinson's disease ; any pre- or intraoperative antiemetic medication had been administered . All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously . The verbal nausea score ( 1=none, 2=mild, 3=moderate, 4=severe) was recorded every 30 min for 4 h , then before and 2 h after each antiemetic dose . All emetic episodes and the interval between administration and effect were also noted . Patients were interviewed 36 - 48 h postoperatively on subjective effects , side-effects and individual acceptance . After oral premedication with diazepam , anaesthesia was induced with thiopental , in a few cases with etomidate or propofol . Relaxation was achieved with pancuronium or atracurium and , when indicated , with succinylcholine . Muscular relaxation was antagonized with neostigmin and glycopyrrolate . Gastric content was aspirated once after intubation . Anaesthesia was maintained with nitrous oxide/oxygen , enflurane , halothane or isoflurane and fentanyl up to 0.3 mg . Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test . Categoric variables were examined by the 2 test . Significance was defined as P 0.05. Results . Of 271 patients , 100 ( 37% ) experienced PONV . The groups were statistically comparable with respect to demographic data , type and duration of operation , emesis record , perioperative uterotonic medication . Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h , the other patients up to 17 h after extubation . Nausea scores and emetic episodes were identical before antiemetic medication . The reduction of these parameters after medication was similar . Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group . In both groups the first medication failed in 4 cases during the initial 2 h . Twenty of the ondansetron and 16 of the droperidol patients needed a second dose ; among these 2 and 4 , respectively , a third ampoule . No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups . Onset and quality of emetic action were identical in both groups . It was not possible to evaluate 25 interviews due to linguistic or amnestic problems . Multiple side-effects were noted frequently . Injection pain was reported significantly more often in the droperidol , pruritus in the ondansetron group . Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment . Conclusions . Ondansetron ( 8 mg ) and droperidol ( 1.25 mg ) proved to be equally effective when used as a postoperative antiemetic . Both drugs showed similar side-effects . Due to differences in methods it was difficult to compare our results to those obtained in other studies . Instructions: please typing these entity words according to sentence: Ondansetron, placebo, postoperative nausea, vomiting, PONV, antiemetics, prophylaxis, therapy, ondansetron, droperidol, treatment, PONV, Methods, double - blind study, October, ASA, inpatients, general anaesthesia, intubation, Patients, emergency, operation, patient, breast feeding, allergies, antihistamines, drug addiction, convulsions, disease, antiemetic, medication, All, patients, antiemetic, emetic, ondansetron, droperidol, nausea, antiemetic, emetic, administration, Patients, premedication, diazepam, thiopental, etomidate, propofol, Relaxation, pancuronium, atracurium, succinylcholine, relaxation, glycopyrrolate, intubation, enflurane, halothane, isoflurane, fentanyl, evaluation, Student 's, Mann - Whitney U test, test, patients, PONV, operation, emesis, record, medication, patients, ondansetron, droperidol, antiemetic, patients, Nausea, emetic, antiemetic, medication, medication, ondansetron, droperidol, medication, ondansetron, droperidol, patients, medication, emetic, interviews, linguistic, Injection, pain, droperidol, pruritus, ondansetron, ondansetron, droperidol, patients, drug, future, PONV, treatment, Ondansetron, droperidol, postoperative, antiemetic, drugs, methods Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Introduction . Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting ( PONV ) , but it has not been proved to be superior to established antiemetics for prophylaxis or therapy . We compared ondansetron vs droperidol for the treatment of PONV . Methods . Our prospective , randomized double-blind study was performed between 15 October 1992 and July 1993 ; it included 271 gynaecological ASA I - III inpatients who had been operated on under general anaesthesia with intubation . Patients were excluded if : there was no informed consent ; it was an ambulatory or emergency operation ; the patient was pregnant or breast feeding ; allergies were being treated with antihistamines ; drug addiction was present or convulsions or Parkinson's disease ; any pre- or intraoperative antiemetic medication had been administered . All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously . The verbal nausea score ( 1=none, 2=mild, 3=moderate, 4=severe) was recorded every 30 min for 4 h , then before and 2 h after each antiemetic dose . All emetic episodes and the interval between administration and effect were also noted . Patients were interviewed 36 - 48 h postoperatively on subjective effects , side-effects and individual acceptance . After oral premedication with diazepam , anaesthesia was induced with thiopental , in a few cases with etomidate or propofol . Relaxation was achieved with pancuronium or atracurium and , when indicated , with succinylcholine . Muscular relaxation was antagonized with neostigmin and glycopyrrolate . Gastric content was aspirated once after intubation . Anaesthesia was maintained with nitrous oxide/oxygen , enflurane , halothane or isoflurane and fentanyl up to 0.3 mg . Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test . Categoric variables were examined by the 2 test . Significance was defined as P 0.05. Results . Of 271 patients , 100 ( 37% ) experienced PONV . The groups were statistically comparable with respect to demographic data , type and duration of operation , emesis record , perioperative uterotonic medication . Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h , the other patients up to 17 h after extubation . Nausea scores and emetic episodes were identical before antiemetic medication . The reduction of these parameters after medication was similar . Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group . In both groups the first medication failed in 4 cases during the initial 2 h . Twenty of the ondansetron and 16 of the droperidol patients needed a second dose ; among these 2 and 4 , respectively , a third ampoule . No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups . Onset and quality of emetic action were identical in both groups . It was not possible to evaluate 25 interviews due to linguistic or amnestic problems . Multiple side-effects were noted frequently . Injection pain was reported significantly more often in the droperidol , pruritus in the ondansetron group . Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment . Conclusions . Ondansetron ( 8 mg ) and droperidol ( 1.25 mg ) proved to be equally effective when used as a postoperative antiemetic . Both drugs showed similar side-effects . Due to differences in methods it was difficult to compare our results to those obtained in other studies .	[ "Introduction", ".", "Ondansetron", "is", "more", "effective", "than", "a", "placebo", "in", "treating", "postoperative", "nausea", "and", "vomiting", "(", "PONV", ")", ",", "but", "it", "has", "not", "been", "proved", "to", "be", "superior", "to", "established", "antiemetics", "for", "prophylaxis", "or", "therapy", ".", "We", "compared", "ondansetron", "vs", "droperidol", "for", "the", "treatment", "of", "PONV", ".", "Methods", ".", "Our", "prospective", ",", "randomized", "double", "-", "blind", "study", "was", "performed", "between", "15", "October", "1992", "and", "July", "1993", ";", "it", "included", "271", "gynaecological", "ASA", "I", "-", "III", "inpatients", "who", "had", "been", "operated", "on", "under", "general", "anaesthesia", "with", "intubation", ".", "Patients", "were", "excluded", "if", ":", "there", "was", "no", "informed", "consent", ";", "it", "was", "an", "ambulatory", "or", "emergency", "operation", ";", "the", "patient", "was", "pregnant", "or", "breast", "feeding", ";", "allergies", "were", "being", "treated", "with", "antihistamines", ";", "drug", "addiction", "was", "present", "or", "convulsions", "or", "Parkinson", "'s", "disease", ";", "any", "pre-", "or", "intraoperative", "antiemetic", "medication", "had", "been", "administered", ".", "All", "patients", "wishing", "an", "antiemetic", "and", "/", "or", "suffering", "from", "at", "least", "one", "emetic", "episode", "during", "the", "first", "24", "h", "postoperatively", "received", "either", "8", "mg", "ondansetron", "or", "1.25", "mg", "droperidol", "from", "identical", "4", "ml", "ampoules", "intravenously", ".", "The", "verbal", "nausea", "score", "(", "1", "=", "none", ",", "2", "=", "mild", ",", "3", "=", "moderate", ",", "4", "=", "severe", ")", "was", "recorded", "every", "30", "min", "for", "4", "h", ",", "then", "before", "and", "2", "h", "after", "each", "antiemetic", "dose", ".", "All", "emetic", "episodes", "and", "the", "interval", "between", "administration", "and", "effect", "were", "also", "noted", ".", "Patients", "were", "interviewed", "36", "-", "48", "h", "postoperatively", "on", "subjective", "effects", ",", "side", "-", "effects", "and", "individual", "acceptance", ".", "After", "oral", "premedication", "with", "diazepam", ",", "anaesthesia", "was", "induced", "with", "thiopental", ",", "in", "a", "few", "cases", "with", "etomidate", "or", "propofol", ".", "Relaxation", "was", "achieved", "with", "pancuronium", "or", "atracurium", "and", ",", "when", "indicated", ",", "with", "succinylcholine", ".", "Muscular", "relaxation", "was", "antagonized", "with", "neostigmin", "and", "glycopyrrolate", ".", "Gastric", "content", "was", "aspirated", "once", "after", "intubation", ".", "Anaesthesia", "was", "maintained", "with", "nitrous", "oxide", "/", "oxygen", ",", "enflurane", ",", "halothane", "or", "isoflurane", "and", "fentanyl", "up", "to", "0.3", "mg", ".", "Statistical", "evaluation", "was", "performed", "by", "the", "unpaired", "Student", "'s", "t", "-", "test", "and", "the", "Mann", "-", "Whitney", "U", "test", ".", "Categoric", "variables", "were", "examined", "by", "the", "2", "test", ".", "Significance", "was", "defined", "as", "P", "0.05", ".", "Results", ".", "Of", "271", "patients", ",", "100", "(", "37", "%", ")", "experienced", "PONV", ".", "The", "groups", "were", "statistically", "comparable", "with", "respect", "to", "demographic", "data", ",", "type", "and", "duration", "of", "operation", ",", "emesis", "record", ",", "perioperative", "uterotonic", "medication", ".", "Twenty", "patients", "in", "the", "ondansetron", "group", "and", "27", "in", "the", "droperidol", "group", "received", "the", "first", "antiemetic", "within", "2", "h", ",", "the", "other", "patients", "up", "to", "17", "h", "after", "extubation", ".", "Nausea", "scores", "and", "emetic", "episodes", "were", "identical", "before", "antiemetic", "medication", ".", "The", "reduction", "of", "these", "parameters", "after", "medication", "was", "similar", ".", "Complete", "response", "over", "6", "h", "was", "60", "%", "in", "the", "ondansetron", "and", "68", "%", "in", "the", "droperidol", "group", ".", "In", "both", "groups", "the", "first", "medication", "failed", "in", "4", "cases", "during", "the", "initial", "2", "h", ".", "Twenty", "of", "the", "ondansetron", "and", "16", "of", "the", "droperidol", "patients", "needed", "a", "second", "dose", ";", "among", "these", "2", "and", "4", ",", "respectively", ",", "a", "third", "ampoule", ".", "No", "rescue", "medication", "was", "necessary", "over", "24", "h", "and", "a", "mean", "of", "1.4", "ampoules", "was", "administered", "in", "both", "groups", ".", "Onset", "and", "quality", "of", "emetic", "action", "were", "identical", "in", "both", "groups", ".", "It", "was", "not", "possible", "to", "evaluate", "25", "interviews", "due", "to", "linguistic", "or", "amnestic", "problems", ".", "Multiple", "side", "-", "effects", "were", "noted", "frequently", ".", "Injection", "pain", "was", "reported", "significantly", "more", "often", "in", "the", "droperidol", ",", "pruritus", "in", "the", "ondansetron", "group", ".", "Ninety", "-", "three", "percent", "of", "the", "ondansetron", "and", "85", "%", "of", "the", "droperidol", "patients", "opted", "for", "the", "same", "drug", "for", "future", "PONV", "treatment", ".", "Conclusions", ".", "Ondansetron", "(", "8", "mg", ")", "and", "droperidol", "(", "1.25", "mg", ")", "proved", "to", "be", "equally", "effective", "when", "used", "as", "a", "postoperative", "antiemetic", ".", "Both", "drugs", "showed", "similar", "side", "-", "effects", ".", "Due", "to", "differences", "in", "methods", "it", "was", "difficult", "to", "compare", "our", "results", "to", "those", "obtained", "in", "other", "studies", "." ]	[ "umlsterm" ]
Ondansetron, placebo, postoperative nausea, vomiting, PONV, antiemetics, prophylaxis, therapy, ondansetron, droperidol, treatment, PONV, Methods, double - blind study, October, ASA, inpatients, general anaesthesia, intubation, Patients, emergency, operation, patient, breast feeding, allergies, antihistamines, drug addiction, convulsions, disease, antiemetic, medication, All, patients, antiemetic, emetic, ondansetron, droperidol, nausea, antiemetic, emetic, administration, Patients, premedication, diazepam, thiopental, etomidate, propofol, Relaxation, pancuronium, atracurium, succinylcholine, relaxation, glycopyrrolate, intubation, enflurane, halothane, isoflurane, fentanyl, evaluation, Student 's, Mann - Whitney U test, test, patients, PONV, operation, emesis, record, medication, patients, ondansetron, droperidol, antiemetic, patients, Nausea, emetic, antiemetic, medication, medication, ondansetron, droperidol, medication, ondansetron, droperidol, patients, medication, emetic, interviews, linguistic, Injection, pain, droperidol, pruritus, ondansetron, ondansetron, droperidol, patients, drug, future, PONV, treatment, Ondansetron, droperidol, postoperative, antiemetic, drugs, methods	DerAnaesthesist.40430504.eng.abstr_task2	Sentence: Introduction . Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting ( PONV ) , but it has not been proved to be superior to established antiemetics for prophylaxis or therapy . We compared ondansetron vs droperidol for the treatment of PONV . Methods . Our prospective , randomized double-blind study was performed between 15 October 1992 and July 1993 ; it included 271 gynaecological ASA I - III inpatients who had been operated on under general anaesthesia with intubation . Patients were excluded if : there was no informed consent ; it was an ambulatory or emergency operation ; the patient was pregnant or breast feeding ; allergies were being treated with antihistamines ; drug addiction was present or convulsions or Parkinson's disease ; any pre- or intraoperative antiemetic medication had been administered . All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously . The verbal nausea score ( 1=none, 2=mild, 3=moderate, 4=severe) was recorded every 30 min for 4 h , then before and 2 h after each antiemetic dose . All emetic episodes and the interval between administration and effect were also noted . Patients were interviewed 36 - 48 h postoperatively on subjective effects , side-effects and individual acceptance . After oral premedication with diazepam , anaesthesia was induced with thiopental , in a few cases with etomidate or propofol . Relaxation was achieved with pancuronium or atracurium and , when indicated , with succinylcholine . Muscular relaxation was antagonized with neostigmin and glycopyrrolate . Gastric content was aspirated once after intubation . Anaesthesia was maintained with nitrous oxide/oxygen , enflurane , halothane or isoflurane and fentanyl up to 0.3 mg . Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test . Categoric variables were examined by the 2 test . Significance was defined as P 0.05. Results . Of 271 patients , 100 ( 37% ) experienced PONV . The groups were statistically comparable with respect to demographic data , type and duration of operation , emesis record , perioperative uterotonic medication . Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h , the other patients up to 17 h after extubation . Nausea scores and emetic episodes were identical before antiemetic medication . The reduction of these parameters after medication was similar . Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group . In both groups the first medication failed in 4 cases during the initial 2 h . Twenty of the ondansetron and 16 of the droperidol patients needed a second dose ; among these 2 and 4 , respectively , a third ampoule . No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups . Onset and quality of emetic action were identical in both groups . It was not possible to evaluate 25 interviews due to linguistic or amnestic problems . Multiple side-effects were noted frequently . Injection pain was reported significantly more often in the droperidol , pruritus in the ondansetron group . Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment . Conclusions . Ondansetron ( 8 mg ) and droperidol ( 1.25 mg ) proved to be equally effective when used as a postoperative antiemetic . Both drugs showed similar side-effects . Due to differences in methods it was difficult to compare our results to those obtained in other studies . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Introduction . Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting ( PONV ) , but it has not been proved to be superior to established antiemetics for prophylaxis or therapy . We compared ondansetron vs droperidol for the treatment of PONV . Methods . Our prospective , randomized double-blind study was performed between 15 October 1992 and July 1993 ; it included 271 gynaecological ASA I - III inpatients who had been operated on under general anaesthesia with intubation . Patients were excluded if : there was no informed consent ; it was an ambulatory or emergency operation ; the patient was pregnant or breast feeding ; allergies were being treated with antihistamines ; drug addiction was present or convulsions or Parkinson's disease ; any pre- or intraoperative antiemetic medication had been administered . All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously . The verbal nausea score ( 1=none, 2=mild, 3=moderate, 4=severe) was recorded every 30 min for 4 h , then before and 2 h after each antiemetic dose . All emetic episodes and the interval between administration and effect were also noted . Patients were interviewed 36 - 48 h postoperatively on subjective effects , side-effects and individual acceptance . After oral premedication with diazepam , anaesthesia was induced with thiopental , in a few cases with etomidate or propofol . Relaxation was achieved with pancuronium or atracurium and , when indicated , with succinylcholine . Muscular relaxation was antagonized with neostigmin and glycopyrrolate . Gastric content was aspirated once after intubation . Anaesthesia was maintained with nitrous oxide/oxygen , enflurane , halothane or isoflurane and fentanyl up to 0.3 mg . Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test . Categoric variables were examined by the 2 test . Significance was defined as P 0.05. Results . Of 271 patients , 100 ( 37% ) experienced PONV . The groups were statistically comparable with respect to demographic data , type and duration of operation , emesis record , perioperative uterotonic medication . Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h , the other patients up to 17 h after extubation . Nausea scores and emetic episodes were identical before antiemetic medication . The reduction of these parameters after medication was similar . Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group . In both groups the first medication failed in 4 cases during the initial 2 h . Twenty of the ondansetron and 16 of the droperidol patients needed a second dose ; among these 2 and 4 , respectively , a third ampoule . No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups . Onset and quality of emetic action were identical in both groups . It was not possible to evaluate 25 interviews due to linguistic or amnestic problems . Multiple side-effects were noted frequently . Injection pain was reported significantly more often in the droperidol , pruritus in the ondansetron group . Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment . Conclusions . Ondansetron ( 8 mg ) and droperidol ( 1.25 mg ) proved to be equally effective when used as a postoperative antiemetic . Both drugs showed similar side-effects . Due to differences in methods it was difficult to compare our results to those obtained in other studies .	[ "Introduction", ".", "Ondansetron", "is", "more", "effective", "than", "a", "placebo", "in", "treating", "postoperative", "nausea", "and", "vomiting", "(", "PONV", ")", ",", "but", "it", "has", "not", "been", "proved", "to", "be", "superior", "to", "established", "antiemetics", "for", "prophylaxis", "or", "therapy", ".", "We", "compared", "ondansetron", "vs", "droperidol", "for", "the", "treatment", "of", "PONV", ".", "Methods", ".", "Our", "prospective", ",", "randomized", "double", "-", "blind", "study", "was", "performed", "between", "15", "October", "1992", "and", "July", "1993", ";", "it", "included", "271", "gynaecological", "ASA", "I", "-", "III", "inpatients", "who", "had", "been", "operated", "on", "under", "general", "anaesthesia", "with", "intubation", ".", "Patients", "were", "excluded", "if", ":", "there", "was", "no", "informed", "consent", ";", "it", "was", "an", "ambulatory", "or", "emergency", "operation", ";", "the", "patient", "was", "pregnant", "or", "breast", "feeding", ";", "allergies", "were", "being", "treated", "with", "antihistamines", ";", "drug", "addiction", "was", "present", "or", "convulsions", "or", "Parkinson", "'s", "disease", ";", "any", "pre-", "or", "intraoperative", "antiemetic", "medication", "had", "been", "administered", ".", "All", "patients", "wishing", "an", "antiemetic", "and", "/", "or", "suffering", "from", "at", "least", "one", "emetic", "episode", "during", "the", "first", "24", "h", "postoperatively", "received", "either", "8", "mg", "ondansetron", "or", "1.25", "mg", "droperidol", "from", "identical", "4", "ml", "ampoules", "intravenously", ".", "The", "verbal", "nausea", "score", "(", "1", "=", "none", ",", "2", "=", "mild", ",", "3", "=", "moderate", ",", "4", "=", "severe", ")", "was", "recorded", "every", "30", "min", "for", "4", "h", ",", "then", "before", "and", "2", "h", "after", "each", "antiemetic", "dose", ".", "All", "emetic", "episodes", "and", "the", "interval", "between", "administration", "and", "effect", "were", "also", "noted", ".", "Patients", "were", "interviewed", "36", "-", "48", "h", "postoperatively", "on", "subjective", "effects", ",", "side", "-", "effects", "and", "individual", "acceptance", ".", "After", "oral", "premedication", "with", "diazepam", ",", "anaesthesia", "was", "induced", "with", "thiopental", ",", "in", "a", "few", "cases", "with", "etomidate", "or", "propofol", ".", "Relaxation", "was", "achieved", "with", "pancuronium", "or", "atracurium", "and", ",", "when", "indicated", ",", "with", "succinylcholine", ".", "Muscular", "relaxation", "was", "antagonized", "with", "neostigmin", "and", "glycopyrrolate", ".", "Gastric", "content", "was", "aspirated", "once", "after", "intubation", ".", "Anaesthesia", "was", "maintained", "with", "nitrous", "oxide", "/", "oxygen", ",", "enflurane", ",", "halothane", "or", "isoflurane", "and", "fentanyl", "up", "to", "0.3", "mg", ".", "Statistical", "evaluation", "was", "performed", "by", "the", "unpaired", "Student", "'s", "t", "-", "test", "and", "the", "Mann", "-", "Whitney", "U", "test", ".", "Categoric", "variables", "were", "examined", "by", "the", "2", "test", ".", "Significance", "was", "defined", "as", "P", "0.05", ".", "Results", ".", "Of", "271", "patients", ",", "100", "(", "37", "%", ")", "experienced", "PONV", ".", "The", "groups", "were", "statistically", "comparable", "with", "respect", "to", "demographic", "data", ",", "type", "and", "duration", "of", "operation", ",", "emesis", "record", ",", "perioperative", "uterotonic", "medication", ".", "Twenty", "patients", "in", "the", "ondansetron", "group", "and", "27", "in", "the", "droperidol", "group", "received", "the", "first", "antiemetic", "within", "2", "h", ",", "the", "other", "patients", "up", "to", "17", "h", "after", "extubation", ".", "Nausea", "scores", "and", "emetic", "episodes", "were", "identical", "before", "antiemetic", "medication", ".", "The", "reduction", "of", "these", "parameters", "after", "medication", "was", "similar", ".", "Complete", "response", "over", "6", "h", "was", "60", "%", "in", "the", "ondansetron", "and", "68", "%", "in", "the", "droperidol", "group", ".", "In", "both", "groups", "the", "first", "medication", "failed", "in", "4", "cases", "during", "the", "initial", "2", "h", ".", "Twenty", "of", "the", "ondansetron", "and", "16", "of", "the", "droperidol", "patients", "needed", "a", "second", "dose", ";", "among", "these", "2", "and", "4", ",", "respectively", ",", "a", "third", "ampoule", ".", "No", "rescue", "medication", "was", "necessary", "over", "24", "h", "and", "a", "mean", "of", "1.4", "ampoules", "was", "administered", "in", "both", "groups", ".", "Onset", "and", "quality", "of", "emetic", "action", "were", "identical", "in", "both", "groups", ".", "It", "was", "not", "possible", "to", "evaluate", "25", "interviews", "due", "to", "linguistic", "or", "amnestic", "problems", ".", "Multiple", "side", "-", "effects", "were", "noted", "frequently", ".", "Injection", "pain", "was", "reported", "significantly", "more", "often", "in", "the", "droperidol", ",", "pruritus", "in", "the", "ondansetron", "group", ".", "Ninety", "-", "three", "percent", "of", "the", "ondansetron", "and", "85", "%", "of", "the", "droperidol", "patients", "opted", "for", "the", "same", "drug", "for", "future", "PONV", "treatment", ".", "Conclusions", ".", "Ondansetron", "(", "8", "mg", ")", "and", "droperidol", "(", "1.25", "mg", ")", "proved", "to", "be", "equally", "effective", "when", "used", "as", "a", "postoperative", "antiemetic", ".", "Both", "drugs", "showed", "similar", "side", "-", "effects", ".", "Due", "to", "differences", "in", "methods", "it", "was", "difficult", "to", "compare", "our", "results", "to", "those", "obtained", "in", "other", "studies", "." ]	[ "umlsterm" ]
Isoniazid is a DRUG, isoniazid is a DRUG, Acetaminophen is a DRUG, acetaminophen is a DRUG, Isoniazid is a DRUG, isoniazid is a DRUG, acetaminophen is a DRUG, isoniazid is a DRUG, isoniazid is a DRUG, acetaminophen is a DRUG, isoniazid is a DRUG, Carbamazepine is a DRUG, Isoniazid is a DRUG, carbamazepine is a DRUG, Carbamazepine is a DRUG, isoniazid is a DRUG, carbamazepine is a DRUG, anticonvulsant is a GROUP, Ketoconazole is a DRUG, Ketoconazole is a DRUG, Isoniazid is a DRUG, Phenytoin is a DRUG, Isoniazid is a DRUG, phenytoin is a DRUG, phenytoin is a DRUG, anticonvulsant is a GROUP, isoniazid is a DRUG, theophylline is a DRUG, theophylline is a DRUG, isoniazid is a DRUG, theophylline is a DRUG, theophylline is a DRUG, theophylline is a DRUG, Valproate is a DRUG, valproate is a DRUG, isoniazid is a DRUG, valproate is a DRUG, isoniazid is a DRUG, valproate is a DRUG, valproate is a DRUG	Isoniazid_ddi_task0	Sentence: Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food. Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats. Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made. Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist. Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made. Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made. Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG	[ "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O" ]	Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food. Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats. Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made. Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist. Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made. Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made. Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.	[ "Food", ":", "Isoniazid", "should", "not", "be", "administered", "with", "food", ".", "Studies", "have", "shown", "that", "the", "bioavailability", "of", "isoniazid", "is", "reduced", "significantly", "when", "administered", "with", "food", ".", "Acetaminophen", ":", "A", "report", "of", "severe", "acetaminophen", "toxicity", "was", "reported", "in", "a", "patient", "receiving", "Isoniazid", ".", "It", "is", "believed", "that", "the", "toxicity", "may", "have", "resulted", "from", "a", "previously", "unrecognized", "interaction", "between", "isoniazid", "and", "acetaminophen", "and", "a", "molecular", "basis", "for", "this", "interaction", "has", "been", "proposed", ".", "However", ",", "current", "evidence", "suggests", "that", "isoniazid", "does", "induce", "P-450IIE1", ",", "a", "mixed", "-", "function", "oxidase", "enzyme", "that", "appears", "to", "generate", "the", "toxic", "metabolites", ",", "in", "the", "liver", ".", "Furthermore", "it", "has", "been", "proposed", "that", "isoniazid", "resulted", "In", "induction", "of", "P-450IIE1", "in", "the", "patients", "liver", "which", ",", "in", "turn", ",", "resulted", "in", "a", "greater", "proportion", "of", "the", "ingested", "acetaminophen", "being", "converted", "to", "the", "toxic", "metabolites", ".", "Studies", "have", "demonstrated", "that", "pretreatment", "with", "isoniazid", "potentiates", "a", "cetaminophen", "hepatoxicity", "in", "rats", ".", "Carbamazepine", ":", "Isoniazid", "is", "known", "to", "slow", "the", "metabolism", "of", "carbamazepine", "and", "increase", "its", "serum", "levels", "Carbamazepine", "levels", "should", "be", "determined", "prior", "to", "concurrent", "administration", "with", "isoniazid", ",", "signs", "and", "symptoms", "of", "carbamazepine", "toxicity", "should", "be", "monitored", "closely", ",", "and", "appropriate", "dosage", "adjustment", "of", "the", "anticonvulsant", "should", "be", "made", ".", "Ketoconazole", ":", "Potential", "interaction", "of", "Ketoconazole", "and", "Isoniazid", "may", "exist", ".", "Phenytoin", ":", "Isoniazid", "may", "increase", "serum", "levels", "of", "phenytoin", ".", "To", "avoid", "phenytoin", "intoxication", ",", "appropriate", "adjustment", "of", "the", "anticonvulsant", "should", "be", "made", ".", "Therophylline", ":", "A", "recent", "study", "has", "shown", "that", "concomitan", "administration", "of", "isoniazid", "and", "theophylline", "may", "cause", "elevated", "plasma", "levels", "of", "theophylline", ",", "and", "in", "some", "instances", "a", "slight", "decrease", "in", "the", "elimination", "of", "isoniazid", ".", "Since", "the", "therapeutic", "range", "of", "theophylline", "is", "narrow", "theophylline", "serum", "levels", "should", "be", "monitored", "closely", ",", "and", "appropriate", "dosage", "adjustments", "of", "theophylline", "should", "be", "made", ".", "Valproate", ":", "A", "recent", "case", "study", "has", "shown", "a", "possible", "increase", "in", "the", "plasma", "level", "of", "valproate", "when", "co", "administered", "with", "isoniazid", ".", "Plasma", "valproate", "concentration", "should", "be", "monitored", "when", "isoniazid", "and", "valproate", "are", "co", "administered", ",", "and", "appropriate", "dosage", "adjustments", "of", "valproate", "should", "be", "made", "." ]	[ "GROUP", "DRUG" ]
Isoniazid is a DRUG, isoniazid is a DRUG, Acetaminophen is a DRUG, acetaminophen is a DRUG, Isoniazid is a DRUG, isoniazid is a DRUG, acetaminophen is a DRUG, isoniazid is a DRUG, isoniazid is a DRUG, acetaminophen is a DRUG, isoniazid is a DRUG, Carbamazepine is a DRUG, Isoniazid is a DRUG, carbamazepine is a DRUG, Carbamazepine is a DRUG, isoniazid is a DRUG, carbamazepine is a DRUG, anticonvulsant is a GROUP, Ketoconazole is a DRUG, Ketoconazole is a DRUG, Isoniazid is a DRUG, Phenytoin is a DRUG, Isoniazid is a DRUG, phenytoin is a DRUG, phenytoin is a DRUG, anticonvulsant is a GROUP, isoniazid is a DRUG, theophylline is a DRUG, theophylline is a DRUG, isoniazid is a DRUG, theophylline is a DRUG, theophylline is a DRUG, theophylline is a DRUG, Valproate is a DRUG, valproate is a DRUG, isoniazid is a DRUG, valproate is a DRUG, isoniazid is a DRUG, valproate is a DRUG, valproate is a DRUG	Isoniazid_ddi_task1	Sentence: Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food. Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats. Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made. Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist. Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made. Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made. Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made. Instructions: please typing these entity words according to sentence: Isoniazid, isoniazid, Acetaminophen, acetaminophen, Isoniazid, isoniazid, acetaminophen, isoniazid, isoniazid, acetaminophen, isoniazid, Carbamazepine, Isoniazid, carbamazepine, Carbamazepine, isoniazid, carbamazepine, anticonvulsant, Ketoconazole, Ketoconazole, Isoniazid, Phenytoin, Isoniazid, phenytoin, phenytoin, anticonvulsant, isoniazid, theophylline, theophylline, isoniazid, theophylline, theophylline, theophylline, Valproate, valproate, isoniazid, valproate, isoniazid, valproate, valproate Options: GROUP, DRUG	[ "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O" ]	Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food. Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats. Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made. Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist. Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made. Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made. Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.	[ "Food", ":", "Isoniazid", "should", "not", "be", "administered", "with", "food", ".", "Studies", "have", "shown", "that", "the", "bioavailability", "of", "isoniazid", "is", "reduced", "significantly", "when", "administered", "with", "food", ".", "Acetaminophen", ":", "A", "report", "of", "severe", "acetaminophen", "toxicity", "was", "reported", "in", "a", "patient", "receiving", "Isoniazid", ".", "It", "is", "believed", "that", "the", "toxicity", "may", "have", "resulted", "from", "a", "previously", "unrecognized", "interaction", "between", "isoniazid", "and", "acetaminophen", "and", "a", "molecular", "basis", "for", "this", "interaction", "has", "been", "proposed", ".", "However", ",", "current", "evidence", "suggests", "that", "isoniazid", "does", "induce", "P-450IIE1", ",", "a", "mixed", "-", "function", "oxidase", "enzyme", "that", "appears", "to", "generate", "the", "toxic", "metabolites", ",", "in", "the", "liver", ".", "Furthermore", "it", "has", "been", "proposed", "that", "isoniazid", "resulted", "In", "induction", "of", "P-450IIE1", "in", "the", "patients", "liver", "which", ",", "in", "turn", ",", "resulted", "in", "a", "greater", "proportion", "of", "the", "ingested", "acetaminophen", "being", "converted", "to", "the", "toxic", "metabolites", ".", "Studies", "have", "demonstrated", "that", "pretreatment", "with", "isoniazid", "potentiates", "a", "cetaminophen", "hepatoxicity", "in", "rats", ".", "Carbamazepine", ":", "Isoniazid", "is", "known", "to", "slow", "the", "metabolism", "of", "carbamazepine", "and", "increase", "its", "serum", "levels", "Carbamazepine", "levels", "should", "be", "determined", "prior", "to", "concurrent", "administration", "with", "isoniazid", ",", "signs", "and", "symptoms", "of", "carbamazepine", "toxicity", "should", "be", "monitored", "closely", ",", "and", "appropriate", "dosage", "adjustment", "of", "the", "anticonvulsant", "should", "be", "made", ".", "Ketoconazole", ":", "Potential", "interaction", "of", "Ketoconazole", "and", "Isoniazid", "may", "exist", ".", "Phenytoin", ":", "Isoniazid", "may", "increase", "serum", "levels", "of", "phenytoin", ".", "To", "avoid", "phenytoin", "intoxication", ",", "appropriate", "adjustment", "of", "the", "anticonvulsant", "should", "be", "made", ".", "Therophylline", ":", "A", "recent", "study", "has", "shown", "that", "concomitan", "administration", "of", "isoniazid", "and", "theophylline", "may", "cause", "elevated", "plasma", "levels", "of", "theophylline", ",", "and", "in", "some", "instances", "a", "slight", "decrease", "in", "the", "elimination", "of", "isoniazid", ".", "Since", "the", "therapeutic", "range", "of", "theophylline", "is", "narrow", "theophylline", "serum", "levels", "should", "be", "monitored", "closely", ",", "and", "appropriate", "dosage", "adjustments", "of", "theophylline", "should", "be", "made", ".", "Valproate", ":", "A", "recent", "case", "study", "has", "shown", "a", "possible", "increase", "in", "the", "plasma", "level", "of", "valproate", "when", "co", "administered", "with", "isoniazid", ".", "Plasma", "valproate", "concentration", "should", "be", "monitored", "when", "isoniazid", "and", "valproate", "are", "co", "administered", ",", "and", "appropriate", "dosage", "adjustments", "of", "valproate", "should", "be", "made", "." ]	[ "GROUP", "DRUG" ]
Isoniazid, isoniazid, Acetaminophen, acetaminophen, Isoniazid, isoniazid, acetaminophen, isoniazid, isoniazid, acetaminophen, isoniazid, Carbamazepine, Isoniazid, carbamazepine, Carbamazepine, isoniazid, carbamazepine, anticonvulsant, Ketoconazole, Ketoconazole, Isoniazid, Phenytoin, Isoniazid, phenytoin, phenytoin, anticonvulsant, isoniazid, theophylline, theophylline, isoniazid, theophylline, theophylline, theophylline, Valproate, valproate, isoniazid, valproate, isoniazid, valproate, valproate	Isoniazid_ddi_task2	Sentence: Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food. Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats. Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made. Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist. Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made. Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made. Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O" ]	Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food. Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats. Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made. Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist. Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made. Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made. Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.	[ "Food", ":", "Isoniazid", "should", "not", "be", "administered", "with", "food", ".", "Studies", "have", "shown", "that", "the", "bioavailability", "of", "isoniazid", "is", "reduced", "significantly", "when", "administered", "with", "food", ".", "Acetaminophen", ":", "A", "report", "of", "severe", "acetaminophen", "toxicity", "was", "reported", "in", "a", "patient", "receiving", "Isoniazid", ".", "It", "is", "believed", "that", "the", "toxicity", "may", "have", "resulted", "from", "a", "previously", "unrecognized", "interaction", "between", "isoniazid", "and", "acetaminophen", "and", "a", "molecular", "basis", "for", "this", "interaction", "has", "been", "proposed", ".", "However", ",", "current", "evidence", "suggests", "that", "isoniazid", "does", "induce", "P-450IIE1", ",", "a", "mixed", "-", "function", "oxidase", "enzyme", "that", "appears", "to", "generate", "the", "toxic", "metabolites", ",", "in", "the", "liver", ".", "Furthermore", "it", "has", "been", "proposed", "that", "isoniazid", "resulted", "In", "induction", "of", "P-450IIE1", "in", "the", "patients", "liver", "which", ",", "in", "turn", ",", "resulted", "in", "a", "greater", "proportion", "of", "the", "ingested", "acetaminophen", "being", "converted", "to", "the", "toxic", "metabolites", ".", "Studies", "have", "demonstrated", "that", "pretreatment", "with", "isoniazid", "potentiates", "a", "cetaminophen", "hepatoxicity", "in", "rats", ".", "Carbamazepine", ":", "Isoniazid", "is", "known", "to", "slow", "the", "metabolism", "of", "carbamazepine", "and", "increase", "its", "serum", "levels", "Carbamazepine", "levels", "should", "be", "determined", "prior", "to", "concurrent", "administration", "with", "isoniazid", ",", "signs", "and", "symptoms", "of", "carbamazepine", "toxicity", "should", "be", "monitored", "closely", ",", "and", "appropriate", "dosage", "adjustment", "of", "the", "anticonvulsant", "should", "be", "made", ".", "Ketoconazole", ":", "Potential", "interaction", "of", "Ketoconazole", "and", "Isoniazid", "may", "exist", ".", "Phenytoin", ":", "Isoniazid", "may", "increase", "serum", "levels", "of", "phenytoin", ".", "To", "avoid", "phenytoin", "intoxication", ",", "appropriate", "adjustment", "of", "the", "anticonvulsant", "should", "be", "made", ".", "Therophylline", ":", "A", "recent", "study", "has", "shown", "that", "concomitan", "administration", "of", "isoniazid", "and", "theophylline", "may", "cause", "elevated", "plasma", "levels", "of", "theophylline", ",", "and", "in", "some", "instances", "a", "slight", "decrease", "in", "the", "elimination", "of", "isoniazid", ".", "Since", "the", "therapeutic", "range", "of", "theophylline", "is", "narrow", "theophylline", "serum", "levels", "should", "be", "monitored", "closely", ",", "and", "appropriate", "dosage", "adjustments", "of", "theophylline", "should", "be", "made", ".", "Valproate", ":", "A", "recent", "case", "study", "has", "shown", "a", "possible", "increase", "in", "the", "plasma", "level", "of", "valproate", "when", "co", "administered", "with", "isoniazid", ".", "Plasma", "valproate", "concentration", "should", "be", "monitored", "when", "isoniazid", "and", "valproate", "are", "co", "administered", ",", "and", "appropriate", "dosage", "adjustments", "of", "valproate", "should", "be", "made", "." ]	[ "GROUP", "DRUG" ]
Sunlight exposure is a Intervention_Control, vitamin D supplementation is a Intervention_Pharmacological, vitamin D - deficient is a Participant_Condition, Vitamin D is a Intervention_Pharmacological, advised sunlight exposure is a Intervention_Physical, Vitamin D supplementation is a Intervention_Pharmacological, Baseline serum is a Outcome_Physical, mean is a Outcome_Physical	46969_task0	Sentence: Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants : a randomized clinical trial . UNLABELLED Vitamin D deficiency is very common in non-western immigrants . In this randomized clinical trial , vitamin D 800 IU/day or 100,000 IU/3 months were compared with advised sunlight exposure . Vitamin D supplementation was more effective than advised sunlight exposure in improving vitamin D status and lowering parathyroid hormone levels . INTRODUCTION Vitamin D deficiency ( 25-hydroxyvitamin D [ 25 ( OH ) D ] < 25 nmol/l ) is common among non-western immigrants . It can be treated with vitamin D supplementation or sunlight exposure . METHODS To determine whether the effect of vitamin D ( 3 ) supplementation ( daily 800 IU or 100,000 IU/3 months ) or sunlight exposure advice is similar with regard to serum 25 ( OH ) D and parathyroid hormone ( PTH ) concentrations . Randomized clinical trial in 11 general practices in The Netherlands . Non-western immigrants , aged 18-65 years ( n = 232 ) and serum 25 ( OH ) D < 25 nmol/l were randomly assigned to supplementation ( daily 800 IU or 100,000 IU/3 months ) or advice for sunlight exposure for 6 months ( March-September ) . Blood samples were collected at baseline , during treatment ( 3 months , 6 months ) , and at follow-up ( 12 months ) . Statistical analysis was performed with multilevel regression modelling . RESULTS The intention-to-treat analysis included 211 persons . Baseline serum 25 ( OH ) D was 22.5 ± 11.1 nmol/l . After 6 months , mean serum 25 ( OH ) D increased to 53 nmol/l with 800 IU/day , to 50.5 nmol/l with 100,000 IU/3 months , and to 29.1 nmol/l with advised sunlight exposure ( supplementation vs sunshine p < 0.001 ) . Serum PTH decreased significantly in all groups after 3 months , more in the supplementation groups than in the advised sunlight group ( p < 0.05 ) . There was no significant effect on physical performance and functional limitations . CONCLUSION Vitamin D supplementation is more effective than advised sunlight exposure for treating vitamin D deficiency in non-western immigrants . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Intervention_Control, Outcome_Physical	[ "B-Intervention_Control", "I-Intervention_Control", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants : a randomized clinical trial . UNLABELLED Vitamin D deficiency is very common in non-western immigrants . In this randomized clinical trial , vitamin D 800 IU/day or 100,000 IU/3 months were compared with advised sunlight exposure . Vitamin D supplementation was more effective than advised sunlight exposure in improving vitamin D status and lowering parathyroid hormone levels . INTRODUCTION Vitamin D deficiency ( 25-hydroxyvitamin D [ 25 ( OH ) D ] < 25 nmol/l ) is common among non-western immigrants . It can be treated with vitamin D supplementation or sunlight exposure . METHODS To determine whether the effect of vitamin D ( 3 ) supplementation ( daily 800 IU or 100,000 IU/3 months ) or sunlight exposure advice is similar with regard to serum 25 ( OH ) D and parathyroid hormone ( PTH ) concentrations . Randomized clinical trial in 11 general practices in The Netherlands . Non-western immigrants , aged 18-65 years ( n = 232 ) and serum 25 ( OH ) D < 25 nmol/l were randomly assigned to supplementation ( daily 800 IU or 100,000 IU/3 months ) or advice for sunlight exposure for 6 months ( March-September ) . Blood samples were collected at baseline , during treatment ( 3 months , 6 months ) , and at follow-up ( 12 months ) . Statistical analysis was performed with multilevel regression modelling . RESULTS The intention-to-treat analysis included 211 persons . Baseline serum 25 ( OH ) D was 22.5 ± 11.1 nmol/l . After 6 months , mean serum 25 ( OH ) D increased to 53 nmol/l with 800 IU/day , to 50.5 nmol/l with 100,000 IU/3 months , and to 29.1 nmol/l with advised sunlight exposure ( supplementation vs sunshine p < 0.001 ) . Serum PTH decreased significantly in all groups after 3 months , more in the supplementation groups than in the advised sunlight group ( p < 0.05 ) . There was no significant effect on physical performance and functional limitations . CONCLUSION Vitamin D supplementation is more effective than advised sunlight exposure for treating vitamin D deficiency in non-western immigrants .	[ "Sunlight", "exposure", "or", "vitamin", "D", "supplementation", "for", "vitamin", "D", "-", "deficient", "non", "-", "western", "immigrants", ":", "a", "randomized", "clinical", "trial", ".", "UNLABELLED", "Vitamin", "D", "deficiency", "is", "very", "common", "in", "non", "-", "western", "immigrants", ".", "In", "this", "randomized", "clinical", "trial", ",", "vitamin", "D", "800", "IU", "/", "day", "or", "100,000", "IU/3", "months", "were", "compared", "with", "advised", "sunlight", "exposure", ".", "Vitamin", "D", "supplementation", "was", "more", "effective", "than", "advised", "sunlight", "exposure", "in", "improving", "vitamin", "D", "status", "and", "lowering", "parathyroid", "hormone", "levels", ".", "INTRODUCTION", "Vitamin", "D", "deficiency", "(", "25-hydroxyvitamin", "D", "[", "25", "(", "OH", ")", "D", "]", "<", "25", "nmol", "/", "l", ")", "is", "common", "among", "non", "-", "western", "immigrants", ".", "It", "can", "be", "treated", "with", "vitamin", "D", "supplementation", "or", "sunlight", "exposure", ".", "METHODS", "To", "determine", "whether", "the", "effect", "of", "vitamin", "D", "(", "3", ")", "supplementation", "(", "daily", "800", "IU", "or", "100,000", "IU/3", "months", ")", "or", "sunlight", "exposure", "advice", "is", "similar", "with", "regard", "to", "serum", "25", "(", "OH", ")", "D", "and", "parathyroid", "hormone", "(", "PTH", ")", "concentrations", ".", "Randomized", "clinical", "trial", "in", "11", "general", "practices", "in", "The", "Netherlands", ".", "Non", "-", "western", "immigrants", ",", "aged", "18", "-", "65", "years", "(", "n", "=", "232", ")", "and", "serum", "25", "(", "OH", ")", "D", "<", "25", "nmol", "/", "l", "were", "randomly", "assigned", "to", "supplementation", "(", "daily", "800", "IU", "or", "100,000", "IU/3", "months", ")", "or", "advice", "for", "sunlight", "exposure", "for", "6", "months", "(", "March", "-", "September", ")", ".", "Blood", "samples", "were", "collected", "at", "baseline", ",", "during", "treatment", "(", "3", "months", ",", "6", "months", ")", ",", "and", "at", "follow", "-", "up", "(", "12", "months", ")", ".", "Statistical", "analysis", "was", "performed", "with", "multilevel", "regression", "modelling", ".", "RESULTS", "The", "intention", "-", "to", "-", "treat", "analysis", "included", "211", "persons", ".", "Baseline", "serum", "25", "(", "OH", ")", "D", "was", "22.5", "±", "11.1", "nmol", "/", "l", ".", "After", "6", "months", ",", "mean", "serum", "25", "(", "OH", ")", "D", "increased", "to", "53", "nmol", "/", "l", "with", "800", "IU", "/", "day", ",", "to", "50.5", "nmol", "/", "l", "with", "100,000", "IU/3", "months", ",", "and", "to", "29.1", "nmol", "/", "l", "with", "advised", "sunlight", "exposure", "(", "supplementation", "vs", "sunshine", "p", "<", "0.001", ")", ".", "Serum", "PTH", "decreased", "significantly", "in", "all", "groups", "after", "3", "months", ",", "more", "in", "the", "supplementation", "groups", "than", "in", "the", "advised", "sunlight", "group", "(", "p", "<", "0.05", ")", ".", "There", "was", "no", "significant", "effect", "on", "physical", "performance", "and", "functional", "limitations", ".", "CONCLUSION", "Vitamin", "D", "supplementation", "is", "more", "effective", "than", "advised", "sunlight", "exposure", "for", "treating", "vitamin", "D", "deficiency", "in", "non", "-", "western", "immigrants", "." ]	[ "Intervention_Pharmacological", "Intervention_Physical", "Intervention_Control", "Participant_Condition", "Outcome_Physical" ]
Sunlight exposure is a Intervention_Control, vitamin D supplementation is a Intervention_Pharmacological, vitamin D - deficient is a Participant_Condition, Vitamin D is a Intervention_Pharmacological, advised sunlight exposure is a Intervention_Physical, Vitamin D supplementation is a Intervention_Pharmacological, Baseline serum is a Outcome_Physical, mean is a Outcome_Physical	46969_task1	Sentence: Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants : a randomized clinical trial . UNLABELLED Vitamin D deficiency is very common in non-western immigrants . In this randomized clinical trial , vitamin D 800 IU/day or 100,000 IU/3 months were compared with advised sunlight exposure . Vitamin D supplementation was more effective than advised sunlight exposure in improving vitamin D status and lowering parathyroid hormone levels . INTRODUCTION Vitamin D deficiency ( 25-hydroxyvitamin D [ 25 ( OH ) D ] < 25 nmol/l ) is common among non-western immigrants . It can be treated with vitamin D supplementation or sunlight exposure . METHODS To determine whether the effect of vitamin D ( 3 ) supplementation ( daily 800 IU or 100,000 IU/3 months ) or sunlight exposure advice is similar with regard to serum 25 ( OH ) D and parathyroid hormone ( PTH ) concentrations . Randomized clinical trial in 11 general practices in The Netherlands . Non-western immigrants , aged 18-65 years ( n = 232 ) and serum 25 ( OH ) D < 25 nmol/l were randomly assigned to supplementation ( daily 800 IU or 100,000 IU/3 months ) or advice for sunlight exposure for 6 months ( March-September ) . Blood samples were collected at baseline , during treatment ( 3 months , 6 months ) , and at follow-up ( 12 months ) . Statistical analysis was performed with multilevel regression modelling . RESULTS The intention-to-treat analysis included 211 persons . Baseline serum 25 ( OH ) D was 22.5 ± 11.1 nmol/l . After 6 months , mean serum 25 ( OH ) D increased to 53 nmol/l with 800 IU/day , to 50.5 nmol/l with 100,000 IU/3 months , and to 29.1 nmol/l with advised sunlight exposure ( supplementation vs sunshine p < 0.001 ) . Serum PTH decreased significantly in all groups after 3 months , more in the supplementation groups than in the advised sunlight group ( p < 0.05 ) . There was no significant effect on physical performance and functional limitations . CONCLUSION Vitamin D supplementation is more effective than advised sunlight exposure for treating vitamin D deficiency in non-western immigrants . Instructions: please typing these entity words according to sentence: Sunlight exposure, vitamin D supplementation, vitamin D - deficient, Vitamin D, advised sunlight exposure, Vitamin D supplementation, Baseline serum, mean Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Intervention_Control, Outcome_Physical	[ "B-Intervention_Control", "I-Intervention_Control", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants : a randomized clinical trial . UNLABELLED Vitamin D deficiency is very common in non-western immigrants . In this randomized clinical trial , vitamin D 800 IU/day or 100,000 IU/3 months were compared with advised sunlight exposure . Vitamin D supplementation was more effective than advised sunlight exposure in improving vitamin D status and lowering parathyroid hormone levels . INTRODUCTION Vitamin D deficiency ( 25-hydroxyvitamin D [ 25 ( OH ) D ] < 25 nmol/l ) is common among non-western immigrants . It can be treated with vitamin D supplementation or sunlight exposure . METHODS To determine whether the effect of vitamin D ( 3 ) supplementation ( daily 800 IU or 100,000 IU/3 months ) or sunlight exposure advice is similar with regard to serum 25 ( OH ) D and parathyroid hormone ( PTH ) concentrations . Randomized clinical trial in 11 general practices in The Netherlands . Non-western immigrants , aged 18-65 years ( n = 232 ) and serum 25 ( OH ) D < 25 nmol/l were randomly assigned to supplementation ( daily 800 IU or 100,000 IU/3 months ) or advice for sunlight exposure for 6 months ( March-September ) . Blood samples were collected at baseline , during treatment ( 3 months , 6 months ) , and at follow-up ( 12 months ) . Statistical analysis was performed with multilevel regression modelling . RESULTS The intention-to-treat analysis included 211 persons . Baseline serum 25 ( OH ) D was 22.5 ± 11.1 nmol/l . After 6 months , mean serum 25 ( OH ) D increased to 53 nmol/l with 800 IU/day , to 50.5 nmol/l with 100,000 IU/3 months , and to 29.1 nmol/l with advised sunlight exposure ( supplementation vs sunshine p < 0.001 ) . Serum PTH decreased significantly in all groups after 3 months , more in the supplementation groups than in the advised sunlight group ( p < 0.05 ) . There was no significant effect on physical performance and functional limitations . CONCLUSION Vitamin D supplementation is more effective than advised sunlight exposure for treating vitamin D deficiency in non-western immigrants .	[ "Sunlight", "exposure", "or", "vitamin", "D", "supplementation", "for", "vitamin", "D", "-", "deficient", "non", "-", "western", "immigrants", ":", "a", "randomized", "clinical", "trial", ".", "UNLABELLED", "Vitamin", "D", "deficiency", "is", "very", "common", "in", "non", "-", "western", "immigrants", ".", "In", "this", "randomized", "clinical", "trial", ",", "vitamin", "D", "800", "IU", "/", "day", "or", "100,000", "IU/3", "months", "were", "compared", "with", "advised", "sunlight", "exposure", ".", "Vitamin", "D", "supplementation", "was", "more", "effective", "than", "advised", "sunlight", "exposure", "in", "improving", "vitamin", "D", "status", "and", "lowering", "parathyroid", "hormone", "levels", ".", "INTRODUCTION", "Vitamin", "D", "deficiency", "(", "25-hydroxyvitamin", "D", "[", "25", "(", "OH", ")", "D", "]", "<", "25", "nmol", "/", "l", ")", "is", "common", "among", "non", "-", "western", "immigrants", ".", "It", "can", "be", "treated", "with", "vitamin", "D", "supplementation", "or", "sunlight", "exposure", ".", "METHODS", "To", "determine", "whether", "the", "effect", "of", "vitamin", "D", "(", "3", ")", "supplementation", "(", "daily", "800", "IU", "or", "100,000", "IU/3", "months", ")", "or", "sunlight", "exposure", "advice", "is", "similar", "with", "regard", "to", "serum", "25", "(", "OH", ")", "D", "and", "parathyroid", "hormone", "(", "PTH", ")", "concentrations", ".", "Randomized", "clinical", "trial", "in", "11", "general", "practices", "in", "The", "Netherlands", ".", "Non", "-", "western", "immigrants", ",", "aged", "18", "-", "65", "years", "(", "n", "=", "232", ")", "and", "serum", "25", "(", "OH", ")", "D", "<", "25", "nmol", "/", "l", "were", "randomly", "assigned", "to", "supplementation", "(", "daily", "800", "IU", "or", "100,000", "IU/3", "months", ")", "or", "advice", "for", "sunlight", "exposure", "for", "6", "months", "(", "March", "-", "September", ")", ".", "Blood", "samples", "were", "collected", "at", "baseline", ",", "during", "treatment", "(", "3", "months", ",", "6", "months", ")", ",", "and", "at", "follow", "-", "up", "(", "12", "months", ")", ".", "Statistical", "analysis", "was", "performed", "with", "multilevel", "regression", "modelling", ".", "RESULTS", "The", "intention", "-", "to", "-", "treat", "analysis", "included", "211", "persons", ".", "Baseline", "serum", "25", "(", "OH", ")", "D", "was", "22.5", "±", "11.1", "nmol", "/", "l", ".", "After", "6", "months", ",", "mean", "serum", "25", "(", "OH", ")", "D", "increased", "to", "53", "nmol", "/", "l", "with", "800", "IU", "/", "day", ",", "to", "50.5", "nmol", "/", "l", "with", "100,000", "IU/3", "months", ",", "and", "to", "29.1", "nmol", "/", "l", "with", "advised", "sunlight", "exposure", "(", "supplementation", "vs", "sunshine", "p", "<", "0.001", ")", ".", "Serum", "PTH", "decreased", "significantly", "in", "all", "groups", "after", "3", "months", ",", "more", "in", "the", "supplementation", "groups", "than", "in", "the", "advised", "sunlight", "group", "(", "p", "<", "0.05", ")", ".", "There", "was", "no", "significant", "effect", "on", "physical", "performance", "and", "functional", "limitations", ".", "CONCLUSION", "Vitamin", "D", "supplementation", "is", "more", "effective", "than", "advised", "sunlight", "exposure", "for", "treating", "vitamin", "D", "deficiency", "in", "non", "-", "western", "immigrants", "." ]	[ "Intervention_Pharmacological", "Intervention_Physical", "Intervention_Control", "Participant_Condition", "Outcome_Physical" ]
Sunlight exposure, vitamin D supplementation, vitamin D - deficient, Vitamin D, advised sunlight exposure, Vitamin D supplementation, Baseline serum, mean	46969_task2	Sentence: Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants : a randomized clinical trial . UNLABELLED Vitamin D deficiency is very common in non-western immigrants . In this randomized clinical trial , vitamin D 800 IU/day or 100,000 IU/3 months were compared with advised sunlight exposure . Vitamin D supplementation was more effective than advised sunlight exposure in improving vitamin D status and lowering parathyroid hormone levels . INTRODUCTION Vitamin D deficiency ( 25-hydroxyvitamin D [ 25 ( OH ) D ] < 25 nmol/l ) is common among non-western immigrants . It can be treated with vitamin D supplementation or sunlight exposure . METHODS To determine whether the effect of vitamin D ( 3 ) supplementation ( daily 800 IU or 100,000 IU/3 months ) or sunlight exposure advice is similar with regard to serum 25 ( OH ) D and parathyroid hormone ( PTH ) concentrations . Randomized clinical trial in 11 general practices in The Netherlands . Non-western immigrants , aged 18-65 years ( n = 232 ) and serum 25 ( OH ) D < 25 nmol/l were randomly assigned to supplementation ( daily 800 IU or 100,000 IU/3 months ) or advice for sunlight exposure for 6 months ( March-September ) . Blood samples were collected at baseline , during treatment ( 3 months , 6 months ) , and at follow-up ( 12 months ) . Statistical analysis was performed with multilevel regression modelling . RESULTS The intention-to-treat analysis included 211 persons . Baseline serum 25 ( OH ) D was 22.5 ± 11.1 nmol/l . After 6 months , mean serum 25 ( OH ) D increased to 53 nmol/l with 800 IU/day , to 50.5 nmol/l with 100,000 IU/3 months , and to 29.1 nmol/l with advised sunlight exposure ( supplementation vs sunshine p < 0.001 ) . Serum PTH decreased significantly in all groups after 3 months , more in the supplementation groups than in the advised sunlight group ( p < 0.05 ) . There was no significant effect on physical performance and functional limitations . CONCLUSION Vitamin D supplementation is more effective than advised sunlight exposure for treating vitamin D deficiency in non-western immigrants . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Control", "I-Intervention_Control", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants : a randomized clinical trial . UNLABELLED Vitamin D deficiency is very common in non-western immigrants . In this randomized clinical trial , vitamin D 800 IU/day or 100,000 IU/3 months were compared with advised sunlight exposure . Vitamin D supplementation was more effective than advised sunlight exposure in improving vitamin D status and lowering parathyroid hormone levels . INTRODUCTION Vitamin D deficiency ( 25-hydroxyvitamin D [ 25 ( OH ) D ] < 25 nmol/l ) is common among non-western immigrants . It can be treated with vitamin D supplementation or sunlight exposure . METHODS To determine whether the effect of vitamin D ( 3 ) supplementation ( daily 800 IU or 100,000 IU/3 months ) or sunlight exposure advice is similar with regard to serum 25 ( OH ) D and parathyroid hormone ( PTH ) concentrations . Randomized clinical trial in 11 general practices in The Netherlands . Non-western immigrants , aged 18-65 years ( n = 232 ) and serum 25 ( OH ) D < 25 nmol/l were randomly assigned to supplementation ( daily 800 IU or 100,000 IU/3 months ) or advice for sunlight exposure for 6 months ( March-September ) . Blood samples were collected at baseline , during treatment ( 3 months , 6 months ) , and at follow-up ( 12 months ) . Statistical analysis was performed with multilevel regression modelling . RESULTS The intention-to-treat analysis included 211 persons . Baseline serum 25 ( OH ) D was 22.5 ± 11.1 nmol/l . After 6 months , mean serum 25 ( OH ) D increased to 53 nmol/l with 800 IU/day , to 50.5 nmol/l with 100,000 IU/3 months , and to 29.1 nmol/l with advised sunlight exposure ( supplementation vs sunshine p < 0.001 ) . Serum PTH decreased significantly in all groups after 3 months , more in the supplementation groups than in the advised sunlight group ( p < 0.05 ) . There was no significant effect on physical performance and functional limitations . CONCLUSION Vitamin D supplementation is more effective than advised sunlight exposure for treating vitamin D deficiency in non-western immigrants .	[ "Sunlight", "exposure", "or", "vitamin", "D", "supplementation", "for", "vitamin", "D", "-", "deficient", "non", "-", "western", "immigrants", ":", "a", "randomized", "clinical", "trial", ".", "UNLABELLED", "Vitamin", "D", "deficiency", "is", "very", "common", "in", "non", "-", "western", "immigrants", ".", "In", "this", "randomized", "clinical", "trial", ",", "vitamin", "D", "800", "IU", "/", "day", "or", "100,000", "IU/3", "months", "were", "compared", "with", "advised", "sunlight", "exposure", ".", "Vitamin", "D", "supplementation", "was", "more", "effective", "than", "advised", "sunlight", "exposure", "in", "improving", "vitamin", "D", "status", "and", "lowering", "parathyroid", "hormone", "levels", ".", "INTRODUCTION", "Vitamin", "D", "deficiency", "(", "25-hydroxyvitamin", "D", "[", "25", "(", "OH", ")", "D", "]", "<", "25", "nmol", "/", "l", ")", "is", "common", "among", "non", "-", "western", "immigrants", ".", "It", "can", "be", "treated", "with", "vitamin", "D", "supplementation", "or", "sunlight", "exposure", ".", "METHODS", "To", "determine", "whether", "the", "effect", "of", "vitamin", "D", "(", "3", ")", "supplementation", "(", "daily", "800", "IU", "or", "100,000", "IU/3", "months", ")", "or", "sunlight", "exposure", "advice", "is", "similar", "with", "regard", "to", "serum", "25", "(", "OH", ")", "D", "and", "parathyroid", "hormone", "(", "PTH", ")", "concentrations", ".", "Randomized", "clinical", "trial", "in", "11", "general", "practices", "in", "The", "Netherlands", ".", "Non", "-", "western", "immigrants", ",", "aged", "18", "-", "65", "years", "(", "n", "=", "232", ")", "and", "serum", "25", "(", "OH", ")", "D", "<", "25", "nmol", "/", "l", "were", "randomly", "assigned", "to", "supplementation", "(", "daily", "800", "IU", "or", "100,000", "IU/3", "months", ")", "or", "advice", "for", "sunlight", "exposure", "for", "6", "months", "(", "March", "-", "September", ")", ".", "Blood", "samples", "were", "collected", "at", "baseline", ",", "during", "treatment", "(", "3", "months", ",", "6", "months", ")", ",", "and", "at", "follow", "-", "up", "(", "12", "months", ")", ".", "Statistical", "analysis", "was", "performed", "with", "multilevel", "regression", "modelling", ".", "RESULTS", "The", "intention", "-", "to", "-", "treat", "analysis", "included", "211", "persons", ".", "Baseline", "serum", "25", "(", "OH", ")", "D", "was", "22.5", "±", "11.1", "nmol", "/", "l", ".", "After", "6", "months", ",", "mean", "serum", "25", "(", "OH", ")", "D", "increased", "to", "53", "nmol", "/", "l", "with", "800", "IU", "/", "day", ",", "to", "50.5", "nmol", "/", "l", "with", "100,000", "IU/3", "months", ",", "and", "to", "29.1", "nmol", "/", "l", "with", "advised", "sunlight", "exposure", "(", "supplementation", "vs", "sunshine", "p", "<", "0.001", ")", ".", "Serum", "PTH", "decreased", "significantly", "in", "all", "groups", "after", "3", "months", ",", "more", "in", "the", "supplementation", "groups", "than", "in", "the", "advised", "sunlight", "group", "(", "p", "<", "0.05", ")", ".", "There", "was", "no", "significant", "effect", "on", "physical", "performance", "and", "functional", "limitations", ".", "CONCLUSION", "Vitamin", "D", "supplementation", "is", "more", "effective", "than", "advised", "sunlight", "exposure", "for", "treating", "vitamin", "D", "deficiency", "in", "non", "-", "western", "immigrants", "." ]	[ "Intervention_Pharmacological", "Intervention_Physical", "Intervention_Control", "Participant_Condition", "Outcome_Physical" ]
anoctamin-6 is a GENE-Y, Tmem16f is a GENE-Y, phosphatidylserine is a CHEMICAL	22936354_task0	Sentence: Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues.	[ "Inactivation", "of", "anoctamin-6", "/", "Tmem16f", ",", "a", "regulator", "of", "phosphatidylserine", "scrambling", "in", "osteoblasts", ",", "leads", "to", "decreased", "mineral", "deposition", "in", "skeletal", "tissues", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
anoctamin-6 is a GENE-Y, Tmem16f is a GENE-Y, phosphatidylserine is a CHEMICAL	22936354_task1	Sentence: Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues. Instructions: please typing these entity words according to sentence: anoctamin-6, Tmem16f, phosphatidylserine Options: GENE-Y, CHEMICAL	[ "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues.	[ "Inactivation", "of", "anoctamin-6", "/", "Tmem16f", ",", "a", "regulator", "of", "phosphatidylserine", "scrambling", "in", "osteoblasts", ",", "leads", "to", "decreased", "mineral", "deposition", "in", "skeletal", "tissues", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
anoctamin-6, Tmem16f, phosphatidylserine	22936354_task2	Sentence: Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues.	[ "Inactivation", "of", "anoctamin-6", "/", "Tmem16f", ",", "a", "regulator", "of", "phosphatidylserine", "scrambling", "in", "osteoblasts", ",", "leads", "to", "decreased", "mineral", "deposition", "in", "skeletal", "tissues", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
CBP / p300 is a protein_molecule, Raf / Rac - signaling pathways is an other_name, NF - ATc is a protein_molecule, T cell activation is an other_name	39759_task0	Sentence: CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name, protein_molecule	[ "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]	CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation.	[ "CBP", "/", "p300", "integrates", "Raf", "/", "Rac", "-", "signaling", "pathways", "in", "the", "transcriptional", "induction", "of", "NF", "-", "ATc", "during", "T", "cell", "activation", "." ]	[ "protein_domain_or_region", "protein_family_or_group", "other_name", "atom", "cell_type", "protein_molecule" ]
CBP / p300 is a protein_molecule, Raf / Rac - signaling pathways is an other_name, NF - ATc is a protein_molecule, T cell activation is an other_name	39759_task1	Sentence: CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation. Instructions: please typing these entity words according to sentence: CBP / p300, Raf / Rac - signaling pathways, NF - ATc, T cell activation Options: other_name, protein_molecule	[ "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]	CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation.	[ "CBP", "/", "p300", "integrates", "Raf", "/", "Rac", "-", "signaling", "pathways", "in", "the", "transcriptional", "induction", "of", "NF", "-", "ATc", "during", "T", "cell", "activation", "." ]	[ "protein_domain_or_region", "protein_family_or_group", "other_name", "atom", "cell_type", "protein_molecule" ]
CBP / p300, Raf / Rac - signaling pathways, NF - ATc, T cell activation	39759_task2	Sentence: CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation. Instructions: please extract entity words from the input sentence	[ "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]	CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation.	[ "CBP", "/", "p300", "integrates", "Raf", "/", "Rac", "-", "signaling", "pathways", "in", "the", "transcriptional", "induction", "of", "NF", "-", "ATc", "during", "T", "cell", "activation", "." ]	[ "protein_domain_or_region", "protein_family_or_group", "other_name", "atom", "cell_type", "protein_molecule" ]
metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, melanoma infiltrante is a MORFOLOGIA_NEOPLASIA, melanoma is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, realce ependimario is a MORFOLOGIA_NEOPLASIA, afectación leptomeníngea is a MORFOLOGIA_NEOPLASIA, recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central is a MORFOLOGIA_NEOPLASIA, afectación leptomeníngea is a MORFOLOGIA_NEOPLASIA, invasión leptomeníngea is a MORFOLOGIA_NEOPLASIA	715_task0	Sentence: Anamnesis Se trata de una mujer de 50 años, con alergia al contraste yodado y a la metoclopramida, sin hábitos tóxicos, ni antecedentes laborales o familiares de interés. Tiene antecedentes patológicos de síndrome ansioso-depresivo de más de 20 años de evolución en tratamiento con duloxetina. Su historia oncológica se inicia en marzo de 2012, a raíz de cuadro de cefalea opresiva de predominio frontal y de obstrucción nasal izquierda, por lo que acude a consulta en múltiples ocasiones en médico de Atención Primaria y Urgencias Hospitalarias, orientándose como sinusitis refractaria a tratamiento médico. Exploración física Buen estado general. Dolor en la palpación de senos paranasales, de predominio maxilar izquierdo. Auscultación cardiorrespiratoria sin alteraciones. Abdomen blando y depresible, no es doloroso durante la palpación, sin masas ni hepatoesplenomegalia. Pruebas complementarias Se realiza una analítica en la que destaca LDH de 880 U/l con el resto de marcadores tumorales negativos y una radiografía de senos paranasales que muestra ocupación de seno maxilar izquierdo. Se completa estudio con resonancia magnética (RM) facial en la que aparece una lesión sólida expansiva en seno maxilar izquierdo que se extiende hasta fosa nasal izquierda, con infiltración de partes blandas. Como estudio de extensión, se realiza una tomografía computarizada (TC) torácica y abdominal que describe lesiones sugestivas de metástasis en ambos campos pulmonares, hígado, bazo, subcutáneas y adenopatías inguinales. También se realiza una gammagrafía ósea (GGO) y una RM craneal sin metástasis óseas ni en sistema nervioso central. Diagnóstico Se realiza una biopsia de la lesión en mucosa nasal izquierda que es compatible con melanoma infiltrante, con estudio molecular negativo para BRAF y KIT. Por ello, se diagnostica melanoma de mucosa de seno maxilar izquierdo no mutado, estadio IV (por metástasis hepáticas, pulmonares, esplénicas y cutáneas). Tratamiento Dada la ausencia de mutaciones que permitan beneficiarse de tratamiento antidiana, se decide iniciar tratamiento de primera línea dentro de ensayo clínico con ipilimumab (3 mg/kg vs. 10 mg/kg) por 4 ciclos, que finaliza en septiembre de 2012. Presenta muy buena tolerancia y obtiene una respuesta completa, por lo que inicia controles por RM craneal y TC toracoabdominal cada 3 meses hasta marzo de 2017 y posteriormente controles cada 6 meses. En el último control en septiembre de 2017, presenta una respuesta completa mantenida a los 5 años de finalizar el tratamiento. Evolución En enero de 2018, inicia cuadro de dolor cervicodorsolumbar progresivo por el que acude a la consulta del médico de Atención Primaria y Traumatología en diversas ocasiones, se realiza RM lumbar y GGO que no muestran alteraciones ni lesiones sugestivas de metástasis. A finales de febrero ingresa por diversos episodios de crisis comicial de ausencia, con TC craneal que muestra dos lesiones sólidas con signos de sangrado y dilatación del sistema ventricular. Se completa estudio con RM cerebral que informa de dos lesiones intraventriculares sugestivas de metástasis en asta frontal izquierda de 15 x 16 mm y atrio ventricular izquierdo de 24 x 23 mm, con hidrocefalia arreabsortiva por sangrado intraventricular y realce ependimario del atrio ventricular que no permite descartar diseminación del líquido cefalorraquídeo ni afectación leptomeníngea. Se realiza también TC toracoabdominal que no evidencia diseminación de enfermedad a otros niveles. Se orienta como recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, con posible afectación leptomeníngea, a los 5 años y 6 meses de finalizar tratamiento. Se inicia tratamiento corticoide y anticomicial con dexametasona 4 mg cada 6 horas y levetiracetam 500 mg cada 12 horas endovenosos. Durante el ingreso presenta dos episodios de crisis tónico-clónicas generalizadas con periodo poscrítico prolongado y disminución del nivel de conciencia, por lo que se añade lacosamida 200 mg cada 12 h y se aumenta levetiracetam a 1.000 mg cada 12 horas. Requiere ingreso en la Unidad de Cuidados Intensivos para observación durante 48 h, sin presentar nuevos episodios de comicialidad ni empeoramiento clínico. Inicia rehabilitación y seguimiento por parte de Psicooncología por cuadro de ansiedad e insomnio, que se controla con mirtazapina 15 mg al día. Se presenta el caso en comité de tumores y se desestima tratamiento quirúrgico por invasión leptomeníngea. Se decide tratamiento con radioterapia holocraneal (30 Gy en 10 fracciones) y posteriormente tratamiento con anti-PD-1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Se trata de una mujer de 50 años, con alergia al contraste yodado y a la metoclopramida, sin hábitos tóxicos, ni antecedentes laborales o familiares de interés. Tiene antecedentes patológicos de síndrome ansioso-depresivo de más de 20 años de evolución en tratamiento con duloxetina. Su historia oncológica se inicia en marzo de 2012, a raíz de cuadro de cefalea opresiva de predominio frontal y de obstrucción nasal izquierda, por lo que acude a consulta en múltiples ocasiones en médico de Atención Primaria y Urgencias Hospitalarias, orientándose como sinusitis refractaria a tratamiento médico. Exploración física Buen estado general. Dolor en la palpación de senos paranasales, de predominio maxilar izquierdo. Auscultación cardiorrespiratoria sin alteraciones. Abdomen blando y depresible, no es doloroso durante la palpación, sin masas ni hepatoesplenomegalia. Pruebas complementarias Se realiza una analítica en la que destaca LDH de 880 U/l con el resto de marcadores tumorales negativos y una radiografía de senos paranasales que muestra ocupación de seno maxilar izquierdo. Se completa estudio con resonancia magnética (RM) facial en la que aparece una lesión sólida expansiva en seno maxilar izquierdo que se extiende hasta fosa nasal izquierda, con infiltración de partes blandas. Como estudio de extensión, se realiza una tomografía computarizada (TC) torácica y abdominal que describe lesiones sugestivas de metástasis en ambos campos pulmonares, hígado, bazo, subcutáneas y adenopatías inguinales. También se realiza una gammagrafía ósea (GGO) y una RM craneal sin metástasis óseas ni en sistema nervioso central. Diagnóstico Se realiza una biopsia de la lesión en mucosa nasal izquierda que es compatible con melanoma infiltrante, con estudio molecular negativo para BRAF y KIT. Por ello, se diagnostica melanoma de mucosa de seno maxilar izquierdo no mutado, estadio IV (por metástasis hepáticas, pulmonares, esplénicas y cutáneas). Tratamiento Dada la ausencia de mutaciones que permitan beneficiarse de tratamiento antidiana, se decide iniciar tratamiento de primera línea dentro de ensayo clínico con ipilimumab (3 mg/kg vs. 10 mg/kg) por 4 ciclos, que finaliza en septiembre de 2012. Presenta muy buena tolerancia y obtiene una respuesta completa, por lo que inicia controles por RM craneal y TC toracoabdominal cada 3 meses hasta marzo de 2017 y posteriormente controles cada 6 meses. En el último control en septiembre de 2017, presenta una respuesta completa mantenida a los 5 años de finalizar el tratamiento. Evolución En enero de 2018, inicia cuadro de dolor cervicodorsolumbar progresivo por el que acude a la consulta del médico de Atención Primaria y Traumatología en diversas ocasiones, se realiza RM lumbar y GGO que no muestran alteraciones ni lesiones sugestivas de metástasis. A finales de febrero ingresa por diversos episodios de crisis comicial de ausencia, con TC craneal que muestra dos lesiones sólidas con signos de sangrado y dilatación del sistema ventricular. Se completa estudio con RM cerebral que informa de dos lesiones intraventriculares sugestivas de metástasis en asta frontal izquierda de 15 x 16 mm y atrio ventricular izquierdo de 24 x 23 mm, con hidrocefalia arreabsortiva por sangrado intraventricular y realce ependimario del atrio ventricular que no permite descartar diseminación del líquido cefalorraquídeo ni afectación leptomeníngea. Se realiza también TC toracoabdominal que no evidencia diseminación de enfermedad a otros niveles. Se orienta como recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, con posible afectación leptomeníngea, a los 5 años y 6 meses de finalizar tratamiento. Se inicia tratamiento corticoide y anticomicial con dexametasona 4 mg cada 6 horas y levetiracetam 500 mg cada 12 horas endovenosos. Durante el ingreso presenta dos episodios de crisis tónico-clónicas generalizadas con periodo poscrítico prolongado y disminución del nivel de conciencia, por lo que se añade lacosamida 200 mg cada 12 h y se aumenta levetiracetam a 1.000 mg cada 12 horas. Requiere ingreso en la Unidad de Cuidados Intensivos para observación durante 48 h, sin presentar nuevos episodios de comicialidad ni empeoramiento clínico. Inicia rehabilitación y seguimiento por parte de Psicooncología por cuadro de ansiedad e insomnio, que se controla con mirtazapina 15 mg al día. Se presenta el caso en comité de tumores y se desestima tratamiento quirúrgico por invasión leptomeníngea. Se decide tratamiento con radioterapia holocraneal (30 Gy en 10 fracciones) y posteriormente tratamiento con anti-PD-1.	[ "Anamnesis", "\n", "Se", "trata", "de", "una", "mujer", "de", "50", "años", ",", "con", "alergia", "al", "contraste", "yodado", "y", "a", "la", "metoclopramida", ",", "sin", "hábitos", "tóxicos", ",", "ni", "antecedentes", "laborales", "o", "familiares", "de", "interés", ".", "Tiene", "antecedentes", "patológicos", "de", "síndrome", "ansioso", "-", "depresivo", "de", "más", "de", "20", "años", "de", "evolución", "en", "tratamiento", "con", "duloxetina", ".", "\n", "Su", "historia", "oncológica", "se", "inicia", "en", "marzo", "de", "2012", ",", "a", "raíz", "de", "cuadro", "de", "cefalea", "opresiva", "de", "predominio", "frontal", "y", "de", "obstrucción", "nasal", "izquierda", ",", "por", "lo", "que", "acude", "a", "consulta", "en", "múltiples", "ocasiones", "en", "médico", "de", "Atención", "Primaria", "y", "Urgencias", "Hospitalarias", ",", "orientándose", "como", "sinusitis", "refractaria", "a", "tratamiento", "médico", ".", "\n\n", "Exploración", "física", "\n", "Buen", "estado", "general", ".", "Dolor", "en", "la", "palpación", "de", "senos", "paranasales", ",", "de", "predominio", "maxilar", "izquierdo", ".", "Auscultación", "cardiorrespiratoria", "sin", "alteraciones", ".", "Abdomen", "blando", "y", "depresible", ",", "no", "es", "doloroso", "durante", "la", "palpación", ",", "sin", "masas", "ni", "hepatoesplenomegalia", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "analítica", "en", "la", "que", "destaca", "LDH", "de", "880", "U", "/", "l", "con", "el", "resto", "de", "marcadores", "tumorales", "negativos", "y", "una", "radiografía", "de", "senos", "paranasales", "que", "muestra", "ocupación", "de", "seno", "maxilar", "izquierdo", ".", "Se", "completa", "estudio", "con", "resonancia", "magnética", "(", "RM", ")", "facial", "en", "la", "que", "aparece", "una", "lesión", "sólida", "expansiva", "en", "seno", "maxilar", "izquierdo", "que", "se", "extiende", "hasta", "fosa", "nasal", "izquierda", ",", "con", "infiltración", "de", "partes", "blandas", ".", "\n", "Como", "estudio", "de", "extensión", ",", "se", "realiza", "una", "tomografía", "computarizada", "(", "TC", ")", "torácica", "y", "abdominal", "que", "describe", "lesiones", "sugestivas", "de", "metástasis", "en", "ambos", "campos", "pulmonares", ",", "hígado", ",", "bazo", ",", "subcutáneas", "y", "adenopatías", "inguinales", ".", "También", "se", "realiza", "una", "gammagrafía", "ósea", "(", "GGO", ")", "y", "una", "RM", "craneal", "sin", "metástasis", "óseas", "ni", "en", "sistema", "nervioso", "central", ".", "\n\n", "Diagnóstico", "\n", "Se", "realiza", "una", "biopsia", "de", "la", "lesión", "en", "mucosa", "nasal", "izquierda", "que", "es", "compatible", "con", "melanoma", "infiltrante", ",", "con", "estudio", "molecular", "negativo", "para", "BRAF", "y", "KIT", ".", "Por", "ello", ",", "se", "diagnostica", "melanoma", "de", "mucosa", "de", "seno", "maxilar", "izquierdo", "no", "mutado", ",", "estadio", "IV", "(", "por", "metástasis", "hepáticas", ",", "pulmonares", ",", "esplénicas", "y", "cutáneas", ")", ".", "\n\n", "Tratamiento", "\n", "Dada", "la", "ausencia", "de", "mutaciones", "que", "permitan", "beneficiarse", "de", "tratamiento", "antidiana", ",", "se", "decide", "iniciar", "tratamiento", "de", "primera", "línea", "dentro", "de", "ensayo", "clínico", "con", "ipilimumab", "(", "3", "mg", "/", "kg", "vs", ".", "10", "mg", "/", "kg", ")", "por", "4", "ciclos", ",", "que", "finaliza", "en", "septiembre", "de", "2012", ".", "\n", "Presenta", "muy", "buena", "tolerancia", "y", "obtiene", "una", "respuesta", "completa", ",", "por", "lo", "que", "inicia", "controles", "por", "RM", "craneal", "y", "TC", "toracoabdominal", "cada", "3", "meses", "hasta", "marzo", "de", "2017", "y", "posteriormente", "controles", "cada", "6", "meses", ".", "En", "el", "último", "control", "en", "septiembre", "de", "2017", ",", "presenta", "una", "respuesta", "completa", "mantenida", "a", "los", "5", "años", "de", "finalizar", "el", "tratamiento", ".", "\n\n", "Evolución", "\n", "En", "enero", "de", "2018", ",", "inicia", "cuadro", "de", "dolor", "cervicodorsolumbar", "progresivo", "por", "el", "que", "acude", "a", "la", "consulta", "del", "médico", "de", "Atención", "Primaria", "y", "Traumatología", "en", "diversas", "ocasiones", ",", "se", "realiza", "RM", "lumbar", "y", "GGO", "que", "no", "muestran", "alteraciones", "ni", "lesiones", "sugestivas", "de", "metástasis", ".", "\n", "A", "finales", "de", "febrero", "ingresa", "por", "diversos", "episodios", "de", "crisis", "comicial", "de", "ausencia", ",", "con", "TC", "craneal", "que", "muestra", "dos", "lesiones", "sólidas", "con", "signos", "de", "sangrado", "y", "dilatación", "del", "sistema", "ventricular", ".", "Se", "completa", "estudio", "con", "RM", "cerebral", "que", "informa", "de", "dos", "lesiones", "intraventriculares", "sugestivas", "de", "metástasis", "en", "asta", "frontal", "izquierda", "de", "15", "x", "16", "mm", "y", "atrio", "ventricular", "izquierdo", "de", "24", "x", "23", "mm", ",", "con", "hidrocefalia", "arreabsortiva", "por", "sangrado", "intraventricular", "y", "realce", "ependimario", "del", "atrio", "ventricular", "que", "no", "permite", "descartar", "diseminación", "del", "líquido", "cefalorraquídeo", "ni", "afectación", "leptomeníngea", ".", "Se", "realiza", "también", "TC", "toracoabdominal", "que", "no", "evidencia", "diseminación", "de", "enfermedad", "a", "otros", "niveles", ".", "Se", "orienta", "como", "recidiva", "de", "melanoma", "maligno", "de", "mucosa", "a", "nivel", "de", "sistema", "nervioso", "central", ",", "con", "posible", "afectación", "leptomeníngea", ",", "a", "los", "5", "años", "y", "6", "meses", "de", "finalizar", "tratamiento", ".", "\n", "Se", "inicia", "tratamiento", "corticoide", "y", "anticomicial", "con", "dexametasona", "4", "mg", "cada", "6", "horas", "y", "levetiracetam", "500", "mg", "cada", "12", "horas", "endovenosos", ".", "Durante", "el", "ingreso", "presenta", "dos", "episodios", "de", "crisis", "tónico", "-", "clónicas", "generalizadas", "con", "periodo", "poscrítico", "prolongado", "y", "disminución", "del", "nivel", "de", "conciencia", ",", "por", "lo", "que", "se", "añade", "lacosamida", "200", "mg", "cada", "12", "h", "y", "se", "aumenta", "levetiracetam", "a", "1.000", "mg", "cada", "12", "horas", ".", "Requiere", "ingreso", "en", "la", "Unidad", "de", "Cuidados", "Intensivos", "para", "observación", "durante", "48", "h", ",", "sin", "presentar", "nuevos", "episodios", "de", "comicialidad", "ni", "empeoramiento", "clínico", ".", "Inicia", "rehabilitación", "y", "seguimiento", "por", "parte", "de", "Psicooncología", "por", "cuadro", "de", "ansiedad", "e", "insomnio", ",", "que", "se", "controla", "con", "mirtazapina", "15", "mg", "al", "día", ".", "\n", "Se", "presenta", "el", "caso", "en", "comité", "de", "tumores", "y", "se", "desestima", "tratamiento", "quirúrgico", "por", "invasión", "leptomeníngea", ".", "Se", "decide", "tratamiento", "con", "radioterapia", "holocraneal", "(", "30", "Gy", "en", "10", "fracciones", ")", "y", "posteriormente", "tratamiento", "con", "anti", "-", "PD-1", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, melanoma infiltrante is a MORFOLOGIA_NEOPLASIA, melanoma is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, realce ependimario is a MORFOLOGIA_NEOPLASIA, afectación leptomeníngea is a MORFOLOGIA_NEOPLASIA, recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central is a MORFOLOGIA_NEOPLASIA, afectación leptomeníngea is a MORFOLOGIA_NEOPLASIA, invasión leptomeníngea is a MORFOLOGIA_NEOPLASIA	715_task1	Sentence: Anamnesis Se trata de una mujer de 50 años, con alergia al contraste yodado y a la metoclopramida, sin hábitos tóxicos, ni antecedentes laborales o familiares de interés. Tiene antecedentes patológicos de síndrome ansioso-depresivo de más de 20 años de evolución en tratamiento con duloxetina. Su historia oncológica se inicia en marzo de 2012, a raíz de cuadro de cefalea opresiva de predominio frontal y de obstrucción nasal izquierda, por lo que acude a consulta en múltiples ocasiones en médico de Atención Primaria y Urgencias Hospitalarias, orientándose como sinusitis refractaria a tratamiento médico. Exploración física Buen estado general. Dolor en la palpación de senos paranasales, de predominio maxilar izquierdo. Auscultación cardiorrespiratoria sin alteraciones. Abdomen blando y depresible, no es doloroso durante la palpación, sin masas ni hepatoesplenomegalia. Pruebas complementarias Se realiza una analítica en la que destaca LDH de 880 U/l con el resto de marcadores tumorales negativos y una radiografía de senos paranasales que muestra ocupación de seno maxilar izquierdo. Se completa estudio con resonancia magnética (RM) facial en la que aparece una lesión sólida expansiva en seno maxilar izquierdo que se extiende hasta fosa nasal izquierda, con infiltración de partes blandas. Como estudio de extensión, se realiza una tomografía computarizada (TC) torácica y abdominal que describe lesiones sugestivas de metástasis en ambos campos pulmonares, hígado, bazo, subcutáneas y adenopatías inguinales. También se realiza una gammagrafía ósea (GGO) y una RM craneal sin metástasis óseas ni en sistema nervioso central. Diagnóstico Se realiza una biopsia de la lesión en mucosa nasal izquierda que es compatible con melanoma infiltrante, con estudio molecular negativo para BRAF y KIT. Por ello, se diagnostica melanoma de mucosa de seno maxilar izquierdo no mutado, estadio IV (por metástasis hepáticas, pulmonares, esplénicas y cutáneas). Tratamiento Dada la ausencia de mutaciones que permitan beneficiarse de tratamiento antidiana, se decide iniciar tratamiento de primera línea dentro de ensayo clínico con ipilimumab (3 mg/kg vs. 10 mg/kg) por 4 ciclos, que finaliza en septiembre de 2012. Presenta muy buena tolerancia y obtiene una respuesta completa, por lo que inicia controles por RM craneal y TC toracoabdominal cada 3 meses hasta marzo de 2017 y posteriormente controles cada 6 meses. En el último control en septiembre de 2017, presenta una respuesta completa mantenida a los 5 años de finalizar el tratamiento. Evolución En enero de 2018, inicia cuadro de dolor cervicodorsolumbar progresivo por el que acude a la consulta del médico de Atención Primaria y Traumatología en diversas ocasiones, se realiza RM lumbar y GGO que no muestran alteraciones ni lesiones sugestivas de metástasis. A finales de febrero ingresa por diversos episodios de crisis comicial de ausencia, con TC craneal que muestra dos lesiones sólidas con signos de sangrado y dilatación del sistema ventricular. Se completa estudio con RM cerebral que informa de dos lesiones intraventriculares sugestivas de metástasis en asta frontal izquierda de 15 x 16 mm y atrio ventricular izquierdo de 24 x 23 mm, con hidrocefalia arreabsortiva por sangrado intraventricular y realce ependimario del atrio ventricular que no permite descartar diseminación del líquido cefalorraquídeo ni afectación leptomeníngea. Se realiza también TC toracoabdominal que no evidencia diseminación de enfermedad a otros niveles. Se orienta como recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, con posible afectación leptomeníngea, a los 5 años y 6 meses de finalizar tratamiento. Se inicia tratamiento corticoide y anticomicial con dexametasona 4 mg cada 6 horas y levetiracetam 500 mg cada 12 horas endovenosos. Durante el ingreso presenta dos episodios de crisis tónico-clónicas generalizadas con periodo poscrítico prolongado y disminución del nivel de conciencia, por lo que se añade lacosamida 200 mg cada 12 h y se aumenta levetiracetam a 1.000 mg cada 12 horas. Requiere ingreso en la Unidad de Cuidados Intensivos para observación durante 48 h, sin presentar nuevos episodios de comicialidad ni empeoramiento clínico. Inicia rehabilitación y seguimiento por parte de Psicooncología por cuadro de ansiedad e insomnio, que se controla con mirtazapina 15 mg al día. Se presenta el caso en comité de tumores y se desestima tratamiento quirúrgico por invasión leptomeníngea. Se decide tratamiento con radioterapia holocraneal (30 Gy en 10 fracciones) y posteriormente tratamiento con anti-PD-1. Instructions: please typing these entity words according to sentence: metástasis, metástasis, melanoma infiltrante, melanoma, metástasis, metástasis, metástasis, realce ependimario, afectación leptomeníngea, recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, afectación leptomeníngea, invasión leptomeníngea Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Se trata de una mujer de 50 años, con alergia al contraste yodado y a la metoclopramida, sin hábitos tóxicos, ni antecedentes laborales o familiares de interés. Tiene antecedentes patológicos de síndrome ansioso-depresivo de más de 20 años de evolución en tratamiento con duloxetina. Su historia oncológica se inicia en marzo de 2012, a raíz de cuadro de cefalea opresiva de predominio frontal y de obstrucción nasal izquierda, por lo que acude a consulta en múltiples ocasiones en médico de Atención Primaria y Urgencias Hospitalarias, orientándose como sinusitis refractaria a tratamiento médico. Exploración física Buen estado general. Dolor en la palpación de senos paranasales, de predominio maxilar izquierdo. Auscultación cardiorrespiratoria sin alteraciones. Abdomen blando y depresible, no es doloroso durante la palpación, sin masas ni hepatoesplenomegalia. Pruebas complementarias Se realiza una analítica en la que destaca LDH de 880 U/l con el resto de marcadores tumorales negativos y una radiografía de senos paranasales que muestra ocupación de seno maxilar izquierdo. Se completa estudio con resonancia magnética (RM) facial en la que aparece una lesión sólida expansiva en seno maxilar izquierdo que se extiende hasta fosa nasal izquierda, con infiltración de partes blandas. Como estudio de extensión, se realiza una tomografía computarizada (TC) torácica y abdominal que describe lesiones sugestivas de metástasis en ambos campos pulmonares, hígado, bazo, subcutáneas y adenopatías inguinales. También se realiza una gammagrafía ósea (GGO) y una RM craneal sin metástasis óseas ni en sistema nervioso central. Diagnóstico Se realiza una biopsia de la lesión en mucosa nasal izquierda que es compatible con melanoma infiltrante, con estudio molecular negativo para BRAF y KIT. Por ello, se diagnostica melanoma de mucosa de seno maxilar izquierdo no mutado, estadio IV (por metástasis hepáticas, pulmonares, esplénicas y cutáneas). Tratamiento Dada la ausencia de mutaciones que permitan beneficiarse de tratamiento antidiana, se decide iniciar tratamiento de primera línea dentro de ensayo clínico con ipilimumab (3 mg/kg vs. 10 mg/kg) por 4 ciclos, que finaliza en septiembre de 2012. Presenta muy buena tolerancia y obtiene una respuesta completa, por lo que inicia controles por RM craneal y TC toracoabdominal cada 3 meses hasta marzo de 2017 y posteriormente controles cada 6 meses. En el último control en septiembre de 2017, presenta una respuesta completa mantenida a los 5 años de finalizar el tratamiento. Evolución En enero de 2018, inicia cuadro de dolor cervicodorsolumbar progresivo por el que acude a la consulta del médico de Atención Primaria y Traumatología en diversas ocasiones, se realiza RM lumbar y GGO que no muestran alteraciones ni lesiones sugestivas de metástasis. A finales de febrero ingresa por diversos episodios de crisis comicial de ausencia, con TC craneal que muestra dos lesiones sólidas con signos de sangrado y dilatación del sistema ventricular. Se completa estudio con RM cerebral que informa de dos lesiones intraventriculares sugestivas de metástasis en asta frontal izquierda de 15 x 16 mm y atrio ventricular izquierdo de 24 x 23 mm, con hidrocefalia arreabsortiva por sangrado intraventricular y realce ependimario del atrio ventricular que no permite descartar diseminación del líquido cefalorraquídeo ni afectación leptomeníngea. Se realiza también TC toracoabdominal que no evidencia diseminación de enfermedad a otros niveles. Se orienta como recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, con posible afectación leptomeníngea, a los 5 años y 6 meses de finalizar tratamiento. Se inicia tratamiento corticoide y anticomicial con dexametasona 4 mg cada 6 horas y levetiracetam 500 mg cada 12 horas endovenosos. Durante el ingreso presenta dos episodios de crisis tónico-clónicas generalizadas con periodo poscrítico prolongado y disminución del nivel de conciencia, por lo que se añade lacosamida 200 mg cada 12 h y se aumenta levetiracetam a 1.000 mg cada 12 horas. Requiere ingreso en la Unidad de Cuidados Intensivos para observación durante 48 h, sin presentar nuevos episodios de comicialidad ni empeoramiento clínico. Inicia rehabilitación y seguimiento por parte de Psicooncología por cuadro de ansiedad e insomnio, que se controla con mirtazapina 15 mg al día. Se presenta el caso en comité de tumores y se desestima tratamiento quirúrgico por invasión leptomeníngea. Se decide tratamiento con radioterapia holocraneal (30 Gy en 10 fracciones) y posteriormente tratamiento con anti-PD-1.	[ "Anamnesis", "\n", "Se", "trata", "de", "una", "mujer", "de", "50", "años", ",", "con", "alergia", "al", "contraste", "yodado", "y", "a", "la", "metoclopramida", ",", "sin", "hábitos", "tóxicos", ",", "ni", "antecedentes", "laborales", "o", "familiares", "de", "interés", ".", "Tiene", "antecedentes", "patológicos", "de", "síndrome", "ansioso", "-", "depresivo", "de", "más", "de", "20", "años", "de", "evolución", "en", "tratamiento", "con", "duloxetina", ".", "\n", "Su", "historia", "oncológica", "se", "inicia", "en", "marzo", "de", "2012", ",", "a", "raíz", "de", "cuadro", "de", "cefalea", "opresiva", "de", "predominio", "frontal", "y", "de", "obstrucción", "nasal", "izquierda", ",", "por", "lo", "que", "acude", "a", "consulta", "en", "múltiples", "ocasiones", "en", "médico", "de", "Atención", "Primaria", "y", "Urgencias", "Hospitalarias", ",", "orientándose", "como", "sinusitis", "refractaria", "a", "tratamiento", "médico", ".", "\n\n", "Exploración", "física", "\n", "Buen", "estado", "general", ".", "Dolor", "en", "la", "palpación", "de", "senos", "paranasales", ",", "de", "predominio", "maxilar", "izquierdo", ".", "Auscultación", "cardiorrespiratoria", "sin", "alteraciones", ".", "Abdomen", "blando", "y", "depresible", ",", "no", "es", "doloroso", "durante", "la", "palpación", ",", "sin", "masas", "ni", "hepatoesplenomegalia", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "analítica", "en", "la", "que", "destaca", "LDH", "de", "880", "U", "/", "l", "con", "el", "resto", "de", "marcadores", "tumorales", "negativos", "y", "una", "radiografía", "de", "senos", "paranasales", "que", "muestra", "ocupación", "de", "seno", "maxilar", "izquierdo", ".", "Se", "completa", "estudio", "con", "resonancia", "magnética", "(", "RM", ")", "facial", "en", "la", "que", "aparece", "una", "lesión", "sólida", "expansiva", "en", "seno", "maxilar", "izquierdo", "que", "se", "extiende", "hasta", "fosa", "nasal", "izquierda", ",", "con", "infiltración", "de", "partes", "blandas", ".", "\n", "Como", "estudio", "de", "extensión", ",", "se", "realiza", "una", "tomografía", "computarizada", "(", "TC", ")", "torácica", "y", "abdominal", "que", "describe", "lesiones", "sugestivas", "de", "metástasis", "en", "ambos", "campos", "pulmonares", ",", "hígado", ",", "bazo", ",", "subcutáneas", "y", "adenopatías", "inguinales", ".", "También", "se", "realiza", "una", "gammagrafía", "ósea", "(", "GGO", ")", "y", "una", "RM", "craneal", "sin", "metástasis", "óseas", "ni", "en", "sistema", "nervioso", "central", ".", "\n\n", "Diagnóstico", "\n", "Se", "realiza", "una", "biopsia", "de", "la", "lesión", "en", "mucosa", "nasal", "izquierda", "que", "es", "compatible", "con", "melanoma", "infiltrante", ",", "con", "estudio", "molecular", "negativo", "para", "BRAF", "y", "KIT", ".", "Por", "ello", ",", "se", "diagnostica", "melanoma", "de", "mucosa", "de", "seno", "maxilar", "izquierdo", "no", "mutado", ",", "estadio", "IV", "(", "por", "metástasis", "hepáticas", ",", "pulmonares", ",", "esplénicas", "y", "cutáneas", ")", ".", "\n\n", "Tratamiento", "\n", "Dada", "la", "ausencia", "de", "mutaciones", "que", "permitan", "beneficiarse", "de", "tratamiento", "antidiana", ",", "se", "decide", "iniciar", "tratamiento", "de", "primera", "línea", "dentro", "de", "ensayo", "clínico", "con", "ipilimumab", "(", "3", "mg", "/", "kg", "vs", ".", "10", "mg", "/", "kg", ")", "por", "4", "ciclos", ",", "que", "finaliza", "en", "septiembre", "de", "2012", ".", "\n", "Presenta", "muy", "buena", "tolerancia", "y", "obtiene", "una", "respuesta", "completa", ",", "por", "lo", "que", "inicia", "controles", "por", "RM", "craneal", "y", "TC", "toracoabdominal", "cada", "3", "meses", "hasta", "marzo", "de", "2017", "y", "posteriormente", "controles", "cada", "6", "meses", ".", "En", "el", "último", "control", "en", "septiembre", "de", "2017", ",", "presenta", "una", "respuesta", "completa", "mantenida", "a", "los", "5", "años", "de", "finalizar", "el", "tratamiento", ".", "\n\n", "Evolución", "\n", "En", "enero", "de", "2018", ",", "inicia", "cuadro", "de", "dolor", "cervicodorsolumbar", "progresivo", "por", "el", "que", "acude", "a", "la", "consulta", "del", "médico", "de", "Atención", "Primaria", "y", "Traumatología", "en", "diversas", "ocasiones", ",", "se", "realiza", "RM", "lumbar", "y", "GGO", "que", "no", "muestran", "alteraciones", "ni", "lesiones", "sugestivas", "de", "metástasis", ".", "\n", "A", "finales", "de", "febrero", "ingresa", "por", "diversos", "episodios", "de", "crisis", "comicial", "de", "ausencia", ",", "con", "TC", "craneal", "que", "muestra", "dos", "lesiones", "sólidas", "con", "signos", "de", "sangrado", "y", "dilatación", "del", "sistema", "ventricular", ".", "Se", "completa", "estudio", "con", "RM", "cerebral", "que", "informa", "de", "dos", "lesiones", "intraventriculares", "sugestivas", "de", "metástasis", "en", "asta", "frontal", "izquierda", "de", "15", "x", "16", "mm", "y", "atrio", "ventricular", "izquierdo", "de", "24", "x", "23", "mm", ",", "con", "hidrocefalia", "arreabsortiva", "por", "sangrado", "intraventricular", "y", "realce", "ependimario", "del", "atrio", "ventricular", "que", "no", "permite", "descartar", "diseminación", "del", "líquido", "cefalorraquídeo", "ni", "afectación", "leptomeníngea", ".", "Se", "realiza", "también", "TC", "toracoabdominal", "que", "no", "evidencia", "diseminación", "de", "enfermedad", "a", "otros", "niveles", ".", "Se", "orienta", "como", "recidiva", "de", "melanoma", "maligno", "de", "mucosa", "a", "nivel", "de", "sistema", "nervioso", "central", ",", "con", "posible", "afectación", "leptomeníngea", ",", "a", "los", "5", "años", "y", "6", "meses", "de", "finalizar", "tratamiento", ".", "\n", "Se", "inicia", "tratamiento", "corticoide", "y", "anticomicial", "con", "dexametasona", "4", "mg", "cada", "6", "horas", "y", "levetiracetam", "500", "mg", "cada", "12", "horas", "endovenosos", ".", "Durante", "el", "ingreso", "presenta", "dos", "episodios", "de", "crisis", "tónico", "-", "clónicas", "generalizadas", "con", "periodo", "poscrítico", "prolongado", "y", "disminución", "del", "nivel", "de", "conciencia", ",", "por", "lo", "que", "se", "añade", "lacosamida", "200", "mg", "cada", "12", "h", "y", "se", "aumenta", "levetiracetam", "a", "1.000", "mg", "cada", "12", "horas", ".", "Requiere", "ingreso", "en", "la", "Unidad", "de", "Cuidados", "Intensivos", "para", "observación", "durante", "48", "h", ",", "sin", "presentar", "nuevos", "episodios", "de", "comicialidad", "ni", "empeoramiento", "clínico", ".", "Inicia", "rehabilitación", "y", "seguimiento", "por", "parte", "de", "Psicooncología", "por", "cuadro", "de", "ansiedad", "e", "insomnio", ",", "que", "se", "controla", "con", "mirtazapina", "15", "mg", "al", "día", ".", "\n", "Se", "presenta", "el", "caso", "en", "comité", "de", "tumores", "y", "se", "desestima", "tratamiento", "quirúrgico", "por", "invasión", "leptomeníngea", ".", "Se", "decide", "tratamiento", "con", "radioterapia", "holocraneal", "(", "30", "Gy", "en", "10", "fracciones", ")", "y", "posteriormente", "tratamiento", "con", "anti", "-", "PD-1", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
metástasis, metástasis, melanoma infiltrante, melanoma, metástasis, metástasis, metástasis, realce ependimario, afectación leptomeníngea, recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, afectación leptomeníngea, invasión leptomeníngea	715_task2	Sentence: Anamnesis Se trata de una mujer de 50 años, con alergia al contraste yodado y a la metoclopramida, sin hábitos tóxicos, ni antecedentes laborales o familiares de interés. Tiene antecedentes patológicos de síndrome ansioso-depresivo de más de 20 años de evolución en tratamiento con duloxetina. Su historia oncológica se inicia en marzo de 2012, a raíz de cuadro de cefalea opresiva de predominio frontal y de obstrucción nasal izquierda, por lo que acude a consulta en múltiples ocasiones en médico de Atención Primaria y Urgencias Hospitalarias, orientándose como sinusitis refractaria a tratamiento médico. Exploración física Buen estado general. Dolor en la palpación de senos paranasales, de predominio maxilar izquierdo. Auscultación cardiorrespiratoria sin alteraciones. Abdomen blando y depresible, no es doloroso durante la palpación, sin masas ni hepatoesplenomegalia. Pruebas complementarias Se realiza una analítica en la que destaca LDH de 880 U/l con el resto de marcadores tumorales negativos y una radiografía de senos paranasales que muestra ocupación de seno maxilar izquierdo. Se completa estudio con resonancia magnética (RM) facial en la que aparece una lesión sólida expansiva en seno maxilar izquierdo que se extiende hasta fosa nasal izquierda, con infiltración de partes blandas. Como estudio de extensión, se realiza una tomografía computarizada (TC) torácica y abdominal que describe lesiones sugestivas de metástasis en ambos campos pulmonares, hígado, bazo, subcutáneas y adenopatías inguinales. También se realiza una gammagrafía ósea (GGO) y una RM craneal sin metástasis óseas ni en sistema nervioso central. Diagnóstico Se realiza una biopsia de la lesión en mucosa nasal izquierda que es compatible con melanoma infiltrante, con estudio molecular negativo para BRAF y KIT. Por ello, se diagnostica melanoma de mucosa de seno maxilar izquierdo no mutado, estadio IV (por metástasis hepáticas, pulmonares, esplénicas y cutáneas). Tratamiento Dada la ausencia de mutaciones que permitan beneficiarse de tratamiento antidiana, se decide iniciar tratamiento de primera línea dentro de ensayo clínico con ipilimumab (3 mg/kg vs. 10 mg/kg) por 4 ciclos, que finaliza en septiembre de 2012. Presenta muy buena tolerancia y obtiene una respuesta completa, por lo que inicia controles por RM craneal y TC toracoabdominal cada 3 meses hasta marzo de 2017 y posteriormente controles cada 6 meses. En el último control en septiembre de 2017, presenta una respuesta completa mantenida a los 5 años de finalizar el tratamiento. Evolución En enero de 2018, inicia cuadro de dolor cervicodorsolumbar progresivo por el que acude a la consulta del médico de Atención Primaria y Traumatología en diversas ocasiones, se realiza RM lumbar y GGO que no muestran alteraciones ni lesiones sugestivas de metástasis. A finales de febrero ingresa por diversos episodios de crisis comicial de ausencia, con TC craneal que muestra dos lesiones sólidas con signos de sangrado y dilatación del sistema ventricular. Se completa estudio con RM cerebral que informa de dos lesiones intraventriculares sugestivas de metástasis en asta frontal izquierda de 15 x 16 mm y atrio ventricular izquierdo de 24 x 23 mm, con hidrocefalia arreabsortiva por sangrado intraventricular y realce ependimario del atrio ventricular que no permite descartar diseminación del líquido cefalorraquídeo ni afectación leptomeníngea. Se realiza también TC toracoabdominal que no evidencia diseminación de enfermedad a otros niveles. Se orienta como recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, con posible afectación leptomeníngea, a los 5 años y 6 meses de finalizar tratamiento. Se inicia tratamiento corticoide y anticomicial con dexametasona 4 mg cada 6 horas y levetiracetam 500 mg cada 12 horas endovenosos. Durante el ingreso presenta dos episodios de crisis tónico-clónicas generalizadas con periodo poscrítico prolongado y disminución del nivel de conciencia, por lo que se añade lacosamida 200 mg cada 12 h y se aumenta levetiracetam a 1.000 mg cada 12 horas. Requiere ingreso en la Unidad de Cuidados Intensivos para observación durante 48 h, sin presentar nuevos episodios de comicialidad ni empeoramiento clínico. Inicia rehabilitación y seguimiento por parte de Psicooncología por cuadro de ansiedad e insomnio, que se controla con mirtazapina 15 mg al día. Se presenta el caso en comité de tumores y se desestima tratamiento quirúrgico por invasión leptomeníngea. Se decide tratamiento con radioterapia holocraneal (30 Gy en 10 fracciones) y posteriormente tratamiento con anti-PD-1. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Se trata de una mujer de 50 años, con alergia al contraste yodado y a la metoclopramida, sin hábitos tóxicos, ni antecedentes laborales o familiares de interés. Tiene antecedentes patológicos de síndrome ansioso-depresivo de más de 20 años de evolución en tratamiento con duloxetina. Su historia oncológica se inicia en marzo de 2012, a raíz de cuadro de cefalea opresiva de predominio frontal y de obstrucción nasal izquierda, por lo que acude a consulta en múltiples ocasiones en médico de Atención Primaria y Urgencias Hospitalarias, orientándose como sinusitis refractaria a tratamiento médico. Exploración física Buen estado general. Dolor en la palpación de senos paranasales, de predominio maxilar izquierdo. Auscultación cardiorrespiratoria sin alteraciones. Abdomen blando y depresible, no es doloroso durante la palpación, sin masas ni hepatoesplenomegalia. Pruebas complementarias Se realiza una analítica en la que destaca LDH de 880 U/l con el resto de marcadores tumorales negativos y una radiografía de senos paranasales que muestra ocupación de seno maxilar izquierdo. Se completa estudio con resonancia magnética (RM) facial en la que aparece una lesión sólida expansiva en seno maxilar izquierdo que se extiende hasta fosa nasal izquierda, con infiltración de partes blandas. Como estudio de extensión, se realiza una tomografía computarizada (TC) torácica y abdominal que describe lesiones sugestivas de metástasis en ambos campos pulmonares, hígado, bazo, subcutáneas y adenopatías inguinales. También se realiza una gammagrafía ósea (GGO) y una RM craneal sin metástasis óseas ni en sistema nervioso central. Diagnóstico Se realiza una biopsia de la lesión en mucosa nasal izquierda que es compatible con melanoma infiltrante, con estudio molecular negativo para BRAF y KIT. Por ello, se diagnostica melanoma de mucosa de seno maxilar izquierdo no mutado, estadio IV (por metástasis hepáticas, pulmonares, esplénicas y cutáneas). Tratamiento Dada la ausencia de mutaciones que permitan beneficiarse de tratamiento antidiana, se decide iniciar tratamiento de primera línea dentro de ensayo clínico con ipilimumab (3 mg/kg vs. 10 mg/kg) por 4 ciclos, que finaliza en septiembre de 2012. Presenta muy buena tolerancia y obtiene una respuesta completa, por lo que inicia controles por RM craneal y TC toracoabdominal cada 3 meses hasta marzo de 2017 y posteriormente controles cada 6 meses. En el último control en septiembre de 2017, presenta una respuesta completa mantenida a los 5 años de finalizar el tratamiento. Evolución En enero de 2018, inicia cuadro de dolor cervicodorsolumbar progresivo por el que acude a la consulta del médico de Atención Primaria y Traumatología en diversas ocasiones, se realiza RM lumbar y GGO que no muestran alteraciones ni lesiones sugestivas de metástasis. A finales de febrero ingresa por diversos episodios de crisis comicial de ausencia, con TC craneal que muestra dos lesiones sólidas con signos de sangrado y dilatación del sistema ventricular. Se completa estudio con RM cerebral que informa de dos lesiones intraventriculares sugestivas de metástasis en asta frontal izquierda de 15 x 16 mm y atrio ventricular izquierdo de 24 x 23 mm, con hidrocefalia arreabsortiva por sangrado intraventricular y realce ependimario del atrio ventricular que no permite descartar diseminación del líquido cefalorraquídeo ni afectación leptomeníngea. Se realiza también TC toracoabdominal que no evidencia diseminación de enfermedad a otros niveles. Se orienta como recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, con posible afectación leptomeníngea, a los 5 años y 6 meses de finalizar tratamiento. Se inicia tratamiento corticoide y anticomicial con dexametasona 4 mg cada 6 horas y levetiracetam 500 mg cada 12 horas endovenosos. Durante el ingreso presenta dos episodios de crisis tónico-clónicas generalizadas con periodo poscrítico prolongado y disminución del nivel de conciencia, por lo que se añade lacosamida 200 mg cada 12 h y se aumenta levetiracetam a 1.000 mg cada 12 horas. Requiere ingreso en la Unidad de Cuidados Intensivos para observación durante 48 h, sin presentar nuevos episodios de comicialidad ni empeoramiento clínico. Inicia rehabilitación y seguimiento por parte de Psicooncología por cuadro de ansiedad e insomnio, que se controla con mirtazapina 15 mg al día. Se presenta el caso en comité de tumores y se desestima tratamiento quirúrgico por invasión leptomeníngea. Se decide tratamiento con radioterapia holocraneal (30 Gy en 10 fracciones) y posteriormente tratamiento con anti-PD-1.	[ "Anamnesis", "\n", "Se", "trata", "de", "una", "mujer", "de", "50", "años", ",", "con", "alergia", "al", "contraste", "yodado", "y", "a", "la", "metoclopramida", ",", "sin", "hábitos", "tóxicos", ",", "ni", "antecedentes", "laborales", "o", "familiares", "de", "interés", ".", "Tiene", "antecedentes", "patológicos", "de", "síndrome", "ansioso", "-", "depresivo", "de", "más", "de", "20", "años", "de", "evolución", "en", "tratamiento", "con", "duloxetina", ".", "\n", "Su", "historia", "oncológica", "se", "inicia", "en", "marzo", "de", "2012", ",", "a", "raíz", "de", "cuadro", "de", "cefalea", "opresiva", "de", "predominio", "frontal", "y", "de", "obstrucción", "nasal", "izquierda", ",", "por", "lo", "que", "acude", "a", "consulta", "en", "múltiples", "ocasiones", "en", "médico", "de", "Atención", "Primaria", "y", "Urgencias", "Hospitalarias", ",", "orientándose", "como", "sinusitis", "refractaria", "a", "tratamiento", "médico", ".", "\n\n", "Exploración", "física", "\n", "Buen", "estado", "general", ".", "Dolor", "en", "la", "palpación", "de", "senos", "paranasales", ",", "de", "predominio", "maxilar", "izquierdo", ".", "Auscultación", "cardiorrespiratoria", "sin", "alteraciones", ".", "Abdomen", "blando", "y", "depresible", ",", "no", "es", "doloroso", "durante", "la", "palpación", ",", "sin", "masas", "ni", "hepatoesplenomegalia", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "analítica", "en", "la", "que", "destaca", "LDH", "de", "880", "U", "/", "l", "con", "el", "resto", "de", "marcadores", "tumorales", "negativos", "y", "una", "radiografía", "de", "senos", "paranasales", "que", "muestra", "ocupación", "de", "seno", "maxilar", "izquierdo", ".", "Se", "completa", "estudio", "con", "resonancia", "magnética", "(", "RM", ")", "facial", "en", "la", "que", "aparece", "una", "lesión", "sólida", "expansiva", "en", "seno", "maxilar", "izquierdo", "que", "se", "extiende", "hasta", "fosa", "nasal", "izquierda", ",", "con", "infiltración", "de", "partes", "blandas", ".", "\n", "Como", "estudio", "de", "extensión", ",", "se", "realiza", "una", "tomografía", "computarizada", "(", "TC", ")", "torácica", "y", "abdominal", "que", "describe", "lesiones", "sugestivas", "de", "metástasis", "en", "ambos", "campos", "pulmonares", ",", "hígado", ",", "bazo", ",", "subcutáneas", "y", "adenopatías", "inguinales", ".", "También", "se", "realiza", "una", "gammagrafía", "ósea", "(", "GGO", ")", "y", "una", "RM", "craneal", "sin", "metástasis", "óseas", "ni", "en", "sistema", "nervioso", "central", ".", "\n\n", "Diagnóstico", "\n", "Se", "realiza", "una", "biopsia", "de", "la", "lesión", "en", "mucosa", "nasal", "izquierda", "que", "es", "compatible", "con", "melanoma", "infiltrante", ",", "con", "estudio", "molecular", "negativo", "para", "BRAF", "y", "KIT", ".", "Por", "ello", ",", "se", "diagnostica", "melanoma", "de", "mucosa", "de", "seno", "maxilar", "izquierdo", "no", "mutado", ",", "estadio", "IV", "(", "por", "metástasis", "hepáticas", ",", "pulmonares", ",", "esplénicas", "y", "cutáneas", ")", ".", "\n\n", "Tratamiento", "\n", "Dada", "la", "ausencia", "de", "mutaciones", "que", "permitan", "beneficiarse", "de", "tratamiento", "antidiana", ",", "se", "decide", "iniciar", "tratamiento", "de", "primera", "línea", "dentro", "de", "ensayo", "clínico", "con", "ipilimumab", "(", "3", "mg", "/", "kg", "vs", ".", "10", "mg", "/", "kg", ")", "por", "4", "ciclos", ",", "que", "finaliza", "en", "septiembre", "de", "2012", ".", "\n", "Presenta", "muy", "buena", "tolerancia", "y", "obtiene", "una", "respuesta", "completa", ",", "por", "lo", "que", "inicia", "controles", "por", "RM", "craneal", "y", "TC", "toracoabdominal", "cada", "3", "meses", "hasta", "marzo", "de", "2017", "y", "posteriormente", "controles", "cada", "6", "meses", ".", "En", "el", "último", "control", "en", "septiembre", "de", "2017", ",", "presenta", "una", "respuesta", "completa", "mantenida", "a", "los", "5", "años", "de", "finalizar", "el", "tratamiento", ".", "\n\n", "Evolución", "\n", "En", "enero", "de", "2018", ",", "inicia", "cuadro", "de", "dolor", "cervicodorsolumbar", "progresivo", "por", "el", "que", "acude", "a", "la", "consulta", "del", "médico", "de", "Atención", "Primaria", "y", "Traumatología", "en", "diversas", "ocasiones", ",", "se", "realiza", "RM", "lumbar", "y", "GGO", "que", "no", "muestran", "alteraciones", "ni", "lesiones", "sugestivas", "de", "metástasis", ".", "\n", "A", "finales", "de", "febrero", "ingresa", "por", "diversos", "episodios", "de", "crisis", "comicial", "de", "ausencia", ",", "con", "TC", "craneal", "que", "muestra", "dos", "lesiones", "sólidas", "con", "signos", "de", "sangrado", "y", "dilatación", "del", "sistema", "ventricular", ".", "Se", "completa", "estudio", "con", "RM", "cerebral", "que", "informa", "de", "dos", "lesiones", "intraventriculares", "sugestivas", "de", "metástasis", "en", "asta", "frontal", "izquierda", "de", "15", "x", "16", "mm", "y", "atrio", "ventricular", "izquierdo", "de", "24", "x", "23", "mm", ",", "con", "hidrocefalia", "arreabsortiva", "por", "sangrado", "intraventricular", "y", "realce", "ependimario", "del", "atrio", "ventricular", "que", "no", "permite", "descartar", "diseminación", "del", "líquido", "cefalorraquídeo", "ni", "afectación", "leptomeníngea", ".", "Se", "realiza", "también", "TC", "toracoabdominal", "que", "no", "evidencia", "diseminación", "de", "enfermedad", "a", "otros", "niveles", ".", "Se", "orienta", "como", "recidiva", "de", "melanoma", "maligno", "de", "mucosa", "a", "nivel", "de", "sistema", "nervioso", "central", ",", "con", "posible", "afectación", "leptomeníngea", ",", "a", "los", "5", "años", "y", "6", "meses", "de", "finalizar", "tratamiento", ".", "\n", "Se", "inicia", "tratamiento", "corticoide", "y", "anticomicial", "con", "dexametasona", "4", "mg", "cada", "6", "horas", "y", "levetiracetam", "500", "mg", "cada", "12", "horas", "endovenosos", ".", "Durante", "el", "ingreso", "presenta", "dos", "episodios", "de", "crisis", "tónico", "-", "clónicas", "generalizadas", "con", "periodo", "poscrítico", "prolongado", "y", "disminución", "del", "nivel", "de", "conciencia", ",", "por", "lo", "que", "se", "añade", "lacosamida", "200", "mg", "cada", "12", "h", "y", "se", "aumenta", "levetiracetam", "a", "1.000", "mg", "cada", "12", "horas", ".", "Requiere", "ingreso", "en", "la", "Unidad", "de", "Cuidados", "Intensivos", "para", "observación", "durante", "48", "h", ",", "sin", "presentar", "nuevos", "episodios", "de", "comicialidad", "ni", "empeoramiento", "clínico", ".", "Inicia", "rehabilitación", "y", "seguimiento", "por", "parte", "de", "Psicooncología", "por", "cuadro", "de", "ansiedad", "e", "insomnio", ",", "que", "se", "controla", "con", "mirtazapina", "15", "mg", "al", "día", ".", "\n", "Se", "presenta", "el", "caso", "en", "comité", "de", "tumores", "y", "se", "desestima", "tratamiento", "quirúrgico", "por", "invasión", "leptomeníngea", ".", "Se", "decide", "tratamiento", "con", "radioterapia", "holocraneal", "(", "30", "Gy", "en", "10", "fracciones", ")", "y", "posteriormente", "tratamiento", "con", "anti", "-", "PD-1", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
Ipratropium bromide nasal spray is a Intervention_Pharmacological, rhinorrhea is a Participant_Condition, laryngectomized patient is a Participant_Condition, total laryngectomy is a Participant_Condition, ipratropium bromide ( IB ) is a Intervention_Pharmacological, placebo - controlled is a Intervention_Control, severity is a Outcome_Physical, duration of their rhinorrhea is a Outcome_Physical, saline nasal spray is a Intervention_Control, Six is a Participant_Sample-size, decline in severity is a Outcome_Other, decline in duration of the rhinorrhea is a Outcome_Physical, severity and duration of rhinorrhea is a Outcome_Physical, Wilcoxon signed - rank test is a Outcome_Other, quality of life is a Outcome_Other	6706_task0	Sentence: Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient : a pilot study . Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control . This study was undertaken to evaluate the effect of ipratropium bromide ( IB ) , an anticholinergic nasal spray , on rhinorrhea in these patients . This was designed as a prospective , randomized , double-blind , placebo-controlled , crossover pilot study . Participants were selected if they had a total laryngectomy and complained of rhinorrhea . They were asked to rate the severity and duration of their rhinorrhea each day throughout the study on a scale from zero to six . Each participant was initially given a saline nasal spray for one week . They were then randomized to use either IB or saline for the double-blinded portion of the study . Two sprays of IB at a dose of 42 micrograms/spray ( 0.06 % ) , or saline , were administered intranasally twice daily for two weeks , after which time the participants were given another nasal spray ( either IB or saline ) for the crossover portion of the study . Six patients entered and completed the study . Those patients using the IB recorded a mean 55 % decline in severity and a mean 51 % decline in duration of the rhinorrhea as compared to placebo . The relief in both severity and duration of rhinorrhea obtained by patients was analyzed using the Wilcoxon signed-rank test and found to be highly significant ( p < 0.001 ) . Despite the limitations of a small sample size in this study , ipratropium bromide nasal spray significantly reduced both the severity and duration of rhinorrhea in laryngectomized patients . We suggest ipratropium nasal spray as a safe , effective way to treat chronic rhinorrhea in laryngectomized patients , improving their quality of life . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]	Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient : a pilot study . Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control . This study was undertaken to evaluate the effect of ipratropium bromide ( IB ) , an anticholinergic nasal spray , on rhinorrhea in these patients . This was designed as a prospective , randomized , double-blind , placebo-controlled , crossover pilot study . Participants were selected if they had a total laryngectomy and complained of rhinorrhea . They were asked to rate the severity and duration of their rhinorrhea each day throughout the study on a scale from zero to six . Each participant was initially given a saline nasal spray for one week . They were then randomized to use either IB or saline for the double-blinded portion of the study . Two sprays of IB at a dose of 42 micrograms/spray ( 0.06 % ) , or saline , were administered intranasally twice daily for two weeks , after which time the participants were given another nasal spray ( either IB or saline ) for the crossover portion of the study . Six patients entered and completed the study . Those patients using the IB recorded a mean 55 % decline in severity and a mean 51 % decline in duration of the rhinorrhea as compared to placebo . The relief in both severity and duration of rhinorrhea obtained by patients was analyzed using the Wilcoxon signed-rank test and found to be highly significant ( p < 0.001 ) . Despite the limitations of a small sample size in this study , ipratropium bromide nasal spray significantly reduced both the severity and duration of rhinorrhea in laryngectomized patients . We suggest ipratropium nasal spray as a safe , effective way to treat chronic rhinorrhea in laryngectomized patients , improving their quality of life .	[ "Ipratropium", "bromide", "nasal", "spray", "for", "treatment", "of", "rhinorrhea", "in", "the", "laryngectomized", "patient", ":", "a", "pilot", "study", ".", "Many", "who", "have", "had", "a", "total", "laryngectomy", "complain", "of", "unrelenting", "rhinorrhea", "that", "is", "often", "very", "difficult", "to", "control", ".", "This", "study", "was", "undertaken", "to", "evaluate", "the", "effect", "of", "ipratropium", "bromide", "(", "IB", ")", ",", "an", "anticholinergic", "nasal", "spray", ",", "on", "rhinorrhea", "in", "these", "patients", ".", "This", "was", "designed", "as", "a", "prospective", ",", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "crossover", "pilot", "study", ".", "Participants", "were", "selected", "if", "they", "had", "a", "total", "laryngectomy", "and", "complained", "of", "rhinorrhea", ".", "They", "were", "asked", "to", "rate", "the", "severity", "and", "duration", "of", "their", "rhinorrhea", "each", "day", "throughout", "the", "study", "on", "a", "scale", "from", "zero", "to", "six", ".", "Each", "participant", "was", "initially", "given", "a", "saline", "nasal", "spray", "for", "one", "week", ".", "They", "were", "then", "randomized", "to", "use", "either", "IB", "or", "saline", "for", "the", "double", "-", "blinded", "portion", "of", "the", "study", ".", "Two", "sprays", "of", "IB", "at", "a", "dose", "of", "42", "micrograms", "/", "spray", "(", "0.06", "%", ")", ",", "or", "saline", ",", "were", "administered", "intranasally", "twice", "daily", "for", "two", "weeks", ",", "after", "which", "time", "the", "participants", "were", "given", "another", "nasal", "spray", "(", "either", "IB", "or", "saline", ")", "for", "the", "crossover", "portion", "of", "the", "study", ".", "Six", "patients", "entered", "and", "completed", "the", "study", ".", "Those", "patients", "using", "the", "IB", "recorded", "a", "mean", "55", "%", "decline", "in", "severity", "and", "a", "mean", "51", "%", "decline", "in", "duration", "of", "the", "rhinorrhea", "as", "compared", "to", "placebo", ".", "The", "relief", "in", "both", "severity", "and", "duration", "of", "rhinorrhea", "obtained", "by", "patients", "was", "analyzed", "using", "the", "Wilcoxon", "signed", "-", "rank", "test", "and", "found", "to", "be", "highly", "significant", "(", "p", "<", "0.001", ")", ".", "Despite", "the", "limitations", "of", "a", "small", "sample", "size", "in", "this", "study", ",", "ipratropium", "bromide", "nasal", "spray", "significantly", "reduced", "both", "the", "severity", "and", "duration", "of", "rhinorrhea", "in", "laryngectomized", "patients", ".", "We", "suggest", "ipratropium", "nasal", "spray", "as", "a", "safe", ",", "effective", "way", "to", "treat", "chronic", "rhinorrhea", "in", "laryngectomized", "patients", ",", "improving", "their", "quality", "of", "life", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Intervention_Control", "Participant_Sample-size" ]
Ipratropium bromide nasal spray is a Intervention_Pharmacological, rhinorrhea is a Participant_Condition, laryngectomized patient is a Participant_Condition, total laryngectomy is a Participant_Condition, ipratropium bromide ( IB ) is a Intervention_Pharmacological, placebo - controlled is a Intervention_Control, severity is a Outcome_Physical, duration of their rhinorrhea is a Outcome_Physical, saline nasal spray is a Intervention_Control, Six is a Participant_Sample-size, decline in severity is a Outcome_Other, decline in duration of the rhinorrhea is a Outcome_Physical, severity and duration of rhinorrhea is a Outcome_Physical, Wilcoxon signed - rank test is a Outcome_Other, quality of life is a Outcome_Other	6706_task1	Sentence: Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient : a pilot study . Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control . This study was undertaken to evaluate the effect of ipratropium bromide ( IB ) , an anticholinergic nasal spray , on rhinorrhea in these patients . This was designed as a prospective , randomized , double-blind , placebo-controlled , crossover pilot study . Participants were selected if they had a total laryngectomy and complained of rhinorrhea . They were asked to rate the severity and duration of their rhinorrhea each day throughout the study on a scale from zero to six . Each participant was initially given a saline nasal spray for one week . They were then randomized to use either IB or saline for the double-blinded portion of the study . Two sprays of IB at a dose of 42 micrograms/spray ( 0.06 % ) , or saline , were administered intranasally twice daily for two weeks , after which time the participants were given another nasal spray ( either IB or saline ) for the crossover portion of the study . Six patients entered and completed the study . Those patients using the IB recorded a mean 55 % decline in severity and a mean 51 % decline in duration of the rhinorrhea as compared to placebo . The relief in both severity and duration of rhinorrhea obtained by patients was analyzed using the Wilcoxon signed-rank test and found to be highly significant ( p < 0.001 ) . Despite the limitations of a small sample size in this study , ipratropium bromide nasal spray significantly reduced both the severity and duration of rhinorrhea in laryngectomized patients . We suggest ipratropium nasal spray as a safe , effective way to treat chronic rhinorrhea in laryngectomized patients , improving their quality of life . Instructions: please typing these entity words according to sentence: Ipratropium bromide nasal spray, rhinorrhea, laryngectomized patient, total laryngectomy, ipratropium bromide ( IB ), placebo - controlled, severity, duration of their rhinorrhea, saline nasal spray, Six, decline in severity, decline in duration of the rhinorrhea, severity and duration of rhinorrhea, Wilcoxon signed - rank test, quality of life Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]	Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient : a pilot study . Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control . This study was undertaken to evaluate the effect of ipratropium bromide ( IB ) , an anticholinergic nasal spray , on rhinorrhea in these patients . This was designed as a prospective , randomized , double-blind , placebo-controlled , crossover pilot study . Participants were selected if they had a total laryngectomy and complained of rhinorrhea . They were asked to rate the severity and duration of their rhinorrhea each day throughout the study on a scale from zero to six . Each participant was initially given a saline nasal spray for one week . They were then randomized to use either IB or saline for the double-blinded portion of the study . Two sprays of IB at a dose of 42 micrograms/spray ( 0.06 % ) , or saline , were administered intranasally twice daily for two weeks , after which time the participants were given another nasal spray ( either IB or saline ) for the crossover portion of the study . Six patients entered and completed the study . Those patients using the IB recorded a mean 55 % decline in severity and a mean 51 % decline in duration of the rhinorrhea as compared to placebo . The relief in both severity and duration of rhinorrhea obtained by patients was analyzed using the Wilcoxon signed-rank test and found to be highly significant ( p < 0.001 ) . Despite the limitations of a small sample size in this study , ipratropium bromide nasal spray significantly reduced both the severity and duration of rhinorrhea in laryngectomized patients . We suggest ipratropium nasal spray as a safe , effective way to treat chronic rhinorrhea in laryngectomized patients , improving their quality of life .	[ "Ipratropium", "bromide", "nasal", "spray", "for", "treatment", "of", "rhinorrhea", "in", "the", "laryngectomized", "patient", ":", "a", "pilot", "study", ".", "Many", "who", "have", "had", "a", "total", "laryngectomy", "complain", "of", "unrelenting", "rhinorrhea", "that", "is", "often", "very", "difficult", "to", "control", ".", "This", "study", "was", "undertaken", "to", "evaluate", "the", "effect", "of", "ipratropium", "bromide", "(", "IB", ")", ",", "an", "anticholinergic", "nasal", "spray", ",", "on", "rhinorrhea", "in", "these", "patients", ".", "This", "was", "designed", "as", "a", "prospective", ",", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "crossover", "pilot", "study", ".", "Participants", "were", "selected", "if", "they", "had", "a", "total", "laryngectomy", "and", "complained", "of", "rhinorrhea", ".", "They", "were", "asked", "to", "rate", "the", "severity", "and", "duration", "of", "their", "rhinorrhea", "each", "day", "throughout", "the", "study", "on", "a", "scale", "from", "zero", "to", "six", ".", "Each", "participant", "was", "initially", "given", "a", "saline", "nasal", "spray", "for", "one", "week", ".", "They", "were", "then", "randomized", "to", "use", "either", "IB", "or", "saline", "for", "the", "double", "-", "blinded", "portion", "of", "the", "study", ".", "Two", "sprays", "of", "IB", "at", "a", "dose", "of", "42", "micrograms", "/", "spray", "(", "0.06", "%", ")", ",", "or", "saline", ",", "were", "administered", "intranasally", "twice", "daily", "for", "two", "weeks", ",", "after", "which", "time", "the", "participants", "were", "given", "another", "nasal", "spray", "(", "either", "IB", "or", "saline", ")", "for", "the", "crossover", "portion", "of", "the", "study", ".", "Six", "patients", "entered", "and", "completed", "the", "study", ".", "Those", "patients", "using", "the", "IB", "recorded", "a", "mean", "55", "%", "decline", "in", "severity", "and", "a", "mean", "51", "%", "decline", "in", "duration", "of", "the", "rhinorrhea", "as", "compared", "to", "placebo", ".", "The", "relief", "in", "both", "severity", "and", "duration", "of", "rhinorrhea", "obtained", "by", "patients", "was", "analyzed", "using", "the", "Wilcoxon", "signed", "-", "rank", "test", "and", "found", "to", "be", "highly", "significant", "(", "p", "<", "0.001", ")", ".", "Despite", "the", "limitations", "of", "a", "small", "sample", "size", "in", "this", "study", ",", "ipratropium", "bromide", "nasal", "spray", "significantly", "reduced", "both", "the", "severity", "and", "duration", "of", "rhinorrhea", "in", "laryngectomized", "patients", ".", "We", "suggest", "ipratropium", "nasal", "spray", "as", "a", "safe", ",", "effective", "way", "to", "treat", "chronic", "rhinorrhea", "in", "laryngectomized", "patients", ",", "improving", "their", "quality", "of", "life", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Intervention_Control", "Participant_Sample-size" ]
Ipratropium bromide nasal spray, rhinorrhea, laryngectomized patient, total laryngectomy, ipratropium bromide ( IB ), placebo - controlled, severity, duration of their rhinorrhea, saline nasal spray, Six, decline in severity, decline in duration of the rhinorrhea, severity and duration of rhinorrhea, Wilcoxon signed - rank test, quality of life	6706_task2	Sentence: Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient : a pilot study . Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control . This study was undertaken to evaluate the effect of ipratropium bromide ( IB ) , an anticholinergic nasal spray , on rhinorrhea in these patients . This was designed as a prospective , randomized , double-blind , placebo-controlled , crossover pilot study . Participants were selected if they had a total laryngectomy and complained of rhinorrhea . They were asked to rate the severity and duration of their rhinorrhea each day throughout the study on a scale from zero to six . Each participant was initially given a saline nasal spray for one week . They were then randomized to use either IB or saline for the double-blinded portion of the study . Two sprays of IB at a dose of 42 micrograms/spray ( 0.06 % ) , or saline , were administered intranasally twice daily for two weeks , after which time the participants were given another nasal spray ( either IB or saline ) for the crossover portion of the study . Six patients entered and completed the study . Those patients using the IB recorded a mean 55 % decline in severity and a mean 51 % decline in duration of the rhinorrhea as compared to placebo . The relief in both severity and duration of rhinorrhea obtained by patients was analyzed using the Wilcoxon signed-rank test and found to be highly significant ( p < 0.001 ) . Despite the limitations of a small sample size in this study , ipratropium bromide nasal spray significantly reduced both the severity and duration of rhinorrhea in laryngectomized patients . We suggest ipratropium nasal spray as a safe , effective way to treat chronic rhinorrhea in laryngectomized patients , improving their quality of life . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]	Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient : a pilot study . Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control . This study was undertaken to evaluate the effect of ipratropium bromide ( IB ) , an anticholinergic nasal spray , on rhinorrhea in these patients . This was designed as a prospective , randomized , double-blind , placebo-controlled , crossover pilot study . Participants were selected if they had a total laryngectomy and complained of rhinorrhea . They were asked to rate the severity and duration of their rhinorrhea each day throughout the study on a scale from zero to six . Each participant was initially given a saline nasal spray for one week . They were then randomized to use either IB or saline for the double-blinded portion of the study . Two sprays of IB at a dose of 42 micrograms/spray ( 0.06 % ) , or saline , were administered intranasally twice daily for two weeks , after which time the participants were given another nasal spray ( either IB or saline ) for the crossover portion of the study . Six patients entered and completed the study . Those patients using the IB recorded a mean 55 % decline in severity and a mean 51 % decline in duration of the rhinorrhea as compared to placebo . The relief in both severity and duration of rhinorrhea obtained by patients was analyzed using the Wilcoxon signed-rank test and found to be highly significant ( p < 0.001 ) . Despite the limitations of a small sample size in this study , ipratropium bromide nasal spray significantly reduced both the severity and duration of rhinorrhea in laryngectomized patients . We suggest ipratropium nasal spray as a safe , effective way to treat chronic rhinorrhea in laryngectomized patients , improving their quality of life .	[ "Ipratropium", "bromide", "nasal", "spray", "for", "treatment", "of", "rhinorrhea", "in", "the", "laryngectomized", "patient", ":", "a", "pilot", "study", ".", "Many", "who", "have", "had", "a", "total", "laryngectomy", "complain", "of", "unrelenting", "rhinorrhea", "that", "is", "often", "very", "difficult", "to", "control", ".", "This", "study", "was", "undertaken", "to", "evaluate", "the", "effect", "of", "ipratropium", "bromide", "(", "IB", ")", ",", "an", "anticholinergic", "nasal", "spray", ",", "on", "rhinorrhea", "in", "these", "patients", ".", "This", "was", "designed", "as", "a", "prospective", ",", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "crossover", "pilot", "study", ".", "Participants", "were", "selected", "if", "they", "had", "a", "total", "laryngectomy", "and", "complained", "of", "rhinorrhea", ".", "They", "were", "asked", "to", "rate", "the", "severity", "and", "duration", "of", "their", "rhinorrhea", "each", "day", "throughout", "the", "study", "on", "a", "scale", "from", "zero", "to", "six", ".", "Each", "participant", "was", "initially", "given", "a", "saline", "nasal", "spray", "for", "one", "week", ".", "They", "were", "then", "randomized", "to", "use", "either", "IB", "or", "saline", "for", "the", "double", "-", "blinded", "portion", "of", "the", "study", ".", "Two", "sprays", "of", "IB", "at", "a", "dose", "of", "42", "micrograms", "/", "spray", "(", "0.06", "%", ")", ",", "or", "saline", ",", "were", "administered", "intranasally", "twice", "daily", "for", "two", "weeks", ",", "after", "which", "time", "the", "participants", "were", "given", "another", "nasal", "spray", "(", "either", "IB", "or", "saline", ")", "for", "the", "crossover", "portion", "of", "the", "study", ".", "Six", "patients", "entered", "and", "completed", "the", "study", ".", "Those", "patients", "using", "the", "IB", "recorded", "a", "mean", "55", "%", "decline", "in", "severity", "and", "a", "mean", "51", "%", "decline", "in", "duration", "of", "the", "rhinorrhea", "as", "compared", "to", "placebo", ".", "The", "relief", "in", "both", "severity", "and", "duration", "of", "rhinorrhea", "obtained", "by", "patients", "was", "analyzed", "using", "the", "Wilcoxon", "signed", "-", "rank", "test", "and", "found", "to", "be", "highly", "significant", "(", "p", "<", "0.001", ")", ".", "Despite", "the", "limitations", "of", "a", "small", "sample", "size", "in", "this", "study", ",", "ipratropium", "bromide", "nasal", "spray", "significantly", "reduced", "both", "the", "severity", "and", "duration", "of", "rhinorrhea", "in", "laryngectomized", "patients", ".", "We", "suggest", "ipratropium", "nasal", "spray", "as", "a", "safe", ",", "effective", "way", "to", "treat", "chronic", "rhinorrhea", "in", "laryngectomized", "patients", ",", "improving", "their", "quality", "of", "life", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Intervention_Control", "Participant_Sample-size" ]
avidin is a Protein, avidin is a Protein, streptavidin is a Protein, avidin is a Protein, avidin is a Protein, avidin is a Protein, avidin is a Protein, Streptavidin is a Protein, avidin is a Protein, avidin is a Protein	354_task0	Sentence: Studies on the biotin-binding site of avidin. Minimized fragments that bind biotin. The object of this study was to define minimized biotin-binding fragments, or 'prorecognition sites', of either the egg-white glycoprotein avidin or its bacterial analogue streptavidin. Because of the extreme stability to enzymic hydrolysis, fragments of avidin were prepared by chemical means and examined for their individual biotin-binding capacity. Treatment of avidin with hydroxylamine was shown to result in new cleavage sites in addition to the known Asn-Gly cleavage site (position 88-89 in avidin). Notably, the Asn-Glu and Asp-Lys peptide bonds (positions 42-43 and 57-58 respectively) were readily cleaved; in addition, lesser levels of hydrolysis of the Gln-Pro (61-62) and Asn-Asp (12-13 and 104-105) bonds could be detected. The smallest biotin-binding peptide fragment, derived from hydroxylamine cleavage of either native or non-glycosylated avidin, was identified to comprise residues 1-42. CNBr cleavage resulted in a 78-amino acid-residue fragment (residues 19-96) that still retained activity. The data ascribe an important biotin-binding function to the overlapping region (residues 19-42) of avidin, which bears the single tyrosine moiety. This contention was corroborated by synthesizing a tridecapeptide corresponding to residues 26-38 of avidin; this peptide was shown to recognize biotin. Streptavidin was not susceptible to either enzymic or chemical cleavage methods used in this work. The approach taken in this study enabled the experimental distinction between the chemical and structural elements of the binding site. The capacity to assign biotin-binding activity to the tyrosine-containing domain of avidin underscores its primary chemical contribution to the binding of biotin by avidin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]	Studies on the biotin-binding site of avidin. Minimized fragments that bind biotin. The object of this study was to define minimized biotin-binding fragments, or 'prorecognition sites', of either the egg-white glycoprotein avidin or its bacterial analogue streptavidin. Because of the extreme stability to enzymic hydrolysis, fragments of avidin were prepared by chemical means and examined for their individual biotin-binding capacity. Treatment of avidin with hydroxylamine was shown to result in new cleavage sites in addition to the known Asn-Gly cleavage site (position 88-89 in avidin). Notably, the Asn-Glu and Asp-Lys peptide bonds (positions 42-43 and 57-58 respectively) were readily cleaved; in addition, lesser levels of hydrolysis of the Gln-Pro (61-62) and Asn-Asp (12-13 and 104-105) bonds could be detected. The smallest biotin-binding peptide fragment, derived from hydroxylamine cleavage of either native or non-glycosylated avidin, was identified to comprise residues 1-42. CNBr cleavage resulted in a 78-amino acid-residue fragment (residues 19-96) that still retained activity. The data ascribe an important biotin-binding function to the overlapping region (residues 19-42) of avidin, which bears the single tyrosine moiety. This contention was corroborated by synthesizing a tridecapeptide corresponding to residues 26-38 of avidin; this peptide was shown to recognize biotin. Streptavidin was not susceptible to either enzymic or chemical cleavage methods used in this work. The approach taken in this study enabled the experimental distinction between the chemical and structural elements of the binding site. The capacity to assign biotin-binding activity to the tyrosine-containing domain of avidin underscores its primary chemical contribution to the binding of biotin by avidin.	[ "Studies", "on", "the", "biotin", "-", "binding", "site", "of", "avidin", ".", " ", "Minimized", "fragments", "that", "bind", "biotin", ".", "\n", "The", "object", "of", "this", "study", "was", "to", "define", "minimized", "biotin", "-", "binding", "fragments", ",", "or", "'", "prorecognition", "sites", "'", ",", "of", "either", "the", "egg", "-", "white", "glycoprotein", "avidin", "or", "its", "bacterial", "analogue", "streptavidin", ".", "Because", "of", "the", "extreme", "stability", "to", "enzymic", "hydrolysis", ",", "fragments", "of", "avidin", "were", "prepared", "by", "chemical", "means", "and", "examined", "for", "their", "individual", "biotin", "-", "binding", "capacity", ".", "Treatment", "of", "avidin", "with", "hydroxylamine", "was", "shown", "to", "result", "in", "new", "cleavage", "sites", "in", "addition", "to", "the", "known", "Asn", "-", "Gly", "cleavage", "site", "(", "position", "88", "-", "89", "in", "avidin", ")", ".", "Notably", ",", "the", "Asn", "-", "Glu", "and", "Asp", "-", "Lys", "peptide", "bonds", "(", "positions", "42", "-", "43", "and", "57", "-", "58", "respectively", ")", "were", "readily", "cleaved", ";", "in", "addition", ",", "lesser", "levels", "of", "hydrolysis", "of", "the", "Gln", "-", "Pro", "(", "61", "-", "62", ")", "and", "Asn", "-", "Asp", "(", "12", "-", "13", "and", "104", "-", "105", ")", "bonds", "could", "be", "detected", ".", "The", "smallest", "biotin", "-", "binding", "peptide", "fragment", ",", "derived", "from", "hydroxylamine", "cleavage", "of", "either", "native", "or", "non", "-", "glycosylated", "avidin", ",", "was", "identified", "to", "comprise", "residues", "1", "-", "42", ".", "CNBr", "cleavage", "resulted", "in", "a", "78-amino", "acid", "-", "residue", "fragment", "(", "residues", "19", "-", "96", ")", "that", "still", "retained", "activity", ".", "The", "data", "ascribe", "an", "important", "biotin", "-", "binding", "function", "to", "the", "overlapping", "region", "(", "residues", "19", "-", "42", ")", "of", "avidin", ",", "which", "bears", "the", "single", "tyrosine", "moiety", ".", "This", "contention", "was", "corroborated", "by", "synthesizing", "a", "tridecapeptide", "corresponding", "to", "residues", "26", "-", "38", "of", "avidin", ";", "this", "peptide", "was", "shown", "to", "recognize", "biotin", ".", "Streptavidin", "was", "not", "susceptible", "to", "either", "enzymic", "or", "chemical", "cleavage", "methods", "used", "in", "this", "work", ".", "The", "approach", "taken", "in", "this", "study", "enabled", "the", "experimental", "distinction", "between", "the", "chemical", "and", "structural", "elements", "of", "the", "binding", "site", ".", "The", "capacity", "to", "assign", "biotin", "-", "binding", "activity", "to", "the", "tyrosine", "-", "containing", "domain", "of", "avidin", "underscores", "its", "primary", "chemical", "contribution", "to", "the", "binding", "of", "biotin", "by", "avidin", ".", "\n" ]	[ "Protein" ]
avidin is a Protein, avidin is a Protein, streptavidin is a Protein, avidin is a Protein, avidin is a Protein, avidin is a Protein, avidin is a Protein, Streptavidin is a Protein, avidin is a Protein, avidin is a Protein	354_task1	Sentence: Studies on the biotin-binding site of avidin. Minimized fragments that bind biotin. The object of this study was to define minimized biotin-binding fragments, or 'prorecognition sites', of either the egg-white glycoprotein avidin or its bacterial analogue streptavidin. Because of the extreme stability to enzymic hydrolysis, fragments of avidin were prepared by chemical means and examined for their individual biotin-binding capacity. Treatment of avidin with hydroxylamine was shown to result in new cleavage sites in addition to the known Asn-Gly cleavage site (position 88-89 in avidin). Notably, the Asn-Glu and Asp-Lys peptide bonds (positions 42-43 and 57-58 respectively) were readily cleaved; in addition, lesser levels of hydrolysis of the Gln-Pro (61-62) and Asn-Asp (12-13 and 104-105) bonds could be detected. The smallest biotin-binding peptide fragment, derived from hydroxylamine cleavage of either native or non-glycosylated avidin, was identified to comprise residues 1-42. CNBr cleavage resulted in a 78-amino acid-residue fragment (residues 19-96) that still retained activity. The data ascribe an important biotin-binding function to the overlapping region (residues 19-42) of avidin, which bears the single tyrosine moiety. This contention was corroborated by synthesizing a tridecapeptide corresponding to residues 26-38 of avidin; this peptide was shown to recognize biotin. Streptavidin was not susceptible to either enzymic or chemical cleavage methods used in this work. The approach taken in this study enabled the experimental distinction between the chemical and structural elements of the binding site. The capacity to assign biotin-binding activity to the tyrosine-containing domain of avidin underscores its primary chemical contribution to the binding of biotin by avidin. Instructions: please typing these entity words according to sentence: avidin, avidin, streptavidin, avidin, avidin, avidin, avidin, Streptavidin, avidin, avidin Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]	Studies on the biotin-binding site of avidin. Minimized fragments that bind biotin. The object of this study was to define minimized biotin-binding fragments, or 'prorecognition sites', of either the egg-white glycoprotein avidin or its bacterial analogue streptavidin. Because of the extreme stability to enzymic hydrolysis, fragments of avidin were prepared by chemical means and examined for their individual biotin-binding capacity. Treatment of avidin with hydroxylamine was shown to result in new cleavage sites in addition to the known Asn-Gly cleavage site (position 88-89 in avidin). Notably, the Asn-Glu and Asp-Lys peptide bonds (positions 42-43 and 57-58 respectively) were readily cleaved; in addition, lesser levels of hydrolysis of the Gln-Pro (61-62) and Asn-Asp (12-13 and 104-105) bonds could be detected. The smallest biotin-binding peptide fragment, derived from hydroxylamine cleavage of either native or non-glycosylated avidin, was identified to comprise residues 1-42. CNBr cleavage resulted in a 78-amino acid-residue fragment (residues 19-96) that still retained activity. The data ascribe an important biotin-binding function to the overlapping region (residues 19-42) of avidin, which bears the single tyrosine moiety. This contention was corroborated by synthesizing a tridecapeptide corresponding to residues 26-38 of avidin; this peptide was shown to recognize biotin. Streptavidin was not susceptible to either enzymic or chemical cleavage methods used in this work. The approach taken in this study enabled the experimental distinction between the chemical and structural elements of the binding site. The capacity to assign biotin-binding activity to the tyrosine-containing domain of avidin underscores its primary chemical contribution to the binding of biotin by avidin.	[ "Studies", "on", "the", "biotin", "-", "binding", "site", "of", "avidin", ".", " ", "Minimized", "fragments", "that", "bind", "biotin", ".", "\n", "The", "object", "of", "this", "study", "was", "to", "define", "minimized", "biotin", "-", "binding", "fragments", ",", "or", "'", "prorecognition", "sites", "'", ",", "of", "either", "the", "egg", "-", "white", "glycoprotein", "avidin", "or", "its", "bacterial", "analogue", "streptavidin", ".", "Because", "of", "the", "extreme", "stability", "to", "enzymic", "hydrolysis", ",", "fragments", "of", "avidin", "were", "prepared", "by", "chemical", "means", "and", "examined", "for", "their", "individual", "biotin", "-", "binding", "capacity", ".", "Treatment", "of", "avidin", "with", "hydroxylamine", "was", "shown", "to", "result", "in", "new", "cleavage", "sites", "in", "addition", "to", "the", "known", "Asn", "-", "Gly", "cleavage", "site", "(", "position", "88", "-", "89", "in", "avidin", ")", ".", "Notably", ",", "the", "Asn", "-", "Glu", "and", "Asp", "-", "Lys", "peptide", "bonds", "(", "positions", "42", "-", "43", "and", "57", "-", "58", "respectively", ")", "were", "readily", "cleaved", ";", "in", "addition", ",", "lesser", "levels", "of", "hydrolysis", "of", "the", "Gln", "-", "Pro", "(", "61", "-", "62", ")", "and", "Asn", "-", "Asp", "(", "12", "-", "13", "and", "104", "-", "105", ")", "bonds", "could", "be", "detected", ".", "The", "smallest", "biotin", "-", "binding", "peptide", "fragment", ",", "derived", "from", "hydroxylamine", "cleavage", "of", "either", "native", "or", "non", "-", "glycosylated", "avidin", ",", "was", "identified", "to", "comprise", "residues", "1", "-", "42", ".", "CNBr", "cleavage", "resulted", "in", "a", "78-amino", "acid", "-", "residue", "fragment", "(", "residues", "19", "-", "96", ")", "that", "still", "retained", "activity", ".", "The", "data", "ascribe", "an", "important", "biotin", "-", "binding", "function", "to", "the", "overlapping", "region", "(", "residues", "19", "-", "42", ")", "of", "avidin", ",", "which", "bears", "the", "single", "tyrosine", "moiety", ".", "This", "contention", "was", "corroborated", "by", "synthesizing", "a", "tridecapeptide", "corresponding", "to", "residues", "26", "-", "38", "of", "avidin", ";", "this", "peptide", "was", "shown", "to", "recognize", "biotin", ".", "Streptavidin", "was", "not", "susceptible", "to", "either", "enzymic", "or", "chemical", "cleavage", "methods", "used", "in", "this", "work", ".", "The", "approach", "taken", "in", "this", "study", "enabled", "the", "experimental", "distinction", "between", "the", "chemical", "and", "structural", "elements", "of", "the", "binding", "site", ".", "The", "capacity", "to", "assign", "biotin", "-", "binding", "activity", "to", "the", "tyrosine", "-", "containing", "domain", "of", "avidin", "underscores", "its", "primary", "chemical", "contribution", "to", "the", "binding", "of", "biotin", "by", "avidin", ".", "\n" ]	[ "Protein" ]
avidin, avidin, streptavidin, avidin, avidin, avidin, avidin, Streptavidin, avidin, avidin	354_task2	Sentence: Studies on the biotin-binding site of avidin. Minimized fragments that bind biotin. The object of this study was to define minimized biotin-binding fragments, or 'prorecognition sites', of either the egg-white glycoprotein avidin or its bacterial analogue streptavidin. Because of the extreme stability to enzymic hydrolysis, fragments of avidin were prepared by chemical means and examined for their individual biotin-binding capacity. Treatment of avidin with hydroxylamine was shown to result in new cleavage sites in addition to the known Asn-Gly cleavage site (position 88-89 in avidin). Notably, the Asn-Glu and Asp-Lys peptide bonds (positions 42-43 and 57-58 respectively) were readily cleaved; in addition, lesser levels of hydrolysis of the Gln-Pro (61-62) and Asn-Asp (12-13 and 104-105) bonds could be detected. The smallest biotin-binding peptide fragment, derived from hydroxylamine cleavage of either native or non-glycosylated avidin, was identified to comprise residues 1-42. CNBr cleavage resulted in a 78-amino acid-residue fragment (residues 19-96) that still retained activity. The data ascribe an important biotin-binding function to the overlapping region (residues 19-42) of avidin, which bears the single tyrosine moiety. This contention was corroborated by synthesizing a tridecapeptide corresponding to residues 26-38 of avidin; this peptide was shown to recognize biotin. Streptavidin was not susceptible to either enzymic or chemical cleavage methods used in this work. The approach taken in this study enabled the experimental distinction between the chemical and structural elements of the binding site. The capacity to assign biotin-binding activity to the tyrosine-containing domain of avidin underscores its primary chemical contribution to the binding of biotin by avidin. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]	Studies on the biotin-binding site of avidin. Minimized fragments that bind biotin. The object of this study was to define minimized biotin-binding fragments, or 'prorecognition sites', of either the egg-white glycoprotein avidin or its bacterial analogue streptavidin. Because of the extreme stability to enzymic hydrolysis, fragments of avidin were prepared by chemical means and examined for their individual biotin-binding capacity. Treatment of avidin with hydroxylamine was shown to result in new cleavage sites in addition to the known Asn-Gly cleavage site (position 88-89 in avidin). Notably, the Asn-Glu and Asp-Lys peptide bonds (positions 42-43 and 57-58 respectively) were readily cleaved; in addition, lesser levels of hydrolysis of the Gln-Pro (61-62) and Asn-Asp (12-13 and 104-105) bonds could be detected. The smallest biotin-binding peptide fragment, derived from hydroxylamine cleavage of either native or non-glycosylated avidin, was identified to comprise residues 1-42. CNBr cleavage resulted in a 78-amino acid-residue fragment (residues 19-96) that still retained activity. The data ascribe an important biotin-binding function to the overlapping region (residues 19-42) of avidin, which bears the single tyrosine moiety. This contention was corroborated by synthesizing a tridecapeptide corresponding to residues 26-38 of avidin; this peptide was shown to recognize biotin. Streptavidin was not susceptible to either enzymic or chemical cleavage methods used in this work. The approach taken in this study enabled the experimental distinction between the chemical and structural elements of the binding site. The capacity to assign biotin-binding activity to the tyrosine-containing domain of avidin underscores its primary chemical contribution to the binding of biotin by avidin.	[ "Studies", "on", "the", "biotin", "-", "binding", "site", "of", "avidin", ".", " ", "Minimized", "fragments", "that", "bind", "biotin", ".", "\n", "The", "object", "of", "this", "study", "was", "to", "define", "minimized", "biotin", "-", "binding", "fragments", ",", "or", "'", "prorecognition", "sites", "'", ",", "of", "either", "the", "egg", "-", "white", "glycoprotein", "avidin", "or", "its", "bacterial", "analogue", "streptavidin", ".", "Because", "of", "the", "extreme", "stability", "to", "enzymic", "hydrolysis", ",", "fragments", "of", "avidin", "were", "prepared", "by", "chemical", "means", "and", "examined", "for", "their", "individual", "biotin", "-", "binding", "capacity", ".", "Treatment", "of", "avidin", "with", "hydroxylamine", "was", "shown", "to", "result", "in", "new", "cleavage", "sites", "in", "addition", "to", "the", "known", "Asn", "-", "Gly", "cleavage", "site", "(", "position", "88", "-", "89", "in", "avidin", ")", ".", "Notably", ",", "the", "Asn", "-", "Glu", "and", "Asp", "-", "Lys", "peptide", "bonds", "(", "positions", "42", "-", "43", "and", "57", "-", "58", "respectively", ")", "were", "readily", "cleaved", ";", "in", "addition", ",", "lesser", "levels", "of", "hydrolysis", "of", "the", "Gln", "-", "Pro", "(", "61", "-", "62", ")", "and", "Asn", "-", "Asp", "(", "12", "-", "13", "and", "104", "-", "105", ")", "bonds", "could", "be", "detected", ".", "The", "smallest", "biotin", "-", "binding", "peptide", "fragment", ",", "derived", "from", "hydroxylamine", "cleavage", "of", "either", "native", "or", "non", "-", "glycosylated", "avidin", ",", "was", "identified", "to", "comprise", "residues", "1", "-", "42", ".", "CNBr", "cleavage", "resulted", "in", "a", "78-amino", "acid", "-", "residue", "fragment", "(", "residues", "19", "-", "96", ")", "that", "still", "retained", "activity", ".", "The", "data", "ascribe", "an", "important", "biotin", "-", "binding", "function", "to", "the", "overlapping", "region", "(", "residues", "19", "-", "42", ")", "of", "avidin", ",", "which", "bears", "the", "single", "tyrosine", "moiety", ".", "This", "contention", "was", "corroborated", "by", "synthesizing", "a", "tridecapeptide", "corresponding", "to", "residues", "26", "-", "38", "of", "avidin", ";", "this", "peptide", "was", "shown", "to", "recognize", "biotin", ".", "Streptavidin", "was", "not", "susceptible", "to", "either", "enzymic", "or", "chemical", "cleavage", "methods", "used", "in", "this", "work", ".", "The", "approach", "taken", "in", "this", "study", "enabled", "the", "experimental", "distinction", "between", "the", "chemical", "and", "structural", "elements", "of", "the", "binding", "site", ".", "The", "capacity", "to", "assign", "biotin", "-", "binding", "activity", "to", "the", "tyrosine", "-", "containing", "domain", "of", "avidin", "underscores", "its", "primary", "chemical", "contribution", "to", "the", "binding", "of", "biotin", "by", "avidin", ".", "\n" ]	[ "Protein" ]
Infektionen is an umlsterm, lebensbedrohlichen is an umlsterm, Komplikationen is an umlsterm, Infektionen is an umlsterm, Hautorganismen is an umlsterm, Haut is an umlsterm, Patienten is an umlsterm, Haut is an umlsterm, Pflegepersonals is an umlsterm, Infektionen is an umlsterm, Desinfektionsmitteln is an umlsterm, antithrombotischen Mitteln is an umlsterm, Silber is an umlsterm, Kurzzeitgebrauch is an umlsterm, Antiseptika is an umlsterm, Antibiotika is an umlsterm, Verwendung is an umlsterm	IntensiveMedizin.90360349.ger.abstr_task0	Sentence: Katheterinduzierte Infektionen sind die haeufigsten lebensbedrohlichen Komplikationen in Bezug auf intravaskulaere Katheter . In den meisten Faellen , der mit Katheter verbundenen Infektionen ist die Ursache in Hautorganismen zu suchen , welche entweder auf der Haut des Patienten entstehen und auf die aeussere Oberflaeche des Katheters wandern oder auf der Haut des Pflegepersonals entstehen , welche eine Kontamination des Verbindungsstueckes mit nachfolgender bakterieller Migration entlang der inneren Oberflaeche des Katheters verursachen . Einige Massnahmen wurden im Rahmen von klinischen Studien berichtet , welche gegen vaskulaere , katheterinduzierte Infektionen schuetzen sollen . Praeventive Massnahmen , welche antimikrobielle Mittel beruecksichtigen , sind u.a. die Applikation von topischen Desinfektionsmitteln , das Spuelen von Kathetern mit einer Kombination von antimikrobiellen und antithrombotischen Mitteln , die Anwendung von mit Silber impraegnierten subkutanen Manschetten zur zentralvenoese Katheter im Kurzzeitgebrauch , eine antimikrobielle Beschichtung der Katheter entweder mit Antiseptika oder mit Antibiotika und die Verwendung eines antiseptisch ausgestatteten Katheterverbindungsstueckes . Schutzmassnahmen , welche keine antimikrobielle Mittel verwenden , sind z.B. das Plazieren und die Erhaltung vaskulaerer Katheter durch ein in der Infusionstherapie versiertes Team und die Errichtung maximaler Sterilbarrieren . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Katheterinduzierte Infektionen sind die haeufigsten lebensbedrohlichen Komplikationen in Bezug auf intravaskulaere Katheter . In den meisten Faellen , der mit Katheter verbundenen Infektionen ist die Ursache in Hautorganismen zu suchen , welche entweder auf der Haut des Patienten entstehen und auf die aeussere Oberflaeche des Katheters wandern oder auf der Haut des Pflegepersonals entstehen , welche eine Kontamination des Verbindungsstueckes mit nachfolgender bakterieller Migration entlang der inneren Oberflaeche des Katheters verursachen . Einige Massnahmen wurden im Rahmen von klinischen Studien berichtet , welche gegen vaskulaere , katheterinduzierte Infektionen schuetzen sollen . Praeventive Massnahmen , welche antimikrobielle Mittel beruecksichtigen , sind u.a. die Applikation von topischen Desinfektionsmitteln , das Spuelen von Kathetern mit einer Kombination von antimikrobiellen und antithrombotischen Mitteln , die Anwendung von mit Silber impraegnierten subkutanen Manschetten zur zentralvenoese Katheter im Kurzzeitgebrauch , eine antimikrobielle Beschichtung der Katheter entweder mit Antiseptika oder mit Antibiotika und die Verwendung eines antiseptisch ausgestatteten Katheterverbindungsstueckes . Schutzmassnahmen , welche keine antimikrobielle Mittel verwenden , sind z.B. das Plazieren und die Erhaltung vaskulaerer Katheter durch ein in der Infusionstherapie versiertes Team und die Errichtung maximaler Sterilbarrieren .	[ "Katheterinduzierte", "Infektionen", "sind", "die", "haeufigsten", "lebensbedrohlichen", "Komplikationen", "in", "Bezug", "auf", "intravaskulaere", "Katheter", ".", "In", "den", "meisten", "Faellen", ",", "der", "mit", "Katheter", "verbundenen", "Infektionen", "ist", "die", "Ursache", "in", "Hautorganismen", "zu", "suchen", ",", "welche", "entweder", "auf", "der", "Haut", "des", "Patienten", "entstehen", "und", "auf", "die", "aeussere", "Oberflaeche", "des", "Katheters", "wandern", "oder", "auf", "der", "Haut", "des", "Pflegepersonals", "entstehen", ",", "welche", "eine", "Kontamination", "des", "Verbindungsstueckes", "mit", "nachfolgender", "bakterieller", "Migration", "entlang", "der", "inneren", "Oberflaeche", "des", "Katheters", "verursachen", ".", "Einige", "Massnahmen", "wurden", "im", "Rahmen", "von", "klinischen", "Studien", "berichtet", ",", "welche", "gegen", "vaskulaere", ",", "katheterinduzierte", "Infektionen", "schuetzen", "sollen", ".", "Praeventive", "Massnahmen", ",", "welche", "antimikrobielle", "Mittel", "beruecksichtigen", ",", "sind", "u.a", ".", "die", "Applikation", "von", "topischen", "Desinfektionsmitteln", ",", "das", "Spuelen", "von", "Kathetern", "mit", "einer", "Kombination", "von", "antimikrobiellen", "und", "antithrombotischen", "Mitteln", ",", "die", "Anwendung", "von", "mit", "Silber", "impraegnierten", "subkutanen", "Manschetten", "zur", "zentralvenoese", "Katheter", "im", "Kurzzeitgebrauch", ",", "eine", "antimikrobielle", "Beschichtung", "der", "Katheter", "entweder", "mit", "Antiseptika", "oder", "mit", "Antibiotika", "und", "die", "Verwendung", "eines", "antiseptisch", "ausgestatteten", "Katheterverbindungsstueckes", ".", "Schutzmassnahmen", ",", "welche", "keine", "antimikrobielle", "Mittel", "verwenden", ",", "sind", "z.", "B.", "das", "Plazieren", "und", "die", "Erhaltung", "vaskulaerer", "Katheter", "durch", "ein", "in", "der", "Infusionstherapie", "versiertes", "Team", "und", "die", "Errichtung", "maximaler", "Sterilbarrieren", "." ]	[ "umlsterm" ]
Infektionen is an umlsterm, lebensbedrohlichen is an umlsterm, Komplikationen is an umlsterm, Infektionen is an umlsterm, Hautorganismen is an umlsterm, Haut is an umlsterm, Patienten is an umlsterm, Haut is an umlsterm, Pflegepersonals is an umlsterm, Infektionen is an umlsterm, Desinfektionsmitteln is an umlsterm, antithrombotischen Mitteln is an umlsterm, Silber is an umlsterm, Kurzzeitgebrauch is an umlsterm, Antiseptika is an umlsterm, Antibiotika is an umlsterm, Verwendung is an umlsterm	IntensiveMedizin.90360349.ger.abstr_task1	Sentence: Katheterinduzierte Infektionen sind die haeufigsten lebensbedrohlichen Komplikationen in Bezug auf intravaskulaere Katheter . In den meisten Faellen , der mit Katheter verbundenen Infektionen ist die Ursache in Hautorganismen zu suchen , welche entweder auf der Haut des Patienten entstehen und auf die aeussere Oberflaeche des Katheters wandern oder auf der Haut des Pflegepersonals entstehen , welche eine Kontamination des Verbindungsstueckes mit nachfolgender bakterieller Migration entlang der inneren Oberflaeche des Katheters verursachen . Einige Massnahmen wurden im Rahmen von klinischen Studien berichtet , welche gegen vaskulaere , katheterinduzierte Infektionen schuetzen sollen . Praeventive Massnahmen , welche antimikrobielle Mittel beruecksichtigen , sind u.a. die Applikation von topischen Desinfektionsmitteln , das Spuelen von Kathetern mit einer Kombination von antimikrobiellen und antithrombotischen Mitteln , die Anwendung von mit Silber impraegnierten subkutanen Manschetten zur zentralvenoese Katheter im Kurzzeitgebrauch , eine antimikrobielle Beschichtung der Katheter entweder mit Antiseptika oder mit Antibiotika und die Verwendung eines antiseptisch ausgestatteten Katheterverbindungsstueckes . Schutzmassnahmen , welche keine antimikrobielle Mittel verwenden , sind z.B. das Plazieren und die Erhaltung vaskulaerer Katheter durch ein in der Infusionstherapie versiertes Team und die Errichtung maximaler Sterilbarrieren . Instructions: please typing these entity words according to sentence: Infektionen, lebensbedrohlichen, Komplikationen, Infektionen, Hautorganismen, Haut, Patienten, Haut, Pflegepersonals, Infektionen, Desinfektionsmitteln, antithrombotischen Mitteln, Silber, Kurzzeitgebrauch, Antiseptika, Antibiotika, Verwendung Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Katheterinduzierte Infektionen sind die haeufigsten lebensbedrohlichen Komplikationen in Bezug auf intravaskulaere Katheter . In den meisten Faellen , der mit Katheter verbundenen Infektionen ist die Ursache in Hautorganismen zu suchen , welche entweder auf der Haut des Patienten entstehen und auf die aeussere Oberflaeche des Katheters wandern oder auf der Haut des Pflegepersonals entstehen , welche eine Kontamination des Verbindungsstueckes mit nachfolgender bakterieller Migration entlang der inneren Oberflaeche des Katheters verursachen . Einige Massnahmen wurden im Rahmen von klinischen Studien berichtet , welche gegen vaskulaere , katheterinduzierte Infektionen schuetzen sollen . Praeventive Massnahmen , welche antimikrobielle Mittel beruecksichtigen , sind u.a. die Applikation von topischen Desinfektionsmitteln , das Spuelen von Kathetern mit einer Kombination von antimikrobiellen und antithrombotischen Mitteln , die Anwendung von mit Silber impraegnierten subkutanen Manschetten zur zentralvenoese Katheter im Kurzzeitgebrauch , eine antimikrobielle Beschichtung der Katheter entweder mit Antiseptika oder mit Antibiotika und die Verwendung eines antiseptisch ausgestatteten Katheterverbindungsstueckes . Schutzmassnahmen , welche keine antimikrobielle Mittel verwenden , sind z.B. das Plazieren und die Erhaltung vaskulaerer Katheter durch ein in der Infusionstherapie versiertes Team und die Errichtung maximaler Sterilbarrieren .	[ "Katheterinduzierte", "Infektionen", "sind", "die", "haeufigsten", "lebensbedrohlichen", "Komplikationen", "in", "Bezug", "auf", "intravaskulaere", "Katheter", ".", "In", "den", "meisten", "Faellen", ",", "der", "mit", "Katheter", "verbundenen", "Infektionen", "ist", "die", "Ursache", "in", "Hautorganismen", "zu", "suchen", ",", "welche", "entweder", "auf", "der", "Haut", "des", "Patienten", "entstehen", "und", "auf", "die", "aeussere", "Oberflaeche", "des", "Katheters", "wandern", "oder", "auf", "der", "Haut", "des", "Pflegepersonals", "entstehen", ",", "welche", "eine", "Kontamination", "des", "Verbindungsstueckes", "mit", "nachfolgender", "bakterieller", "Migration", "entlang", "der", "inneren", "Oberflaeche", "des", "Katheters", "verursachen", ".", "Einige", "Massnahmen", "wurden", "im", "Rahmen", "von", "klinischen", "Studien", "berichtet", ",", "welche", "gegen", "vaskulaere", ",", "katheterinduzierte", "Infektionen", "schuetzen", "sollen", ".", "Praeventive", "Massnahmen", ",", "welche", "antimikrobielle", "Mittel", "beruecksichtigen", ",", "sind", "u.a", ".", "die", "Applikation", "von", "topischen", "Desinfektionsmitteln", ",", "das", "Spuelen", "von", "Kathetern", "mit", "einer", "Kombination", "von", "antimikrobiellen", "und", "antithrombotischen", "Mitteln", ",", "die", "Anwendung", "von", "mit", "Silber", "impraegnierten", "subkutanen", "Manschetten", "zur", "zentralvenoese", "Katheter", "im", "Kurzzeitgebrauch", ",", "eine", "antimikrobielle", "Beschichtung", "der", "Katheter", "entweder", "mit", "Antiseptika", "oder", "mit", "Antibiotika", "und", "die", "Verwendung", "eines", "antiseptisch", "ausgestatteten", "Katheterverbindungsstueckes", ".", "Schutzmassnahmen", ",", "welche", "keine", "antimikrobielle", "Mittel", "verwenden", ",", "sind", "z.", "B.", "das", "Plazieren", "und", "die", "Erhaltung", "vaskulaerer", "Katheter", "durch", "ein", "in", "der", "Infusionstherapie", "versiertes", "Team", "und", "die", "Errichtung", "maximaler", "Sterilbarrieren", "." ]	[ "umlsterm" ]
Infektionen, lebensbedrohlichen, Komplikationen, Infektionen, Hautorganismen, Haut, Patienten, Haut, Pflegepersonals, Infektionen, Desinfektionsmitteln, antithrombotischen Mitteln, Silber, Kurzzeitgebrauch, Antiseptika, Antibiotika, Verwendung	IntensiveMedizin.90360349.ger.abstr_task2	Sentence: Katheterinduzierte Infektionen sind die haeufigsten lebensbedrohlichen Komplikationen in Bezug auf intravaskulaere Katheter . In den meisten Faellen , der mit Katheter verbundenen Infektionen ist die Ursache in Hautorganismen zu suchen , welche entweder auf der Haut des Patienten entstehen und auf die aeussere Oberflaeche des Katheters wandern oder auf der Haut des Pflegepersonals entstehen , welche eine Kontamination des Verbindungsstueckes mit nachfolgender bakterieller Migration entlang der inneren Oberflaeche des Katheters verursachen . Einige Massnahmen wurden im Rahmen von klinischen Studien berichtet , welche gegen vaskulaere , katheterinduzierte Infektionen schuetzen sollen . Praeventive Massnahmen , welche antimikrobielle Mittel beruecksichtigen , sind u.a. die Applikation von topischen Desinfektionsmitteln , das Spuelen von Kathetern mit einer Kombination von antimikrobiellen und antithrombotischen Mitteln , die Anwendung von mit Silber impraegnierten subkutanen Manschetten zur zentralvenoese Katheter im Kurzzeitgebrauch , eine antimikrobielle Beschichtung der Katheter entweder mit Antiseptika oder mit Antibiotika und die Verwendung eines antiseptisch ausgestatteten Katheterverbindungsstueckes . Schutzmassnahmen , welche keine antimikrobielle Mittel verwenden , sind z.B. das Plazieren und die Erhaltung vaskulaerer Katheter durch ein in der Infusionstherapie versiertes Team und die Errichtung maximaler Sterilbarrieren . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Katheterinduzierte Infektionen sind die haeufigsten lebensbedrohlichen Komplikationen in Bezug auf intravaskulaere Katheter . In den meisten Faellen , der mit Katheter verbundenen Infektionen ist die Ursache in Hautorganismen zu suchen , welche entweder auf der Haut des Patienten entstehen und auf die aeussere Oberflaeche des Katheters wandern oder auf der Haut des Pflegepersonals entstehen , welche eine Kontamination des Verbindungsstueckes mit nachfolgender bakterieller Migration entlang der inneren Oberflaeche des Katheters verursachen . Einige Massnahmen wurden im Rahmen von klinischen Studien berichtet , welche gegen vaskulaere , katheterinduzierte Infektionen schuetzen sollen . Praeventive Massnahmen , welche antimikrobielle Mittel beruecksichtigen , sind u.a. die Applikation von topischen Desinfektionsmitteln , das Spuelen von Kathetern mit einer Kombination von antimikrobiellen und antithrombotischen Mitteln , die Anwendung von mit Silber impraegnierten subkutanen Manschetten zur zentralvenoese Katheter im Kurzzeitgebrauch , eine antimikrobielle Beschichtung der Katheter entweder mit Antiseptika oder mit Antibiotika und die Verwendung eines antiseptisch ausgestatteten Katheterverbindungsstueckes . Schutzmassnahmen , welche keine antimikrobielle Mittel verwenden , sind z.B. das Plazieren und die Erhaltung vaskulaerer Katheter durch ein in der Infusionstherapie versiertes Team und die Errichtung maximaler Sterilbarrieren .	[ "Katheterinduzierte", "Infektionen", "sind", "die", "haeufigsten", "lebensbedrohlichen", "Komplikationen", "in", "Bezug", "auf", "intravaskulaere", "Katheter", ".", "In", "den", "meisten", "Faellen", ",", "der", "mit", "Katheter", "verbundenen", "Infektionen", "ist", "die", "Ursache", "in", "Hautorganismen", "zu", "suchen", ",", "welche", "entweder", "auf", "der", "Haut", "des", "Patienten", "entstehen", "und", "auf", "die", "aeussere", "Oberflaeche", "des", "Katheters", "wandern", "oder", "auf", "der", "Haut", "des", "Pflegepersonals", "entstehen", ",", "welche", "eine", "Kontamination", "des", "Verbindungsstueckes", "mit", "nachfolgender", "bakterieller", "Migration", "entlang", "der", "inneren", "Oberflaeche", "des", "Katheters", "verursachen", ".", "Einige", "Massnahmen", "wurden", "im", "Rahmen", "von", "klinischen", "Studien", "berichtet", ",", "welche", "gegen", "vaskulaere", ",", "katheterinduzierte", "Infektionen", "schuetzen", "sollen", ".", "Praeventive", "Massnahmen", ",", "welche", "antimikrobielle", "Mittel", "beruecksichtigen", ",", "sind", "u.a", ".", "die", "Applikation", "von", "topischen", "Desinfektionsmitteln", ",", "das", "Spuelen", "von", "Kathetern", "mit", "einer", "Kombination", "von", "antimikrobiellen", "und", "antithrombotischen", "Mitteln", ",", "die", "Anwendung", "von", "mit", "Silber", "impraegnierten", "subkutanen", "Manschetten", "zur", "zentralvenoese", "Katheter", "im", "Kurzzeitgebrauch", ",", "eine", "antimikrobielle", "Beschichtung", "der", "Katheter", "entweder", "mit", "Antiseptika", "oder", "mit", "Antibiotika", "und", "die", "Verwendung", "eines", "antiseptisch", "ausgestatteten", "Katheterverbindungsstueckes", ".", "Schutzmassnahmen", ",", "welche", "keine", "antimikrobielle", "Mittel", "verwenden", ",", "sind", "z.", "B.", "das", "Plazieren", "und", "die", "Erhaltung", "vaskulaerer", "Katheter", "durch", "ein", "in", "der", "Infusionstherapie", "versiertes", "Team", "und", "die", "Errichtung", "maximaler", "Sterilbarrieren", "." ]	[ "umlsterm" ]
recombinant hirudin is a Chemicals & Drugs	7472_task0	Sentence: Rotational thrombelastometry for the bedside monitoring of recombinant hirudin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Chemicals & Drugs	[ "O", "O", "O", "O", "O", "O", "O", "B-Chemicals & Drugs", "I-Chemicals & Drugs", "O" ]	Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.	[ "Rotational", "thrombelastometry", "for", "the", "bedside", "monitoring", "of", "recombinant", "hirudin", "." ]	[ "Diseases & Disorders", "", "Chemicals & Drugs" ]
recombinant hirudin is a Chemicals & Drugs	7472_task1	Sentence: Rotational thrombelastometry for the bedside monitoring of recombinant hirudin. Instructions: please typing these entity words according to sentence: recombinant hirudin Options: Chemicals & Drugs	[ "O", "O", "O", "O", "O", "O", "O", "B-Chemicals & Drugs", "I-Chemicals & Drugs", "O" ]	Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.	[ "Rotational", "thrombelastometry", "for", "the", "bedside", "monitoring", "of", "recombinant", "hirudin", "." ]	[ "Diseases & Disorders", "", "Chemicals & Drugs" ]
recombinant hirudin	7472_task2	Sentence: Rotational thrombelastometry for the bedside monitoring of recombinant hirudin. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Chemicals & Drugs", "I-Chemicals & Drugs", "O" ]	Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.	[ "Rotational", "thrombelastometry", "for", "the", "bedside", "monitoring", "of", "recombinant", "hirudin", "." ]	[ "Diseases & Disorders", "", "Chemicals & Drugs" ]
fluoxetine is a CHEMICAL, hippocampal glucocorticoid receptor is a GENE-Y	23353902_task0	Sentence: Gender-specific effects of fluoxetine on hippocampal glucocorticoid receptor phosphorylation and behavior in chronically stressed rats. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]	Gender-specific effects of fluoxetine on hippocampal glucocorticoid receptor phosphorylation and behavior in chronically stressed rats.	[ "Gender", "-", "specific", "effects", "of", "fluoxetine", "on", "hippocampal", "glucocorticoid", "receptor", "phosphorylation", "and", "behavior", "in", "chronically", "stressed", "rats", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
fluoxetine is a CHEMICAL, hippocampal glucocorticoid receptor is a GENE-Y	23353902_task1	Sentence: Gender-specific effects of fluoxetine on hippocampal glucocorticoid receptor phosphorylation and behavior in chronically stressed rats. Instructions: please typing these entity words according to sentence: fluoxetine, hippocampal glucocorticoid receptor Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]	Gender-specific effects of fluoxetine on hippocampal glucocorticoid receptor phosphorylation and behavior in chronically stressed rats.	[ "Gender", "-", "specific", "effects", "of", "fluoxetine", "on", "hippocampal", "glucocorticoid", "receptor", "phosphorylation", "and", "behavior", "in", "chronically", "stressed", "rats", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
fluoxetine, hippocampal glucocorticoid receptor	23353902_task2	Sentence: Gender-specific effects of fluoxetine on hippocampal glucocorticoid receptor phosphorylation and behavior in chronically stressed rats. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]	Gender-specific effects of fluoxetine on hippocampal glucocorticoid receptor phosphorylation and behavior in chronically stressed rats.	[ "Gender", "-", "specific", "effects", "of", "fluoxetine", "on", "hippocampal", "glucocorticoid", "receptor", "phosphorylation", "and", "behavior", "in", "chronically", "stressed", "rats", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
beta - adrenoceptor blockade is a Outcome_Physical, prizidilol hydrochloride . is a Intervention_Pharmacological, Prizidilol hydrochloride is a Intervention_Pharmacological, beta - adrenoceptor blockade . is a Outcome_Physical, healthy volunteers is a Participant_Condition, Isoprenaline is a Intervention_Pharmacological, heart rate dose - response curves is a Outcome_Physical, diastolic blood pressure is a Outcome_Physical, propranolol is a Intervention_Pharmacological	78161_task0	Sentence: An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride . 1 Prizidilol hydrochloride ( SK & F 92657 ) is a new compound which causes both arteriolar dilatation and beta-adrenoceptor blockade . The effect of a single oral dose on the responses of heart rate and blood pressure to isoprenaline infusion has been studied in healthy volunteers . 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol , indicating antagonism by this compound at beta-adrenoceptors in the heart . 3 Isoprenaline dose-response curves for decreases in diastolic blood pressure also showed shifts to the right after oral prizidilol , providing evidence of beta-adrenoceptor antagonism by this drug in peripheral resistance vessels . 4 The peak effect of a 40 mg dose of propranolol was greater than that of a 200 mg dose of prizidilol but both drugs caused persistent beta-adrenoceptor blockade for at least 7 h after ingestion . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride . 1 Prizidilol hydrochloride ( SK & F 92657 ) is a new compound which causes both arteriolar dilatation and beta-adrenoceptor blockade . The effect of a single oral dose on the responses of heart rate and blood pressure to isoprenaline infusion has been studied in healthy volunteers . 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol , indicating antagonism by this compound at beta-adrenoceptors in the heart . 3 Isoprenaline dose-response curves for decreases in diastolic blood pressure also showed shifts to the right after oral prizidilol , providing evidence of beta-adrenoceptor antagonism by this drug in peripheral resistance vessels . 4 The peak effect of a 40 mg dose of propranolol was greater than that of a 200 mg dose of prizidilol but both drugs caused persistent beta-adrenoceptor blockade for at least 7 h after ingestion .	[ "An", "assessment", "of", "beta", "-", "adrenoceptor", "blockade", "in", "man", "by", "prizidilol", "hydrochloride", ".", "1", "Prizidilol", "hydrochloride", "(", "SK", "&", "F", "92657", ")", "is", "a", "new", "compound", "which", "causes", "both", "arteriolar", "dilatation", "and", "beta", "-", "adrenoceptor", "blockade", ".", "The", "effect", "of", "a", "single", "oral", "dose", "on", "the", "responses", "of", "heart", "rate", "and", "blood", "pressure", "to", "isoprenaline", "infusion", "has", "been", "studied", "in", "healthy", "volunteers", ".", "2", "Isoprenaline", "heart", "rate", "dose", "-", "response", "curves", "showed", "parallel", "shifts", "to", "the", "right", "after", "oral", "prizidilol", ",", "indicating", "antagonism", "by", "this", "compound", "at", "beta", "-", "adrenoceptors", "in", "the", "heart", ".", "3", "Isoprenaline", "dose", "-", "response", "curves", "for", "decreases", "in", "diastolic", "blood", "pressure", "also", "showed", "shifts", "to", "the", "right", "after", "oral", "prizidilol", ",", "providing", "evidence", "of", "beta", "-", "adrenoceptor", "antagonism", "by", "this", "drug", "in", "peripheral", "resistance", "vessels", ".", "4", "The", "peak", "effect", "of", "a", "40", "mg", "dose", "of", "propranolol", "was", "greater", "than", "that", "of", "a", "200", "mg", "dose", "of", "prizidilol", "but", "both", "drugs", "caused", "persistent", "beta", "-", "adrenoceptor", "blockade", "for", "at", "least", "7", "h", "after", "ingestion", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition" ]
beta - adrenoceptor blockade is a Outcome_Physical, prizidilol hydrochloride . is a Intervention_Pharmacological, Prizidilol hydrochloride is a Intervention_Pharmacological, beta - adrenoceptor blockade . is a Outcome_Physical, healthy volunteers is a Participant_Condition, Isoprenaline is a Intervention_Pharmacological, heart rate dose - response curves is a Outcome_Physical, diastolic blood pressure is a Outcome_Physical, propranolol is a Intervention_Pharmacological	78161_task1	Sentence: An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride . 1 Prizidilol hydrochloride ( SK & F 92657 ) is a new compound which causes both arteriolar dilatation and beta-adrenoceptor blockade . The effect of a single oral dose on the responses of heart rate and blood pressure to isoprenaline infusion has been studied in healthy volunteers . 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol , indicating antagonism by this compound at beta-adrenoceptors in the heart . 3 Isoprenaline dose-response curves for decreases in diastolic blood pressure also showed shifts to the right after oral prizidilol , providing evidence of beta-adrenoceptor antagonism by this drug in peripheral resistance vessels . 4 The peak effect of a 40 mg dose of propranolol was greater than that of a 200 mg dose of prizidilol but both drugs caused persistent beta-adrenoceptor blockade for at least 7 h after ingestion . Instructions: please typing these entity words according to sentence: beta - adrenoceptor blockade, prizidilol hydrochloride ., Prizidilol hydrochloride, beta - adrenoceptor blockade ., healthy volunteers, Isoprenaline, heart rate dose - response curves, diastolic blood pressure, propranolol Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition	[ "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride . 1 Prizidilol hydrochloride ( SK & F 92657 ) is a new compound which causes both arteriolar dilatation and beta-adrenoceptor blockade . The effect of a single oral dose on the responses of heart rate and blood pressure to isoprenaline infusion has been studied in healthy volunteers . 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol , indicating antagonism by this compound at beta-adrenoceptors in the heart . 3 Isoprenaline dose-response curves for decreases in diastolic blood pressure also showed shifts to the right after oral prizidilol , providing evidence of beta-adrenoceptor antagonism by this drug in peripheral resistance vessels . 4 The peak effect of a 40 mg dose of propranolol was greater than that of a 200 mg dose of prizidilol but both drugs caused persistent beta-adrenoceptor blockade for at least 7 h after ingestion .	[ "An", "assessment", "of", "beta", "-", "adrenoceptor", "blockade", "in", "man", "by", "prizidilol", "hydrochloride", ".", "1", "Prizidilol", "hydrochloride", "(", "SK", "&", "F", "92657", ")", "is", "a", "new", "compound", "which", "causes", "both", "arteriolar", "dilatation", "and", "beta", "-", "adrenoceptor", "blockade", ".", "The", "effect", "of", "a", "single", "oral", "dose", "on", "the", "responses", "of", "heart", "rate", "and", "blood", "pressure", "to", "isoprenaline", "infusion", "has", "been", "studied", "in", "healthy", "volunteers", ".", "2", "Isoprenaline", "heart", "rate", "dose", "-", "response", "curves", "showed", "parallel", "shifts", "to", "the", "right", "after", "oral", "prizidilol", ",", "indicating", "antagonism", "by", "this", "compound", "at", "beta", "-", "adrenoceptors", "in", "the", "heart", ".", "3", "Isoprenaline", "dose", "-", "response", "curves", "for", "decreases", "in", "diastolic", "blood", "pressure", "also", "showed", "shifts", "to", "the", "right", "after", "oral", "prizidilol", ",", "providing", "evidence", "of", "beta", "-", "adrenoceptor", "antagonism", "by", "this", "drug", "in", "peripheral", "resistance", "vessels", ".", "4", "The", "peak", "effect", "of", "a", "40", "mg", "dose", "of", "propranolol", "was", "greater", "than", "that", "of", "a", "200", "mg", "dose", "of", "prizidilol", "but", "both", "drugs", "caused", "persistent", "beta", "-", "adrenoceptor", "blockade", "for", "at", "least", "7", "h", "after", "ingestion", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition" ]
beta - adrenoceptor blockade, prizidilol hydrochloride ., Prizidilol hydrochloride, beta - adrenoceptor blockade ., healthy volunteers, Isoprenaline, heart rate dose - response curves, diastolic blood pressure, propranolol	78161_task2	Sentence: An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride . 1 Prizidilol hydrochloride ( SK & F 92657 ) is a new compound which causes both arteriolar dilatation and beta-adrenoceptor blockade . The effect of a single oral dose on the responses of heart rate and blood pressure to isoprenaline infusion has been studied in healthy volunteers . 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol , indicating antagonism by this compound at beta-adrenoceptors in the heart . 3 Isoprenaline dose-response curves for decreases in diastolic blood pressure also showed shifts to the right after oral prizidilol , providing evidence of beta-adrenoceptor antagonism by this drug in peripheral resistance vessels . 4 The peak effect of a 40 mg dose of propranolol was greater than that of a 200 mg dose of prizidilol but both drugs caused persistent beta-adrenoceptor blockade for at least 7 h after ingestion . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride . 1 Prizidilol hydrochloride ( SK & F 92657 ) is a new compound which causes both arteriolar dilatation and beta-adrenoceptor blockade . The effect of a single oral dose on the responses of heart rate and blood pressure to isoprenaline infusion has been studied in healthy volunteers . 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol , indicating antagonism by this compound at beta-adrenoceptors in the heart . 3 Isoprenaline dose-response curves for decreases in diastolic blood pressure also showed shifts to the right after oral prizidilol , providing evidence of beta-adrenoceptor antagonism by this drug in peripheral resistance vessels . 4 The peak effect of a 40 mg dose of propranolol was greater than that of a 200 mg dose of prizidilol but both drugs caused persistent beta-adrenoceptor blockade for at least 7 h after ingestion .	[ "An", "assessment", "of", "beta", "-", "adrenoceptor", "blockade", "in", "man", "by", "prizidilol", "hydrochloride", ".", "1", "Prizidilol", "hydrochloride", "(", "SK", "&", "F", "92657", ")", "is", "a", "new", "compound", "which", "causes", "both", "arteriolar", "dilatation", "and", "beta", "-", "adrenoceptor", "blockade", ".", "The", "effect", "of", "a", "single", "oral", "dose", "on", "the", "responses", "of", "heart", "rate", "and", "blood", "pressure", "to", "isoprenaline", "infusion", "has", "been", "studied", "in", "healthy", "volunteers", ".", "2", "Isoprenaline", "heart", "rate", "dose", "-", "response", "curves", "showed", "parallel", "shifts", "to", "the", "right", "after", "oral", "prizidilol", ",", "indicating", "antagonism", "by", "this", "compound", "at", "beta", "-", "adrenoceptors", "in", "the", "heart", ".", "3", "Isoprenaline", "dose", "-", "response", "curves", "for", "decreases", "in", "diastolic", "blood", "pressure", "also", "showed", "shifts", "to", "the", "right", "after", "oral", "prizidilol", ",", "providing", "evidence", "of", "beta", "-", "adrenoceptor", "antagonism", "by", "this", "drug", "in", "peripheral", "resistance", "vessels", ".", "4", "The", "peak", "effect", "of", "a", "40", "mg", "dose", "of", "propranolol", "was", "greater", "than", "that", "of", "a", "200", "mg", "dose", "of", "prizidilol", "but", "both", "drugs", "caused", "persistent", "beta", "-", "adrenoceptor", "blockade", "for", "at", "least", "7", "h", "after", "ingestion", "." ]	[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition" ]
thrombin is a GENE-Y, W215A is a GENE-N, E217A is a GENE-N	15252033_task0	Sentence: The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N	[ "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]	The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket.	[ "The", "anticoagulant", "thrombin", "mutant", "W215A", "/", "E217A", "has", "a", "collapsed", "primary", "specificity", "pocket", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
thrombin is a GENE-Y, W215A is a GENE-N, E217A is a GENE-N	15252033_task1	Sentence: The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. Instructions: please typing these entity words according to sentence: thrombin, W215A, E217A Options: GENE-Y, GENE-N	[ "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]	The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket.	[ "The", "anticoagulant", "thrombin", "mutant", "W215A", "/", "E217A", "has", "a", "collapsed", "primary", "specificity", "pocket", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
thrombin, W215A, E217A	15252033_task2	Sentence: The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]	The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket.	[ "The", "anticoagulant", "thrombin", "mutant", "W215A", "/", "E217A", "has", "a", "collapsed", "primary", "specificity", "pocket", "." ]	[ "CHEMICAL", "GENE-Y", "GENE-N" ]
Mammakarzinome is an umlsterm, Mutationen is an umlsterm, Gene is an umlsterm, Frauen is an umlsterm, Lebens is an umlsterm, Mammakarzinom is an umlsterm, Erkrankungsalter is an umlsterm, Frauen is an umlsterm, Mammakarzinoms is an umlsterm, Frauen is an umlsterm, genetischer Praedisposition is an umlsterm, Mammakarzinom is an umlsterm, Brustselbstuntersuchung is an umlsterm, Sonographie is an umlsterm, Mammographie is an umlsterm, Magnetresonanztomographie is an umlsterm	DerRadiologe.70370591.ger.abstr_task0	Sentence: Mammakarzinome sind in etwa 5 % auf eine genetische Disposition zurueckzufuehren . Am haeufigsten finden sich Mutationen im Bereich der Gene BRCA1 und BRCA2. Frauen mit einer genetischen Disposition erkranken in etwa 70-90 % im Laufe ihres Lebens an einem Mammakarzinom . Das Erkrankungsalter bei diesen Frauen liegt in der Regel deutlich niedriger als bei den spontanen Formen des Mammakarzinoms , so dass vorhandene Frueherkennungskonzepte auf der Basis eines Mammographiescreenings nicht ohne weiteres auf dieses Hochrisikokollektiv uebertragbar sind . Im folgenden wird ein integriertes Konzept zur Frueherkennung bei Frauen mit genetischer Praedisposition fuer ein Mammakarzinom auf der Basis von Brustselbstuntersuchung , klinischer Untersuchung , Sonographie , Mammographie und Magnetresonanztomographie vorgestellt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Mammakarzinome sind in etwa 5 % auf eine genetische Disposition zurueckzufuehren . Am haeufigsten finden sich Mutationen im Bereich der Gene BRCA1 und BRCA2. Frauen mit einer genetischen Disposition erkranken in etwa 70-90 % im Laufe ihres Lebens an einem Mammakarzinom . Das Erkrankungsalter bei diesen Frauen liegt in der Regel deutlich niedriger als bei den spontanen Formen des Mammakarzinoms , so dass vorhandene Frueherkennungskonzepte auf der Basis eines Mammographiescreenings nicht ohne weiteres auf dieses Hochrisikokollektiv uebertragbar sind . Im folgenden wird ein integriertes Konzept zur Frueherkennung bei Frauen mit genetischer Praedisposition fuer ein Mammakarzinom auf der Basis von Brustselbstuntersuchung , klinischer Untersuchung , Sonographie , Mammographie und Magnetresonanztomographie vorgestellt .	[ "Mammakarzinome", "sind", "in", "etwa", "5", "%", "auf", "eine", "genetische", "Disposition", "zurueckzufuehren", ".", "Am", "haeufigsten", "finden", "sich", "Mutationen", "im", "Bereich", "der", "Gene", "BRCA1", "und", "BRCA2", ".", "Frauen", "mit", "einer", "genetischen", "Disposition", "erkranken", "in", "etwa", "70", "-", "90", "%", "im", "Laufe", "ihres", "Lebens", "an", "einem", "Mammakarzinom", ".", "Das", "Erkrankungsalter", "bei", "diesen", "Frauen", "liegt", "in", "der", "Regel", "deutlich", "niedriger", "als", "bei", "den", "spontanen", "Formen", "des", "Mammakarzinoms", ",", "so", "dass", "vorhandene", "Frueherkennungskonzepte", "auf", "der", "Basis", "eines", "Mammographiescreenings", "nicht", "ohne", "weiteres", "auf", "dieses", "Hochrisikokollektiv", "uebertragbar", "sind", ".", "Im", "folgenden", "wird", "ein", "integriertes", "Konzept", "zur", "Frueherkennung", "bei", "Frauen", "mit", "genetischer", "Praedisposition", "fuer", "ein", "Mammakarzinom", "auf", "der", "Basis", "von", "Brustselbstuntersuchung", ",", "klinischer", "Untersuchung", ",", "Sonographie", ",", "Mammographie", "und", "Magnetresonanztomographie", "vorgestellt", "." ]	[ "umlsterm" ]
Mammakarzinome is an umlsterm, Mutationen is an umlsterm, Gene is an umlsterm, Frauen is an umlsterm, Lebens is an umlsterm, Mammakarzinom is an umlsterm, Erkrankungsalter is an umlsterm, Frauen is an umlsterm, Mammakarzinoms is an umlsterm, Frauen is an umlsterm, genetischer Praedisposition is an umlsterm, Mammakarzinom is an umlsterm, Brustselbstuntersuchung is an umlsterm, Sonographie is an umlsterm, Mammographie is an umlsterm, Magnetresonanztomographie is an umlsterm	DerRadiologe.70370591.ger.abstr_task1	Sentence: Mammakarzinome sind in etwa 5 % auf eine genetische Disposition zurueckzufuehren . Am haeufigsten finden sich Mutationen im Bereich der Gene BRCA1 und BRCA2. Frauen mit einer genetischen Disposition erkranken in etwa 70-90 % im Laufe ihres Lebens an einem Mammakarzinom . Das Erkrankungsalter bei diesen Frauen liegt in der Regel deutlich niedriger als bei den spontanen Formen des Mammakarzinoms , so dass vorhandene Frueherkennungskonzepte auf der Basis eines Mammographiescreenings nicht ohne weiteres auf dieses Hochrisikokollektiv uebertragbar sind . Im folgenden wird ein integriertes Konzept zur Frueherkennung bei Frauen mit genetischer Praedisposition fuer ein Mammakarzinom auf der Basis von Brustselbstuntersuchung , klinischer Untersuchung , Sonographie , Mammographie und Magnetresonanztomographie vorgestellt . Instructions: please typing these entity words according to sentence: Mammakarzinome, Mutationen, Gene, Frauen, Lebens, Mammakarzinom, Erkrankungsalter, Frauen, Mammakarzinoms, Frauen, genetischer Praedisposition, Mammakarzinom, Brustselbstuntersuchung, Sonographie, Mammographie, Magnetresonanztomographie Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Mammakarzinome sind in etwa 5 % auf eine genetische Disposition zurueckzufuehren . Am haeufigsten finden sich Mutationen im Bereich der Gene BRCA1 und BRCA2. Frauen mit einer genetischen Disposition erkranken in etwa 70-90 % im Laufe ihres Lebens an einem Mammakarzinom . Das Erkrankungsalter bei diesen Frauen liegt in der Regel deutlich niedriger als bei den spontanen Formen des Mammakarzinoms , so dass vorhandene Frueherkennungskonzepte auf der Basis eines Mammographiescreenings nicht ohne weiteres auf dieses Hochrisikokollektiv uebertragbar sind . Im folgenden wird ein integriertes Konzept zur Frueherkennung bei Frauen mit genetischer Praedisposition fuer ein Mammakarzinom auf der Basis von Brustselbstuntersuchung , klinischer Untersuchung , Sonographie , Mammographie und Magnetresonanztomographie vorgestellt .	[ "Mammakarzinome", "sind", "in", "etwa", "5", "%", "auf", "eine", "genetische", "Disposition", "zurueckzufuehren", ".", "Am", "haeufigsten", "finden", "sich", "Mutationen", "im", "Bereich", "der", "Gene", "BRCA1", "und", "BRCA2", ".", "Frauen", "mit", "einer", "genetischen", "Disposition", "erkranken", "in", "etwa", "70", "-", "90", "%", "im", "Laufe", "ihres", "Lebens", "an", "einem", "Mammakarzinom", ".", "Das", "Erkrankungsalter", "bei", "diesen", "Frauen", "liegt", "in", "der", "Regel", "deutlich", "niedriger", "als", "bei", "den", "spontanen", "Formen", "des", "Mammakarzinoms", ",", "so", "dass", "vorhandene", "Frueherkennungskonzepte", "auf", "der", "Basis", "eines", "Mammographiescreenings", "nicht", "ohne", "weiteres", "auf", "dieses", "Hochrisikokollektiv", "uebertragbar", "sind", ".", "Im", "folgenden", "wird", "ein", "integriertes", "Konzept", "zur", "Frueherkennung", "bei", "Frauen", "mit", "genetischer", "Praedisposition", "fuer", "ein", "Mammakarzinom", "auf", "der", "Basis", "von", "Brustselbstuntersuchung", ",", "klinischer", "Untersuchung", ",", "Sonographie", ",", "Mammographie", "und", "Magnetresonanztomographie", "vorgestellt", "." ]	[ "umlsterm" ]
Mammakarzinome, Mutationen, Gene, Frauen, Lebens, Mammakarzinom, Erkrankungsalter, Frauen, Mammakarzinoms, Frauen, genetischer Praedisposition, Mammakarzinom, Brustselbstuntersuchung, Sonographie, Mammographie, Magnetresonanztomographie	DerRadiologe.70370591.ger.abstr_task2	Sentence: Mammakarzinome sind in etwa 5 % auf eine genetische Disposition zurueckzufuehren . Am haeufigsten finden sich Mutationen im Bereich der Gene BRCA1 und BRCA2. Frauen mit einer genetischen Disposition erkranken in etwa 70-90 % im Laufe ihres Lebens an einem Mammakarzinom . Das Erkrankungsalter bei diesen Frauen liegt in der Regel deutlich niedriger als bei den spontanen Formen des Mammakarzinoms , so dass vorhandene Frueherkennungskonzepte auf der Basis eines Mammographiescreenings nicht ohne weiteres auf dieses Hochrisikokollektiv uebertragbar sind . Im folgenden wird ein integriertes Konzept zur Frueherkennung bei Frauen mit genetischer Praedisposition fuer ein Mammakarzinom auf der Basis von Brustselbstuntersuchung , klinischer Untersuchung , Sonographie , Mammographie und Magnetresonanztomographie vorgestellt . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]	Mammakarzinome sind in etwa 5 % auf eine genetische Disposition zurueckzufuehren . Am haeufigsten finden sich Mutationen im Bereich der Gene BRCA1 und BRCA2. Frauen mit einer genetischen Disposition erkranken in etwa 70-90 % im Laufe ihres Lebens an einem Mammakarzinom . Das Erkrankungsalter bei diesen Frauen liegt in der Regel deutlich niedriger als bei den spontanen Formen des Mammakarzinoms , so dass vorhandene Frueherkennungskonzepte auf der Basis eines Mammographiescreenings nicht ohne weiteres auf dieses Hochrisikokollektiv uebertragbar sind . Im folgenden wird ein integriertes Konzept zur Frueherkennung bei Frauen mit genetischer Praedisposition fuer ein Mammakarzinom auf der Basis von Brustselbstuntersuchung , klinischer Untersuchung , Sonographie , Mammographie und Magnetresonanztomographie vorgestellt .	[ "Mammakarzinome", "sind", "in", "etwa", "5", "%", "auf", "eine", "genetische", "Disposition", "zurueckzufuehren", ".", "Am", "haeufigsten", "finden", "sich", "Mutationen", "im", "Bereich", "der", "Gene", "BRCA1", "und", "BRCA2", ".", "Frauen", "mit", "einer", "genetischen", "Disposition", "erkranken", "in", "etwa", "70", "-", "90", "%", "im", "Laufe", "ihres", "Lebens", "an", "einem", "Mammakarzinom", ".", "Das", "Erkrankungsalter", "bei", "diesen", "Frauen", "liegt", "in", "der", "Regel", "deutlich", "niedriger", "als", "bei", "den", "spontanen", "Formen", "des", "Mammakarzinoms", ",", "so", "dass", "vorhandene", "Frueherkennungskonzepte", "auf", "der", "Basis", "eines", "Mammographiescreenings", "nicht", "ohne", "weiteres", "auf", "dieses", "Hochrisikokollektiv", "uebertragbar", "sind", ".", "Im", "folgenden", "wird", "ein", "integriertes", "Konzept", "zur", "Frueherkennung", "bei", "Frauen", "mit", "genetischer", "Praedisposition", "fuer", "ein", "Mammakarzinom", "auf", "der", "Basis", "von", "Brustselbstuntersuchung", ",", "klinischer", "Untersuchung", ",", "Sonographie", ",", "Mammographie", "und", "Magnetresonanztomographie", "vorgestellt", "." ]	[ "umlsterm" ]
ETS1 is a Protein, GM - CSF is a Protein, promoter is a Entity, Granulocyte - macrophage colony stimulating factor is a Protein, GM - CSF is a Protein, Cis - acting elements is a Entity, GM - CSF is a Protein, ETS1 is a Protein, ETS1 is a Protein, GM - CSF is a Protein, ETS1 is a Protein, ETS1 is a Protein, GM - CSF is a Protein, ETS1 is a Protein, ETS1 is a Protein	727_task0	Sentence: ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkappaB, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NFkappaB or AP1 transcription factors are supplied by co-transfection. We confirm that binding of endogenous NFkappaB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkappaB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkappaB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkappaB, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NFkappaB or AP1 transcription factors are supplied by co-transfection. We confirm that binding of endogenous NFkappaB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkappaB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkappaB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells.	[ "ETS1", ",", "NFkappaB", "and", "AP1", "synergistically", "transactivate", "the", "human", "GM", "-", "CSF", "promoter", ".", "\n", "Activation", "of", "helper", "T", "cells", "results", "in", "coordinate", "expression", "of", "a", "number", "of", "cytokines", "involved", "in", "differentiation", ",", "proliferation", "and", "activation", "of", "the", "haematopoietic", "system", ".", "Granulocyte", "-", "macrophage", "colony", "stimulating", "factor", "(", "GM", "-", "CSF", ")", "is", "one", "such", "cytokine", ",", "whose", "increased", "expression", "results", "mostly", "from", "increases", "in", "transcription", ".", "Cis", "-", "acting", "elements", "with", "NFkappaB", ",", "AP1", "and", "ETS", "-", "like", "binding", "motifs", "have", "been", "identified", "in", "the", "promoter", "region", "of", "the", "GM", "-", "CSF", "gene", ",", "and", "are", "important", "or", "essential", "for", "transcriptional", "activity", "following", "T", "cell", "activation", ".", "ETS1", "is", "a", "transcription", "factor", "of", "the", "ETS", "family", "that", "is", "expressed", "in", "T", "cells", ".", "We", "have", "previously", "shown", "that", "ETS1", "can", "transactivate", "GM", "-", "CSF", "in", "Jurkat", "T", "cells", ",", "but", "only", "after", "the", "cells", "have", "been", "stimulated", "by", "treatment", "with", "PMA", "and", "ionomycin", ",", "agents", "that", "mimic", "T", "cell", "activation", ".", "Thus", "we", "proposed", "that", "ETS1", ",", "which", "is", "expressed", "constitutively", "in", "Jurkat", "cells", ",", "may", "act", "in", "concert", "with", "PMA", "/", "ionomycin", "inducible", "factors", ".", "Here", "we", "show", "that", "ETS1", "can", "transactivate", "a", "GM", "-", "CSF", "reporter", "construct", "in", "unstimulated", "Jurkat", "cells", ",", "providing", "that", "either", "NFkappaB", "or", "AP1", "transcription", "factors", "are", "supplied", "by", "co", "-", "transfection", ".", "We", "confirm", "that", "binding", "of", "endogenous", "NFkappaB", "and", "AP1", "is", "induced", "following", "PMA", "/", "ionomycin", "treatment", "of", "T", "cells", ".", "Transactivation", "by", "ETS1", ",", "NFkappaB", "and", "AP1", "is", "synergistic", ",", "and", "mutation", "of", "the", "individual", "binding", "sites", "reveals", "that", "the", "transcriptional", "activities", "of", "these", "factors", "are", "interdependent", ".", "Our", "results", "suggest", "that", "constitutive", "ETS1", ",", "and", "inducible", "NFkappaB", "and", "AP1", ",", "cooperate", "as", "part", "of", "a", "higher", "order", "transcriptional", "complex", "in", "activated", "T", "cells", "." ]	[ "Protein", "Entity" ]
ETS1 is a Protein, GM - CSF is a Protein, promoter is a Entity, Granulocyte - macrophage colony stimulating factor is a Protein, GM - CSF is a Protein, Cis - acting elements is a Entity, GM - CSF is a Protein, ETS1 is a Protein, ETS1 is a Protein, GM - CSF is a Protein, ETS1 is a Protein, ETS1 is a Protein, GM - CSF is a Protein, ETS1 is a Protein, ETS1 is a Protein	727_task1	Sentence: ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkappaB, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NFkappaB or AP1 transcription factors are supplied by co-transfection. We confirm that binding of endogenous NFkappaB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkappaB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkappaB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells. Instructions: please typing these entity words according to sentence: ETS1, GM - CSF, promoter, Granulocyte - macrophage colony stimulating factor, GM - CSF, Cis - acting elements, GM - CSF, ETS1, ETS1, GM - CSF, ETS1, ETS1, GM - CSF, ETS1, ETS1 Options: Entity, Protein	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkappaB, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NFkappaB or AP1 transcription factors are supplied by co-transfection. We confirm that binding of endogenous NFkappaB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkappaB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkappaB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells.	[ "ETS1", ",", "NFkappaB", "and", "AP1", "synergistically", "transactivate", "the", "human", "GM", "-", "CSF", "promoter", ".", "\n", "Activation", "of", "helper", "T", "cells", "results", "in", "coordinate", "expression", "of", "a", "number", "of", "cytokines", "involved", "in", "differentiation", ",", "proliferation", "and", "activation", "of", "the", "haematopoietic", "system", ".", "Granulocyte", "-", "macrophage", "colony", "stimulating", "factor", "(", "GM", "-", "CSF", ")", "is", "one", "such", "cytokine", ",", "whose", "increased", "expression", "results", "mostly", "from", "increases", "in", "transcription", ".", "Cis", "-", "acting", "elements", "with", "NFkappaB", ",", "AP1", "and", "ETS", "-", "like", "binding", "motifs", "have", "been", "identified", "in", "the", "promoter", "region", "of", "the", "GM", "-", "CSF", "gene", ",", "and", "are", "important", "or", "essential", "for", "transcriptional", "activity", "following", "T", "cell", "activation", ".", "ETS1", "is", "a", "transcription", "factor", "of", "the", "ETS", "family", "that", "is", "expressed", "in", "T", "cells", ".", "We", "have", "previously", "shown", "that", "ETS1", "can", "transactivate", "GM", "-", "CSF", "in", "Jurkat", "T", "cells", ",", "but", "only", "after", "the", "cells", "have", "been", "stimulated", "by", "treatment", "with", "PMA", "and", "ionomycin", ",", "agents", "that", "mimic", "T", "cell", "activation", ".", "Thus", "we", "proposed", "that", "ETS1", ",", "which", "is", "expressed", "constitutively", "in", "Jurkat", "cells", ",", "may", "act", "in", "concert", "with", "PMA", "/", "ionomycin", "inducible", "factors", ".", "Here", "we", "show", "that", "ETS1", "can", "transactivate", "a", "GM", "-", "CSF", "reporter", "construct", "in", "unstimulated", "Jurkat", "cells", ",", "providing", "that", "either", "NFkappaB", "or", "AP1", "transcription", "factors", "are", "supplied", "by", "co", "-", "transfection", ".", "We", "confirm", "that", "binding", "of", "endogenous", "NFkappaB", "and", "AP1", "is", "induced", "following", "PMA", "/", "ionomycin", "treatment", "of", "T", "cells", ".", "Transactivation", "by", "ETS1", ",", "NFkappaB", "and", "AP1", "is", "synergistic", ",", "and", "mutation", "of", "the", "individual", "binding", "sites", "reveals", "that", "the", "transcriptional", "activities", "of", "these", "factors", "are", "interdependent", ".", "Our", "results", "suggest", "that", "constitutive", "ETS1", ",", "and", "inducible", "NFkappaB", "and", "AP1", ",", "cooperate", "as", "part", "of", "a", "higher", "order", "transcriptional", "complex", "in", "activated", "T", "cells", "." ]	[ "Protein", "Entity" ]
ETS1, GM - CSF, promoter, Granulocyte - macrophage colony stimulating factor, GM - CSF, Cis - acting elements, GM - CSF, ETS1, ETS1, GM - CSF, ETS1, ETS1, GM - CSF, ETS1, ETS1	727_task2	Sentence: ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkappaB, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NFkappaB or AP1 transcription factors are supplied by co-transfection. We confirm that binding of endogenous NFkappaB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkappaB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkappaB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells. Instructions: please extract entity words from the input sentence	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkappaB, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NFkappaB or AP1 transcription factors are supplied by co-transfection. We confirm that binding of endogenous NFkappaB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkappaB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkappaB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells.	[ "ETS1", ",", "NFkappaB", "and", "AP1", "synergistically", "transactivate", "the", "human", "GM", "-", "CSF", "promoter", ".", "\n", "Activation", "of", "helper", "T", "cells", "results", "in", "coordinate", "expression", "of", "a", "number", "of", "cytokines", "involved", "in", "differentiation", ",", "proliferation", "and", "activation", "of", "the", "haematopoietic", "system", ".", "Granulocyte", "-", "macrophage", "colony", "stimulating", "factor", "(", "GM", "-", "CSF", ")", "is", "one", "such", "cytokine", ",", "whose", "increased", "expression", "results", "mostly", "from", "increases", "in", "transcription", ".", "Cis", "-", "acting", "elements", "with", "NFkappaB", ",", "AP1", "and", "ETS", "-", "like", "binding", "motifs", "have", "been", "identified", "in", "the", "promoter", "region", "of", "the", "GM", "-", "CSF", "gene", ",", "and", "are", "important", "or", "essential", "for", "transcriptional", "activity", "following", "T", "cell", "activation", ".", "ETS1", "is", "a", "transcription", "factor", "of", "the", "ETS", "family", "that", "is", "expressed", "in", "T", "cells", ".", "We", "have", "previously", "shown", "that", "ETS1", "can", "transactivate", "GM", "-", "CSF", "in", "Jurkat", "T", "cells", ",", "but", "only", "after", "the", "cells", "have", "been", "stimulated", "by", "treatment", "with", "PMA", "and", "ionomycin", ",", "agents", "that", "mimic", "T", "cell", "activation", ".", "Thus", "we", "proposed", "that", "ETS1", ",", "which", "is", "expressed", "constitutively", "in", "Jurkat", "cells", ",", "may", "act", "in", "concert", "with", "PMA", "/", "ionomycin", "inducible", "factors", ".", "Here", "we", "show", "that", "ETS1", "can", "transactivate", "a", "GM", "-", "CSF", "reporter", "construct", "in", "unstimulated", "Jurkat", "cells", ",", "providing", "that", "either", "NFkappaB", "or", "AP1", "transcription", "factors", "are", "supplied", "by", "co", "-", "transfection", ".", "We", "confirm", "that", "binding", "of", "endogenous", "NFkappaB", "and", "AP1", "is", "induced", "following", "PMA", "/", "ionomycin", "treatment", "of", "T", "cells", ".", "Transactivation", "by", "ETS1", ",", "NFkappaB", "and", "AP1", "is", "synergistic", ",", "and", "mutation", "of", "the", "individual", "binding", "sites", "reveals", "that", "the", "transcriptional", "activities", "of", "these", "factors", "are", "interdependent", ".", "Our", "results", "suggest", "that", "constitutive", "ETS1", ",", "and", "inducible", "NFkappaB", "and", "AP1", ",", "cooperate", "as", "part", "of", "a", "higher", "order", "transcriptional", "complex", "in", "activated", "T", "cells", "." ]	[ "Protein", "Entity" ]
heart failure is a Condition, NYHA is a Measurement, II - IV is a Value, previous is a Temporal, treatment is a Procedure, diuretics is a Drug	NCT01942109_inc_task0	Sentence: heart failure NYHA II-IV previous treatment with diuretics age>18 years Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Value, Procedure, Measurement, Drug	[ "B-Condition", "I-Condition", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Temporal", "B-Procedure", "O", "B-Drug", "O", "O", "O", "O" ]	heart failure NYHA II-IV previous treatment with diuretics age>18 years	[ "heart", "failure", "NYHA", "II", "-", "IV", "\n", "previous", "treatment", "with", "diuretics", "\n", "age>18", "years", "\n" ]	[ "Condition", "Procedure", "Drug", "Value", "Temporal", "Measurement", "Person" ]
heart failure is a Condition, NYHA is a Measurement, II - IV is a Value, previous is a Temporal, treatment is a Procedure, diuretics is a Drug	NCT01942109_inc_task1	Sentence: heart failure NYHA II-IV previous treatment with diuretics age>18 years Instructions: please typing these entity words according to sentence: heart failure, NYHA, II - IV, previous, treatment, diuretics Options: Temporal, Condition, Value, Procedure, Measurement, Drug	[ "B-Condition", "I-Condition", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Temporal", "B-Procedure", "O", "B-Drug", "O", "O", "O", "O" ]	heart failure NYHA II-IV previous treatment with diuretics age>18 years	[ "heart", "failure", "NYHA", "II", "-", "IV", "\n", "previous", "treatment", "with", "diuretics", "\n", "age>18", "years", "\n" ]	[ "Condition", "Procedure", "Drug", "Value", "Temporal", "Measurement", "Person" ]
heart failure, NYHA, II - IV, previous, treatment, diuretics	NCT01942109_inc_task2	Sentence: heart failure NYHA II-IV previous treatment with diuretics age>18 years Instructions: please extract entity words from the input sentence	[ "B-Condition", "I-Condition", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Temporal", "B-Procedure", "O", "B-Drug", "O", "O", "O", "O" ]	heart failure NYHA II-IV previous treatment with diuretics age>18 years	[ "heart", "failure", "NYHA", "II", "-", "IV", "\n", "previous", "treatment", "with", "diuretics", "\n", "age>18", "years", "\n" ]	[ "Condition", "Procedure", "Drug", "Value", "Temporal", "Measurement", "Person" ]
Jesus is a NOMBRE_SUJETO_ASISTENCIA, Barrios Larrea is a NOMBRE_SUJETO_ASISTENCIA, Calle Tres Palomas , 27 is a CALLE, 48 20895745 94 is a ID_ASEGURAMIENTO, Calle Ibarra , 1 is a CALLE, Donostia - San Sebastián is a TERRITORIO, 20080 is a TERRITORIO, 03/03/1956 is a FECHAS, España is a PAIS, 59 años is a EDAD_SUJETO_ASISTENCIA, 27/07/2015 is a FECHAS, 8934679 is a ID_CONTACTO_ASISTENCIAL, Sergio Andrés Torres Bayona is a NOMBRE_PERSONAL_SANITARIO, 20 20 28563 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 59 años is a EDAD_SUJETO_ASISTENCIA, Sergio Andrés Torres Bayona is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitario Donostia is a HOSPITAL, C/ Doctor Beguiristain , 117 is a CALLE, 20080 is a TERRITORIO, Donostia - San Sebastián is a TERRITORIO, sergioandrestorres@hotmail.com is a CORREO_ELECTRONICO	429_task0	Sentence: Datos del paciente. Nombre: Jesus. Apellidos: Barrios Larrea. NHC: Calle Tres Palomas, 27. NASS: 48 20895745 94. Domicilio: Calle Ibarra, 1. Localidad/ Provincia: Donostia-San Sebastián. CP: 20080. Datos asistenciales. Fecha de nacimiento: 03/03/1956. País: España. Edad: 59 años Sexo:H. Fecha de Ingreso: 27/07/2015. Servicio: Neurocirugía. Episodio: 8934679. Médico: Sergio Andrés Torres Bayona NºCol: 20 20 28563. Informe clínico del paciente: varón de 59 años, diagnosticado de carcinoma escamoso de laringe T2N2b, que se trató inicialmente con tres ciclos de quimioterapia sin remisión, por lo que tres meses después se realizó una laringectomía supraglótica, con vaciamiento radical incompleto modificado del lado izquierdo. La anatomía patológica demostró un carcinoma escamoso infiltrante en hemiepiglotis izquierda con 8 de 11 ganglios linfáticos positivos de la cadena yugular interna, subdigástricos y supraclaviculares izquierdos. Posteriormente recibió quimioterapia y radioterapia sobre supraglotis e hipofaringe y áreas ganglionares bilaterales. Nueve meses después de la cirugía consultó por cefalea de tres semanas de evolución asociada a diplopia binocular y visión borrosa del ojo derecho, evidenciándose oftalmoparesia del III, IV y VI pares craneales derechos. Una resonancia magnética (RM) cerebral mostró una masa en la porción posterior y lateral del seno cavernoso derecho, con protusión hacia la cisterna prepontina, bien delimitada, con captación homogénea de gadolinio y unas dimensiones de 11x14,4x12,2 mm. En la ventana ósea de la TAC no se observaron ni lesiones líticas ni invasión del ala o seno esfenoidal. La TAC toraco-abdomino-pélvica fue negativa. El diagnóstico diferencial radiológico fue de schwannoma, meningioma o metástasis. Se realizó una biopsia abierta con abordaje transilviano a la pared lateral del seno cavernoso donde se observó la invasión tumoral del espacio intradural. El resultado anatomopatológico fue de carcinoma escamoso. Posteriormente se administró radioterapia a titulo paliativo. Tres semanas después de la cirugía el paciente consultó por dolor dorsal sin clínica neurológica. Un estudio de RM de raquis mostró lesiones focales en los cuerpos D4, D6 y D10 sospechosas de implantes metastásicos. Con el tratamiento radioterápico se alivió la cefalea, pero desarrolló una oftalmoplejía, conservando únicamente la abducción del ojo derecho. El paciente falleció nueve meses tras el diagnóstico de la metástasis en el seno cavernoso. Remitido por: Dr. Sergio Andrés Torres Bayona Servicio de Neurocirugía Hospital Universitario Donostia C/ Doctor Beguiristain, 117 20080 Donostia-San Sebastián E-mail: sergioandrestorres@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_CONTACTO_ASISTENCIAL, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Jesus. Apellidos: Barrios Larrea. NHC: Calle Tres Palomas, 27. NASS: 48 20895745 94. Domicilio: Calle Ibarra, 1. Localidad/ Provincia: Donostia-San Sebastián. CP: 20080. Datos asistenciales. Fecha de nacimiento: 03/03/1956. País: España. Edad: 59 años Sexo:H. Fecha de Ingreso: 27/07/2015. Servicio: Neurocirugía. Episodio: 8934679. Médico: Sergio Andrés Torres Bayona NºCol: 20 20 28563. Informe clínico del paciente: varón de 59 años, diagnosticado de carcinoma escamoso de laringe T2N2b, que se trató inicialmente con tres ciclos de quimioterapia sin remisión, por lo que tres meses después se realizó una laringectomía supraglótica, con vaciamiento radical incompleto modificado del lado izquierdo. La anatomía patológica demostró un carcinoma escamoso infiltrante en hemiepiglotis izquierda con 8 de 11 ganglios linfáticos positivos de la cadena yugular interna, subdigástricos y supraclaviculares izquierdos. Posteriormente recibió quimioterapia y radioterapia sobre supraglotis e hipofaringe y áreas ganglionares bilaterales. Nueve meses después de la cirugía consultó por cefalea de tres semanas de evolución asociada a diplopia binocular y visión borrosa del ojo derecho, evidenciándose oftalmoparesia del III, IV y VI pares craneales derechos. Una resonancia magnética (RM) cerebral mostró una masa en la porción posterior y lateral del seno cavernoso derecho, con protusión hacia la cisterna prepontina, bien delimitada, con captación homogénea de gadolinio y unas dimensiones de 11x14,4x12,2 mm. En la ventana ósea de la TAC no se observaron ni lesiones líticas ni invasión del ala o seno esfenoidal. La TAC toraco-abdomino-pélvica fue negativa. El diagnóstico diferencial radiológico fue de schwannoma, meningioma o metástasis. Se realizó una biopsia abierta con abordaje transilviano a la pared lateral del seno cavernoso donde se observó la invasión tumoral del espacio intradural. El resultado anatomopatológico fue de carcinoma escamoso. Posteriormente se administró radioterapia a titulo paliativo. Tres semanas después de la cirugía el paciente consultó por dolor dorsal sin clínica neurológica. Un estudio de RM de raquis mostró lesiones focales en los cuerpos D4, D6 y D10 sospechosas de implantes metastásicos. Con el tratamiento radioterápico se alivió la cefalea, pero desarrolló una oftalmoplejía, conservando únicamente la abducción del ojo derecho. El paciente falleció nueve meses tras el diagnóstico de la metástasis en el seno cavernoso. Remitido por: Dr. Sergio Andrés Torres Bayona Servicio de Neurocirugía Hospital Universitario Donostia C/ Doctor Beguiristain, 117 20080 Donostia-San Sebastián E-mail: sergioandrestorres@hotmail.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Jesus", ".", "\n", "Apellidos", ":", "Barrios", "Larrea", ".", "\n", "NHC", ":", "Calle", "Tres", "Palomas", ",", "27", ".", "\n", "NASS", ":", "48", "20895745", "94", ".", "\n", "Domicilio", ":", "Calle", "Ibarra", ",", "1", ".", "\n", "Localidad/", "Provincia", ":", "Donostia", "-", "San", "Sebastián", ".", "\n", "CP", ":", "20080", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "03/03/1956", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "59", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "27/07/2015", ".", "\n", "Servicio", ":", "Neurocirugía", ".", "\n", "Episodio", ":", "8934679", ".", "\n", "Médico", ":", "Sergio", "Andrés", "Torres", "Bayona", "NºCol", ":", "20", "20", "28563", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "varón", "de", "59", "años", ",", "diagnosticado", "de", "carcinoma", "escamoso", "de", "laringe", "T2N2b", ",", "que", "se", "trató", "inicialmente", "con", "tres", "ciclos", "de", "quimioterapia", "sin", "remisión", ",", "por", "lo", "que", "tres", "meses", "después", "se", "realizó", "una", "laringectomía", "supraglótica", ",", "con", "vaciamiento", "radical", "incompleto", "modificado", "del", "lado", "izquierdo", ".", "La", "anatomía", "patológica", "demostró", "un", "carcinoma", "escamoso", "infiltrante", "en", "hemiepiglotis", "izquierda", "con", "8", "de", "11", "ganglios", "linfáticos", "positivos", "de", "la", "cadena", "yugular", "interna", ",", "subdigástricos", "y", "supraclaviculares", "izquierdos", ".", "Posteriormente", "recibió", "quimioterapia", "y", "radioterapia", "sobre", "supraglotis", "e", "hipofaringe", "y", "áreas", "ganglionares", "bilaterales", ".", "\n", "Nueve", "meses", "después", "de", "la", "cirugía", "consultó", "por", "cefalea", "de", "tres", "semanas", "de", "evolución", "asociada", "a", "diplopia", "binocular", "y", "visión", "borrosa", "del", "ojo", "derecho", ",", "evidenciándose", "oftalmoparesia", "del", "III", ",", "IV", "y", "VI", "pares", "craneales", "derechos", ".", "Una", "resonancia", "magnética", "(", "RM", ")", "cerebral", "mostró", "una", "masa", "en", "la", "porción", "posterior", "y", "lateral", "del", "seno", "cavernoso", "derecho", ",", "con", "protusión", "hacia", "la", "cisterna", "prepontina", ",", "bien", "delimitada", ",", "con", "captación", "homogénea", "de", "gadolinio", "y", "unas", "dimensiones", "de", "11x14,4x12,2", "mm", ".", "En", "la", "ventana", "ósea", "de", "la", "TAC", "no", "se", "observaron", "ni", "lesiones", "líticas", "ni", "invasión", "del", "ala", "o", "seno", "esfenoidal", ".", "La", "TAC", "toraco", "-", "abdomino", "-", "pélvica", "fue", "negativa", ".", "El", "diagnóstico", "diferencial", "radiológico", "fue", "de", "schwannoma", ",", "meningioma", "o", "metástasis", ".", "\n", "Se", "realizó", "una", "biopsia", "abierta", "con", "abordaje", "transilviano", "a", "la", "pared", "lateral", "del", "seno", "cavernoso", "donde", "se", "observó", "la", "invasión", "tumoral", "del", "espacio", "intradural", ".", "El", "resultado", "anatomopatológico", "fue", "de", "carcinoma", "escamoso", ".", "Posteriormente", "se", "administró", "radioterapia", "a", "titulo", "paliativo", ".", "Tres", "semanas", "después", "de", "la", "cirugía", "el", "paciente", "consultó", "por", "dolor", "dorsal", "sin", "clínica", "neurológica", ".", "Un", "estudio", "de", "RM", "de", "raquis", "mostró", "lesiones", "focales", "en", "los", "cuerpos", "D4", ",", "D6", "y", "D10", "sospechosas", "de", "implantes", "metastásicos", ".", "\n", "Con", "el", "tratamiento", "radioterápico", "se", "alivió", "la", "cefalea", ",", "pero", "desarrolló", "una", "oftalmoplejía", ",", "conservando", "únicamente", "la", "abducción", "del", "ojo", "derecho", ".", "El", "paciente", "falleció", "nueve", "meses", "tras", "el", "diagnóstico", "de", "la", "metástasis", "en", "el", "seno", "cavernoso", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Sergio", "Andrés", "Torres", "Bayona", "Servicio", "de", "Neurocirugía", "Hospital", "Universitario", "Donostia", "C/", "Doctor", "Beguiristain", ",", "117", "20080", "Donostia", "-", "San", "Sebastián", "E", "-", "mail", ":", "sergioandrestorres@hotmail.com", "\n" ]	[ "HOSPITAL", "CORREO_ELECTRONICO", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "TERRITORIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "ID_CONTACTO_ASISTENCIAL", "EDAD_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Jesus is a NOMBRE_SUJETO_ASISTENCIA, Barrios Larrea is a NOMBRE_SUJETO_ASISTENCIA, Calle Tres Palomas , 27 is a CALLE, 48 20895745 94 is a ID_ASEGURAMIENTO, Calle Ibarra , 1 is a CALLE, Donostia - San Sebastián is a TERRITORIO, 20080 is a TERRITORIO, 03/03/1956 is a FECHAS, España is a PAIS, 59 años is a EDAD_SUJETO_ASISTENCIA, 27/07/2015 is a FECHAS, 8934679 is a ID_CONTACTO_ASISTENCIAL, Sergio Andrés Torres Bayona is a NOMBRE_PERSONAL_SANITARIO, 20 20 28563 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 59 años is a EDAD_SUJETO_ASISTENCIA, Sergio Andrés Torres Bayona is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitario Donostia is a HOSPITAL, C/ Doctor Beguiristain , 117 is a CALLE, 20080 is a TERRITORIO, Donostia - San Sebastián is a TERRITORIO, sergioandrestorres@hotmail.com is a CORREO_ELECTRONICO	429_task1	Sentence: Datos del paciente. Nombre: Jesus. Apellidos: Barrios Larrea. NHC: Calle Tres Palomas, 27. NASS: 48 20895745 94. Domicilio: Calle Ibarra, 1. Localidad/ Provincia: Donostia-San Sebastián. CP: 20080. Datos asistenciales. Fecha de nacimiento: 03/03/1956. País: España. Edad: 59 años Sexo:H. Fecha de Ingreso: 27/07/2015. Servicio: Neurocirugía. Episodio: 8934679. Médico: Sergio Andrés Torres Bayona NºCol: 20 20 28563. Informe clínico del paciente: varón de 59 años, diagnosticado de carcinoma escamoso de laringe T2N2b, que se trató inicialmente con tres ciclos de quimioterapia sin remisión, por lo que tres meses después se realizó una laringectomía supraglótica, con vaciamiento radical incompleto modificado del lado izquierdo. La anatomía patológica demostró un carcinoma escamoso infiltrante en hemiepiglotis izquierda con 8 de 11 ganglios linfáticos positivos de la cadena yugular interna, subdigástricos y supraclaviculares izquierdos. Posteriormente recibió quimioterapia y radioterapia sobre supraglotis e hipofaringe y áreas ganglionares bilaterales. Nueve meses después de la cirugía consultó por cefalea de tres semanas de evolución asociada a diplopia binocular y visión borrosa del ojo derecho, evidenciándose oftalmoparesia del III, IV y VI pares craneales derechos. Una resonancia magnética (RM) cerebral mostró una masa en la porción posterior y lateral del seno cavernoso derecho, con protusión hacia la cisterna prepontina, bien delimitada, con captación homogénea de gadolinio y unas dimensiones de 11x14,4x12,2 mm. En la ventana ósea de la TAC no se observaron ni lesiones líticas ni invasión del ala o seno esfenoidal. La TAC toraco-abdomino-pélvica fue negativa. El diagnóstico diferencial radiológico fue de schwannoma, meningioma o metástasis. Se realizó una biopsia abierta con abordaje transilviano a la pared lateral del seno cavernoso donde se observó la invasión tumoral del espacio intradural. El resultado anatomopatológico fue de carcinoma escamoso. Posteriormente se administró radioterapia a titulo paliativo. Tres semanas después de la cirugía el paciente consultó por dolor dorsal sin clínica neurológica. Un estudio de RM de raquis mostró lesiones focales en los cuerpos D4, D6 y D10 sospechosas de implantes metastásicos. Con el tratamiento radioterápico se alivió la cefalea, pero desarrolló una oftalmoplejía, conservando únicamente la abducción del ojo derecho. El paciente falleció nueve meses tras el diagnóstico de la metástasis en el seno cavernoso. Remitido por: Dr. Sergio Andrés Torres Bayona Servicio de Neurocirugía Hospital Universitario Donostia C/ Doctor Beguiristain, 117 20080 Donostia-San Sebastián E-mail: sergioandrestorres@hotmail.com Instructions: please typing these entity words according to sentence: Jesus, Barrios Larrea, Calle Tres Palomas , 27, 48 20895745 94, Calle Ibarra , 1, Donostia - San Sebastián, 20080, 03/03/1956, España, 59 años, 27/07/2015, 8934679, Sergio Andrés Torres Bayona, 20 20 28563, varón, 59 años, Sergio Andrés Torres Bayona, Hospital Universitario Donostia, C/ Doctor Beguiristain , 117, 20080, Donostia - San Sebastián, sergioandrestorres@hotmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_CONTACTO_ASISTENCIAL, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Jesus. Apellidos: Barrios Larrea. NHC: Calle Tres Palomas, 27. NASS: 48 20895745 94. Domicilio: Calle Ibarra, 1. Localidad/ Provincia: Donostia-San Sebastián. CP: 20080. Datos asistenciales. Fecha de nacimiento: 03/03/1956. País: España. Edad: 59 años Sexo:H. Fecha de Ingreso: 27/07/2015. Servicio: Neurocirugía. Episodio: 8934679. Médico: Sergio Andrés Torres Bayona NºCol: 20 20 28563. Informe clínico del paciente: varón de 59 años, diagnosticado de carcinoma escamoso de laringe T2N2b, que se trató inicialmente con tres ciclos de quimioterapia sin remisión, por lo que tres meses después se realizó una laringectomía supraglótica, con vaciamiento radical incompleto modificado del lado izquierdo. La anatomía patológica demostró un carcinoma escamoso infiltrante en hemiepiglotis izquierda con 8 de 11 ganglios linfáticos positivos de la cadena yugular interna, subdigástricos y supraclaviculares izquierdos. Posteriormente recibió quimioterapia y radioterapia sobre supraglotis e hipofaringe y áreas ganglionares bilaterales. Nueve meses después de la cirugía consultó por cefalea de tres semanas de evolución asociada a diplopia binocular y visión borrosa del ojo derecho, evidenciándose oftalmoparesia del III, IV y VI pares craneales derechos. Una resonancia magnética (RM) cerebral mostró una masa en la porción posterior y lateral del seno cavernoso derecho, con protusión hacia la cisterna prepontina, bien delimitada, con captación homogénea de gadolinio y unas dimensiones de 11x14,4x12,2 mm. En la ventana ósea de la TAC no se observaron ni lesiones líticas ni invasión del ala o seno esfenoidal. La TAC toraco-abdomino-pélvica fue negativa. El diagnóstico diferencial radiológico fue de schwannoma, meningioma o metástasis. Se realizó una biopsia abierta con abordaje transilviano a la pared lateral del seno cavernoso donde se observó la invasión tumoral del espacio intradural. El resultado anatomopatológico fue de carcinoma escamoso. Posteriormente se administró radioterapia a titulo paliativo. Tres semanas después de la cirugía el paciente consultó por dolor dorsal sin clínica neurológica. Un estudio de RM de raquis mostró lesiones focales en los cuerpos D4, D6 y D10 sospechosas de implantes metastásicos. Con el tratamiento radioterápico se alivió la cefalea, pero desarrolló una oftalmoplejía, conservando únicamente la abducción del ojo derecho. El paciente falleció nueve meses tras el diagnóstico de la metástasis en el seno cavernoso. Remitido por: Dr. Sergio Andrés Torres Bayona Servicio de Neurocirugía Hospital Universitario Donostia C/ Doctor Beguiristain, 117 20080 Donostia-San Sebastián E-mail: sergioandrestorres@hotmail.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Jesus", ".", "\n", "Apellidos", ":", "Barrios", "Larrea", ".", "\n", "NHC", ":", "Calle", "Tres", "Palomas", ",", "27", ".", "\n", "NASS", ":", "48", "20895745", "94", ".", "\n", "Domicilio", ":", "Calle", "Ibarra", ",", "1", ".", "\n", "Localidad/", "Provincia", ":", "Donostia", "-", "San", "Sebastián", ".", "\n", "CP", ":", "20080", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "03/03/1956", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "59", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "27/07/2015", ".", "\n", "Servicio", ":", "Neurocirugía", ".", "\n", "Episodio", ":", "8934679", ".", "\n", "Médico", ":", "Sergio", "Andrés", "Torres", "Bayona", "NºCol", ":", "20", "20", "28563", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "varón", "de", "59", "años", ",", "diagnosticado", "de", "carcinoma", "escamoso", "de", "laringe", "T2N2b", ",", "que", "se", "trató", "inicialmente", "con", "tres", "ciclos", "de", "quimioterapia", "sin", "remisión", ",", "por", "lo", "que", "tres", "meses", "después", "se", "realizó", "una", "laringectomía", "supraglótica", ",", "con", "vaciamiento", "radical", "incompleto", "modificado", "del", "lado", "izquierdo", ".", "La", "anatomía", "patológica", "demostró", "un", "carcinoma", "escamoso", "infiltrante", "en", "hemiepiglotis", "izquierda", "con", "8", "de", "11", "ganglios", "linfáticos", "positivos", "de", "la", "cadena", "yugular", "interna", ",", "subdigástricos", "y", "supraclaviculares", "izquierdos", ".", "Posteriormente", "recibió", "quimioterapia", "y", "radioterapia", "sobre", "supraglotis", "e", "hipofaringe", "y", "áreas", "ganglionares", "bilaterales", ".", "\n", "Nueve", "meses", "después", "de", "la", "cirugía", "consultó", "por", "cefalea", "de", "tres", "semanas", "de", "evolución", "asociada", "a", "diplopia", "binocular", "y", "visión", "borrosa", "del", "ojo", "derecho", ",", "evidenciándose", "oftalmoparesia", "del", "III", ",", "IV", "y", "VI", "pares", "craneales", "derechos", ".", "Una", "resonancia", "magnética", "(", "RM", ")", "cerebral", "mostró", "una", "masa", "en", "la", "porción", "posterior", "y", "lateral", "del", "seno", "cavernoso", "derecho", ",", "con", "protusión", "hacia", "la", "cisterna", "prepontina", ",", "bien", "delimitada", ",", "con", "captación", "homogénea", "de", "gadolinio", "y", "unas", "dimensiones", "de", "11x14,4x12,2", "mm", ".", "En", "la", "ventana", "ósea", "de", "la", "TAC", "no", "se", "observaron", "ni", "lesiones", "líticas", "ni", "invasión", "del", "ala", "o", "seno", "esfenoidal", ".", "La", "TAC", "toraco", "-", "abdomino", "-", "pélvica", "fue", "negativa", ".", "El", "diagnóstico", "diferencial", "radiológico", "fue", "de", "schwannoma", ",", "meningioma", "o", "metástasis", ".", "\n", "Se", "realizó", "una", "biopsia", "abierta", "con", "abordaje", "transilviano", "a", "la", "pared", "lateral", "del", "seno", "cavernoso", "donde", "se", "observó", "la", "invasión", "tumoral", "del", "espacio", "intradural", ".", "El", "resultado", "anatomopatológico", "fue", "de", "carcinoma", "escamoso", ".", "Posteriormente", "se", "administró", "radioterapia", "a", "titulo", "paliativo", ".", "Tres", "semanas", "después", "de", "la", "cirugía", "el", "paciente", "consultó", "por", "dolor", "dorsal", "sin", "clínica", "neurológica", ".", "Un", "estudio", "de", "RM", "de", "raquis", "mostró", "lesiones", "focales", "en", "los", "cuerpos", "D4", ",", "D6", "y", "D10", "sospechosas", "de", "implantes", "metastásicos", ".", "\n", "Con", "el", "tratamiento", "radioterápico", "se", "alivió", "la", "cefalea", ",", "pero", "desarrolló", "una", "oftalmoplejía", ",", "conservando", "únicamente", "la", "abducción", "del", "ojo", "derecho", ".", "El", "paciente", "falleció", "nueve", "meses", "tras", "el", "diagnóstico", "de", "la", "metástasis", "en", "el", "seno", "cavernoso", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Sergio", "Andrés", "Torres", "Bayona", "Servicio", "de", "Neurocirugía", "Hospital", "Universitario", "Donostia", "C/", "Doctor", "Beguiristain", ",", "117", "20080", "Donostia", "-", "San", "Sebastián", "E", "-", "mail", ":", "sergioandrestorres@hotmail.com", "\n" ]	[ "HOSPITAL", "CORREO_ELECTRONICO", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "TERRITORIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "ID_CONTACTO_ASISTENCIAL", "EDAD_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Jesus, Barrios Larrea, Calle Tres Palomas , 27, 48 20895745 94, Calle Ibarra , 1, Donostia - San Sebastián, 20080, 03/03/1956, España, 59 años, 27/07/2015, 8934679, Sergio Andrés Torres Bayona, 20 20 28563, varón, 59 años, Sergio Andrés Torres Bayona, Hospital Universitario Donostia, C/ Doctor Beguiristain , 117, 20080, Donostia - San Sebastián, sergioandrestorres@hotmail.com	429_task2	Sentence: Datos del paciente. Nombre: Jesus. Apellidos: Barrios Larrea. NHC: Calle Tres Palomas, 27. NASS: 48 20895745 94. Domicilio: Calle Ibarra, 1. Localidad/ Provincia: Donostia-San Sebastián. CP: 20080. Datos asistenciales. Fecha de nacimiento: 03/03/1956. País: España. Edad: 59 años Sexo:H. Fecha de Ingreso: 27/07/2015. Servicio: Neurocirugía. Episodio: 8934679. Médico: Sergio Andrés Torres Bayona NºCol: 20 20 28563. Informe clínico del paciente: varón de 59 años, diagnosticado de carcinoma escamoso de laringe T2N2b, que se trató inicialmente con tres ciclos de quimioterapia sin remisión, por lo que tres meses después se realizó una laringectomía supraglótica, con vaciamiento radical incompleto modificado del lado izquierdo. La anatomía patológica demostró un carcinoma escamoso infiltrante en hemiepiglotis izquierda con 8 de 11 ganglios linfáticos positivos de la cadena yugular interna, subdigástricos y supraclaviculares izquierdos. Posteriormente recibió quimioterapia y radioterapia sobre supraglotis e hipofaringe y áreas ganglionares bilaterales. Nueve meses después de la cirugía consultó por cefalea de tres semanas de evolución asociada a diplopia binocular y visión borrosa del ojo derecho, evidenciándose oftalmoparesia del III, IV y VI pares craneales derechos. Una resonancia magnética (RM) cerebral mostró una masa en la porción posterior y lateral del seno cavernoso derecho, con protusión hacia la cisterna prepontina, bien delimitada, con captación homogénea de gadolinio y unas dimensiones de 11x14,4x12,2 mm. En la ventana ósea de la TAC no se observaron ni lesiones líticas ni invasión del ala o seno esfenoidal. La TAC toraco-abdomino-pélvica fue negativa. El diagnóstico diferencial radiológico fue de schwannoma, meningioma o metástasis. Se realizó una biopsia abierta con abordaje transilviano a la pared lateral del seno cavernoso donde se observó la invasión tumoral del espacio intradural. El resultado anatomopatológico fue de carcinoma escamoso. Posteriormente se administró radioterapia a titulo paliativo. Tres semanas después de la cirugía el paciente consultó por dolor dorsal sin clínica neurológica. Un estudio de RM de raquis mostró lesiones focales en los cuerpos D4, D6 y D10 sospechosas de implantes metastásicos. Con el tratamiento radioterápico se alivió la cefalea, pero desarrolló una oftalmoplejía, conservando únicamente la abducción del ojo derecho. El paciente falleció nueve meses tras el diagnóstico de la metástasis en el seno cavernoso. Remitido por: Dr. Sergio Andrés Torres Bayona Servicio de Neurocirugía Hospital Universitario Donostia C/ Doctor Beguiristain, 117 20080 Donostia-San Sebastián E-mail: sergioandrestorres@hotmail.com Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Jesus. Apellidos: Barrios Larrea. NHC: Calle Tres Palomas, 27. NASS: 48 20895745 94. Domicilio: Calle Ibarra, 1. Localidad/ Provincia: Donostia-San Sebastián. CP: 20080. Datos asistenciales. Fecha de nacimiento: 03/03/1956. País: España. Edad: 59 años Sexo:H. Fecha de Ingreso: 27/07/2015. Servicio: Neurocirugía. Episodio: 8934679. Médico: Sergio Andrés Torres Bayona NºCol: 20 20 28563. Informe clínico del paciente: varón de 59 años, diagnosticado de carcinoma escamoso de laringe T2N2b, que se trató inicialmente con tres ciclos de quimioterapia sin remisión, por lo que tres meses después se realizó una laringectomía supraglótica, con vaciamiento radical incompleto modificado del lado izquierdo. La anatomía patológica demostró un carcinoma escamoso infiltrante en hemiepiglotis izquierda con 8 de 11 ganglios linfáticos positivos de la cadena yugular interna, subdigástricos y supraclaviculares izquierdos. Posteriormente recibió quimioterapia y radioterapia sobre supraglotis e hipofaringe y áreas ganglionares bilaterales. Nueve meses después de la cirugía consultó por cefalea de tres semanas de evolución asociada a diplopia binocular y visión borrosa del ojo derecho, evidenciándose oftalmoparesia del III, IV y VI pares craneales derechos. Una resonancia magnética (RM) cerebral mostró una masa en la porción posterior y lateral del seno cavernoso derecho, con protusión hacia la cisterna prepontina, bien delimitada, con captación homogénea de gadolinio y unas dimensiones de 11x14,4x12,2 mm. En la ventana ósea de la TAC no se observaron ni lesiones líticas ni invasión del ala o seno esfenoidal. La TAC toraco-abdomino-pélvica fue negativa. El diagnóstico diferencial radiológico fue de schwannoma, meningioma o metástasis. Se realizó una biopsia abierta con abordaje transilviano a la pared lateral del seno cavernoso donde se observó la invasión tumoral del espacio intradural. El resultado anatomopatológico fue de carcinoma escamoso. Posteriormente se administró radioterapia a titulo paliativo. Tres semanas después de la cirugía el paciente consultó por dolor dorsal sin clínica neurológica. Un estudio de RM de raquis mostró lesiones focales en los cuerpos D4, D6 y D10 sospechosas de implantes metastásicos. Con el tratamiento radioterápico se alivió la cefalea, pero desarrolló una oftalmoplejía, conservando únicamente la abducción del ojo derecho. El paciente falleció nueve meses tras el diagnóstico de la metástasis en el seno cavernoso. Remitido por: Dr. Sergio Andrés Torres Bayona Servicio de Neurocirugía Hospital Universitario Donostia C/ Doctor Beguiristain, 117 20080 Donostia-San Sebastián E-mail: sergioandrestorres@hotmail.com	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Jesus", ".", "\n", "Apellidos", ":", "Barrios", "Larrea", ".", "\n", "NHC", ":", "Calle", "Tres", "Palomas", ",", "27", ".", "\n", "NASS", ":", "48", "20895745", "94", ".", "\n", "Domicilio", ":", "Calle", "Ibarra", ",", "1", ".", "\n", "Localidad/", "Provincia", ":", "Donostia", "-", "San", "Sebastián", ".", "\n", "CP", ":", "20080", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "03/03/1956", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "59", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "27/07/2015", ".", "\n", "Servicio", ":", "Neurocirugía", ".", "\n", "Episodio", ":", "8934679", ".", "\n", "Médico", ":", "Sergio", "Andrés", "Torres", "Bayona", "NºCol", ":", "20", "20", "28563", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "varón", "de", "59", "años", ",", "diagnosticado", "de", "carcinoma", "escamoso", "de", "laringe", "T2N2b", ",", "que", "se", "trató", "inicialmente", "con", "tres", "ciclos", "de", "quimioterapia", "sin", "remisión", ",", "por", "lo", "que", "tres", "meses", "después", "se", "realizó", "una", "laringectomía", "supraglótica", ",", "con", "vaciamiento", "radical", "incompleto", "modificado", "del", "lado", "izquierdo", ".", "La", "anatomía", "patológica", "demostró", "un", "carcinoma", "escamoso", "infiltrante", "en", "hemiepiglotis", "izquierda", "con", "8", "de", "11", "ganglios", "linfáticos", "positivos", "de", "la", "cadena", "yugular", "interna", ",", "subdigástricos", "y", "supraclaviculares", "izquierdos", ".", "Posteriormente", "recibió", "quimioterapia", "y", "radioterapia", "sobre", "supraglotis", "e", "hipofaringe", "y", "áreas", "ganglionares", "bilaterales", ".", "\n", "Nueve", "meses", "después", "de", "la", "cirugía", "consultó", "por", "cefalea", "de", "tres", "semanas", "de", "evolución", "asociada", "a", "diplopia", "binocular", "y", "visión", "borrosa", "del", "ojo", "derecho", ",", "evidenciándose", "oftalmoparesia", "del", "III", ",", "IV", "y", "VI", "pares", "craneales", "derechos", ".", "Una", "resonancia", "magnética", "(", "RM", ")", "cerebral", "mostró", "una", "masa", "en", "la", "porción", "posterior", "y", "lateral", "del", "seno", "cavernoso", "derecho", ",", "con", "protusión", "hacia", "la", "cisterna", "prepontina", ",", "bien", "delimitada", ",", "con", "captación", "homogénea", "de", "gadolinio", "y", "unas", "dimensiones", "de", "11x14,4x12,2", "mm", ".", "En", "la", "ventana", "ósea", "de", "la", "TAC", "no", "se", "observaron", "ni", "lesiones", "líticas", "ni", "invasión", "del", "ala", "o", "seno", "esfenoidal", ".", "La", "TAC", "toraco", "-", "abdomino", "-", "pélvica", "fue", "negativa", ".", "El", "diagnóstico", "diferencial", "radiológico", "fue", "de", "schwannoma", ",", "meningioma", "o", "metástasis", ".", "\n", "Se", "realizó", "una", "biopsia", "abierta", "con", "abordaje", "transilviano", "a", "la", "pared", "lateral", "del", "seno", "cavernoso", "donde", "se", "observó", "la", "invasión", "tumoral", "del", "espacio", "intradural", ".", "El", "resultado", "anatomopatológico", "fue", "de", "carcinoma", "escamoso", ".", "Posteriormente", "se", "administró", "radioterapia", "a", "titulo", "paliativo", ".", "Tres", "semanas", "después", "de", "la", "cirugía", "el", "paciente", "consultó", "por", "dolor", "dorsal", "sin", "clínica", "neurológica", ".", "Un", "estudio", "de", "RM", "de", "raquis", "mostró", "lesiones", "focales", "en", "los", "cuerpos", "D4", ",", "D6", "y", "D10", "sospechosas", "de", "implantes", "metastásicos", ".", "\n", "Con", "el", "tratamiento", "radioterápico", "se", "alivió", "la", "cefalea", ",", "pero", "desarrolló", "una", "oftalmoplejía", ",", "conservando", "únicamente", "la", "abducción", "del", "ojo", "derecho", ".", "El", "paciente", "falleció", "nueve", "meses", "tras", "el", "diagnóstico", "de", "la", "metástasis", "en", "el", "seno", "cavernoso", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Sergio", "Andrés", "Torres", "Bayona", "Servicio", "de", "Neurocirugía", "Hospital", "Universitario", "Donostia", "C/", "Doctor", "Beguiristain", ",", "117", "20080", "Donostia", "-", "San", "Sebastián", "E", "-", "mail", ":", "sergioandrestorres@hotmail.com", "\n" ]	[ "HOSPITAL", "CORREO_ELECTRONICO", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "TERRITORIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "ID_CONTACTO_ASISTENCIAL", "EDAD_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
animal experiments is an umlsterm, clinical studies is an umlsterm, liquid ventilation is an umlsterm, gas is an umlsterm, breathing is an umlsterm, mechanics is an umlsterm, lungs is an umlsterm, toxicity is an umlsterm, infants is an umlsterm, future is an umlsterm, catalogue is an umlsterm, liquid ventilation is an umlsterm, open is an umlsterm, therapeutic is an umlsterm, diagnostic is an umlsterm, liquid ventilation is an umlsterm, method is an umlsterm, method is an umlsterm, artificial ventilation is an umlsterm, neonates is an umlsterm	PerinatalMedizin.80100063.eng.abstr_task0	Sentence: In animal experiments and clinical studies liquid ventilation with perfluorcarbons improves gas exchange and breathing mechanics in damaged lungs . According to the data on the toxicity of perfluorcarbons available today , it could potentially be applied in infants in the future , too . However , the catalogue of unanswered questions is still too long for controlled clinical phase III studies to be conducted . Further possible applications of liquid ventilation offer hope of solving open therapeutic and diagnostic problems . Taking into account all available data about liquid ventilation with perfluorcarbons today , we still do not know whether it is a real alternative method for respiratory support ; however , further studies to investigate whether the method is an alternative strategy for artificial ventilation in neonates are justified . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	In animal experiments and clinical studies liquid ventilation with perfluorcarbons improves gas exchange and breathing mechanics in damaged lungs . According to the data on the toxicity of perfluorcarbons available today , it could potentially be applied in infants in the future , too . However , the catalogue of unanswered questions is still too long for controlled clinical phase III studies to be conducted . Further possible applications of liquid ventilation offer hope of solving open therapeutic and diagnostic problems . Taking into account all available data about liquid ventilation with perfluorcarbons today , we still do not know whether it is a real alternative method for respiratory support ; however , further studies to investigate whether the method is an alternative strategy for artificial ventilation in neonates are justified .	[ "In", "animal", "experiments", "and", "clinical", "studies", "liquid", "ventilation", "with", "perfluorcarbons", "improves", "gas", "exchange", "and", "breathing", "mechanics", "in", "damaged", "lungs", ".", "According", "to", "the", "data", "on", "the", "toxicity", "of", "perfluorcarbons", "available", "today", ",", "it", "could", "potentially", "be", "applied", "in", "infants", "in", "the", "future", ",", "too", ".", "However", ",", "the", "catalogue", "of", "unanswered", "questions", "is", "still", "too", "long", "for", "controlled", "clinical", "phase", "III", "studies", "to", "be", "conducted", ".", "Further", "possible", "applications", "of", "liquid", "ventilation", "offer", "hope", "of", "solving", "open", "therapeutic", "and", "diagnostic", "problems", ".", "Taking", "into", "account", "all", "available", "data", "about", "liquid", "ventilation", "with", "perfluorcarbons", "today", ",", "we", "still", "do", "not", "know", "whether", "it", "is", "a", "real", "alternative", "method", "for", "respiratory", "support", ";", "however", ",", "further", "studies", "to", "investigate", "whether", "the", "method", "is", "an", "alternative", "strategy", "for", "artificial", "ventilation", "in", "neonates", "are", "justified", "." ]	[ "umlsterm" ]
animal experiments is an umlsterm, clinical studies is an umlsterm, liquid ventilation is an umlsterm, gas is an umlsterm, breathing is an umlsterm, mechanics is an umlsterm, lungs is an umlsterm, toxicity is an umlsterm, infants is an umlsterm, future is an umlsterm, catalogue is an umlsterm, liquid ventilation is an umlsterm, open is an umlsterm, therapeutic is an umlsterm, diagnostic is an umlsterm, liquid ventilation is an umlsterm, method is an umlsterm, method is an umlsterm, artificial ventilation is an umlsterm, neonates is an umlsterm	PerinatalMedizin.80100063.eng.abstr_task1	Sentence: In animal experiments and clinical studies liquid ventilation with perfluorcarbons improves gas exchange and breathing mechanics in damaged lungs . According to the data on the toxicity of perfluorcarbons available today , it could potentially be applied in infants in the future , too . However , the catalogue of unanswered questions is still too long for controlled clinical phase III studies to be conducted . Further possible applications of liquid ventilation offer hope of solving open therapeutic and diagnostic problems . Taking into account all available data about liquid ventilation with perfluorcarbons today , we still do not know whether it is a real alternative method for respiratory support ; however , further studies to investigate whether the method is an alternative strategy for artificial ventilation in neonates are justified . Instructions: please typing these entity words according to sentence: animal experiments, clinical studies, liquid ventilation, gas, breathing, mechanics, lungs, toxicity, infants, future, catalogue, liquid ventilation, open, therapeutic, diagnostic, liquid ventilation, method, method, artificial ventilation, neonates Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	In animal experiments and clinical studies liquid ventilation with perfluorcarbons improves gas exchange and breathing mechanics in damaged lungs . According to the data on the toxicity of perfluorcarbons available today , it could potentially be applied in infants in the future , too . However , the catalogue of unanswered questions is still too long for controlled clinical phase III studies to be conducted . Further possible applications of liquid ventilation offer hope of solving open therapeutic and diagnostic problems . Taking into account all available data about liquid ventilation with perfluorcarbons today , we still do not know whether it is a real alternative method for respiratory support ; however , further studies to investigate whether the method is an alternative strategy for artificial ventilation in neonates are justified .	[ "In", "animal", "experiments", "and", "clinical", "studies", "liquid", "ventilation", "with", "perfluorcarbons", "improves", "gas", "exchange", "and", "breathing", "mechanics", "in", "damaged", "lungs", ".", "According", "to", "the", "data", "on", "the", "toxicity", "of", "perfluorcarbons", "available", "today", ",", "it", "could", "potentially", "be", "applied", "in", "infants", "in", "the", "future", ",", "too", ".", "However", ",", "the", "catalogue", "of", "unanswered", "questions", "is", "still", "too", "long", "for", "controlled", "clinical", "phase", "III", "studies", "to", "be", "conducted", ".", "Further", "possible", "applications", "of", "liquid", "ventilation", "offer", "hope", "of", "solving", "open", "therapeutic", "and", "diagnostic", "problems", ".", "Taking", "into", "account", "all", "available", "data", "about", "liquid", "ventilation", "with", "perfluorcarbons", "today", ",", "we", "still", "do", "not", "know", "whether", "it", "is", "a", "real", "alternative", "method", "for", "respiratory", "support", ";", "however", ",", "further", "studies", "to", "investigate", "whether", "the", "method", "is", "an", "alternative", "strategy", "for", "artificial", "ventilation", "in", "neonates", "are", "justified", "." ]	[ "umlsterm" ]
animal experiments, clinical studies, liquid ventilation, gas, breathing, mechanics, lungs, toxicity, infants, future, catalogue, liquid ventilation, open, therapeutic, diagnostic, liquid ventilation, method, method, artificial ventilation, neonates	PerinatalMedizin.80100063.eng.abstr_task2	Sentence: In animal experiments and clinical studies liquid ventilation with perfluorcarbons improves gas exchange and breathing mechanics in damaged lungs . According to the data on the toxicity of perfluorcarbons available today , it could potentially be applied in infants in the future , too . However , the catalogue of unanswered questions is still too long for controlled clinical phase III studies to be conducted . Further possible applications of liquid ventilation offer hope of solving open therapeutic and diagnostic problems . Taking into account all available data about liquid ventilation with perfluorcarbons today , we still do not know whether it is a real alternative method for respiratory support ; however , further studies to investigate whether the method is an alternative strategy for artificial ventilation in neonates are justified . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	In animal experiments and clinical studies liquid ventilation with perfluorcarbons improves gas exchange and breathing mechanics in damaged lungs . According to the data on the toxicity of perfluorcarbons available today , it could potentially be applied in infants in the future , too . However , the catalogue of unanswered questions is still too long for controlled clinical phase III studies to be conducted . Further possible applications of liquid ventilation offer hope of solving open therapeutic and diagnostic problems . Taking into account all available data about liquid ventilation with perfluorcarbons today , we still do not know whether it is a real alternative method for respiratory support ; however , further studies to investigate whether the method is an alternative strategy for artificial ventilation in neonates are justified .	[ "In", "animal", "experiments", "and", "clinical", "studies", "liquid", "ventilation", "with", "perfluorcarbons", "improves", "gas", "exchange", "and", "breathing", "mechanics", "in", "damaged", "lungs", ".", "According", "to", "the", "data", "on", "the", "toxicity", "of", "perfluorcarbons", "available", "today", ",", "it", "could", "potentially", "be", "applied", "in", "infants", "in", "the", "future", ",", "too", ".", "However", ",", "the", "catalogue", "of", "unanswered", "questions", "is", "still", "too", "long", "for", "controlled", "clinical", "phase", "III", "studies", "to", "be", "conducted", ".", "Further", "possible", "applications", "of", "liquid", "ventilation", "offer", "hope", "of", "solving", "open", "therapeutic", "and", "diagnostic", "problems", ".", "Taking", "into", "account", "all", "available", "data", "about", "liquid", "ventilation", "with", "perfluorcarbons", "today", ",", "we", "still", "do", "not", "know", "whether", "it", "is", "a", "real", "alternative", "method", "for", "respiratory", "support", ";", "however", ",", "further", "studies", "to", "investigate", "whether", "the", "method", "is", "an", "alternative", "strategy", "for", "artificial", "ventilation", "in", "neonates", "are", "justified", "." ]	[ "umlsterm" ]
Praxis is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Psychotherapie is an umlsterm, Therapiephasen is an umlsterm, Objektbeziehungen is an umlsterm, Therapieprozesses is an umlsterm, Behandlung is an umlsterm, Therapieprozesses is an umlsterm, Prognose is an umlsterm	Psychotherapeut.80430369.ger.abstr_task0	Sentence: Es wird ein aus der klinischen Praxis gewachsenes psychodynamisches Konzept der Behandlung strukturell schwer gestoerter Patientinen Patienten in einer integrativen stationaeren Psychotherapie vorgestellt . In den einzelnen Therapiephasen sich herauskristallisierende Prozessmerkmale werden beschrieben und der Leitkategorie " Objektbeziehungen " zugeordnet . Besonderes Gewicht wird auf die Darstellung des therapeutischen Vorgehens gelegt . Anhand der entwickelten beziehungsorientierten Modellvorstellungen zu Ebenen und Phasen des Therapieprozesses koennen die in der Behandlung von strukturell schwergestoerten Patienten/innen vielgestaltig auftretenden Phaenomene in idealtypische Zusammenhaenge eingeordnet werden . Das Verstaendnis dieser psychodynamischen Zusammenhaenge schafft differenzierte Voraussetzungen fuer konstruktiv wirksame Interventionen insbesondere bei Krisen und Stagnationen des Therapieprozesses und kann somit die Prognose der Patienten/innen guenstiger gestalten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Es wird ein aus der klinischen Praxis gewachsenes psychodynamisches Konzept der Behandlung strukturell schwer gestoerter Patientinen Patienten in einer integrativen stationaeren Psychotherapie vorgestellt . In den einzelnen Therapiephasen sich herauskristallisierende Prozessmerkmale werden beschrieben und der Leitkategorie " Objektbeziehungen " zugeordnet . Besonderes Gewicht wird auf die Darstellung des therapeutischen Vorgehens gelegt . Anhand der entwickelten beziehungsorientierten Modellvorstellungen zu Ebenen und Phasen des Therapieprozesses koennen die in der Behandlung von strukturell schwergestoerten Patienten/innen vielgestaltig auftretenden Phaenomene in idealtypische Zusammenhaenge eingeordnet werden . Das Verstaendnis dieser psychodynamischen Zusammenhaenge schafft differenzierte Voraussetzungen fuer konstruktiv wirksame Interventionen insbesondere bei Krisen und Stagnationen des Therapieprozesses und kann somit die Prognose der Patienten/innen guenstiger gestalten .	[ "Es", "wird", "ein", "aus", "der", "klinischen", "Praxis", "gewachsenes", "psychodynamisches", "Konzept", "der", "Behandlung", "strukturell", "schwer", "gestoerter", "Patientinen", "Patienten", "in", "einer", "integrativen", "stationaeren", "Psychotherapie", "vorgestellt", ".", "In", "den", "einzelnen", "Therapiephasen", "sich", "herauskristallisierende", "Prozessmerkmale", "werden", "beschrieben", "und", "der", "Leitkategorie", "\"", "Objektbeziehungen", "\"", "zugeordnet", ".", "Besonderes", "Gewicht", "wird", "auf", "die", "Darstellung", "des", "therapeutischen", "Vorgehens", "gelegt", ".", "Anhand", "der", "entwickelten", "beziehungsorientierten", "Modellvorstellungen", "zu", "Ebenen", "und", "Phasen", "des", "Therapieprozesses", "koennen", "die", "in", "der", "Behandlung", "von", "strukturell", "schwergestoerten", "Patienten", "/", "innen", "vielgestaltig", "auftretenden", "Phaenomene", "in", "idealtypische", "Zusammenhaenge", "eingeordnet", "werden", ".", "Das", "Verstaendnis", "dieser", "psychodynamischen", "Zusammenhaenge", "schafft", "differenzierte", "Voraussetzungen", "fuer", "konstruktiv", "wirksame", "Interventionen", "insbesondere", "bei", "Krisen", "und", "Stagnationen", "des", "Therapieprozesses", "und", "kann", "somit", "die", "Prognose", "der", "Patienten", "/", "innen", "guenstiger", "gestalten", "." ]	[ "umlsterm" ]
Praxis is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Psychotherapie is an umlsterm, Therapiephasen is an umlsterm, Objektbeziehungen is an umlsterm, Therapieprozesses is an umlsterm, Behandlung is an umlsterm, Therapieprozesses is an umlsterm, Prognose is an umlsterm	Psychotherapeut.80430369.ger.abstr_task1	Sentence: Es wird ein aus der klinischen Praxis gewachsenes psychodynamisches Konzept der Behandlung strukturell schwer gestoerter Patientinen Patienten in einer integrativen stationaeren Psychotherapie vorgestellt . In den einzelnen Therapiephasen sich herauskristallisierende Prozessmerkmale werden beschrieben und der Leitkategorie " Objektbeziehungen " zugeordnet . Besonderes Gewicht wird auf die Darstellung des therapeutischen Vorgehens gelegt . Anhand der entwickelten beziehungsorientierten Modellvorstellungen zu Ebenen und Phasen des Therapieprozesses koennen die in der Behandlung von strukturell schwergestoerten Patienten/innen vielgestaltig auftretenden Phaenomene in idealtypische Zusammenhaenge eingeordnet werden . Das Verstaendnis dieser psychodynamischen Zusammenhaenge schafft differenzierte Voraussetzungen fuer konstruktiv wirksame Interventionen insbesondere bei Krisen und Stagnationen des Therapieprozesses und kann somit die Prognose der Patienten/innen guenstiger gestalten . Instructions: please typing these entity words according to sentence: Praxis, Behandlung, Patienten, Psychotherapie, Therapiephasen, Objektbeziehungen, Therapieprozesses, Behandlung, Therapieprozesses, Prognose Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Es wird ein aus der klinischen Praxis gewachsenes psychodynamisches Konzept der Behandlung strukturell schwer gestoerter Patientinen Patienten in einer integrativen stationaeren Psychotherapie vorgestellt . In den einzelnen Therapiephasen sich herauskristallisierende Prozessmerkmale werden beschrieben und der Leitkategorie " Objektbeziehungen " zugeordnet . Besonderes Gewicht wird auf die Darstellung des therapeutischen Vorgehens gelegt . Anhand der entwickelten beziehungsorientierten Modellvorstellungen zu Ebenen und Phasen des Therapieprozesses koennen die in der Behandlung von strukturell schwergestoerten Patienten/innen vielgestaltig auftretenden Phaenomene in idealtypische Zusammenhaenge eingeordnet werden . Das Verstaendnis dieser psychodynamischen Zusammenhaenge schafft differenzierte Voraussetzungen fuer konstruktiv wirksame Interventionen insbesondere bei Krisen und Stagnationen des Therapieprozesses und kann somit die Prognose der Patienten/innen guenstiger gestalten .	[ "Es", "wird", "ein", "aus", "der", "klinischen", "Praxis", "gewachsenes", "psychodynamisches", "Konzept", "der", "Behandlung", "strukturell", "schwer", "gestoerter", "Patientinen", "Patienten", "in", "einer", "integrativen", "stationaeren", "Psychotherapie", "vorgestellt", ".", "In", "den", "einzelnen", "Therapiephasen", "sich", "herauskristallisierende", "Prozessmerkmale", "werden", "beschrieben", "und", "der", "Leitkategorie", "\"", "Objektbeziehungen", "\"", "zugeordnet", ".", "Besonderes", "Gewicht", "wird", "auf", "die", "Darstellung", "des", "therapeutischen", "Vorgehens", "gelegt", ".", "Anhand", "der", "entwickelten", "beziehungsorientierten", "Modellvorstellungen", "zu", "Ebenen", "und", "Phasen", "des", "Therapieprozesses", "koennen", "die", "in", "der", "Behandlung", "von", "strukturell", "schwergestoerten", "Patienten", "/", "innen", "vielgestaltig", "auftretenden", "Phaenomene", "in", "idealtypische", "Zusammenhaenge", "eingeordnet", "werden", ".", "Das", "Verstaendnis", "dieser", "psychodynamischen", "Zusammenhaenge", "schafft", "differenzierte", "Voraussetzungen", "fuer", "konstruktiv", "wirksame", "Interventionen", "insbesondere", "bei", "Krisen", "und", "Stagnationen", "des", "Therapieprozesses", "und", "kann", "somit", "die", "Prognose", "der", "Patienten", "/", "innen", "guenstiger", "gestalten", "." ]	[ "umlsterm" ]
Praxis, Behandlung, Patienten, Psychotherapie, Therapiephasen, Objektbeziehungen, Therapieprozesses, Behandlung, Therapieprozesses, Prognose	Psychotherapeut.80430369.ger.abstr_task2	Sentence: Es wird ein aus der klinischen Praxis gewachsenes psychodynamisches Konzept der Behandlung strukturell schwer gestoerter Patientinen Patienten in einer integrativen stationaeren Psychotherapie vorgestellt . In den einzelnen Therapiephasen sich herauskristallisierende Prozessmerkmale werden beschrieben und der Leitkategorie " Objektbeziehungen " zugeordnet . Besonderes Gewicht wird auf die Darstellung des therapeutischen Vorgehens gelegt . Anhand der entwickelten beziehungsorientierten Modellvorstellungen zu Ebenen und Phasen des Therapieprozesses koennen die in der Behandlung von strukturell schwergestoerten Patienten/innen vielgestaltig auftretenden Phaenomene in idealtypische Zusammenhaenge eingeordnet werden . Das Verstaendnis dieser psychodynamischen Zusammenhaenge schafft differenzierte Voraussetzungen fuer konstruktiv wirksame Interventionen insbesondere bei Krisen und Stagnationen des Therapieprozesses und kann somit die Prognose der Patienten/innen guenstiger gestalten . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Es wird ein aus der klinischen Praxis gewachsenes psychodynamisches Konzept der Behandlung strukturell schwer gestoerter Patientinen Patienten in einer integrativen stationaeren Psychotherapie vorgestellt . In den einzelnen Therapiephasen sich herauskristallisierende Prozessmerkmale werden beschrieben und der Leitkategorie " Objektbeziehungen " zugeordnet . Besonderes Gewicht wird auf die Darstellung des therapeutischen Vorgehens gelegt . Anhand der entwickelten beziehungsorientierten Modellvorstellungen zu Ebenen und Phasen des Therapieprozesses koennen die in der Behandlung von strukturell schwergestoerten Patienten/innen vielgestaltig auftretenden Phaenomene in idealtypische Zusammenhaenge eingeordnet werden . Das Verstaendnis dieser psychodynamischen Zusammenhaenge schafft differenzierte Voraussetzungen fuer konstruktiv wirksame Interventionen insbesondere bei Krisen und Stagnationen des Therapieprozesses und kann somit die Prognose der Patienten/innen guenstiger gestalten .	[ "Es", "wird", "ein", "aus", "der", "klinischen", "Praxis", "gewachsenes", "psychodynamisches", "Konzept", "der", "Behandlung", "strukturell", "schwer", "gestoerter", "Patientinen", "Patienten", "in", "einer", "integrativen", "stationaeren", "Psychotherapie", "vorgestellt", ".", "In", "den", "einzelnen", "Therapiephasen", "sich", "herauskristallisierende", "Prozessmerkmale", "werden", "beschrieben", "und", "der", "Leitkategorie", "\"", "Objektbeziehungen", "\"", "zugeordnet", ".", "Besonderes", "Gewicht", "wird", "auf", "die", "Darstellung", "des", "therapeutischen", "Vorgehens", "gelegt", ".", "Anhand", "der", "entwickelten", "beziehungsorientierten", "Modellvorstellungen", "zu", "Ebenen", "und", "Phasen", "des", "Therapieprozesses", "koennen", "die", "in", "der", "Behandlung", "von", "strukturell", "schwergestoerten", "Patienten", "/", "innen", "vielgestaltig", "auftretenden", "Phaenomene", "in", "idealtypische", "Zusammenhaenge", "eingeordnet", "werden", ".", "Das", "Verstaendnis", "dieser", "psychodynamischen", "Zusammenhaenge", "schafft", "differenzierte", "Voraussetzungen", "fuer", "konstruktiv", "wirksame", "Interventionen", "insbesondere", "bei", "Krisen", "und", "Stagnationen", "des", "Therapieprozesses", "und", "kann", "somit", "die", "Prognose", "der", "Patienten", "/", "innen", "guenstiger", "gestalten", "." ]	[ "umlsterm" ]
PGE is a protein, thromboxane is a compound, TXB is a compound, COX-1 is a protein, COX-2 is a protein	DS.d1047_task0	Sentence: We also assess prostaglandin (PGE (2)) and thromboxane (TXB (2)) inhibition to establish the correlation between behavioural measures and the degree of selectivity for COX-1 and COX-2. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O" ]	We also assess prostaglandin (PGE (2)) and thromboxane (TXB (2)) inhibition to establish the correlation between behavioural measures and the degree of selectivity for COX-1 and COX-2.	[ "We", "also", "assess", "prostaglandin", "(", "PGE", "(", "2", ")", ")", "and", "thromboxane", "(", "TXB", "(", "2", ")", ")", "inhibition", "to", "establish", "the", "correlation", "between", "behavioural", "measures", "and", "the", "degree", "of", "selectivity", "for", "COX-1", "and", "COX-2", "." ]	[ "compound", "protein" ]
PGE is a protein, thromboxane is a compound, TXB is a compound, COX-1 is a protein, COX-2 is a protein	DS.d1047_task1	Sentence: We also assess prostaglandin (PGE (2)) and thromboxane (TXB (2)) inhibition to establish the correlation between behavioural measures and the degree of selectivity for COX-1 and COX-2. Instructions: please typing these entity words according to sentence: PGE, thromboxane, TXB, COX-1, COX-2 Options: compound, protein	[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O" ]	We also assess prostaglandin (PGE (2)) and thromboxane (TXB (2)) inhibition to establish the correlation between behavioural measures and the degree of selectivity for COX-1 and COX-2.	[ "We", "also", "assess", "prostaglandin", "(", "PGE", "(", "2", ")", ")", "and", "thromboxane", "(", "TXB", "(", "2", ")", ")", "inhibition", "to", "establish", "the", "correlation", "between", "behavioural", "measures", "and", "the", "degree", "of", "selectivity", "for", "COX-1", "and", "COX-2", "." ]	[ "compound", "protein" ]
PGE, thromboxane, TXB, COX-1, COX-2	DS.d1047_task2	Sentence: We also assess prostaglandin (PGE (2)) and thromboxane (TXB (2)) inhibition to establish the correlation between behavioural measures and the degree of selectivity for COX-1 and COX-2. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O" ]	We also assess prostaglandin (PGE (2)) and thromboxane (TXB (2)) inhibition to establish the correlation between behavioural measures and the degree of selectivity for COX-1 and COX-2.	[ "We", "also", "assess", "prostaglandin", "(", "PGE", "(", "2", ")", ")", "and", "thromboxane", "(", "TXB", "(", "2", ")", ")", "inhibition", "to", "establish", "the", "correlation", "between", "behavioural", "measures", "and", "the", "degree", "of", "selectivity", "for", "COX-1", "and", "COX-2", "." ]	[ "compound", "protein" ]
adults is a Participant_Age, acute lymphoblastic leukemia is a Participant_Condition, vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both is a Intervention_Pharmacological, cytarabine is a Intervention_Pharmacological, mitoxantrone is a Intervention_Pharmacological, resistant disease is a Outcome_Physical, 4-drug induction ( the L-20 regimen ) . is a Intervention_Pharmacological, consolidation , maintenance therapy , and central nervous system prophylaxis is a Intervention_Pharmacological, median follow - up for survivors is a Outcome_Mortality, median patient age was 43 years is a Participant_Age, 164 is a Participant_Sample-size, frequency of complete remission is a Outcome_Physical, Induction deaths is a Outcome_Mortality, median survival is a Outcome_Mortality, survival rate is a Outcome_Mortality, long - term outcomes is a Outcome_Other	57808_task0	Sentence: Treatment of adults with acute lymphoblastic leukemia : do the specifics of the regimen matter ? : Results from a prospective randomized trial . BACKGROUND Induction therapy for adults with acute lymphoblastic leukemia ( ALL ) is similar across essentially all regimens , comprised of vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both . Given the lack of randomized data , to date , no regimen has emerged as standard . The authors previously evaluated cytarabine 3 g/m ( 2 ) daily for 5 days with mitoxantrone 80 mg/m ( 2 ) ( the ALL-2 regimen ) as a novel induction regimen . Compared with historic controls , the ALL-2 regimen was superior in terms of incidence of complete remission , failure with resistant disease , and activity in patients with Philadelphia chromosome ( Ph ) -positive ALL . METHODS The authors conducted a multicenter , prospective , randomized trial of the ALL-2 regimen compared with a standard 4-drug induction ( the L-20 regimen ) . Patients also received consolidation , maintenance therapy , and central nervous system prophylaxis . The trial accrued patients from August 1996 to October 2004 . RESULTS The median follow-up for survivors was 7 years , and the median patient age was 43 years . Responses were evaluated in 164 patients . The treatment arms were balanced in terms of pretreatment characteristics . The frequency of complete remission for the ALL-2 regimen versus the L-20 regimen was 83 % versus 71 % ( P = .06 ) . More patients on the L-20 arm failed with resistant disease ( 21 % vs 8 % ; P = .02 ) . Induction deaths were comparable at 9 % ( ALL-2 ) versus 7 % ( L-20 ) . The median survival was similar ; and , at 5 years , the survival rate was 33 % alive on the ALL-2 arm versus 27 % on the L-20 . CONCLUSIONS Despite superior results of induction therapy with the ALL-2 regimen , this treatment did not improve long-term outcomes . When coupled to the reported experience of other studies in adults with ALL , the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen . Cancer 2013 . © 2012 American Cancer Society . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other	[ "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Treatment of adults with acute lymphoblastic leukemia : do the specifics of the regimen matter ? : Results from a prospective randomized trial . BACKGROUND Induction therapy for adults with acute lymphoblastic leukemia ( ALL ) is similar across essentially all regimens , comprised of vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both . Given the lack of randomized data , to date , no regimen has emerged as standard . The authors previously evaluated cytarabine 3 g/m ( 2 ) daily for 5 days with mitoxantrone 80 mg/m ( 2 ) ( the ALL-2 regimen ) as a novel induction regimen . Compared with historic controls , the ALL-2 regimen was superior in terms of incidence of complete remission , failure with resistant disease , and activity in patients with Philadelphia chromosome ( Ph ) -positive ALL . METHODS The authors conducted a multicenter , prospective , randomized trial of the ALL-2 regimen compared with a standard 4-drug induction ( the L-20 regimen ) . Patients also received consolidation , maintenance therapy , and central nervous system prophylaxis . The trial accrued patients from August 1996 to October 2004 . RESULTS The median follow-up for survivors was 7 years , and the median patient age was 43 years . Responses were evaluated in 164 patients . The treatment arms were balanced in terms of pretreatment characteristics . The frequency of complete remission for the ALL-2 regimen versus the L-20 regimen was 83 % versus 71 % ( P = .06 ) . More patients on the L-20 arm failed with resistant disease ( 21 % vs 8 % ; P = .02 ) . Induction deaths were comparable at 9 % ( ALL-2 ) versus 7 % ( L-20 ) . The median survival was similar ; and , at 5 years , the survival rate was 33 % alive on the ALL-2 arm versus 27 % on the L-20 . CONCLUSIONS Despite superior results of induction therapy with the ALL-2 regimen , this treatment did not improve long-term outcomes . When coupled to the reported experience of other studies in adults with ALL , the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen . Cancer 2013 . © 2012 American Cancer Society .	[ "Treatment", "of", "adults", "with", "acute", "lymphoblastic", "leukemia", ":", "do", "the", "specifics", "of", "the", "regimen", "matter", "?", ":", "Results", "from", "a", "prospective", "randomized", "trial", ".", "BACKGROUND", "Induction", "therapy", "for", "adults", "with", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "is", "similar", "across", "essentially", "all", "regimens", ",", "comprised", "of", "vincristine", ",", "corticosteroids", ",", "and", "anthracyclines", "intensified", "with", "cyclophosphamide", ",", "asparaginase", ",", "or", "both", ".", "Given", "the", "lack", "of", "randomized", "data", ",", "to", "date", ",", "no", "regimen", "has", "emerged", "as", "standard", ".", "The", "authors", "previously", "evaluated", "cytarabine", "3", "g", "/", "m", "(", "2", ")", "daily", "for", "5", "days", "with", "mitoxantrone", "80", "mg", "/", "m", "(", "2", ")", "(", "the", "ALL-2", "regimen", ")", "as", "a", "novel", "induction", "regimen", ".", "Compared", "with", "historic", "controls", ",", "the", "ALL-2", "regimen", "was", "superior", "in", "terms", "of", "incidence", "of", "complete", "remission", ",", "failure", "with", "resistant", "disease", ",", "and", "activity", "in", "patients", "with", "Philadelphia", "chromosome", "(", "Ph", ")", "-positive", "ALL", ".", "METHODS", "The", "authors", "conducted", "a", "multicenter", ",", "prospective", ",", "randomized", "trial", "of", "the", "ALL-2", "regimen", "compared", "with", "a", "standard", "4-drug", "induction", "(", "the", "L-20", "regimen", ")", ".", "Patients", "also", "received", "consolidation", ",", "maintenance", "therapy", ",", "and", "central", "nervous", "system", "prophylaxis", ".", "The", "trial", "accrued", "patients", "from", "August", "1996", "to", "October", "2004", ".", "RESULTS", "The", "median", "follow", "-", "up", "for", "survivors", "was", "7", "years", ",", "and", "the", "median", "patient", "age", "was", "43", "years", ".", "Responses", "were", "evaluated", "in", "164", "patients", ".", "The", "treatment", "arms", "were", "balanced", "in", "terms", "of", "pretreatment", "characteristics", ".", "The", "frequency", "of", "complete", "remission", "for", "the", "ALL-2", "regimen", "versus", "the", "L-20", "regimen", "was", "83", "%", "versus", "71", "%", "(", "P", "=", ".06", ")", ".", "More", "patients", "on", "the", "L-20", "arm", "failed", "with", "resistant", "disease", "(", "21", "%", "vs", "8", "%", ";", "P", "=", ".02", ")", ".", "Induction", "deaths", "were", "comparable", "at", "9", "%", "(", "ALL-2", ")", "versus", "7", "%", "(", "L-20", ")", ".", "The", "median", "survival", "was", "similar", ";", "and", ",", "at", "5", "years", ",", "the", "survival", "rate", "was", "33", "%", "alive", "on", "the", "ALL-2", "arm", "versus", "27", "%", "on", "the", "L-20", ".", "CONCLUSIONS", "Despite", "superior", "results", "of", "induction", "therapy", "with", "the", "ALL-2", "regimen", ",", "this", "treatment", "did", "not", "improve", "long", "-", "term", "outcomes", ".", "When", "coupled", "to", "the", "reported", "experience", "of", "other", "studies", "in", "adults", "with", "ALL", ",", "the", "results", "of", "this", "randomized", "trial", "raise", "the", "possibility", "that", "ultimate", "outcomes", "in", "adult", "ALL", "may", "be", "independent", "of", "the", "specific", "regimen", "chosen", ".", "Cancer", "2013", ".", "©", "2012", "American", "Cancer", "Society", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Age", "Outcome_Mortality", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
adults is a Participant_Age, acute lymphoblastic leukemia is a Participant_Condition, vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both is a Intervention_Pharmacological, cytarabine is a Intervention_Pharmacological, mitoxantrone is a Intervention_Pharmacological, resistant disease is a Outcome_Physical, 4-drug induction ( the L-20 regimen ) . is a Intervention_Pharmacological, consolidation , maintenance therapy , and central nervous system prophylaxis is a Intervention_Pharmacological, median follow - up for survivors is a Outcome_Mortality, median patient age was 43 years is a Participant_Age, 164 is a Participant_Sample-size, frequency of complete remission is a Outcome_Physical, Induction deaths is a Outcome_Mortality, median survival is a Outcome_Mortality, survival rate is a Outcome_Mortality, long - term outcomes is a Outcome_Other	57808_task1	Sentence: Treatment of adults with acute lymphoblastic leukemia : do the specifics of the regimen matter ? : Results from a prospective randomized trial . BACKGROUND Induction therapy for adults with acute lymphoblastic leukemia ( ALL ) is similar across essentially all regimens , comprised of vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both . Given the lack of randomized data , to date , no regimen has emerged as standard . The authors previously evaluated cytarabine 3 g/m ( 2 ) daily for 5 days with mitoxantrone 80 mg/m ( 2 ) ( the ALL-2 regimen ) as a novel induction regimen . Compared with historic controls , the ALL-2 regimen was superior in terms of incidence of complete remission , failure with resistant disease , and activity in patients with Philadelphia chromosome ( Ph ) -positive ALL . METHODS The authors conducted a multicenter , prospective , randomized trial of the ALL-2 regimen compared with a standard 4-drug induction ( the L-20 regimen ) . Patients also received consolidation , maintenance therapy , and central nervous system prophylaxis . The trial accrued patients from August 1996 to October 2004 . RESULTS The median follow-up for survivors was 7 years , and the median patient age was 43 years . Responses were evaluated in 164 patients . The treatment arms were balanced in terms of pretreatment characteristics . The frequency of complete remission for the ALL-2 regimen versus the L-20 regimen was 83 % versus 71 % ( P = .06 ) . More patients on the L-20 arm failed with resistant disease ( 21 % vs 8 % ; P = .02 ) . Induction deaths were comparable at 9 % ( ALL-2 ) versus 7 % ( L-20 ) . The median survival was similar ; and , at 5 years , the survival rate was 33 % alive on the ALL-2 arm versus 27 % on the L-20 . CONCLUSIONS Despite superior results of induction therapy with the ALL-2 regimen , this treatment did not improve long-term outcomes . When coupled to the reported experience of other studies in adults with ALL , the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen . Cancer 2013 . © 2012 American Cancer Society . Instructions: please typing these entity words according to sentence: adults, acute lymphoblastic leukemia, vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both, cytarabine, mitoxantrone, resistant disease, 4-drug induction ( the L-20 regimen ) ., consolidation , maintenance therapy , and central nervous system prophylaxis, median follow - up for survivors, median patient age was 43 years, 164, frequency of complete remission, Induction deaths, median survival, survival rate, long - term outcomes Options: Intervention_Pharmacological, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other	[ "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Treatment of adults with acute lymphoblastic leukemia : do the specifics of the regimen matter ? : Results from a prospective randomized trial . BACKGROUND Induction therapy for adults with acute lymphoblastic leukemia ( ALL ) is similar across essentially all regimens , comprised of vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both . Given the lack of randomized data , to date , no regimen has emerged as standard . The authors previously evaluated cytarabine 3 g/m ( 2 ) daily for 5 days with mitoxantrone 80 mg/m ( 2 ) ( the ALL-2 regimen ) as a novel induction regimen . Compared with historic controls , the ALL-2 regimen was superior in terms of incidence of complete remission , failure with resistant disease , and activity in patients with Philadelphia chromosome ( Ph ) -positive ALL . METHODS The authors conducted a multicenter , prospective , randomized trial of the ALL-2 regimen compared with a standard 4-drug induction ( the L-20 regimen ) . Patients also received consolidation , maintenance therapy , and central nervous system prophylaxis . The trial accrued patients from August 1996 to October 2004 . RESULTS The median follow-up for survivors was 7 years , and the median patient age was 43 years . Responses were evaluated in 164 patients . The treatment arms were balanced in terms of pretreatment characteristics . The frequency of complete remission for the ALL-2 regimen versus the L-20 regimen was 83 % versus 71 % ( P = .06 ) . More patients on the L-20 arm failed with resistant disease ( 21 % vs 8 % ; P = .02 ) . Induction deaths were comparable at 9 % ( ALL-2 ) versus 7 % ( L-20 ) . The median survival was similar ; and , at 5 years , the survival rate was 33 % alive on the ALL-2 arm versus 27 % on the L-20 . CONCLUSIONS Despite superior results of induction therapy with the ALL-2 regimen , this treatment did not improve long-term outcomes . When coupled to the reported experience of other studies in adults with ALL , the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen . Cancer 2013 . © 2012 American Cancer Society .	[ "Treatment", "of", "adults", "with", "acute", "lymphoblastic", "leukemia", ":", "do", "the", "specifics", "of", "the", "regimen", "matter", "?", ":", "Results", "from", "a", "prospective", "randomized", "trial", ".", "BACKGROUND", "Induction", "therapy", "for", "adults", "with", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "is", "similar", "across", "essentially", "all", "regimens", ",", "comprised", "of", "vincristine", ",", "corticosteroids", ",", "and", "anthracyclines", "intensified", "with", "cyclophosphamide", ",", "asparaginase", ",", "or", "both", ".", "Given", "the", "lack", "of", "randomized", "data", ",", "to", "date", ",", "no", "regimen", "has", "emerged", "as", "standard", ".", "The", "authors", "previously", "evaluated", "cytarabine", "3", "g", "/", "m", "(", "2", ")", "daily", "for", "5", "days", "with", "mitoxantrone", "80", "mg", "/", "m", "(", "2", ")", "(", "the", "ALL-2", "regimen", ")", "as", "a", "novel", "induction", "regimen", ".", "Compared", "with", "historic", "controls", ",", "the", "ALL-2", "regimen", "was", "superior", "in", "terms", "of", "incidence", "of", "complete", "remission", ",", "failure", "with", "resistant", "disease", ",", "and", "activity", "in", "patients", "with", "Philadelphia", "chromosome", "(", "Ph", ")", "-positive", "ALL", ".", "METHODS", "The", "authors", "conducted", "a", "multicenter", ",", "prospective", ",", "randomized", "trial", "of", "the", "ALL-2", "regimen", "compared", "with", "a", "standard", "4-drug", "induction", "(", "the", "L-20", "regimen", ")", ".", "Patients", "also", "received", "consolidation", ",", "maintenance", "therapy", ",", "and", "central", "nervous", "system", "prophylaxis", ".", "The", "trial", "accrued", "patients", "from", "August", "1996", "to", "October", "2004", ".", "RESULTS", "The", "median", "follow", "-", "up", "for", "survivors", "was", "7", "years", ",", "and", "the", "median", "patient", "age", "was", "43", "years", ".", "Responses", "were", "evaluated", "in", "164", "patients", ".", "The", "treatment", "arms", "were", "balanced", "in", "terms", "of", "pretreatment", "characteristics", ".", "The", "frequency", "of", "complete", "remission", "for", "the", "ALL-2", "regimen", "versus", "the", "L-20", "regimen", "was", "83", "%", "versus", "71", "%", "(", "P", "=", ".06", ")", ".", "More", "patients", "on", "the", "L-20", "arm", "failed", "with", "resistant", "disease", "(", "21", "%", "vs", "8", "%", ";", "P", "=", ".02", ")", ".", "Induction", "deaths", "were", "comparable", "at", "9", "%", "(", "ALL-2", ")", "versus", "7", "%", "(", "L-20", ")", ".", "The", "median", "survival", "was", "similar", ";", "and", ",", "at", "5", "years", ",", "the", "survival", "rate", "was", "33", "%", "alive", "on", "the", "ALL-2", "arm", "versus", "27", "%", "on", "the", "L-20", ".", "CONCLUSIONS", "Despite", "superior", "results", "of", "induction", "therapy", "with", "the", "ALL-2", "regimen", ",", "this", "treatment", "did", "not", "improve", "long", "-", "term", "outcomes", ".", "When", "coupled", "to", "the", "reported", "experience", "of", "other", "studies", "in", "adults", "with", "ALL", ",", "the", "results", "of", "this", "randomized", "trial", "raise", "the", "possibility", "that", "ultimate", "outcomes", "in", "adult", "ALL", "may", "be", "independent", "of", "the", "specific", "regimen", "chosen", ".", "Cancer", "2013", ".", "©", "2012", "American", "Cancer", "Society", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Age", "Outcome_Mortality", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
adults, acute lymphoblastic leukemia, vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both, cytarabine, mitoxantrone, resistant disease, 4-drug induction ( the L-20 regimen ) ., consolidation , maintenance therapy , and central nervous system prophylaxis, median follow - up for survivors, median patient age was 43 years, 164, frequency of complete remission, Induction deaths, median survival, survival rate, long - term outcomes	57808_task2	Sentence: Treatment of adults with acute lymphoblastic leukemia : do the specifics of the regimen matter ? : Results from a prospective randomized trial . BACKGROUND Induction therapy for adults with acute lymphoblastic leukemia ( ALL ) is similar across essentially all regimens , comprised of vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both . Given the lack of randomized data , to date , no regimen has emerged as standard . The authors previously evaluated cytarabine 3 g/m ( 2 ) daily for 5 days with mitoxantrone 80 mg/m ( 2 ) ( the ALL-2 regimen ) as a novel induction regimen . Compared with historic controls , the ALL-2 regimen was superior in terms of incidence of complete remission , failure with resistant disease , and activity in patients with Philadelphia chromosome ( Ph ) -positive ALL . METHODS The authors conducted a multicenter , prospective , randomized trial of the ALL-2 regimen compared with a standard 4-drug induction ( the L-20 regimen ) . Patients also received consolidation , maintenance therapy , and central nervous system prophylaxis . The trial accrued patients from August 1996 to October 2004 . RESULTS The median follow-up for survivors was 7 years , and the median patient age was 43 years . Responses were evaluated in 164 patients . The treatment arms were balanced in terms of pretreatment characteristics . The frequency of complete remission for the ALL-2 regimen versus the L-20 regimen was 83 % versus 71 % ( P = .06 ) . More patients on the L-20 arm failed with resistant disease ( 21 % vs 8 % ; P = .02 ) . Induction deaths were comparable at 9 % ( ALL-2 ) versus 7 % ( L-20 ) . The median survival was similar ; and , at 5 years , the survival rate was 33 % alive on the ALL-2 arm versus 27 % on the L-20 . CONCLUSIONS Despite superior results of induction therapy with the ALL-2 regimen , this treatment did not improve long-term outcomes . When coupled to the reported experience of other studies in adults with ALL , the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen . Cancer 2013 . © 2012 American Cancer Society . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Treatment of adults with acute lymphoblastic leukemia : do the specifics of the regimen matter ? : Results from a prospective randomized trial . BACKGROUND Induction therapy for adults with acute lymphoblastic leukemia ( ALL ) is similar across essentially all regimens , comprised of vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both . Given the lack of randomized data , to date , no regimen has emerged as standard . The authors previously evaluated cytarabine 3 g/m ( 2 ) daily for 5 days with mitoxantrone 80 mg/m ( 2 ) ( the ALL-2 regimen ) as a novel induction regimen . Compared with historic controls , the ALL-2 regimen was superior in terms of incidence of complete remission , failure with resistant disease , and activity in patients with Philadelphia chromosome ( Ph ) -positive ALL . METHODS The authors conducted a multicenter , prospective , randomized trial of the ALL-2 regimen compared with a standard 4-drug induction ( the L-20 regimen ) . Patients also received consolidation , maintenance therapy , and central nervous system prophylaxis . The trial accrued patients from August 1996 to October 2004 . RESULTS The median follow-up for survivors was 7 years , and the median patient age was 43 years . Responses were evaluated in 164 patients . The treatment arms were balanced in terms of pretreatment characteristics . The frequency of complete remission for the ALL-2 regimen versus the L-20 regimen was 83 % versus 71 % ( P = .06 ) . More patients on the L-20 arm failed with resistant disease ( 21 % vs 8 % ; P = .02 ) . Induction deaths were comparable at 9 % ( ALL-2 ) versus 7 % ( L-20 ) . The median survival was similar ; and , at 5 years , the survival rate was 33 % alive on the ALL-2 arm versus 27 % on the L-20 . CONCLUSIONS Despite superior results of induction therapy with the ALL-2 regimen , this treatment did not improve long-term outcomes . When coupled to the reported experience of other studies in adults with ALL , the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen . Cancer 2013 . © 2012 American Cancer Society .	[ "Treatment", "of", "adults", "with", "acute", "lymphoblastic", "leukemia", ":", "do", "the", "specifics", "of", "the", "regimen", "matter", "?", ":", "Results", "from", "a", "prospective", "randomized", "trial", ".", "BACKGROUND", "Induction", "therapy", "for", "adults", "with", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "is", "similar", "across", "essentially", "all", "regimens", ",", "comprised", "of", "vincristine", ",", "corticosteroids", ",", "and", "anthracyclines", "intensified", "with", "cyclophosphamide", ",", "asparaginase", ",", "or", "both", ".", "Given", "the", "lack", "of", "randomized", "data", ",", "to", "date", ",", "no", "regimen", "has", "emerged", "as", "standard", ".", "The", "authors", "previously", "evaluated", "cytarabine", "3", "g", "/", "m", "(", "2", ")", "daily", "for", "5", "days", "with", "mitoxantrone", "80", "mg", "/", "m", "(", "2", ")", "(", "the", "ALL-2", "regimen", ")", "as", "a", "novel", "induction", "regimen", ".", "Compared", "with", "historic", "controls", ",", "the", "ALL-2", "regimen", "was", "superior", "in", "terms", "of", "incidence", "of", "complete", "remission", ",", "failure", "with", "resistant", "disease", ",", "and", "activity", "in", "patients", "with", "Philadelphia", "chromosome", "(", "Ph", ")", "-positive", "ALL", ".", "METHODS", "The", "authors", "conducted", "a", "multicenter", ",", "prospective", ",", "randomized", "trial", "of", "the", "ALL-2", "regimen", "compared", "with", "a", "standard", "4-drug", "induction", "(", "the", "L-20", "regimen", ")", ".", "Patients", "also", "received", "consolidation", ",", "maintenance", "therapy", ",", "and", "central", "nervous", "system", "prophylaxis", ".", "The", "trial", "accrued", "patients", "from", "August", "1996", "to", "October", "2004", ".", "RESULTS", "The", "median", "follow", "-", "up", "for", "survivors", "was", "7", "years", ",", "and", "the", "median", "patient", "age", "was", "43", "years", ".", "Responses", "were", "evaluated", "in", "164", "patients", ".", "The", "treatment", "arms", "were", "balanced", "in", "terms", "of", "pretreatment", "characteristics", ".", "The", "frequency", "of", "complete", "remission", "for", "the", "ALL-2", "regimen", "versus", "the", "L-20", "regimen", "was", "83", "%", "versus", "71", "%", "(", "P", "=", ".06", ")", ".", "More", "patients", "on", "the", "L-20", "arm", "failed", "with", "resistant", "disease", "(", "21", "%", "vs", "8", "%", ";", "P", "=", ".02", ")", ".", "Induction", "deaths", "were", "comparable", "at", "9", "%", "(", "ALL-2", ")", "versus", "7", "%", "(", "L-20", ")", ".", "The", "median", "survival", "was", "similar", ";", "and", ",", "at", "5", "years", ",", "the", "survival", "rate", "was", "33", "%", "alive", "on", "the", "ALL-2", "arm", "versus", "27", "%", "on", "the", "L-20", ".", "CONCLUSIONS", "Despite", "superior", "results", "of", "induction", "therapy", "with", "the", "ALL-2", "regimen", ",", "this", "treatment", "did", "not", "improve", "long", "-", "term", "outcomes", ".", "When", "coupled", "to", "the", "reported", "experience", "of", "other", "studies", "in", "adults", "with", "ALL", ",", "the", "results", "of", "this", "randomized", "trial", "raise", "the", "possibility", "that", "ultimate", "outcomes", "in", "adult", "ALL", "may", "be", "independent", "of", "the", "specific", "regimen", "chosen", ".", "Cancer", "2013", ".", "©", "2012", "American", "Cancer", "Society", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Age", "Outcome_Mortality", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]
old is an umlsterm, female is an umlsterm, patient is an umlsterm, fractures is an umlsterm, minor is an umlsterm, trauma is an umlsterm, pelvis is an umlsterm, pseudoarthrosis is an umlsterm, simulated is an umlsterm, metastatic disease is an umlsterm, differential diagnosis is an umlsterm, fractures is an umlsterm	DerUnfallchirurg.91020656.eng.abstr_task0	Sentence: We report a case of a 64-year old female patient , who developed a total instability of the pelvic ring within one year as a result of increasing insufficiency fractures . A minor trauma of the pelvis was assumed to be the trigger of this process retrospectively . The radiographic appearance of the multiple pseudoarthrosis simulated a metastatic disease . The differential diagnosis and the typical pattern of sacral insufficiency fractures ( SIF ) are described . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	We report a case of a 64-year old female patient , who developed a total instability of the pelvic ring within one year as a result of increasing insufficiency fractures . A minor trauma of the pelvis was assumed to be the trigger of this process retrospectively . The radiographic appearance of the multiple pseudoarthrosis simulated a metastatic disease . The differential diagnosis and the typical pattern of sacral insufficiency fractures ( SIF ) are described .	[ "We", "report", "a", "case", "of", "a", "64-year", "old", "female", "patient", ",", "who", "developed", "a", "total", "instability", "of", "the", "pelvic", "ring", "within", "one", "year", "as", "a", "result", "of", "increasing", "insufficiency", "fractures", ".", "A", "minor", "trauma", "of", "the", "pelvis", "was", "assumed", "to", "be", "the", "trigger", "of", "this", "process", "retrospectively", ".", "The", "radiographic", "appearance", "of", "the", "multiple", "pseudoarthrosis", "simulated", "a", "metastatic", "disease", ".", "The", "differential", "diagnosis", "and", "the", "typical", "pattern", "of", "sacral", "insufficiency", "fractures", "(", "SIF", ")", "are", "described", "." ]	[ "umlsterm" ]
old is an umlsterm, female is an umlsterm, patient is an umlsterm, fractures is an umlsterm, minor is an umlsterm, trauma is an umlsterm, pelvis is an umlsterm, pseudoarthrosis is an umlsterm, simulated is an umlsterm, metastatic disease is an umlsterm, differential diagnosis is an umlsterm, fractures is an umlsterm	DerUnfallchirurg.91020656.eng.abstr_task1	Sentence: We report a case of a 64-year old female patient , who developed a total instability of the pelvic ring within one year as a result of increasing insufficiency fractures . A minor trauma of the pelvis was assumed to be the trigger of this process retrospectively . The radiographic appearance of the multiple pseudoarthrosis simulated a metastatic disease . The differential diagnosis and the typical pattern of sacral insufficiency fractures ( SIF ) are described . Instructions: please typing these entity words according to sentence: old, female, patient, fractures, minor, trauma, pelvis, pseudoarthrosis, simulated, metastatic disease, differential diagnosis, fractures Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	We report a case of a 64-year old female patient , who developed a total instability of the pelvic ring within one year as a result of increasing insufficiency fractures . A minor trauma of the pelvis was assumed to be the trigger of this process retrospectively . The radiographic appearance of the multiple pseudoarthrosis simulated a metastatic disease . The differential diagnosis and the typical pattern of sacral insufficiency fractures ( SIF ) are described .	[ "We", "report", "a", "case", "of", "a", "64-year", "old", "female", "patient", ",", "who", "developed", "a", "total", "instability", "of", "the", "pelvic", "ring", "within", "one", "year", "as", "a", "result", "of", "increasing", "insufficiency", "fractures", ".", "A", "minor", "trauma", "of", "the", "pelvis", "was", "assumed", "to", "be", "the", "trigger", "of", "this", "process", "retrospectively", ".", "The", "radiographic", "appearance", "of", "the", "multiple", "pseudoarthrosis", "simulated", "a", "metastatic", "disease", ".", "The", "differential", "diagnosis", "and", "the", "typical", "pattern", "of", "sacral", "insufficiency", "fractures", "(", "SIF", ")", "are", "described", "." ]	[ "umlsterm" ]
old, female, patient, fractures, minor, trauma, pelvis, pseudoarthrosis, simulated, metastatic disease, differential diagnosis, fractures	DerUnfallchirurg.91020656.eng.abstr_task2	Sentence: We report a case of a 64-year old female patient , who developed a total instability of the pelvic ring within one year as a result of increasing insufficiency fractures . A minor trauma of the pelvis was assumed to be the trigger of this process retrospectively . The radiographic appearance of the multiple pseudoarthrosis simulated a metastatic disease . The differential diagnosis and the typical pattern of sacral insufficiency fractures ( SIF ) are described . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	We report a case of a 64-year old female patient , who developed a total instability of the pelvic ring within one year as a result of increasing insufficiency fractures . A minor trauma of the pelvis was assumed to be the trigger of this process retrospectively . The radiographic appearance of the multiple pseudoarthrosis simulated a metastatic disease . The differential diagnosis and the typical pattern of sacral insufficiency fractures ( SIF ) are described .	[ "We", "report", "a", "case", "of", "a", "64-year", "old", "female", "patient", ",", "who", "developed", "a", "total", "instability", "of", "the", "pelvic", "ring", "within", "one", "year", "as", "a", "result", "of", "increasing", "insufficiency", "fractures", ".", "A", "minor", "trauma", "of", "the", "pelvis", "was", "assumed", "to", "be", "the", "trigger", "of", "this", "process", "retrospectively", ".", "The", "radiographic", "appearance", "of", "the", "multiple", "pseudoarthrosis", "simulated", "a", "metastatic", "disease", ".", "The", "differential", "diagnosis", "and", "the", "typical", "pattern", "of", "sacral", "insufficiency", "fractures", "(", "SIF", ")", "are", "described", "." ]	[ "umlsterm" ]
IgG is a Individual_protein, vinculin is a Individual_protein, talin is a Individual_protein, actin - binding protein is a Individual_protein	60_task0	Sentence: Although binding patterns of different sera were not identical, almost all sera caused IgG binding to platelet components of 87-90 kD, 140 kD (identified as vinculin) and 220-240 kD (tentatively identified as talin and actin-binding protein). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O" ]	Although binding patterns of different sera were not identical, almost all sera caused IgG binding to platelet components of 87-90 kD, 140 kD (identified as vinculin) and 220-240 kD (tentatively identified as talin and actin-binding protein).	[ "Although", "binding", "patterns", "of", "different", "sera", "were", "not", "identical", ",", "almost", "all", "sera", "caused", "IgG", "binding", "to", "platelet", "components", "of", "87", "-", "90", "kD", ",", "140", "kD", "(", "identified", "as", "vinculin", ")", "and", "220", "-", "240", "kD", "(", "tentatively", "identified", "as", "talin", "and", "actin", "-", "binding", "protein", ")", "." ]	[ "Individual_protein" ]
IgG is a Individual_protein, vinculin is a Individual_protein, talin is a Individual_protein, actin - binding protein is a Individual_protein	60_task1	Sentence: Although binding patterns of different sera were not identical, almost all sera caused IgG binding to platelet components of 87-90 kD, 140 kD (identified as vinculin) and 220-240 kD (tentatively identified as talin and actin-binding protein). Instructions: please typing these entity words according to sentence: IgG, vinculin, talin, actin - binding protein Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O" ]	Although binding patterns of different sera were not identical, almost all sera caused IgG binding to platelet components of 87-90 kD, 140 kD (identified as vinculin) and 220-240 kD (tentatively identified as talin and actin-binding protein).	[ "Although", "binding", "patterns", "of", "different", "sera", "were", "not", "identical", ",", "almost", "all", "sera", "caused", "IgG", "binding", "to", "platelet", "components", "of", "87", "-", "90", "kD", ",", "140", "kD", "(", "identified", "as", "vinculin", ")", "and", "220", "-", "240", "kD", "(", "tentatively", "identified", "as", "talin", "and", "actin", "-", "binding", "protein", ")", "." ]	[ "Individual_protein" ]
IgG, vinculin, talin, actin - binding protein	60_task2	Sentence: Although binding patterns of different sera were not identical, almost all sera caused IgG binding to platelet components of 87-90 kD, 140 kD (identified as vinculin) and 220-240 kD (tentatively identified as talin and actin-binding protein). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O" ]	Although binding patterns of different sera were not identical, almost all sera caused IgG binding to platelet components of 87-90 kD, 140 kD (identified as vinculin) and 220-240 kD (tentatively identified as talin and actin-binding protein).	[ "Although", "binding", "patterns", "of", "different", "sera", "were", "not", "identical", ",", "almost", "all", "sera", "caused", "IgG", "binding", "to", "platelet", "components", "of", "87", "-", "90", "kD", ",", "140", "kD", "(", "identified", "as", "vinculin", ")", "and", "220", "-", "240", "kD", "(", "tentatively", "identified", "as", "talin", "and", "actin", "-", "binding", "protein", ")", "." ]	[ "Individual_protein" ]
Rehabilitation outcomes is a Outcome_Physical, risk factors is a Outcome_Mental, psychological well - being is a Outcome_Mental, functional capacity is a Outcome_Mental, work resumption is a Outcome_Mental, post - percutaneous coronary interventions ( PCI ) is a Intervention_Educational, control ( standard care plus telephone follow - up is a Intervention_Control, post - PCI is a Intervention_Educational, serum cholesterol levels is a Outcome_Physical, exercise participation is a Outcome_Physical, body mass index ( BMI ) is a Outcome_Physical, returned to work is a Outcome_Mental, risk factor profiles and work resumption patterns is a Outcome_Other	6334_task0	Sentence: Rehabilitation outcomes following percutaneous coronary interventions ( PCI ) . This prospective study evaluated the effect of an individualized , comprehensive , home-based cardiac rehabilitation program combining exercise training with risk factor modification and psychosocial counseling on risk factors , psychological well-being , functional capacity , and work resumption in 99 post-percutaneous coronary interventions ( PCI ) patients randomized to control ( standard care plus telephone follow-up , n=49 ) or intervention ( individualized , comprehensive , home-based cardiac rehabilitation , n=50 ) groups . Data were collected at time 1 ( T ( 1 ) ) during hospital admission , time 2 ( T ( 2 ) ) approximately 2 months post-PCI , and time 3 ( T ( 3 ) ) approximately 12 months post-PCI . Results suggest that the allocation to an individualized , comprehensive , home-based cardiac rehabilitation program provided more advantageous outcomes . At both follow-ups , the intervention group showed within-group improvement in serum cholesterol levels ( P < 0.02 ; P < 0.01 ) and exercise participation ( P < 0.001 ; P < 0.001 ) with differences in exercise participation favoring the intervention group ( P < 0.01 ) at T ( 2 ) . Repeated measures ANOVA showed significant improvements over time in body mass index ( BMI ) ( P < 0.01 ) , psychological well-being ( P < 0.001 ) , and functional capacity ( P < 0.001 ) for both groups . More patients in the intervention group had returned to work at T ( 2 ) ( P < 0.001 ) and did so more quickly ( P < 0.01 ) . These findings suggest that an individualized , comprehensive , home-based cardiac rehabilitation program improves risk factor profiles and work resumption patterns for patients following PCI . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Control, Intervention_Educational, Outcome_Physical, Outcome_Other, Outcome_Mental	[ "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O" ]	Rehabilitation outcomes following percutaneous coronary interventions ( PCI ) . This prospective study evaluated the effect of an individualized , comprehensive , home-based cardiac rehabilitation program combining exercise training with risk factor modification and psychosocial counseling on risk factors , psychological well-being , functional capacity , and work resumption in 99 post-percutaneous coronary interventions ( PCI ) patients randomized to control ( standard care plus telephone follow-up , n=49 ) or intervention ( individualized , comprehensive , home-based cardiac rehabilitation , n=50 ) groups . Data were collected at time 1 ( T ( 1 ) ) during hospital admission , time 2 ( T ( 2 ) ) approximately 2 months post-PCI , and time 3 ( T ( 3 ) ) approximately 12 months post-PCI . Results suggest that the allocation to an individualized , comprehensive , home-based cardiac rehabilitation program provided more advantageous outcomes . At both follow-ups , the intervention group showed within-group improvement in serum cholesterol levels ( P < 0.02 ; P < 0.01 ) and exercise participation ( P < 0.001 ; P < 0.001 ) with differences in exercise participation favoring the intervention group ( P < 0.01 ) at T ( 2 ) . Repeated measures ANOVA showed significant improvements over time in body mass index ( BMI ) ( P < 0.01 ) , psychological well-being ( P < 0.001 ) , and functional capacity ( P < 0.001 ) for both groups . More patients in the intervention group had returned to work at T ( 2 ) ( P < 0.001 ) and did so more quickly ( P < 0.01 ) . These findings suggest that an individualized , comprehensive , home-based cardiac rehabilitation program improves risk factor profiles and work resumption patterns for patients following PCI .	[ "Rehabilitation", "outcomes", "following", "percutaneous", "coronary", "interventions", "(", "PCI", ")", ".", "This", "prospective", "study", "evaluated", "the", "effect", "of", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "combining", "exercise", "training", "with", "risk", "factor", "modification", "and", "psychosocial", "counseling", "on", "risk", "factors", ",", "psychological", "well", "-", "being", ",", "functional", "capacity", ",", "and", "work", "resumption", "in", "99", "post", "-", "percutaneous", "coronary", "interventions", "(", "PCI", ")", "patients", "randomized", "to", "control", "(", "standard", "care", "plus", "telephone", "follow", "-", "up", ",", "n=49", ")", "or", "intervention", "(", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", ",", "n=50", ")", "groups", ".", "Data", "were", "collected", "at", "time", "1", "(", "T", "(", "1", ")", ")", "during", "hospital", "admission", ",", "time", "2", "(", "T", "(", "2", ")", ")", "approximately", "2", "months", "post", "-", "PCI", ",", "and", "time", "3", "(", "T", "(", "3", ")", ")", "approximately", "12", "months", "post", "-", "PCI", ".", "Results", "suggest", "that", "the", "allocation", "to", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "provided", "more", "advantageous", "outcomes", ".", "At", "both", "follow", "-", "ups", ",", "the", "intervention", "group", "showed", "within", "-", "group", "improvement", "in", "serum", "cholesterol", "levels", "(", "P", "<", "0.02", ";", "P", "<", "0.01", ")", "and", "exercise", "participation", "(", "P", "<", "0.001", ";", "P", "<", "0.001", ")", "with", "differences", "in", "exercise", "participation", "favoring", "the", "intervention", "group", "(", "P", "<", "0.01", ")", "at", "T", "(", "2", ")", ".", "Repeated", "measures", "ANOVA", "showed", "significant", "improvements", "over", "time", "in", "body", "mass", "index", "(", "BMI", ")", "(", "P", "<", "0.01", ")", ",", "psychological", "well", "-", "being", "(", "P", "<", "0.001", ")", ",", "and", "functional", "capacity", "(", "P", "<", "0.001", ")", "for", "both", "groups", ".", "More", "patients", "in", "the", "intervention", "group", "had", "returned", "to", "work", "at", "T", "(", "2", ")", "(", "P", "<", "0.001", ")", "and", "did", "so", "more", "quickly", "(", "P", "<", "0.01", ")", ".", "These", "findings", "suggest", "that", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "improves", "risk", "factor", "profiles", "and", "work", "resumption", "patterns", "for", "patients", "following", "PCI", "." ]	[ "Outcome_Other", "Intervention_Educational", "Intervention_Control", "Outcome_Mental", "Outcome_Physical" ]
Rehabilitation outcomes is a Outcome_Physical, risk factors is a Outcome_Mental, psychological well - being is a Outcome_Mental, functional capacity is a Outcome_Mental, work resumption is a Outcome_Mental, post - percutaneous coronary interventions ( PCI ) is a Intervention_Educational, control ( standard care plus telephone follow - up is a Intervention_Control, post - PCI is a Intervention_Educational, serum cholesterol levels is a Outcome_Physical, exercise participation is a Outcome_Physical, body mass index ( BMI ) is a Outcome_Physical, returned to work is a Outcome_Mental, risk factor profiles and work resumption patterns is a Outcome_Other	6334_task1	Sentence: Rehabilitation outcomes following percutaneous coronary interventions ( PCI ) . This prospective study evaluated the effect of an individualized , comprehensive , home-based cardiac rehabilitation program combining exercise training with risk factor modification and psychosocial counseling on risk factors , psychological well-being , functional capacity , and work resumption in 99 post-percutaneous coronary interventions ( PCI ) patients randomized to control ( standard care plus telephone follow-up , n=49 ) or intervention ( individualized , comprehensive , home-based cardiac rehabilitation , n=50 ) groups . Data were collected at time 1 ( T ( 1 ) ) during hospital admission , time 2 ( T ( 2 ) ) approximately 2 months post-PCI , and time 3 ( T ( 3 ) ) approximately 12 months post-PCI . Results suggest that the allocation to an individualized , comprehensive , home-based cardiac rehabilitation program provided more advantageous outcomes . At both follow-ups , the intervention group showed within-group improvement in serum cholesterol levels ( P < 0.02 ; P < 0.01 ) and exercise participation ( P < 0.001 ; P < 0.001 ) with differences in exercise participation favoring the intervention group ( P < 0.01 ) at T ( 2 ) . Repeated measures ANOVA showed significant improvements over time in body mass index ( BMI ) ( P < 0.01 ) , psychological well-being ( P < 0.001 ) , and functional capacity ( P < 0.001 ) for both groups . More patients in the intervention group had returned to work at T ( 2 ) ( P < 0.001 ) and did so more quickly ( P < 0.01 ) . These findings suggest that an individualized , comprehensive , home-based cardiac rehabilitation program improves risk factor profiles and work resumption patterns for patients following PCI . Instructions: please typing these entity words according to sentence: Rehabilitation outcomes, risk factors, psychological well - being, functional capacity, work resumption, post - percutaneous coronary interventions ( PCI ), control ( standard care plus telephone follow - up, post - PCI, serum cholesterol levels, exercise participation, body mass index ( BMI ), returned to work, risk factor profiles and work resumption patterns Options: Intervention_Control, Intervention_Educational, Outcome_Physical, Outcome_Other, Outcome_Mental	[ "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O" ]	Rehabilitation outcomes following percutaneous coronary interventions ( PCI ) . This prospective study evaluated the effect of an individualized , comprehensive , home-based cardiac rehabilitation program combining exercise training with risk factor modification and psychosocial counseling on risk factors , psychological well-being , functional capacity , and work resumption in 99 post-percutaneous coronary interventions ( PCI ) patients randomized to control ( standard care plus telephone follow-up , n=49 ) or intervention ( individualized , comprehensive , home-based cardiac rehabilitation , n=50 ) groups . Data were collected at time 1 ( T ( 1 ) ) during hospital admission , time 2 ( T ( 2 ) ) approximately 2 months post-PCI , and time 3 ( T ( 3 ) ) approximately 12 months post-PCI . Results suggest that the allocation to an individualized , comprehensive , home-based cardiac rehabilitation program provided more advantageous outcomes . At both follow-ups , the intervention group showed within-group improvement in serum cholesterol levels ( P < 0.02 ; P < 0.01 ) and exercise participation ( P < 0.001 ; P < 0.001 ) with differences in exercise participation favoring the intervention group ( P < 0.01 ) at T ( 2 ) . Repeated measures ANOVA showed significant improvements over time in body mass index ( BMI ) ( P < 0.01 ) , psychological well-being ( P < 0.001 ) , and functional capacity ( P < 0.001 ) for both groups . More patients in the intervention group had returned to work at T ( 2 ) ( P < 0.001 ) and did so more quickly ( P < 0.01 ) . These findings suggest that an individualized , comprehensive , home-based cardiac rehabilitation program improves risk factor profiles and work resumption patterns for patients following PCI .	[ "Rehabilitation", "outcomes", "following", "percutaneous", "coronary", "interventions", "(", "PCI", ")", ".", "This", "prospective", "study", "evaluated", "the", "effect", "of", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "combining", "exercise", "training", "with", "risk", "factor", "modification", "and", "psychosocial", "counseling", "on", "risk", "factors", ",", "psychological", "well", "-", "being", ",", "functional", "capacity", ",", "and", "work", "resumption", "in", "99", "post", "-", "percutaneous", "coronary", "interventions", "(", "PCI", ")", "patients", "randomized", "to", "control", "(", "standard", "care", "plus", "telephone", "follow", "-", "up", ",", "n=49", ")", "or", "intervention", "(", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", ",", "n=50", ")", "groups", ".", "Data", "were", "collected", "at", "time", "1", "(", "T", "(", "1", ")", ")", "during", "hospital", "admission", ",", "time", "2", "(", "T", "(", "2", ")", ")", "approximately", "2", "months", "post", "-", "PCI", ",", "and", "time", "3", "(", "T", "(", "3", ")", ")", "approximately", "12", "months", "post", "-", "PCI", ".", "Results", "suggest", "that", "the", "allocation", "to", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "provided", "more", "advantageous", "outcomes", ".", "At", "both", "follow", "-", "ups", ",", "the", "intervention", "group", "showed", "within", "-", "group", "improvement", "in", "serum", "cholesterol", "levels", "(", "P", "<", "0.02", ";", "P", "<", "0.01", ")", "and", "exercise", "participation", "(", "P", "<", "0.001", ";", "P", "<", "0.001", ")", "with", "differences", "in", "exercise", "participation", "favoring", "the", "intervention", "group", "(", "P", "<", "0.01", ")", "at", "T", "(", "2", ")", ".", "Repeated", "measures", "ANOVA", "showed", "significant", "improvements", "over", "time", "in", "body", "mass", "index", "(", "BMI", ")", "(", "P", "<", "0.01", ")", ",", "psychological", "well", "-", "being", "(", "P", "<", "0.001", ")", ",", "and", "functional", "capacity", "(", "P", "<", "0.001", ")", "for", "both", "groups", ".", "More", "patients", "in", "the", "intervention", "group", "had", "returned", "to", "work", "at", "T", "(", "2", ")", "(", "P", "<", "0.001", ")", "and", "did", "so", "more", "quickly", "(", "P", "<", "0.01", ")", ".", "These", "findings", "suggest", "that", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "improves", "risk", "factor", "profiles", "and", "work", "resumption", "patterns", "for", "patients", "following", "PCI", "." ]	[ "Outcome_Other", "Intervention_Educational", "Intervention_Control", "Outcome_Mental", "Outcome_Physical" ]
Rehabilitation outcomes, risk factors, psychological well - being, functional capacity, work resumption, post - percutaneous coronary interventions ( PCI ), control ( standard care plus telephone follow - up, post - PCI, serum cholesterol levels, exercise participation, body mass index ( BMI ), returned to work, risk factor profiles and work resumption patterns	6334_task2	Sentence: Rehabilitation outcomes following percutaneous coronary interventions ( PCI ) . This prospective study evaluated the effect of an individualized , comprehensive , home-based cardiac rehabilitation program combining exercise training with risk factor modification and psychosocial counseling on risk factors , psychological well-being , functional capacity , and work resumption in 99 post-percutaneous coronary interventions ( PCI ) patients randomized to control ( standard care plus telephone follow-up , n=49 ) or intervention ( individualized , comprehensive , home-based cardiac rehabilitation , n=50 ) groups . Data were collected at time 1 ( T ( 1 ) ) during hospital admission , time 2 ( T ( 2 ) ) approximately 2 months post-PCI , and time 3 ( T ( 3 ) ) approximately 12 months post-PCI . Results suggest that the allocation to an individualized , comprehensive , home-based cardiac rehabilitation program provided more advantageous outcomes . At both follow-ups , the intervention group showed within-group improvement in serum cholesterol levels ( P < 0.02 ; P < 0.01 ) and exercise participation ( P < 0.001 ; P < 0.001 ) with differences in exercise participation favoring the intervention group ( P < 0.01 ) at T ( 2 ) . Repeated measures ANOVA showed significant improvements over time in body mass index ( BMI ) ( P < 0.01 ) , psychological well-being ( P < 0.001 ) , and functional capacity ( P < 0.001 ) for both groups . More patients in the intervention group had returned to work at T ( 2 ) ( P < 0.001 ) and did so more quickly ( P < 0.01 ) . These findings suggest that an individualized , comprehensive , home-based cardiac rehabilitation program improves risk factor profiles and work resumption patterns for patients following PCI . Instructions: please extract entity words from the input sentence	[ "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O" ]	Rehabilitation outcomes following percutaneous coronary interventions ( PCI ) . This prospective study evaluated the effect of an individualized , comprehensive , home-based cardiac rehabilitation program combining exercise training with risk factor modification and psychosocial counseling on risk factors , psychological well-being , functional capacity , and work resumption in 99 post-percutaneous coronary interventions ( PCI ) patients randomized to control ( standard care plus telephone follow-up , n=49 ) or intervention ( individualized , comprehensive , home-based cardiac rehabilitation , n=50 ) groups . Data were collected at time 1 ( T ( 1 ) ) during hospital admission , time 2 ( T ( 2 ) ) approximately 2 months post-PCI , and time 3 ( T ( 3 ) ) approximately 12 months post-PCI . Results suggest that the allocation to an individualized , comprehensive , home-based cardiac rehabilitation program provided more advantageous outcomes . At both follow-ups , the intervention group showed within-group improvement in serum cholesterol levels ( P < 0.02 ; P < 0.01 ) and exercise participation ( P < 0.001 ; P < 0.001 ) with differences in exercise participation favoring the intervention group ( P < 0.01 ) at T ( 2 ) . Repeated measures ANOVA showed significant improvements over time in body mass index ( BMI ) ( P < 0.01 ) , psychological well-being ( P < 0.001 ) , and functional capacity ( P < 0.001 ) for both groups . More patients in the intervention group had returned to work at T ( 2 ) ( P < 0.001 ) and did so more quickly ( P < 0.01 ) . These findings suggest that an individualized , comprehensive , home-based cardiac rehabilitation program improves risk factor profiles and work resumption patterns for patients following PCI .	[ "Rehabilitation", "outcomes", "following", "percutaneous", "coronary", "interventions", "(", "PCI", ")", ".", "This", "prospective", "study", "evaluated", "the", "effect", "of", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "combining", "exercise", "training", "with", "risk", "factor", "modification", "and", "psychosocial", "counseling", "on", "risk", "factors", ",", "psychological", "well", "-", "being", ",", "functional", "capacity", ",", "and", "work", "resumption", "in", "99", "post", "-", "percutaneous", "coronary", "interventions", "(", "PCI", ")", "patients", "randomized", "to", "control", "(", "standard", "care", "plus", "telephone", "follow", "-", "up", ",", "n=49", ")", "or", "intervention", "(", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", ",", "n=50", ")", "groups", ".", "Data", "were", "collected", "at", "time", "1", "(", "T", "(", "1", ")", ")", "during", "hospital", "admission", ",", "time", "2", "(", "T", "(", "2", ")", ")", "approximately", "2", "months", "post", "-", "PCI", ",", "and", "time", "3", "(", "T", "(", "3", ")", ")", "approximately", "12", "months", "post", "-", "PCI", ".", "Results", "suggest", "that", "the", "allocation", "to", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "provided", "more", "advantageous", "outcomes", ".", "At", "both", "follow", "-", "ups", ",", "the", "intervention", "group", "showed", "within", "-", "group", "improvement", "in", "serum", "cholesterol", "levels", "(", "P", "<", "0.02", ";", "P", "<", "0.01", ")", "and", "exercise", "participation", "(", "P", "<", "0.001", ";", "P", "<", "0.001", ")", "with", "differences", "in", "exercise", "participation", "favoring", "the", "intervention", "group", "(", "P", "<", "0.01", ")", "at", "T", "(", "2", ")", ".", "Repeated", "measures", "ANOVA", "showed", "significant", "improvements", "over", "time", "in", "body", "mass", "index", "(", "BMI", ")", "(", "P", "<", "0.01", ")", ",", "psychological", "well", "-", "being", "(", "P", "<", "0.001", ")", ",", "and", "functional", "capacity", "(", "P", "<", "0.001", ")", "for", "both", "groups", ".", "More", "patients", "in", "the", "intervention", "group", "had", "returned", "to", "work", "at", "T", "(", "2", ")", "(", "P", "<", "0.001", ")", "and", "did", "so", "more", "quickly", "(", "P", "<", "0.01", ")", ".", "These", "findings", "suggest", "that", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "improves", "risk", "factor", "profiles", "and", "work", "resumption", "patterns", "for", "patients", "following", "PCI", "." ]	[ "Outcome_Other", "Intervention_Educational", "Intervention_Control", "Outcome_Mental", "Outcome_Physical" ]
Kalksalzablagerungen is an umlsterm, licht- is an umlsterm, rasterelektronenmikroskopisch is an umlsterm, Natur is an umlsterm, Nadeln is an umlsterm, Natriumurats is an umlsterm, Wasser is an umlsterm, rasterelektronenmikroskopisch is an umlsterm, Kalzium is an umlsterm, Phosphor is an umlsterm, Fadengranulomen is an umlsterm, Geweben is an umlsterm, Knorpelarten is an umlsterm	ZfuerRheumatologie.00590240.ger.abstr_task0	Sentence: Verkalkungen von Gichttophi sind zwar ein bekanntes Ereignis , dennoch fehlen detaillierte Untersuchungsbefunde zur Zusammensetzung dieser sekundaeren Kalksalzablagerungen . Es sollte deshalb licht- und rasterelektronenmikroskopisch sowie roentgenmikroanalytisch die Natur solcher Verkalkungen geklaert werden . In ungefaerbten Schnittpraeparaten verkalkter Gichttophi herrschten die negativ doppelbrechenden Nadeln des Natriumurats vor , nach Inkubation in destilliertem Wasser waren sie verschwunden und lediglich plumpe unterschiedlich grosse positiv doppelbrechende Kristalle zurueckgeblieben ; ein gleichartiges Ergebnis wurde rasterelektronenmikroskopisch erhalten . Roentgenmikroanalytisch liessen hohe Zaehlraten fuer Kalzium und Phosphor auf die Anwesenheit von Kalziumpyrophosphat-Dihydrat schliessen . Das Auftreten von Kalziumpyrophosphatkristallen in Gichttophi und auch Fadengranulomen laesst die Schlussfolgerung zu , dass diese Kristalle nicht nur in artikulaeren Geweben im engeren Sinne oder verschiedenen Knorpelarten auftreten . Der biochemische Mechanismus , der zur Kristallbildung fuehrt , bleibt zwar unbekannt , es darf aber vermutet werden , dass die Verkalkung Folge einer vorausgegangenen Bindegewebsschaedigung ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Verkalkungen von Gichttophi sind zwar ein bekanntes Ereignis , dennoch fehlen detaillierte Untersuchungsbefunde zur Zusammensetzung dieser sekundaeren Kalksalzablagerungen . Es sollte deshalb licht- und rasterelektronenmikroskopisch sowie roentgenmikroanalytisch die Natur solcher Verkalkungen geklaert werden . In ungefaerbten Schnittpraeparaten verkalkter Gichttophi herrschten die negativ doppelbrechenden Nadeln des Natriumurats vor , nach Inkubation in destilliertem Wasser waren sie verschwunden und lediglich plumpe unterschiedlich grosse positiv doppelbrechende Kristalle zurueckgeblieben ; ein gleichartiges Ergebnis wurde rasterelektronenmikroskopisch erhalten . Roentgenmikroanalytisch liessen hohe Zaehlraten fuer Kalzium und Phosphor auf die Anwesenheit von Kalziumpyrophosphat-Dihydrat schliessen . Das Auftreten von Kalziumpyrophosphatkristallen in Gichttophi und auch Fadengranulomen laesst die Schlussfolgerung zu , dass diese Kristalle nicht nur in artikulaeren Geweben im engeren Sinne oder verschiedenen Knorpelarten auftreten . Der biochemische Mechanismus , der zur Kristallbildung fuehrt , bleibt zwar unbekannt , es darf aber vermutet werden , dass die Verkalkung Folge einer vorausgegangenen Bindegewebsschaedigung ist .	[ "Verkalkungen", "von", "Gichttophi", "sind", "zwar", "ein", "bekanntes", "Ereignis", ",", "dennoch", "fehlen", "detaillierte", "Untersuchungsbefunde", "zur", "Zusammensetzung", "dieser", "sekundaeren", "Kalksalzablagerungen", ".", "Es", "sollte", "deshalb", "licht-", "und", "rasterelektronenmikroskopisch", "sowie", "roentgenmikroanalytisch", "die", "Natur", "solcher", "Verkalkungen", "geklaert", "werden", ".", "In", "ungefaerbten", "Schnittpraeparaten", "verkalkter", "Gichttophi", "herrschten", "die", "negativ", "doppelbrechenden", "Nadeln", "des", "Natriumurats", "vor", ",", "nach", "Inkubation", "in", "destilliertem", "Wasser", "waren", "sie", "verschwunden", "und", "lediglich", "plumpe", "unterschiedlich", "grosse", "positiv", "doppelbrechende", "Kristalle", "zurueckgeblieben", ";", "ein", "gleichartiges", "Ergebnis", "wurde", "rasterelektronenmikroskopisch", "erhalten", ".", "Roentgenmikroanalytisch", "liessen", "hohe", "Zaehlraten", "fuer", "Kalzium", "und", "Phosphor", "auf", "die", "Anwesenheit", "von", "Kalziumpyrophosphat", "-", "Dihydrat", "schliessen", ".", "Das", "Auftreten", "von", "Kalziumpyrophosphatkristallen", "in", "Gichttophi", "und", "auch", "Fadengranulomen", "laesst", "die", "Schlussfolgerung", "zu", ",", "dass", "diese", "Kristalle", "nicht", "nur", "in", "artikulaeren", "Geweben", "im", "engeren", "Sinne", "oder", "verschiedenen", "Knorpelarten", "auftreten", ".", "Der", "biochemische", "Mechanismus", ",", "der", "zur", "Kristallbildung", "fuehrt", ",", "bleibt", "zwar", "unbekannt", ",", "es", "darf", "aber", "vermutet", "werden", ",", "dass", "die", "Verkalkung", "Folge", "einer", "vorausgegangenen", "Bindegewebsschaedigung", "ist", "." ]	[ "umlsterm" ]
Kalksalzablagerungen is an umlsterm, licht- is an umlsterm, rasterelektronenmikroskopisch is an umlsterm, Natur is an umlsterm, Nadeln is an umlsterm, Natriumurats is an umlsterm, Wasser is an umlsterm, rasterelektronenmikroskopisch is an umlsterm, Kalzium is an umlsterm, Phosphor is an umlsterm, Fadengranulomen is an umlsterm, Geweben is an umlsterm, Knorpelarten is an umlsterm	ZfuerRheumatologie.00590240.ger.abstr_task1	Sentence: Verkalkungen von Gichttophi sind zwar ein bekanntes Ereignis , dennoch fehlen detaillierte Untersuchungsbefunde zur Zusammensetzung dieser sekundaeren Kalksalzablagerungen . Es sollte deshalb licht- und rasterelektronenmikroskopisch sowie roentgenmikroanalytisch die Natur solcher Verkalkungen geklaert werden . In ungefaerbten Schnittpraeparaten verkalkter Gichttophi herrschten die negativ doppelbrechenden Nadeln des Natriumurats vor , nach Inkubation in destilliertem Wasser waren sie verschwunden und lediglich plumpe unterschiedlich grosse positiv doppelbrechende Kristalle zurueckgeblieben ; ein gleichartiges Ergebnis wurde rasterelektronenmikroskopisch erhalten . Roentgenmikroanalytisch liessen hohe Zaehlraten fuer Kalzium und Phosphor auf die Anwesenheit von Kalziumpyrophosphat-Dihydrat schliessen . Das Auftreten von Kalziumpyrophosphatkristallen in Gichttophi und auch Fadengranulomen laesst die Schlussfolgerung zu , dass diese Kristalle nicht nur in artikulaeren Geweben im engeren Sinne oder verschiedenen Knorpelarten auftreten . Der biochemische Mechanismus , der zur Kristallbildung fuehrt , bleibt zwar unbekannt , es darf aber vermutet werden , dass die Verkalkung Folge einer vorausgegangenen Bindegewebsschaedigung ist . Instructions: please typing these entity words according to sentence: Kalksalzablagerungen, licht-, rasterelektronenmikroskopisch, Natur, Nadeln, Natriumurats, Wasser, rasterelektronenmikroskopisch, Kalzium, Phosphor, Fadengranulomen, Geweben, Knorpelarten Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Verkalkungen von Gichttophi sind zwar ein bekanntes Ereignis , dennoch fehlen detaillierte Untersuchungsbefunde zur Zusammensetzung dieser sekundaeren Kalksalzablagerungen . Es sollte deshalb licht- und rasterelektronenmikroskopisch sowie roentgenmikroanalytisch die Natur solcher Verkalkungen geklaert werden . In ungefaerbten Schnittpraeparaten verkalkter Gichttophi herrschten die negativ doppelbrechenden Nadeln des Natriumurats vor , nach Inkubation in destilliertem Wasser waren sie verschwunden und lediglich plumpe unterschiedlich grosse positiv doppelbrechende Kristalle zurueckgeblieben ; ein gleichartiges Ergebnis wurde rasterelektronenmikroskopisch erhalten . Roentgenmikroanalytisch liessen hohe Zaehlraten fuer Kalzium und Phosphor auf die Anwesenheit von Kalziumpyrophosphat-Dihydrat schliessen . Das Auftreten von Kalziumpyrophosphatkristallen in Gichttophi und auch Fadengranulomen laesst die Schlussfolgerung zu , dass diese Kristalle nicht nur in artikulaeren Geweben im engeren Sinne oder verschiedenen Knorpelarten auftreten . Der biochemische Mechanismus , der zur Kristallbildung fuehrt , bleibt zwar unbekannt , es darf aber vermutet werden , dass die Verkalkung Folge einer vorausgegangenen Bindegewebsschaedigung ist .	[ "Verkalkungen", "von", "Gichttophi", "sind", "zwar", "ein", "bekanntes", "Ereignis", ",", "dennoch", "fehlen", "detaillierte", "Untersuchungsbefunde", "zur", "Zusammensetzung", "dieser", "sekundaeren", "Kalksalzablagerungen", ".", "Es", "sollte", "deshalb", "licht-", "und", "rasterelektronenmikroskopisch", "sowie", "roentgenmikroanalytisch", "die", "Natur", "solcher", "Verkalkungen", "geklaert", "werden", ".", "In", "ungefaerbten", "Schnittpraeparaten", "verkalkter", "Gichttophi", "herrschten", "die", "negativ", "doppelbrechenden", "Nadeln", "des", "Natriumurats", "vor", ",", "nach", "Inkubation", "in", "destilliertem", "Wasser", "waren", "sie", "verschwunden", "und", "lediglich", "plumpe", "unterschiedlich", "grosse", "positiv", "doppelbrechende", "Kristalle", "zurueckgeblieben", ";", "ein", "gleichartiges", "Ergebnis", "wurde", "rasterelektronenmikroskopisch", "erhalten", ".", "Roentgenmikroanalytisch", "liessen", "hohe", "Zaehlraten", "fuer", "Kalzium", "und", "Phosphor", "auf", "die", "Anwesenheit", "von", "Kalziumpyrophosphat", "-", "Dihydrat", "schliessen", ".", "Das", "Auftreten", "von", "Kalziumpyrophosphatkristallen", "in", "Gichttophi", "und", "auch", "Fadengranulomen", "laesst", "die", "Schlussfolgerung", "zu", ",", "dass", "diese", "Kristalle", "nicht", "nur", "in", "artikulaeren", "Geweben", "im", "engeren", "Sinne", "oder", "verschiedenen", "Knorpelarten", "auftreten", ".", "Der", "biochemische", "Mechanismus", ",", "der", "zur", "Kristallbildung", "fuehrt", ",", "bleibt", "zwar", "unbekannt", ",", "es", "darf", "aber", "vermutet", "werden", ",", "dass", "die", "Verkalkung", "Folge", "einer", "vorausgegangenen", "Bindegewebsschaedigung", "ist", "." ]	[ "umlsterm" ]
Kalksalzablagerungen, licht-, rasterelektronenmikroskopisch, Natur, Nadeln, Natriumurats, Wasser, rasterelektronenmikroskopisch, Kalzium, Phosphor, Fadengranulomen, Geweben, Knorpelarten	ZfuerRheumatologie.00590240.ger.abstr_task2	Sentence: Verkalkungen von Gichttophi sind zwar ein bekanntes Ereignis , dennoch fehlen detaillierte Untersuchungsbefunde zur Zusammensetzung dieser sekundaeren Kalksalzablagerungen . Es sollte deshalb licht- und rasterelektronenmikroskopisch sowie roentgenmikroanalytisch die Natur solcher Verkalkungen geklaert werden . In ungefaerbten Schnittpraeparaten verkalkter Gichttophi herrschten die negativ doppelbrechenden Nadeln des Natriumurats vor , nach Inkubation in destilliertem Wasser waren sie verschwunden und lediglich plumpe unterschiedlich grosse positiv doppelbrechende Kristalle zurueckgeblieben ; ein gleichartiges Ergebnis wurde rasterelektronenmikroskopisch erhalten . Roentgenmikroanalytisch liessen hohe Zaehlraten fuer Kalzium und Phosphor auf die Anwesenheit von Kalziumpyrophosphat-Dihydrat schliessen . Das Auftreten von Kalziumpyrophosphatkristallen in Gichttophi und auch Fadengranulomen laesst die Schlussfolgerung zu , dass diese Kristalle nicht nur in artikulaeren Geweben im engeren Sinne oder verschiedenen Knorpelarten auftreten . Der biochemische Mechanismus , der zur Kristallbildung fuehrt , bleibt zwar unbekannt , es darf aber vermutet werden , dass die Verkalkung Folge einer vorausgegangenen Bindegewebsschaedigung ist . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Verkalkungen von Gichttophi sind zwar ein bekanntes Ereignis , dennoch fehlen detaillierte Untersuchungsbefunde zur Zusammensetzung dieser sekundaeren Kalksalzablagerungen . Es sollte deshalb licht- und rasterelektronenmikroskopisch sowie roentgenmikroanalytisch die Natur solcher Verkalkungen geklaert werden . In ungefaerbten Schnittpraeparaten verkalkter Gichttophi herrschten die negativ doppelbrechenden Nadeln des Natriumurats vor , nach Inkubation in destilliertem Wasser waren sie verschwunden und lediglich plumpe unterschiedlich grosse positiv doppelbrechende Kristalle zurueckgeblieben ; ein gleichartiges Ergebnis wurde rasterelektronenmikroskopisch erhalten . Roentgenmikroanalytisch liessen hohe Zaehlraten fuer Kalzium und Phosphor auf die Anwesenheit von Kalziumpyrophosphat-Dihydrat schliessen . Das Auftreten von Kalziumpyrophosphatkristallen in Gichttophi und auch Fadengranulomen laesst die Schlussfolgerung zu , dass diese Kristalle nicht nur in artikulaeren Geweben im engeren Sinne oder verschiedenen Knorpelarten auftreten . Der biochemische Mechanismus , der zur Kristallbildung fuehrt , bleibt zwar unbekannt , es darf aber vermutet werden , dass die Verkalkung Folge einer vorausgegangenen Bindegewebsschaedigung ist .	[ "Verkalkungen", "von", "Gichttophi", "sind", "zwar", "ein", "bekanntes", "Ereignis", ",", "dennoch", "fehlen", "detaillierte", "Untersuchungsbefunde", "zur", "Zusammensetzung", "dieser", "sekundaeren", "Kalksalzablagerungen", ".", "Es", "sollte", "deshalb", "licht-", "und", "rasterelektronenmikroskopisch", "sowie", "roentgenmikroanalytisch", "die", "Natur", "solcher", "Verkalkungen", "geklaert", "werden", ".", "In", "ungefaerbten", "Schnittpraeparaten", "verkalkter", "Gichttophi", "herrschten", "die", "negativ", "doppelbrechenden", "Nadeln", "des", "Natriumurats", "vor", ",", "nach", "Inkubation", "in", "destilliertem", "Wasser", "waren", "sie", "verschwunden", "und", "lediglich", "plumpe", "unterschiedlich", "grosse", "positiv", "doppelbrechende", "Kristalle", "zurueckgeblieben", ";", "ein", "gleichartiges", "Ergebnis", "wurde", "rasterelektronenmikroskopisch", "erhalten", ".", "Roentgenmikroanalytisch", "liessen", "hohe", "Zaehlraten", "fuer", "Kalzium", "und", "Phosphor", "auf", "die", "Anwesenheit", "von", "Kalziumpyrophosphat", "-", "Dihydrat", "schliessen", ".", "Das", "Auftreten", "von", "Kalziumpyrophosphatkristallen", "in", "Gichttophi", "und", "auch", "Fadengranulomen", "laesst", "die", "Schlussfolgerung", "zu", ",", "dass", "diese", "Kristalle", "nicht", "nur", "in", "artikulaeren", "Geweben", "im", "engeren", "Sinne", "oder", "verschiedenen", "Knorpelarten", "auftreten", ".", "Der", "biochemische", "Mechanismus", ",", "der", "zur", "Kristallbildung", "fuehrt", ",", "bleibt", "zwar", "unbekannt", ",", "es", "darf", "aber", "vermutet", "werden", ",", "dass", "die", "Verkalkung", "Folge", "einer", "vorausgegangenen", "Bindegewebsschaedigung", "ist", "." ]	[ "umlsterm" ]
Tagesklinik is an umlsterm, Altenberatung is an umlsterm, Bundesregierung is an umlsterm, Stadt is an umlsterm, Allgemeinmedizin is an umlsterm, Altenhilfe is an umlsterm, psychischen Stoerung is an umlsterm, aelteren Menschen is an umlsterm, Pflegebeduerftigkeit is an umlsterm, Allgemeinkrankenhaeusern is an umlsterm, Patienten is an umlsterm, Erstdiagnose is an umlsterm, Altenhilfe is an umlsterm, Behandlung is an umlsterm	ZfuerGerontologie+Geriatrie.00330059.ger.abstr_task0	Sentence: Ziel der Evaluationsstudie , ueber deren ausgewaehlte Ergebnisse dieser Beitrag berichtet , ist es , die Auswirkungen eines Gerontopsychiatrischen Zentrums ( GZ : eine Kombination von ambulantem Dienst , Tagesklinik und Altenberatung ) auf den von der Expertenkommission der Bundesregierung geforderten und ausfuehrlich begruendeten Wandlungsprozess von intramuralen " ( stationaeren ) " zu extramuralen " ( tagesklinischen und klinisch-ambulanten , " i . w . hausgestuetzten regionalen Versorgungsstrukturen ) erstmalig einer empirischen Pruefung zu unterziehen . Auf der Basis umfangreicher Quer- und Laengsschnittdaten werden durch einen Vergleich der Versorgungsregion der Stadt Bielefeld ( ohne GZ ) mit der des Kreises Guetersloh ( mit GZ ) Veraenderungen in den regionalen Versorgungsteilstrukturen der Gerontopsychiatrie ( Subsystem A ) , der Allgemeinmedizin ( Subsystem B ) und der Altenhilfe ( Subsystem C ) analysiert . Die Untersuchung ergibt hinsichtlich Subsystem A , Dass ein GZ auf die intendierte Strukturform von intra- zu extramuraler Versorgung erheblichen Einfluss hat , ohne dabei seine Klientel nach Art und Schweregrad der psychischen Stoerung zu selegieren . Dabei erweist sich eine zugehende klinisch-ambulante , hausgestuetzte Versorgung bei funktionell psychisch gestoerten aelteren Menschen hinsichtlich der Entwicklung der Krankheitsschwere und des Umfangs der Hilfs- und Pflegebeduerftigkeit als besonders erfolgreich . Effekte des GZ auf das Subsystem B zeigen sich z . B. in den schon bald nach seiner Einrichtung sich entwickelnden Kooperationsbeziehungen zu den Allgemeinkrankenhaeusern der Versorgungsregion Guetersloh , in denen 2/5 ( ! ) aller gerontopsychiatrischen Patienten ( mit einer psychiatrischen Erstdiagnose nach ICD-9) behandelt werden . Ein Effekt des GZ auf das System der Altenhilfe ( Subsystem C ) findet moeglicherweise darin seine Ausdruck , dass in der Versorgungsregion Guetersloh die Heimeinweisungsrate nach klinisch-stationaerer Behandlung deutlich geringer als in der Bielefelder Kontrollregion ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ziel der Evaluationsstudie , ueber deren ausgewaehlte Ergebnisse dieser Beitrag berichtet , ist es , die Auswirkungen eines Gerontopsychiatrischen Zentrums ( GZ : eine Kombination von ambulantem Dienst , Tagesklinik und Altenberatung ) auf den von der Expertenkommission der Bundesregierung geforderten und ausfuehrlich begruendeten Wandlungsprozess von intramuralen " ( stationaeren ) " zu extramuralen " ( tagesklinischen und klinisch-ambulanten , " i . w . hausgestuetzten regionalen Versorgungsstrukturen ) erstmalig einer empirischen Pruefung zu unterziehen . Auf der Basis umfangreicher Quer- und Laengsschnittdaten werden durch einen Vergleich der Versorgungsregion der Stadt Bielefeld ( ohne GZ ) mit der des Kreises Guetersloh ( mit GZ ) Veraenderungen in den regionalen Versorgungsteilstrukturen der Gerontopsychiatrie ( Subsystem A ) , der Allgemeinmedizin ( Subsystem B ) und der Altenhilfe ( Subsystem C ) analysiert . Die Untersuchung ergibt hinsichtlich Subsystem A , Dass ein GZ auf die intendierte Strukturform von intra- zu extramuraler Versorgung erheblichen Einfluss hat , ohne dabei seine Klientel nach Art und Schweregrad der psychischen Stoerung zu selegieren . Dabei erweist sich eine zugehende klinisch-ambulante , hausgestuetzte Versorgung bei funktionell psychisch gestoerten aelteren Menschen hinsichtlich der Entwicklung der Krankheitsschwere und des Umfangs der Hilfs- und Pflegebeduerftigkeit als besonders erfolgreich . Effekte des GZ auf das Subsystem B zeigen sich z . B. in den schon bald nach seiner Einrichtung sich entwickelnden Kooperationsbeziehungen zu den Allgemeinkrankenhaeusern der Versorgungsregion Guetersloh , in denen 2/5 ( ! ) aller gerontopsychiatrischen Patienten ( mit einer psychiatrischen Erstdiagnose nach ICD-9) behandelt werden . Ein Effekt des GZ auf das System der Altenhilfe ( Subsystem C ) findet moeglicherweise darin seine Ausdruck , dass in der Versorgungsregion Guetersloh die Heimeinweisungsrate nach klinisch-stationaerer Behandlung deutlich geringer als in der Bielefelder Kontrollregion ist .	[ "Ziel", "der", "Evaluationsstudie", ",", "ueber", "deren", "ausgewaehlte", "Ergebnisse", "dieser", "Beitrag", "berichtet", ",", "ist", "es", ",", "die", "Auswirkungen", "eines", "Gerontopsychiatrischen", "Zentrums", "(", "GZ", ":", "eine", "Kombination", "von", "ambulantem", "Dienst", ",", "Tagesklinik", "und", "Altenberatung", ")", "auf", "den", "von", "der", "Expertenkommission", "der", "Bundesregierung", "geforderten", "und", "ausfuehrlich", "begruendeten", "Wandlungsprozess", "von", "intramuralen", "\"", "(", "stationaeren", ")", "\"", "zu", "extramuralen", "\"", "(", "tagesklinischen", "und", "klinisch", "-", "ambulanten", ",", "\"", "i", ".", "w", ".", "hausgestuetzten", "regionalen", "Versorgungsstrukturen", ")", "erstmalig", "einer", "empirischen", "Pruefung", "zu", "unterziehen", ".", "Auf", "der", "Basis", "umfangreicher", "Quer-", "und", "Laengsschnittdaten", "werden", "durch", "einen", "Vergleich", "der", "Versorgungsregion", "der", "Stadt", "Bielefeld", "(", "ohne", "GZ", ")", "mit", "der", "des", "Kreises", "Guetersloh", "(", "mit", "GZ", ")", "Veraenderungen", "in", "den", "regionalen", "Versorgungsteilstrukturen", "der", "Gerontopsychiatrie", "(", "Subsystem", "A", ")", ",", "der", "Allgemeinmedizin", "(", "Subsystem", "B", ")", "und", "der", "Altenhilfe", "(", "Subsystem", "C", ")", "analysiert", ".", "Die", "Untersuchung", "ergibt", "hinsichtlich", "Subsystem", "A", ",", "Dass", "ein", "GZ", "auf", "die", "intendierte", "Strukturform", "von", "intra-", "zu", "extramuraler", "Versorgung", "erheblichen", "Einfluss", "hat", ",", "ohne", "dabei", "seine", "Klientel", "nach", "Art", "und", "Schweregrad", "der", "psychischen", "Stoerung", "zu", "selegieren", ".", "Dabei", "erweist", "sich", "eine", "zugehende", "klinisch", "-", "ambulante", ",", "hausgestuetzte", "Versorgung", "bei", "funktionell", "psychisch", "gestoerten", "aelteren", "Menschen", "hinsichtlich", "der", "Entwicklung", "der", "Krankheitsschwere", "und", "des", "Umfangs", "der", "Hilfs-", "und", "Pflegebeduerftigkeit", "als", "besonders", "erfolgreich", ".", "Effekte", "des", "GZ", "auf", "das", "Subsystem", "B", "zeigen", "sich", "z", ".", "B.", "in", "den", "schon", "bald", "nach", "seiner", "Einrichtung", "sich", "entwickelnden", "Kooperationsbeziehungen", "zu", "den", "Allgemeinkrankenhaeusern", "der", "Versorgungsregion", "Guetersloh", ",", "in", "denen", "2/5", "(", "!", ")", "aller", "gerontopsychiatrischen", "Patienten", "(", "mit", "einer", "psychiatrischen", "Erstdiagnose", "nach", "ICD-9", ")", "behandelt", "werden", ".", "Ein", "Effekt", "des", "GZ", "auf", "das", "System", "der", "Altenhilfe", "(", "Subsystem", "C", ")", "findet", "moeglicherweise", "darin", "seine", "Ausdruck", ",", "dass", "in", "der", "Versorgungsregion", "Guetersloh", "die", "Heimeinweisungsrate", "nach", "klinisch", "-", "stationaerer", "Behandlung", "deutlich", "geringer", "als", "in", "der", "Bielefelder", "Kontrollregion", "ist", "." ]	[ "umlsterm" ]
Tagesklinik is an umlsterm, Altenberatung is an umlsterm, Bundesregierung is an umlsterm, Stadt is an umlsterm, Allgemeinmedizin is an umlsterm, Altenhilfe is an umlsterm, psychischen Stoerung is an umlsterm, aelteren Menschen is an umlsterm, Pflegebeduerftigkeit is an umlsterm, Allgemeinkrankenhaeusern is an umlsterm, Patienten is an umlsterm, Erstdiagnose is an umlsterm, Altenhilfe is an umlsterm, Behandlung is an umlsterm	ZfuerGerontologie+Geriatrie.00330059.ger.abstr_task1	Sentence: Ziel der Evaluationsstudie , ueber deren ausgewaehlte Ergebnisse dieser Beitrag berichtet , ist es , die Auswirkungen eines Gerontopsychiatrischen Zentrums ( GZ : eine Kombination von ambulantem Dienst , Tagesklinik und Altenberatung ) auf den von der Expertenkommission der Bundesregierung geforderten und ausfuehrlich begruendeten Wandlungsprozess von intramuralen " ( stationaeren ) " zu extramuralen " ( tagesklinischen und klinisch-ambulanten , " i . w . hausgestuetzten regionalen Versorgungsstrukturen ) erstmalig einer empirischen Pruefung zu unterziehen . Auf der Basis umfangreicher Quer- und Laengsschnittdaten werden durch einen Vergleich der Versorgungsregion der Stadt Bielefeld ( ohne GZ ) mit der des Kreises Guetersloh ( mit GZ ) Veraenderungen in den regionalen Versorgungsteilstrukturen der Gerontopsychiatrie ( Subsystem A ) , der Allgemeinmedizin ( Subsystem B ) und der Altenhilfe ( Subsystem C ) analysiert . Die Untersuchung ergibt hinsichtlich Subsystem A , Dass ein GZ auf die intendierte Strukturform von intra- zu extramuraler Versorgung erheblichen Einfluss hat , ohne dabei seine Klientel nach Art und Schweregrad der psychischen Stoerung zu selegieren . Dabei erweist sich eine zugehende klinisch-ambulante , hausgestuetzte Versorgung bei funktionell psychisch gestoerten aelteren Menschen hinsichtlich der Entwicklung der Krankheitsschwere und des Umfangs der Hilfs- und Pflegebeduerftigkeit als besonders erfolgreich . Effekte des GZ auf das Subsystem B zeigen sich z . B. in den schon bald nach seiner Einrichtung sich entwickelnden Kooperationsbeziehungen zu den Allgemeinkrankenhaeusern der Versorgungsregion Guetersloh , in denen 2/5 ( ! ) aller gerontopsychiatrischen Patienten ( mit einer psychiatrischen Erstdiagnose nach ICD-9) behandelt werden . Ein Effekt des GZ auf das System der Altenhilfe ( Subsystem C ) findet moeglicherweise darin seine Ausdruck , dass in der Versorgungsregion Guetersloh die Heimeinweisungsrate nach klinisch-stationaerer Behandlung deutlich geringer als in der Bielefelder Kontrollregion ist . Instructions: please typing these entity words according to sentence: Tagesklinik, Altenberatung, Bundesregierung, Stadt, Allgemeinmedizin, Altenhilfe, psychischen Stoerung, aelteren Menschen, Pflegebeduerftigkeit, Allgemeinkrankenhaeusern, Patienten, Erstdiagnose, Altenhilfe, Behandlung Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ziel der Evaluationsstudie , ueber deren ausgewaehlte Ergebnisse dieser Beitrag berichtet , ist es , die Auswirkungen eines Gerontopsychiatrischen Zentrums ( GZ : eine Kombination von ambulantem Dienst , Tagesklinik und Altenberatung ) auf den von der Expertenkommission der Bundesregierung geforderten und ausfuehrlich begruendeten Wandlungsprozess von intramuralen " ( stationaeren ) " zu extramuralen " ( tagesklinischen und klinisch-ambulanten , " i . w . hausgestuetzten regionalen Versorgungsstrukturen ) erstmalig einer empirischen Pruefung zu unterziehen . Auf der Basis umfangreicher Quer- und Laengsschnittdaten werden durch einen Vergleich der Versorgungsregion der Stadt Bielefeld ( ohne GZ ) mit der des Kreises Guetersloh ( mit GZ ) Veraenderungen in den regionalen Versorgungsteilstrukturen der Gerontopsychiatrie ( Subsystem A ) , der Allgemeinmedizin ( Subsystem B ) und der Altenhilfe ( Subsystem C ) analysiert . Die Untersuchung ergibt hinsichtlich Subsystem A , Dass ein GZ auf die intendierte Strukturform von intra- zu extramuraler Versorgung erheblichen Einfluss hat , ohne dabei seine Klientel nach Art und Schweregrad der psychischen Stoerung zu selegieren . Dabei erweist sich eine zugehende klinisch-ambulante , hausgestuetzte Versorgung bei funktionell psychisch gestoerten aelteren Menschen hinsichtlich der Entwicklung der Krankheitsschwere und des Umfangs der Hilfs- und Pflegebeduerftigkeit als besonders erfolgreich . Effekte des GZ auf das Subsystem B zeigen sich z . B. in den schon bald nach seiner Einrichtung sich entwickelnden Kooperationsbeziehungen zu den Allgemeinkrankenhaeusern der Versorgungsregion Guetersloh , in denen 2/5 ( ! ) aller gerontopsychiatrischen Patienten ( mit einer psychiatrischen Erstdiagnose nach ICD-9) behandelt werden . Ein Effekt des GZ auf das System der Altenhilfe ( Subsystem C ) findet moeglicherweise darin seine Ausdruck , dass in der Versorgungsregion Guetersloh die Heimeinweisungsrate nach klinisch-stationaerer Behandlung deutlich geringer als in der Bielefelder Kontrollregion ist .	[ "Ziel", "der", "Evaluationsstudie", ",", "ueber", "deren", "ausgewaehlte", "Ergebnisse", "dieser", "Beitrag", "berichtet", ",", "ist", "es", ",", "die", "Auswirkungen", "eines", "Gerontopsychiatrischen", "Zentrums", "(", "GZ", ":", "eine", "Kombination", "von", "ambulantem", "Dienst", ",", "Tagesklinik", "und", "Altenberatung", ")", "auf", "den", "von", "der", "Expertenkommission", "der", "Bundesregierung", "geforderten", "und", "ausfuehrlich", "begruendeten", "Wandlungsprozess", "von", "intramuralen", "\"", "(", "stationaeren", ")", "\"", "zu", "extramuralen", "\"", "(", "tagesklinischen", "und", "klinisch", "-", "ambulanten", ",", "\"", "i", ".", "w", ".", "hausgestuetzten", "regionalen", "Versorgungsstrukturen", ")", "erstmalig", "einer", "empirischen", "Pruefung", "zu", "unterziehen", ".", "Auf", "der", "Basis", "umfangreicher", "Quer-", "und", "Laengsschnittdaten", "werden", "durch", "einen", "Vergleich", "der", "Versorgungsregion", "der", "Stadt", "Bielefeld", "(", "ohne", "GZ", ")", "mit", "der", "des", "Kreises", "Guetersloh", "(", "mit", "GZ", ")", "Veraenderungen", "in", "den", "regionalen", "Versorgungsteilstrukturen", "der", "Gerontopsychiatrie", "(", "Subsystem", "A", ")", ",", "der", "Allgemeinmedizin", "(", "Subsystem", "B", ")", "und", "der", "Altenhilfe", "(", "Subsystem", "C", ")", "analysiert", ".", "Die", "Untersuchung", "ergibt", "hinsichtlich", "Subsystem", "A", ",", "Dass", "ein", "GZ", "auf", "die", "intendierte", "Strukturform", "von", "intra-", "zu", "extramuraler", "Versorgung", "erheblichen", "Einfluss", "hat", ",", "ohne", "dabei", "seine", "Klientel", "nach", "Art", "und", "Schweregrad", "der", "psychischen", "Stoerung", "zu", "selegieren", ".", "Dabei", "erweist", "sich", "eine", "zugehende", "klinisch", "-", "ambulante", ",", "hausgestuetzte", "Versorgung", "bei", "funktionell", "psychisch", "gestoerten", "aelteren", "Menschen", "hinsichtlich", "der", "Entwicklung", "der", "Krankheitsschwere", "und", "des", "Umfangs", "der", "Hilfs-", "und", "Pflegebeduerftigkeit", "als", "besonders", "erfolgreich", ".", "Effekte", "des", "GZ", "auf", "das", "Subsystem", "B", "zeigen", "sich", "z", ".", "B.", "in", "den", "schon", "bald", "nach", "seiner", "Einrichtung", "sich", "entwickelnden", "Kooperationsbeziehungen", "zu", "den", "Allgemeinkrankenhaeusern", "der", "Versorgungsregion", "Guetersloh", ",", "in", "denen", "2/5", "(", "!", ")", "aller", "gerontopsychiatrischen", "Patienten", "(", "mit", "einer", "psychiatrischen", "Erstdiagnose", "nach", "ICD-9", ")", "behandelt", "werden", ".", "Ein", "Effekt", "des", "GZ", "auf", "das", "System", "der", "Altenhilfe", "(", "Subsystem", "C", ")", "findet", "moeglicherweise", "darin", "seine", "Ausdruck", ",", "dass", "in", "der", "Versorgungsregion", "Guetersloh", "die", "Heimeinweisungsrate", "nach", "klinisch", "-", "stationaerer", "Behandlung", "deutlich", "geringer", "als", "in", "der", "Bielefelder", "Kontrollregion", "ist", "." ]	[ "umlsterm" ]
Tagesklinik, Altenberatung, Bundesregierung, Stadt, Allgemeinmedizin, Altenhilfe, psychischen Stoerung, aelteren Menschen, Pflegebeduerftigkeit, Allgemeinkrankenhaeusern, Patienten, Erstdiagnose, Altenhilfe, Behandlung	ZfuerGerontologie+Geriatrie.00330059.ger.abstr_task2	Sentence: Ziel der Evaluationsstudie , ueber deren ausgewaehlte Ergebnisse dieser Beitrag berichtet , ist es , die Auswirkungen eines Gerontopsychiatrischen Zentrums ( GZ : eine Kombination von ambulantem Dienst , Tagesklinik und Altenberatung ) auf den von der Expertenkommission der Bundesregierung geforderten und ausfuehrlich begruendeten Wandlungsprozess von intramuralen " ( stationaeren ) " zu extramuralen " ( tagesklinischen und klinisch-ambulanten , " i . w . hausgestuetzten regionalen Versorgungsstrukturen ) erstmalig einer empirischen Pruefung zu unterziehen . Auf der Basis umfangreicher Quer- und Laengsschnittdaten werden durch einen Vergleich der Versorgungsregion der Stadt Bielefeld ( ohne GZ ) mit der des Kreises Guetersloh ( mit GZ ) Veraenderungen in den regionalen Versorgungsteilstrukturen der Gerontopsychiatrie ( Subsystem A ) , der Allgemeinmedizin ( Subsystem B ) und der Altenhilfe ( Subsystem C ) analysiert . Die Untersuchung ergibt hinsichtlich Subsystem A , Dass ein GZ auf die intendierte Strukturform von intra- zu extramuraler Versorgung erheblichen Einfluss hat , ohne dabei seine Klientel nach Art und Schweregrad der psychischen Stoerung zu selegieren . Dabei erweist sich eine zugehende klinisch-ambulante , hausgestuetzte Versorgung bei funktionell psychisch gestoerten aelteren Menschen hinsichtlich der Entwicklung der Krankheitsschwere und des Umfangs der Hilfs- und Pflegebeduerftigkeit als besonders erfolgreich . Effekte des GZ auf das Subsystem B zeigen sich z . B. in den schon bald nach seiner Einrichtung sich entwickelnden Kooperationsbeziehungen zu den Allgemeinkrankenhaeusern der Versorgungsregion Guetersloh , in denen 2/5 ( ! ) aller gerontopsychiatrischen Patienten ( mit einer psychiatrischen Erstdiagnose nach ICD-9) behandelt werden . Ein Effekt des GZ auf das System der Altenhilfe ( Subsystem C ) findet moeglicherweise darin seine Ausdruck , dass in der Versorgungsregion Guetersloh die Heimeinweisungsrate nach klinisch-stationaerer Behandlung deutlich geringer als in der Bielefelder Kontrollregion ist . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ziel der Evaluationsstudie , ueber deren ausgewaehlte Ergebnisse dieser Beitrag berichtet , ist es , die Auswirkungen eines Gerontopsychiatrischen Zentrums ( GZ : eine Kombination von ambulantem Dienst , Tagesklinik und Altenberatung ) auf den von der Expertenkommission der Bundesregierung geforderten und ausfuehrlich begruendeten Wandlungsprozess von intramuralen " ( stationaeren ) " zu extramuralen " ( tagesklinischen und klinisch-ambulanten , " i . w . hausgestuetzten regionalen Versorgungsstrukturen ) erstmalig einer empirischen Pruefung zu unterziehen . Auf der Basis umfangreicher Quer- und Laengsschnittdaten werden durch einen Vergleich der Versorgungsregion der Stadt Bielefeld ( ohne GZ ) mit der des Kreises Guetersloh ( mit GZ ) Veraenderungen in den regionalen Versorgungsteilstrukturen der Gerontopsychiatrie ( Subsystem A ) , der Allgemeinmedizin ( Subsystem B ) und der Altenhilfe ( Subsystem C ) analysiert . Die Untersuchung ergibt hinsichtlich Subsystem A , Dass ein GZ auf die intendierte Strukturform von intra- zu extramuraler Versorgung erheblichen Einfluss hat , ohne dabei seine Klientel nach Art und Schweregrad der psychischen Stoerung zu selegieren . Dabei erweist sich eine zugehende klinisch-ambulante , hausgestuetzte Versorgung bei funktionell psychisch gestoerten aelteren Menschen hinsichtlich der Entwicklung der Krankheitsschwere und des Umfangs der Hilfs- und Pflegebeduerftigkeit als besonders erfolgreich . Effekte des GZ auf das Subsystem B zeigen sich z . B. in den schon bald nach seiner Einrichtung sich entwickelnden Kooperationsbeziehungen zu den Allgemeinkrankenhaeusern der Versorgungsregion Guetersloh , in denen 2/5 ( ! ) aller gerontopsychiatrischen Patienten ( mit einer psychiatrischen Erstdiagnose nach ICD-9) behandelt werden . Ein Effekt des GZ auf das System der Altenhilfe ( Subsystem C ) findet moeglicherweise darin seine Ausdruck , dass in der Versorgungsregion Guetersloh die Heimeinweisungsrate nach klinisch-stationaerer Behandlung deutlich geringer als in der Bielefelder Kontrollregion ist .	[ "Ziel", "der", "Evaluationsstudie", ",", "ueber", "deren", "ausgewaehlte", "Ergebnisse", "dieser", "Beitrag", "berichtet", ",", "ist", "es", ",", "die", "Auswirkungen", "eines", "Gerontopsychiatrischen", "Zentrums", "(", "GZ", ":", "eine", "Kombination", "von", "ambulantem", "Dienst", ",", "Tagesklinik", "und", "Altenberatung", ")", "auf", "den", "von", "der", "Expertenkommission", "der", "Bundesregierung", "geforderten", "und", "ausfuehrlich", "begruendeten", "Wandlungsprozess", "von", "intramuralen", "\"", "(", "stationaeren", ")", "\"", "zu", "extramuralen", "\"", "(", "tagesklinischen", "und", "klinisch", "-", "ambulanten", ",", "\"", "i", ".", "w", ".", "hausgestuetzten", "regionalen", "Versorgungsstrukturen", ")", "erstmalig", "einer", "empirischen", "Pruefung", "zu", "unterziehen", ".", "Auf", "der", "Basis", "umfangreicher", "Quer-", "und", "Laengsschnittdaten", "werden", "durch", "einen", "Vergleich", "der", "Versorgungsregion", "der", "Stadt", "Bielefeld", "(", "ohne", "GZ", ")", "mit", "der", "des", "Kreises", "Guetersloh", "(", "mit", "GZ", ")", "Veraenderungen", "in", "den", "regionalen", "Versorgungsteilstrukturen", "der", "Gerontopsychiatrie", "(", "Subsystem", "A", ")", ",", "der", "Allgemeinmedizin", "(", "Subsystem", "B", ")", "und", "der", "Altenhilfe", "(", "Subsystem", "C", ")", "analysiert", ".", "Die", "Untersuchung", "ergibt", "hinsichtlich", "Subsystem", "A", ",", "Dass", "ein", "GZ", "auf", "die", "intendierte", "Strukturform", "von", "intra-", "zu", "extramuraler", "Versorgung", "erheblichen", "Einfluss", "hat", ",", "ohne", "dabei", "seine", "Klientel", "nach", "Art", "und", "Schweregrad", "der", "psychischen", "Stoerung", "zu", "selegieren", ".", "Dabei", "erweist", "sich", "eine", "zugehende", "klinisch", "-", "ambulante", ",", "hausgestuetzte", "Versorgung", "bei", "funktionell", "psychisch", "gestoerten", "aelteren", "Menschen", "hinsichtlich", "der", "Entwicklung", "der", "Krankheitsschwere", "und", "des", "Umfangs", "der", "Hilfs-", "und", "Pflegebeduerftigkeit", "als", "besonders", "erfolgreich", ".", "Effekte", "des", "GZ", "auf", "das", "Subsystem", "B", "zeigen", "sich", "z", ".", "B.", "in", "den", "schon", "bald", "nach", "seiner", "Einrichtung", "sich", "entwickelnden", "Kooperationsbeziehungen", "zu", "den", "Allgemeinkrankenhaeusern", "der", "Versorgungsregion", "Guetersloh", ",", "in", "denen", "2/5", "(", "!", ")", "aller", "gerontopsychiatrischen", "Patienten", "(", "mit", "einer", "psychiatrischen", "Erstdiagnose", "nach", "ICD-9", ")", "behandelt", "werden", ".", "Ein", "Effekt", "des", "GZ", "auf", "das", "System", "der", "Altenhilfe", "(", "Subsystem", "C", ")", "findet", "moeglicherweise", "darin", "seine", "Ausdruck", ",", "dass", "in", "der", "Versorgungsregion", "Guetersloh", "die", "Heimeinweisungsrate", "nach", "klinisch", "-", "stationaerer", "Behandlung", "deutlich", "geringer", "als", "in", "der", "Bielefelder", "Kontrollregion", "ist", "." ]	[ "umlsterm" ]
RUNX1 is a Gene_or_gene_product, DNA is a Cellular_component, BCR - ABL+ leukemias is a Cancer, 21 is a Cellular_component, clonal is a Cell, imatinib is a Simple_chemical, chromosomal is a Cellular_component, RUNX1 is a Gene_or_gene_product, acute myeloblastic leukemias is a Cancer, AMLs is a Cancer, acute lymphoblastic leukemias is a Cancer, ALLs is a Cancer, chronic myelogenous leukemias is a Cancer, CMLs is a Cancer, BCR - ABL+ leukemias is a Cancer, chromosome 21 is a Cellular_component, myeloid blast crisis [ BC ] CML is a Cancer, chronic phase CML is a Cancer, DNA is a Cellular_component, RUNX1 is a Gene_or_gene_product, BCR - ABL+ ALLs is a Cancer, lymphoid BC CML is a Cancer, RUNX1 is a Gene_or_gene_product, 21 is a Cellular_component, chromosomal is a Cellular_component, RUNX1 is a Gene_or_gene_product, PRDM16 is a Gene_or_gene_product, chromosome 1p36 is a Cellular_component, patients is a Organism, myeloid BC CMLs is a Cancer, BCR - ABL+ ALL is a Cancer, patients is a Organism, RUNX1 is a Gene_or_gene_product, BCR is a Gene_or_gene_product, ABL is a Gene_or_gene_product, RUNX1 is a Gene_or_gene_product, CML is a Cancer, BCR - ABL+ ALL is a Cancer	104_task0	Sentence: RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cellular_component, Organism, Simple_chemical, Cancer, Gene_or_gene_product, Cell	[ "B-Gene_or_gene_product", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Organism", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O" ]	RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL.	[ "RUNX1", "DNA", "-", "binding", "mutations", "and", "RUNX1-PRDM16", "cryptic", "fusions", "in", "BCR", "-", "ABL+", "leukemias", "are", "frequently", "associated", "with", "secondary", "trisomy", "21", "and", "may", "contribute", "to", "clonal", "evolution", "and", "imatinib", "resistance", ".", "\n", "Acquired", "molecular", "abnormalities", "(", "mutations", "or", "chromosomal", "translocations", ")", "of", "the", "RUNX1", "transcription", "factor", "gene", "are", "frequent", "in", "acute", "myeloblastic", "leukemias", "(", "AMLs", ")", "and", "in", "therapy", "-", "related", "myelodysplastic", "syndromes", ",", "but", "rarely", "in", "acute", "lymphoblastic", "leukemias", "(", "ALLs", ")", "and", "chronic", "myelogenous", "leukemias", "(", "CMLs", ")", ".", "Among", "18", "BCR", "-", "ABL+", "leukemias", "presenting", "acquired", "trisomy", "of", "chromosome", "21", ",", "we", "report", "a", "high", "frequency", "(", "33", "%", ")", "of", "recurrent", "point", "mutations", "(", "4", "in", "myeloid", "blast", "crisis", "[", "BC", "]", "CML", "and", "one", "in", "chronic", "phase", "CML", ")", "within", "the", "DNA", "-", "binding", "region", "of", "RUNX1", ".", "We", "did", "not", "found", "any", "mutation", "in", "de", "novo", "BCR", "-", "ABL+", "ALLs", "or", "lymphoid", "BC", "CML", ".", "Emergence", "of", "the", "RUNX1", "mutations", "was", "detected", "at", "diagnosis", "or", "before", "the", "acquisition", "of", "trisomy", "21", "during", "disease", "progression", ".", "In", "addition", ",", "we", "also", "report", "a", "high", "frequency", "of", "cryptic", "chromosomal", "RUNX1", "translocation", "to", "a", "novel", "recently", "described", "gene", "partner", ",", "PRDM16", "on", "chromosome", "1p36", ",", "for", "3", "(", "21.4", "%", ")", "of", "14", "investigated", "patients", ":", "2", "myeloid", "BC", "CMLs", "and", ",", "for", "the", "first", "time", ",", "1", "therapy", "-", "related", "BCR", "-", "ABL+", "ALL", ".", "Two", "patients", "presented", "both", "RUNX1", "mutations", "and", "RUNX1-PRDM16", "fusion", ".", "These", "events", "are", "associated", "with", "a", "short", "survival", "and", "support", "the", "concept", "of", "a", "cooperative", "effect", "of", "BCR", "-", "ABL", "with", "molecular", "RUNX1", "abnormalities", "on", "the", "differentiation", "arrest", "phenotype", "observed", "during", "progression", "of", "CML", "and", "in", "BCR", "-", "ABL+", "ALL", ".", "\n" ]	[ "Cancer", "Cellular_component", "Simple_chemical", "Organism", "Gene_or_gene_product", "Cell" ]
RUNX1 is a Gene_or_gene_product, DNA is a Cellular_component, BCR - ABL+ leukemias is a Cancer, 21 is a Cellular_component, clonal is a Cell, imatinib is a Simple_chemical, chromosomal is a Cellular_component, RUNX1 is a Gene_or_gene_product, acute myeloblastic leukemias is a Cancer, AMLs is a Cancer, acute lymphoblastic leukemias is a Cancer, ALLs is a Cancer, chronic myelogenous leukemias is a Cancer, CMLs is a Cancer, BCR - ABL+ leukemias is a Cancer, chromosome 21 is a Cellular_component, myeloid blast crisis [ BC ] CML is a Cancer, chronic phase CML is a Cancer, DNA is a Cellular_component, RUNX1 is a Gene_or_gene_product, BCR - ABL+ ALLs is a Cancer, lymphoid BC CML is a Cancer, RUNX1 is a Gene_or_gene_product, 21 is a Cellular_component, chromosomal is a Cellular_component, RUNX1 is a Gene_or_gene_product, PRDM16 is a Gene_or_gene_product, chromosome 1p36 is a Cellular_component, patients is a Organism, myeloid BC CMLs is a Cancer, BCR - ABL+ ALL is a Cancer, patients is a Organism, RUNX1 is a Gene_or_gene_product, BCR is a Gene_or_gene_product, ABL is a Gene_or_gene_product, RUNX1 is a Gene_or_gene_product, CML is a Cancer, BCR - ABL+ ALL is a Cancer	104_task1	Sentence: RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL. Instructions: please typing these entity words according to sentence: RUNX1, DNA, BCR - ABL+ leukemias, 21, clonal, imatinib, chromosomal, RUNX1, acute myeloblastic leukemias, AMLs, acute lymphoblastic leukemias, ALLs, chronic myelogenous leukemias, CMLs, BCR - ABL+ leukemias, chromosome 21, myeloid blast crisis [ BC ] CML, chronic phase CML, DNA, RUNX1, BCR - ABL+ ALLs, lymphoid BC CML, RUNX1, 21, chromosomal, RUNX1, PRDM16, chromosome 1p36, patients, myeloid BC CMLs, BCR - ABL+ ALL, patients, RUNX1, BCR, ABL, RUNX1, CML, BCR - ABL+ ALL Options: Cellular_component, Organism, Simple_chemical, Cancer, Gene_or_gene_product, Cell	[ "B-Gene_or_gene_product", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Organism", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O" ]	RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL.	[ "RUNX1", "DNA", "-", "binding", "mutations", "and", "RUNX1-PRDM16", "cryptic", "fusions", "in", "BCR", "-", "ABL+", "leukemias", "are", "frequently", "associated", "with", "secondary", "trisomy", "21", "and", "may", "contribute", "to", "clonal", "evolution", "and", "imatinib", "resistance", ".", "\n", "Acquired", "molecular", "abnormalities", "(", "mutations", "or", "chromosomal", "translocations", ")", "of", "the", "RUNX1", "transcription", "factor", "gene", "are", "frequent", "in", "acute", "myeloblastic", "leukemias", "(", "AMLs", ")", "and", "in", "therapy", "-", "related", "myelodysplastic", "syndromes", ",", "but", "rarely", "in", "acute", "lymphoblastic", "leukemias", "(", "ALLs", ")", "and", "chronic", "myelogenous", "leukemias", "(", "CMLs", ")", ".", "Among", "18", "BCR", "-", "ABL+", "leukemias", "presenting", "acquired", "trisomy", "of", "chromosome", "21", ",", "we", "report", "a", "high", "frequency", "(", "33", "%", ")", "of", "recurrent", "point", "mutations", "(", "4", "in", "myeloid", "blast", "crisis", "[", "BC", "]", "CML", "and", "one", "in", "chronic", "phase", "CML", ")", "within", "the", "DNA", "-", "binding", "region", "of", "RUNX1", ".", "We", "did", "not", "found", "any", "mutation", "in", "de", "novo", "BCR", "-", "ABL+", "ALLs", "or", "lymphoid", "BC", "CML", ".", "Emergence", "of", "the", "RUNX1", "mutations", "was", "detected", "at", "diagnosis", "or", "before", "the", "acquisition", "of", "trisomy", "21", "during", "disease", "progression", ".", "In", "addition", ",", "we", "also", "report", "a", "high", "frequency", "of", "cryptic", "chromosomal", "RUNX1", "translocation", "to", "a", "novel", "recently", "described", "gene", "partner", ",", "PRDM16", "on", "chromosome", "1p36", ",", "for", "3", "(", "21.4", "%", ")", "of", "14", "investigated", "patients", ":", "2", "myeloid", "BC", "CMLs", "and", ",", "for", "the", "first", "time", ",", "1", "therapy", "-", "related", "BCR", "-", "ABL+", "ALL", ".", "Two", "patients", "presented", "both", "RUNX1", "mutations", "and", "RUNX1-PRDM16", "fusion", ".", "These", "events", "are", "associated", "with", "a", "short", "survival", "and", "support", "the", "concept", "of", "a", "cooperative", "effect", "of", "BCR", "-", "ABL", "with", "molecular", "RUNX1", "abnormalities", "on", "the", "differentiation", "arrest", "phenotype", "observed", "during", "progression", "of", "CML", "and", "in", "BCR", "-", "ABL+", "ALL", ".", "\n" ]	[ "Cancer", "Cellular_component", "Simple_chemical", "Organism", "Gene_or_gene_product", "Cell" ]
RUNX1, DNA, BCR - ABL+ leukemias, 21, clonal, imatinib, chromosomal, RUNX1, acute myeloblastic leukemias, AMLs, acute lymphoblastic leukemias, ALLs, chronic myelogenous leukemias, CMLs, BCR - ABL+ leukemias, chromosome 21, myeloid blast crisis [ BC ] CML, chronic phase CML, DNA, RUNX1, BCR - ABL+ ALLs, lymphoid BC CML, RUNX1, 21, chromosomal, RUNX1, PRDM16, chromosome 1p36, patients, myeloid BC CMLs, BCR - ABL+ ALL, patients, RUNX1, BCR, ABL, RUNX1, CML, BCR - ABL+ ALL	104_task2	Sentence: RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL. Instructions: please extract entity words from the input sentence	[ "B-Gene_or_gene_product", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Organism", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O" ]	RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL.	[ "RUNX1", "DNA", "-", "binding", "mutations", "and", "RUNX1-PRDM16", "cryptic", "fusions", "in", "BCR", "-", "ABL+", "leukemias", "are", "frequently", "associated", "with", "secondary", "trisomy", "21", "and", "may", "contribute", "to", "clonal", "evolution", "and", "imatinib", "resistance", ".", "\n", "Acquired", "molecular", "abnormalities", "(", "mutations", "or", "chromosomal", "translocations", ")", "of", "the", "RUNX1", "transcription", "factor", "gene", "are", "frequent", "in", "acute", "myeloblastic", "leukemias", "(", "AMLs", ")", "and", "in", "therapy", "-", "related", "myelodysplastic", "syndromes", ",", "but", "rarely", "in", "acute", "lymphoblastic", "leukemias", "(", "ALLs", ")", "and", "chronic", "myelogenous", "leukemias", "(", "CMLs", ")", ".", "Among", "18", "BCR", "-", "ABL+", "leukemias", "presenting", "acquired", "trisomy", "of", "chromosome", "21", ",", "we", "report", "a", "high", "frequency", "(", "33", "%", ")", "of", "recurrent", "point", "mutations", "(", "4", "in", "myeloid", "blast", "crisis", "[", "BC", "]", "CML", "and", "one", "in", "chronic", "phase", "CML", ")", "within", "the", "DNA", "-", "binding", "region", "of", "RUNX1", ".", "We", "did", "not", "found", "any", "mutation", "in", "de", "novo", "BCR", "-", "ABL+", "ALLs", "or", "lymphoid", "BC", "CML", ".", "Emergence", "of", "the", "RUNX1", "mutations", "was", "detected", "at", "diagnosis", "or", "before", "the", "acquisition", "of", "trisomy", "21", "during", "disease", "progression", ".", "In", "addition", ",", "we", "also", "report", "a", "high", "frequency", "of", "cryptic", "chromosomal", "RUNX1", "translocation", "to", "a", "novel", "recently", "described", "gene", "partner", ",", "PRDM16", "on", "chromosome", "1p36", ",", "for", "3", "(", "21.4", "%", ")", "of", "14", "investigated", "patients", ":", "2", "myeloid", "BC", "CMLs", "and", ",", "for", "the", "first", "time", ",", "1", "therapy", "-", "related", "BCR", "-", "ABL+", "ALL", ".", "Two", "patients", "presented", "both", "RUNX1", "mutations", "and", "RUNX1-PRDM16", "fusion", ".", "These", "events", "are", "associated", "with", "a", "short", "survival", "and", "support", "the", "concept", "of", "a", "cooperative", "effect", "of", "BCR", "-", "ABL", "with", "molecular", "RUNX1", "abnormalities", "on", "the", "differentiation", "arrest", "phenotype", "observed", "during", "progression", "of", "CML", "and", "in", "BCR", "-", "ABL+", "ALL", ".", "\n" ]	[ "Cancer", "Cellular_component", "Simple_chemical", "Organism", "Gene_or_gene_product", "Cell" ]
Omega-3 fatty acids supplementation is a Intervention_Pharmacological, autism is a Participant_Condition, placebo - controlled is a Intervention_Control, . is a Outcome_Physical, neurodevelopmental disorders . is a Participant_Condition, 1.5 g / d of omega-3 fatty acids ( .84 g / d eicosapentaenoic acid is a Intervention_Pharmacological, .7 g / d docosahexaenoic acid ) supplementation is a Intervention_Pharmacological, 13 is a Participant_Sample-size, aged 5 to 17 years is a Participant_Age, severe tantrums , aggression , or self - injurious behavior is a Participant_Condition, Aberrant Behavior Checklist ( ABC ) is a Outcome_Mental, hyperactivity and stereotypy is a Outcome_Physical, adverse effects is a Outcome_Adverse-effects	27707_task0	Sentence: Omega-3 fatty acids supplementation in children with autism : a double-blind randomized , placebo-controlled pilot study . BACKGROUND There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders . METHODS We conducted a randomized , double-blind , placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids ( .84 g/d eicosapentaenoic acid , .7 g/d docosahexaenoic acid ) supplementation in 13 children ( aged 5 to 17 years ) with autistic disorders accompanied by severe tantrums , aggression , or self-injurious behavior . The outcome measure was the Aberrant Behavior Checklist ( ABC ) at 6 weeks . RESULTS We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy , each with a large effect size . Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity . No clinically relevant adverse effects were elicited in either group . CONCLUSIONS The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Mental	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Omega-3 fatty acids supplementation in children with autism : a double-blind randomized , placebo-controlled pilot study . BACKGROUND There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders . METHODS We conducted a randomized , double-blind , placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids ( .84 g/d eicosapentaenoic acid , .7 g/d docosahexaenoic acid ) supplementation in 13 children ( aged 5 to 17 years ) with autistic disorders accompanied by severe tantrums , aggression , or self-injurious behavior . The outcome measure was the Aberrant Behavior Checklist ( ABC ) at 6 weeks . RESULTS We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy , each with a large effect size . Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity . No clinically relevant adverse effects were elicited in either group . CONCLUSIONS The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism .	[ "Omega-3", "fatty", "acids", "supplementation", "in", "children", "with", "autism", ":", "a", "double", "-", "blind", "randomized", ",", "placebo", "-", "controlled", "pilot", "study", ".", "BACKGROUND", "There", "is", "increasing", "evidence", "that", "fatty", "acid", "deficiencies", "or", "imbalances", "may", "contribute", "to", "childhood", "neurodevelopmental", "disorders", ".", "METHODS", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "6-week", "pilot", "trial", "investigating", "the", "effects", "of", "1.5", "g", "/", "d", "of", "omega-3", "fatty", "acids", "(", ".84", "g", "/", "d", "eicosapentaenoic", "acid", ",", ".7", "g", "/", "d", "docosahexaenoic", "acid", ")", "supplementation", "in", "13", "children", "(", "aged", "5", "to", "17", "years", ")", "with", "autistic", "disorders", "accompanied", "by", "severe", "tantrums", ",", "aggression", ",", "or", "self", "-", "injurious", "behavior", ".", "The", "outcome", "measure", "was", "the", "Aberrant", "Behavior", "Checklist", "(", "ABC", ")", "at", "6", "weeks", ".", "RESULTS", "We", "observed", "an", "advantage", "of", "omega-3", "fatty", "acids", "compared", "with", "placebo", "for", "hyperactivity", "and", "stereotypy", ",", "each", "with", "a", "large", "effect", "size", ".", "Repeated", "-", "measures", "ANOVA", "indicated", "a", "trend", "toward", "superiority", "of", "omega-3", "fatty", "acids", "over", "placebo", "for", "hyperactivity", ".", "No", "clinically", "relevant", "adverse", "effects", "were", "elicited", "in", "either", "group", ".", "CONCLUSIONS", "The", "results", "of", "this", "study", "provide", "preliminary", "evidence", "that", "omega-3", "fatty", "acids", "may", "be", "an", "effective", "treatment", "for", "children", "with", "autism", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Mental", "Outcome_Physical", "Intervention_Control", "Participant_Age", "Outcome_Adverse-effects", "Outcome_Other", "Participant_Sample-size" ]
Omega-3 fatty acids supplementation is a Intervention_Pharmacological, autism is a Participant_Condition, placebo - controlled is a Intervention_Control, . is a Outcome_Physical, neurodevelopmental disorders . is a Participant_Condition, 1.5 g / d of omega-3 fatty acids ( .84 g / d eicosapentaenoic acid is a Intervention_Pharmacological, .7 g / d docosahexaenoic acid ) supplementation is a Intervention_Pharmacological, 13 is a Participant_Sample-size, aged 5 to 17 years is a Participant_Age, severe tantrums , aggression , or self - injurious behavior is a Participant_Condition, Aberrant Behavior Checklist ( ABC ) is a Outcome_Mental, hyperactivity and stereotypy is a Outcome_Physical, adverse effects is a Outcome_Adverse-effects	27707_task1	Sentence: Omega-3 fatty acids supplementation in children with autism : a double-blind randomized , placebo-controlled pilot study . BACKGROUND There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders . METHODS We conducted a randomized , double-blind , placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids ( .84 g/d eicosapentaenoic acid , .7 g/d docosahexaenoic acid ) supplementation in 13 children ( aged 5 to 17 years ) with autistic disorders accompanied by severe tantrums , aggression , or self-injurious behavior . The outcome measure was the Aberrant Behavior Checklist ( ABC ) at 6 weeks . RESULTS We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy , each with a large effect size . Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity . No clinically relevant adverse effects were elicited in either group . CONCLUSIONS The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism . Instructions: please typing these entity words according to sentence: Omega-3 fatty acids supplementation, autism, placebo - controlled, ., neurodevelopmental disorders ., 1.5 g / d of omega-3 fatty acids ( .84 g / d eicosapentaenoic acid, .7 g / d docosahexaenoic acid ) supplementation, 13, aged 5 to 17 years, severe tantrums , aggression , or self - injurious behavior, Aberrant Behavior Checklist ( ABC ), hyperactivity and stereotypy, adverse effects Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Mental	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Omega-3 fatty acids supplementation in children with autism : a double-blind randomized , placebo-controlled pilot study . BACKGROUND There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders . METHODS We conducted a randomized , double-blind , placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids ( .84 g/d eicosapentaenoic acid , .7 g/d docosahexaenoic acid ) supplementation in 13 children ( aged 5 to 17 years ) with autistic disorders accompanied by severe tantrums , aggression , or self-injurious behavior . The outcome measure was the Aberrant Behavior Checklist ( ABC ) at 6 weeks . RESULTS We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy , each with a large effect size . Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity . No clinically relevant adverse effects were elicited in either group . CONCLUSIONS The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism .	[ "Omega-3", "fatty", "acids", "supplementation", "in", "children", "with", "autism", ":", "a", "double", "-", "blind", "randomized", ",", "placebo", "-", "controlled", "pilot", "study", ".", "BACKGROUND", "There", "is", "increasing", "evidence", "that", "fatty", "acid", "deficiencies", "or", "imbalances", "may", "contribute", "to", "childhood", "neurodevelopmental", "disorders", ".", "METHODS", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "6-week", "pilot", "trial", "investigating", "the", "effects", "of", "1.5", "g", "/", "d", "of", "omega-3", "fatty", "acids", "(", ".84", "g", "/", "d", "eicosapentaenoic", "acid", ",", ".7", "g", "/", "d", "docosahexaenoic", "acid", ")", "supplementation", "in", "13", "children", "(", "aged", "5", "to", "17", "years", ")", "with", "autistic", "disorders", "accompanied", "by", "severe", "tantrums", ",", "aggression", ",", "or", "self", "-", "injurious", "behavior", ".", "The", "outcome", "measure", "was", "the", "Aberrant", "Behavior", "Checklist", "(", "ABC", ")", "at", "6", "weeks", ".", "RESULTS", "We", "observed", "an", "advantage", "of", "omega-3", "fatty", "acids", "compared", "with", "placebo", "for", "hyperactivity", "and", "stereotypy", ",", "each", "with", "a", "large", "effect", "size", ".", "Repeated", "-", "measures", "ANOVA", "indicated", "a", "trend", "toward", "superiority", "of", "omega-3", "fatty", "acids", "over", "placebo", "for", "hyperactivity", ".", "No", "clinically", "relevant", "adverse", "effects", "were", "elicited", "in", "either", "group", ".", "CONCLUSIONS", "The", "results", "of", "this", "study", "provide", "preliminary", "evidence", "that", "omega-3", "fatty", "acids", "may", "be", "an", "effective", "treatment", "for", "children", "with", "autism", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Mental", "Outcome_Physical", "Intervention_Control", "Participant_Age", "Outcome_Adverse-effects", "Outcome_Other", "Participant_Sample-size" ]
Omega-3 fatty acids supplementation, autism, placebo - controlled, ., neurodevelopmental disorders ., 1.5 g / d of omega-3 fatty acids ( .84 g / d eicosapentaenoic acid, .7 g / d docosahexaenoic acid ) supplementation, 13, aged 5 to 17 years, severe tantrums , aggression , or self - injurious behavior, Aberrant Behavior Checklist ( ABC ), hyperactivity and stereotypy, adverse effects	27707_task2	Sentence: Omega-3 fatty acids supplementation in children with autism : a double-blind randomized , placebo-controlled pilot study . BACKGROUND There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders . METHODS We conducted a randomized , double-blind , placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids ( .84 g/d eicosapentaenoic acid , .7 g/d docosahexaenoic acid ) supplementation in 13 children ( aged 5 to 17 years ) with autistic disorders accompanied by severe tantrums , aggression , or self-injurious behavior . The outcome measure was the Aberrant Behavior Checklist ( ABC ) at 6 weeks . RESULTS We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy , each with a large effect size . Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity . No clinically relevant adverse effects were elicited in either group . CONCLUSIONS The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Omega-3 fatty acids supplementation in children with autism : a double-blind randomized , placebo-controlled pilot study . BACKGROUND There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders . METHODS We conducted a randomized , double-blind , placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids ( .84 g/d eicosapentaenoic acid , .7 g/d docosahexaenoic acid ) supplementation in 13 children ( aged 5 to 17 years ) with autistic disorders accompanied by severe tantrums , aggression , or self-injurious behavior . The outcome measure was the Aberrant Behavior Checklist ( ABC ) at 6 weeks . RESULTS We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy , each with a large effect size . Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity . No clinically relevant adverse effects were elicited in either group . CONCLUSIONS The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism .	[ "Omega-3", "fatty", "acids", "supplementation", "in", "children", "with", "autism", ":", "a", "double", "-", "blind", "randomized", ",", "placebo", "-", "controlled", "pilot", "study", ".", "BACKGROUND", "There", "is", "increasing", "evidence", "that", "fatty", "acid", "deficiencies", "or", "imbalances", "may", "contribute", "to", "childhood", "neurodevelopmental", "disorders", ".", "METHODS", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "6-week", "pilot", "trial", "investigating", "the", "effects", "of", "1.5", "g", "/", "d", "of", "omega-3", "fatty", "acids", "(", ".84", "g", "/", "d", "eicosapentaenoic", "acid", ",", ".7", "g", "/", "d", "docosahexaenoic", "acid", ")", "supplementation", "in", "13", "children", "(", "aged", "5", "to", "17", "years", ")", "with", "autistic", "disorders", "accompanied", "by", "severe", "tantrums", ",", "aggression", ",", "or", "self", "-", "injurious", "behavior", ".", "The", "outcome", "measure", "was", "the", "Aberrant", "Behavior", "Checklist", "(", "ABC", ")", "at", "6", "weeks", ".", "RESULTS", "We", "observed", "an", "advantage", "of", "omega-3", "fatty", "acids", "compared", "with", "placebo", "for", "hyperactivity", "and", "stereotypy", ",", "each", "with", "a", "large", "effect", "size", ".", "Repeated", "-", "measures", "ANOVA", "indicated", "a", "trend", "toward", "superiority", "of", "omega-3", "fatty", "acids", "over", "placebo", "for", "hyperactivity", ".", "No", "clinically", "relevant", "adverse", "effects", "were", "elicited", "in", "either", "group", ".", "CONCLUSIONS", "The", "results", "of", "this", "study", "provide", "preliminary", "evidence", "that", "omega-3", "fatty", "acids", "may", "be", "an", "effective", "treatment", "for", "children", "with", "autism", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Mental", "Outcome_Physical", "Intervention_Control", "Participant_Age", "Outcome_Adverse-effects", "Outcome_Other", "Participant_Sample-size" ]
HLA - B is a protein, carbamazepine is a compound	DS.d532_task0	Sentence: Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy.	[ "Although", "the", "current", "studies", "associating", "particular", "genes", "and", "their", "variants", "with", "seizure", "control", "or", "adverse", "events", "have", "inherent", "weaknesses", "and", "have", "not", "provided", "unifying", "conclusions", ",", "several", "results", ",", "for", "example", "that", "Asian", "patients", "with", "a", "particular", "HLA", "allele", ",", "HLA", "-", "B", "*", "1502", ",", "are", "at", "a", "higher", "risk", "for", "Stevens", "-", "Johnson", "syndrome", "when", "using", "carbamazepine", ",", "are", "helpful", "to", "increase", "our", "knowledge", "how", "genetic", "variation", "affects", "the", "treatment", "of", "epilepsy", "." ]	[ "compound", "protein" ]
HLA - B is a protein, carbamazepine is a compound	DS.d532_task1	Sentence: Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy. Instructions: please typing these entity words according to sentence: HLA - B, carbamazepine Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy.	[ "Although", "the", "current", "studies", "associating", "particular", "genes", "and", "their", "variants", "with", "seizure", "control", "or", "adverse", "events", "have", "inherent", "weaknesses", "and", "have", "not", "provided", "unifying", "conclusions", ",", "several", "results", ",", "for", "example", "that", "Asian", "patients", "with", "a", "particular", "HLA", "allele", ",", "HLA", "-", "B", "*", "1502", ",", "are", "at", "a", "higher", "risk", "for", "Stevens", "-", "Johnson", "syndrome", "when", "using", "carbamazepine", ",", "are", "helpful", "to", "increase", "our", "knowledge", "how", "genetic", "variation", "affects", "the", "treatment", "of", "epilepsy", "." ]	[ "compound", "protein" ]
HLA - B, carbamazepine	DS.d532_task2	Sentence: Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy.	[ "Although", "the", "current", "studies", "associating", "particular", "genes", "and", "their", "variants", "with", "seizure", "control", "or", "adverse", "events", "have", "inherent", "weaknesses", "and", "have", "not", "provided", "unifying", "conclusions", ",", "several", "results", ",", "for", "example", "that", "Asian", "patients", "with", "a", "particular", "HLA", "allele", ",", "HLA", "-", "B", "*", "1502", ",", "are", "at", "a", "higher", "risk", "for", "Stevens", "-", "Johnson", "syndrome", "when", "using", "carbamazepine", ",", "are", "helpful", "to", "increase", "our", "knowledge", "how", "genetic", "variation", "affects", "the", "treatment", "of", "epilepsy", "." ]	[ "compound", "protein" ]
nitric oxide is an umlsterm, clinical medicine is an umlsterm, use is an umlsterm, therapy is an umlsterm, intensive care is an umlsterm, patients is an umlsterm, respiratory distress syndrome is an umlsterm, interactions is an umlsterm, anaesthetic is an umlsterm, attention is an umlsterm, literature is an umlsterm, date is an umlsterm, need is an umlsterm, research is an umlsterm, review is an umlsterm, literature is an umlsterm, anaesthetics is an umlsterm, human body is an umlsterm	DerAnaesthesist.70460659.eng.abstr_task0	Sentence: Due to its important physiological and pathophysiological actions , the pluripotent signaling molecule nitric oxide ( NO ) is increasingly of interest in clinical medicine . Despite increasing use by anaesthetists in inhalational therapy for intensive care patients with respiratory distress syndrome , the potential interactions of anaesthetic agents and NO have thus far received little attention . The literature available to date on this topic is somewhat controversial , and highlights the need for additional research in this area . This review summarises the pertinent literature in this area for the anaesthetist and describes potential mechanisms by which anaesthetics may interfere with the synthesis and/or effects of NO in the human body . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Due to its important physiological and pathophysiological actions , the pluripotent signaling molecule nitric oxide ( NO ) is increasingly of interest in clinical medicine . Despite increasing use by anaesthetists in inhalational therapy for intensive care patients with respiratory distress syndrome , the potential interactions of anaesthetic agents and NO have thus far received little attention . The literature available to date on this topic is somewhat controversial , and highlights the need for additional research in this area . This review summarises the pertinent literature in this area for the anaesthetist and describes potential mechanisms by which anaesthetics may interfere with the synthesis and/or effects of NO in the human body .	[ "Due", "to", "its", "important", "physiological", "and", "pathophysiological", "actions", ",", "the", "pluripotent", "signaling", "molecule", "nitric", "oxide", "(", "NO", ")", "is", "increasingly", "of", "interest", "in", "clinical", "medicine", ".", "Despite", "increasing", "use", "by", "anaesthetists", "in", "inhalational", "therapy", "for", "intensive", "care", "patients", "with", "respiratory", "distress", "syndrome", ",", "the", "potential", "interactions", "of", "anaesthetic", "agents", "and", "NO", "have", "thus", "far", "received", "little", "attention", ".", "The", "literature", "available", "to", "date", "on", "this", "topic", "is", "somewhat", "controversial", ",", "and", "highlights", "the", "need", "for", "additional", "research", "in", "this", "area", ".", "This", "review", "summarises", "the", "pertinent", "literature", "in", "this", "area", "for", "the", "anaesthetist", "and", "describes", "potential", "mechanisms", "by", "which", "anaesthetics", "may", "interfere", "with", "the", "synthesis", "and", "/", "or", "effects", "of", "NO", "in", "the", "human", "body", "." ]	[ "umlsterm" ]
nitric oxide is an umlsterm, clinical medicine is an umlsterm, use is an umlsterm, therapy is an umlsterm, intensive care is an umlsterm, patients is an umlsterm, respiratory distress syndrome is an umlsterm, interactions is an umlsterm, anaesthetic is an umlsterm, attention is an umlsterm, literature is an umlsterm, date is an umlsterm, need is an umlsterm, research is an umlsterm, review is an umlsterm, literature is an umlsterm, anaesthetics is an umlsterm, human body is an umlsterm	DerAnaesthesist.70460659.eng.abstr_task1	Sentence: Due to its important physiological and pathophysiological actions , the pluripotent signaling molecule nitric oxide ( NO ) is increasingly of interest in clinical medicine . Despite increasing use by anaesthetists in inhalational therapy for intensive care patients with respiratory distress syndrome , the potential interactions of anaesthetic agents and NO have thus far received little attention . The literature available to date on this topic is somewhat controversial , and highlights the need for additional research in this area . This review summarises the pertinent literature in this area for the anaesthetist and describes potential mechanisms by which anaesthetics may interfere with the synthesis and/or effects of NO in the human body . Instructions: please typing these entity words according to sentence: nitric oxide, clinical medicine, use, therapy, intensive care, patients, respiratory distress syndrome, interactions, anaesthetic, attention, literature, date, need, research, review, literature, anaesthetics, human body Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Due to its important physiological and pathophysiological actions , the pluripotent signaling molecule nitric oxide ( NO ) is increasingly of interest in clinical medicine . Despite increasing use by anaesthetists in inhalational therapy for intensive care patients with respiratory distress syndrome , the potential interactions of anaesthetic agents and NO have thus far received little attention . The literature available to date on this topic is somewhat controversial , and highlights the need for additional research in this area . This review summarises the pertinent literature in this area for the anaesthetist and describes potential mechanisms by which anaesthetics may interfere with the synthesis and/or effects of NO in the human body .	[ "Due", "to", "its", "important", "physiological", "and", "pathophysiological", "actions", ",", "the", "pluripotent", "signaling", "molecule", "nitric", "oxide", "(", "NO", ")", "is", "increasingly", "of", "interest", "in", "clinical", "medicine", ".", "Despite", "increasing", "use", "by", "anaesthetists", "in", "inhalational", "therapy", "for", "intensive", "care", "patients", "with", "respiratory", "distress", "syndrome", ",", "the", "potential", "interactions", "of", "anaesthetic", "agents", "and", "NO", "have", "thus", "far", "received", "little", "attention", ".", "The", "literature", "available", "to", "date", "on", "this", "topic", "is", "somewhat", "controversial", ",", "and", "highlights", "the", "need", "for", "additional", "research", "in", "this", "area", ".", "This", "review", "summarises", "the", "pertinent", "literature", "in", "this", "area", "for", "the", "anaesthetist", "and", "describes", "potential", "mechanisms", "by", "which", "anaesthetics", "may", "interfere", "with", "the", "synthesis", "and", "/", "or", "effects", "of", "NO", "in", "the", "human", "body", "." ]	[ "umlsterm" ]
nitric oxide, clinical medicine, use, therapy, intensive care, patients, respiratory distress syndrome, interactions, anaesthetic, attention, literature, date, need, research, review, literature, anaesthetics, human body	DerAnaesthesist.70460659.eng.abstr_task2	Sentence: Due to its important physiological and pathophysiological actions , the pluripotent signaling molecule nitric oxide ( NO ) is increasingly of interest in clinical medicine . Despite increasing use by anaesthetists in inhalational therapy for intensive care patients with respiratory distress syndrome , the potential interactions of anaesthetic agents and NO have thus far received little attention . The literature available to date on this topic is somewhat controversial , and highlights the need for additional research in this area . This review summarises the pertinent literature in this area for the anaesthetist and describes potential mechanisms by which anaesthetics may interfere with the synthesis and/or effects of NO in the human body . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Due to its important physiological and pathophysiological actions , the pluripotent signaling molecule nitric oxide ( NO ) is increasingly of interest in clinical medicine . Despite increasing use by anaesthetists in inhalational therapy for intensive care patients with respiratory distress syndrome , the potential interactions of anaesthetic agents and NO have thus far received little attention . The literature available to date on this topic is somewhat controversial , and highlights the need for additional research in this area . This review summarises the pertinent literature in this area for the anaesthetist and describes potential mechanisms by which anaesthetics may interfere with the synthesis and/or effects of NO in the human body .	[ "Due", "to", "its", "important", "physiological", "and", "pathophysiological", "actions", ",", "the", "pluripotent", "signaling", "molecule", "nitric", "oxide", "(", "NO", ")", "is", "increasingly", "of", "interest", "in", "clinical", "medicine", ".", "Despite", "increasing", "use", "by", "anaesthetists", "in", "inhalational", "therapy", "for", "intensive", "care", "patients", "with", "respiratory", "distress", "syndrome", ",", "the", "potential", "interactions", "of", "anaesthetic", "agents", "and", "NO", "have", "thus", "far", "received", "little", "attention", ".", "The", "literature", "available", "to", "date", "on", "this", "topic", "is", "somewhat", "controversial", ",", "and", "highlights", "the", "need", "for", "additional", "research", "in", "this", "area", ".", "This", "review", "summarises", "the", "pertinent", "literature", "in", "this", "area", "for", "the", "anaesthetist", "and", "describes", "potential", "mechanisms", "by", "which", "anaesthetics", "may", "interfere", "with", "the", "synthesis", "and", "/", "or", "effects", "of", "NO", "in", "the", "human", "body", "." ]	[ "umlsterm" ]

Schaedel - Hirn - Verletzungen, Verletzungen, unfallchirurgischen, Patienten, Schaedel - Hirn - Trauma, SHT, Patienten, Commotio cerebri, Patienten, Therapie, Patienten, Haematomausraeumung, Blutungen, Drainage, Patienten, Diagnostik, Therapie, Verletzungen, Behandlung, Patienten, SHT, Krankenhaeusern, Roentgendiagnostik, SHT, Krankenhaus, SHT, lebensbedrohlichen, Blutungen, Druckentlastung, Blutmassen, Blutungen, hinteren Schaedelgrube, Hirnnervenverletzungen, Schaedelbasisverletzungen, Liquorfisteln, Literatur, Patienten, SHT

DerChirurg.60671107.ger.abstr_task2

Sentence: Zusammenfassung . Schaedel-Hirn-Verletzungen sind sowohl bei Polytraumen wie auch als isolierte Verletzungen sehr haeufig . In unserer Klinik der unfallchirurgischen Schwerpunktversorgung wurden in einem Zeitraum von 21 Monaten 489 Patienten mit einem Schaedel-Hirn-Trauma ( SHT ) behandelt . Dies entspricht 6,5 % aller stationaer behandelten Patienten . Waehrend bei Commotio cerebri ( CC 85,9 % , der Patienten ) immer eine konservative Therapie und komplikationsloser Verlauf festzustellen war , musste bei den 69 Patienten mit Contusio cerebri in 18 Faellen eine Craniotomie mit Haematomausraeumung bei sub- und epiduralen Blutungen und Drainage erfolgen . Bei zwei dieser Patienten war eine Revision wegen Nachblutung erforderlich . Eine Bildtelephonverbindung mit einem neurochirurgischen Zentrum wurde zweimal in Anspruch genommen . In vier Faellen mit Komplex-/Begleitverletzungen erfolgte die Verlegung in ein neurochirurgisches Zentrum . Die Letalitaet betrug 14,5 % . Es werden die Diagnostik und Therapie bei den einzelnen Verletzungen und die Voraussetzungen fuer die Behandlung von Patienten mit SHT in peripheren Krankenhaeusern dargestellt : Notarzt Notaufnahmemanagement , Neurologe , , Roentgendiagnostik mit CT , Operationsausstattung und qualifizierte Operateure . Falls diese Voraussetzungen gegeben sind , kann ein Grossteil auch schwerer SHT im peripheren Krankenhaus versorgt werden . Sind einige dieser Voraussetzungen nicht erfuellt , sollte bei jedem potentiell operationspflichtigen SHT die fruehzeitige Verlegung in ein Zentrum erfolgen . Nur bei akut lebensbedrohlichen Blutungen , bei denen aus zeitlichen Gruenden eine Verlegung nicht moeglich ist , muss auch in Kliniken der Grundversorgung ohne adaequate Voraussetzungen eine Craniotomie und Druckentlastung erfolgen . Bei Begleitverletzungen , wie intracerebrale Blutmassen , Ventrikeleinbruch , Blutungen in der hinteren Schaedelgrube , Hirnnervenverletzungen , Carotis- oder Sinus-cavernosus-Verletzung , Schaedelbasisverletzungen mit Liquorfisteln oder Pneumoencephalon sollen auch fuer Kliniken der Schwerpunktversorgung eine Indikation zur Verlegung in ein neurochirurgisches Zentrum sein . Diese Selektion ermoeglicht in peripheren Kliniken vergleichbare Behandlungsergebnisse , wie in der Literatur angegeben , und vermeidet die Ueberlastung neurochirurgischer Zentren mit Patienten nach SHT . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Zusammenfassung . Schaedel-Hirn-Verletzungen sind sowohl bei Polytraumen wie auch als isolierte Verletzungen sehr haeufig . In unserer Klinik der unfallchirurgischen Schwerpunktversorgung wurden in einem Zeitraum von 21 Monaten 489 Patienten mit einem Schaedel-Hirn-Trauma ( SHT ) behandelt . Dies entspricht 6,5 % aller stationaer behandelten Patienten . Waehrend bei Commotio cerebri ( CC 85,9 % , der Patienten ) immer eine konservative Therapie und komplikationsloser Verlauf festzustellen war , musste bei den 69 Patienten mit Contusio cerebri in 18 Faellen eine Craniotomie mit Haematomausraeumung bei sub- und epiduralen Blutungen und Drainage erfolgen . Bei zwei dieser Patienten war eine Revision wegen Nachblutung erforderlich . Eine Bildtelephonverbindung mit einem neurochirurgischen Zentrum wurde zweimal in Anspruch genommen . In vier Faellen mit Komplex-/Begleitverletzungen erfolgte die Verlegung in ein neurochirurgisches Zentrum . Die Letalitaet betrug 14,5 % . Es werden die Diagnostik und Therapie bei den einzelnen Verletzungen und die Voraussetzungen fuer die Behandlung von Patienten mit SHT in peripheren Krankenhaeusern dargestellt : Notarzt Notaufnahmemanagement , Neurologe , , Roentgendiagnostik mit CT , Operationsausstattung und qualifizierte Operateure . Falls diese Voraussetzungen gegeben sind , kann ein Grossteil auch schwerer SHT im peripheren Krankenhaus versorgt werden . Sind einige dieser Voraussetzungen nicht erfuellt , sollte bei jedem potentiell operationspflichtigen SHT die fruehzeitige Verlegung in ein Zentrum erfolgen . Nur bei akut lebensbedrohlichen Blutungen , bei denen aus zeitlichen Gruenden eine Verlegung nicht moeglich ist , muss auch in Kliniken der Grundversorgung ohne adaequate Voraussetzungen eine Craniotomie und Druckentlastung erfolgen . Bei Begleitverletzungen , wie intracerebrale Blutmassen , Ventrikeleinbruch , Blutungen in der hinteren Schaedelgrube , Hirnnervenverletzungen , Carotis- oder Sinus-cavernosus-Verletzung , Schaedelbasisverletzungen mit Liquorfisteln oder Pneumoencephalon sollen auch fuer Kliniken der Schwerpunktversorgung eine Indikation zur Verlegung in ein neurochirurgisches Zentrum sein . Diese Selektion ermoeglicht in peripheren Kliniken vergleichbare Behandlungsergebnisse , wie in der Literatur angegeben , und vermeidet die Ueberlastung neurochirurgischer Zentren mit Patienten nach SHT .

[ "Zusammenfassung", ".", "Schaedel", "-", "Hirn", "-", "Verletzungen", "sind", "sowohl", "bei", "Polytraumen", "wie", "auch", "als", "isolierte", "Verletzungen", "sehr", "haeufig", ".", "In", "unserer", "Klinik", "der", "unfallchirurgischen", "Schwerpunktversorgung", "wurden", "in", "einem", "Zeitraum", "von", "21", "Monaten", "489", "Patienten", "mit", "einem", "Schaedel", "-", "Hirn", "-", "Trauma", "(", "SHT", ")", "behandelt", ".", "Dies", "entspricht", "6,5", "%", "aller", "stationaer", "behandelten", "Patienten", ".", "Waehrend", "bei", "Commotio", "cerebri", "(", "CC", "85,9", "%", ",", "der", "Patienten", ")", "immer", "eine", "konservative", "Therapie", "und", "komplikationsloser", "Verlauf", "festzustellen", "war", ",", "musste", "bei", "den", "69", "Patienten", "mit", "Contusio", "cerebri", "in", "18", "Faellen", "eine", "Craniotomie", "mit", "Haematomausraeumung", "bei", "sub-", "und", "epiduralen", "Blutungen", "und", "Drainage", "erfolgen", ".", "Bei", "zwei", "dieser", "Patienten", "war", "eine", "Revision", "wegen", "Nachblutung", "erforderlich", ".", "Eine", "Bildtelephonverbindung", "mit", "einem", "neurochirurgischen", "Zentrum", "wurde", "zweimal", "in", "Anspruch", "genommen", ".", "In", "vier", "Faellen", "mit", "Komplex-/Begleitverletzungen", "erfolgte", "die", "Verlegung", "in", "ein", "neurochirurgisches", "Zentrum", ".", "Die", "Letalitaet", "betrug", "14,5", "%", ".", "Es", "werden", "die", "Diagnostik", "und", "Therapie", "bei", "den", "einzelnen", "Verletzungen", "und", "die", "Voraussetzungen", "fuer", "die", "Behandlung", "von", "Patienten", "mit", "SHT", "in", "peripheren", "Krankenhaeusern", "dargestellt", ":", "Notarzt", "Notaufnahmemanagement", ",", "Neurologe", ",", ",", "Roentgendiagnostik", "mit", "CT", ",", "Operationsausstattung", "und", "qualifizierte", "Operateure", ".", "Falls", "diese", "Voraussetzungen", "gegeben", "sind", ",", "kann", "ein", "Grossteil", "auch", "schwerer", "SHT", "im", "peripheren", "Krankenhaus", "versorgt", "werden", ".", "Sind", "einige", "dieser", "Voraussetzungen", "nicht", "erfuellt", ",", "sollte", "bei", "jedem", "potentiell", "operationspflichtigen", "SHT", "die", "fruehzeitige", "Verlegung", "in", "ein", "Zentrum", "erfolgen", ".", "Nur", "bei", "akut", "lebensbedrohlichen", "Blutungen", ",", "bei", "denen", "aus", "zeitlichen", "Gruenden", "eine", "Verlegung", "nicht", "moeglich", "ist", ",", "muss", "auch", "in", "Kliniken", "der", "Grundversorgung", "ohne", "adaequate", "Voraussetzungen", "eine", "Craniotomie", "und", "Druckentlastung", "erfolgen", ".", "Bei", "Begleitverletzungen", ",", "wie", "intracerebrale", "Blutmassen", ",", "Ventrikeleinbruch", ",", "Blutungen", "in", "der", "hinteren", "Schaedelgrube", ",", "Hirnnervenverletzungen", ",", "Carotis-", "oder", "Sinus", "-", "cavernosus", "-", "Verletzung", ",", "Schaedelbasisverletzungen", "mit", "Liquorfisteln", "oder", "Pneumoencephalon", "sollen", "auch", "fuer", "Kliniken", "der", "Schwerpunktversorgung", "eine", "Indikation", "zur", "Verlegung", "in", "ein", "neurochirurgisches", "Zentrum", "sein", ".", "Diese", "Selektion", "ermoeglicht", "in", "peripheren", "Kliniken", "vergleichbare", "Behandlungsergebnisse", ",", "wie", "in", "der", "Literatur", "angegeben", ",", "und", "vermeidet", "die", "Ueberlastung", "neurochirurgischer", "Zentren", "mit", "Patienten", "nach", "SHT", "." ]

[ "umlsterm" ]

plasma 6-keto - prostaglandin F1 alpha concentration is an outcome, serum HDL2 cholesterol concentration is an outcome, regular exercise is an intervention

68_task0

Sentence: The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, outcome

[ "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "B-intervention", "I-intervention", "O" ]

The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise .

[ "The", "increase", "in", "plasma", "6-keto", "-", "prostaglandin", "F1", "alpha", "concentration", "was", "associated", "with", "an", "increase", "in", "serum", "HDL2", "cholesterol", "concentration", "in", "the", "group", "taking", "regular", "exercise", "." ]

[ "outcome", "intervention" ]

plasma 6-keto - prostaglandin F1 alpha concentration is an outcome, serum HDL2 cholesterol concentration is an outcome, regular exercise is an intervention

68_task1

Sentence: The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise . Instructions: please typing these entity words according to sentence: plasma 6-keto - prostaglandin F1 alpha concentration, serum HDL2 cholesterol concentration, regular exercise Options: intervention, outcome

[ "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "B-intervention", "I-intervention", "O" ]

The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise .

[ "The", "increase", "in", "plasma", "6-keto", "-", "prostaglandin", "F1", "alpha", "concentration", "was", "associated", "with", "an", "increase", "in", "serum", "HDL2", "cholesterol", "concentration", "in", "the", "group", "taking", "regular", "exercise", "." ]

[ "outcome", "intervention" ]

plasma 6-keto - prostaglandin F1 alpha concentration, serum HDL2 cholesterol concentration, regular exercise

68_task2

Sentence: The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "B-intervention", "I-intervention", "O" ]

The increase in plasma 6-keto-prostaglandin F1 alpha concentration was associated with an increase in serum HDL2 cholesterol concentration in the group taking regular exercise .

[ "The", "increase", "in", "plasma", "6-keto", "-", "prostaglandin", "F1", "alpha", "concentration", "was", "associated", "with", "an", "increase", "in", "serum", "HDL2", "cholesterol", "concentration", "in", "the", "group", "taking", "regular", "exercise", "." ]

[ "outcome", "intervention" ]

miRNAs is a Non-Specific_miRNAs, RNU44 is a Genes/Proteins, RNU49 is a Genes/Proteins

9030_task0

Sentence: The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Genes/Proteins, Non-Specific_miRNAs

[ "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Genes/Proteins", "O", "B-Genes/Proteins", "O", "O", "O", "O" ]

The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls.

[ "The", "relative", "expression", "of", "miRNAs", "was", "measured", "by", "real", "-", "time", "PCR", "using", "RNU44", "and", "RNU49", "as", "endogenous", "controls", "." ]

[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species", "Specific_miRNAs", "Genes/Proteins" ]

miRNAs is a Non-Specific_miRNAs, RNU44 is a Genes/Proteins, RNU49 is a Genes/Proteins

9030_task1

Sentence: The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls. Instructions: please typing these entity words according to sentence: miRNAs, RNU44, RNU49 Options: Genes/Proteins, Non-Specific_miRNAs

[ "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Genes/Proteins", "O", "B-Genes/Proteins", "O", "O", "O", "O" ]

The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls.

[ "The", "relative", "expression", "of", "miRNAs", "was", "measured", "by", "real", "-", "time", "PCR", "using", "RNU44", "and", "RNU49", "as", "endogenous", "controls", "." ]

[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species", "Specific_miRNAs", "Genes/Proteins" ]

miRNAs, RNU44, RNU49

9030_task2

Sentence: The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Non-Specific_miRNAs", "O", "O", "O", "O", "O", "O", "O", "O", "B-Genes/Proteins", "O", "B-Genes/Proteins", "O", "O", "O", "O" ]

The relative expression of miRNAs was measured by real-time PCR using RNU44 and RNU49 as endogenous controls.

[ "The", "relative", "expression", "of", "miRNAs", "was", "measured", "by", "real", "-", "time", "PCR", "using", "RNU44", "and", "RNU49", "as", "endogenous", "controls", "." ]

[ "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species", "Specific_miRNAs", "Genes/Proteins" ]

Children is a Participant_Age, with persistent conduct problems who dropout of treatment . is a Participant_Condition, Dropout is a Outcome_Other, dropout rate of children is a Outcome_Other, 32 is a Participant_Sample-size, CBT approach with conjoint family therapy and an eclectic approach . is a Intervention_Educational, overall dropout rate is a Outcome_Other, parental dissatisfaction with the treatment service is a Outcome_Other, naturalistic follow - up is a Intervention_Educational, Forty - six is a Participant_Sample-size, parental perception of a less organised treatment is a Outcome_Other

5953_task0

Sentence: Children with persistent conduct problems who dropout of treatment . Dropout of treatment is one of the key issues in outcome in a child and adolescent mental health service . We report two studies focusing on the treatment process and the dropout rate of children with persistent conduct problems presenting to a community mental health service , using a prospective design . The first study included 32 children and used a randomised controlled treatment design comparing a CBT approach with conjoint family therapy and an eclectic approach . The overall dropout rate was 36 % . Dropout occurred significantly less frequently in the CBT group . The dropout group was associated with mothers who were younger and less educated , a poorer rating by the clinicians at the last meeting , parental dissatisfaction with the treatment service and perception that the treatment was less organised and having less behavioural tasks . In the second study we used a naturalistic follow-up design . Forty-six children were included . The overall dropout rate was 48 % . Again , the children who defaulted were rated by clinicians as less likely to have improved and dropout was also significantly associated with parental perception of a less organised treatment . In both studies dropout usually occurred after assessment and at the early phase of treatment . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Intervention_Educational, Participant_Age, Participant_Sample-size, Outcome_Other

[ "B-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Children with persistent conduct problems who dropout of treatment . Dropout of treatment is one of the key issues in outcome in a child and adolescent mental health service . We report two studies focusing on the treatment process and the dropout rate of children with persistent conduct problems presenting to a community mental health service , using a prospective design . The first study included 32 children and used a randomised controlled treatment design comparing a CBT approach with conjoint family therapy and an eclectic approach . The overall dropout rate was 36 % . Dropout occurred significantly less frequently in the CBT group . The dropout group was associated with mothers who were younger and less educated , a poorer rating by the clinicians at the last meeting , parental dissatisfaction with the treatment service and perception that the treatment was less organised and having less behavioural tasks . In the second study we used a naturalistic follow-up design . Forty-six children were included . The overall dropout rate was 48 % . Again , the children who defaulted were rated by clinicians as less likely to have improved and dropout was also significantly associated with parental perception of a less organised treatment . In both studies dropout usually occurred after assessment and at the early phase of treatment .

[ "Children", "with", "persistent", "conduct", "problems", "who", "dropout", "of", "treatment", ".", "Dropout", "of", "treatment", "is", "one", "of", "the", "key", "issues", "in", "outcome", "in", "a", "child", "and", "adolescent", "mental", "health", "service", ".", "We", "report", "two", "studies", "focusing", "on", "the", "treatment", "process", "and", "the", "dropout", "rate", "of", "children", "with", "persistent", "conduct", "problems", "presenting", "to", "a", "community", "mental", "health", "service", ",", "using", "a", "prospective", "design", ".", "The", "first", "study", "included", "32", "children", "and", "used", "a", "randomised", "controlled", "treatment", "design", "comparing", "a", "CBT", "approach", "with", "conjoint", "family", "therapy", "and", "an", "eclectic", "approach", ".", "The", "overall", "dropout", "rate", "was", "36", "%", ".", "Dropout", "occurred", "significantly", "less", "frequently", "in", "the", "CBT", "group", ".", "The", "dropout", "group", "was", "associated", "with", "mothers", "who", "were", "younger", "and", "less", "educated", ",", "a", "poorer", "rating", "by", "the", "clinicians", "at", "the", "last", "meeting", ",", "parental", "dissatisfaction", "with", "the", "treatment", "service", "and", "perception", "that", "the", "treatment", "was", "less", "organised", "and", "having", "less", "behavioural", "tasks", ".", "In", "the", "second", "study", "we", "used", "a", "naturalistic", "follow", "-", "up", "design", ".", "Forty", "-", "six", "children", "were", "included", ".", "The", "overall", "dropout", "rate", "was", "48", "%", ".", "Again", ",", "the", "children", "who", "defaulted", "were", "rated", "by", "clinicians", "as", "less", "likely", "to", "have", "improved", "and", "dropout", "was", "also", "significantly", "associated", "with", "parental", "perception", "of", "a", "less", "organised", "treatment", ".", "In", "both", "studies", "dropout", "usually", "occurred", "after", "assessment", "and", "at", "the", "early", "phase", "of", "treatment", "." ]

[ "Intervention_Educational", "Participant_Condition", "Outcome_Other", "Participant_Sample-size", "Participant_Age" ]

Children is a Participant_Age, with persistent conduct problems who dropout of treatment . is a Participant_Condition, Dropout is a Outcome_Other, dropout rate of children is a Outcome_Other, 32 is a Participant_Sample-size, CBT approach with conjoint family therapy and an eclectic approach . is a Intervention_Educational, overall dropout rate is a Outcome_Other, parental dissatisfaction with the treatment service is a Outcome_Other, naturalistic follow - up is a Intervention_Educational, Forty - six is a Participant_Sample-size, parental perception of a less organised treatment is a Outcome_Other

5953_task1

Sentence: Children with persistent conduct problems who dropout of treatment . Dropout of treatment is one of the key issues in outcome in a child and adolescent mental health service . We report two studies focusing on the treatment process and the dropout rate of children with persistent conduct problems presenting to a community mental health service , using a prospective design . The first study included 32 children and used a randomised controlled treatment design comparing a CBT approach with conjoint family therapy and an eclectic approach . The overall dropout rate was 36 % . Dropout occurred significantly less frequently in the CBT group . The dropout group was associated with mothers who were younger and less educated , a poorer rating by the clinicians at the last meeting , parental dissatisfaction with the treatment service and perception that the treatment was less organised and having less behavioural tasks . In the second study we used a naturalistic follow-up design . Forty-six children were included . The overall dropout rate was 48 % . Again , the children who defaulted were rated by clinicians as less likely to have improved and dropout was also significantly associated with parental perception of a less organised treatment . In both studies dropout usually occurred after assessment and at the early phase of treatment . Instructions: please typing these entity words according to sentence: Children, with persistent conduct problems who dropout of treatment ., Dropout, dropout rate of children, 32, CBT approach with conjoint family therapy and an eclectic approach ., overall dropout rate, parental dissatisfaction with the treatment service, naturalistic follow - up, Forty - six, parental perception of a less organised treatment Options: Participant_Condition, Intervention_Educational, Participant_Age, Participant_Sample-size, Outcome_Other

[ "B-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Children with persistent conduct problems who dropout of treatment . Dropout of treatment is one of the key issues in outcome in a child and adolescent mental health service . We report two studies focusing on the treatment process and the dropout rate of children with persistent conduct problems presenting to a community mental health service , using a prospective design . The first study included 32 children and used a randomised controlled treatment design comparing a CBT approach with conjoint family therapy and an eclectic approach . The overall dropout rate was 36 % . Dropout occurred significantly less frequently in the CBT group . The dropout group was associated with mothers who were younger and less educated , a poorer rating by the clinicians at the last meeting , parental dissatisfaction with the treatment service and perception that the treatment was less organised and having less behavioural tasks . In the second study we used a naturalistic follow-up design . Forty-six children were included . The overall dropout rate was 48 % . Again , the children who defaulted were rated by clinicians as less likely to have improved and dropout was also significantly associated with parental perception of a less organised treatment . In both studies dropout usually occurred after assessment and at the early phase of treatment .

[ "Children", "with", "persistent", "conduct", "problems", "who", "dropout", "of", "treatment", ".", "Dropout", "of", "treatment", "is", "one", "of", "the", "key", "issues", "in", "outcome", "in", "a", "child", "and", "adolescent", "mental", "health", "service", ".", "We", "report", "two", "studies", "focusing", "on", "the", "treatment", "process", "and", "the", "dropout", "rate", "of", "children", "with", "persistent", "conduct", "problems", "presenting", "to", "a", "community", "mental", "health", "service", ",", "using", "a", "prospective", "design", ".", "The", "first", "study", "included", "32", "children", "and", "used", "a", "randomised", "controlled", "treatment", "design", "comparing", "a", "CBT", "approach", "with", "conjoint", "family", "therapy", "and", "an", "eclectic", "approach", ".", "The", "overall", "dropout", "rate", "was", "36", "%", ".", "Dropout", "occurred", "significantly", "less", "frequently", "in", "the", "CBT", "group", ".", "The", "dropout", "group", "was", "associated", "with", "mothers", "who", "were", "younger", "and", "less", "educated", ",", "a", "poorer", "rating", "by", "the", "clinicians", "at", "the", "last", "meeting", ",", "parental", "dissatisfaction", "with", "the", "treatment", "service", "and", "perception", "that", "the", "treatment", "was", "less", "organised", "and", "having", "less", "behavioural", "tasks", ".", "In", "the", "second", "study", "we", "used", "a", "naturalistic", "follow", "-", "up", "design", ".", "Forty", "-", "six", "children", "were", "included", ".", "The", "overall", "dropout", "rate", "was", "48", "%", ".", "Again", ",", "the", "children", "who", "defaulted", "were", "rated", "by", "clinicians", "as", "less", "likely", "to", "have", "improved", "and", "dropout", "was", "also", "significantly", "associated", "with", "parental", "perception", "of", "a", "less", "organised", "treatment", ".", "In", "both", "studies", "dropout", "usually", "occurred", "after", "assessment", "and", "at", "the", "early", "phase", "of", "treatment", "." ]

[ "Intervention_Educational", "Participant_Condition", "Outcome_Other", "Participant_Sample-size", "Participant_Age" ]

Children, with persistent conduct problems who dropout of treatment ., Dropout, dropout rate of children, 32, CBT approach with conjoint family therapy and an eclectic approach ., overall dropout rate, parental dissatisfaction with the treatment service, naturalistic follow - up, Forty - six, parental perception of a less organised treatment

5953_task2

Sentence: Children with persistent conduct problems who dropout of treatment . Dropout of treatment is one of the key issues in outcome in a child and adolescent mental health service . We report two studies focusing on the treatment process and the dropout rate of children with persistent conduct problems presenting to a community mental health service , using a prospective design . The first study included 32 children and used a randomised controlled treatment design comparing a CBT approach with conjoint family therapy and an eclectic approach . The overall dropout rate was 36 % . Dropout occurred significantly less frequently in the CBT group . The dropout group was associated with mothers who were younger and less educated , a poorer rating by the clinicians at the last meeting , parental dissatisfaction with the treatment service and perception that the treatment was less organised and having less behavioural tasks . In the second study we used a naturalistic follow-up design . Forty-six children were included . The overall dropout rate was 48 % . Again , the children who defaulted were rated by clinicians as less likely to have improved and dropout was also significantly associated with parental perception of a less organised treatment . In both studies dropout usually occurred after assessment and at the early phase of treatment . Instructions: please extract entity words from the input sentence

[ "B-Participant_Age", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Children with persistent conduct problems who dropout of treatment . Dropout of treatment is one of the key issues in outcome in a child and adolescent mental health service . We report two studies focusing on the treatment process and the dropout rate of children with persistent conduct problems presenting to a community mental health service , using a prospective design . The first study included 32 children and used a randomised controlled treatment design comparing a CBT approach with conjoint family therapy and an eclectic approach . The overall dropout rate was 36 % . Dropout occurred significantly less frequently in the CBT group . The dropout group was associated with mothers who were younger and less educated , a poorer rating by the clinicians at the last meeting , parental dissatisfaction with the treatment service and perception that the treatment was less organised and having less behavioural tasks . In the second study we used a naturalistic follow-up design . Forty-six children were included . The overall dropout rate was 48 % . Again , the children who defaulted were rated by clinicians as less likely to have improved and dropout was also significantly associated with parental perception of a less organised treatment . In both studies dropout usually occurred after assessment and at the early phase of treatment .

[ "Children", "with", "persistent", "conduct", "problems", "who", "dropout", "of", "treatment", ".", "Dropout", "of", "treatment", "is", "one", "of", "the", "key", "issues", "in", "outcome", "in", "a", "child", "and", "adolescent", "mental", "health", "service", ".", "We", "report", "two", "studies", "focusing", "on", "the", "treatment", "process", "and", "the", "dropout", "rate", "of", "children", "with", "persistent", "conduct", "problems", "presenting", "to", "a", "community", "mental", "health", "service", ",", "using", "a", "prospective", "design", ".", "The", "first", "study", "included", "32", "children", "and", "used", "a", "randomised", "controlled", "treatment", "design", "comparing", "a", "CBT", "approach", "with", "conjoint", "family", "therapy", "and", "an", "eclectic", "approach", ".", "The", "overall", "dropout", "rate", "was", "36", "%", ".", "Dropout", "occurred", "significantly", "less", "frequently", "in", "the", "CBT", "group", ".", "The", "dropout", "group", "was", "associated", "with", "mothers", "who", "were", "younger", "and", "less", "educated", ",", "a", "poorer", "rating", "by", "the", "clinicians", "at", "the", "last", "meeting", ",", "parental", "dissatisfaction", "with", "the", "treatment", "service", "and", "perception", "that", "the", "treatment", "was", "less", "organised", "and", "having", "less", "behavioural", "tasks", ".", "In", "the", "second", "study", "we", "used", "a", "naturalistic", "follow", "-", "up", "design", ".", "Forty", "-", "six", "children", "were", "included", ".", "The", "overall", "dropout", "rate", "was", "48", "%", ".", "Again", ",", "the", "children", "who", "defaulted", "were", "rated", "by", "clinicians", "as", "less", "likely", "to", "have", "improved", "and", "dropout", "was", "also", "significantly", "associated", "with", "parental", "perception", "of", "a", "less", "organised", "treatment", ".", "In", "both", "studies", "dropout", "usually", "occurred", "after", "assessment", "and", "at", "the", "early", "phase", "of", "treatment", "." ]

[ "Intervention_Educational", "Participant_Condition", "Outcome_Other", "Participant_Sample-size", "Participant_Age" ]

Ondansetron is an umlsterm, placebo is an umlsterm, postoperative nausea is an umlsterm, vomiting is an umlsterm, PONV is an umlsterm, antiemetics is an umlsterm, prophylaxis is an umlsterm, therapy is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, treatment is an umlsterm, PONV is an umlsterm, Methods is an umlsterm, double - blind study is an umlsterm, October is an umlsterm, ASA is an umlsterm, inpatients is an umlsterm, general anaesthesia is an umlsterm, intubation is an umlsterm, Patients is an umlsterm, emergency is an umlsterm, operation is an umlsterm, patient is an umlsterm, breast feeding is an umlsterm, allergies is an umlsterm, antihistamines is an umlsterm, drug addiction is an umlsterm, convulsions is an umlsterm, disease is an umlsterm, antiemetic is an umlsterm, medication is an umlsterm, All is an umlsterm, patients is an umlsterm, antiemetic is an umlsterm, emetic is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, nausea is an umlsterm, antiemetic is an umlsterm, emetic is an umlsterm, administration is an umlsterm, Patients is an umlsterm, premedication is an umlsterm, diazepam is an umlsterm, thiopental is an umlsterm, etomidate is an umlsterm, propofol is an umlsterm, Relaxation is an umlsterm, pancuronium is an umlsterm, atracurium is an umlsterm, succinylcholine is an umlsterm, relaxation is an umlsterm, glycopyrrolate is an umlsterm, intubation is an umlsterm, enflurane is an umlsterm, halothane is an umlsterm, isoflurane is an umlsterm, fentanyl is an umlsterm, evaluation is an umlsterm, Student 's is an umlsterm, Mann - Whitney U test is an umlsterm, test is an umlsterm, patients is an umlsterm, PONV is an umlsterm, operation is an umlsterm, emesis is an umlsterm, record is an umlsterm, medication is an umlsterm, patients is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, antiemetic is an umlsterm, patients is an umlsterm, Nausea is an umlsterm, emetic is an umlsterm, antiemetic is an umlsterm, medication is an umlsterm, medication is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, medication is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, patients is an umlsterm, medication is an umlsterm, emetic is an umlsterm, interviews is an umlsterm, linguistic is an umlsterm, Injection is an umlsterm, pain is an umlsterm, droperidol is an umlsterm, pruritus is an umlsterm, ondansetron is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, patients is an umlsterm, drug is an umlsterm, future is an umlsterm, PONV is an umlsterm, treatment is an umlsterm, Ondansetron is an umlsterm, droperidol is an umlsterm, postoperative is an umlsterm, antiemetic is an umlsterm, drugs is an umlsterm, methods is an umlsterm

DerAnaesthesist.40430504.eng.abstr_task0

Sentence: Introduction . Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting ( PONV ) , but it has not been proved to be superior to established antiemetics for prophylaxis or therapy . We compared ondansetron vs droperidol for the treatment of PONV . Methods . Our prospective , randomized double-blind study was performed between 15 October 1992 and July 1993 ; it included 271 gynaecological ASA I - III inpatients who had been operated on under general anaesthesia with intubation . Patients were excluded if : there was no informed consent ; it was an ambulatory or emergency operation ; the patient was pregnant or breast feeding ; allergies were being treated with antihistamines ; drug addiction was present or convulsions or Parkinson's disease ; any pre- or intraoperative antiemetic medication had been administered . All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously . The verbal nausea score ( 1=none, 2=mild, 3=moderate, 4=severe) was recorded every 30 min for 4 h , then before and 2 h after each antiemetic dose . All emetic episodes and the interval between administration and effect were also noted . Patients were interviewed 36 - 48 h postoperatively on subjective effects , side-effects and individual acceptance . After oral premedication with diazepam , anaesthesia was induced with thiopental , in a few cases with etomidate or propofol . Relaxation was achieved with pancuronium or atracurium and , when indicated , with succinylcholine . Muscular relaxation was antagonized with neostigmin and glycopyrrolate . Gastric content was aspirated once after intubation . Anaesthesia was maintained with nitrous oxide/oxygen , enflurane , halothane or isoflurane and fentanyl up to 0.3 mg . Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test . Categoric variables were examined by the 2 test . Significance was defined as P 0.05. Results . Of 271 patients , 100 ( 37% ) experienced PONV . The groups were statistically comparable with respect to demographic data , type and duration of operation , emesis record , perioperative uterotonic medication . Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h , the other patients up to 17 h after extubation . Nausea scores and emetic episodes were identical before antiemetic medication . The reduction of these parameters after medication was similar . Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group . In both groups the first medication failed in 4 cases during the initial 2 h . Twenty of the ondansetron and 16 of the droperidol patients needed a second dose ; among these 2 and 4 , respectively , a third ampoule . No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups . Onset and quality of emetic action were identical in both groups . It was not possible to evaluate 25 interviews due to linguistic or amnestic problems . Multiple side-effects were noted frequently . Injection pain was reported significantly more often in the droperidol , pruritus in the ondansetron group . Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment . Conclusions . Ondansetron ( 8 mg ) and droperidol ( 1.25 mg ) proved to be equally effective when used as a postoperative antiemetic . Both drugs showed similar side-effects . Due to differences in methods it was difficult to compare our results to those obtained in other studies . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Introduction . Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting ( PONV ) , but it has not been proved to be superior to established antiemetics for prophylaxis or therapy . We compared ondansetron vs droperidol for the treatment of PONV . Methods . Our prospective , randomized double-blind study was performed between 15 October 1992 and July 1993 ; it included 271 gynaecological ASA I - III inpatients who had been operated on under general anaesthesia with intubation . Patients were excluded if : there was no informed consent ; it was an ambulatory or emergency operation ; the patient was pregnant or breast feeding ; allergies were being treated with antihistamines ; drug addiction was present or convulsions or Parkinson's disease ; any pre- or intraoperative antiemetic medication had been administered . All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously . The verbal nausea score ( 1=none, 2=mild, 3=moderate, 4=severe) was recorded every 30 min for 4 h , then before and 2 h after each antiemetic dose . All emetic episodes and the interval between administration and effect were also noted . Patients were interviewed 36 - 48 h postoperatively on subjective effects , side-effects and individual acceptance . After oral premedication with diazepam , anaesthesia was induced with thiopental , in a few cases with etomidate or propofol . Relaxation was achieved with pancuronium or atracurium and , when indicated , with succinylcholine . Muscular relaxation was antagonized with neostigmin and glycopyrrolate . Gastric content was aspirated once after intubation . Anaesthesia was maintained with nitrous oxide/oxygen , enflurane , halothane or isoflurane and fentanyl up to 0.3 mg . Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test . Categoric variables were examined by the 2 test . Significance was defined as P 0.05. Results . Of 271 patients , 100 ( 37% ) experienced PONV . The groups were statistically comparable with respect to demographic data , type and duration of operation , emesis record , perioperative uterotonic medication . Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h , the other patients up to 17 h after extubation . Nausea scores and emetic episodes were identical before antiemetic medication . The reduction of these parameters after medication was similar . Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group . In both groups the first medication failed in 4 cases during the initial 2 h . Twenty of the ondansetron and 16 of the droperidol patients needed a second dose ; among these 2 and 4 , respectively , a third ampoule . No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups . Onset and quality of emetic action were identical in both groups . It was not possible to evaluate 25 interviews due to linguistic or amnestic problems . Multiple side-effects were noted frequently . Injection pain was reported significantly more often in the droperidol , pruritus in the ondansetron group . Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment . Conclusions . Ondansetron ( 8 mg ) and droperidol ( 1.25 mg ) proved to be equally effective when used as a postoperative antiemetic . Both drugs showed similar side-effects . Due to differences in methods it was difficult to compare our results to those obtained in other studies .

[ "Introduction", ".", "Ondansetron", "is", "more", "effective", "than", "a", "placebo", "in", "treating", "postoperative", "nausea", "and", "vomiting", "(", "PONV", ")", ",", "but", "it", "has", "not", "been", "proved", "to", "be", "superior", "to", "established", "antiemetics", "for", "prophylaxis", "or", "therapy", ".", "We", "compared", "ondansetron", "vs", "droperidol", "for", "the", "treatment", "of", "PONV", ".", "Methods", ".", "Our", "prospective", ",", "randomized", "double", "-", "blind", "study", "was", "performed", "between", "15", "October", "1992", "and", "July", "1993", ";", "it", "included", "271", "gynaecological", "ASA", "I", "-", "III", "inpatients", "who", "had", "been", "operated", "on", "under", "general", "anaesthesia", "with", "intubation", ".", "Patients", "were", "excluded", "if", ":", "there", "was", "no", "informed", "consent", ";", "it", "was", "an", "ambulatory", "or", "emergency", "operation", ";", "the", "patient", "was", "pregnant", "or", "breast", "feeding", ";", "allergies", "were", "being", "treated", "with", "antihistamines", ";", "drug", "addiction", "was", "present", "or", "convulsions", "or", "Parkinson", "'s", "disease", ";", "any", "pre-", "or", "intraoperative", "antiemetic", "medication", "had", "been", "administered", ".", "All", "patients", "wishing", "an", "antiemetic", "and", "/", "or", "suffering", "from", "at", "least", "one", "emetic", "episode", "during", "the", "first", "24", "h", "postoperatively", "received", "either", "8", "mg", "ondansetron", "or", "1.25", "mg", "droperidol", "from", "identical", "4", "ml", "ampoules", "intravenously", ".", "The", "verbal", "nausea", "score", "(", "1", "=", "none", ",", "2", "=", "mild", ",", "3", "=", "moderate", ",", "4", "=", "severe", ")", "was", "recorded", "every", "30", "min", "for", "4", "h", ",", "then", "before", "and", "2", "h", "after", "each", "antiemetic", "dose", ".", "All", "emetic", "episodes", "and", "the", "interval", "between", "administration", "and", "effect", "were", "also", "noted", ".", "Patients", "were", "interviewed", "36", "-", "48", "h", "postoperatively", "on", "subjective", "effects", ",", "side", "-", "effects", "and", "individual", "acceptance", ".", "After", "oral", "premedication", "with", "diazepam", ",", "anaesthesia", "was", "induced", "with", "thiopental", ",", "in", "a", "few", "cases", "with", "etomidate", "or", "propofol", ".", "Relaxation", "was", "achieved", "with", "pancuronium", "or", "atracurium", "and", ",", "when", "indicated", ",", "with", "succinylcholine", ".", "Muscular", "relaxation", "was", "antagonized", "with", "neostigmin", "and", "glycopyrrolate", ".", "Gastric", "content", "was", "aspirated", "once", "after", "intubation", ".", "Anaesthesia", "was", "maintained", "with", "nitrous", "oxide", "/", "oxygen", ",", "enflurane", ",", "halothane", "or", "isoflurane", "and", "fentanyl", "up", "to", "0.3", "mg", ".", "Statistical", "evaluation", "was", "performed", "by", "the", "unpaired", "Student", "'s", "t", "-", "test", "and", "the", "Mann", "-", "Whitney", "U", "test", ".", "Categoric", "variables", "were", "examined", "by", "the", "2", "test", ".", "Significance", "was", "defined", "as", "P", "0.05", ".", "Results", ".", "Of", "271", "patients", ",", "100", "(", "37", "%", ")", "experienced", "PONV", ".", "The", "groups", "were", "statistically", "comparable", "with", "respect", "to", "demographic", "data", ",", "type", "and", "duration", "of", "operation", ",", "emesis", "record", ",", "perioperative", "uterotonic", "medication", ".", "Twenty", "patients", "in", "the", "ondansetron", "group", "and", "27", "in", "the", "droperidol", "group", "received", "the", "first", "antiemetic", "within", "2", "h", ",", "the", "other", "patients", "up", "to", "17", "h", "after", "extubation", ".", "Nausea", "scores", "and", "emetic", "episodes", "were", "identical", "before", "antiemetic", "medication", ".", "The", "reduction", "of", "these", "parameters", "after", "medication", "was", "similar", ".", "Complete", "response", "over", "6", "h", "was", "60", "%", "in", "the", "ondansetron", "and", "68", "%", "in", "the", "droperidol", "group", ".", "In", "both", "groups", "the", "first", "medication", "failed", "in", "4", "cases", "during", "the", "initial", "2", "h", ".", "Twenty", "of", "the", "ondansetron", "and", "16", "of", "the", "droperidol", "patients", "needed", "a", "second", "dose", ";", "among", "these", "2", "and", "4", ",", "respectively", ",", "a", "third", "ampoule", ".", "No", "rescue", "medication", "was", "necessary", "over", "24", "h", "and", "a", "mean", "of", "1.4", "ampoules", "was", "administered", "in", "both", "groups", ".", "Onset", "and", "quality", "of", "emetic", "action", "were", "identical", "in", "both", "groups", ".", "It", "was", "not", "possible", "to", "evaluate", "25", "interviews", "due", "to", "linguistic", "or", "amnestic", "problems", ".", "Multiple", "side", "-", "effects", "were", "noted", "frequently", ".", "Injection", "pain", "was", "reported", "significantly", "more", "often", "in", "the", "droperidol", ",", "pruritus", "in", "the", "ondansetron", "group", ".", "Ninety", "-", "three", "percent", "of", "the", "ondansetron", "and", "85", "%", "of", "the", "droperidol", "patients", "opted", "for", "the", "same", "drug", "for", "future", "PONV", "treatment", ".", "Conclusions", ".", "Ondansetron", "(", "8", "mg", ")", "and", "droperidol", "(", "1.25", "mg", ")", "proved", "to", "be", "equally", "effective", "when", "used", "as", "a", "postoperative", "antiemetic", ".", "Both", "drugs", "showed", "similar", "side", "-", "effects", ".", "Due", "to", "differences", "in", "methods", "it", "was", "difficult", "to", "compare", "our", "results", "to", "those", "obtained", "in", "other", "studies", "." ]

[ "umlsterm" ]

Ondansetron is an umlsterm, placebo is an umlsterm, postoperative nausea is an umlsterm, vomiting is an umlsterm, PONV is an umlsterm, antiemetics is an umlsterm, prophylaxis is an umlsterm, therapy is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, treatment is an umlsterm, PONV is an umlsterm, Methods is an umlsterm, double - blind study is an umlsterm, October is an umlsterm, ASA is an umlsterm, inpatients is an umlsterm, general anaesthesia is an umlsterm, intubation is an umlsterm, Patients is an umlsterm, emergency is an umlsterm, operation is an umlsterm, patient is an umlsterm, breast feeding is an umlsterm, allergies is an umlsterm, antihistamines is an umlsterm, drug addiction is an umlsterm, convulsions is an umlsterm, disease is an umlsterm, antiemetic is an umlsterm, medication is an umlsterm, All is an umlsterm, patients is an umlsterm, antiemetic is an umlsterm, emetic is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, nausea is an umlsterm, antiemetic is an umlsterm, emetic is an umlsterm, administration is an umlsterm, Patients is an umlsterm, premedication is an umlsterm, diazepam is an umlsterm, thiopental is an umlsterm, etomidate is an umlsterm, propofol is an umlsterm, Relaxation is an umlsterm, pancuronium is an umlsterm, atracurium is an umlsterm, succinylcholine is an umlsterm, relaxation is an umlsterm, glycopyrrolate is an umlsterm, intubation is an umlsterm, enflurane is an umlsterm, halothane is an umlsterm, isoflurane is an umlsterm, fentanyl is an umlsterm, evaluation is an umlsterm, Student 's is an umlsterm, Mann - Whitney U test is an umlsterm, test is an umlsterm, patients is an umlsterm, PONV is an umlsterm, operation is an umlsterm, emesis is an umlsterm, record is an umlsterm, medication is an umlsterm, patients is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, antiemetic is an umlsterm, patients is an umlsterm, Nausea is an umlsterm, emetic is an umlsterm, antiemetic is an umlsterm, medication is an umlsterm, medication is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, medication is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, patients is an umlsterm, medication is an umlsterm, emetic is an umlsterm, interviews is an umlsterm, linguistic is an umlsterm, Injection is an umlsterm, pain is an umlsterm, droperidol is an umlsterm, pruritus is an umlsterm, ondansetron is an umlsterm, ondansetron is an umlsterm, droperidol is an umlsterm, patients is an umlsterm, drug is an umlsterm, future is an umlsterm, PONV is an umlsterm, treatment is an umlsterm, Ondansetron is an umlsterm, droperidol is an umlsterm, postoperative is an umlsterm, antiemetic is an umlsterm, drugs is an umlsterm, methods is an umlsterm

DerAnaesthesist.40430504.eng.abstr_task1

Sentence: Introduction . Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting ( PONV ) , but it has not been proved to be superior to established antiemetics for prophylaxis or therapy . We compared ondansetron vs droperidol for the treatment of PONV . Methods . Our prospective , randomized double-blind study was performed between 15 October 1992 and July 1993 ; it included 271 gynaecological ASA I - III inpatients who had been operated on under general anaesthesia with intubation . Patients were excluded if : there was no informed consent ; it was an ambulatory or emergency operation ; the patient was pregnant or breast feeding ; allergies were being treated with antihistamines ; drug addiction was present or convulsions or Parkinson's disease ; any pre- or intraoperative antiemetic medication had been administered . All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously . The verbal nausea score ( 1=none, 2=mild, 3=moderate, 4=severe) was recorded every 30 min for 4 h , then before and 2 h after each antiemetic dose . All emetic episodes and the interval between administration and effect were also noted . Patients were interviewed 36 - 48 h postoperatively on subjective effects , side-effects and individual acceptance . After oral premedication with diazepam , anaesthesia was induced with thiopental , in a few cases with etomidate or propofol . Relaxation was achieved with pancuronium or atracurium and , when indicated , with succinylcholine . Muscular relaxation was antagonized with neostigmin and glycopyrrolate . Gastric content was aspirated once after intubation . Anaesthesia was maintained with nitrous oxide/oxygen , enflurane , halothane or isoflurane and fentanyl up to 0.3 mg . Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test . Categoric variables were examined by the 2 test . Significance was defined as P 0.05. Results . Of 271 patients , 100 ( 37% ) experienced PONV . The groups were statistically comparable with respect to demographic data , type and duration of operation , emesis record , perioperative uterotonic medication . Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h , the other patients up to 17 h after extubation . Nausea scores and emetic episodes were identical before antiemetic medication . The reduction of these parameters after medication was similar . Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group . In both groups the first medication failed in 4 cases during the initial 2 h . Twenty of the ondansetron and 16 of the droperidol patients needed a second dose ; among these 2 and 4 , respectively , a third ampoule . No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups . Onset and quality of emetic action were identical in both groups . It was not possible to evaluate 25 interviews due to linguistic or amnestic problems . Multiple side-effects were noted frequently . Injection pain was reported significantly more often in the droperidol , pruritus in the ondansetron group . Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment . Conclusions . Ondansetron ( 8 mg ) and droperidol ( 1.25 mg ) proved to be equally effective when used as a postoperative antiemetic . Both drugs showed similar side-effects . Due to differences in methods it was difficult to compare our results to those obtained in other studies . Instructions: please typing these entity words according to sentence: Ondansetron, placebo, postoperative nausea, vomiting, PONV, antiemetics, prophylaxis, therapy, ondansetron, droperidol, treatment, PONV, Methods, double - blind study, October, ASA, inpatients, general anaesthesia, intubation, Patients, emergency, operation, patient, breast feeding, allergies, antihistamines, drug addiction, convulsions, disease, antiemetic, medication, All, patients, antiemetic, emetic, ondansetron, droperidol, nausea, antiemetic, emetic, administration, Patients, premedication, diazepam, thiopental, etomidate, propofol, Relaxation, pancuronium, atracurium, succinylcholine, relaxation, glycopyrrolate, intubation, enflurane, halothane, isoflurane, fentanyl, evaluation, Student 's, Mann - Whitney U test, test, patients, PONV, operation, emesis, record, medication, patients, ondansetron, droperidol, antiemetic, patients, Nausea, emetic, antiemetic, medication, medication, ondansetron, droperidol, medication, ondansetron, droperidol, patients, medication, emetic, interviews, linguistic, Injection, pain, droperidol, pruritus, ondansetron, ondansetron, droperidol, patients, drug, future, PONV, treatment, Ondansetron, droperidol, postoperative, antiemetic, drugs, methods Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Introduction . Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting ( PONV ) , but it has not been proved to be superior to established antiemetics for prophylaxis or therapy . We compared ondansetron vs droperidol for the treatment of PONV . Methods . Our prospective , randomized double-blind study was performed between 15 October 1992 and July 1993 ; it included 271 gynaecological ASA I - III inpatients who had been operated on under general anaesthesia with intubation . Patients were excluded if : there was no informed consent ; it was an ambulatory or emergency operation ; the patient was pregnant or breast feeding ; allergies were being treated with antihistamines ; drug addiction was present or convulsions or Parkinson's disease ; any pre- or intraoperative antiemetic medication had been administered . All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously . The verbal nausea score ( 1=none, 2=mild, 3=moderate, 4=severe) was recorded every 30 min for 4 h , then before and 2 h after each antiemetic dose . All emetic episodes and the interval between administration and effect were also noted . Patients were interviewed 36 - 48 h postoperatively on subjective effects , side-effects and individual acceptance . After oral premedication with diazepam , anaesthesia was induced with thiopental , in a few cases with etomidate or propofol . Relaxation was achieved with pancuronium or atracurium and , when indicated , with succinylcholine . Muscular relaxation was antagonized with neostigmin and glycopyrrolate . Gastric content was aspirated once after intubation . Anaesthesia was maintained with nitrous oxide/oxygen , enflurane , halothane or isoflurane and fentanyl up to 0.3 mg . Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test . Categoric variables were examined by the 2 test . Significance was defined as P 0.05. Results . Of 271 patients , 100 ( 37% ) experienced PONV . The groups were statistically comparable with respect to demographic data , type and duration of operation , emesis record , perioperative uterotonic medication . Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h , the other patients up to 17 h after extubation . Nausea scores and emetic episodes were identical before antiemetic medication . The reduction of these parameters after medication was similar . Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group . In both groups the first medication failed in 4 cases during the initial 2 h . Twenty of the ondansetron and 16 of the droperidol patients needed a second dose ; among these 2 and 4 , respectively , a third ampoule . No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups . Onset and quality of emetic action were identical in both groups . It was not possible to evaluate 25 interviews due to linguistic or amnestic problems . Multiple side-effects were noted frequently . Injection pain was reported significantly more often in the droperidol , pruritus in the ondansetron group . Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment . Conclusions . Ondansetron ( 8 mg ) and droperidol ( 1.25 mg ) proved to be equally effective when used as a postoperative antiemetic . Both drugs showed similar side-effects . Due to differences in methods it was difficult to compare our results to those obtained in other studies .

[ "Introduction", ".", "Ondansetron", "is", "more", "effective", "than", "a", "placebo", "in", "treating", "postoperative", "nausea", "and", "vomiting", "(", "PONV", ")", ",", "but", "it", "has", "not", "been", "proved", "to", "be", "superior", "to", "established", "antiemetics", "for", "prophylaxis", "or", "therapy", ".", "We", "compared", "ondansetron", "vs", "droperidol", "for", "the", "treatment", "of", "PONV", ".", "Methods", ".", "Our", "prospective", ",", "randomized", "double", "-", "blind", "study", "was", "performed", "between", "15", "October", "1992", "and", "July", "1993", ";", "it", "included", "271", "gynaecological", "ASA", "I", "-", "III", "inpatients", "who", "had", "been", "operated", "on", "under", "general", "anaesthesia", "with", "intubation", ".", "Patients", "were", "excluded", "if", ":", "there", "was", "no", "informed", "consent", ";", "it", "was", "an", "ambulatory", "or", "emergency", "operation", ";", "the", "patient", "was", "pregnant", "or", "breast", "feeding", ";", "allergies", "were", "being", "treated", "with", "antihistamines", ";", "drug", "addiction", "was", "present", "or", "convulsions", "or", "Parkinson", "'s", "disease", ";", "any", "pre-", "or", "intraoperative", "antiemetic", "medication", "had", "been", "administered", ".", "All", "patients", "wishing", "an", "antiemetic", "and", "/", "or", "suffering", "from", "at", "least", "one", "emetic", "episode", "during", "the", "first", "24", "h", "postoperatively", "received", "either", "8", "mg", "ondansetron", "or", "1.25", "mg", "droperidol", "from", "identical", "4", "ml", "ampoules", "intravenously", ".", "The", "verbal", "nausea", "score", "(", "1", "=", "none", ",", "2", "=", "mild", ",", "3", "=", "moderate", ",", "4", "=", "severe", ")", "was", "recorded", "every", "30", "min", "for", "4", "h", ",", "then", "before", "and", "2", "h", "after", "each", "antiemetic", "dose", ".", "All", "emetic", "episodes", "and", "the", "interval", "between", "administration", "and", "effect", "were", "also", "noted", ".", "Patients", "were", "interviewed", "36", "-", "48", "h", "postoperatively", "on", "subjective", "effects", ",", "side", "-", "effects", "and", "individual", "acceptance", ".", "After", "oral", "premedication", "with", "diazepam", ",", "anaesthesia", "was", "induced", "with", "thiopental", ",", "in", "a", "few", "cases", "with", "etomidate", "or", "propofol", ".", "Relaxation", "was", "achieved", "with", "pancuronium", "or", "atracurium", "and", ",", "when", "indicated", ",", "with", "succinylcholine", ".", "Muscular", "relaxation", "was", "antagonized", "with", "neostigmin", "and", "glycopyrrolate", ".", "Gastric", "content", "was", "aspirated", "once", "after", "intubation", ".", "Anaesthesia", "was", "maintained", "with", "nitrous", "oxide", "/", "oxygen", ",", "enflurane", ",", "halothane", "or", "isoflurane", "and", "fentanyl", "up", "to", "0.3", "mg", ".", "Statistical", "evaluation", "was", "performed", "by", "the", "unpaired", "Student", "'s", "t", "-", "test", "and", "the", "Mann", "-", "Whitney", "U", "test", ".", "Categoric", "variables", "were", "examined", "by", "the", "2", "test", ".", "Significance", "was", "defined", "as", "P", "0.05", ".", "Results", ".", "Of", "271", "patients", ",", "100", "(", "37", "%", ")", "experienced", "PONV", ".", "The", "groups", "were", "statistically", "comparable", "with", "respect", "to", "demographic", "data", ",", "type", "and", "duration", "of", "operation", ",", "emesis", "record", ",", "perioperative", "uterotonic", "medication", ".", "Twenty", "patients", "in", "the", "ondansetron", "group", "and", "27", "in", "the", "droperidol", "group", "received", "the", "first", "antiemetic", "within", "2", "h", ",", "the", "other", "patients", "up", "to", "17", "h", "after", "extubation", ".", "Nausea", "scores", "and", "emetic", "episodes", "were", "identical", "before", "antiemetic", "medication", ".", "The", "reduction", "of", "these", "parameters", "after", "medication", "was", "similar", ".", "Complete", "response", "over", "6", "h", "was", "60", "%", "in", "the", "ondansetron", "and", "68", "%", "in", "the", "droperidol", "group", ".", "In", "both", "groups", "the", "first", "medication", "failed", "in", "4", "cases", "during", "the", "initial", "2", "h", ".", "Twenty", "of", "the", "ondansetron", "and", "16", "of", "the", "droperidol", "patients", "needed", "a", "second", "dose", ";", "among", "these", "2", "and", "4", ",", "respectively", ",", "a", "third", "ampoule", ".", "No", "rescue", "medication", "was", "necessary", "over", "24", "h", "and", "a", "mean", "of", "1.4", "ampoules", "was", "administered", "in", "both", "groups", ".", "Onset", "and", "quality", "of", "emetic", "action", "were", "identical", "in", "both", "groups", ".", "It", "was", "not", "possible", "to", "evaluate", "25", "interviews", "due", "to", "linguistic", "or", "amnestic", "problems", ".", "Multiple", "side", "-", "effects", "were", "noted", "frequently", ".", "Injection", "pain", "was", "reported", "significantly", "more", "often", "in", "the", "droperidol", ",", "pruritus", "in", "the", "ondansetron", "group", ".", "Ninety", "-", "three", "percent", "of", "the", "ondansetron", "and", "85", "%", "of", "the", "droperidol", "patients", "opted", "for", "the", "same", "drug", "for", "future", "PONV", "treatment", ".", "Conclusions", ".", "Ondansetron", "(", "8", "mg", ")", "and", "droperidol", "(", "1.25", "mg", ")", "proved", "to", "be", "equally", "effective", "when", "used", "as", "a", "postoperative", "antiemetic", ".", "Both", "drugs", "showed", "similar", "side", "-", "effects", ".", "Due", "to", "differences", "in", "methods", "it", "was", "difficult", "to", "compare", "our", "results", "to", "those", "obtained", "in", "other", "studies", "." ]

[ "umlsterm" ]

Ondansetron, placebo, postoperative nausea, vomiting, PONV, antiemetics, prophylaxis, therapy, ondansetron, droperidol, treatment, PONV, Methods, double - blind study, October, ASA, inpatients, general anaesthesia, intubation, Patients, emergency, operation, patient, breast feeding, allergies, antihistamines, drug addiction, convulsions, disease, antiemetic, medication, All, patients, antiemetic, emetic, ondansetron, droperidol, nausea, antiemetic, emetic, administration, Patients, premedication, diazepam, thiopental, etomidate, propofol, Relaxation, pancuronium, atracurium, succinylcholine, relaxation, glycopyrrolate, intubation, enflurane, halothane, isoflurane, fentanyl, evaluation, Student 's, Mann - Whitney U test, test, patients, PONV, operation, emesis, record, medication, patients, ondansetron, droperidol, antiemetic, patients, Nausea, emetic, antiemetic, medication, medication, ondansetron, droperidol, medication, ondansetron, droperidol, patients, medication, emetic, interviews, linguistic, Injection, pain, droperidol, pruritus, ondansetron, ondansetron, droperidol, patients, drug, future, PONV, treatment, Ondansetron, droperidol, postoperative, antiemetic, drugs, methods

DerAnaesthesist.40430504.eng.abstr_task2

Sentence: Introduction . Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting ( PONV ) , but it has not been proved to be superior to established antiemetics for prophylaxis or therapy . We compared ondansetron vs droperidol for the treatment of PONV . Methods . Our prospective , randomized double-blind study was performed between 15 October 1992 and July 1993 ; it included 271 gynaecological ASA I - III inpatients who had been operated on under general anaesthesia with intubation . Patients were excluded if : there was no informed consent ; it was an ambulatory or emergency operation ; the patient was pregnant or breast feeding ; allergies were being treated with antihistamines ; drug addiction was present or convulsions or Parkinson's disease ; any pre- or intraoperative antiemetic medication had been administered . All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously . The verbal nausea score ( 1=none, 2=mild, 3=moderate, 4=severe) was recorded every 30 min for 4 h , then before and 2 h after each antiemetic dose . All emetic episodes and the interval between administration and effect were also noted . Patients were interviewed 36 - 48 h postoperatively on subjective effects , side-effects and individual acceptance . After oral premedication with diazepam , anaesthesia was induced with thiopental , in a few cases with etomidate or propofol . Relaxation was achieved with pancuronium or atracurium and , when indicated , with succinylcholine . Muscular relaxation was antagonized with neostigmin and glycopyrrolate . Gastric content was aspirated once after intubation . Anaesthesia was maintained with nitrous oxide/oxygen , enflurane , halothane or isoflurane and fentanyl up to 0.3 mg . Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test . Categoric variables were examined by the 2 test . Significance was defined as P 0.05. Results . Of 271 patients , 100 ( 37% ) experienced PONV . The groups were statistically comparable with respect to demographic data , type and duration of operation , emesis record , perioperative uterotonic medication . Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h , the other patients up to 17 h after extubation . Nausea scores and emetic episodes were identical before antiemetic medication . The reduction of these parameters after medication was similar . Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group . In both groups the first medication failed in 4 cases during the initial 2 h . Twenty of the ondansetron and 16 of the droperidol patients needed a second dose ; among these 2 and 4 , respectively , a third ampoule . No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups . Onset and quality of emetic action were identical in both groups . It was not possible to evaluate 25 interviews due to linguistic or amnestic problems . Multiple side-effects were noted frequently . Injection pain was reported significantly more often in the droperidol , pruritus in the ondansetron group . Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment . Conclusions . Ondansetron ( 8 mg ) and droperidol ( 1.25 mg ) proved to be equally effective when used as a postoperative antiemetic . Both drugs showed similar side-effects . Due to differences in methods it was difficult to compare our results to those obtained in other studies . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Introduction . Ondansetron is more effective than a placebo in treating postoperative nausea and vomiting ( PONV ) , but it has not been proved to be superior to established antiemetics for prophylaxis or therapy . We compared ondansetron vs droperidol for the treatment of PONV . Methods . Our prospective , randomized double-blind study was performed between 15 October 1992 and July 1993 ; it included 271 gynaecological ASA I - III inpatients who had been operated on under general anaesthesia with intubation . Patients were excluded if : there was no informed consent ; it was an ambulatory or emergency operation ; the patient was pregnant or breast feeding ; allergies were being treated with antihistamines ; drug addiction was present or convulsions or Parkinson's disease ; any pre- or intraoperative antiemetic medication had been administered . All patients wishing an antiemetic and/or suffering from at least one emetic episode during the first 24 h postoperatively received either 8 mg ondansetron or 1.25 mg droperidol from identical 4 ml ampoules intravenously . The verbal nausea score ( 1=none, 2=mild, 3=moderate, 4=severe) was recorded every 30 min for 4 h , then before and 2 h after each antiemetic dose . All emetic episodes and the interval between administration and effect were also noted . Patients were interviewed 36 - 48 h postoperatively on subjective effects , side-effects and individual acceptance . After oral premedication with diazepam , anaesthesia was induced with thiopental , in a few cases with etomidate or propofol . Relaxation was achieved with pancuronium or atracurium and , when indicated , with succinylcholine . Muscular relaxation was antagonized with neostigmin and glycopyrrolate . Gastric content was aspirated once after intubation . Anaesthesia was maintained with nitrous oxide/oxygen , enflurane , halothane or isoflurane and fentanyl up to 0.3 mg . Statistical evaluation was performed by the unpaired Student's t-test and the Mann-Whitney U test . Categoric variables were examined by the 2 test . Significance was defined as P 0.05. Results . Of 271 patients , 100 ( 37% ) experienced PONV . The groups were statistically comparable with respect to demographic data , type and duration of operation , emesis record , perioperative uterotonic medication . Twenty patients in the ondansetron group and 27 in the droperidol group received the first antiemetic within 2 h , the other patients up to 17 h after extubation . Nausea scores and emetic episodes were identical before antiemetic medication . The reduction of these parameters after medication was similar . Complete response over 6 h was 60% in the ondansetron and 68% in the droperidol group . In both groups the first medication failed in 4 cases during the initial 2 h . Twenty of the ondansetron and 16 of the droperidol patients needed a second dose ; among these 2 and 4 , respectively , a third ampoule . No rescue medication was necessary over 24 h and a mean of 1.4 ampoules was administered in both groups . Onset and quality of emetic action were identical in both groups . It was not possible to evaluate 25 interviews due to linguistic or amnestic problems . Multiple side-effects were noted frequently . Injection pain was reported significantly more often in the droperidol , pruritus in the ondansetron group . Ninety-three percent of the ondansetron and 85% of the droperidol patients opted for the same drug for future PONV treatment . Conclusions . Ondansetron ( 8 mg ) and droperidol ( 1.25 mg ) proved to be equally effective when used as a postoperative antiemetic . Both drugs showed similar side-effects . Due to differences in methods it was difficult to compare our results to those obtained in other studies .

[ "Introduction", ".", "Ondansetron", "is", "more", "effective", "than", "a", "placebo", "in", "treating", "postoperative", "nausea", "and", "vomiting", "(", "PONV", ")", ",", "but", "it", "has", "not", "been", "proved", "to", "be", "superior", "to", "established", "antiemetics", "for", "prophylaxis", "or", "therapy", ".", "We", "compared", "ondansetron", "vs", "droperidol", "for", "the", "treatment", "of", "PONV", ".", "Methods", ".", "Our", "prospective", ",", "randomized", "double", "-", "blind", "study", "was", "performed", "between", "15", "October", "1992", "and", "July", "1993", ";", "it", "included", "271", "gynaecological", "ASA", "I", "-", "III", "inpatients", "who", "had", "been", "operated", "on", "under", "general", "anaesthesia", "with", "intubation", ".", "Patients", "were", "excluded", "if", ":", "there", "was", "no", "informed", "consent", ";", "it", "was", "an", "ambulatory", "or", "emergency", "operation", ";", "the", "patient", "was", "pregnant", "or", "breast", "feeding", ";", "allergies", "were", "being", "treated", "with", "antihistamines", ";", "drug", "addiction", "was", "present", "or", "convulsions", "or", "Parkinson", "'s", "disease", ";", "any", "pre-", "or", "intraoperative", "antiemetic", "medication", "had", "been", "administered", ".", "All", "patients", "wishing", "an", "antiemetic", "and", "/", "or", "suffering", "from", "at", "least", "one", "emetic", "episode", "during", "the", "first", "24", "h", "postoperatively", "received", "either", "8", "mg", "ondansetron", "or", "1.25", "mg", "droperidol", "from", "identical", "4", "ml", "ampoules", "intravenously", ".", "The", "verbal", "nausea", "score", "(", "1", "=", "none", ",", "2", "=", "mild", ",", "3", "=", "moderate", ",", "4", "=", "severe", ")", "was", "recorded", "every", "30", "min", "for", "4", "h", ",", "then", "before", "and", "2", "h", "after", "each", "antiemetic", "dose", ".", "All", "emetic", "episodes", "and", "the", "interval", "between", "administration", "and", "effect", "were", "also", "noted", ".", "Patients", "were", "interviewed", "36", "-", "48", "h", "postoperatively", "on", "subjective", "effects", ",", "side", "-", "effects", "and", "individual", "acceptance", ".", "After", "oral", "premedication", "with", "diazepam", ",", "anaesthesia", "was", "induced", "with", "thiopental", ",", "in", "a", "few", "cases", "with", "etomidate", "or", "propofol", ".", "Relaxation", "was", "achieved", "with", "pancuronium", "or", "atracurium", "and", ",", "when", "indicated", ",", "with", "succinylcholine", ".", "Muscular", "relaxation", "was", "antagonized", "with", "neostigmin", "and", "glycopyrrolate", ".", "Gastric", "content", "was", "aspirated", "once", "after", "intubation", ".", "Anaesthesia", "was", "maintained", "with", "nitrous", "oxide", "/", "oxygen", ",", "enflurane", ",", "halothane", "or", "isoflurane", "and", "fentanyl", "up", "to", "0.3", "mg", ".", "Statistical", "evaluation", "was", "performed", "by", "the", "unpaired", "Student", "'s", "t", "-", "test", "and", "the", "Mann", "-", "Whitney", "U", "test", ".", "Categoric", "variables", "were", "examined", "by", "the", "2", "test", ".", "Significance", "was", "defined", "as", "P", "0.05", ".", "Results", ".", "Of", "271", "patients", ",", "100", "(", "37", "%", ")", "experienced", "PONV", ".", "The", "groups", "were", "statistically", "comparable", "with", "respect", "to", "demographic", "data", ",", "type", "and", "duration", "of", "operation", ",", "emesis", "record", ",", "perioperative", "uterotonic", "medication", ".", "Twenty", "patients", "in", "the", "ondansetron", "group", "and", "27", "in", "the", "droperidol", "group", "received", "the", "first", "antiemetic", "within", "2", "h", ",", "the", "other", "patients", "up", "to", "17", "h", "after", "extubation", ".", "Nausea", "scores", "and", "emetic", "episodes", "were", "identical", "before", "antiemetic", "medication", ".", "The", "reduction", "of", "these", "parameters", "after", "medication", "was", "similar", ".", "Complete", "response", "over", "6", "h", "was", "60", "%", "in", "the", "ondansetron", "and", "68", "%", "in", "the", "droperidol", "group", ".", "In", "both", "groups", "the", "first", "medication", "failed", "in", "4", "cases", "during", "the", "initial", "2", "h", ".", "Twenty", "of", "the", "ondansetron", "and", "16", "of", "the", "droperidol", "patients", "needed", "a", "second", "dose", ";", "among", "these", "2", "and", "4", ",", "respectively", ",", "a", "third", "ampoule", ".", "No", "rescue", "medication", "was", "necessary", "over", "24", "h", "and", "a", "mean", "of", "1.4", "ampoules", "was", "administered", "in", "both", "groups", ".", "Onset", "and", "quality", "of", "emetic", "action", "were", "identical", "in", "both", "groups", ".", "It", "was", "not", "possible", "to", "evaluate", "25", "interviews", "due", "to", "linguistic", "or", "amnestic", "problems", ".", "Multiple", "side", "-", "effects", "were", "noted", "frequently", ".", "Injection", "pain", "was", "reported", "significantly", "more", "often", "in", "the", "droperidol", ",", "pruritus", "in", "the", "ondansetron", "group", ".", "Ninety", "-", "three", "percent", "of", "the", "ondansetron", "and", "85", "%", "of", "the", "droperidol", "patients", "opted", "for", "the", "same", "drug", "for", "future", "PONV", "treatment", ".", "Conclusions", ".", "Ondansetron", "(", "8", "mg", ")", "and", "droperidol", "(", "1.25", "mg", ")", "proved", "to", "be", "equally", "effective", "when", "used", "as", "a", "postoperative", "antiemetic", ".", "Both", "drugs", "showed", "similar", "side", "-", "effects", ".", "Due", "to", "differences", "in", "methods", "it", "was", "difficult", "to", "compare", "our", "results", "to", "those", "obtained", "in", "other", "studies", "." ]

[ "umlsterm" ]

Isoniazid is a DRUG, isoniazid is a DRUG, Acetaminophen is a DRUG, acetaminophen is a DRUG, Isoniazid is a DRUG, isoniazid is a DRUG, acetaminophen is a DRUG, isoniazid is a DRUG, isoniazid is a DRUG, acetaminophen is a DRUG, isoniazid is a DRUG, Carbamazepine is a DRUG, Isoniazid is a DRUG, carbamazepine is a DRUG, Carbamazepine is a DRUG, isoniazid is a DRUG, carbamazepine is a DRUG, anticonvulsant is a GROUP, Ketoconazole is a DRUG, Ketoconazole is a DRUG, Isoniazid is a DRUG, Phenytoin is a DRUG, Isoniazid is a DRUG, phenytoin is a DRUG, phenytoin is a DRUG, anticonvulsant is a GROUP, isoniazid is a DRUG, theophylline is a DRUG, theophylline is a DRUG, isoniazid is a DRUG, theophylline is a DRUG, theophylline is a DRUG, theophylline is a DRUG, Valproate is a DRUG, valproate is a DRUG, isoniazid is a DRUG, valproate is a DRUG, isoniazid is a DRUG, valproate is a DRUG, valproate is a DRUG

Isoniazid_ddi_task0

Sentence: Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food. Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats. Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made. Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist. Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made. Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made. Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG

[ "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O" ]

Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food. Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats. Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made. Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist. Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made. Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made. Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.

[ "Food", ":", "Isoniazid", "should", "not", "be", "administered", "with", "food", ".", "Studies", "have", "shown", "that", "the", "bioavailability", "of", "isoniazid", "is", "reduced", "significantly", "when", "administered", "with", "food", ".", "Acetaminophen", ":", "A", "report", "of", "severe", "acetaminophen", "toxicity", "was", "reported", "in", "a", "patient", "receiving", "Isoniazid", ".", "It", "is", "believed", "that", "the", "toxicity", "may", "have", "resulted", "from", "a", "previously", "unrecognized", "interaction", "between", "isoniazid", "and", "acetaminophen", "and", "a", "molecular", "basis", "for", "this", "interaction", "has", "been", "proposed", ".", "However", ",", "current", "evidence", "suggests", "that", "isoniazid", "does", "induce", "P-450IIE1", ",", "a", "mixed", "-", "function", "oxidase", "enzyme", "that", "appears", "to", "generate", "the", "toxic", "metabolites", ",", "in", "the", "liver", ".", "Furthermore", "it", "has", "been", "proposed", "that", "isoniazid", "resulted", "In", "induction", "of", "P-450IIE1", "in", "the", "patients", "liver", "which", ",", "in", "turn", ",", "resulted", "in", "a", "greater", "proportion", "of", "the", "ingested", "acetaminophen", "being", "converted", "to", "the", "toxic", "metabolites", ".", "Studies", "have", "demonstrated", "that", "pretreatment", "with", "isoniazid", "potentiates", "a", "cetaminophen", "hepatoxicity", "in", "rats", ".", "Carbamazepine", ":", "Isoniazid", "is", "known", "to", "slow", "the", "metabolism", "of", "carbamazepine", "and", "increase", "its", "serum", "levels", "Carbamazepine", "levels", "should", "be", "determined", "prior", "to", "concurrent", "administration", "with", "isoniazid", ",", "signs", "and", "symptoms", "of", "carbamazepine", "toxicity", "should", "be", "monitored", "closely", ",", "and", "appropriate", "dosage", "adjustment", "of", "the", "anticonvulsant", "should", "be", "made", ".", "Ketoconazole", ":", "Potential", "interaction", "of", "Ketoconazole", "and", "Isoniazid", "may", "exist", ".", "Phenytoin", ":", "Isoniazid", "may", "increase", "serum", "levels", "of", "phenytoin", ".", "To", "avoid", "phenytoin", "intoxication", ",", "appropriate", "adjustment", "of", "the", "anticonvulsant", "should", "be", "made", ".", "Therophylline", ":", "A", "recent", "study", "has", "shown", "that", "concomitan", "administration", "of", "isoniazid", "and", "theophylline", "may", "cause", "elevated", "plasma", "levels", "of", "theophylline", ",", "and", "in", "some", "instances", "a", "slight", "decrease", "in", "the", "elimination", "of", "isoniazid", ".", "Since", "the", "therapeutic", "range", "of", "theophylline", "is", "narrow", "theophylline", "serum", "levels", "should", "be", "monitored", "closely", ",", "and", "appropriate", "dosage", "adjustments", "of", "theophylline", "should", "be", "made", ".", "Valproate", ":", "A", "recent", "case", "study", "has", "shown", "a", "possible", "increase", "in", "the", "plasma", "level", "of", "valproate", "when", "co", "administered", "with", "isoniazid", ".", "Plasma", "valproate", "concentration", "should", "be", "monitored", "when", "isoniazid", "and", "valproate", "are", "co", "administered", ",", "and", "appropriate", "dosage", "adjustments", "of", "valproate", "should", "be", "made", "." ]

[ "GROUP", "DRUG" ]

Isoniazid is a DRUG, isoniazid is a DRUG, Acetaminophen is a DRUG, acetaminophen is a DRUG, Isoniazid is a DRUG, isoniazid is a DRUG, acetaminophen is a DRUG, isoniazid is a DRUG, isoniazid is a DRUG, acetaminophen is a DRUG, isoniazid is a DRUG, Carbamazepine is a DRUG, Isoniazid is a DRUG, carbamazepine is a DRUG, Carbamazepine is a DRUG, isoniazid is a DRUG, carbamazepine is a DRUG, anticonvulsant is a GROUP, Ketoconazole is a DRUG, Ketoconazole is a DRUG, Isoniazid is a DRUG, Phenytoin is a DRUG, Isoniazid is a DRUG, phenytoin is a DRUG, phenytoin is a DRUG, anticonvulsant is a GROUP, isoniazid is a DRUG, theophylline is a DRUG, theophylline is a DRUG, isoniazid is a DRUG, theophylline is a DRUG, theophylline is a DRUG, theophylline is a DRUG, Valproate is a DRUG, valproate is a DRUG, isoniazid is a DRUG, valproate is a DRUG, isoniazid is a DRUG, valproate is a DRUG, valproate is a DRUG

Isoniazid_ddi_task1

Sentence: Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food. Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats. Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made. Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist. Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made. Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made. Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made. Instructions: please typing these entity words according to sentence: Isoniazid, isoniazid, Acetaminophen, acetaminophen, Isoniazid, isoniazid, acetaminophen, isoniazid, isoniazid, acetaminophen, isoniazid, Carbamazepine, Isoniazid, carbamazepine, Carbamazepine, isoniazid, carbamazepine, anticonvulsant, Ketoconazole, Ketoconazole, Isoniazid, Phenytoin, Isoniazid, phenytoin, phenytoin, anticonvulsant, isoniazid, theophylline, theophylline, isoniazid, theophylline, theophylline, theophylline, Valproate, valproate, isoniazid, valproate, isoniazid, valproate, valproate Options: GROUP, DRUG

[ "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O" ]

Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food. Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats. Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made. Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist. Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made. Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made. Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.

[ "Food", ":", "Isoniazid", "should", "not", "be", "administered", "with", "food", ".", "Studies", "have", "shown", "that", "the", "bioavailability", "of", "isoniazid", "is", "reduced", "significantly", "when", "administered", "with", "food", ".", "Acetaminophen", ":", "A", "report", "of", "severe", "acetaminophen", "toxicity", "was", "reported", "in", "a", "patient", "receiving", "Isoniazid", ".", "It", "is", "believed", "that", "the", "toxicity", "may", "have", "resulted", "from", "a", "previously", "unrecognized", "interaction", "between", "isoniazid", "and", "acetaminophen", "and", "a", "molecular", "basis", "for", "this", "interaction", "has", "been", "proposed", ".", "However", ",", "current", "evidence", "suggests", "that", "isoniazid", "does", "induce", "P-450IIE1", ",", "a", "mixed", "-", "function", "oxidase", "enzyme", "that", "appears", "to", "generate", "the", "toxic", "metabolites", ",", "in", "the", "liver", ".", "Furthermore", "it", "has", "been", "proposed", "that", "isoniazid", "resulted", "In", "induction", "of", "P-450IIE1", "in", "the", "patients", "liver", "which", ",", "in", "turn", ",", "resulted", "in", "a", "greater", "proportion", "of", "the", "ingested", "acetaminophen", "being", "converted", "to", "the", "toxic", "metabolites", ".", "Studies", "have", "demonstrated", "that", "pretreatment", "with", "isoniazid", "potentiates", "a", "cetaminophen", "hepatoxicity", "in", "rats", ".", "Carbamazepine", ":", "Isoniazid", "is", "known", "to", "slow", "the", "metabolism", "of", "carbamazepine", "and", "increase", "its", "serum", "levels", "Carbamazepine", "levels", "should", "be", "determined", "prior", "to", "concurrent", "administration", "with", "isoniazid", ",", "signs", "and", "symptoms", "of", "carbamazepine", "toxicity", "should", "be", "monitored", "closely", ",", "and", "appropriate", "dosage", "adjustment", "of", "the", "anticonvulsant", "should", "be", "made", ".", "Ketoconazole", ":", "Potential", "interaction", "of", "Ketoconazole", "and", "Isoniazid", "may", "exist", ".", "Phenytoin", ":", "Isoniazid", "may", "increase", "serum", "levels", "of", "phenytoin", ".", "To", "avoid", "phenytoin", "intoxication", ",", "appropriate", "adjustment", "of", "the", "anticonvulsant", "should", "be", "made", ".", "Therophylline", ":", "A", "recent", "study", "has", "shown", "that", "concomitan", "administration", "of", "isoniazid", "and", "theophylline", "may", "cause", "elevated", "plasma", "levels", "of", "theophylline", ",", "and", "in", "some", "instances", "a", "slight", "decrease", "in", "the", "elimination", "of", "isoniazid", ".", "Since", "the", "therapeutic", "range", "of", "theophylline", "is", "narrow", "theophylline", "serum", "levels", "should", "be", "monitored", "closely", ",", "and", "appropriate", "dosage", "adjustments", "of", "theophylline", "should", "be", "made", ".", "Valproate", ":", "A", "recent", "case", "study", "has", "shown", "a", "possible", "increase", "in", "the", "plasma", "level", "of", "valproate", "when", "co", "administered", "with", "isoniazid", ".", "Plasma", "valproate", "concentration", "should", "be", "monitored", "when", "isoniazid", "and", "valproate", "are", "co", "administered", ",", "and", "appropriate", "dosage", "adjustments", "of", "valproate", "should", "be", "made", "." ]

[ "GROUP", "DRUG" ]

Isoniazid, isoniazid, Acetaminophen, acetaminophen, Isoniazid, isoniazid, acetaminophen, isoniazid, isoniazid, acetaminophen, isoniazid, Carbamazepine, Isoniazid, carbamazepine, Carbamazepine, isoniazid, carbamazepine, anticonvulsant, Ketoconazole, Ketoconazole, Isoniazid, Phenytoin, Isoniazid, phenytoin, phenytoin, anticonvulsant, isoniazid, theophylline, theophylline, isoniazid, theophylline, theophylline, theophylline, Valproate, valproate, isoniazid, valproate, isoniazid, valproate, valproate

Isoniazid_ddi_task2

Sentence: Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food. Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats. Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made. Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist. Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made. Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made. Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O" ]

Food: Isoniazid should not be administered with food. Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food. Acetaminophen: A report of severe acetaminophen toxicity was reported in a patient receiving Isoniazid. It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed. However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver. Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites. Studies have demonstrated that pretreatment with isoniazid potentiates a cetaminophen hepatoxicity in rats. Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made. Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist. Phenytoin: Isoniazid may increase serum levels of phenytoin. To avoid phenytoin intoxication, appropriate adjustment of the anticonvulsant should be made. Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. Since the therapeutic range of theophylline is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made. Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid. Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.

[ "Food", ":", "Isoniazid", "should", "not", "be", "administered", "with", "food", ".", "Studies", "have", "shown", "that", "the", "bioavailability", "of", "isoniazid", "is", "reduced", "significantly", "when", "administered", "with", "food", ".", "Acetaminophen", ":", "A", "report", "of", "severe", "acetaminophen", "toxicity", "was", "reported", "in", "a", "patient", "receiving", "Isoniazid", ".", "It", "is", "believed", "that", "the", "toxicity", "may", "have", "resulted", "from", "a", "previously", "unrecognized", "interaction", "between", "isoniazid", "and", "acetaminophen", "and", "a", "molecular", "basis", "for", "this", "interaction", "has", "been", "proposed", ".", "However", ",", "current", "evidence", "suggests", "that", "isoniazid", "does", "induce", "P-450IIE1", ",", "a", "mixed", "-", "function", "oxidase", "enzyme", "that", "appears", "to", "generate", "the", "toxic", "metabolites", ",", "in", "the", "liver", ".", "Furthermore", "it", "has", "been", "proposed", "that", "isoniazid", "resulted", "In", "induction", "of", "P-450IIE1", "in", "the", "patients", "liver", "which", ",", "in", "turn", ",", "resulted", "in", "a", "greater", "proportion", "of", "the", "ingested", "acetaminophen", "being", "converted", "to", "the", "toxic", "metabolites", ".", "Studies", "have", "demonstrated", "that", "pretreatment", "with", "isoniazid", "potentiates", "a", "cetaminophen", "hepatoxicity", "in", "rats", ".", "Carbamazepine", ":", "Isoniazid", "is", "known", "to", "slow", "the", "metabolism", "of", "carbamazepine", "and", "increase", "its", "serum", "levels", "Carbamazepine", "levels", "should", "be", "determined", "prior", "to", "concurrent", "administration", "with", "isoniazid", ",", "signs", "and", "symptoms", "of", "carbamazepine", "toxicity", "should", "be", "monitored", "closely", ",", "and", "appropriate", "dosage", "adjustment", "of", "the", "anticonvulsant", "should", "be", "made", ".", "Ketoconazole", ":", "Potential", "interaction", "of", "Ketoconazole", "and", "Isoniazid", "may", "exist", ".", "Phenytoin", ":", "Isoniazid", "may", "increase", "serum", "levels", "of", "phenytoin", ".", "To", "avoid", "phenytoin", "intoxication", ",", "appropriate", "adjustment", "of", "the", "anticonvulsant", "should", "be", "made", ".", "Therophylline", ":", "A", "recent", "study", "has", "shown", "that", "concomitan", "administration", "of", "isoniazid", "and", "theophylline", "may", "cause", "elevated", "plasma", "levels", "of", "theophylline", ",", "and", "in", "some", "instances", "a", "slight", "decrease", "in", "the", "elimination", "of", "isoniazid", ".", "Since", "the", "therapeutic", "range", "of", "theophylline", "is", "narrow", "theophylline", "serum", "levels", "should", "be", "monitored", "closely", ",", "and", "appropriate", "dosage", "adjustments", "of", "theophylline", "should", "be", "made", ".", "Valproate", ":", "A", "recent", "case", "study", "has", "shown", "a", "possible", "increase", "in", "the", "plasma", "level", "of", "valproate", "when", "co", "administered", "with", "isoniazid", ".", "Plasma", "valproate", "concentration", "should", "be", "monitored", "when", "isoniazid", "and", "valproate", "are", "co", "administered", ",", "and", "appropriate", "dosage", "adjustments", "of", "valproate", "should", "be", "made", "." ]

[ "GROUP", "DRUG" ]

Sunlight exposure is a Intervention_Control, vitamin D supplementation is a Intervention_Pharmacological, vitamin D - deficient is a Participant_Condition, Vitamin D is a Intervention_Pharmacological, advised sunlight exposure is a Intervention_Physical, Vitamin D supplementation is a Intervention_Pharmacological, Baseline serum is a Outcome_Physical, mean is a Outcome_Physical

46969_task0

Sentence: Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants : a randomized clinical trial . UNLABELLED Vitamin D deficiency is very common in non-western immigrants . In this randomized clinical trial , vitamin D 800 IU/day or 100,000 IU/3 months were compared with advised sunlight exposure . Vitamin D supplementation was more effective than advised sunlight exposure in improving vitamin D status and lowering parathyroid hormone levels . INTRODUCTION Vitamin D deficiency ( 25-hydroxyvitamin D [ 25 ( OH ) D ] < 25 nmol/l ) is common among non-western immigrants . It can be treated with vitamin D supplementation or sunlight exposure . METHODS To determine whether the effect of vitamin D ( 3 ) supplementation ( daily 800 IU or 100,000 IU/3 months ) or sunlight exposure advice is similar with regard to serum 25 ( OH ) D and parathyroid hormone ( PTH ) concentrations . Randomized clinical trial in 11 general practices in The Netherlands . Non-western immigrants , aged 18-65 years ( n = 232 ) and serum 25 ( OH ) D < 25 nmol/l were randomly assigned to supplementation ( daily 800 IU or 100,000 IU/3 months ) or advice for sunlight exposure for 6 months ( March-September ) . Blood samples were collected at baseline , during treatment ( 3 months , 6 months ) , and at follow-up ( 12 months ) . Statistical analysis was performed with multilevel regression modelling . RESULTS The intention-to-treat analysis included 211 persons . Baseline serum 25 ( OH ) D was 22.5 ± 11.1 nmol/l . After 6 months , mean serum 25 ( OH ) D increased to 53 nmol/l with 800 IU/day , to 50.5 nmol/l with 100,000 IU/3 months , and to 29.1 nmol/l with advised sunlight exposure ( supplementation vs sunshine p < 0.001 ) . Serum PTH decreased significantly in all groups after 3 months , more in the supplementation groups than in the advised sunlight group ( p < 0.05 ) . There was no significant effect on physical performance and functional limitations . CONCLUSION Vitamin D supplementation is more effective than advised sunlight exposure for treating vitamin D deficiency in non-western immigrants . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Intervention_Control, Outcome_Physical

[ "B-Intervention_Control", "I-Intervention_Control", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants : a randomized clinical trial . UNLABELLED Vitamin D deficiency is very common in non-western immigrants . In this randomized clinical trial , vitamin D 800 IU/day or 100,000 IU/3 months were compared with advised sunlight exposure . Vitamin D supplementation was more effective than advised sunlight exposure in improving vitamin D status and lowering parathyroid hormone levels . INTRODUCTION Vitamin D deficiency ( 25-hydroxyvitamin D [ 25 ( OH ) D ] < 25 nmol/l ) is common among non-western immigrants . It can be treated with vitamin D supplementation or sunlight exposure . METHODS To determine whether the effect of vitamin D ( 3 ) supplementation ( daily 800 IU or 100,000 IU/3 months ) or sunlight exposure advice is similar with regard to serum 25 ( OH ) D and parathyroid hormone ( PTH ) concentrations . Randomized clinical trial in 11 general practices in The Netherlands . Non-western immigrants , aged 18-65 years ( n = 232 ) and serum 25 ( OH ) D < 25 nmol/l were randomly assigned to supplementation ( daily 800 IU or 100,000 IU/3 months ) or advice for sunlight exposure for 6 months ( March-September ) . Blood samples were collected at baseline , during treatment ( 3 months , 6 months ) , and at follow-up ( 12 months ) . Statistical analysis was performed with multilevel regression modelling . RESULTS The intention-to-treat analysis included 211 persons . Baseline serum 25 ( OH ) D was 22.5 ± 11.1 nmol/l . After 6 months , mean serum 25 ( OH ) D increased to 53 nmol/l with 800 IU/day , to 50.5 nmol/l with 100,000 IU/3 months , and to 29.1 nmol/l with advised sunlight exposure ( supplementation vs sunshine p < 0.001 ) . Serum PTH decreased significantly in all groups after 3 months , more in the supplementation groups than in the advised sunlight group ( p < 0.05 ) . There was no significant effect on physical performance and functional limitations . CONCLUSION Vitamin D supplementation is more effective than advised sunlight exposure for treating vitamin D deficiency in non-western immigrants .

[ "Sunlight", "exposure", "or", "vitamin", "D", "supplementation", "for", "vitamin", "D", "-", "deficient", "non", "-", "western", "immigrants", ":", "a", "randomized", "clinical", "trial", ".", "UNLABELLED", "Vitamin", "D", "deficiency", "is", "very", "common", "in", "non", "-", "western", "immigrants", ".", "In", "this", "randomized", "clinical", "trial", ",", "vitamin", "D", "800", "IU", "/", "day", "or", "100,000", "IU/3", "months", "were", "compared", "with", "advised", "sunlight", "exposure", ".", "Vitamin", "D", "supplementation", "was", "more", "effective", "than", "advised", "sunlight", "exposure", "in", "improving", "vitamin", "D", "status", "and", "lowering", "parathyroid", "hormone", "levels", ".", "INTRODUCTION", "Vitamin", "D", "deficiency", "(", "25-hydroxyvitamin", "D", "[", "25", "(", "OH", ")", "D", "]", "<", "25", "nmol", "/", "l", ")", "is", "common", "among", "non", "-", "western", "immigrants", ".", "It", "can", "be", "treated", "with", "vitamin", "D", "supplementation", "or", "sunlight", "exposure", ".", "METHODS", "To", "determine", "whether", "the", "effect", "of", "vitamin", "D", "(", "3", ")", "supplementation", "(", "daily", "800", "IU", "or", "100,000", "IU/3", "months", ")", "or", "sunlight", "exposure", "advice", "is", "similar", "with", "regard", "to", "serum", "25", "(", "OH", ")", "D", "and", "parathyroid", "hormone", "(", "PTH", ")", "concentrations", ".", "Randomized", "clinical", "trial", "in", "11", "general", "practices", "in", "The", "Netherlands", ".", "Non", "-", "western", "immigrants", ",", "aged", "18", "-", "65", "years", "(", "n", "=", "232", ")", "and", "serum", "25", "(", "OH", ")", "D", "<", "25", "nmol", "/", "l", "were", "randomly", "assigned", "to", "supplementation", "(", "daily", "800", "IU", "or", "100,000", "IU/3", "months", ")", "or", "advice", "for", "sunlight", "exposure", "for", "6", "months", "(", "March", "-", "September", ")", ".", "Blood", "samples", "were", "collected", "at", "baseline", ",", "during", "treatment", "(", "3", "months", ",", "6", "months", ")", ",", "and", "at", "follow", "-", "up", "(", "12", "months", ")", ".", "Statistical", "analysis", "was", "performed", "with", "multilevel", "regression", "modelling", ".", "RESULTS", "The", "intention", "-", "to", "-", "treat", "analysis", "included", "211", "persons", ".", "Baseline", "serum", "25", "(", "OH", ")", "D", "was", "22.5", "±", "11.1", "nmol", "/", "l", ".", "After", "6", "months", ",", "mean", "serum", "25", "(", "OH", ")", "D", "increased", "to", "53", "nmol", "/", "l", "with", "800", "IU", "/", "day", ",", "to", "50.5", "nmol", "/", "l", "with", "100,000", "IU/3", "months", ",", "and", "to", "29.1", "nmol", "/", "l", "with", "advised", "sunlight", "exposure", "(", "supplementation", "vs", "sunshine", "p", "<", "0.001", ")", ".", "Serum", "PTH", "decreased", "significantly", "in", "all", "groups", "after", "3", "months", ",", "more", "in", "the", "supplementation", "groups", "than", "in", "the", "advised", "sunlight", "group", "(", "p", "<", "0.05", ")", ".", "There", "was", "no", "significant", "effect", "on", "physical", "performance", "and", "functional", "limitations", ".", "CONCLUSION", "Vitamin", "D", "supplementation", "is", "more", "effective", "than", "advised", "sunlight", "exposure", "for", "treating", "vitamin", "D", "deficiency", "in", "non", "-", "western", "immigrants", "." ]

[ "Intervention_Pharmacological", "Intervention_Physical", "Intervention_Control", "Participant_Condition", "Outcome_Physical" ]

Sunlight exposure is a Intervention_Control, vitamin D supplementation is a Intervention_Pharmacological, vitamin D - deficient is a Participant_Condition, Vitamin D is a Intervention_Pharmacological, advised sunlight exposure is a Intervention_Physical, Vitamin D supplementation is a Intervention_Pharmacological, Baseline serum is a Outcome_Physical, mean is a Outcome_Physical

46969_task1

Sentence: Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants : a randomized clinical trial . UNLABELLED Vitamin D deficiency is very common in non-western immigrants . In this randomized clinical trial , vitamin D 800 IU/day or 100,000 IU/3 months were compared with advised sunlight exposure . Vitamin D supplementation was more effective than advised sunlight exposure in improving vitamin D status and lowering parathyroid hormone levels . INTRODUCTION Vitamin D deficiency ( 25-hydroxyvitamin D [ 25 ( OH ) D ] < 25 nmol/l ) is common among non-western immigrants . It can be treated with vitamin D supplementation or sunlight exposure . METHODS To determine whether the effect of vitamin D ( 3 ) supplementation ( daily 800 IU or 100,000 IU/3 months ) or sunlight exposure advice is similar with regard to serum 25 ( OH ) D and parathyroid hormone ( PTH ) concentrations . Randomized clinical trial in 11 general practices in The Netherlands . Non-western immigrants , aged 18-65 years ( n = 232 ) and serum 25 ( OH ) D < 25 nmol/l were randomly assigned to supplementation ( daily 800 IU or 100,000 IU/3 months ) or advice for sunlight exposure for 6 months ( March-September ) . Blood samples were collected at baseline , during treatment ( 3 months , 6 months ) , and at follow-up ( 12 months ) . Statistical analysis was performed with multilevel regression modelling . RESULTS The intention-to-treat analysis included 211 persons . Baseline serum 25 ( OH ) D was 22.5 ± 11.1 nmol/l . After 6 months , mean serum 25 ( OH ) D increased to 53 nmol/l with 800 IU/day , to 50.5 nmol/l with 100,000 IU/3 months , and to 29.1 nmol/l with advised sunlight exposure ( supplementation vs sunshine p < 0.001 ) . Serum PTH decreased significantly in all groups after 3 months , more in the supplementation groups than in the advised sunlight group ( p < 0.05 ) . There was no significant effect on physical performance and functional limitations . CONCLUSION Vitamin D supplementation is more effective than advised sunlight exposure for treating vitamin D deficiency in non-western immigrants . Instructions: please typing these entity words according to sentence: Sunlight exposure, vitamin D supplementation, vitamin D - deficient, Vitamin D, advised sunlight exposure, Vitamin D supplementation, Baseline serum, mean Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Intervention_Control, Outcome_Physical

[ "B-Intervention_Control", "I-Intervention_Control", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants : a randomized clinical trial . UNLABELLED Vitamin D deficiency is very common in non-western immigrants . In this randomized clinical trial , vitamin D 800 IU/day or 100,000 IU/3 months were compared with advised sunlight exposure . Vitamin D supplementation was more effective than advised sunlight exposure in improving vitamin D status and lowering parathyroid hormone levels . INTRODUCTION Vitamin D deficiency ( 25-hydroxyvitamin D [ 25 ( OH ) D ] < 25 nmol/l ) is common among non-western immigrants . It can be treated with vitamin D supplementation or sunlight exposure . METHODS To determine whether the effect of vitamin D ( 3 ) supplementation ( daily 800 IU or 100,000 IU/3 months ) or sunlight exposure advice is similar with regard to serum 25 ( OH ) D and parathyroid hormone ( PTH ) concentrations . Randomized clinical trial in 11 general practices in The Netherlands . Non-western immigrants , aged 18-65 years ( n = 232 ) and serum 25 ( OH ) D < 25 nmol/l were randomly assigned to supplementation ( daily 800 IU or 100,000 IU/3 months ) or advice for sunlight exposure for 6 months ( March-September ) . Blood samples were collected at baseline , during treatment ( 3 months , 6 months ) , and at follow-up ( 12 months ) . Statistical analysis was performed with multilevel regression modelling . RESULTS The intention-to-treat analysis included 211 persons . Baseline serum 25 ( OH ) D was 22.5 ± 11.1 nmol/l . After 6 months , mean serum 25 ( OH ) D increased to 53 nmol/l with 800 IU/day , to 50.5 nmol/l with 100,000 IU/3 months , and to 29.1 nmol/l with advised sunlight exposure ( supplementation vs sunshine p < 0.001 ) . Serum PTH decreased significantly in all groups after 3 months , more in the supplementation groups than in the advised sunlight group ( p < 0.05 ) . There was no significant effect on physical performance and functional limitations . CONCLUSION Vitamin D supplementation is more effective than advised sunlight exposure for treating vitamin D deficiency in non-western immigrants .

[ "Sunlight", "exposure", "or", "vitamin", "D", "supplementation", "for", "vitamin", "D", "-", "deficient", "non", "-", "western", "immigrants", ":", "a", "randomized", "clinical", "trial", ".", "UNLABELLED", "Vitamin", "D", "deficiency", "is", "very", "common", "in", "non", "-", "western", "immigrants", ".", "In", "this", "randomized", "clinical", "trial", ",", "vitamin", "D", "800", "IU", "/", "day", "or", "100,000", "IU/3", "months", "were", "compared", "with", "advised", "sunlight", "exposure", ".", "Vitamin", "D", "supplementation", "was", "more", "effective", "than", "advised", "sunlight", "exposure", "in", "improving", "vitamin", "D", "status", "and", "lowering", "parathyroid", "hormone", "levels", ".", "INTRODUCTION", "Vitamin", "D", "deficiency", "(", "25-hydroxyvitamin", "D", "[", "25", "(", "OH", ")", "D", "]", "<", "25", "nmol", "/", "l", ")", "is", "common", "among", "non", "-", "western", "immigrants", ".", "It", "can", "be", "treated", "with", "vitamin", "D", "supplementation", "or", "sunlight", "exposure", ".", "METHODS", "To", "determine", "whether", "the", "effect", "of", "vitamin", "D", "(", "3", ")", "supplementation", "(", "daily", "800", "IU", "or", "100,000", "IU/3", "months", ")", "or", "sunlight", "exposure", "advice", "is", "similar", "with", "regard", "to", "serum", "25", "(", "OH", ")", "D", "and", "parathyroid", "hormone", "(", "PTH", ")", "concentrations", ".", "Randomized", "clinical", "trial", "in", "11", "general", "practices", "in", "The", "Netherlands", ".", "Non", "-", "western", "immigrants", ",", "aged", "18", "-", "65", "years", "(", "n", "=", "232", ")", "and", "serum", "25", "(", "OH", ")", "D", "<", "25", "nmol", "/", "l", "were", "randomly", "assigned", "to", "supplementation", "(", "daily", "800", "IU", "or", "100,000", "IU/3", "months", ")", "or", "advice", "for", "sunlight", "exposure", "for", "6", "months", "(", "March", "-", "September", ")", ".", "Blood", "samples", "were", "collected", "at", "baseline", ",", "during", "treatment", "(", "3", "months", ",", "6", "months", ")", ",", "and", "at", "follow", "-", "up", "(", "12", "months", ")", ".", "Statistical", "analysis", "was", "performed", "with", "multilevel", "regression", "modelling", ".", "RESULTS", "The", "intention", "-", "to", "-", "treat", "analysis", "included", "211", "persons", ".", "Baseline", "serum", "25", "(", "OH", ")", "D", "was", "22.5", "±", "11.1", "nmol", "/", "l", ".", "After", "6", "months", ",", "mean", "serum", "25", "(", "OH", ")", "D", "increased", "to", "53", "nmol", "/", "l", "with", "800", "IU", "/", "day", ",", "to", "50.5", "nmol", "/", "l", "with", "100,000", "IU/3", "months", ",", "and", "to", "29.1", "nmol", "/", "l", "with", "advised", "sunlight", "exposure", "(", "supplementation", "vs", "sunshine", "p", "<", "0.001", ")", ".", "Serum", "PTH", "decreased", "significantly", "in", "all", "groups", "after", "3", "months", ",", "more", "in", "the", "supplementation", "groups", "than", "in", "the", "advised", "sunlight", "group", "(", "p", "<", "0.05", ")", ".", "There", "was", "no", "significant", "effect", "on", "physical", "performance", "and", "functional", "limitations", ".", "CONCLUSION", "Vitamin", "D", "supplementation", "is", "more", "effective", "than", "advised", "sunlight", "exposure", "for", "treating", "vitamin", "D", "deficiency", "in", "non", "-", "western", "immigrants", "." ]

[ "Intervention_Pharmacological", "Intervention_Physical", "Intervention_Control", "Participant_Condition", "Outcome_Physical" ]

Sunlight exposure, vitamin D supplementation, vitamin D - deficient, Vitamin D, advised sunlight exposure, Vitamin D supplementation, Baseline serum, mean

46969_task2

Sentence: Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants : a randomized clinical trial . UNLABELLED Vitamin D deficiency is very common in non-western immigrants . In this randomized clinical trial , vitamin D 800 IU/day or 100,000 IU/3 months were compared with advised sunlight exposure . Vitamin D supplementation was more effective than advised sunlight exposure in improving vitamin D status and lowering parathyroid hormone levels . INTRODUCTION Vitamin D deficiency ( 25-hydroxyvitamin D [ 25 ( OH ) D ] < 25 nmol/l ) is common among non-western immigrants . It can be treated with vitamin D supplementation or sunlight exposure . METHODS To determine whether the effect of vitamin D ( 3 ) supplementation ( daily 800 IU or 100,000 IU/3 months ) or sunlight exposure advice is similar with regard to serum 25 ( OH ) D and parathyroid hormone ( PTH ) concentrations . Randomized clinical trial in 11 general practices in The Netherlands . Non-western immigrants , aged 18-65 years ( n = 232 ) and serum 25 ( OH ) D < 25 nmol/l were randomly assigned to supplementation ( daily 800 IU or 100,000 IU/3 months ) or advice for sunlight exposure for 6 months ( March-September ) . Blood samples were collected at baseline , during treatment ( 3 months , 6 months ) , and at follow-up ( 12 months ) . Statistical analysis was performed with multilevel regression modelling . RESULTS The intention-to-treat analysis included 211 persons . Baseline serum 25 ( OH ) D was 22.5 ± 11.1 nmol/l . After 6 months , mean serum 25 ( OH ) D increased to 53 nmol/l with 800 IU/day , to 50.5 nmol/l with 100,000 IU/3 months , and to 29.1 nmol/l with advised sunlight exposure ( supplementation vs sunshine p < 0.001 ) . Serum PTH decreased significantly in all groups after 3 months , more in the supplementation groups than in the advised sunlight group ( p < 0.05 ) . There was no significant effect on physical performance and functional limitations . CONCLUSION Vitamin D supplementation is more effective than advised sunlight exposure for treating vitamin D deficiency in non-western immigrants . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Control", "I-Intervention_Control", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Sunlight exposure or vitamin D supplementation for vitamin D-deficient non-western immigrants : a randomized clinical trial . UNLABELLED Vitamin D deficiency is very common in non-western immigrants . In this randomized clinical trial , vitamin D 800 IU/day or 100,000 IU/3 months were compared with advised sunlight exposure . Vitamin D supplementation was more effective than advised sunlight exposure in improving vitamin D status and lowering parathyroid hormone levels . INTRODUCTION Vitamin D deficiency ( 25-hydroxyvitamin D [ 25 ( OH ) D ] < 25 nmol/l ) is common among non-western immigrants . It can be treated with vitamin D supplementation or sunlight exposure . METHODS To determine whether the effect of vitamin D ( 3 ) supplementation ( daily 800 IU or 100,000 IU/3 months ) or sunlight exposure advice is similar with regard to serum 25 ( OH ) D and parathyroid hormone ( PTH ) concentrations . Randomized clinical trial in 11 general practices in The Netherlands . Non-western immigrants , aged 18-65 years ( n = 232 ) and serum 25 ( OH ) D < 25 nmol/l were randomly assigned to supplementation ( daily 800 IU or 100,000 IU/3 months ) or advice for sunlight exposure for 6 months ( March-September ) . Blood samples were collected at baseline , during treatment ( 3 months , 6 months ) , and at follow-up ( 12 months ) . Statistical analysis was performed with multilevel regression modelling . RESULTS The intention-to-treat analysis included 211 persons . Baseline serum 25 ( OH ) D was 22.5 ± 11.1 nmol/l . After 6 months , mean serum 25 ( OH ) D increased to 53 nmol/l with 800 IU/day , to 50.5 nmol/l with 100,000 IU/3 months , and to 29.1 nmol/l with advised sunlight exposure ( supplementation vs sunshine p < 0.001 ) . Serum PTH decreased significantly in all groups after 3 months , more in the supplementation groups than in the advised sunlight group ( p < 0.05 ) . There was no significant effect on physical performance and functional limitations . CONCLUSION Vitamin D supplementation is more effective than advised sunlight exposure for treating vitamin D deficiency in non-western immigrants .

[ "Sunlight", "exposure", "or", "vitamin", "D", "supplementation", "for", "vitamin", "D", "-", "deficient", "non", "-", "western", "immigrants", ":", "a", "randomized", "clinical", "trial", ".", "UNLABELLED", "Vitamin", "D", "deficiency", "is", "very", "common", "in", "non", "-", "western", "immigrants", ".", "In", "this", "randomized", "clinical", "trial", ",", "vitamin", "D", "800", "IU", "/", "day", "or", "100,000", "IU/3", "months", "were", "compared", "with", "advised", "sunlight", "exposure", ".", "Vitamin", "D", "supplementation", "was", "more", "effective", "than", "advised", "sunlight", "exposure", "in", "improving", "vitamin", "D", "status", "and", "lowering", "parathyroid", "hormone", "levels", ".", "INTRODUCTION", "Vitamin", "D", "deficiency", "(", "25-hydroxyvitamin", "D", "[", "25", "(", "OH", ")", "D", "]", "<", "25", "nmol", "/", "l", ")", "is", "common", "among", "non", "-", "western", "immigrants", ".", "It", "can", "be", "treated", "with", "vitamin", "D", "supplementation", "or", "sunlight", "exposure", ".", "METHODS", "To", "determine", "whether", "the", "effect", "of", "vitamin", "D", "(", "3", ")", "supplementation", "(", "daily", "800", "IU", "or", "100,000", "IU/3", "months", ")", "or", "sunlight", "exposure", "advice", "is", "similar", "with", "regard", "to", "serum", "25", "(", "OH", ")", "D", "and", "parathyroid", "hormone", "(", "PTH", ")", "concentrations", ".", "Randomized", "clinical", "trial", "in", "11", "general", "practices", "in", "The", "Netherlands", ".", "Non", "-", "western", "immigrants", ",", "aged", "18", "-", "65", "years", "(", "n", "=", "232", ")", "and", "serum", "25", "(", "OH", ")", "D", "<", "25", "nmol", "/", "l", "were", "randomly", "assigned", "to", "supplementation", "(", "daily", "800", "IU", "or", "100,000", "IU/3", "months", ")", "or", "advice", "for", "sunlight", "exposure", "for", "6", "months", "(", "March", "-", "September", ")", ".", "Blood", "samples", "were", "collected", "at", "baseline", ",", "during", "treatment", "(", "3", "months", ",", "6", "months", ")", ",", "and", "at", "follow", "-", "up", "(", "12", "months", ")", ".", "Statistical", "analysis", "was", "performed", "with", "multilevel", "regression", "modelling", ".", "RESULTS", "The", "intention", "-", "to", "-", "treat", "analysis", "included", "211", "persons", ".", "Baseline", "serum", "25", "(", "OH", ")", "D", "was", "22.5", "±", "11.1", "nmol", "/", "l", ".", "After", "6", "months", ",", "mean", "serum", "25", "(", "OH", ")", "D", "increased", "to", "53", "nmol", "/", "l", "with", "800", "IU", "/", "day", ",", "to", "50.5", "nmol", "/", "l", "with", "100,000", "IU/3", "months", ",", "and", "to", "29.1", "nmol", "/", "l", "with", "advised", "sunlight", "exposure", "(", "supplementation", "vs", "sunshine", "p", "<", "0.001", ")", ".", "Serum", "PTH", "decreased", "significantly", "in", "all", "groups", "after", "3", "months", ",", "more", "in", "the", "supplementation", "groups", "than", "in", "the", "advised", "sunlight", "group", "(", "p", "<", "0.05", ")", ".", "There", "was", "no", "significant", "effect", "on", "physical", "performance", "and", "functional", "limitations", ".", "CONCLUSION", "Vitamin", "D", "supplementation", "is", "more", "effective", "than", "advised", "sunlight", "exposure", "for", "treating", "vitamin", "D", "deficiency", "in", "non", "-", "western", "immigrants", "." ]

[ "Intervention_Pharmacological", "Intervention_Physical", "Intervention_Control", "Participant_Condition", "Outcome_Physical" ]

anoctamin-6 is a GENE-Y, Tmem16f is a GENE-Y, phosphatidylserine is a CHEMICAL

22936354_task0

Sentence: Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues.

[ "Inactivation", "of", "anoctamin-6", "/", "Tmem16f", ",", "a", "regulator", "of", "phosphatidylserine", "scrambling", "in", "osteoblasts", ",", "leads", "to", "decreased", "mineral", "deposition", "in", "skeletal", "tissues", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

anoctamin-6 is a GENE-Y, Tmem16f is a GENE-Y, phosphatidylserine is a CHEMICAL

22936354_task1

Sentence: Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues. Instructions: please typing these entity words according to sentence: anoctamin-6, Tmem16f, phosphatidylserine Options: GENE-Y, CHEMICAL

[ "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues.

[ "Inactivation", "of", "anoctamin-6", "/", "Tmem16f", ",", "a", "regulator", "of", "phosphatidylserine", "scrambling", "in", "osteoblasts", ",", "leads", "to", "decreased", "mineral", "deposition", "in", "skeletal", "tissues", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

anoctamin-6, Tmem16f, phosphatidylserine

22936354_task2

Sentence: Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Inactivation of anoctamin-6/Tmem16f, a regulator of phosphatidylserine scrambling in osteoblasts, leads to decreased mineral deposition in skeletal tissues.

[ "Inactivation", "of", "anoctamin-6", "/", "Tmem16f", ",", "a", "regulator", "of", "phosphatidylserine", "scrambling", "in", "osteoblasts", ",", "leads", "to", "decreased", "mineral", "deposition", "in", "skeletal", "tissues", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

CBP / p300 is a protein_molecule, Raf / Rac - signaling pathways is an other_name, NF - ATc is a protein_molecule, T cell activation is an other_name

39759_task0

Sentence: CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_name, protein_molecule

[ "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]

CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation.

[ "CBP", "/", "p300", "integrates", "Raf", "/", "Rac", "-", "signaling", "pathways", "in", "the", "transcriptional", "induction", "of", "NF", "-", "ATc", "during", "T", "cell", "activation", "." ]

[ "protein_domain_or_region", "protein_family_or_group", "other_name", "atom", "cell_type", "protein_molecule" ]

CBP / p300 is a protein_molecule, Raf / Rac - signaling pathways is an other_name, NF - ATc is a protein_molecule, T cell activation is an other_name

39759_task1

Sentence: CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation. Instructions: please typing these entity words according to sentence: CBP / p300, Raf / Rac - signaling pathways, NF - ATc, T cell activation Options: other_name, protein_molecule

[ "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]

CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation.

[ "CBP", "/", "p300", "integrates", "Raf", "/", "Rac", "-", "signaling", "pathways", "in", "the", "transcriptional", "induction", "of", "NF", "-", "ATc", "during", "T", "cell", "activation", "." ]

[ "protein_domain_or_region", "protein_family_or_group", "other_name", "atom", "cell_type", "protein_molecule" ]

CBP / p300, Raf / Rac - signaling pathways, NF - ATc, T cell activation

39759_task2

Sentence: CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation. Instructions: please extract entity words from the input sentence

[ "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]

CBP/p300 integrates Raf/Rac-signaling pathways in the transcriptional induction of NF-ATc during T cell activation.

[ "CBP", "/", "p300", "integrates", "Raf", "/", "Rac", "-", "signaling", "pathways", "in", "the", "transcriptional", "induction", "of", "NF", "-", "ATc", "during", "T", "cell", "activation", "." ]

[ "protein_domain_or_region", "protein_family_or_group", "other_name", "atom", "cell_type", "protein_molecule" ]

metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, melanoma infiltrante is a MORFOLOGIA_NEOPLASIA, melanoma is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, realce ependimario is a MORFOLOGIA_NEOPLASIA, afectación leptomeníngea is a MORFOLOGIA_NEOPLASIA, recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central is a MORFOLOGIA_NEOPLASIA, afectación leptomeníngea is a MORFOLOGIA_NEOPLASIA, invasión leptomeníngea is a MORFOLOGIA_NEOPLASIA

715_task0

Sentence: Anamnesis Se trata de una mujer de 50 años, con alergia al contraste yodado y a la metoclopramida, sin hábitos tóxicos, ni antecedentes laborales o familiares de interés. Tiene antecedentes patológicos de síndrome ansioso-depresivo de más de 20 años de evolución en tratamiento con duloxetina. Su historia oncológica se inicia en marzo de 2012, a raíz de cuadro de cefalea opresiva de predominio frontal y de obstrucción nasal izquierda, por lo que acude a consulta en múltiples ocasiones en médico de Atención Primaria y Urgencias Hospitalarias, orientándose como sinusitis refractaria a tratamiento médico. Exploración física Buen estado general. Dolor en la palpación de senos paranasales, de predominio maxilar izquierdo. Auscultación cardiorrespiratoria sin alteraciones. Abdomen blando y depresible, no es doloroso durante la palpación, sin masas ni hepatoesplenomegalia. Pruebas complementarias Se realiza una analítica en la que destaca LDH de 880 U/l con el resto de marcadores tumorales negativos y una radiografía de senos paranasales que muestra ocupación de seno maxilar izquierdo. Se completa estudio con resonancia magnética (RM) facial en la que aparece una lesión sólida expansiva en seno maxilar izquierdo que se extiende hasta fosa nasal izquierda, con infiltración de partes blandas. Como estudio de extensión, se realiza una tomografía computarizada (TC) torácica y abdominal que describe lesiones sugestivas de metástasis en ambos campos pulmonares, hígado, bazo, subcutáneas y adenopatías inguinales. También se realiza una gammagrafía ósea (GGO) y una RM craneal sin metástasis óseas ni en sistema nervioso central. Diagnóstico Se realiza una biopsia de la lesión en mucosa nasal izquierda que es compatible con melanoma infiltrante, con estudio molecular negativo para BRAF y KIT. Por ello, se diagnostica melanoma de mucosa de seno maxilar izquierdo no mutado, estadio IV (por metástasis hepáticas, pulmonares, esplénicas y cutáneas). Tratamiento Dada la ausencia de mutaciones que permitan beneficiarse de tratamiento antidiana, se decide iniciar tratamiento de primera línea dentro de ensayo clínico con ipilimumab (3 mg/kg vs. 10 mg/kg) por 4 ciclos, que finaliza en septiembre de 2012. Presenta muy buena tolerancia y obtiene una respuesta completa, por lo que inicia controles por RM craneal y TC toracoabdominal cada 3 meses hasta marzo de 2017 y posteriormente controles cada 6 meses. En el último control en septiembre de 2017, presenta una respuesta completa mantenida a los 5 años de finalizar el tratamiento. Evolución En enero de 2018, inicia cuadro de dolor cervicodorsolumbar progresivo por el que acude a la consulta del médico de Atención Primaria y Traumatología en diversas ocasiones, se realiza RM lumbar y GGO que no muestran alteraciones ni lesiones sugestivas de metástasis. A finales de febrero ingresa por diversos episodios de crisis comicial de ausencia, con TC craneal que muestra dos lesiones sólidas con signos de sangrado y dilatación del sistema ventricular. Se completa estudio con RM cerebral que informa de dos lesiones intraventriculares sugestivas de metástasis en asta frontal izquierda de 15 x 16 mm y atrio ventricular izquierdo de 24 x 23 mm, con hidrocefalia arreabsortiva por sangrado intraventricular y realce ependimario del atrio ventricular que no permite descartar diseminación del líquido cefalorraquídeo ni afectación leptomeníngea. Se realiza también TC toracoabdominal que no evidencia diseminación de enfermedad a otros niveles. Se orienta como recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, con posible afectación leptomeníngea, a los 5 años y 6 meses de finalizar tratamiento. Se inicia tratamiento corticoide y anticomicial con dexametasona 4 mg cada 6 horas y levetiracetam 500 mg cada 12 horas endovenosos. Durante el ingreso presenta dos episodios de crisis tónico-clónicas generalizadas con periodo poscrítico prolongado y disminución del nivel de conciencia, por lo que se añade lacosamida 200 mg cada 12 h y se aumenta levetiracetam a 1.000 mg cada 12 horas. Requiere ingreso en la Unidad de Cuidados Intensivos para observación durante 48 h, sin presentar nuevos episodios de comicialidad ni empeoramiento clínico. Inicia rehabilitación y seguimiento por parte de Psicooncología por cuadro de ansiedad e insomnio, que se controla con mirtazapina 15 mg al día. Se presenta el caso en comité de tumores y se desestima tratamiento quirúrgico por invasión leptomeníngea. Se decide tratamiento con radioterapia holocraneal (30 Gy en 10 fracciones) y posteriormente tratamiento con anti-PD-1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Se trata de una mujer de 50 años, con alergia al contraste yodado y a la metoclopramida, sin hábitos tóxicos, ni antecedentes laborales o familiares de interés. Tiene antecedentes patológicos de síndrome ansioso-depresivo de más de 20 años de evolución en tratamiento con duloxetina. Su historia oncológica se inicia en marzo de 2012, a raíz de cuadro de cefalea opresiva de predominio frontal y de obstrucción nasal izquierda, por lo que acude a consulta en múltiples ocasiones en médico de Atención Primaria y Urgencias Hospitalarias, orientándose como sinusitis refractaria a tratamiento médico. Exploración física Buen estado general. Dolor en la palpación de senos paranasales, de predominio maxilar izquierdo. Auscultación cardiorrespiratoria sin alteraciones. Abdomen blando y depresible, no es doloroso durante la palpación, sin masas ni hepatoesplenomegalia. Pruebas complementarias Se realiza una analítica en la que destaca LDH de 880 U/l con el resto de marcadores tumorales negativos y una radiografía de senos paranasales que muestra ocupación de seno maxilar izquierdo. Se completa estudio con resonancia magnética (RM) facial en la que aparece una lesión sólida expansiva en seno maxilar izquierdo que se extiende hasta fosa nasal izquierda, con infiltración de partes blandas. Como estudio de extensión, se realiza una tomografía computarizada (TC) torácica y abdominal que describe lesiones sugestivas de metástasis en ambos campos pulmonares, hígado, bazo, subcutáneas y adenopatías inguinales. También se realiza una gammagrafía ósea (GGO) y una RM craneal sin metástasis óseas ni en sistema nervioso central. Diagnóstico Se realiza una biopsia de la lesión en mucosa nasal izquierda que es compatible con melanoma infiltrante, con estudio molecular negativo para BRAF y KIT. Por ello, se diagnostica melanoma de mucosa de seno maxilar izquierdo no mutado, estadio IV (por metástasis hepáticas, pulmonares, esplénicas y cutáneas). Tratamiento Dada la ausencia de mutaciones que permitan beneficiarse de tratamiento antidiana, se decide iniciar tratamiento de primera línea dentro de ensayo clínico con ipilimumab (3 mg/kg vs. 10 mg/kg) por 4 ciclos, que finaliza en septiembre de 2012. Presenta muy buena tolerancia y obtiene una respuesta completa, por lo que inicia controles por RM craneal y TC toracoabdominal cada 3 meses hasta marzo de 2017 y posteriormente controles cada 6 meses. En el último control en septiembre de 2017, presenta una respuesta completa mantenida a los 5 años de finalizar el tratamiento. Evolución En enero de 2018, inicia cuadro de dolor cervicodorsolumbar progresivo por el que acude a la consulta del médico de Atención Primaria y Traumatología en diversas ocasiones, se realiza RM lumbar y GGO que no muestran alteraciones ni lesiones sugestivas de metástasis. A finales de febrero ingresa por diversos episodios de crisis comicial de ausencia, con TC craneal que muestra dos lesiones sólidas con signos de sangrado y dilatación del sistema ventricular. Se completa estudio con RM cerebral que informa de dos lesiones intraventriculares sugestivas de metástasis en asta frontal izquierda de 15 x 16 mm y atrio ventricular izquierdo de 24 x 23 mm, con hidrocefalia arreabsortiva por sangrado intraventricular y realce ependimario del atrio ventricular que no permite descartar diseminación del líquido cefalorraquídeo ni afectación leptomeníngea. Se realiza también TC toracoabdominal que no evidencia diseminación de enfermedad a otros niveles. Se orienta como recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, con posible afectación leptomeníngea, a los 5 años y 6 meses de finalizar tratamiento. Se inicia tratamiento corticoide y anticomicial con dexametasona 4 mg cada 6 horas y levetiracetam 500 mg cada 12 horas endovenosos. Durante el ingreso presenta dos episodios de crisis tónico-clónicas generalizadas con periodo poscrítico prolongado y disminución del nivel de conciencia, por lo que se añade lacosamida 200 mg cada 12 h y se aumenta levetiracetam a 1.000 mg cada 12 horas. Requiere ingreso en la Unidad de Cuidados Intensivos para observación durante 48 h, sin presentar nuevos episodios de comicialidad ni empeoramiento clínico. Inicia rehabilitación y seguimiento por parte de Psicooncología por cuadro de ansiedad e insomnio, que se controla con mirtazapina 15 mg al día. Se presenta el caso en comité de tumores y se desestima tratamiento quirúrgico por invasión leptomeníngea. Se decide tratamiento con radioterapia holocraneal (30 Gy en 10 fracciones) y posteriormente tratamiento con anti-PD-1.

[ "Anamnesis", "\n", "Se", "trata", "de", "una", "mujer", "de", "50", "años", ",", "con", "alergia", "al", "contraste", "yodado", "y", "a", "la", "metoclopramida", ",", "sin", "hábitos", "tóxicos", ",", "ni", "antecedentes", "laborales", "o", "familiares", "de", "interés", ".", "Tiene", "antecedentes", "patológicos", "de", "síndrome", "ansioso", "-", "depresivo", "de", "más", "de", "20", "años", "de", "evolución", "en", "tratamiento", "con", "duloxetina", ".", "\n", "Su", "historia", "oncológica", "se", "inicia", "en", "marzo", "de", "2012", ",", "a", "raíz", "de", "cuadro", "de", "cefalea", "opresiva", "de", "predominio", "frontal", "y", "de", "obstrucción", "nasal", "izquierda", ",", "por", "lo", "que", "acude", "a", "consulta", "en", "múltiples", "ocasiones", "en", "médico", "de", "Atención", "Primaria", "y", "Urgencias", "Hospitalarias", ",", "orientándose", "como", "sinusitis", "refractaria", "a", "tratamiento", "médico", ".", "\n\n", "Exploración", "física", "\n", "Buen", "estado", "general", ".", "Dolor", "en", "la", "palpación", "de", "senos", "paranasales", ",", "de", "predominio", "maxilar", "izquierdo", ".", "Auscultación", "cardiorrespiratoria", "sin", "alteraciones", ".", "Abdomen", "blando", "y", "depresible", ",", "no", "es", "doloroso", "durante", "la", "palpación", ",", "sin", "masas", "ni", "hepatoesplenomegalia", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "analítica", "en", "la", "que", "destaca", "LDH", "de", "880", "U", "/", "l", "con", "el", "resto", "de", "marcadores", "tumorales", "negativos", "y", "una", "radiografía", "de", "senos", "paranasales", "que", "muestra", "ocupación", "de", "seno", "maxilar", "izquierdo", ".", "Se", "completa", "estudio", "con", "resonancia", "magnética", "(", "RM", ")", "facial", "en", "la", "que", "aparece", "una", "lesión", "sólida", "expansiva", "en", "seno", "maxilar", "izquierdo", "que", "se", "extiende", "hasta", "fosa", "nasal", "izquierda", ",", "con", "infiltración", "de", "partes", "blandas", ".", "\n", "Como", "estudio", "de", "extensión", ",", "se", "realiza", "una", "tomografía", "computarizada", "(", "TC", ")", "torácica", "y", "abdominal", "que", "describe", "lesiones", "sugestivas", "de", "metástasis", "en", "ambos", "campos", "pulmonares", ",", "hígado", ",", "bazo", ",", "subcutáneas", "y", "adenopatías", "inguinales", ".", "También", "se", "realiza", "una", "gammagrafía", "ósea", "(", "GGO", ")", "y", "una", "RM", "craneal", "sin", "metástasis", "óseas", "ni", "en", "sistema", "nervioso", "central", ".", "\n\n", "Diagnóstico", "\n", "Se", "realiza", "una", "biopsia", "de", "la", "lesión", "en", "mucosa", "nasal", "izquierda", "que", "es", "compatible", "con", "melanoma", "infiltrante", ",", "con", "estudio", "molecular", "negativo", "para", "BRAF", "y", "KIT", ".", "Por", "ello", ",", "se", "diagnostica", "melanoma", "de", "mucosa", "de", "seno", "maxilar", "izquierdo", "no", "mutado", ",", "estadio", "IV", "(", "por", "metástasis", "hepáticas", ",", "pulmonares", ",", "esplénicas", "y", "cutáneas", ")", ".", "\n\n", "Tratamiento", "\n", "Dada", "la", "ausencia", "de", "mutaciones", "que", "permitan", "beneficiarse", "de", "tratamiento", "antidiana", ",", "se", "decide", "iniciar", "tratamiento", "de", "primera", "línea", "dentro", "de", "ensayo", "clínico", "con", "ipilimumab", "(", "3", "mg", "/", "kg", "vs", ".", "10", "mg", "/", "kg", ")", "por", "4", "ciclos", ",", "que", "finaliza", "en", "septiembre", "de", "2012", ".", "\n", "Presenta", "muy", "buena", "tolerancia", "y", "obtiene", "una", "respuesta", "completa", ",", "por", "lo", "que", "inicia", "controles", "por", "RM", "craneal", "y", "TC", "toracoabdominal", "cada", "3", "meses", "hasta", "marzo", "de", "2017", "y", "posteriormente", "controles", "cada", "6", "meses", ".", "En", "el", "último", "control", "en", "septiembre", "de", "2017", ",", "presenta", "una", "respuesta", "completa", "mantenida", "a", "los", "5", "años", "de", "finalizar", "el", "tratamiento", ".", "\n\n", "Evolución", "\n", "En", "enero", "de", "2018", ",", "inicia", "cuadro", "de", "dolor", "cervicodorsolumbar", "progresivo", "por", "el", "que", "acude", "a", "la", "consulta", "del", "médico", "de", "Atención", "Primaria", "y", "Traumatología", "en", "diversas", "ocasiones", ",", "se", "realiza", "RM", "lumbar", "y", "GGO", "que", "no", "muestran", "alteraciones", "ni", "lesiones", "sugestivas", "de", "metástasis", ".", "\n", "A", "finales", "de", "febrero", "ingresa", "por", "diversos", "episodios", "de", "crisis", "comicial", "de", "ausencia", ",", "con", "TC", "craneal", "que", "muestra", "dos", "lesiones", "sólidas", "con", "signos", "de", "sangrado", "y", "dilatación", "del", "sistema", "ventricular", ".", "Se", "completa", "estudio", "con", "RM", "cerebral", "que", "informa", "de", "dos", "lesiones", "intraventriculares", "sugestivas", "de", "metástasis", "en", "asta", "frontal", "izquierda", "de", "15", "x", "16", "mm", "y", "atrio", "ventricular", "izquierdo", "de", "24", "x", "23", "mm", ",", "con", "hidrocefalia", "arreabsortiva", "por", "sangrado", "intraventricular", "y", "realce", "ependimario", "del", "atrio", "ventricular", "que", "no", "permite", "descartar", "diseminación", "del", "líquido", "cefalorraquídeo", "ni", "afectación", "leptomeníngea", ".", "Se", "realiza", "también", "TC", "toracoabdominal", "que", "no", "evidencia", "diseminación", "de", "enfermedad", "a", "otros", "niveles", ".", "Se", "orienta", "como", "recidiva", "de", "melanoma", "maligno", "de", "mucosa", "a", "nivel", "de", "sistema", "nervioso", "central", ",", "con", "posible", "afectación", "leptomeníngea", ",", "a", "los", "5", "años", "y", "6", "meses", "de", "finalizar", "tratamiento", ".", "\n", "Se", "inicia", "tratamiento", "corticoide", "y", "anticomicial", "con", "dexametasona", "4", "mg", "cada", "6", "horas", "y", "levetiracetam", "500", "mg", "cada", "12", "horas", "endovenosos", ".", "Durante", "el", "ingreso", "presenta", "dos", "episodios", "de", "crisis", "tónico", "-", "clónicas", "generalizadas", "con", "periodo", "poscrítico", "prolongado", "y", "disminución", "del", "nivel", "de", "conciencia", ",", "por", "lo", "que", "se", "añade", "lacosamida", "200", "mg", "cada", "12", "h", "y", "se", "aumenta", "levetiracetam", "a", "1.000", "mg", "cada", "12", "horas", ".", "Requiere", "ingreso", "en", "la", "Unidad", "de", "Cuidados", "Intensivos", "para", "observación", "durante", "48", "h", ",", "sin", "presentar", "nuevos", "episodios", "de", "comicialidad", "ni", "empeoramiento", "clínico", ".", "Inicia", "rehabilitación", "y", "seguimiento", "por", "parte", "de", "Psicooncología", "por", "cuadro", "de", "ansiedad", "e", "insomnio", ",", "que", "se", "controla", "con", "mirtazapina", "15", "mg", "al", "día", ".", "\n", "Se", "presenta", "el", "caso", "en", "comité", "de", "tumores", "y", "se", "desestima", "tratamiento", "quirúrgico", "por", "invasión", "leptomeníngea", ".", "Se", "decide", "tratamiento", "con", "radioterapia", "holocraneal", "(", "30", "Gy", "en", "10", "fracciones", ")", "y", "posteriormente", "tratamiento", "con", "anti", "-", "PD-1", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, melanoma infiltrante is a MORFOLOGIA_NEOPLASIA, melanoma is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, realce ependimario is a MORFOLOGIA_NEOPLASIA, afectación leptomeníngea is a MORFOLOGIA_NEOPLASIA, recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central is a MORFOLOGIA_NEOPLASIA, afectación leptomeníngea is a MORFOLOGIA_NEOPLASIA, invasión leptomeníngea is a MORFOLOGIA_NEOPLASIA

715_task1

Sentence: Anamnesis Se trata de una mujer de 50 años, con alergia al contraste yodado y a la metoclopramida, sin hábitos tóxicos, ni antecedentes laborales o familiares de interés. Tiene antecedentes patológicos de síndrome ansioso-depresivo de más de 20 años de evolución en tratamiento con duloxetina. Su historia oncológica se inicia en marzo de 2012, a raíz de cuadro de cefalea opresiva de predominio frontal y de obstrucción nasal izquierda, por lo que acude a consulta en múltiples ocasiones en médico de Atención Primaria y Urgencias Hospitalarias, orientándose como sinusitis refractaria a tratamiento médico. Exploración física Buen estado general. Dolor en la palpación de senos paranasales, de predominio maxilar izquierdo. Auscultación cardiorrespiratoria sin alteraciones. Abdomen blando y depresible, no es doloroso durante la palpación, sin masas ni hepatoesplenomegalia. Pruebas complementarias Se realiza una analítica en la que destaca LDH de 880 U/l con el resto de marcadores tumorales negativos y una radiografía de senos paranasales que muestra ocupación de seno maxilar izquierdo. Se completa estudio con resonancia magnética (RM) facial en la que aparece una lesión sólida expansiva en seno maxilar izquierdo que se extiende hasta fosa nasal izquierda, con infiltración de partes blandas. Como estudio de extensión, se realiza una tomografía computarizada (TC) torácica y abdominal que describe lesiones sugestivas de metástasis en ambos campos pulmonares, hígado, bazo, subcutáneas y adenopatías inguinales. También se realiza una gammagrafía ósea (GGO) y una RM craneal sin metástasis óseas ni en sistema nervioso central. Diagnóstico Se realiza una biopsia de la lesión en mucosa nasal izquierda que es compatible con melanoma infiltrante, con estudio molecular negativo para BRAF y KIT. Por ello, se diagnostica melanoma de mucosa de seno maxilar izquierdo no mutado, estadio IV (por metástasis hepáticas, pulmonares, esplénicas y cutáneas). Tratamiento Dada la ausencia de mutaciones que permitan beneficiarse de tratamiento antidiana, se decide iniciar tratamiento de primera línea dentro de ensayo clínico con ipilimumab (3 mg/kg vs. 10 mg/kg) por 4 ciclos, que finaliza en septiembre de 2012. Presenta muy buena tolerancia y obtiene una respuesta completa, por lo que inicia controles por RM craneal y TC toracoabdominal cada 3 meses hasta marzo de 2017 y posteriormente controles cada 6 meses. En el último control en septiembre de 2017, presenta una respuesta completa mantenida a los 5 años de finalizar el tratamiento. Evolución En enero de 2018, inicia cuadro de dolor cervicodorsolumbar progresivo por el que acude a la consulta del médico de Atención Primaria y Traumatología en diversas ocasiones, se realiza RM lumbar y GGO que no muestran alteraciones ni lesiones sugestivas de metástasis. A finales de febrero ingresa por diversos episodios de crisis comicial de ausencia, con TC craneal que muestra dos lesiones sólidas con signos de sangrado y dilatación del sistema ventricular. Se completa estudio con RM cerebral que informa de dos lesiones intraventriculares sugestivas de metástasis en asta frontal izquierda de 15 x 16 mm y atrio ventricular izquierdo de 24 x 23 mm, con hidrocefalia arreabsortiva por sangrado intraventricular y realce ependimario del atrio ventricular que no permite descartar diseminación del líquido cefalorraquídeo ni afectación leptomeníngea. Se realiza también TC toracoabdominal que no evidencia diseminación de enfermedad a otros niveles. Se orienta como recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, con posible afectación leptomeníngea, a los 5 años y 6 meses de finalizar tratamiento. Se inicia tratamiento corticoide y anticomicial con dexametasona 4 mg cada 6 horas y levetiracetam 500 mg cada 12 horas endovenosos. Durante el ingreso presenta dos episodios de crisis tónico-clónicas generalizadas con periodo poscrítico prolongado y disminución del nivel de conciencia, por lo que se añade lacosamida 200 mg cada 12 h y se aumenta levetiracetam a 1.000 mg cada 12 horas. Requiere ingreso en la Unidad de Cuidados Intensivos para observación durante 48 h, sin presentar nuevos episodios de comicialidad ni empeoramiento clínico. Inicia rehabilitación y seguimiento por parte de Psicooncología por cuadro de ansiedad e insomnio, que se controla con mirtazapina 15 mg al día. Se presenta el caso en comité de tumores y se desestima tratamiento quirúrgico por invasión leptomeníngea. Se decide tratamiento con radioterapia holocraneal (30 Gy en 10 fracciones) y posteriormente tratamiento con anti-PD-1. Instructions: please typing these entity words according to sentence: metástasis, metástasis, melanoma infiltrante, melanoma, metástasis, metástasis, metástasis, realce ependimario, afectación leptomeníngea, recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, afectación leptomeníngea, invasión leptomeníngea Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Se trata de una mujer de 50 años, con alergia al contraste yodado y a la metoclopramida, sin hábitos tóxicos, ni antecedentes laborales o familiares de interés. Tiene antecedentes patológicos de síndrome ansioso-depresivo de más de 20 años de evolución en tratamiento con duloxetina. Su historia oncológica se inicia en marzo de 2012, a raíz de cuadro de cefalea opresiva de predominio frontal y de obstrucción nasal izquierda, por lo que acude a consulta en múltiples ocasiones en médico de Atención Primaria y Urgencias Hospitalarias, orientándose como sinusitis refractaria a tratamiento médico. Exploración física Buen estado general. Dolor en la palpación de senos paranasales, de predominio maxilar izquierdo. Auscultación cardiorrespiratoria sin alteraciones. Abdomen blando y depresible, no es doloroso durante la palpación, sin masas ni hepatoesplenomegalia. Pruebas complementarias Se realiza una analítica en la que destaca LDH de 880 U/l con el resto de marcadores tumorales negativos y una radiografía de senos paranasales que muestra ocupación de seno maxilar izquierdo. Se completa estudio con resonancia magnética (RM) facial en la que aparece una lesión sólida expansiva en seno maxilar izquierdo que se extiende hasta fosa nasal izquierda, con infiltración de partes blandas. Como estudio de extensión, se realiza una tomografía computarizada (TC) torácica y abdominal que describe lesiones sugestivas de metástasis en ambos campos pulmonares, hígado, bazo, subcutáneas y adenopatías inguinales. También se realiza una gammagrafía ósea (GGO) y una RM craneal sin metástasis óseas ni en sistema nervioso central. Diagnóstico Se realiza una biopsia de la lesión en mucosa nasal izquierda que es compatible con melanoma infiltrante, con estudio molecular negativo para BRAF y KIT. Por ello, se diagnostica melanoma de mucosa de seno maxilar izquierdo no mutado, estadio IV (por metástasis hepáticas, pulmonares, esplénicas y cutáneas). Tratamiento Dada la ausencia de mutaciones que permitan beneficiarse de tratamiento antidiana, se decide iniciar tratamiento de primera línea dentro de ensayo clínico con ipilimumab (3 mg/kg vs. 10 mg/kg) por 4 ciclos, que finaliza en septiembre de 2012. Presenta muy buena tolerancia y obtiene una respuesta completa, por lo que inicia controles por RM craneal y TC toracoabdominal cada 3 meses hasta marzo de 2017 y posteriormente controles cada 6 meses. En el último control en septiembre de 2017, presenta una respuesta completa mantenida a los 5 años de finalizar el tratamiento. Evolución En enero de 2018, inicia cuadro de dolor cervicodorsolumbar progresivo por el que acude a la consulta del médico de Atención Primaria y Traumatología en diversas ocasiones, se realiza RM lumbar y GGO que no muestran alteraciones ni lesiones sugestivas de metástasis. A finales de febrero ingresa por diversos episodios de crisis comicial de ausencia, con TC craneal que muestra dos lesiones sólidas con signos de sangrado y dilatación del sistema ventricular. Se completa estudio con RM cerebral que informa de dos lesiones intraventriculares sugestivas de metástasis en asta frontal izquierda de 15 x 16 mm y atrio ventricular izquierdo de 24 x 23 mm, con hidrocefalia arreabsortiva por sangrado intraventricular y realce ependimario del atrio ventricular que no permite descartar diseminación del líquido cefalorraquídeo ni afectación leptomeníngea. Se realiza también TC toracoabdominal que no evidencia diseminación de enfermedad a otros niveles. Se orienta como recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, con posible afectación leptomeníngea, a los 5 años y 6 meses de finalizar tratamiento. Se inicia tratamiento corticoide y anticomicial con dexametasona 4 mg cada 6 horas y levetiracetam 500 mg cada 12 horas endovenosos. Durante el ingreso presenta dos episodios de crisis tónico-clónicas generalizadas con periodo poscrítico prolongado y disminución del nivel de conciencia, por lo que se añade lacosamida 200 mg cada 12 h y se aumenta levetiracetam a 1.000 mg cada 12 horas. Requiere ingreso en la Unidad de Cuidados Intensivos para observación durante 48 h, sin presentar nuevos episodios de comicialidad ni empeoramiento clínico. Inicia rehabilitación y seguimiento por parte de Psicooncología por cuadro de ansiedad e insomnio, que se controla con mirtazapina 15 mg al día. Se presenta el caso en comité de tumores y se desestima tratamiento quirúrgico por invasión leptomeníngea. Se decide tratamiento con radioterapia holocraneal (30 Gy en 10 fracciones) y posteriormente tratamiento con anti-PD-1.

[ "Anamnesis", "\n", "Se", "trata", "de", "una", "mujer", "de", "50", "años", ",", "con", "alergia", "al", "contraste", "yodado", "y", "a", "la", "metoclopramida", ",", "sin", "hábitos", "tóxicos", ",", "ni", "antecedentes", "laborales", "o", "familiares", "de", "interés", ".", "Tiene", "antecedentes", "patológicos", "de", "síndrome", "ansioso", "-", "depresivo", "de", "más", "de", "20", "años", "de", "evolución", "en", "tratamiento", "con", "duloxetina", ".", "\n", "Su", "historia", "oncológica", "se", "inicia", "en", "marzo", "de", "2012", ",", "a", "raíz", "de", "cuadro", "de", "cefalea", "opresiva", "de", "predominio", "frontal", "y", "de", "obstrucción", "nasal", "izquierda", ",", "por", "lo", "que", "acude", "a", "consulta", "en", "múltiples", "ocasiones", "en", "médico", "de", "Atención", "Primaria", "y", "Urgencias", "Hospitalarias", ",", "orientándose", "como", "sinusitis", "refractaria", "a", "tratamiento", "médico", ".", "\n\n", "Exploración", "física", "\n", "Buen", "estado", "general", ".", "Dolor", "en", "la", "palpación", "de", "senos", "paranasales", ",", "de", "predominio", "maxilar", "izquierdo", ".", "Auscultación", "cardiorrespiratoria", "sin", "alteraciones", ".", "Abdomen", "blando", "y", "depresible", ",", "no", "es", "doloroso", "durante", "la", "palpación", ",", "sin", "masas", "ni", "hepatoesplenomegalia", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "analítica", "en", "la", "que", "destaca", "LDH", "de", "880", "U", "/", "l", "con", "el", "resto", "de", "marcadores", "tumorales", "negativos", "y", "una", "radiografía", "de", "senos", "paranasales", "que", "muestra", "ocupación", "de", "seno", "maxilar", "izquierdo", ".", "Se", "completa", "estudio", "con", "resonancia", "magnética", "(", "RM", ")", "facial", "en", "la", "que", "aparece", "una", "lesión", "sólida", "expansiva", "en", "seno", "maxilar", "izquierdo", "que", "se", "extiende", "hasta", "fosa", "nasal", "izquierda", ",", "con", "infiltración", "de", "partes", "blandas", ".", "\n", "Como", "estudio", "de", "extensión", ",", "se", "realiza", "una", "tomografía", "computarizada", "(", "TC", ")", "torácica", "y", "abdominal", "que", "describe", "lesiones", "sugestivas", "de", "metástasis", "en", "ambos", "campos", "pulmonares", ",", "hígado", ",", "bazo", ",", "subcutáneas", "y", "adenopatías", "inguinales", ".", "También", "se", "realiza", "una", "gammagrafía", "ósea", "(", "GGO", ")", "y", "una", "RM", "craneal", "sin", "metástasis", "óseas", "ni", "en", "sistema", "nervioso", "central", ".", "\n\n", "Diagnóstico", "\n", "Se", "realiza", "una", "biopsia", "de", "la", "lesión", "en", "mucosa", "nasal", "izquierda", "que", "es", "compatible", "con", "melanoma", "infiltrante", ",", "con", "estudio", "molecular", "negativo", "para", "BRAF", "y", "KIT", ".", "Por", "ello", ",", "se", "diagnostica", "melanoma", "de", "mucosa", "de", "seno", "maxilar", "izquierdo", "no", "mutado", ",", "estadio", "IV", "(", "por", "metástasis", "hepáticas", ",", "pulmonares", ",", "esplénicas", "y", "cutáneas", ")", ".", "\n\n", "Tratamiento", "\n", "Dada", "la", "ausencia", "de", "mutaciones", "que", "permitan", "beneficiarse", "de", "tratamiento", "antidiana", ",", "se", "decide", "iniciar", "tratamiento", "de", "primera", "línea", "dentro", "de", "ensayo", "clínico", "con", "ipilimumab", "(", "3", "mg", "/", "kg", "vs", ".", "10", "mg", "/", "kg", ")", "por", "4", "ciclos", ",", "que", "finaliza", "en", "septiembre", "de", "2012", ".", "\n", "Presenta", "muy", "buena", "tolerancia", "y", "obtiene", "una", "respuesta", "completa", ",", "por", "lo", "que", "inicia", "controles", "por", "RM", "craneal", "y", "TC", "toracoabdominal", "cada", "3", "meses", "hasta", "marzo", "de", "2017", "y", "posteriormente", "controles", "cada", "6", "meses", ".", "En", "el", "último", "control", "en", "septiembre", "de", "2017", ",", "presenta", "una", "respuesta", "completa", "mantenida", "a", "los", "5", "años", "de", "finalizar", "el", "tratamiento", ".", "\n\n", "Evolución", "\n", "En", "enero", "de", "2018", ",", "inicia", "cuadro", "de", "dolor", "cervicodorsolumbar", "progresivo", "por", "el", "que", "acude", "a", "la", "consulta", "del", "médico", "de", "Atención", "Primaria", "y", "Traumatología", "en", "diversas", "ocasiones", ",", "se", "realiza", "RM", "lumbar", "y", "GGO", "que", "no", "muestran", "alteraciones", "ni", "lesiones", "sugestivas", "de", "metástasis", ".", "\n", "A", "finales", "de", "febrero", "ingresa", "por", "diversos", "episodios", "de", "crisis", "comicial", "de", "ausencia", ",", "con", "TC", "craneal", "que", "muestra", "dos", "lesiones", "sólidas", "con", "signos", "de", "sangrado", "y", "dilatación", "del", "sistema", "ventricular", ".", "Se", "completa", "estudio", "con", "RM", "cerebral", "que", "informa", "de", "dos", "lesiones", "intraventriculares", "sugestivas", "de", "metástasis", "en", "asta", "frontal", "izquierda", "de", "15", "x", "16", "mm", "y", "atrio", "ventricular", "izquierdo", "de", "24", "x", "23", "mm", ",", "con", "hidrocefalia", "arreabsortiva", "por", "sangrado", "intraventricular", "y", "realce", "ependimario", "del", "atrio", "ventricular", "que", "no", "permite", "descartar", "diseminación", "del", "líquido", "cefalorraquídeo", "ni", "afectación", "leptomeníngea", ".", "Se", "realiza", "también", "TC", "toracoabdominal", "que", "no", "evidencia", "diseminación", "de", "enfermedad", "a", "otros", "niveles", ".", "Se", "orienta", "como", "recidiva", "de", "melanoma", "maligno", "de", "mucosa", "a", "nivel", "de", "sistema", "nervioso", "central", ",", "con", "posible", "afectación", "leptomeníngea", ",", "a", "los", "5", "años", "y", "6", "meses", "de", "finalizar", "tratamiento", ".", "\n", "Se", "inicia", "tratamiento", "corticoide", "y", "anticomicial", "con", "dexametasona", "4", "mg", "cada", "6", "horas", "y", "levetiracetam", "500", "mg", "cada", "12", "horas", "endovenosos", ".", "Durante", "el", "ingreso", "presenta", "dos", "episodios", "de", "crisis", "tónico", "-", "clónicas", "generalizadas", "con", "periodo", "poscrítico", "prolongado", "y", "disminución", "del", "nivel", "de", "conciencia", ",", "por", "lo", "que", "se", "añade", "lacosamida", "200", "mg", "cada", "12", "h", "y", "se", "aumenta", "levetiracetam", "a", "1.000", "mg", "cada", "12", "horas", ".", "Requiere", "ingreso", "en", "la", "Unidad", "de", "Cuidados", "Intensivos", "para", "observación", "durante", "48", "h", ",", "sin", "presentar", "nuevos", "episodios", "de", "comicialidad", "ni", "empeoramiento", "clínico", ".", "Inicia", "rehabilitación", "y", "seguimiento", "por", "parte", "de", "Psicooncología", "por", "cuadro", "de", "ansiedad", "e", "insomnio", ",", "que", "se", "controla", "con", "mirtazapina", "15", "mg", "al", "día", ".", "\n", "Se", "presenta", "el", "caso", "en", "comité", "de", "tumores", "y", "se", "desestima", "tratamiento", "quirúrgico", "por", "invasión", "leptomeníngea", ".", "Se", "decide", "tratamiento", "con", "radioterapia", "holocraneal", "(", "30", "Gy", "en", "10", "fracciones", ")", "y", "posteriormente", "tratamiento", "con", "anti", "-", "PD-1", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

metástasis, metástasis, melanoma infiltrante, melanoma, metástasis, metástasis, metástasis, realce ependimario, afectación leptomeníngea, recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, afectación leptomeníngea, invasión leptomeníngea

715_task2

Sentence: Anamnesis Se trata de una mujer de 50 años, con alergia al contraste yodado y a la metoclopramida, sin hábitos tóxicos, ni antecedentes laborales o familiares de interés. Tiene antecedentes patológicos de síndrome ansioso-depresivo de más de 20 años de evolución en tratamiento con duloxetina. Su historia oncológica se inicia en marzo de 2012, a raíz de cuadro de cefalea opresiva de predominio frontal y de obstrucción nasal izquierda, por lo que acude a consulta en múltiples ocasiones en médico de Atención Primaria y Urgencias Hospitalarias, orientándose como sinusitis refractaria a tratamiento médico. Exploración física Buen estado general. Dolor en la palpación de senos paranasales, de predominio maxilar izquierdo. Auscultación cardiorrespiratoria sin alteraciones. Abdomen blando y depresible, no es doloroso durante la palpación, sin masas ni hepatoesplenomegalia. Pruebas complementarias Se realiza una analítica en la que destaca LDH de 880 U/l con el resto de marcadores tumorales negativos y una radiografía de senos paranasales que muestra ocupación de seno maxilar izquierdo. Se completa estudio con resonancia magnética (RM) facial en la que aparece una lesión sólida expansiva en seno maxilar izquierdo que se extiende hasta fosa nasal izquierda, con infiltración de partes blandas. Como estudio de extensión, se realiza una tomografía computarizada (TC) torácica y abdominal que describe lesiones sugestivas de metástasis en ambos campos pulmonares, hígado, bazo, subcutáneas y adenopatías inguinales. También se realiza una gammagrafía ósea (GGO) y una RM craneal sin metástasis óseas ni en sistema nervioso central. Diagnóstico Se realiza una biopsia de la lesión en mucosa nasal izquierda que es compatible con melanoma infiltrante, con estudio molecular negativo para BRAF y KIT. Por ello, se diagnostica melanoma de mucosa de seno maxilar izquierdo no mutado, estadio IV (por metástasis hepáticas, pulmonares, esplénicas y cutáneas). Tratamiento Dada la ausencia de mutaciones que permitan beneficiarse de tratamiento antidiana, se decide iniciar tratamiento de primera línea dentro de ensayo clínico con ipilimumab (3 mg/kg vs. 10 mg/kg) por 4 ciclos, que finaliza en septiembre de 2012. Presenta muy buena tolerancia y obtiene una respuesta completa, por lo que inicia controles por RM craneal y TC toracoabdominal cada 3 meses hasta marzo de 2017 y posteriormente controles cada 6 meses. En el último control en septiembre de 2017, presenta una respuesta completa mantenida a los 5 años de finalizar el tratamiento. Evolución En enero de 2018, inicia cuadro de dolor cervicodorsolumbar progresivo por el que acude a la consulta del médico de Atención Primaria y Traumatología en diversas ocasiones, se realiza RM lumbar y GGO que no muestran alteraciones ni lesiones sugestivas de metástasis. A finales de febrero ingresa por diversos episodios de crisis comicial de ausencia, con TC craneal que muestra dos lesiones sólidas con signos de sangrado y dilatación del sistema ventricular. Se completa estudio con RM cerebral que informa de dos lesiones intraventriculares sugestivas de metástasis en asta frontal izquierda de 15 x 16 mm y atrio ventricular izquierdo de 24 x 23 mm, con hidrocefalia arreabsortiva por sangrado intraventricular y realce ependimario del atrio ventricular que no permite descartar diseminación del líquido cefalorraquídeo ni afectación leptomeníngea. Se realiza también TC toracoabdominal que no evidencia diseminación de enfermedad a otros niveles. Se orienta como recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, con posible afectación leptomeníngea, a los 5 años y 6 meses de finalizar tratamiento. Se inicia tratamiento corticoide y anticomicial con dexametasona 4 mg cada 6 horas y levetiracetam 500 mg cada 12 horas endovenosos. Durante el ingreso presenta dos episodios de crisis tónico-clónicas generalizadas con periodo poscrítico prolongado y disminución del nivel de conciencia, por lo que se añade lacosamida 200 mg cada 12 h y se aumenta levetiracetam a 1.000 mg cada 12 horas. Requiere ingreso en la Unidad de Cuidados Intensivos para observación durante 48 h, sin presentar nuevos episodios de comicialidad ni empeoramiento clínico. Inicia rehabilitación y seguimiento por parte de Psicooncología por cuadro de ansiedad e insomnio, que se controla con mirtazapina 15 mg al día. Se presenta el caso en comité de tumores y se desestima tratamiento quirúrgico por invasión leptomeníngea. Se decide tratamiento con radioterapia holocraneal (30 Gy en 10 fracciones) y posteriormente tratamiento con anti-PD-1. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Se trata de una mujer de 50 años, con alergia al contraste yodado y a la metoclopramida, sin hábitos tóxicos, ni antecedentes laborales o familiares de interés. Tiene antecedentes patológicos de síndrome ansioso-depresivo de más de 20 años de evolución en tratamiento con duloxetina. Su historia oncológica se inicia en marzo de 2012, a raíz de cuadro de cefalea opresiva de predominio frontal y de obstrucción nasal izquierda, por lo que acude a consulta en múltiples ocasiones en médico de Atención Primaria y Urgencias Hospitalarias, orientándose como sinusitis refractaria a tratamiento médico. Exploración física Buen estado general. Dolor en la palpación de senos paranasales, de predominio maxilar izquierdo. Auscultación cardiorrespiratoria sin alteraciones. Abdomen blando y depresible, no es doloroso durante la palpación, sin masas ni hepatoesplenomegalia. Pruebas complementarias Se realiza una analítica en la que destaca LDH de 880 U/l con el resto de marcadores tumorales negativos y una radiografía de senos paranasales que muestra ocupación de seno maxilar izquierdo. Se completa estudio con resonancia magnética (RM) facial en la que aparece una lesión sólida expansiva en seno maxilar izquierdo que se extiende hasta fosa nasal izquierda, con infiltración de partes blandas. Como estudio de extensión, se realiza una tomografía computarizada (TC) torácica y abdominal que describe lesiones sugestivas de metástasis en ambos campos pulmonares, hígado, bazo, subcutáneas y adenopatías inguinales. También se realiza una gammagrafía ósea (GGO) y una RM craneal sin metástasis óseas ni en sistema nervioso central. Diagnóstico Se realiza una biopsia de la lesión en mucosa nasal izquierda que es compatible con melanoma infiltrante, con estudio molecular negativo para BRAF y KIT. Por ello, se diagnostica melanoma de mucosa de seno maxilar izquierdo no mutado, estadio IV (por metástasis hepáticas, pulmonares, esplénicas y cutáneas). Tratamiento Dada la ausencia de mutaciones que permitan beneficiarse de tratamiento antidiana, se decide iniciar tratamiento de primera línea dentro de ensayo clínico con ipilimumab (3 mg/kg vs. 10 mg/kg) por 4 ciclos, que finaliza en septiembre de 2012. Presenta muy buena tolerancia y obtiene una respuesta completa, por lo que inicia controles por RM craneal y TC toracoabdominal cada 3 meses hasta marzo de 2017 y posteriormente controles cada 6 meses. En el último control en septiembre de 2017, presenta una respuesta completa mantenida a los 5 años de finalizar el tratamiento. Evolución En enero de 2018, inicia cuadro de dolor cervicodorsolumbar progresivo por el que acude a la consulta del médico de Atención Primaria y Traumatología en diversas ocasiones, se realiza RM lumbar y GGO que no muestran alteraciones ni lesiones sugestivas de metástasis. A finales de febrero ingresa por diversos episodios de crisis comicial de ausencia, con TC craneal que muestra dos lesiones sólidas con signos de sangrado y dilatación del sistema ventricular. Se completa estudio con RM cerebral que informa de dos lesiones intraventriculares sugestivas de metástasis en asta frontal izquierda de 15 x 16 mm y atrio ventricular izquierdo de 24 x 23 mm, con hidrocefalia arreabsortiva por sangrado intraventricular y realce ependimario del atrio ventricular que no permite descartar diseminación del líquido cefalorraquídeo ni afectación leptomeníngea. Se realiza también TC toracoabdominal que no evidencia diseminación de enfermedad a otros niveles. Se orienta como recidiva de melanoma maligno de mucosa a nivel de sistema nervioso central, con posible afectación leptomeníngea, a los 5 años y 6 meses de finalizar tratamiento. Se inicia tratamiento corticoide y anticomicial con dexametasona 4 mg cada 6 horas y levetiracetam 500 mg cada 12 horas endovenosos. Durante el ingreso presenta dos episodios de crisis tónico-clónicas generalizadas con periodo poscrítico prolongado y disminución del nivel de conciencia, por lo que se añade lacosamida 200 mg cada 12 h y se aumenta levetiracetam a 1.000 mg cada 12 horas. Requiere ingreso en la Unidad de Cuidados Intensivos para observación durante 48 h, sin presentar nuevos episodios de comicialidad ni empeoramiento clínico. Inicia rehabilitación y seguimiento por parte de Psicooncología por cuadro de ansiedad e insomnio, que se controla con mirtazapina 15 mg al día. Se presenta el caso en comité de tumores y se desestima tratamiento quirúrgico por invasión leptomeníngea. Se decide tratamiento con radioterapia holocraneal (30 Gy en 10 fracciones) y posteriormente tratamiento con anti-PD-1.

[ "Anamnesis", "\n", "Se", "trata", "de", "una", "mujer", "de", "50", "años", ",", "con", "alergia", "al", "contraste", "yodado", "y", "a", "la", "metoclopramida", ",", "sin", "hábitos", "tóxicos", ",", "ni", "antecedentes", "laborales", "o", "familiares", "de", "interés", ".", "Tiene", "antecedentes", "patológicos", "de", "síndrome", "ansioso", "-", "depresivo", "de", "más", "de", "20", "años", "de", "evolución", "en", "tratamiento", "con", "duloxetina", ".", "\n", "Su", "historia", "oncológica", "se", "inicia", "en", "marzo", "de", "2012", ",", "a", "raíz", "de", "cuadro", "de", "cefalea", "opresiva", "de", "predominio", "frontal", "y", "de", "obstrucción", "nasal", "izquierda", ",", "por", "lo", "que", "acude", "a", "consulta", "en", "múltiples", "ocasiones", "en", "médico", "de", "Atención", "Primaria", "y", "Urgencias", "Hospitalarias", ",", "orientándose", "como", "sinusitis", "refractaria", "a", "tratamiento", "médico", ".", "\n\n", "Exploración", "física", "\n", "Buen", "estado", "general", ".", "Dolor", "en", "la", "palpación", "de", "senos", "paranasales", ",", "de", "predominio", "maxilar", "izquierdo", ".", "Auscultación", "cardiorrespiratoria", "sin", "alteraciones", ".", "Abdomen", "blando", "y", "depresible", ",", "no", "es", "doloroso", "durante", "la", "palpación", ",", "sin", "masas", "ni", "hepatoesplenomegalia", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "realiza", "una", "analítica", "en", "la", "que", "destaca", "LDH", "de", "880", "U", "/", "l", "con", "el", "resto", "de", "marcadores", "tumorales", "negativos", "y", "una", "radiografía", "de", "senos", "paranasales", "que", "muestra", "ocupación", "de", "seno", "maxilar", "izquierdo", ".", "Se", "completa", "estudio", "con", "resonancia", "magnética", "(", "RM", ")", "facial", "en", "la", "que", "aparece", "una", "lesión", "sólida", "expansiva", "en", "seno", "maxilar", "izquierdo", "que", "se", "extiende", "hasta", "fosa", "nasal", "izquierda", ",", "con", "infiltración", "de", "partes", "blandas", ".", "\n", "Como", "estudio", "de", "extensión", ",", "se", "realiza", "una", "tomografía", "computarizada", "(", "TC", ")", "torácica", "y", "abdominal", "que", "describe", "lesiones", "sugestivas", "de", "metástasis", "en", "ambos", "campos", "pulmonares", ",", "hígado", ",", "bazo", ",", "subcutáneas", "y", "adenopatías", "inguinales", ".", "También", "se", "realiza", "una", "gammagrafía", "ósea", "(", "GGO", ")", "y", "una", "RM", "craneal", "sin", "metástasis", "óseas", "ni", "en", "sistema", "nervioso", "central", ".", "\n\n", "Diagnóstico", "\n", "Se", "realiza", "una", "biopsia", "de", "la", "lesión", "en", "mucosa", "nasal", "izquierda", "que", "es", "compatible", "con", "melanoma", "infiltrante", ",", "con", "estudio", "molecular", "negativo", "para", "BRAF", "y", "KIT", ".", "Por", "ello", ",", "se", "diagnostica", "melanoma", "de", "mucosa", "de", "seno", "maxilar", "izquierdo", "no", "mutado", ",", "estadio", "IV", "(", "por", "metástasis", "hepáticas", ",", "pulmonares", ",", "esplénicas", "y", "cutáneas", ")", ".", "\n\n", "Tratamiento", "\n", "Dada", "la", "ausencia", "de", "mutaciones", "que", "permitan", "beneficiarse", "de", "tratamiento", "antidiana", ",", "se", "decide", "iniciar", "tratamiento", "de", "primera", "línea", "dentro", "de", "ensayo", "clínico", "con", "ipilimumab", "(", "3", "mg", "/", "kg", "vs", ".", "10", "mg", "/", "kg", ")", "por", "4", "ciclos", ",", "que", "finaliza", "en", "septiembre", "de", "2012", ".", "\n", "Presenta", "muy", "buena", "tolerancia", "y", "obtiene", "una", "respuesta", "completa", ",", "por", "lo", "que", "inicia", "controles", "por", "RM", "craneal", "y", "TC", "toracoabdominal", "cada", "3", "meses", "hasta", "marzo", "de", "2017", "y", "posteriormente", "controles", "cada", "6", "meses", ".", "En", "el", "último", "control", "en", "septiembre", "de", "2017", ",", "presenta", "una", "respuesta", "completa", "mantenida", "a", "los", "5", "años", "de", "finalizar", "el", "tratamiento", ".", "\n\n", "Evolución", "\n", "En", "enero", "de", "2018", ",", "inicia", "cuadro", "de", "dolor", "cervicodorsolumbar", "progresivo", "por", "el", "que", "acude", "a", "la", "consulta", "del", "médico", "de", "Atención", "Primaria", "y", "Traumatología", "en", "diversas", "ocasiones", ",", "se", "realiza", "RM", "lumbar", "y", "GGO", "que", "no", "muestran", "alteraciones", "ni", "lesiones", "sugestivas", "de", "metástasis", ".", "\n", "A", "finales", "de", "febrero", "ingresa", "por", "diversos", "episodios", "de", "crisis", "comicial", "de", "ausencia", ",", "con", "TC", "craneal", "que", "muestra", "dos", "lesiones", "sólidas", "con", "signos", "de", "sangrado", "y", "dilatación", "del", "sistema", "ventricular", ".", "Se", "completa", "estudio", "con", "RM", "cerebral", "que", "informa", "de", "dos", "lesiones", "intraventriculares", "sugestivas", "de", "metástasis", "en", "asta", "frontal", "izquierda", "de", "15", "x", "16", "mm", "y", "atrio", "ventricular", "izquierdo", "de", "24", "x", "23", "mm", ",", "con", "hidrocefalia", "arreabsortiva", "por", "sangrado", "intraventricular", "y", "realce", "ependimario", "del", "atrio", "ventricular", "que", "no", "permite", "descartar", "diseminación", "del", "líquido", "cefalorraquídeo", "ni", "afectación", "leptomeníngea", ".", "Se", "realiza", "también", "TC", "toracoabdominal", "que", "no", "evidencia", "diseminación", "de", "enfermedad", "a", "otros", "niveles", ".", "Se", "orienta", "como", "recidiva", "de", "melanoma", "maligno", "de", "mucosa", "a", "nivel", "de", "sistema", "nervioso", "central", ",", "con", "posible", "afectación", "leptomeníngea", ",", "a", "los", "5", "años", "y", "6", "meses", "de", "finalizar", "tratamiento", ".", "\n", "Se", "inicia", "tratamiento", "corticoide", "y", "anticomicial", "con", "dexametasona", "4", "mg", "cada", "6", "horas", "y", "levetiracetam", "500", "mg", "cada", "12", "horas", "endovenosos", ".", "Durante", "el", "ingreso", "presenta", "dos", "episodios", "de", "crisis", "tónico", "-", "clónicas", "generalizadas", "con", "periodo", "poscrítico", "prolongado", "y", "disminución", "del", "nivel", "de", "conciencia", ",", "por", "lo", "que", "se", "añade", "lacosamida", "200", "mg", "cada", "12", "h", "y", "se", "aumenta", "levetiracetam", "a", "1.000", "mg", "cada", "12", "horas", ".", "Requiere", "ingreso", "en", "la", "Unidad", "de", "Cuidados", "Intensivos", "para", "observación", "durante", "48", "h", ",", "sin", "presentar", "nuevos", "episodios", "de", "comicialidad", "ni", "empeoramiento", "clínico", ".", "Inicia", "rehabilitación", "y", "seguimiento", "por", "parte", "de", "Psicooncología", "por", "cuadro", "de", "ansiedad", "e", "insomnio", ",", "que", "se", "controla", "con", "mirtazapina", "15", "mg", "al", "día", ".", "\n", "Se", "presenta", "el", "caso", "en", "comité", "de", "tumores", "y", "se", "desestima", "tratamiento", "quirúrgico", "por", "invasión", "leptomeníngea", ".", "Se", "decide", "tratamiento", "con", "radioterapia", "holocraneal", "(", "30", "Gy", "en", "10", "fracciones", ")", "y", "posteriormente", "tratamiento", "con", "anti", "-", "PD-1", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

Ipratropium bromide nasal spray is a Intervention_Pharmacological, rhinorrhea is a Participant_Condition, laryngectomized patient is a Participant_Condition, total laryngectomy is a Participant_Condition, ipratropium bromide ( IB ) is a Intervention_Pharmacological, placebo - controlled is a Intervention_Control, severity is a Outcome_Physical, duration of their rhinorrhea is a Outcome_Physical, saline nasal spray is a Intervention_Control, Six is a Participant_Sample-size, decline in severity is a Outcome_Other, decline in duration of the rhinorrhea is a Outcome_Physical, severity and duration of rhinorrhea is a Outcome_Physical, Wilcoxon signed - rank test is a Outcome_Other, quality of life is a Outcome_Other

6706_task0

Sentence: Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient : a pilot study . Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control . This study was undertaken to evaluate the effect of ipratropium bromide ( IB ) , an anticholinergic nasal spray , on rhinorrhea in these patients . This was designed as a prospective , randomized , double-blind , placebo-controlled , crossover pilot study . Participants were selected if they had a total laryngectomy and complained of rhinorrhea . They were asked to rate the severity and duration of their rhinorrhea each day throughout the study on a scale from zero to six . Each participant was initially given a saline nasal spray for one week . They were then randomized to use either IB or saline for the double-blinded portion of the study . Two sprays of IB at a dose of 42 micrograms/spray ( 0.06 % ) , or saline , were administered intranasally twice daily for two weeks , after which time the participants were given another nasal spray ( either IB or saline ) for the crossover portion of the study . Six patients entered and completed the study . Those patients using the IB recorded a mean 55 % decline in severity and a mean 51 % decline in duration of the rhinorrhea as compared to placebo . The relief in both severity and duration of rhinorrhea obtained by patients was analyzed using the Wilcoxon signed-rank test and found to be highly significant ( p < 0.001 ) . Despite the limitations of a small sample size in this study , ipratropium bromide nasal spray significantly reduced both the severity and duration of rhinorrhea in laryngectomized patients . We suggest ipratropium nasal spray as a safe , effective way to treat chronic rhinorrhea in laryngectomized patients , improving their quality of life . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]

Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient : a pilot study . Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control . This study was undertaken to evaluate the effect of ipratropium bromide ( IB ) , an anticholinergic nasal spray , on rhinorrhea in these patients . This was designed as a prospective , randomized , double-blind , placebo-controlled , crossover pilot study . Participants were selected if they had a total laryngectomy and complained of rhinorrhea . They were asked to rate the severity and duration of their rhinorrhea each day throughout the study on a scale from zero to six . Each participant was initially given a saline nasal spray for one week . They were then randomized to use either IB or saline for the double-blinded portion of the study . Two sprays of IB at a dose of 42 micrograms/spray ( 0.06 % ) , or saline , were administered intranasally twice daily for two weeks , after which time the participants were given another nasal spray ( either IB or saline ) for the crossover portion of the study . Six patients entered and completed the study . Those patients using the IB recorded a mean 55 % decline in severity and a mean 51 % decline in duration of the rhinorrhea as compared to placebo . The relief in both severity and duration of rhinorrhea obtained by patients was analyzed using the Wilcoxon signed-rank test and found to be highly significant ( p < 0.001 ) . Despite the limitations of a small sample size in this study , ipratropium bromide nasal spray significantly reduced both the severity and duration of rhinorrhea in laryngectomized patients . We suggest ipratropium nasal spray as a safe , effective way to treat chronic rhinorrhea in laryngectomized patients , improving their quality of life .

[ "Ipratropium", "bromide", "nasal", "spray", "for", "treatment", "of", "rhinorrhea", "in", "the", "laryngectomized", "patient", ":", "a", "pilot", "study", ".", "Many", "who", "have", "had", "a", "total", "laryngectomy", "complain", "of", "unrelenting", "rhinorrhea", "that", "is", "often", "very", "difficult", "to", "control", ".", "This", "study", "was", "undertaken", "to", "evaluate", "the", "effect", "of", "ipratropium", "bromide", "(", "IB", ")", ",", "an", "anticholinergic", "nasal", "spray", ",", "on", "rhinorrhea", "in", "these", "patients", ".", "This", "was", "designed", "as", "a", "prospective", ",", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "crossover", "pilot", "study", ".", "Participants", "were", "selected", "if", "they", "had", "a", "total", "laryngectomy", "and", "complained", "of", "rhinorrhea", ".", "They", "were", "asked", "to", "rate", "the", "severity", "and", "duration", "of", "their", "rhinorrhea", "each", "day", "throughout", "the", "study", "on", "a", "scale", "from", "zero", "to", "six", ".", "Each", "participant", "was", "initially", "given", "a", "saline", "nasal", "spray", "for", "one", "week", ".", "They", "were", "then", "randomized", "to", "use", "either", "IB", "or", "saline", "for", "the", "double", "-", "blinded", "portion", "of", "the", "study", ".", "Two", "sprays", "of", "IB", "at", "a", "dose", "of", "42", "micrograms", "/", "spray", "(", "0.06", "%", ")", ",", "or", "saline", ",", "were", "administered", "intranasally", "twice", "daily", "for", "two", "weeks", ",", "after", "which", "time", "the", "participants", "were", "given", "another", "nasal", "spray", "(", "either", "IB", "or", "saline", ")", "for", "the", "crossover", "portion", "of", "the", "study", ".", "Six", "patients", "entered", "and", "completed", "the", "study", ".", "Those", "patients", "using", "the", "IB", "recorded", "a", "mean", "55", "%", "decline", "in", "severity", "and", "a", "mean", "51", "%", "decline", "in", "duration", "of", "the", "rhinorrhea", "as", "compared", "to", "placebo", ".", "The", "relief", "in", "both", "severity", "and", "duration", "of", "rhinorrhea", "obtained", "by", "patients", "was", "analyzed", "using", "the", "Wilcoxon", "signed", "-", "rank", "test", "and", "found", "to", "be", "highly", "significant", "(", "p", "<", "0.001", ")", ".", "Despite", "the", "limitations", "of", "a", "small", "sample", "size", "in", "this", "study", ",", "ipratropium", "bromide", "nasal", "spray", "significantly", "reduced", "both", "the", "severity", "and", "duration", "of", "rhinorrhea", "in", "laryngectomized", "patients", ".", "We", "suggest", "ipratropium", "nasal", "spray", "as", "a", "safe", ",", "effective", "way", "to", "treat", "chronic", "rhinorrhea", "in", "laryngectomized", "patients", ",", "improving", "their", "quality", "of", "life", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Intervention_Control", "Participant_Sample-size" ]

Ipratropium bromide nasal spray is a Intervention_Pharmacological, rhinorrhea is a Participant_Condition, laryngectomized patient is a Participant_Condition, total laryngectomy is a Participant_Condition, ipratropium bromide ( IB ) is a Intervention_Pharmacological, placebo - controlled is a Intervention_Control, severity is a Outcome_Physical, duration of their rhinorrhea is a Outcome_Physical, saline nasal spray is a Intervention_Control, Six is a Participant_Sample-size, decline in severity is a Outcome_Other, decline in duration of the rhinorrhea is a Outcome_Physical, severity and duration of rhinorrhea is a Outcome_Physical, Wilcoxon signed - rank test is a Outcome_Other, quality of life is a Outcome_Other

6706_task1

Sentence: Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient : a pilot study . Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control . This study was undertaken to evaluate the effect of ipratropium bromide ( IB ) , an anticholinergic nasal spray , on rhinorrhea in these patients . This was designed as a prospective , randomized , double-blind , placebo-controlled , crossover pilot study . Participants were selected if they had a total laryngectomy and complained of rhinorrhea . They were asked to rate the severity and duration of their rhinorrhea each day throughout the study on a scale from zero to six . Each participant was initially given a saline nasal spray for one week . They were then randomized to use either IB or saline for the double-blinded portion of the study . Two sprays of IB at a dose of 42 micrograms/spray ( 0.06 % ) , or saline , were administered intranasally twice daily for two weeks , after which time the participants were given another nasal spray ( either IB or saline ) for the crossover portion of the study . Six patients entered and completed the study . Those patients using the IB recorded a mean 55 % decline in severity and a mean 51 % decline in duration of the rhinorrhea as compared to placebo . The relief in both severity and duration of rhinorrhea obtained by patients was analyzed using the Wilcoxon signed-rank test and found to be highly significant ( p < 0.001 ) . Despite the limitations of a small sample size in this study , ipratropium bromide nasal spray significantly reduced both the severity and duration of rhinorrhea in laryngectomized patients . We suggest ipratropium nasal spray as a safe , effective way to treat chronic rhinorrhea in laryngectomized patients , improving their quality of life . Instructions: please typing these entity words according to sentence: Ipratropium bromide nasal spray, rhinorrhea, laryngectomized patient, total laryngectomy, ipratropium bromide ( IB ), placebo - controlled, severity, duration of their rhinorrhea, saline nasal spray, Six, decline in severity, decline in duration of the rhinorrhea, severity and duration of rhinorrhea, Wilcoxon signed - rank test, quality of life Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]

Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient : a pilot study . Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control . This study was undertaken to evaluate the effect of ipratropium bromide ( IB ) , an anticholinergic nasal spray , on rhinorrhea in these patients . This was designed as a prospective , randomized , double-blind , placebo-controlled , crossover pilot study . Participants were selected if they had a total laryngectomy and complained of rhinorrhea . They were asked to rate the severity and duration of their rhinorrhea each day throughout the study on a scale from zero to six . Each participant was initially given a saline nasal spray for one week . They were then randomized to use either IB or saline for the double-blinded portion of the study . Two sprays of IB at a dose of 42 micrograms/spray ( 0.06 % ) , or saline , were administered intranasally twice daily for two weeks , after which time the participants were given another nasal spray ( either IB or saline ) for the crossover portion of the study . Six patients entered and completed the study . Those patients using the IB recorded a mean 55 % decline in severity and a mean 51 % decline in duration of the rhinorrhea as compared to placebo . The relief in both severity and duration of rhinorrhea obtained by patients was analyzed using the Wilcoxon signed-rank test and found to be highly significant ( p < 0.001 ) . Despite the limitations of a small sample size in this study , ipratropium bromide nasal spray significantly reduced both the severity and duration of rhinorrhea in laryngectomized patients . We suggest ipratropium nasal spray as a safe , effective way to treat chronic rhinorrhea in laryngectomized patients , improving their quality of life .

[ "Ipratropium", "bromide", "nasal", "spray", "for", "treatment", "of", "rhinorrhea", "in", "the", "laryngectomized", "patient", ":", "a", "pilot", "study", ".", "Many", "who", "have", "had", "a", "total", "laryngectomy", "complain", "of", "unrelenting", "rhinorrhea", "that", "is", "often", "very", "difficult", "to", "control", ".", "This", "study", "was", "undertaken", "to", "evaluate", "the", "effect", "of", "ipratropium", "bromide", "(", "IB", ")", ",", "an", "anticholinergic", "nasal", "spray", ",", "on", "rhinorrhea", "in", "these", "patients", ".", "This", "was", "designed", "as", "a", "prospective", ",", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "crossover", "pilot", "study", ".", "Participants", "were", "selected", "if", "they", "had", "a", "total", "laryngectomy", "and", "complained", "of", "rhinorrhea", ".", "They", "were", "asked", "to", "rate", "the", "severity", "and", "duration", "of", "their", "rhinorrhea", "each", "day", "throughout", "the", "study", "on", "a", "scale", "from", "zero", "to", "six", ".", "Each", "participant", "was", "initially", "given", "a", "saline", "nasal", "spray", "for", "one", "week", ".", "They", "were", "then", "randomized", "to", "use", "either", "IB", "or", "saline", "for", "the", "double", "-", "blinded", "portion", "of", "the", "study", ".", "Two", "sprays", "of", "IB", "at", "a", "dose", "of", "42", "micrograms", "/", "spray", "(", "0.06", "%", ")", ",", "or", "saline", ",", "were", "administered", "intranasally", "twice", "daily", "for", "two", "weeks", ",", "after", "which", "time", "the", "participants", "were", "given", "another", "nasal", "spray", "(", "either", "IB", "or", "saline", ")", "for", "the", "crossover", "portion", "of", "the", "study", ".", "Six", "patients", "entered", "and", "completed", "the", "study", ".", "Those", "patients", "using", "the", "IB", "recorded", "a", "mean", "55", "%", "decline", "in", "severity", "and", "a", "mean", "51", "%", "decline", "in", "duration", "of", "the", "rhinorrhea", "as", "compared", "to", "placebo", ".", "The", "relief", "in", "both", "severity", "and", "duration", "of", "rhinorrhea", "obtained", "by", "patients", "was", "analyzed", "using", "the", "Wilcoxon", "signed", "-", "rank", "test", "and", "found", "to", "be", "highly", "significant", "(", "p", "<", "0.001", ")", ".", "Despite", "the", "limitations", "of", "a", "small", "sample", "size", "in", "this", "study", ",", "ipratropium", "bromide", "nasal", "spray", "significantly", "reduced", "both", "the", "severity", "and", "duration", "of", "rhinorrhea", "in", "laryngectomized", "patients", ".", "We", "suggest", "ipratropium", "nasal", "spray", "as", "a", "safe", ",", "effective", "way", "to", "treat", "chronic", "rhinorrhea", "in", "laryngectomized", "patients", ",", "improving", "their", "quality", "of", "life", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Intervention_Control", "Participant_Sample-size" ]

Ipratropium bromide nasal spray, rhinorrhea, laryngectomized patient, total laryngectomy, ipratropium bromide ( IB ), placebo - controlled, severity, duration of their rhinorrhea, saline nasal spray, Six, decline in severity, decline in duration of the rhinorrhea, severity and duration of rhinorrhea, Wilcoxon signed - rank test, quality of life

6706_task2

Sentence: Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient : a pilot study . Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control . This study was undertaken to evaluate the effect of ipratropium bromide ( IB ) , an anticholinergic nasal spray , on rhinorrhea in these patients . This was designed as a prospective , randomized , double-blind , placebo-controlled , crossover pilot study . Participants were selected if they had a total laryngectomy and complained of rhinorrhea . They were asked to rate the severity and duration of their rhinorrhea each day throughout the study on a scale from zero to six . Each participant was initially given a saline nasal spray for one week . They were then randomized to use either IB or saline for the double-blinded portion of the study . Two sprays of IB at a dose of 42 micrograms/spray ( 0.06 % ) , or saline , were administered intranasally twice daily for two weeks , after which time the participants were given another nasal spray ( either IB or saline ) for the crossover portion of the study . Six patients entered and completed the study . Those patients using the IB recorded a mean 55 % decline in severity and a mean 51 % decline in duration of the rhinorrhea as compared to placebo . The relief in both severity and duration of rhinorrhea obtained by patients was analyzed using the Wilcoxon signed-rank test and found to be highly significant ( p < 0.001 ) . Despite the limitations of a small sample size in this study , ipratropium bromide nasal spray significantly reduced both the severity and duration of rhinorrhea in laryngectomized patients . We suggest ipratropium nasal spray as a safe , effective way to treat chronic rhinorrhea in laryngectomized patients , improving their quality of life . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O" ]

Ipratropium bromide nasal spray for treatment of rhinorrhea in the laryngectomized patient : a pilot study . Many who have had a total laryngectomy complain of unrelenting rhinorrhea that is often very difficult to control . This study was undertaken to evaluate the effect of ipratropium bromide ( IB ) , an anticholinergic nasal spray , on rhinorrhea in these patients . This was designed as a prospective , randomized , double-blind , placebo-controlled , crossover pilot study . Participants were selected if they had a total laryngectomy and complained of rhinorrhea . They were asked to rate the severity and duration of their rhinorrhea each day throughout the study on a scale from zero to six . Each participant was initially given a saline nasal spray for one week . They were then randomized to use either IB or saline for the double-blinded portion of the study . Two sprays of IB at a dose of 42 micrograms/spray ( 0.06 % ) , or saline , were administered intranasally twice daily for two weeks , after which time the participants were given another nasal spray ( either IB or saline ) for the crossover portion of the study . Six patients entered and completed the study . Those patients using the IB recorded a mean 55 % decline in severity and a mean 51 % decline in duration of the rhinorrhea as compared to placebo . The relief in both severity and duration of rhinorrhea obtained by patients was analyzed using the Wilcoxon signed-rank test and found to be highly significant ( p < 0.001 ) . Despite the limitations of a small sample size in this study , ipratropium bromide nasal spray significantly reduced both the severity and duration of rhinorrhea in laryngectomized patients . We suggest ipratropium nasal spray as a safe , effective way to treat chronic rhinorrhea in laryngectomized patients , improving their quality of life .

[ "Ipratropium", "bromide", "nasal", "spray", "for", "treatment", "of", "rhinorrhea", "in", "the", "laryngectomized", "patient", ":", "a", "pilot", "study", ".", "Many", "who", "have", "had", "a", "total", "laryngectomy", "complain", "of", "unrelenting", "rhinorrhea", "that", "is", "often", "very", "difficult", "to", "control", ".", "This", "study", "was", "undertaken", "to", "evaluate", "the", "effect", "of", "ipratropium", "bromide", "(", "IB", ")", ",", "an", "anticholinergic", "nasal", "spray", ",", "on", "rhinorrhea", "in", "these", "patients", ".", "This", "was", "designed", "as", "a", "prospective", ",", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "crossover", "pilot", "study", ".", "Participants", "were", "selected", "if", "they", "had", "a", "total", "laryngectomy", "and", "complained", "of", "rhinorrhea", ".", "They", "were", "asked", "to", "rate", "the", "severity", "and", "duration", "of", "their", "rhinorrhea", "each", "day", "throughout", "the", "study", "on", "a", "scale", "from", "zero", "to", "six", ".", "Each", "participant", "was", "initially", "given", "a", "saline", "nasal", "spray", "for", "one", "week", ".", "They", "were", "then", "randomized", "to", "use", "either", "IB", "or", "saline", "for", "the", "double", "-", "blinded", "portion", "of", "the", "study", ".", "Two", "sprays", "of", "IB", "at", "a", "dose", "of", "42", "micrograms", "/", "spray", "(", "0.06", "%", ")", ",", "or", "saline", ",", "were", "administered", "intranasally", "twice", "daily", "for", "two", "weeks", ",", "after", "which", "time", "the", "participants", "were", "given", "another", "nasal", "spray", "(", "either", "IB", "or", "saline", ")", "for", "the", "crossover", "portion", "of", "the", "study", ".", "Six", "patients", "entered", "and", "completed", "the", "study", ".", "Those", "patients", "using", "the", "IB", "recorded", "a", "mean", "55", "%", "decline", "in", "severity", "and", "a", "mean", "51", "%", "decline", "in", "duration", "of", "the", "rhinorrhea", "as", "compared", "to", "placebo", ".", "The", "relief", "in", "both", "severity", "and", "duration", "of", "rhinorrhea", "obtained", "by", "patients", "was", "analyzed", "using", "the", "Wilcoxon", "signed", "-", "rank", "test", "and", "found", "to", "be", "highly", "significant", "(", "p", "<", "0.001", ")", ".", "Despite", "the", "limitations", "of", "a", "small", "sample", "size", "in", "this", "study", ",", "ipratropium", "bromide", "nasal", "spray", "significantly", "reduced", "both", "the", "severity", "and", "duration", "of", "rhinorrhea", "in", "laryngectomized", "patients", ".", "We", "suggest", "ipratropium", "nasal", "spray", "as", "a", "safe", ",", "effective", "way", "to", "treat", "chronic", "rhinorrhea", "in", "laryngectomized", "patients", ",", "improving", "their", "quality", "of", "life", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Condition", "Intervention_Control", "Participant_Sample-size" ]

avidin is a Protein, avidin is a Protein, streptavidin is a Protein, avidin is a Protein, avidin is a Protein, avidin is a Protein, avidin is a Protein, Streptavidin is a Protein, avidin is a Protein, avidin is a Protein

354_task0

Sentence: Studies on the biotin-binding site of avidin. Minimized fragments that bind biotin. The object of this study was to define minimized biotin-binding fragments, or 'prorecognition sites', of either the egg-white glycoprotein avidin or its bacterial analogue streptavidin. Because of the extreme stability to enzymic hydrolysis, fragments of avidin were prepared by chemical means and examined for their individual biotin-binding capacity. Treatment of avidin with hydroxylamine was shown to result in new cleavage sites in addition to the known Asn-Gly cleavage site (position 88-89 in avidin). Notably, the Asn-Glu and Asp-Lys peptide bonds (positions 42-43 and 57-58 respectively) were readily cleaved; in addition, lesser levels of hydrolysis of the Gln-Pro (61-62) and Asn-Asp (12-13 and 104-105) bonds could be detected. The smallest biotin-binding peptide fragment, derived from hydroxylamine cleavage of either native or non-glycosylated avidin, was identified to comprise residues 1-42. CNBr cleavage resulted in a 78-amino acid-residue fragment (residues 19-96) that still retained activity. The data ascribe an important biotin-binding function to the overlapping region (residues 19-42) of avidin, which bears the single tyrosine moiety. This contention was corroborated by synthesizing a tridecapeptide corresponding to residues 26-38 of avidin; this peptide was shown to recognize biotin. Streptavidin was not susceptible to either enzymic or chemical cleavage methods used in this work. The approach taken in this study enabled the experimental distinction between the chemical and structural elements of the binding site. The capacity to assign biotin-binding activity to the tyrosine-containing domain of avidin underscores its primary chemical contribution to the binding of biotin by avidin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]

Studies on the biotin-binding site of avidin. Minimized fragments that bind biotin. The object of this study was to define minimized biotin-binding fragments, or 'prorecognition sites', of either the egg-white glycoprotein avidin or its bacterial analogue streptavidin. Because of the extreme stability to enzymic hydrolysis, fragments of avidin were prepared by chemical means and examined for their individual biotin-binding capacity. Treatment of avidin with hydroxylamine was shown to result in new cleavage sites in addition to the known Asn-Gly cleavage site (position 88-89 in avidin). Notably, the Asn-Glu and Asp-Lys peptide bonds (positions 42-43 and 57-58 respectively) were readily cleaved; in addition, lesser levels of hydrolysis of the Gln-Pro (61-62) and Asn-Asp (12-13 and 104-105) bonds could be detected. The smallest biotin-binding peptide fragment, derived from hydroxylamine cleavage of either native or non-glycosylated avidin, was identified to comprise residues 1-42. CNBr cleavage resulted in a 78-amino acid-residue fragment (residues 19-96) that still retained activity. The data ascribe an important biotin-binding function to the overlapping region (residues 19-42) of avidin, which bears the single tyrosine moiety. This contention was corroborated by synthesizing a tridecapeptide corresponding to residues 26-38 of avidin; this peptide was shown to recognize biotin. Streptavidin was not susceptible to either enzymic or chemical cleavage methods used in this work. The approach taken in this study enabled the experimental distinction between the chemical and structural elements of the binding site. The capacity to assign biotin-binding activity to the tyrosine-containing domain of avidin underscores its primary chemical contribution to the binding of biotin by avidin.

[ "Studies", "on", "the", "biotin", "-", "binding", "site", "of", "avidin", ".", " ", "Minimized", "fragments", "that", "bind", "biotin", ".", "\n", "The", "object", "of", "this", "study", "was", "to", "define", "minimized", "biotin", "-", "binding", "fragments", ",", "or", "'", "prorecognition", "sites", "'", ",", "of", "either", "the", "egg", "-", "white", "glycoprotein", "avidin", "or", "its", "bacterial", "analogue", "streptavidin", ".", "Because", "of", "the", "extreme", "stability", "to", "enzymic", "hydrolysis", ",", "fragments", "of", "avidin", "were", "prepared", "by", "chemical", "means", "and", "examined", "for", "their", "individual", "biotin", "-", "binding", "capacity", ".", "Treatment", "of", "avidin", "with", "hydroxylamine", "was", "shown", "to", "result", "in", "new", "cleavage", "sites", "in", "addition", "to", "the", "known", "Asn", "-", "Gly", "cleavage", "site", "(", "position", "88", "-", "89", "in", "avidin", ")", ".", "Notably", ",", "the", "Asn", "-", "Glu", "and", "Asp", "-", "Lys", "peptide", "bonds", "(", "positions", "42", "-", "43", "and", "57", "-", "58", "respectively", ")", "were", "readily", "cleaved", ";", "in", "addition", ",", "lesser", "levels", "of", "hydrolysis", "of", "the", "Gln", "-", "Pro", "(", "61", "-", "62", ")", "and", "Asn", "-", "Asp", "(", "12", "-", "13", "and", "104", "-", "105", ")", "bonds", "could", "be", "detected", ".", "The", "smallest", "biotin", "-", "binding", "peptide", "fragment", ",", "derived", "from", "hydroxylamine", "cleavage", "of", "either", "native", "or", "non", "-", "glycosylated", "avidin", ",", "was", "identified", "to", "comprise", "residues", "1", "-", "42", ".", "CNBr", "cleavage", "resulted", "in", "a", "78-amino", "acid", "-", "residue", "fragment", "(", "residues", "19", "-", "96", ")", "that", "still", "retained", "activity", ".", "The", "data", "ascribe", "an", "important", "biotin", "-", "binding", "function", "to", "the", "overlapping", "region", "(", "residues", "19", "-", "42", ")", "of", "avidin", ",", "which", "bears", "the", "single", "tyrosine", "moiety", ".", "This", "contention", "was", "corroborated", "by", "synthesizing", "a", "tridecapeptide", "corresponding", "to", "residues", "26", "-", "38", "of", "avidin", ";", "this", "peptide", "was", "shown", "to", "recognize", "biotin", ".", "Streptavidin", "was", "not", "susceptible", "to", "either", "enzymic", "or", "chemical", "cleavage", "methods", "used", "in", "this", "work", ".", "The", "approach", "taken", "in", "this", "study", "enabled", "the", "experimental", "distinction", "between", "the", "chemical", "and", "structural", "elements", "of", "the", "binding", "site", ".", "The", "capacity", "to", "assign", "biotin", "-", "binding", "activity", "to", "the", "tyrosine", "-", "containing", "domain", "of", "avidin", "underscores", "its", "primary", "chemical", "contribution", "to", "the", "binding", "of", "biotin", "by", "avidin", ".", "\n" ]

[ "Protein" ]

avidin is a Protein, avidin is a Protein, streptavidin is a Protein, avidin is a Protein, avidin is a Protein, avidin is a Protein, avidin is a Protein, Streptavidin is a Protein, avidin is a Protein, avidin is a Protein

354_task1

Sentence: Studies on the biotin-binding site of avidin. Minimized fragments that bind biotin. The object of this study was to define minimized biotin-binding fragments, or 'prorecognition sites', of either the egg-white glycoprotein avidin or its bacterial analogue streptavidin. Because of the extreme stability to enzymic hydrolysis, fragments of avidin were prepared by chemical means and examined for their individual biotin-binding capacity. Treatment of avidin with hydroxylamine was shown to result in new cleavage sites in addition to the known Asn-Gly cleavage site (position 88-89 in avidin). Notably, the Asn-Glu and Asp-Lys peptide bonds (positions 42-43 and 57-58 respectively) were readily cleaved; in addition, lesser levels of hydrolysis of the Gln-Pro (61-62) and Asn-Asp (12-13 and 104-105) bonds could be detected. The smallest biotin-binding peptide fragment, derived from hydroxylamine cleavage of either native or non-glycosylated avidin, was identified to comprise residues 1-42. CNBr cleavage resulted in a 78-amino acid-residue fragment (residues 19-96) that still retained activity. The data ascribe an important biotin-binding function to the overlapping region (residues 19-42) of avidin, which bears the single tyrosine moiety. This contention was corroborated by synthesizing a tridecapeptide corresponding to residues 26-38 of avidin; this peptide was shown to recognize biotin. Streptavidin was not susceptible to either enzymic or chemical cleavage methods used in this work. The approach taken in this study enabled the experimental distinction between the chemical and structural elements of the binding site. The capacity to assign biotin-binding activity to the tyrosine-containing domain of avidin underscores its primary chemical contribution to the binding of biotin by avidin. Instructions: please typing these entity words according to sentence: avidin, avidin, streptavidin, avidin, avidin, avidin, avidin, Streptavidin, avidin, avidin Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]

Studies on the biotin-binding site of avidin. Minimized fragments that bind biotin. The object of this study was to define minimized biotin-binding fragments, or 'prorecognition sites', of either the egg-white glycoprotein avidin or its bacterial analogue streptavidin. Because of the extreme stability to enzymic hydrolysis, fragments of avidin were prepared by chemical means and examined for their individual biotin-binding capacity. Treatment of avidin with hydroxylamine was shown to result in new cleavage sites in addition to the known Asn-Gly cleavage site (position 88-89 in avidin). Notably, the Asn-Glu and Asp-Lys peptide bonds (positions 42-43 and 57-58 respectively) were readily cleaved; in addition, lesser levels of hydrolysis of the Gln-Pro (61-62) and Asn-Asp (12-13 and 104-105) bonds could be detected. The smallest biotin-binding peptide fragment, derived from hydroxylamine cleavage of either native or non-glycosylated avidin, was identified to comprise residues 1-42. CNBr cleavage resulted in a 78-amino acid-residue fragment (residues 19-96) that still retained activity. The data ascribe an important biotin-binding function to the overlapping region (residues 19-42) of avidin, which bears the single tyrosine moiety. This contention was corroborated by synthesizing a tridecapeptide corresponding to residues 26-38 of avidin; this peptide was shown to recognize biotin. Streptavidin was not susceptible to either enzymic or chemical cleavage methods used in this work. The approach taken in this study enabled the experimental distinction between the chemical and structural elements of the binding site. The capacity to assign biotin-binding activity to the tyrosine-containing domain of avidin underscores its primary chemical contribution to the binding of biotin by avidin.

[ "Studies", "on", "the", "biotin", "-", "binding", "site", "of", "avidin", ".", " ", "Minimized", "fragments", "that", "bind", "biotin", ".", "\n", "The", "object", "of", "this", "study", "was", "to", "define", "minimized", "biotin", "-", "binding", "fragments", ",", "or", "'", "prorecognition", "sites", "'", ",", "of", "either", "the", "egg", "-", "white", "glycoprotein", "avidin", "or", "its", "bacterial", "analogue", "streptavidin", ".", "Because", "of", "the", "extreme", "stability", "to", "enzymic", "hydrolysis", ",", "fragments", "of", "avidin", "were", "prepared", "by", "chemical", "means", "and", "examined", "for", "their", "individual", "biotin", "-", "binding", "capacity", ".", "Treatment", "of", "avidin", "with", "hydroxylamine", "was", "shown", "to", "result", "in", "new", "cleavage", "sites", "in", "addition", "to", "the", "known", "Asn", "-", "Gly", "cleavage", "site", "(", "position", "88", "-", "89", "in", "avidin", ")", ".", "Notably", ",", "the", "Asn", "-", "Glu", "and", "Asp", "-", "Lys", "peptide", "bonds", "(", "positions", "42", "-", "43", "and", "57", "-", "58", "respectively", ")", "were", "readily", "cleaved", ";", "in", "addition", ",", "lesser", "levels", "of", "hydrolysis", "of", "the", "Gln", "-", "Pro", "(", "61", "-", "62", ")", "and", "Asn", "-", "Asp", "(", "12", "-", "13", "and", "104", "-", "105", ")", "bonds", "could", "be", "detected", ".", "The", "smallest", "biotin", "-", "binding", "peptide", "fragment", ",", "derived", "from", "hydroxylamine", "cleavage", "of", "either", "native", "or", "non", "-", "glycosylated", "avidin", ",", "was", "identified", "to", "comprise", "residues", "1", "-", "42", ".", "CNBr", "cleavage", "resulted", "in", "a", "78-amino", "acid", "-", "residue", "fragment", "(", "residues", "19", "-", "96", ")", "that", "still", "retained", "activity", ".", "The", "data", "ascribe", "an", "important", "biotin", "-", "binding", "function", "to", "the", "overlapping", "region", "(", "residues", "19", "-", "42", ")", "of", "avidin", ",", "which", "bears", "the", "single", "tyrosine", "moiety", ".", "This", "contention", "was", "corroborated", "by", "synthesizing", "a", "tridecapeptide", "corresponding", "to", "residues", "26", "-", "38", "of", "avidin", ";", "this", "peptide", "was", "shown", "to", "recognize", "biotin", ".", "Streptavidin", "was", "not", "susceptible", "to", "either", "enzymic", "or", "chemical", "cleavage", "methods", "used", "in", "this", "work", ".", "The", "approach", "taken", "in", "this", "study", "enabled", "the", "experimental", "distinction", "between", "the", "chemical", "and", "structural", "elements", "of", "the", "binding", "site", ".", "The", "capacity", "to", "assign", "biotin", "-", "binding", "activity", "to", "the", "tyrosine", "-", "containing", "domain", "of", "avidin", "underscores", "its", "primary", "chemical", "contribution", "to", "the", "binding", "of", "biotin", "by", "avidin", ".", "\n" ]

[ "Protein" ]

avidin, avidin, streptavidin, avidin, avidin, avidin, avidin, Streptavidin, avidin, avidin

354_task2

Sentence: Studies on the biotin-binding site of avidin. Minimized fragments that bind biotin. The object of this study was to define minimized biotin-binding fragments, or 'prorecognition sites', of either the egg-white glycoprotein avidin or its bacterial analogue streptavidin. Because of the extreme stability to enzymic hydrolysis, fragments of avidin were prepared by chemical means and examined for their individual biotin-binding capacity. Treatment of avidin with hydroxylamine was shown to result in new cleavage sites in addition to the known Asn-Gly cleavage site (position 88-89 in avidin). Notably, the Asn-Glu and Asp-Lys peptide bonds (positions 42-43 and 57-58 respectively) were readily cleaved; in addition, lesser levels of hydrolysis of the Gln-Pro (61-62) and Asn-Asp (12-13 and 104-105) bonds could be detected. The smallest biotin-binding peptide fragment, derived from hydroxylamine cleavage of either native or non-glycosylated avidin, was identified to comprise residues 1-42. CNBr cleavage resulted in a 78-amino acid-residue fragment (residues 19-96) that still retained activity. The data ascribe an important biotin-binding function to the overlapping region (residues 19-42) of avidin, which bears the single tyrosine moiety. This contention was corroborated by synthesizing a tridecapeptide corresponding to residues 26-38 of avidin; this peptide was shown to recognize biotin. Streptavidin was not susceptible to either enzymic or chemical cleavage methods used in this work. The approach taken in this study enabled the experimental distinction between the chemical and structural elements of the binding site. The capacity to assign biotin-binding activity to the tyrosine-containing domain of avidin underscores its primary chemical contribution to the binding of biotin by avidin. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]

Studies on the biotin-binding site of avidin. Minimized fragments that bind biotin. The object of this study was to define minimized biotin-binding fragments, or 'prorecognition sites', of either the egg-white glycoprotein avidin or its bacterial analogue streptavidin. Because of the extreme stability to enzymic hydrolysis, fragments of avidin were prepared by chemical means and examined for their individual biotin-binding capacity. Treatment of avidin with hydroxylamine was shown to result in new cleavage sites in addition to the known Asn-Gly cleavage site (position 88-89 in avidin). Notably, the Asn-Glu and Asp-Lys peptide bonds (positions 42-43 and 57-58 respectively) were readily cleaved; in addition, lesser levels of hydrolysis of the Gln-Pro (61-62) and Asn-Asp (12-13 and 104-105) bonds could be detected. The smallest biotin-binding peptide fragment, derived from hydroxylamine cleavage of either native or non-glycosylated avidin, was identified to comprise residues 1-42. CNBr cleavage resulted in a 78-amino acid-residue fragment (residues 19-96) that still retained activity. The data ascribe an important biotin-binding function to the overlapping region (residues 19-42) of avidin, which bears the single tyrosine moiety. This contention was corroborated by synthesizing a tridecapeptide corresponding to residues 26-38 of avidin; this peptide was shown to recognize biotin. Streptavidin was not susceptible to either enzymic or chemical cleavage methods used in this work. The approach taken in this study enabled the experimental distinction between the chemical and structural elements of the binding site. The capacity to assign biotin-binding activity to the tyrosine-containing domain of avidin underscores its primary chemical contribution to the binding of biotin by avidin.

[ "Studies", "on", "the", "biotin", "-", "binding", "site", "of", "avidin", ".", " ", "Minimized", "fragments", "that", "bind", "biotin", ".", "\n", "The", "object", "of", "this", "study", "was", "to", "define", "minimized", "biotin", "-", "binding", "fragments", ",", "or", "'", "prorecognition", "sites", "'", ",", "of", "either", "the", "egg", "-", "white", "glycoprotein", "avidin", "or", "its", "bacterial", "analogue", "streptavidin", ".", "Because", "of", "the", "extreme", "stability", "to", "enzymic", "hydrolysis", ",", "fragments", "of", "avidin", "were", "prepared", "by", "chemical", "means", "and", "examined", "for", "their", "individual", "biotin", "-", "binding", "capacity", ".", "Treatment", "of", "avidin", "with", "hydroxylamine", "was", "shown", "to", "result", "in", "new", "cleavage", "sites", "in", "addition", "to", "the", "known", "Asn", "-", "Gly", "cleavage", "site", "(", "position", "88", "-", "89", "in", "avidin", ")", ".", "Notably", ",", "the", "Asn", "-", "Glu", "and", "Asp", "-", "Lys", "peptide", "bonds", "(", "positions", "42", "-", "43", "and", "57", "-", "58", "respectively", ")", "were", "readily", "cleaved", ";", "in", "addition", ",", "lesser", "levels", "of", "hydrolysis", "of", "the", "Gln", "-", "Pro", "(", "61", "-", "62", ")", "and", "Asn", "-", "Asp", "(", "12", "-", "13", "and", "104", "-", "105", ")", "bonds", "could", "be", "detected", ".", "The", "smallest", "biotin", "-", "binding", "peptide", "fragment", ",", "derived", "from", "hydroxylamine", "cleavage", "of", "either", "native", "or", "non", "-", "glycosylated", "avidin", ",", "was", "identified", "to", "comprise", "residues", "1", "-", "42", ".", "CNBr", "cleavage", "resulted", "in", "a", "78-amino", "acid", "-", "residue", "fragment", "(", "residues", "19", "-", "96", ")", "that", "still", "retained", "activity", ".", "The", "data", "ascribe", "an", "important", "biotin", "-", "binding", "function", "to", "the", "overlapping", "region", "(", "residues", "19", "-", "42", ")", "of", "avidin", ",", "which", "bears", "the", "single", "tyrosine", "moiety", ".", "This", "contention", "was", "corroborated", "by", "synthesizing", "a", "tridecapeptide", "corresponding", "to", "residues", "26", "-", "38", "of", "avidin", ";", "this", "peptide", "was", "shown", "to", "recognize", "biotin", ".", "Streptavidin", "was", "not", "susceptible", "to", "either", "enzymic", "or", "chemical", "cleavage", "methods", "used", "in", "this", "work", ".", "The", "approach", "taken", "in", "this", "study", "enabled", "the", "experimental", "distinction", "between", "the", "chemical", "and", "structural", "elements", "of", "the", "binding", "site", ".", "The", "capacity", "to", "assign", "biotin", "-", "binding", "activity", "to", "the", "tyrosine", "-", "containing", "domain", "of", "avidin", "underscores", "its", "primary", "chemical", "contribution", "to", "the", "binding", "of", "biotin", "by", "avidin", ".", "\n" ]

[ "Protein" ]

Infektionen is an umlsterm, lebensbedrohlichen is an umlsterm, Komplikationen is an umlsterm, Infektionen is an umlsterm, Hautorganismen is an umlsterm, Haut is an umlsterm, Patienten is an umlsterm, Haut is an umlsterm, Pflegepersonals is an umlsterm, Infektionen is an umlsterm, Desinfektionsmitteln is an umlsterm, antithrombotischen Mitteln is an umlsterm, Silber is an umlsterm, Kurzzeitgebrauch is an umlsterm, Antiseptika is an umlsterm, Antibiotika is an umlsterm, Verwendung is an umlsterm

IntensiveMedizin.90360349.ger.abstr_task0

Sentence: Katheterinduzierte Infektionen sind die haeufigsten lebensbedrohlichen Komplikationen in Bezug auf intravaskulaere Katheter . In den meisten Faellen , der mit Katheter verbundenen Infektionen ist die Ursache in Hautorganismen zu suchen , welche entweder auf der Haut des Patienten entstehen und auf die aeussere Oberflaeche des Katheters wandern oder auf der Haut des Pflegepersonals entstehen , welche eine Kontamination des Verbindungsstueckes mit nachfolgender bakterieller Migration entlang der inneren Oberflaeche des Katheters verursachen . Einige Massnahmen wurden im Rahmen von klinischen Studien berichtet , welche gegen vaskulaere , katheterinduzierte Infektionen schuetzen sollen . Praeventive Massnahmen , welche antimikrobielle Mittel beruecksichtigen , sind u.a. die Applikation von topischen Desinfektionsmitteln , das Spuelen von Kathetern mit einer Kombination von antimikrobiellen und antithrombotischen Mitteln , die Anwendung von mit Silber impraegnierten subkutanen Manschetten zur zentralvenoese Katheter im Kurzzeitgebrauch , eine antimikrobielle Beschichtung der Katheter entweder mit Antiseptika oder mit Antibiotika und die Verwendung eines antiseptisch ausgestatteten Katheterverbindungsstueckes . Schutzmassnahmen , welche keine antimikrobielle Mittel verwenden , sind z.B. das Plazieren und die Erhaltung vaskulaerer Katheter durch ein in der Infusionstherapie versiertes Team und die Errichtung maximaler Sterilbarrieren . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Katheterinduzierte Infektionen sind die haeufigsten lebensbedrohlichen Komplikationen in Bezug auf intravaskulaere Katheter . In den meisten Faellen , der mit Katheter verbundenen Infektionen ist die Ursache in Hautorganismen zu suchen , welche entweder auf der Haut des Patienten entstehen und auf die aeussere Oberflaeche des Katheters wandern oder auf der Haut des Pflegepersonals entstehen , welche eine Kontamination des Verbindungsstueckes mit nachfolgender bakterieller Migration entlang der inneren Oberflaeche des Katheters verursachen . Einige Massnahmen wurden im Rahmen von klinischen Studien berichtet , welche gegen vaskulaere , katheterinduzierte Infektionen schuetzen sollen . Praeventive Massnahmen , welche antimikrobielle Mittel beruecksichtigen , sind u.a. die Applikation von topischen Desinfektionsmitteln , das Spuelen von Kathetern mit einer Kombination von antimikrobiellen und antithrombotischen Mitteln , die Anwendung von mit Silber impraegnierten subkutanen Manschetten zur zentralvenoese Katheter im Kurzzeitgebrauch , eine antimikrobielle Beschichtung der Katheter entweder mit Antiseptika oder mit Antibiotika und die Verwendung eines antiseptisch ausgestatteten Katheterverbindungsstueckes . Schutzmassnahmen , welche keine antimikrobielle Mittel verwenden , sind z.B. das Plazieren und die Erhaltung vaskulaerer Katheter durch ein in der Infusionstherapie versiertes Team und die Errichtung maximaler Sterilbarrieren .

[ "Katheterinduzierte", "Infektionen", "sind", "die", "haeufigsten", "lebensbedrohlichen", "Komplikationen", "in", "Bezug", "auf", "intravaskulaere", "Katheter", ".", "In", "den", "meisten", "Faellen", ",", "der", "mit", "Katheter", "verbundenen", "Infektionen", "ist", "die", "Ursache", "in", "Hautorganismen", "zu", "suchen", ",", "welche", "entweder", "auf", "der", "Haut", "des", "Patienten", "entstehen", "und", "auf", "die", "aeussere", "Oberflaeche", "des", "Katheters", "wandern", "oder", "auf", "der", "Haut", "des", "Pflegepersonals", "entstehen", ",", "welche", "eine", "Kontamination", "des", "Verbindungsstueckes", "mit", "nachfolgender", "bakterieller", "Migration", "entlang", "der", "inneren", "Oberflaeche", "des", "Katheters", "verursachen", ".", "Einige", "Massnahmen", "wurden", "im", "Rahmen", "von", "klinischen", "Studien", "berichtet", ",", "welche", "gegen", "vaskulaere", ",", "katheterinduzierte", "Infektionen", "schuetzen", "sollen", ".", "Praeventive", "Massnahmen", ",", "welche", "antimikrobielle", "Mittel", "beruecksichtigen", ",", "sind", "u.a", ".", "die", "Applikation", "von", "topischen", "Desinfektionsmitteln", ",", "das", "Spuelen", "von", "Kathetern", "mit", "einer", "Kombination", "von", "antimikrobiellen", "und", "antithrombotischen", "Mitteln", ",", "die", "Anwendung", "von", "mit", "Silber", "impraegnierten", "subkutanen", "Manschetten", "zur", "zentralvenoese", "Katheter", "im", "Kurzzeitgebrauch", ",", "eine", "antimikrobielle", "Beschichtung", "der", "Katheter", "entweder", "mit", "Antiseptika", "oder", "mit", "Antibiotika", "und", "die", "Verwendung", "eines", "antiseptisch", "ausgestatteten", "Katheterverbindungsstueckes", ".", "Schutzmassnahmen", ",", "welche", "keine", "antimikrobielle", "Mittel", "verwenden", ",", "sind", "z.", "B.", "das", "Plazieren", "und", "die", "Erhaltung", "vaskulaerer", "Katheter", "durch", "ein", "in", "der", "Infusionstherapie", "versiertes", "Team", "und", "die", "Errichtung", "maximaler", "Sterilbarrieren", "." ]

[ "umlsterm" ]

Infektionen is an umlsterm, lebensbedrohlichen is an umlsterm, Komplikationen is an umlsterm, Infektionen is an umlsterm, Hautorganismen is an umlsterm, Haut is an umlsterm, Patienten is an umlsterm, Haut is an umlsterm, Pflegepersonals is an umlsterm, Infektionen is an umlsterm, Desinfektionsmitteln is an umlsterm, antithrombotischen Mitteln is an umlsterm, Silber is an umlsterm, Kurzzeitgebrauch is an umlsterm, Antiseptika is an umlsterm, Antibiotika is an umlsterm, Verwendung is an umlsterm

IntensiveMedizin.90360349.ger.abstr_task1

Sentence: Katheterinduzierte Infektionen sind die haeufigsten lebensbedrohlichen Komplikationen in Bezug auf intravaskulaere Katheter . In den meisten Faellen , der mit Katheter verbundenen Infektionen ist die Ursache in Hautorganismen zu suchen , welche entweder auf der Haut des Patienten entstehen und auf die aeussere Oberflaeche des Katheters wandern oder auf der Haut des Pflegepersonals entstehen , welche eine Kontamination des Verbindungsstueckes mit nachfolgender bakterieller Migration entlang der inneren Oberflaeche des Katheters verursachen . Einige Massnahmen wurden im Rahmen von klinischen Studien berichtet , welche gegen vaskulaere , katheterinduzierte Infektionen schuetzen sollen . Praeventive Massnahmen , welche antimikrobielle Mittel beruecksichtigen , sind u.a. die Applikation von topischen Desinfektionsmitteln , das Spuelen von Kathetern mit einer Kombination von antimikrobiellen und antithrombotischen Mitteln , die Anwendung von mit Silber impraegnierten subkutanen Manschetten zur zentralvenoese Katheter im Kurzzeitgebrauch , eine antimikrobielle Beschichtung der Katheter entweder mit Antiseptika oder mit Antibiotika und die Verwendung eines antiseptisch ausgestatteten Katheterverbindungsstueckes . Schutzmassnahmen , welche keine antimikrobielle Mittel verwenden , sind z.B. das Plazieren und die Erhaltung vaskulaerer Katheter durch ein in der Infusionstherapie versiertes Team und die Errichtung maximaler Sterilbarrieren . Instructions: please typing these entity words according to sentence: Infektionen, lebensbedrohlichen, Komplikationen, Infektionen, Hautorganismen, Haut, Patienten, Haut, Pflegepersonals, Infektionen, Desinfektionsmitteln, antithrombotischen Mitteln, Silber, Kurzzeitgebrauch, Antiseptika, Antibiotika, Verwendung Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Katheterinduzierte Infektionen sind die haeufigsten lebensbedrohlichen Komplikationen in Bezug auf intravaskulaere Katheter . In den meisten Faellen , der mit Katheter verbundenen Infektionen ist die Ursache in Hautorganismen zu suchen , welche entweder auf der Haut des Patienten entstehen und auf die aeussere Oberflaeche des Katheters wandern oder auf der Haut des Pflegepersonals entstehen , welche eine Kontamination des Verbindungsstueckes mit nachfolgender bakterieller Migration entlang der inneren Oberflaeche des Katheters verursachen . Einige Massnahmen wurden im Rahmen von klinischen Studien berichtet , welche gegen vaskulaere , katheterinduzierte Infektionen schuetzen sollen . Praeventive Massnahmen , welche antimikrobielle Mittel beruecksichtigen , sind u.a. die Applikation von topischen Desinfektionsmitteln , das Spuelen von Kathetern mit einer Kombination von antimikrobiellen und antithrombotischen Mitteln , die Anwendung von mit Silber impraegnierten subkutanen Manschetten zur zentralvenoese Katheter im Kurzzeitgebrauch , eine antimikrobielle Beschichtung der Katheter entweder mit Antiseptika oder mit Antibiotika und die Verwendung eines antiseptisch ausgestatteten Katheterverbindungsstueckes . Schutzmassnahmen , welche keine antimikrobielle Mittel verwenden , sind z.B. das Plazieren und die Erhaltung vaskulaerer Katheter durch ein in der Infusionstherapie versiertes Team und die Errichtung maximaler Sterilbarrieren .

[ "Katheterinduzierte", "Infektionen", "sind", "die", "haeufigsten", "lebensbedrohlichen", "Komplikationen", "in", "Bezug", "auf", "intravaskulaere", "Katheter", ".", "In", "den", "meisten", "Faellen", ",", "der", "mit", "Katheter", "verbundenen", "Infektionen", "ist", "die", "Ursache", "in", "Hautorganismen", "zu", "suchen", ",", "welche", "entweder", "auf", "der", "Haut", "des", "Patienten", "entstehen", "und", "auf", "die", "aeussere", "Oberflaeche", "des", "Katheters", "wandern", "oder", "auf", "der", "Haut", "des", "Pflegepersonals", "entstehen", ",", "welche", "eine", "Kontamination", "des", "Verbindungsstueckes", "mit", "nachfolgender", "bakterieller", "Migration", "entlang", "der", "inneren", "Oberflaeche", "des", "Katheters", "verursachen", ".", "Einige", "Massnahmen", "wurden", "im", "Rahmen", "von", "klinischen", "Studien", "berichtet", ",", "welche", "gegen", "vaskulaere", ",", "katheterinduzierte", "Infektionen", "schuetzen", "sollen", ".", "Praeventive", "Massnahmen", ",", "welche", "antimikrobielle", "Mittel", "beruecksichtigen", ",", "sind", "u.a", ".", "die", "Applikation", "von", "topischen", "Desinfektionsmitteln", ",", "das", "Spuelen", "von", "Kathetern", "mit", "einer", "Kombination", "von", "antimikrobiellen", "und", "antithrombotischen", "Mitteln", ",", "die", "Anwendung", "von", "mit", "Silber", "impraegnierten", "subkutanen", "Manschetten", "zur", "zentralvenoese", "Katheter", "im", "Kurzzeitgebrauch", ",", "eine", "antimikrobielle", "Beschichtung", "der", "Katheter", "entweder", "mit", "Antiseptika", "oder", "mit", "Antibiotika", "und", "die", "Verwendung", "eines", "antiseptisch", "ausgestatteten", "Katheterverbindungsstueckes", ".", "Schutzmassnahmen", ",", "welche", "keine", "antimikrobielle", "Mittel", "verwenden", ",", "sind", "z.", "B.", "das", "Plazieren", "und", "die", "Erhaltung", "vaskulaerer", "Katheter", "durch", "ein", "in", "der", "Infusionstherapie", "versiertes", "Team", "und", "die", "Errichtung", "maximaler", "Sterilbarrieren", "." ]

[ "umlsterm" ]

Infektionen, lebensbedrohlichen, Komplikationen, Infektionen, Hautorganismen, Haut, Patienten, Haut, Pflegepersonals, Infektionen, Desinfektionsmitteln, antithrombotischen Mitteln, Silber, Kurzzeitgebrauch, Antiseptika, Antibiotika, Verwendung

IntensiveMedizin.90360349.ger.abstr_task2

Sentence: Katheterinduzierte Infektionen sind die haeufigsten lebensbedrohlichen Komplikationen in Bezug auf intravaskulaere Katheter . In den meisten Faellen , der mit Katheter verbundenen Infektionen ist die Ursache in Hautorganismen zu suchen , welche entweder auf der Haut des Patienten entstehen und auf die aeussere Oberflaeche des Katheters wandern oder auf der Haut des Pflegepersonals entstehen , welche eine Kontamination des Verbindungsstueckes mit nachfolgender bakterieller Migration entlang der inneren Oberflaeche des Katheters verursachen . Einige Massnahmen wurden im Rahmen von klinischen Studien berichtet , welche gegen vaskulaere , katheterinduzierte Infektionen schuetzen sollen . Praeventive Massnahmen , welche antimikrobielle Mittel beruecksichtigen , sind u.a. die Applikation von topischen Desinfektionsmitteln , das Spuelen von Kathetern mit einer Kombination von antimikrobiellen und antithrombotischen Mitteln , die Anwendung von mit Silber impraegnierten subkutanen Manschetten zur zentralvenoese Katheter im Kurzzeitgebrauch , eine antimikrobielle Beschichtung der Katheter entweder mit Antiseptika oder mit Antibiotika und die Verwendung eines antiseptisch ausgestatteten Katheterverbindungsstueckes . Schutzmassnahmen , welche keine antimikrobielle Mittel verwenden , sind z.B. das Plazieren und die Erhaltung vaskulaerer Katheter durch ein in der Infusionstherapie versiertes Team und die Errichtung maximaler Sterilbarrieren . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Katheterinduzierte Infektionen sind die haeufigsten lebensbedrohlichen Komplikationen in Bezug auf intravaskulaere Katheter . In den meisten Faellen , der mit Katheter verbundenen Infektionen ist die Ursache in Hautorganismen zu suchen , welche entweder auf der Haut des Patienten entstehen und auf die aeussere Oberflaeche des Katheters wandern oder auf der Haut des Pflegepersonals entstehen , welche eine Kontamination des Verbindungsstueckes mit nachfolgender bakterieller Migration entlang der inneren Oberflaeche des Katheters verursachen . Einige Massnahmen wurden im Rahmen von klinischen Studien berichtet , welche gegen vaskulaere , katheterinduzierte Infektionen schuetzen sollen . Praeventive Massnahmen , welche antimikrobielle Mittel beruecksichtigen , sind u.a. die Applikation von topischen Desinfektionsmitteln , das Spuelen von Kathetern mit einer Kombination von antimikrobiellen und antithrombotischen Mitteln , die Anwendung von mit Silber impraegnierten subkutanen Manschetten zur zentralvenoese Katheter im Kurzzeitgebrauch , eine antimikrobielle Beschichtung der Katheter entweder mit Antiseptika oder mit Antibiotika und die Verwendung eines antiseptisch ausgestatteten Katheterverbindungsstueckes . Schutzmassnahmen , welche keine antimikrobielle Mittel verwenden , sind z.B. das Plazieren und die Erhaltung vaskulaerer Katheter durch ein in der Infusionstherapie versiertes Team und die Errichtung maximaler Sterilbarrieren .

[ "Katheterinduzierte", "Infektionen", "sind", "die", "haeufigsten", "lebensbedrohlichen", "Komplikationen", "in", "Bezug", "auf", "intravaskulaere", "Katheter", ".", "In", "den", "meisten", "Faellen", ",", "der", "mit", "Katheter", "verbundenen", "Infektionen", "ist", "die", "Ursache", "in", "Hautorganismen", "zu", "suchen", ",", "welche", "entweder", "auf", "der", "Haut", "des", "Patienten", "entstehen", "und", "auf", "die", "aeussere", "Oberflaeche", "des", "Katheters", "wandern", "oder", "auf", "der", "Haut", "des", "Pflegepersonals", "entstehen", ",", "welche", "eine", "Kontamination", "des", "Verbindungsstueckes", "mit", "nachfolgender", "bakterieller", "Migration", "entlang", "der", "inneren", "Oberflaeche", "des", "Katheters", "verursachen", ".", "Einige", "Massnahmen", "wurden", "im", "Rahmen", "von", "klinischen", "Studien", "berichtet", ",", "welche", "gegen", "vaskulaere", ",", "katheterinduzierte", "Infektionen", "schuetzen", "sollen", ".", "Praeventive", "Massnahmen", ",", "welche", "antimikrobielle", "Mittel", "beruecksichtigen", ",", "sind", "u.a", ".", "die", "Applikation", "von", "topischen", "Desinfektionsmitteln", ",", "das", "Spuelen", "von", "Kathetern", "mit", "einer", "Kombination", "von", "antimikrobiellen", "und", "antithrombotischen", "Mitteln", ",", "die", "Anwendung", "von", "mit", "Silber", "impraegnierten", "subkutanen", "Manschetten", "zur", "zentralvenoese", "Katheter", "im", "Kurzzeitgebrauch", ",", "eine", "antimikrobielle", "Beschichtung", "der", "Katheter", "entweder", "mit", "Antiseptika", "oder", "mit", "Antibiotika", "und", "die", "Verwendung", "eines", "antiseptisch", "ausgestatteten", "Katheterverbindungsstueckes", ".", "Schutzmassnahmen", ",", "welche", "keine", "antimikrobielle", "Mittel", "verwenden", ",", "sind", "z.", "B.", "das", "Plazieren", "und", "die", "Erhaltung", "vaskulaerer", "Katheter", "durch", "ein", "in", "der", "Infusionstherapie", "versiertes", "Team", "und", "die", "Errichtung", "maximaler", "Sterilbarrieren", "." ]

[ "umlsterm" ]

recombinant hirudin is a Chemicals & Drugs

7472_task0

Sentence: Rotational thrombelastometry for the bedside monitoring of recombinant hirudin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Chemicals & Drugs

[ "O", "O", "O", "O", "O", "O", "O", "B-Chemicals & Drugs", "I-Chemicals & Drugs", "O" ]

Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.

[ "Rotational", "thrombelastometry", "for", "the", "bedside", "monitoring", "of", "recombinant", "hirudin", "." ]

[ "Diseases & Disorders", "", "Chemicals & Drugs" ]

recombinant hirudin is a Chemicals & Drugs

7472_task1

Sentence: Rotational thrombelastometry for the bedside monitoring of recombinant hirudin. Instructions: please typing these entity words according to sentence: recombinant hirudin Options: Chemicals & Drugs

[ "O", "O", "O", "O", "O", "O", "O", "B-Chemicals & Drugs", "I-Chemicals & Drugs", "O" ]

Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.

[ "Rotational", "thrombelastometry", "for", "the", "bedside", "monitoring", "of", "recombinant", "hirudin", "." ]

[ "Diseases & Disorders", "", "Chemicals & Drugs" ]

recombinant hirudin

7472_task2

Sentence: Rotational thrombelastometry for the bedside monitoring of recombinant hirudin. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Chemicals & Drugs", "I-Chemicals & Drugs", "O" ]

Rotational thrombelastometry for the bedside monitoring of recombinant hirudin.

[ "Rotational", "thrombelastometry", "for", "the", "bedside", "monitoring", "of", "recombinant", "hirudin", "." ]

[ "Diseases & Disorders", "", "Chemicals & Drugs" ]

fluoxetine is a CHEMICAL, hippocampal glucocorticoid receptor is a GENE-Y

23353902_task0

Sentence: Gender-specific effects of fluoxetine on hippocampal glucocorticoid receptor phosphorylation and behavior in chronically stressed rats. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]

Gender-specific effects of fluoxetine on hippocampal glucocorticoid receptor phosphorylation and behavior in chronically stressed rats.

[ "Gender", "-", "specific", "effects", "of", "fluoxetine", "on", "hippocampal", "glucocorticoid", "receptor", "phosphorylation", "and", "behavior", "in", "chronically", "stressed", "rats", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

fluoxetine is a CHEMICAL, hippocampal glucocorticoid receptor is a GENE-Y

23353902_task1

Sentence: Gender-specific effects of fluoxetine on hippocampal glucocorticoid receptor phosphorylation and behavior in chronically stressed rats. Instructions: please typing these entity words according to sentence: fluoxetine, hippocampal glucocorticoid receptor Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]

Gender-specific effects of fluoxetine on hippocampal glucocorticoid receptor phosphorylation and behavior in chronically stressed rats.

[ "Gender", "-", "specific", "effects", "of", "fluoxetine", "on", "hippocampal", "glucocorticoid", "receptor", "phosphorylation", "and", "behavior", "in", "chronically", "stressed", "rats", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

fluoxetine, hippocampal glucocorticoid receptor

23353902_task2

Sentence: Gender-specific effects of fluoxetine on hippocampal glucocorticoid receptor phosphorylation and behavior in chronically stressed rats. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]

Gender-specific effects of fluoxetine on hippocampal glucocorticoid receptor phosphorylation and behavior in chronically stressed rats.

[ "Gender", "-", "specific", "effects", "of", "fluoxetine", "on", "hippocampal", "glucocorticoid", "receptor", "phosphorylation", "and", "behavior", "in", "chronically", "stressed", "rats", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

beta - adrenoceptor blockade is a Outcome_Physical, prizidilol hydrochloride . is a Intervention_Pharmacological, Prizidilol hydrochloride is a Intervention_Pharmacological, beta - adrenoceptor blockade . is a Outcome_Physical, healthy volunteers is a Participant_Condition, Isoprenaline is a Intervention_Pharmacological, heart rate dose - response curves is a Outcome_Physical, diastolic blood pressure is a Outcome_Physical, propranolol is a Intervention_Pharmacological

78161_task0

Sentence: An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride . 1 Prizidilol hydrochloride ( SK & F 92657 ) is a new compound which causes both arteriolar dilatation and beta-adrenoceptor blockade . The effect of a single oral dose on the responses of heart rate and blood pressure to isoprenaline infusion has been studied in healthy volunteers . 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol , indicating antagonism by this compound at beta-adrenoceptors in the heart . 3 Isoprenaline dose-response curves for decreases in diastolic blood pressure also showed shifts to the right after oral prizidilol , providing evidence of beta-adrenoceptor antagonism by this drug in peripheral resistance vessels . 4 The peak effect of a 40 mg dose of propranolol was greater than that of a 200 mg dose of prizidilol but both drugs caused persistent beta-adrenoceptor blockade for at least 7 h after ingestion . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride . 1 Prizidilol hydrochloride ( SK & F 92657 ) is a new compound which causes both arteriolar dilatation and beta-adrenoceptor blockade . The effect of a single oral dose on the responses of heart rate and blood pressure to isoprenaline infusion has been studied in healthy volunteers . 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol , indicating antagonism by this compound at beta-adrenoceptors in the heart . 3 Isoprenaline dose-response curves for decreases in diastolic blood pressure also showed shifts to the right after oral prizidilol , providing evidence of beta-adrenoceptor antagonism by this drug in peripheral resistance vessels . 4 The peak effect of a 40 mg dose of propranolol was greater than that of a 200 mg dose of prizidilol but both drugs caused persistent beta-adrenoceptor blockade for at least 7 h after ingestion .

[ "An", "assessment", "of", "beta", "-", "adrenoceptor", "blockade", "in", "man", "by", "prizidilol", "hydrochloride", ".", "1", "Prizidilol", "hydrochloride", "(", "SK", "&", "F", "92657", ")", "is", "a", "new", "compound", "which", "causes", "both", "arteriolar", "dilatation", "and", "beta", "-", "adrenoceptor", "blockade", ".", "The", "effect", "of", "a", "single", "oral", "dose", "on", "the", "responses", "of", "heart", "rate", "and", "blood", "pressure", "to", "isoprenaline", "infusion", "has", "been", "studied", "in", "healthy", "volunteers", ".", "2", "Isoprenaline", "heart", "rate", "dose", "-", "response", "curves", "showed", "parallel", "shifts", "to", "the", "right", "after", "oral", "prizidilol", ",", "indicating", "antagonism", "by", "this", "compound", "at", "beta", "-", "adrenoceptors", "in", "the", "heart", ".", "3", "Isoprenaline", "dose", "-", "response", "curves", "for", "decreases", "in", "diastolic", "blood", "pressure", "also", "showed", "shifts", "to", "the", "right", "after", "oral", "prizidilol", ",", "providing", "evidence", "of", "beta", "-", "adrenoceptor", "antagonism", "by", "this", "drug", "in", "peripheral", "resistance", "vessels", ".", "4", "The", "peak", "effect", "of", "a", "40", "mg", "dose", "of", "propranolol", "was", "greater", "than", "that", "of", "a", "200", "mg", "dose", "of", "prizidilol", "but", "both", "drugs", "caused", "persistent", "beta", "-", "adrenoceptor", "blockade", "for", "at", "least", "7", "h", "after", "ingestion", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition" ]

beta - adrenoceptor blockade is a Outcome_Physical, prizidilol hydrochloride . is a Intervention_Pharmacological, Prizidilol hydrochloride is a Intervention_Pharmacological, beta - adrenoceptor blockade . is a Outcome_Physical, healthy volunteers is a Participant_Condition, Isoprenaline is a Intervention_Pharmacological, heart rate dose - response curves is a Outcome_Physical, diastolic blood pressure is a Outcome_Physical, propranolol is a Intervention_Pharmacological

78161_task1

Sentence: An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride . 1 Prizidilol hydrochloride ( SK & F 92657 ) is a new compound which causes both arteriolar dilatation and beta-adrenoceptor blockade . The effect of a single oral dose on the responses of heart rate and blood pressure to isoprenaline infusion has been studied in healthy volunteers . 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol , indicating antagonism by this compound at beta-adrenoceptors in the heart . 3 Isoprenaline dose-response curves for decreases in diastolic blood pressure also showed shifts to the right after oral prizidilol , providing evidence of beta-adrenoceptor antagonism by this drug in peripheral resistance vessels . 4 The peak effect of a 40 mg dose of propranolol was greater than that of a 200 mg dose of prizidilol but both drugs caused persistent beta-adrenoceptor blockade for at least 7 h after ingestion . Instructions: please typing these entity words according to sentence: beta - adrenoceptor blockade, prizidilol hydrochloride ., Prizidilol hydrochloride, beta - adrenoceptor blockade ., healthy volunteers, Isoprenaline, heart rate dose - response curves, diastolic blood pressure, propranolol Options: Intervention_Pharmacological, Outcome_Physical, Participant_Condition

[ "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride . 1 Prizidilol hydrochloride ( SK & F 92657 ) is a new compound which causes both arteriolar dilatation and beta-adrenoceptor blockade . The effect of a single oral dose on the responses of heart rate and blood pressure to isoprenaline infusion has been studied in healthy volunteers . 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol , indicating antagonism by this compound at beta-adrenoceptors in the heart . 3 Isoprenaline dose-response curves for decreases in diastolic blood pressure also showed shifts to the right after oral prizidilol , providing evidence of beta-adrenoceptor antagonism by this drug in peripheral resistance vessels . 4 The peak effect of a 40 mg dose of propranolol was greater than that of a 200 mg dose of prizidilol but both drugs caused persistent beta-adrenoceptor blockade for at least 7 h after ingestion .

[ "An", "assessment", "of", "beta", "-", "adrenoceptor", "blockade", "in", "man", "by", "prizidilol", "hydrochloride", ".", "1", "Prizidilol", "hydrochloride", "(", "SK", "&", "F", "92657", ")", "is", "a", "new", "compound", "which", "causes", "both", "arteriolar", "dilatation", "and", "beta", "-", "adrenoceptor", "blockade", ".", "The", "effect", "of", "a", "single", "oral", "dose", "on", "the", "responses", "of", "heart", "rate", "and", "blood", "pressure", "to", "isoprenaline", "infusion", "has", "been", "studied", "in", "healthy", "volunteers", ".", "2", "Isoprenaline", "heart", "rate", "dose", "-", "response", "curves", "showed", "parallel", "shifts", "to", "the", "right", "after", "oral", "prizidilol", ",", "indicating", "antagonism", "by", "this", "compound", "at", "beta", "-", "adrenoceptors", "in", "the", "heart", ".", "3", "Isoprenaline", "dose", "-", "response", "curves", "for", "decreases", "in", "diastolic", "blood", "pressure", "also", "showed", "shifts", "to", "the", "right", "after", "oral", "prizidilol", ",", "providing", "evidence", "of", "beta", "-", "adrenoceptor", "antagonism", "by", "this", "drug", "in", "peripheral", "resistance", "vessels", ".", "4", "The", "peak", "effect", "of", "a", "40", "mg", "dose", "of", "propranolol", "was", "greater", "than", "that", "of", "a", "200", "mg", "dose", "of", "prizidilol", "but", "both", "drugs", "caused", "persistent", "beta", "-", "adrenoceptor", "blockade", "for", "at", "least", "7", "h", "after", "ingestion", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition" ]

beta - adrenoceptor blockade, prizidilol hydrochloride ., Prizidilol hydrochloride, beta - adrenoceptor blockade ., healthy volunteers, Isoprenaline, heart rate dose - response curves, diastolic blood pressure, propranolol

78161_task2

Sentence: An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride . 1 Prizidilol hydrochloride ( SK & F 92657 ) is a new compound which causes both arteriolar dilatation and beta-adrenoceptor blockade . The effect of a single oral dose on the responses of heart rate and blood pressure to isoprenaline infusion has been studied in healthy volunteers . 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol , indicating antagonism by this compound at beta-adrenoceptors in the heart . 3 Isoprenaline dose-response curves for decreases in diastolic blood pressure also showed shifts to the right after oral prizidilol , providing evidence of beta-adrenoceptor antagonism by this drug in peripheral resistance vessels . 4 The peak effect of a 40 mg dose of propranolol was greater than that of a 200 mg dose of prizidilol but both drugs caused persistent beta-adrenoceptor blockade for at least 7 h after ingestion . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Intervention_Pharmacological", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

An assessment of beta-adrenoceptor blockade in man by prizidilol hydrochloride . 1 Prizidilol hydrochloride ( SK & F 92657 ) is a new compound which causes both arteriolar dilatation and beta-adrenoceptor blockade . The effect of a single oral dose on the responses of heart rate and blood pressure to isoprenaline infusion has been studied in healthy volunteers . 2 Isoprenaline heart rate dose-response curves showed parallel shifts to the right after oral prizidilol , indicating antagonism by this compound at beta-adrenoceptors in the heart . 3 Isoprenaline dose-response curves for decreases in diastolic blood pressure also showed shifts to the right after oral prizidilol , providing evidence of beta-adrenoceptor antagonism by this drug in peripheral resistance vessels . 4 The peak effect of a 40 mg dose of propranolol was greater than that of a 200 mg dose of prizidilol but both drugs caused persistent beta-adrenoceptor blockade for at least 7 h after ingestion .

[ "An", "assessment", "of", "beta", "-", "adrenoceptor", "blockade", "in", "man", "by", "prizidilol", "hydrochloride", ".", "1", "Prizidilol", "hydrochloride", "(", "SK", "&", "F", "92657", ")", "is", "a", "new", "compound", "which", "causes", "both", "arteriolar", "dilatation", "and", "beta", "-", "adrenoceptor", "blockade", ".", "The", "effect", "of", "a", "single", "oral", "dose", "on", "the", "responses", "of", "heart", "rate", "and", "blood", "pressure", "to", "isoprenaline", "infusion", "has", "been", "studied", "in", "healthy", "volunteers", ".", "2", "Isoprenaline", "heart", "rate", "dose", "-", "response", "curves", "showed", "parallel", "shifts", "to", "the", "right", "after", "oral", "prizidilol", ",", "indicating", "antagonism", "by", "this", "compound", "at", "beta", "-", "adrenoceptors", "in", "the", "heart", ".", "3", "Isoprenaline", "dose", "-", "response", "curves", "for", "decreases", "in", "diastolic", "blood", "pressure", "also", "showed", "shifts", "to", "the", "right", "after", "oral", "prizidilol", ",", "providing", "evidence", "of", "beta", "-", "adrenoceptor", "antagonism", "by", "this", "drug", "in", "peripheral", "resistance", "vessels", ".", "4", "The", "peak", "effect", "of", "a", "40", "mg", "dose", "of", "propranolol", "was", "greater", "than", "that", "of", "a", "200", "mg", "dose", "of", "prizidilol", "but", "both", "drugs", "caused", "persistent", "beta", "-", "adrenoceptor", "blockade", "for", "at", "least", "7", "h", "after", "ingestion", "." ]

[ "Outcome_Physical", "Intervention_Pharmacological", "Participant_Condition" ]

thrombin is a GENE-Y, W215A is a GENE-N, E217A is a GENE-N

15252033_task0

Sentence: The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N

[ "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]

The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket.

[ "The", "anticoagulant", "thrombin", "mutant", "W215A", "/", "E217A", "has", "a", "collapsed", "primary", "specificity", "pocket", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

thrombin is a GENE-Y, W215A is a GENE-N, E217A is a GENE-N

15252033_task1

Sentence: The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. Instructions: please typing these entity words according to sentence: thrombin, W215A, E217A Options: GENE-Y, GENE-N

[ "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]

The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket.

[ "The", "anticoagulant", "thrombin", "mutant", "W215A", "/", "E217A", "has", "a", "collapsed", "primary", "specificity", "pocket", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

thrombin, W215A, E217A

15252033_task2

Sentence: The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-GENE-Y", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O" ]

The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket.

[ "The", "anticoagulant", "thrombin", "mutant", "W215A", "/", "E217A", "has", "a", "collapsed", "primary", "specificity", "pocket", "." ]

[ "CHEMICAL", "GENE-Y", "GENE-N" ]

Mammakarzinome is an umlsterm, Mutationen is an umlsterm, Gene is an umlsterm, Frauen is an umlsterm, Lebens is an umlsterm, Mammakarzinom is an umlsterm, Erkrankungsalter is an umlsterm, Frauen is an umlsterm, Mammakarzinoms is an umlsterm, Frauen is an umlsterm, genetischer Praedisposition is an umlsterm, Mammakarzinom is an umlsterm, Brustselbstuntersuchung is an umlsterm, Sonographie is an umlsterm, Mammographie is an umlsterm, Magnetresonanztomographie is an umlsterm

DerRadiologe.70370591.ger.abstr_task0

Sentence: Mammakarzinome sind in etwa 5 % auf eine genetische Disposition zurueckzufuehren . Am haeufigsten finden sich Mutationen im Bereich der Gene BRCA1 und BRCA2. Frauen mit einer genetischen Disposition erkranken in etwa 70-90 % im Laufe ihres Lebens an einem Mammakarzinom . Das Erkrankungsalter bei diesen Frauen liegt in der Regel deutlich niedriger als bei den spontanen Formen des Mammakarzinoms , so dass vorhandene Frueherkennungskonzepte auf der Basis eines Mammographiescreenings nicht ohne weiteres auf dieses Hochrisikokollektiv uebertragbar sind . Im folgenden wird ein integriertes Konzept zur Frueherkennung bei Frauen mit genetischer Praedisposition fuer ein Mammakarzinom auf der Basis von Brustselbstuntersuchung , klinischer Untersuchung , Sonographie , Mammographie und Magnetresonanztomographie vorgestellt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Mammakarzinome sind in etwa 5 % auf eine genetische Disposition zurueckzufuehren . Am haeufigsten finden sich Mutationen im Bereich der Gene BRCA1 und BRCA2. Frauen mit einer genetischen Disposition erkranken in etwa 70-90 % im Laufe ihres Lebens an einem Mammakarzinom . Das Erkrankungsalter bei diesen Frauen liegt in der Regel deutlich niedriger als bei den spontanen Formen des Mammakarzinoms , so dass vorhandene Frueherkennungskonzepte auf der Basis eines Mammographiescreenings nicht ohne weiteres auf dieses Hochrisikokollektiv uebertragbar sind . Im folgenden wird ein integriertes Konzept zur Frueherkennung bei Frauen mit genetischer Praedisposition fuer ein Mammakarzinom auf der Basis von Brustselbstuntersuchung , klinischer Untersuchung , Sonographie , Mammographie und Magnetresonanztomographie vorgestellt .

[ "Mammakarzinome", "sind", "in", "etwa", "5", "%", "auf", "eine", "genetische", "Disposition", "zurueckzufuehren", ".", "Am", "haeufigsten", "finden", "sich", "Mutationen", "im", "Bereich", "der", "Gene", "BRCA1", "und", "BRCA2", ".", "Frauen", "mit", "einer", "genetischen", "Disposition", "erkranken", "in", "etwa", "70", "-", "90", "%", "im", "Laufe", "ihres", "Lebens", "an", "einem", "Mammakarzinom", ".", "Das", "Erkrankungsalter", "bei", "diesen", "Frauen", "liegt", "in", "der", "Regel", "deutlich", "niedriger", "als", "bei", "den", "spontanen", "Formen", "des", "Mammakarzinoms", ",", "so", "dass", "vorhandene", "Frueherkennungskonzepte", "auf", "der", "Basis", "eines", "Mammographiescreenings", "nicht", "ohne", "weiteres", "auf", "dieses", "Hochrisikokollektiv", "uebertragbar", "sind", ".", "Im", "folgenden", "wird", "ein", "integriertes", "Konzept", "zur", "Frueherkennung", "bei", "Frauen", "mit", "genetischer", "Praedisposition", "fuer", "ein", "Mammakarzinom", "auf", "der", "Basis", "von", "Brustselbstuntersuchung", ",", "klinischer", "Untersuchung", ",", "Sonographie", ",", "Mammographie", "und", "Magnetresonanztomographie", "vorgestellt", "." ]

[ "umlsterm" ]

Mammakarzinome is an umlsterm, Mutationen is an umlsterm, Gene is an umlsterm, Frauen is an umlsterm, Lebens is an umlsterm, Mammakarzinom is an umlsterm, Erkrankungsalter is an umlsterm, Frauen is an umlsterm, Mammakarzinoms is an umlsterm, Frauen is an umlsterm, genetischer Praedisposition is an umlsterm, Mammakarzinom is an umlsterm, Brustselbstuntersuchung is an umlsterm, Sonographie is an umlsterm, Mammographie is an umlsterm, Magnetresonanztomographie is an umlsterm

DerRadiologe.70370591.ger.abstr_task1

Sentence: Mammakarzinome sind in etwa 5 % auf eine genetische Disposition zurueckzufuehren . Am haeufigsten finden sich Mutationen im Bereich der Gene BRCA1 und BRCA2. Frauen mit einer genetischen Disposition erkranken in etwa 70-90 % im Laufe ihres Lebens an einem Mammakarzinom . Das Erkrankungsalter bei diesen Frauen liegt in der Regel deutlich niedriger als bei den spontanen Formen des Mammakarzinoms , so dass vorhandene Frueherkennungskonzepte auf der Basis eines Mammographiescreenings nicht ohne weiteres auf dieses Hochrisikokollektiv uebertragbar sind . Im folgenden wird ein integriertes Konzept zur Frueherkennung bei Frauen mit genetischer Praedisposition fuer ein Mammakarzinom auf der Basis von Brustselbstuntersuchung , klinischer Untersuchung , Sonographie , Mammographie und Magnetresonanztomographie vorgestellt . Instructions: please typing these entity words according to sentence: Mammakarzinome, Mutationen, Gene, Frauen, Lebens, Mammakarzinom, Erkrankungsalter, Frauen, Mammakarzinoms, Frauen, genetischer Praedisposition, Mammakarzinom, Brustselbstuntersuchung, Sonographie, Mammographie, Magnetresonanztomographie Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Mammakarzinome sind in etwa 5 % auf eine genetische Disposition zurueckzufuehren . Am haeufigsten finden sich Mutationen im Bereich der Gene BRCA1 und BRCA2. Frauen mit einer genetischen Disposition erkranken in etwa 70-90 % im Laufe ihres Lebens an einem Mammakarzinom . Das Erkrankungsalter bei diesen Frauen liegt in der Regel deutlich niedriger als bei den spontanen Formen des Mammakarzinoms , so dass vorhandene Frueherkennungskonzepte auf der Basis eines Mammographiescreenings nicht ohne weiteres auf dieses Hochrisikokollektiv uebertragbar sind . Im folgenden wird ein integriertes Konzept zur Frueherkennung bei Frauen mit genetischer Praedisposition fuer ein Mammakarzinom auf der Basis von Brustselbstuntersuchung , klinischer Untersuchung , Sonographie , Mammographie und Magnetresonanztomographie vorgestellt .

[ "Mammakarzinome", "sind", "in", "etwa", "5", "%", "auf", "eine", "genetische", "Disposition", "zurueckzufuehren", ".", "Am", "haeufigsten", "finden", "sich", "Mutationen", "im", "Bereich", "der", "Gene", "BRCA1", "und", "BRCA2", ".", "Frauen", "mit", "einer", "genetischen", "Disposition", "erkranken", "in", "etwa", "70", "-", "90", "%", "im", "Laufe", "ihres", "Lebens", "an", "einem", "Mammakarzinom", ".", "Das", "Erkrankungsalter", "bei", "diesen", "Frauen", "liegt", "in", "der", "Regel", "deutlich", "niedriger", "als", "bei", "den", "spontanen", "Formen", "des", "Mammakarzinoms", ",", "so", "dass", "vorhandene", "Frueherkennungskonzepte", "auf", "der", "Basis", "eines", "Mammographiescreenings", "nicht", "ohne", "weiteres", "auf", "dieses", "Hochrisikokollektiv", "uebertragbar", "sind", ".", "Im", "folgenden", "wird", "ein", "integriertes", "Konzept", "zur", "Frueherkennung", "bei", "Frauen", "mit", "genetischer", "Praedisposition", "fuer", "ein", "Mammakarzinom", "auf", "der", "Basis", "von", "Brustselbstuntersuchung", ",", "klinischer", "Untersuchung", ",", "Sonographie", ",", "Mammographie", "und", "Magnetresonanztomographie", "vorgestellt", "." ]

[ "umlsterm" ]

Mammakarzinome, Mutationen, Gene, Frauen, Lebens, Mammakarzinom, Erkrankungsalter, Frauen, Mammakarzinoms, Frauen, genetischer Praedisposition, Mammakarzinom, Brustselbstuntersuchung, Sonographie, Mammographie, Magnetresonanztomographie

DerRadiologe.70370591.ger.abstr_task2

Sentence: Mammakarzinome sind in etwa 5 % auf eine genetische Disposition zurueckzufuehren . Am haeufigsten finden sich Mutationen im Bereich der Gene BRCA1 und BRCA2. Frauen mit einer genetischen Disposition erkranken in etwa 70-90 % im Laufe ihres Lebens an einem Mammakarzinom . Das Erkrankungsalter bei diesen Frauen liegt in der Regel deutlich niedriger als bei den spontanen Formen des Mammakarzinoms , so dass vorhandene Frueherkennungskonzepte auf der Basis eines Mammographiescreenings nicht ohne weiteres auf dieses Hochrisikokollektiv uebertragbar sind . Im folgenden wird ein integriertes Konzept zur Frueherkennung bei Frauen mit genetischer Praedisposition fuer ein Mammakarzinom auf der Basis von Brustselbstuntersuchung , klinischer Untersuchung , Sonographie , Mammographie und Magnetresonanztomographie vorgestellt . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]

Mammakarzinome sind in etwa 5 % auf eine genetische Disposition zurueckzufuehren . Am haeufigsten finden sich Mutationen im Bereich der Gene BRCA1 und BRCA2. Frauen mit einer genetischen Disposition erkranken in etwa 70-90 % im Laufe ihres Lebens an einem Mammakarzinom . Das Erkrankungsalter bei diesen Frauen liegt in der Regel deutlich niedriger als bei den spontanen Formen des Mammakarzinoms , so dass vorhandene Frueherkennungskonzepte auf der Basis eines Mammographiescreenings nicht ohne weiteres auf dieses Hochrisikokollektiv uebertragbar sind . Im folgenden wird ein integriertes Konzept zur Frueherkennung bei Frauen mit genetischer Praedisposition fuer ein Mammakarzinom auf der Basis von Brustselbstuntersuchung , klinischer Untersuchung , Sonographie , Mammographie und Magnetresonanztomographie vorgestellt .

[ "Mammakarzinome", "sind", "in", "etwa", "5", "%", "auf", "eine", "genetische", "Disposition", "zurueckzufuehren", ".", "Am", "haeufigsten", "finden", "sich", "Mutationen", "im", "Bereich", "der", "Gene", "BRCA1", "und", "BRCA2", ".", "Frauen", "mit", "einer", "genetischen", "Disposition", "erkranken", "in", "etwa", "70", "-", "90", "%", "im", "Laufe", "ihres", "Lebens", "an", "einem", "Mammakarzinom", ".", "Das", "Erkrankungsalter", "bei", "diesen", "Frauen", "liegt", "in", "der", "Regel", "deutlich", "niedriger", "als", "bei", "den", "spontanen", "Formen", "des", "Mammakarzinoms", ",", "so", "dass", "vorhandene", "Frueherkennungskonzepte", "auf", "der", "Basis", "eines", "Mammographiescreenings", "nicht", "ohne", "weiteres", "auf", "dieses", "Hochrisikokollektiv", "uebertragbar", "sind", ".", "Im", "folgenden", "wird", "ein", "integriertes", "Konzept", "zur", "Frueherkennung", "bei", "Frauen", "mit", "genetischer", "Praedisposition", "fuer", "ein", "Mammakarzinom", "auf", "der", "Basis", "von", "Brustselbstuntersuchung", ",", "klinischer", "Untersuchung", ",", "Sonographie", ",", "Mammographie", "und", "Magnetresonanztomographie", "vorgestellt", "." ]

[ "umlsterm" ]

ETS1 is a Protein, GM - CSF is a Protein, promoter is a Entity, Granulocyte - macrophage colony stimulating factor is a Protein, GM - CSF is a Protein, Cis - acting elements is a Entity, GM - CSF is a Protein, ETS1 is a Protein, ETS1 is a Protein, GM - CSF is a Protein, ETS1 is a Protein, ETS1 is a Protein, GM - CSF is a Protein, ETS1 is a Protein, ETS1 is a Protein

727_task0

Sentence: ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkappaB, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NFkappaB or AP1 transcription factors are supplied by co-transfection. We confirm that binding of endogenous NFkappaB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkappaB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkappaB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkappaB, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NFkappaB or AP1 transcription factors are supplied by co-transfection. We confirm that binding of endogenous NFkappaB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkappaB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkappaB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells.

[ "ETS1", ",", "NFkappaB", "and", "AP1", "synergistically", "transactivate", "the", "human", "GM", "-", "CSF", "promoter", ".", "\n", "Activation", "of", "helper", "T", "cells", "results", "in", "coordinate", "expression", "of", "a", "number", "of", "cytokines", "involved", "in", "differentiation", ",", "proliferation", "and", "activation", "of", "the", "haematopoietic", "system", ".", "Granulocyte", "-", "macrophage", "colony", "stimulating", "factor", "(", "GM", "-", "CSF", ")", "is", "one", "such", "cytokine", ",", "whose", "increased", "expression", "results", "mostly", "from", "increases", "in", "transcription", ".", "Cis", "-", "acting", "elements", "with", "NFkappaB", ",", "AP1", "and", "ETS", "-", "like", "binding", "motifs", "have", "been", "identified", "in", "the", "promoter", "region", "of", "the", "GM", "-", "CSF", "gene", ",", "and", "are", "important", "or", "essential", "for", "transcriptional", "activity", "following", "T", "cell", "activation", ".", "ETS1", "is", "a", "transcription", "factor", "of", "the", "ETS", "family", "that", "is", "expressed", "in", "T", "cells", ".", "We", "have", "previously", "shown", "that", "ETS1", "can", "transactivate", "GM", "-", "CSF", "in", "Jurkat", "T", "cells", ",", "but", "only", "after", "the", "cells", "have", "been", "stimulated", "by", "treatment", "with", "PMA", "and", "ionomycin", ",", "agents", "that", "mimic", "T", "cell", "activation", ".", "Thus", "we", "proposed", "that", "ETS1", ",", "which", "is", "expressed", "constitutively", "in", "Jurkat", "cells", ",", "may", "act", "in", "concert", "with", "PMA", "/", "ionomycin", "inducible", "factors", ".", "Here", "we", "show", "that", "ETS1", "can", "transactivate", "a", "GM", "-", "CSF", "reporter", "construct", "in", "unstimulated", "Jurkat", "cells", ",", "providing", "that", "either", "NFkappaB", "or", "AP1", "transcription", "factors", "are", "supplied", "by", "co", "-", "transfection", ".", "We", "confirm", "that", "binding", "of", "endogenous", "NFkappaB", "and", "AP1", "is", "induced", "following", "PMA", "/", "ionomycin", "treatment", "of", "T", "cells", ".", "Transactivation", "by", "ETS1", ",", "NFkappaB", "and", "AP1", "is", "synergistic", ",", "and", "mutation", "of", "the", "individual", "binding", "sites", "reveals", "that", "the", "transcriptional", "activities", "of", "these", "factors", "are", "interdependent", ".", "Our", "results", "suggest", "that", "constitutive", "ETS1", ",", "and", "inducible", "NFkappaB", "and", "AP1", ",", "cooperate", "as", "part", "of", "a", "higher", "order", "transcriptional", "complex", "in", "activated", "T", "cells", "." ]

[ "Protein", "Entity" ]

ETS1 is a Protein, GM - CSF is a Protein, promoter is a Entity, Granulocyte - macrophage colony stimulating factor is a Protein, GM - CSF is a Protein, Cis - acting elements is a Entity, GM - CSF is a Protein, ETS1 is a Protein, ETS1 is a Protein, GM - CSF is a Protein, ETS1 is a Protein, ETS1 is a Protein, GM - CSF is a Protein, ETS1 is a Protein, ETS1 is a Protein

727_task1

Sentence: ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkappaB, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NFkappaB or AP1 transcription factors are supplied by co-transfection. We confirm that binding of endogenous NFkappaB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkappaB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkappaB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells. Instructions: please typing these entity words according to sentence: ETS1, GM - CSF, promoter, Granulocyte - macrophage colony stimulating factor, GM - CSF, Cis - acting elements, GM - CSF, ETS1, ETS1, GM - CSF, ETS1, ETS1, GM - CSF, ETS1, ETS1 Options: Entity, Protein

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkappaB, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NFkappaB or AP1 transcription factors are supplied by co-transfection. We confirm that binding of endogenous NFkappaB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkappaB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkappaB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells.

[ "ETS1", ",", "NFkappaB", "and", "AP1", "synergistically", "transactivate", "the", "human", "GM", "-", "CSF", "promoter", ".", "\n", "Activation", "of", "helper", "T", "cells", "results", "in", "coordinate", "expression", "of", "a", "number", "of", "cytokines", "involved", "in", "differentiation", ",", "proliferation", "and", "activation", "of", "the", "haematopoietic", "system", ".", "Granulocyte", "-", "macrophage", "colony", "stimulating", "factor", "(", "GM", "-", "CSF", ")", "is", "one", "such", "cytokine", ",", "whose", "increased", "expression", "results", "mostly", "from", "increases", "in", "transcription", ".", "Cis", "-", "acting", "elements", "with", "NFkappaB", ",", "AP1", "and", "ETS", "-", "like", "binding", "motifs", "have", "been", "identified", "in", "the", "promoter", "region", "of", "the", "GM", "-", "CSF", "gene", ",", "and", "are", "important", "or", "essential", "for", "transcriptional", "activity", "following", "T", "cell", "activation", ".", "ETS1", "is", "a", "transcription", "factor", "of", "the", "ETS", "family", "that", "is", "expressed", "in", "T", "cells", ".", "We", "have", "previously", "shown", "that", "ETS1", "can", "transactivate", "GM", "-", "CSF", "in", "Jurkat", "T", "cells", ",", "but", "only", "after", "the", "cells", "have", "been", "stimulated", "by", "treatment", "with", "PMA", "and", "ionomycin", ",", "agents", "that", "mimic", "T", "cell", "activation", ".", "Thus", "we", "proposed", "that", "ETS1", ",", "which", "is", "expressed", "constitutively", "in", "Jurkat", "cells", ",", "may", "act", "in", "concert", "with", "PMA", "/", "ionomycin", "inducible", "factors", ".", "Here", "we", "show", "that", "ETS1", "can", "transactivate", "a", "GM", "-", "CSF", "reporter", "construct", "in", "unstimulated", "Jurkat", "cells", ",", "providing", "that", "either", "NFkappaB", "or", "AP1", "transcription", "factors", "are", "supplied", "by", "co", "-", "transfection", ".", "We", "confirm", "that", "binding", "of", "endogenous", "NFkappaB", "and", "AP1", "is", "induced", "following", "PMA", "/", "ionomycin", "treatment", "of", "T", "cells", ".", "Transactivation", "by", "ETS1", ",", "NFkappaB", "and", "AP1", "is", "synergistic", ",", "and", "mutation", "of", "the", "individual", "binding", "sites", "reveals", "that", "the", "transcriptional", "activities", "of", "these", "factors", "are", "interdependent", ".", "Our", "results", "suggest", "that", "constitutive", "ETS1", ",", "and", "inducible", "NFkappaB", "and", "AP1", ",", "cooperate", "as", "part", "of", "a", "higher", "order", "transcriptional", "complex", "in", "activated", "T", "cells", "." ]

[ "Protein", "Entity" ]

ETS1, GM - CSF, promoter, Granulocyte - macrophage colony stimulating factor, GM - CSF, Cis - acting elements, GM - CSF, ETS1, ETS1, GM - CSF, ETS1, ETS1, GM - CSF, ETS1, ETS1

727_task2

Sentence: ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkappaB, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NFkappaB or AP1 transcription factors are supplied by co-transfection. We confirm that binding of endogenous NFkappaB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkappaB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkappaB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells. Instructions: please extract entity words from the input sentence

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkappaB, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NFkappaB or AP1 transcription factors are supplied by co-transfection. We confirm that binding of endogenous NFkappaB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkappaB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkappaB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells.

[ "ETS1", ",", "NFkappaB", "and", "AP1", "synergistically", "transactivate", "the", "human", "GM", "-", "CSF", "promoter", ".", "\n", "Activation", "of", "helper", "T", "cells", "results", "in", "coordinate", "expression", "of", "a", "number", "of", "cytokines", "involved", "in", "differentiation", ",", "proliferation", "and", "activation", "of", "the", "haematopoietic", "system", ".", "Granulocyte", "-", "macrophage", "colony", "stimulating", "factor", "(", "GM", "-", "CSF", ")", "is", "one", "such", "cytokine", ",", "whose", "increased", "expression", "results", "mostly", "from", "increases", "in", "transcription", ".", "Cis", "-", "acting", "elements", "with", "NFkappaB", ",", "AP1", "and", "ETS", "-", "like", "binding", "motifs", "have", "been", "identified", "in", "the", "promoter", "region", "of", "the", "GM", "-", "CSF", "gene", ",", "and", "are", "important", "or", "essential", "for", "transcriptional", "activity", "following", "T", "cell", "activation", ".", "ETS1", "is", "a", "transcription", "factor", "of", "the", "ETS", "family", "that", "is", "expressed", "in", "T", "cells", ".", "We", "have", "previously", "shown", "that", "ETS1", "can", "transactivate", "GM", "-", "CSF", "in", "Jurkat", "T", "cells", ",", "but", "only", "after", "the", "cells", "have", "been", "stimulated", "by", "treatment", "with", "PMA", "and", "ionomycin", ",", "agents", "that", "mimic", "T", "cell", "activation", ".", "Thus", "we", "proposed", "that", "ETS1", ",", "which", "is", "expressed", "constitutively", "in", "Jurkat", "cells", ",", "may", "act", "in", "concert", "with", "PMA", "/", "ionomycin", "inducible", "factors", ".", "Here", "we", "show", "that", "ETS1", "can", "transactivate", "a", "GM", "-", "CSF", "reporter", "construct", "in", "unstimulated", "Jurkat", "cells", ",", "providing", "that", "either", "NFkappaB", "or", "AP1", "transcription", "factors", "are", "supplied", "by", "co", "-", "transfection", ".", "We", "confirm", "that", "binding", "of", "endogenous", "NFkappaB", "and", "AP1", "is", "induced", "following", "PMA", "/", "ionomycin", "treatment", "of", "T", "cells", ".", "Transactivation", "by", "ETS1", ",", "NFkappaB", "and", "AP1", "is", "synergistic", ",", "and", "mutation", "of", "the", "individual", "binding", "sites", "reveals", "that", "the", "transcriptional", "activities", "of", "these", "factors", "are", "interdependent", ".", "Our", "results", "suggest", "that", "constitutive", "ETS1", ",", "and", "inducible", "NFkappaB", "and", "AP1", ",", "cooperate", "as", "part", "of", "a", "higher", "order", "transcriptional", "complex", "in", "activated", "T", "cells", "." ]

[ "Protein", "Entity" ]

heart failure is a Condition, NYHA is a Measurement, II - IV is a Value, previous is a Temporal, treatment is a Procedure, diuretics is a Drug

NCT01942109_inc_task0

Sentence: heart failure NYHA II-IV previous treatment with diuretics age>18 years Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Value, Procedure, Measurement, Drug

[ "B-Condition", "I-Condition", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Temporal", "B-Procedure", "O", "B-Drug", "O", "O", "O", "O" ]

heart failure NYHA II-IV previous treatment with diuretics age>18 years

[ "heart", "failure", "NYHA", "II", "-", "IV", "\n", "previous", "treatment", "with", "diuretics", "\n", "age>18", "years", "\n" ]

[ "Condition", "Procedure", "Drug", "Value", "Temporal", "Measurement", "Person" ]

heart failure is a Condition, NYHA is a Measurement, II - IV is a Value, previous is a Temporal, treatment is a Procedure, diuretics is a Drug

NCT01942109_inc_task1

Sentence: heart failure NYHA II-IV previous treatment with diuretics age>18 years Instructions: please typing these entity words according to sentence: heart failure, NYHA, II - IV, previous, treatment, diuretics Options: Temporal, Condition, Value, Procedure, Measurement, Drug

[ "B-Condition", "I-Condition", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Temporal", "B-Procedure", "O", "B-Drug", "O", "O", "O", "O" ]

heart failure NYHA II-IV previous treatment with diuretics age>18 years

[ "heart", "failure", "NYHA", "II", "-", "IV", "\n", "previous", "treatment", "with", "diuretics", "\n", "age>18", "years", "\n" ]

[ "Condition", "Procedure", "Drug", "Value", "Temporal", "Measurement", "Person" ]

heart failure, NYHA, II - IV, previous, treatment, diuretics

NCT01942109_inc_task2

Sentence: heart failure NYHA II-IV previous treatment with diuretics age>18 years Instructions: please extract entity words from the input sentence

[ "B-Condition", "I-Condition", "B-Measurement", "B-Value", "I-Value", "I-Value", "O", "B-Temporal", "B-Procedure", "O", "B-Drug", "O", "O", "O", "O" ]

heart failure NYHA II-IV previous treatment with diuretics age>18 years

[ "heart", "failure", "NYHA", "II", "-", "IV", "\n", "previous", "treatment", "with", "diuretics", "\n", "age>18", "years", "\n" ]

[ "Condition", "Procedure", "Drug", "Value", "Temporal", "Measurement", "Person" ]

Jesus is a NOMBRE_SUJETO_ASISTENCIA, Barrios Larrea is a NOMBRE_SUJETO_ASISTENCIA, Calle Tres Palomas , 27 is a CALLE, 48 20895745 94 is a ID_ASEGURAMIENTO, Calle Ibarra , 1 is a CALLE, Donostia - San Sebastián is a TERRITORIO, 20080 is a TERRITORIO, 03/03/1956 is a FECHAS, España is a PAIS, 59 años is a EDAD_SUJETO_ASISTENCIA, 27/07/2015 is a FECHAS, 8934679 is a ID_CONTACTO_ASISTENCIAL, Sergio Andrés Torres Bayona is a NOMBRE_PERSONAL_SANITARIO, 20 20 28563 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 59 años is a EDAD_SUJETO_ASISTENCIA, Sergio Andrés Torres Bayona is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitario Donostia is a HOSPITAL, C/ Doctor Beguiristain , 117 is a CALLE, 20080 is a TERRITORIO, Donostia - San Sebastián is a TERRITORIO, sergioandrestorres@hotmail.com is a CORREO_ELECTRONICO

429_task0

Sentence: Datos del paciente. Nombre: Jesus. Apellidos: Barrios Larrea. NHC: Calle Tres Palomas, 27. NASS: 48 20895745 94. Domicilio: Calle Ibarra, 1. Localidad/ Provincia: Donostia-San Sebastián. CP: 20080. Datos asistenciales. Fecha de nacimiento: 03/03/1956. País: España. Edad: 59 años Sexo:H. Fecha de Ingreso: 27/07/2015. Servicio: Neurocirugía. Episodio: 8934679. Médico: Sergio Andrés Torres Bayona NºCol: 20 20 28563. Informe clínico del paciente: varón de 59 años, diagnosticado de carcinoma escamoso de laringe T2N2b, que se trató inicialmente con tres ciclos de quimioterapia sin remisión, por lo que tres meses después se realizó una laringectomía supraglótica, con vaciamiento radical incompleto modificado del lado izquierdo. La anatomía patológica demostró un carcinoma escamoso infiltrante en hemiepiglotis izquierda con 8 de 11 ganglios linfáticos positivos de la cadena yugular interna, subdigástricos y supraclaviculares izquierdos. Posteriormente recibió quimioterapia y radioterapia sobre supraglotis e hipofaringe y áreas ganglionares bilaterales. Nueve meses después de la cirugía consultó por cefalea de tres semanas de evolución asociada a diplopia binocular y visión borrosa del ojo derecho, evidenciándose oftalmoparesia del III, IV y VI pares craneales derechos. Una resonancia magnética (RM) cerebral mostró una masa en la porción posterior y lateral del seno cavernoso derecho, con protusión hacia la cisterna prepontina, bien delimitada, con captación homogénea de gadolinio y unas dimensiones de 11x14,4x12,2 mm. En la ventana ósea de la TAC no se observaron ni lesiones líticas ni invasión del ala o seno esfenoidal. La TAC toraco-abdomino-pélvica fue negativa. El diagnóstico diferencial radiológico fue de schwannoma, meningioma o metástasis. Se realizó una biopsia abierta con abordaje transilviano a la pared lateral del seno cavernoso donde se observó la invasión tumoral del espacio intradural. El resultado anatomopatológico fue de carcinoma escamoso. Posteriormente se administró radioterapia a titulo paliativo. Tres semanas después de la cirugía el paciente consultó por dolor dorsal sin clínica neurológica. Un estudio de RM de raquis mostró lesiones focales en los cuerpos D4, D6 y D10 sospechosas de implantes metastásicos. Con el tratamiento radioterápico se alivió la cefalea, pero desarrolló una oftalmoplejía, conservando únicamente la abducción del ojo derecho. El paciente falleció nueve meses tras el diagnóstico de la metástasis en el seno cavernoso. Remitido por: Dr. Sergio Andrés Torres Bayona Servicio de Neurocirugía Hospital Universitario Donostia C/ Doctor Beguiristain, 117 20080 Donostia-San Sebastián E-mail: sergioandrestorres@hotmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_CONTACTO_ASISTENCIAL, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Jesus. Apellidos: Barrios Larrea. NHC: Calle Tres Palomas, 27. NASS: 48 20895745 94. Domicilio: Calle Ibarra, 1. Localidad/ Provincia: Donostia-San Sebastián. CP: 20080. Datos asistenciales. Fecha de nacimiento: 03/03/1956. País: España. Edad: 59 años Sexo:H. Fecha de Ingreso: 27/07/2015. Servicio: Neurocirugía. Episodio: 8934679. Médico: Sergio Andrés Torres Bayona NºCol: 20 20 28563. Informe clínico del paciente: varón de 59 años, diagnosticado de carcinoma escamoso de laringe T2N2b, que se trató inicialmente con tres ciclos de quimioterapia sin remisión, por lo que tres meses después se realizó una laringectomía supraglótica, con vaciamiento radical incompleto modificado del lado izquierdo. La anatomía patológica demostró un carcinoma escamoso infiltrante en hemiepiglotis izquierda con 8 de 11 ganglios linfáticos positivos de la cadena yugular interna, subdigástricos y supraclaviculares izquierdos. Posteriormente recibió quimioterapia y radioterapia sobre supraglotis e hipofaringe y áreas ganglionares bilaterales. Nueve meses después de la cirugía consultó por cefalea de tres semanas de evolución asociada a diplopia binocular y visión borrosa del ojo derecho, evidenciándose oftalmoparesia del III, IV y VI pares craneales derechos. Una resonancia magnética (RM) cerebral mostró una masa en la porción posterior y lateral del seno cavernoso derecho, con protusión hacia la cisterna prepontina, bien delimitada, con captación homogénea de gadolinio y unas dimensiones de 11x14,4x12,2 mm. En la ventana ósea de la TAC no se observaron ni lesiones líticas ni invasión del ala o seno esfenoidal. La TAC toraco-abdomino-pélvica fue negativa. El diagnóstico diferencial radiológico fue de schwannoma, meningioma o metástasis. Se realizó una biopsia abierta con abordaje transilviano a la pared lateral del seno cavernoso donde se observó la invasión tumoral del espacio intradural. El resultado anatomopatológico fue de carcinoma escamoso. Posteriormente se administró radioterapia a titulo paliativo. Tres semanas después de la cirugía el paciente consultó por dolor dorsal sin clínica neurológica. Un estudio de RM de raquis mostró lesiones focales en los cuerpos D4, D6 y D10 sospechosas de implantes metastásicos. Con el tratamiento radioterápico se alivió la cefalea, pero desarrolló una oftalmoplejía, conservando únicamente la abducción del ojo derecho. El paciente falleció nueve meses tras el diagnóstico de la metástasis en el seno cavernoso. Remitido por: Dr. Sergio Andrés Torres Bayona Servicio de Neurocirugía Hospital Universitario Donostia C/ Doctor Beguiristain, 117 20080 Donostia-San Sebastián E-mail: sergioandrestorres@hotmail.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Jesus", ".", "\n", "Apellidos", ":", "Barrios", "Larrea", ".", "\n", "NHC", ":", "Calle", "Tres", "Palomas", ",", "27", ".", "\n", "NASS", ":", "48", "20895745", "94", ".", "\n", "Domicilio", ":", "Calle", "Ibarra", ",", "1", ".", "\n", "Localidad/", "Provincia", ":", "Donostia", "-", "San", "Sebastián", ".", "\n", "CP", ":", "20080", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "03/03/1956", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "59", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "27/07/2015", ".", "\n", "Servicio", ":", "Neurocirugía", ".", "\n", "Episodio", ":", "8934679", ".", "\n", "Médico", ":", "Sergio", "Andrés", "Torres", "Bayona", "NºCol", ":", "20", "20", "28563", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "varón", "de", "59", "años", ",", "diagnosticado", "de", "carcinoma", "escamoso", "de", "laringe", "T2N2b", ",", "que", "se", "trató", "inicialmente", "con", "tres", "ciclos", "de", "quimioterapia", "sin", "remisión", ",", "por", "lo", "que", "tres", "meses", "después", "se", "realizó", "una", "laringectomía", "supraglótica", ",", "con", "vaciamiento", "radical", "incompleto", "modificado", "del", "lado", "izquierdo", ".", "La", "anatomía", "patológica", "demostró", "un", "carcinoma", "escamoso", "infiltrante", "en", "hemiepiglotis", "izquierda", "con", "8", "de", "11", "ganglios", "linfáticos", "positivos", "de", "la", "cadena", "yugular", "interna", ",", "subdigástricos", "y", "supraclaviculares", "izquierdos", ".", "Posteriormente", "recibió", "quimioterapia", "y", "radioterapia", "sobre", "supraglotis", "e", "hipofaringe", "y", "áreas", "ganglionares", "bilaterales", ".", "\n", "Nueve", "meses", "después", "de", "la", "cirugía", "consultó", "por", "cefalea", "de", "tres", "semanas", "de", "evolución", "asociada", "a", "diplopia", "binocular", "y", "visión", "borrosa", "del", "ojo", "derecho", ",", "evidenciándose", "oftalmoparesia", "del", "III", ",", "IV", "y", "VI", "pares", "craneales", "derechos", ".", "Una", "resonancia", "magnética", "(", "RM", ")", "cerebral", "mostró", "una", "masa", "en", "la", "porción", "posterior", "y", "lateral", "del", "seno", "cavernoso", "derecho", ",", "con", "protusión", "hacia", "la", "cisterna", "prepontina", ",", "bien", "delimitada", ",", "con", "captación", "homogénea", "de", "gadolinio", "y", "unas", "dimensiones", "de", "11x14,4x12,2", "mm", ".", "En", "la", "ventana", "ósea", "de", "la", "TAC", "no", "se", "observaron", "ni", "lesiones", "líticas", "ni", "invasión", "del", "ala", "o", "seno", "esfenoidal", ".", "La", "TAC", "toraco", "-", "abdomino", "-", "pélvica", "fue", "negativa", ".", "El", "diagnóstico", "diferencial", "radiológico", "fue", "de", "schwannoma", ",", "meningioma", "o", "metástasis", ".", "\n", "Se", "realizó", "una", "biopsia", "abierta", "con", "abordaje", "transilviano", "a", "la", "pared", "lateral", "del", "seno", "cavernoso", "donde", "se", "observó", "la", "invasión", "tumoral", "del", "espacio", "intradural", ".", "El", "resultado", "anatomopatológico", "fue", "de", "carcinoma", "escamoso", ".", "Posteriormente", "se", "administró", "radioterapia", "a", "titulo", "paliativo", ".", "Tres", "semanas", "después", "de", "la", "cirugía", "el", "paciente", "consultó", "por", "dolor", "dorsal", "sin", "clínica", "neurológica", ".", "Un", "estudio", "de", "RM", "de", "raquis", "mostró", "lesiones", "focales", "en", "los", "cuerpos", "D4", ",", "D6", "y", "D10", "sospechosas", "de", "implantes", "metastásicos", ".", "\n", "Con", "el", "tratamiento", "radioterápico", "se", "alivió", "la", "cefalea", ",", "pero", "desarrolló", "una", "oftalmoplejía", ",", "conservando", "únicamente", "la", "abducción", "del", "ojo", "derecho", ".", "El", "paciente", "falleció", "nueve", "meses", "tras", "el", "diagnóstico", "de", "la", "metástasis", "en", "el", "seno", "cavernoso", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Sergio", "Andrés", "Torres", "Bayona", "Servicio", "de", "Neurocirugía", "Hospital", "Universitario", "Donostia", "C/", "Doctor", "Beguiristain", ",", "117", "20080", "Donostia", "-", "San", "Sebastián", "E", "-", "mail", ":", "sergioandrestorres@hotmail.com", "\n" ]

[ "HOSPITAL", "CORREO_ELECTRONICO", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "TERRITORIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "ID_CONTACTO_ASISTENCIAL", "EDAD_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Jesus is a NOMBRE_SUJETO_ASISTENCIA, Barrios Larrea is a NOMBRE_SUJETO_ASISTENCIA, Calle Tres Palomas , 27 is a CALLE, 48 20895745 94 is a ID_ASEGURAMIENTO, Calle Ibarra , 1 is a CALLE, Donostia - San Sebastián is a TERRITORIO, 20080 is a TERRITORIO, 03/03/1956 is a FECHAS, España is a PAIS, 59 años is a EDAD_SUJETO_ASISTENCIA, 27/07/2015 is a FECHAS, 8934679 is a ID_CONTACTO_ASISTENCIAL, Sergio Andrés Torres Bayona is a NOMBRE_PERSONAL_SANITARIO, 20 20 28563 is a ID_TITULACION_PERSONAL_SANITARIO, varón is a SEXO_SUJETO_ASISTENCIA, 59 años is a EDAD_SUJETO_ASISTENCIA, Sergio Andrés Torres Bayona is a NOMBRE_PERSONAL_SANITARIO, Hospital Universitario Donostia is a HOSPITAL, C/ Doctor Beguiristain , 117 is a CALLE, 20080 is a TERRITORIO, Donostia - San Sebastián is a TERRITORIO, sergioandrestorres@hotmail.com is a CORREO_ELECTRONICO

429_task1

Sentence: Datos del paciente. Nombre: Jesus. Apellidos: Barrios Larrea. NHC: Calle Tres Palomas, 27. NASS: 48 20895745 94. Domicilio: Calle Ibarra, 1. Localidad/ Provincia: Donostia-San Sebastián. CP: 20080. Datos asistenciales. Fecha de nacimiento: 03/03/1956. País: España. Edad: 59 años Sexo:H. Fecha de Ingreso: 27/07/2015. Servicio: Neurocirugía. Episodio: 8934679. Médico: Sergio Andrés Torres Bayona NºCol: 20 20 28563. Informe clínico del paciente: varón de 59 años, diagnosticado de carcinoma escamoso de laringe T2N2b, que se trató inicialmente con tres ciclos de quimioterapia sin remisión, por lo que tres meses después se realizó una laringectomía supraglótica, con vaciamiento radical incompleto modificado del lado izquierdo. La anatomía patológica demostró un carcinoma escamoso infiltrante en hemiepiglotis izquierda con 8 de 11 ganglios linfáticos positivos de la cadena yugular interna, subdigástricos y supraclaviculares izquierdos. Posteriormente recibió quimioterapia y radioterapia sobre supraglotis e hipofaringe y áreas ganglionares bilaterales. Nueve meses después de la cirugía consultó por cefalea de tres semanas de evolución asociada a diplopia binocular y visión borrosa del ojo derecho, evidenciándose oftalmoparesia del III, IV y VI pares craneales derechos. Una resonancia magnética (RM) cerebral mostró una masa en la porción posterior y lateral del seno cavernoso derecho, con protusión hacia la cisterna prepontina, bien delimitada, con captación homogénea de gadolinio y unas dimensiones de 11x14,4x12,2 mm. En la ventana ósea de la TAC no se observaron ni lesiones líticas ni invasión del ala o seno esfenoidal. La TAC toraco-abdomino-pélvica fue negativa. El diagnóstico diferencial radiológico fue de schwannoma, meningioma o metástasis. Se realizó una biopsia abierta con abordaje transilviano a la pared lateral del seno cavernoso donde se observó la invasión tumoral del espacio intradural. El resultado anatomopatológico fue de carcinoma escamoso. Posteriormente se administró radioterapia a titulo paliativo. Tres semanas después de la cirugía el paciente consultó por dolor dorsal sin clínica neurológica. Un estudio de RM de raquis mostró lesiones focales en los cuerpos D4, D6 y D10 sospechosas de implantes metastásicos. Con el tratamiento radioterápico se alivió la cefalea, pero desarrolló una oftalmoplejía, conservando únicamente la abducción del ojo derecho. El paciente falleció nueve meses tras el diagnóstico de la metástasis en el seno cavernoso. Remitido por: Dr. Sergio Andrés Torres Bayona Servicio de Neurocirugía Hospital Universitario Donostia C/ Doctor Beguiristain, 117 20080 Donostia-San Sebastián E-mail: sergioandrestorres@hotmail.com Instructions: please typing these entity words according to sentence: Jesus, Barrios Larrea, Calle Tres Palomas , 27, 48 20895745 94, Calle Ibarra , 1, Donostia - San Sebastián, 20080, 03/03/1956, España, 59 años, 27/07/2015, 8934679, Sergio Andrés Torres Bayona, 20 20 28563, varón, 59 años, Sergio Andrés Torres Bayona, Hospital Universitario Donostia, C/ Doctor Beguiristain , 117, 20080, Donostia - San Sebastián, sergioandrestorres@hotmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, FECHAS, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_CONTACTO_ASISTENCIAL, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Jesus. Apellidos: Barrios Larrea. NHC: Calle Tres Palomas, 27. NASS: 48 20895745 94. Domicilio: Calle Ibarra, 1. Localidad/ Provincia: Donostia-San Sebastián. CP: 20080. Datos asistenciales. Fecha de nacimiento: 03/03/1956. País: España. Edad: 59 años Sexo:H. Fecha de Ingreso: 27/07/2015. Servicio: Neurocirugía. Episodio: 8934679. Médico: Sergio Andrés Torres Bayona NºCol: 20 20 28563. Informe clínico del paciente: varón de 59 años, diagnosticado de carcinoma escamoso de laringe T2N2b, que se trató inicialmente con tres ciclos de quimioterapia sin remisión, por lo que tres meses después se realizó una laringectomía supraglótica, con vaciamiento radical incompleto modificado del lado izquierdo. La anatomía patológica demostró un carcinoma escamoso infiltrante en hemiepiglotis izquierda con 8 de 11 ganglios linfáticos positivos de la cadena yugular interna, subdigástricos y supraclaviculares izquierdos. Posteriormente recibió quimioterapia y radioterapia sobre supraglotis e hipofaringe y áreas ganglionares bilaterales. Nueve meses después de la cirugía consultó por cefalea de tres semanas de evolución asociada a diplopia binocular y visión borrosa del ojo derecho, evidenciándose oftalmoparesia del III, IV y VI pares craneales derechos. Una resonancia magnética (RM) cerebral mostró una masa en la porción posterior y lateral del seno cavernoso derecho, con protusión hacia la cisterna prepontina, bien delimitada, con captación homogénea de gadolinio y unas dimensiones de 11x14,4x12,2 mm. En la ventana ósea de la TAC no se observaron ni lesiones líticas ni invasión del ala o seno esfenoidal. La TAC toraco-abdomino-pélvica fue negativa. El diagnóstico diferencial radiológico fue de schwannoma, meningioma o metástasis. Se realizó una biopsia abierta con abordaje transilviano a la pared lateral del seno cavernoso donde se observó la invasión tumoral del espacio intradural. El resultado anatomopatológico fue de carcinoma escamoso. Posteriormente se administró radioterapia a titulo paliativo. Tres semanas después de la cirugía el paciente consultó por dolor dorsal sin clínica neurológica. Un estudio de RM de raquis mostró lesiones focales en los cuerpos D4, D6 y D10 sospechosas de implantes metastásicos. Con el tratamiento radioterápico se alivió la cefalea, pero desarrolló una oftalmoplejía, conservando únicamente la abducción del ojo derecho. El paciente falleció nueve meses tras el diagnóstico de la metástasis en el seno cavernoso. Remitido por: Dr. Sergio Andrés Torres Bayona Servicio de Neurocirugía Hospital Universitario Donostia C/ Doctor Beguiristain, 117 20080 Donostia-San Sebastián E-mail: sergioandrestorres@hotmail.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Jesus", ".", "\n", "Apellidos", ":", "Barrios", "Larrea", ".", "\n", "NHC", ":", "Calle", "Tres", "Palomas", ",", "27", ".", "\n", "NASS", ":", "48", "20895745", "94", ".", "\n", "Domicilio", ":", "Calle", "Ibarra", ",", "1", ".", "\n", "Localidad/", "Provincia", ":", "Donostia", "-", "San", "Sebastián", ".", "\n", "CP", ":", "20080", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "03/03/1956", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "59", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "27/07/2015", ".", "\n", "Servicio", ":", "Neurocirugía", ".", "\n", "Episodio", ":", "8934679", ".", "\n", "Médico", ":", "Sergio", "Andrés", "Torres", "Bayona", "NºCol", ":", "20", "20", "28563", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "varón", "de", "59", "años", ",", "diagnosticado", "de", "carcinoma", "escamoso", "de", "laringe", "T2N2b", ",", "que", "se", "trató", "inicialmente", "con", "tres", "ciclos", "de", "quimioterapia", "sin", "remisión", ",", "por", "lo", "que", "tres", "meses", "después", "se", "realizó", "una", "laringectomía", "supraglótica", ",", "con", "vaciamiento", "radical", "incompleto", "modificado", "del", "lado", "izquierdo", ".", "La", "anatomía", "patológica", "demostró", "un", "carcinoma", "escamoso", "infiltrante", "en", "hemiepiglotis", "izquierda", "con", "8", "de", "11", "ganglios", "linfáticos", "positivos", "de", "la", "cadena", "yugular", "interna", ",", "subdigástricos", "y", "supraclaviculares", "izquierdos", ".", "Posteriormente", "recibió", "quimioterapia", "y", "radioterapia", "sobre", "supraglotis", "e", "hipofaringe", "y", "áreas", "ganglionares", "bilaterales", ".", "\n", "Nueve", "meses", "después", "de", "la", "cirugía", "consultó", "por", "cefalea", "de", "tres", "semanas", "de", "evolución", "asociada", "a", "diplopia", "binocular", "y", "visión", "borrosa", "del", "ojo", "derecho", ",", "evidenciándose", "oftalmoparesia", "del", "III", ",", "IV", "y", "VI", "pares", "craneales", "derechos", ".", "Una", "resonancia", "magnética", "(", "RM", ")", "cerebral", "mostró", "una", "masa", "en", "la", "porción", "posterior", "y", "lateral", "del", "seno", "cavernoso", "derecho", ",", "con", "protusión", "hacia", "la", "cisterna", "prepontina", ",", "bien", "delimitada", ",", "con", "captación", "homogénea", "de", "gadolinio", "y", "unas", "dimensiones", "de", "11x14,4x12,2", "mm", ".", "En", "la", "ventana", "ósea", "de", "la", "TAC", "no", "se", "observaron", "ni", "lesiones", "líticas", "ni", "invasión", "del", "ala", "o", "seno", "esfenoidal", ".", "La", "TAC", "toraco", "-", "abdomino", "-", "pélvica", "fue", "negativa", ".", "El", "diagnóstico", "diferencial", "radiológico", "fue", "de", "schwannoma", ",", "meningioma", "o", "metástasis", ".", "\n", "Se", "realizó", "una", "biopsia", "abierta", "con", "abordaje", "transilviano", "a", "la", "pared", "lateral", "del", "seno", "cavernoso", "donde", "se", "observó", "la", "invasión", "tumoral", "del", "espacio", "intradural", ".", "El", "resultado", "anatomopatológico", "fue", "de", "carcinoma", "escamoso", ".", "Posteriormente", "se", "administró", "radioterapia", "a", "titulo", "paliativo", ".", "Tres", "semanas", "después", "de", "la", "cirugía", "el", "paciente", "consultó", "por", "dolor", "dorsal", "sin", "clínica", "neurológica", ".", "Un", "estudio", "de", "RM", "de", "raquis", "mostró", "lesiones", "focales", "en", "los", "cuerpos", "D4", ",", "D6", "y", "D10", "sospechosas", "de", "implantes", "metastásicos", ".", "\n", "Con", "el", "tratamiento", "radioterápico", "se", "alivió", "la", "cefalea", ",", "pero", "desarrolló", "una", "oftalmoplejía", ",", "conservando", "únicamente", "la", "abducción", "del", "ojo", "derecho", ".", "El", "paciente", "falleció", "nueve", "meses", "tras", "el", "diagnóstico", "de", "la", "metástasis", "en", "el", "seno", "cavernoso", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Sergio", "Andrés", "Torres", "Bayona", "Servicio", "de", "Neurocirugía", "Hospital", "Universitario", "Donostia", "C/", "Doctor", "Beguiristain", ",", "117", "20080", "Donostia", "-", "San", "Sebastián", "E", "-", "mail", ":", "sergioandrestorres@hotmail.com", "\n" ]

[ "HOSPITAL", "CORREO_ELECTRONICO", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "TERRITORIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "ID_CONTACTO_ASISTENCIAL", "EDAD_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Jesus, Barrios Larrea, Calle Tres Palomas , 27, 48 20895745 94, Calle Ibarra , 1, Donostia - San Sebastián, 20080, 03/03/1956, España, 59 años, 27/07/2015, 8934679, Sergio Andrés Torres Bayona, 20 20 28563, varón, 59 años, Sergio Andrés Torres Bayona, Hospital Universitario Donostia, C/ Doctor Beguiristain , 117, 20080, Donostia - San Sebastián, sergioandrestorres@hotmail.com

429_task2

Sentence: Datos del paciente. Nombre: Jesus. Apellidos: Barrios Larrea. NHC: Calle Tres Palomas, 27. NASS: 48 20895745 94. Domicilio: Calle Ibarra, 1. Localidad/ Provincia: Donostia-San Sebastián. CP: 20080. Datos asistenciales. Fecha de nacimiento: 03/03/1956. País: España. Edad: 59 años Sexo:H. Fecha de Ingreso: 27/07/2015. Servicio: Neurocirugía. Episodio: 8934679. Médico: Sergio Andrés Torres Bayona NºCol: 20 20 28563. Informe clínico del paciente: varón de 59 años, diagnosticado de carcinoma escamoso de laringe T2N2b, que se trató inicialmente con tres ciclos de quimioterapia sin remisión, por lo que tres meses después se realizó una laringectomía supraglótica, con vaciamiento radical incompleto modificado del lado izquierdo. La anatomía patológica demostró un carcinoma escamoso infiltrante en hemiepiglotis izquierda con 8 de 11 ganglios linfáticos positivos de la cadena yugular interna, subdigástricos y supraclaviculares izquierdos. Posteriormente recibió quimioterapia y radioterapia sobre supraglotis e hipofaringe y áreas ganglionares bilaterales. Nueve meses después de la cirugía consultó por cefalea de tres semanas de evolución asociada a diplopia binocular y visión borrosa del ojo derecho, evidenciándose oftalmoparesia del III, IV y VI pares craneales derechos. Una resonancia magnética (RM) cerebral mostró una masa en la porción posterior y lateral del seno cavernoso derecho, con protusión hacia la cisterna prepontina, bien delimitada, con captación homogénea de gadolinio y unas dimensiones de 11x14,4x12,2 mm. En la ventana ósea de la TAC no se observaron ni lesiones líticas ni invasión del ala o seno esfenoidal. La TAC toraco-abdomino-pélvica fue negativa. El diagnóstico diferencial radiológico fue de schwannoma, meningioma o metástasis. Se realizó una biopsia abierta con abordaje transilviano a la pared lateral del seno cavernoso donde se observó la invasión tumoral del espacio intradural. El resultado anatomopatológico fue de carcinoma escamoso. Posteriormente se administró radioterapia a titulo paliativo. Tres semanas después de la cirugía el paciente consultó por dolor dorsal sin clínica neurológica. Un estudio de RM de raquis mostró lesiones focales en los cuerpos D4, D6 y D10 sospechosas de implantes metastásicos. Con el tratamiento radioterápico se alivió la cefalea, pero desarrolló una oftalmoplejía, conservando únicamente la abducción del ojo derecho. El paciente falleció nueve meses tras el diagnóstico de la metástasis en el seno cavernoso. Remitido por: Dr. Sergio Andrés Torres Bayona Servicio de Neurocirugía Hospital Universitario Donostia C/ Doctor Beguiristain, 117 20080 Donostia-San Sebastián E-mail: sergioandrestorres@hotmail.com Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ID_CONTACTO_ASISTENCIAL", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "I-TERRITORIO", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Jesus. Apellidos: Barrios Larrea. NHC: Calle Tres Palomas, 27. NASS: 48 20895745 94. Domicilio: Calle Ibarra, 1. Localidad/ Provincia: Donostia-San Sebastián. CP: 20080. Datos asistenciales. Fecha de nacimiento: 03/03/1956. País: España. Edad: 59 años Sexo:H. Fecha de Ingreso: 27/07/2015. Servicio: Neurocirugía. Episodio: 8934679. Médico: Sergio Andrés Torres Bayona NºCol: 20 20 28563. Informe clínico del paciente: varón de 59 años, diagnosticado de carcinoma escamoso de laringe T2N2b, que se trató inicialmente con tres ciclos de quimioterapia sin remisión, por lo que tres meses después se realizó una laringectomía supraglótica, con vaciamiento radical incompleto modificado del lado izquierdo. La anatomía patológica demostró un carcinoma escamoso infiltrante en hemiepiglotis izquierda con 8 de 11 ganglios linfáticos positivos de la cadena yugular interna, subdigástricos y supraclaviculares izquierdos. Posteriormente recibió quimioterapia y radioterapia sobre supraglotis e hipofaringe y áreas ganglionares bilaterales. Nueve meses después de la cirugía consultó por cefalea de tres semanas de evolución asociada a diplopia binocular y visión borrosa del ojo derecho, evidenciándose oftalmoparesia del III, IV y VI pares craneales derechos. Una resonancia magnética (RM) cerebral mostró una masa en la porción posterior y lateral del seno cavernoso derecho, con protusión hacia la cisterna prepontina, bien delimitada, con captación homogénea de gadolinio y unas dimensiones de 11x14,4x12,2 mm. En la ventana ósea de la TAC no se observaron ni lesiones líticas ni invasión del ala o seno esfenoidal. La TAC toraco-abdomino-pélvica fue negativa. El diagnóstico diferencial radiológico fue de schwannoma, meningioma o metástasis. Se realizó una biopsia abierta con abordaje transilviano a la pared lateral del seno cavernoso donde se observó la invasión tumoral del espacio intradural. El resultado anatomopatológico fue de carcinoma escamoso. Posteriormente se administró radioterapia a titulo paliativo. Tres semanas después de la cirugía el paciente consultó por dolor dorsal sin clínica neurológica. Un estudio de RM de raquis mostró lesiones focales en los cuerpos D4, D6 y D10 sospechosas de implantes metastásicos. Con el tratamiento radioterápico se alivió la cefalea, pero desarrolló una oftalmoplejía, conservando únicamente la abducción del ojo derecho. El paciente falleció nueve meses tras el diagnóstico de la metástasis en el seno cavernoso. Remitido por: Dr. Sergio Andrés Torres Bayona Servicio de Neurocirugía Hospital Universitario Donostia C/ Doctor Beguiristain, 117 20080 Donostia-San Sebastián E-mail: sergioandrestorres@hotmail.com

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Jesus", ".", "\n", "Apellidos", ":", "Barrios", "Larrea", ".", "\n", "NHC", ":", "Calle", "Tres", "Palomas", ",", "27", ".", "\n", "NASS", ":", "48", "20895745", "94", ".", "\n", "Domicilio", ":", "Calle", "Ibarra", ",", "1", ".", "\n", "Localidad/", "Provincia", ":", "Donostia", "-", "San", "Sebastián", ".", "\n", "CP", ":", "20080", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "03/03/1956", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "59", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "27/07/2015", ".", "\n", "Servicio", ":", "Neurocirugía", ".", "\n", "Episodio", ":", "8934679", ".", "\n", "Médico", ":", "Sergio", "Andrés", "Torres", "Bayona", "NºCol", ":", "20", "20", "28563", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "varón", "de", "59", "años", ",", "diagnosticado", "de", "carcinoma", "escamoso", "de", "laringe", "T2N2b", ",", "que", "se", "trató", "inicialmente", "con", "tres", "ciclos", "de", "quimioterapia", "sin", "remisión", ",", "por", "lo", "que", "tres", "meses", "después", "se", "realizó", "una", "laringectomía", "supraglótica", ",", "con", "vaciamiento", "radical", "incompleto", "modificado", "del", "lado", "izquierdo", ".", "La", "anatomía", "patológica", "demostró", "un", "carcinoma", "escamoso", "infiltrante", "en", "hemiepiglotis", "izquierda", "con", "8", "de", "11", "ganglios", "linfáticos", "positivos", "de", "la", "cadena", "yugular", "interna", ",", "subdigástricos", "y", "supraclaviculares", "izquierdos", ".", "Posteriormente", "recibió", "quimioterapia", "y", "radioterapia", "sobre", "supraglotis", "e", "hipofaringe", "y", "áreas", "ganglionares", "bilaterales", ".", "\n", "Nueve", "meses", "después", "de", "la", "cirugía", "consultó", "por", "cefalea", "de", "tres", "semanas", "de", "evolución", "asociada", "a", "diplopia", "binocular", "y", "visión", "borrosa", "del", "ojo", "derecho", ",", "evidenciándose", "oftalmoparesia", "del", "III", ",", "IV", "y", "VI", "pares", "craneales", "derechos", ".", "Una", "resonancia", "magnética", "(", "RM", ")", "cerebral", "mostró", "una", "masa", "en", "la", "porción", "posterior", "y", "lateral", "del", "seno", "cavernoso", "derecho", ",", "con", "protusión", "hacia", "la", "cisterna", "prepontina", ",", "bien", "delimitada", ",", "con", "captación", "homogénea", "de", "gadolinio", "y", "unas", "dimensiones", "de", "11x14,4x12,2", "mm", ".", "En", "la", "ventana", "ósea", "de", "la", "TAC", "no", "se", "observaron", "ni", "lesiones", "líticas", "ni", "invasión", "del", "ala", "o", "seno", "esfenoidal", ".", "La", "TAC", "toraco", "-", "abdomino", "-", "pélvica", "fue", "negativa", ".", "El", "diagnóstico", "diferencial", "radiológico", "fue", "de", "schwannoma", ",", "meningioma", "o", "metástasis", ".", "\n", "Se", "realizó", "una", "biopsia", "abierta", "con", "abordaje", "transilviano", "a", "la", "pared", "lateral", "del", "seno", "cavernoso", "donde", "se", "observó", "la", "invasión", "tumoral", "del", "espacio", "intradural", ".", "El", "resultado", "anatomopatológico", "fue", "de", "carcinoma", "escamoso", ".", "Posteriormente", "se", "administró", "radioterapia", "a", "titulo", "paliativo", ".", "Tres", "semanas", "después", "de", "la", "cirugía", "el", "paciente", "consultó", "por", "dolor", "dorsal", "sin", "clínica", "neurológica", ".", "Un", "estudio", "de", "RM", "de", "raquis", "mostró", "lesiones", "focales", "en", "los", "cuerpos", "D4", ",", "D6", "y", "D10", "sospechosas", "de", "implantes", "metastásicos", ".", "\n", "Con", "el", "tratamiento", "radioterápico", "se", "alivió", "la", "cefalea", ",", "pero", "desarrolló", "una", "oftalmoplejía", ",", "conservando", "únicamente", "la", "abducción", "del", "ojo", "derecho", ".", "El", "paciente", "falleció", "nueve", "meses", "tras", "el", "diagnóstico", "de", "la", "metástasis", "en", "el", "seno", "cavernoso", ".", "\n", "Remitido", "por", ":", "Dr", ".", "Sergio", "Andrés", "Torres", "Bayona", "Servicio", "de", "Neurocirugía", "Hospital", "Universitario", "Donostia", "C/", "Doctor", "Beguiristain", ",", "117", "20080", "Donostia", "-", "San", "Sebastián", "E", "-", "mail", ":", "sergioandrestorres@hotmail.com", "\n" ]

[ "HOSPITAL", "CORREO_ELECTRONICO", "CALLE", "NOMBRE_PERSONAL_SANITARIO", "TERRITORIO", "ID_ASEGURAMIENTO", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "ID_CONTACTO_ASISTENCIAL", "EDAD_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

animal experiments is an umlsterm, clinical studies is an umlsterm, liquid ventilation is an umlsterm, gas is an umlsterm, breathing is an umlsterm, mechanics is an umlsterm, lungs is an umlsterm, toxicity is an umlsterm, infants is an umlsterm, future is an umlsterm, catalogue is an umlsterm, liquid ventilation is an umlsterm, open is an umlsterm, therapeutic is an umlsterm, diagnostic is an umlsterm, liquid ventilation is an umlsterm, method is an umlsterm, method is an umlsterm, artificial ventilation is an umlsterm, neonates is an umlsterm

PerinatalMedizin.80100063.eng.abstr_task0

Sentence: In animal experiments and clinical studies liquid ventilation with perfluorcarbons improves gas exchange and breathing mechanics in damaged lungs . According to the data on the toxicity of perfluorcarbons available today , it could potentially be applied in infants in the future , too . However , the catalogue of unanswered questions is still too long for controlled clinical phase III studies to be conducted . Further possible applications of liquid ventilation offer hope of solving open therapeutic and diagnostic problems . Taking into account all available data about liquid ventilation with perfluorcarbons today , we still do not know whether it is a real alternative method for respiratory support ; however , further studies to investigate whether the method is an alternative strategy for artificial ventilation in neonates are justified . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

In animal experiments and clinical studies liquid ventilation with perfluorcarbons improves gas exchange and breathing mechanics in damaged lungs . According to the data on the toxicity of perfluorcarbons available today , it could potentially be applied in infants in the future , too . However , the catalogue of unanswered questions is still too long for controlled clinical phase III studies to be conducted . Further possible applications of liquid ventilation offer hope of solving open therapeutic and diagnostic problems . Taking into account all available data about liquid ventilation with perfluorcarbons today , we still do not know whether it is a real alternative method for respiratory support ; however , further studies to investigate whether the method is an alternative strategy for artificial ventilation in neonates are justified .

[ "In", "animal", "experiments", "and", "clinical", "studies", "liquid", "ventilation", "with", "perfluorcarbons", "improves", "gas", "exchange", "and", "breathing", "mechanics", "in", "damaged", "lungs", ".", "According", "to", "the", "data", "on", "the", "toxicity", "of", "perfluorcarbons", "available", "today", ",", "it", "could", "potentially", "be", "applied", "in", "infants", "in", "the", "future", ",", "too", ".", "However", ",", "the", "catalogue", "of", "unanswered", "questions", "is", "still", "too", "long", "for", "controlled", "clinical", "phase", "III", "studies", "to", "be", "conducted", ".", "Further", "possible", "applications", "of", "liquid", "ventilation", "offer", "hope", "of", "solving", "open", "therapeutic", "and", "diagnostic", "problems", ".", "Taking", "into", "account", "all", "available", "data", "about", "liquid", "ventilation", "with", "perfluorcarbons", "today", ",", "we", "still", "do", "not", "know", "whether", "it", "is", "a", "real", "alternative", "method", "for", "respiratory", "support", ";", "however", ",", "further", "studies", "to", "investigate", "whether", "the", "method", "is", "an", "alternative", "strategy", "for", "artificial", "ventilation", "in", "neonates", "are", "justified", "." ]

[ "umlsterm" ]

animal experiments is an umlsterm, clinical studies is an umlsterm, liquid ventilation is an umlsterm, gas is an umlsterm, breathing is an umlsterm, mechanics is an umlsterm, lungs is an umlsterm, toxicity is an umlsterm, infants is an umlsterm, future is an umlsterm, catalogue is an umlsterm, liquid ventilation is an umlsterm, open is an umlsterm, therapeutic is an umlsterm, diagnostic is an umlsterm, liquid ventilation is an umlsterm, method is an umlsterm, method is an umlsterm, artificial ventilation is an umlsterm, neonates is an umlsterm

PerinatalMedizin.80100063.eng.abstr_task1

Sentence: In animal experiments and clinical studies liquid ventilation with perfluorcarbons improves gas exchange and breathing mechanics in damaged lungs . According to the data on the toxicity of perfluorcarbons available today , it could potentially be applied in infants in the future , too . However , the catalogue of unanswered questions is still too long for controlled clinical phase III studies to be conducted . Further possible applications of liquid ventilation offer hope of solving open therapeutic and diagnostic problems . Taking into account all available data about liquid ventilation with perfluorcarbons today , we still do not know whether it is a real alternative method for respiratory support ; however , further studies to investigate whether the method is an alternative strategy for artificial ventilation in neonates are justified . Instructions: please typing these entity words according to sentence: animal experiments, clinical studies, liquid ventilation, gas, breathing, mechanics, lungs, toxicity, infants, future, catalogue, liquid ventilation, open, therapeutic, diagnostic, liquid ventilation, method, method, artificial ventilation, neonates Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

In animal experiments and clinical studies liquid ventilation with perfluorcarbons improves gas exchange and breathing mechanics in damaged lungs . According to the data on the toxicity of perfluorcarbons available today , it could potentially be applied in infants in the future , too . However , the catalogue of unanswered questions is still too long for controlled clinical phase III studies to be conducted . Further possible applications of liquid ventilation offer hope of solving open therapeutic and diagnostic problems . Taking into account all available data about liquid ventilation with perfluorcarbons today , we still do not know whether it is a real alternative method for respiratory support ; however , further studies to investigate whether the method is an alternative strategy for artificial ventilation in neonates are justified .

[ "In", "animal", "experiments", "and", "clinical", "studies", "liquid", "ventilation", "with", "perfluorcarbons", "improves", "gas", "exchange", "and", "breathing", "mechanics", "in", "damaged", "lungs", ".", "According", "to", "the", "data", "on", "the", "toxicity", "of", "perfluorcarbons", "available", "today", ",", "it", "could", "potentially", "be", "applied", "in", "infants", "in", "the", "future", ",", "too", ".", "However", ",", "the", "catalogue", "of", "unanswered", "questions", "is", "still", "too", "long", "for", "controlled", "clinical", "phase", "III", "studies", "to", "be", "conducted", ".", "Further", "possible", "applications", "of", "liquid", "ventilation", "offer", "hope", "of", "solving", "open", "therapeutic", "and", "diagnostic", "problems", ".", "Taking", "into", "account", "all", "available", "data", "about", "liquid", "ventilation", "with", "perfluorcarbons", "today", ",", "we", "still", "do", "not", "know", "whether", "it", "is", "a", "real", "alternative", "method", "for", "respiratory", "support", ";", "however", ",", "further", "studies", "to", "investigate", "whether", "the", "method", "is", "an", "alternative", "strategy", "for", "artificial", "ventilation", "in", "neonates", "are", "justified", "." ]

[ "umlsterm" ]

animal experiments, clinical studies, liquid ventilation, gas, breathing, mechanics, lungs, toxicity, infants, future, catalogue, liquid ventilation, open, therapeutic, diagnostic, liquid ventilation, method, method, artificial ventilation, neonates

PerinatalMedizin.80100063.eng.abstr_task2

Sentence: In animal experiments and clinical studies liquid ventilation with perfluorcarbons improves gas exchange and breathing mechanics in damaged lungs . According to the data on the toxicity of perfluorcarbons available today , it could potentially be applied in infants in the future , too . However , the catalogue of unanswered questions is still too long for controlled clinical phase III studies to be conducted . Further possible applications of liquid ventilation offer hope of solving open therapeutic and diagnostic problems . Taking into account all available data about liquid ventilation with perfluorcarbons today , we still do not know whether it is a real alternative method for respiratory support ; however , further studies to investigate whether the method is an alternative strategy for artificial ventilation in neonates are justified . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

In animal experiments and clinical studies liquid ventilation with perfluorcarbons improves gas exchange and breathing mechanics in damaged lungs . According to the data on the toxicity of perfluorcarbons available today , it could potentially be applied in infants in the future , too . However , the catalogue of unanswered questions is still too long for controlled clinical phase III studies to be conducted . Further possible applications of liquid ventilation offer hope of solving open therapeutic and diagnostic problems . Taking into account all available data about liquid ventilation with perfluorcarbons today , we still do not know whether it is a real alternative method for respiratory support ; however , further studies to investigate whether the method is an alternative strategy for artificial ventilation in neonates are justified .

[ "In", "animal", "experiments", "and", "clinical", "studies", "liquid", "ventilation", "with", "perfluorcarbons", "improves", "gas", "exchange", "and", "breathing", "mechanics", "in", "damaged", "lungs", ".", "According", "to", "the", "data", "on", "the", "toxicity", "of", "perfluorcarbons", "available", "today", ",", "it", "could", "potentially", "be", "applied", "in", "infants", "in", "the", "future", ",", "too", ".", "However", ",", "the", "catalogue", "of", "unanswered", "questions", "is", "still", "too", "long", "for", "controlled", "clinical", "phase", "III", "studies", "to", "be", "conducted", ".", "Further", "possible", "applications", "of", "liquid", "ventilation", "offer", "hope", "of", "solving", "open", "therapeutic", "and", "diagnostic", "problems", ".", "Taking", "into", "account", "all", "available", "data", "about", "liquid", "ventilation", "with", "perfluorcarbons", "today", ",", "we", "still", "do", "not", "know", "whether", "it", "is", "a", "real", "alternative", "method", "for", "respiratory", "support", ";", "however", ",", "further", "studies", "to", "investigate", "whether", "the", "method", "is", "an", "alternative", "strategy", "for", "artificial", "ventilation", "in", "neonates", "are", "justified", "." ]

[ "umlsterm" ]

Praxis is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Psychotherapie is an umlsterm, Therapiephasen is an umlsterm, Objektbeziehungen is an umlsterm, Therapieprozesses is an umlsterm, Behandlung is an umlsterm, Therapieprozesses is an umlsterm, Prognose is an umlsterm

Psychotherapeut.80430369.ger.abstr_task0

Sentence: Es wird ein aus der klinischen Praxis gewachsenes psychodynamisches Konzept der Behandlung strukturell schwer gestoerter Patientinen Patienten in einer integrativen stationaeren Psychotherapie vorgestellt . In den einzelnen Therapiephasen sich herauskristallisierende Prozessmerkmale werden beschrieben und der Leitkategorie " Objektbeziehungen " zugeordnet . Besonderes Gewicht wird auf die Darstellung des therapeutischen Vorgehens gelegt . Anhand der entwickelten beziehungsorientierten Modellvorstellungen zu Ebenen und Phasen des Therapieprozesses koennen die in der Behandlung von strukturell schwergestoerten Patienten/innen vielgestaltig auftretenden Phaenomene in idealtypische Zusammenhaenge eingeordnet werden . Das Verstaendnis dieser psychodynamischen Zusammenhaenge schafft differenzierte Voraussetzungen fuer konstruktiv wirksame Interventionen insbesondere bei Krisen und Stagnationen des Therapieprozesses und kann somit die Prognose der Patienten/innen guenstiger gestalten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Es wird ein aus der klinischen Praxis gewachsenes psychodynamisches Konzept der Behandlung strukturell schwer gestoerter Patientinen Patienten in einer integrativen stationaeren Psychotherapie vorgestellt . In den einzelnen Therapiephasen sich herauskristallisierende Prozessmerkmale werden beschrieben und der Leitkategorie " Objektbeziehungen " zugeordnet . Besonderes Gewicht wird auf die Darstellung des therapeutischen Vorgehens gelegt . Anhand der entwickelten beziehungsorientierten Modellvorstellungen zu Ebenen und Phasen des Therapieprozesses koennen die in der Behandlung von strukturell schwergestoerten Patienten/innen vielgestaltig auftretenden Phaenomene in idealtypische Zusammenhaenge eingeordnet werden . Das Verstaendnis dieser psychodynamischen Zusammenhaenge schafft differenzierte Voraussetzungen fuer konstruktiv wirksame Interventionen insbesondere bei Krisen und Stagnationen des Therapieprozesses und kann somit die Prognose der Patienten/innen guenstiger gestalten .

[ "Es", "wird", "ein", "aus", "der", "klinischen", "Praxis", "gewachsenes", "psychodynamisches", "Konzept", "der", "Behandlung", "strukturell", "schwer", "gestoerter", "Patientinen", "Patienten", "in", "einer", "integrativen", "stationaeren", "Psychotherapie", "vorgestellt", ".", "In", "den", "einzelnen", "Therapiephasen", "sich", "herauskristallisierende", "Prozessmerkmale", "werden", "beschrieben", "und", "der", "Leitkategorie", "\"", "Objektbeziehungen", "\"", "zugeordnet", ".", "Besonderes", "Gewicht", "wird", "auf", "die", "Darstellung", "des", "therapeutischen", "Vorgehens", "gelegt", ".", "Anhand", "der", "entwickelten", "beziehungsorientierten", "Modellvorstellungen", "zu", "Ebenen", "und", "Phasen", "des", "Therapieprozesses", "koennen", "die", "in", "der", "Behandlung", "von", "strukturell", "schwergestoerten", "Patienten", "/", "innen", "vielgestaltig", "auftretenden", "Phaenomene", "in", "idealtypische", "Zusammenhaenge", "eingeordnet", "werden", ".", "Das", "Verstaendnis", "dieser", "psychodynamischen", "Zusammenhaenge", "schafft", "differenzierte", "Voraussetzungen", "fuer", "konstruktiv", "wirksame", "Interventionen", "insbesondere", "bei", "Krisen", "und", "Stagnationen", "des", "Therapieprozesses", "und", "kann", "somit", "die", "Prognose", "der", "Patienten", "/", "innen", "guenstiger", "gestalten", "." ]

[ "umlsterm" ]

Praxis is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Psychotherapie is an umlsterm, Therapiephasen is an umlsterm, Objektbeziehungen is an umlsterm, Therapieprozesses is an umlsterm, Behandlung is an umlsterm, Therapieprozesses is an umlsterm, Prognose is an umlsterm

Psychotherapeut.80430369.ger.abstr_task1

Sentence: Es wird ein aus der klinischen Praxis gewachsenes psychodynamisches Konzept der Behandlung strukturell schwer gestoerter Patientinen Patienten in einer integrativen stationaeren Psychotherapie vorgestellt . In den einzelnen Therapiephasen sich herauskristallisierende Prozessmerkmale werden beschrieben und der Leitkategorie " Objektbeziehungen " zugeordnet . Besonderes Gewicht wird auf die Darstellung des therapeutischen Vorgehens gelegt . Anhand der entwickelten beziehungsorientierten Modellvorstellungen zu Ebenen und Phasen des Therapieprozesses koennen die in der Behandlung von strukturell schwergestoerten Patienten/innen vielgestaltig auftretenden Phaenomene in idealtypische Zusammenhaenge eingeordnet werden . Das Verstaendnis dieser psychodynamischen Zusammenhaenge schafft differenzierte Voraussetzungen fuer konstruktiv wirksame Interventionen insbesondere bei Krisen und Stagnationen des Therapieprozesses und kann somit die Prognose der Patienten/innen guenstiger gestalten . Instructions: please typing these entity words according to sentence: Praxis, Behandlung, Patienten, Psychotherapie, Therapiephasen, Objektbeziehungen, Therapieprozesses, Behandlung, Therapieprozesses, Prognose Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Es wird ein aus der klinischen Praxis gewachsenes psychodynamisches Konzept der Behandlung strukturell schwer gestoerter Patientinen Patienten in einer integrativen stationaeren Psychotherapie vorgestellt . In den einzelnen Therapiephasen sich herauskristallisierende Prozessmerkmale werden beschrieben und der Leitkategorie " Objektbeziehungen " zugeordnet . Besonderes Gewicht wird auf die Darstellung des therapeutischen Vorgehens gelegt . Anhand der entwickelten beziehungsorientierten Modellvorstellungen zu Ebenen und Phasen des Therapieprozesses koennen die in der Behandlung von strukturell schwergestoerten Patienten/innen vielgestaltig auftretenden Phaenomene in idealtypische Zusammenhaenge eingeordnet werden . Das Verstaendnis dieser psychodynamischen Zusammenhaenge schafft differenzierte Voraussetzungen fuer konstruktiv wirksame Interventionen insbesondere bei Krisen und Stagnationen des Therapieprozesses und kann somit die Prognose der Patienten/innen guenstiger gestalten .

[ "Es", "wird", "ein", "aus", "der", "klinischen", "Praxis", "gewachsenes", "psychodynamisches", "Konzept", "der", "Behandlung", "strukturell", "schwer", "gestoerter", "Patientinen", "Patienten", "in", "einer", "integrativen", "stationaeren", "Psychotherapie", "vorgestellt", ".", "In", "den", "einzelnen", "Therapiephasen", "sich", "herauskristallisierende", "Prozessmerkmale", "werden", "beschrieben", "und", "der", "Leitkategorie", "\"", "Objektbeziehungen", "\"", "zugeordnet", ".", "Besonderes", "Gewicht", "wird", "auf", "die", "Darstellung", "des", "therapeutischen", "Vorgehens", "gelegt", ".", "Anhand", "der", "entwickelten", "beziehungsorientierten", "Modellvorstellungen", "zu", "Ebenen", "und", "Phasen", "des", "Therapieprozesses", "koennen", "die", "in", "der", "Behandlung", "von", "strukturell", "schwergestoerten", "Patienten", "/", "innen", "vielgestaltig", "auftretenden", "Phaenomene", "in", "idealtypische", "Zusammenhaenge", "eingeordnet", "werden", ".", "Das", "Verstaendnis", "dieser", "psychodynamischen", "Zusammenhaenge", "schafft", "differenzierte", "Voraussetzungen", "fuer", "konstruktiv", "wirksame", "Interventionen", "insbesondere", "bei", "Krisen", "und", "Stagnationen", "des", "Therapieprozesses", "und", "kann", "somit", "die", "Prognose", "der", "Patienten", "/", "innen", "guenstiger", "gestalten", "." ]

[ "umlsterm" ]

Praxis, Behandlung, Patienten, Psychotherapie, Therapiephasen, Objektbeziehungen, Therapieprozesses, Behandlung, Therapieprozesses, Prognose

Psychotherapeut.80430369.ger.abstr_task2

Sentence: Es wird ein aus der klinischen Praxis gewachsenes psychodynamisches Konzept der Behandlung strukturell schwer gestoerter Patientinen Patienten in einer integrativen stationaeren Psychotherapie vorgestellt . In den einzelnen Therapiephasen sich herauskristallisierende Prozessmerkmale werden beschrieben und der Leitkategorie " Objektbeziehungen " zugeordnet . Besonderes Gewicht wird auf die Darstellung des therapeutischen Vorgehens gelegt . Anhand der entwickelten beziehungsorientierten Modellvorstellungen zu Ebenen und Phasen des Therapieprozesses koennen die in der Behandlung von strukturell schwergestoerten Patienten/innen vielgestaltig auftretenden Phaenomene in idealtypische Zusammenhaenge eingeordnet werden . Das Verstaendnis dieser psychodynamischen Zusammenhaenge schafft differenzierte Voraussetzungen fuer konstruktiv wirksame Interventionen insbesondere bei Krisen und Stagnationen des Therapieprozesses und kann somit die Prognose der Patienten/innen guenstiger gestalten . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Es wird ein aus der klinischen Praxis gewachsenes psychodynamisches Konzept der Behandlung strukturell schwer gestoerter Patientinen Patienten in einer integrativen stationaeren Psychotherapie vorgestellt . In den einzelnen Therapiephasen sich herauskristallisierende Prozessmerkmale werden beschrieben und der Leitkategorie " Objektbeziehungen " zugeordnet . Besonderes Gewicht wird auf die Darstellung des therapeutischen Vorgehens gelegt . Anhand der entwickelten beziehungsorientierten Modellvorstellungen zu Ebenen und Phasen des Therapieprozesses koennen die in der Behandlung von strukturell schwergestoerten Patienten/innen vielgestaltig auftretenden Phaenomene in idealtypische Zusammenhaenge eingeordnet werden . Das Verstaendnis dieser psychodynamischen Zusammenhaenge schafft differenzierte Voraussetzungen fuer konstruktiv wirksame Interventionen insbesondere bei Krisen und Stagnationen des Therapieprozesses und kann somit die Prognose der Patienten/innen guenstiger gestalten .

[ "Es", "wird", "ein", "aus", "der", "klinischen", "Praxis", "gewachsenes", "psychodynamisches", "Konzept", "der", "Behandlung", "strukturell", "schwer", "gestoerter", "Patientinen", "Patienten", "in", "einer", "integrativen", "stationaeren", "Psychotherapie", "vorgestellt", ".", "In", "den", "einzelnen", "Therapiephasen", "sich", "herauskristallisierende", "Prozessmerkmale", "werden", "beschrieben", "und", "der", "Leitkategorie", "\"", "Objektbeziehungen", "\"", "zugeordnet", ".", "Besonderes", "Gewicht", "wird", "auf", "die", "Darstellung", "des", "therapeutischen", "Vorgehens", "gelegt", ".", "Anhand", "der", "entwickelten", "beziehungsorientierten", "Modellvorstellungen", "zu", "Ebenen", "und", "Phasen", "des", "Therapieprozesses", "koennen", "die", "in", "der", "Behandlung", "von", "strukturell", "schwergestoerten", "Patienten", "/", "innen", "vielgestaltig", "auftretenden", "Phaenomene", "in", "idealtypische", "Zusammenhaenge", "eingeordnet", "werden", ".", "Das", "Verstaendnis", "dieser", "psychodynamischen", "Zusammenhaenge", "schafft", "differenzierte", "Voraussetzungen", "fuer", "konstruktiv", "wirksame", "Interventionen", "insbesondere", "bei", "Krisen", "und", "Stagnationen", "des", "Therapieprozesses", "und", "kann", "somit", "die", "Prognose", "der", "Patienten", "/", "innen", "guenstiger", "gestalten", "." ]

[ "umlsterm" ]

PGE is a protein, thromboxane is a compound, TXB is a compound, COX-1 is a protein, COX-2 is a protein

DS.d1047_task0

Sentence: We also assess prostaglandin (PGE (2)) and thromboxane (TXB (2)) inhibition to establish the correlation between behavioural measures and the degree of selectivity for COX-1 and COX-2. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O" ]

We also assess prostaglandin (PGE (2)) and thromboxane (TXB (2)) inhibition to establish the correlation between behavioural measures and the degree of selectivity for COX-1 and COX-2.

[ "We", "also", "assess", "prostaglandin", "(", "PGE", "(", "2", ")", ")", "and", "thromboxane", "(", "TXB", "(", "2", ")", ")", "inhibition", "to", "establish", "the", "correlation", "between", "behavioural", "measures", "and", "the", "degree", "of", "selectivity", "for", "COX-1", "and", "COX-2", "." ]

[ "compound", "protein" ]

PGE is a protein, thromboxane is a compound, TXB is a compound, COX-1 is a protein, COX-2 is a protein

DS.d1047_task1

Sentence: We also assess prostaglandin (PGE (2)) and thromboxane (TXB (2)) inhibition to establish the correlation between behavioural measures and the degree of selectivity for COX-1 and COX-2. Instructions: please typing these entity words according to sentence: PGE, thromboxane, TXB, COX-1, COX-2 Options: compound, protein

[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O" ]

We also assess prostaglandin (PGE (2)) and thromboxane (TXB (2)) inhibition to establish the correlation between behavioural measures and the degree of selectivity for COX-1 and COX-2.

[ "We", "also", "assess", "prostaglandin", "(", "PGE", "(", "2", ")", ")", "and", "thromboxane", "(", "TXB", "(", "2", ")", ")", "inhibition", "to", "establish", "the", "correlation", "between", "behavioural", "measures", "and", "the", "degree", "of", "selectivity", "for", "COX-1", "and", "COX-2", "." ]

[ "compound", "protein" ]

PGE, thromboxane, TXB, COX-1, COX-2

DS.d1047_task2

Sentence: We also assess prostaglandin (PGE (2)) and thromboxane (TXB (2)) inhibition to establish the correlation between behavioural measures and the degree of selectivity for COX-1 and COX-2. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "B-compound", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "B-protein", "O" ]

We also assess prostaglandin (PGE (2)) and thromboxane (TXB (2)) inhibition to establish the correlation between behavioural measures and the degree of selectivity for COX-1 and COX-2.

[ "We", "also", "assess", "prostaglandin", "(", "PGE", "(", "2", ")", ")", "and", "thromboxane", "(", "TXB", "(", "2", ")", ")", "inhibition", "to", "establish", "the", "correlation", "between", "behavioural", "measures", "and", "the", "degree", "of", "selectivity", "for", "COX-1", "and", "COX-2", "." ]

[ "compound", "protein" ]

adults is a Participant_Age, acute lymphoblastic leukemia is a Participant_Condition, vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both is a Intervention_Pharmacological, cytarabine is a Intervention_Pharmacological, mitoxantrone is a Intervention_Pharmacological, resistant disease is a Outcome_Physical, 4-drug induction ( the L-20 regimen ) . is a Intervention_Pharmacological, consolidation , maintenance therapy , and central nervous system prophylaxis is a Intervention_Pharmacological, median follow - up for survivors is a Outcome_Mortality, median patient age was 43 years is a Participant_Age, 164 is a Participant_Sample-size, frequency of complete remission is a Outcome_Physical, Induction deaths is a Outcome_Mortality, median survival is a Outcome_Mortality, survival rate is a Outcome_Mortality, long - term outcomes is a Outcome_Other

57808_task0

Sentence: Treatment of adults with acute lymphoblastic leukemia : do the specifics of the regimen matter ? : Results from a prospective randomized trial . BACKGROUND Induction therapy for adults with acute lymphoblastic leukemia ( ALL ) is similar across essentially all regimens , comprised of vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both . Given the lack of randomized data , to date , no regimen has emerged as standard . The authors previously evaluated cytarabine 3 g/m ( 2 ) daily for 5 days with mitoxantrone 80 mg/m ( 2 ) ( the ALL-2 regimen ) as a novel induction regimen . Compared with historic controls , the ALL-2 regimen was superior in terms of incidence of complete remission , failure with resistant disease , and activity in patients with Philadelphia chromosome ( Ph ) -positive ALL . METHODS The authors conducted a multicenter , prospective , randomized trial of the ALL-2 regimen compared with a standard 4-drug induction ( the L-20 regimen ) . Patients also received consolidation , maintenance therapy , and central nervous system prophylaxis . The trial accrued patients from August 1996 to October 2004 . RESULTS The median follow-up for survivors was 7 years , and the median patient age was 43 years . Responses were evaluated in 164 patients . The treatment arms were balanced in terms of pretreatment characteristics . The frequency of complete remission for the ALL-2 regimen versus the L-20 regimen was 83 % versus 71 % ( P = .06 ) . More patients on the L-20 arm failed with resistant disease ( 21 % vs 8 % ; P = .02 ) . Induction deaths were comparable at 9 % ( ALL-2 ) versus 7 % ( L-20 ) . The median survival was similar ; and , at 5 years , the survival rate was 33 % alive on the ALL-2 arm versus 27 % on the L-20 . CONCLUSIONS Despite superior results of induction therapy with the ALL-2 regimen , this treatment did not improve long-term outcomes . When coupled to the reported experience of other studies in adults with ALL , the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen . Cancer 2013 . © 2012 American Cancer Society . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other

[ "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Treatment of adults with acute lymphoblastic leukemia : do the specifics of the regimen matter ? : Results from a prospective randomized trial . BACKGROUND Induction therapy for adults with acute lymphoblastic leukemia ( ALL ) is similar across essentially all regimens , comprised of vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both . Given the lack of randomized data , to date , no regimen has emerged as standard . The authors previously evaluated cytarabine 3 g/m ( 2 ) daily for 5 days with mitoxantrone 80 mg/m ( 2 ) ( the ALL-2 regimen ) as a novel induction regimen . Compared with historic controls , the ALL-2 regimen was superior in terms of incidence of complete remission , failure with resistant disease , and activity in patients with Philadelphia chromosome ( Ph ) -positive ALL . METHODS The authors conducted a multicenter , prospective , randomized trial of the ALL-2 regimen compared with a standard 4-drug induction ( the L-20 regimen ) . Patients also received consolidation , maintenance therapy , and central nervous system prophylaxis . The trial accrued patients from August 1996 to October 2004 . RESULTS The median follow-up for survivors was 7 years , and the median patient age was 43 years . Responses were evaluated in 164 patients . The treatment arms were balanced in terms of pretreatment characteristics . The frequency of complete remission for the ALL-2 regimen versus the L-20 regimen was 83 % versus 71 % ( P = .06 ) . More patients on the L-20 arm failed with resistant disease ( 21 % vs 8 % ; P = .02 ) . Induction deaths were comparable at 9 % ( ALL-2 ) versus 7 % ( L-20 ) . The median survival was similar ; and , at 5 years , the survival rate was 33 % alive on the ALL-2 arm versus 27 % on the L-20 . CONCLUSIONS Despite superior results of induction therapy with the ALL-2 regimen , this treatment did not improve long-term outcomes . When coupled to the reported experience of other studies in adults with ALL , the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen . Cancer 2013 . © 2012 American Cancer Society .

[ "Treatment", "of", "adults", "with", "acute", "lymphoblastic", "leukemia", ":", "do", "the", "specifics", "of", "the", "regimen", "matter", "?", ":", "Results", "from", "a", "prospective", "randomized", "trial", ".", "BACKGROUND", "Induction", "therapy", "for", "adults", "with", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "is", "similar", "across", "essentially", "all", "regimens", ",", "comprised", "of", "vincristine", ",", "corticosteroids", ",", "and", "anthracyclines", "intensified", "with", "cyclophosphamide", ",", "asparaginase", ",", "or", "both", ".", "Given", "the", "lack", "of", "randomized", "data", ",", "to", "date", ",", "no", "regimen", "has", "emerged", "as", "standard", ".", "The", "authors", "previously", "evaluated", "cytarabine", "3", "g", "/", "m", "(", "2", ")", "daily", "for", "5", "days", "with", "mitoxantrone", "80", "mg", "/", "m", "(", "2", ")", "(", "the", "ALL-2", "regimen", ")", "as", "a", "novel", "induction", "regimen", ".", "Compared", "with", "historic", "controls", ",", "the", "ALL-2", "regimen", "was", "superior", "in", "terms", "of", "incidence", "of", "complete", "remission", ",", "failure", "with", "resistant", "disease", ",", "and", "activity", "in", "patients", "with", "Philadelphia", "chromosome", "(", "Ph", ")", "-positive", "ALL", ".", "METHODS", "The", "authors", "conducted", "a", "multicenter", ",", "prospective", ",", "randomized", "trial", "of", "the", "ALL-2", "regimen", "compared", "with", "a", "standard", "4-drug", "induction", "(", "the", "L-20", "regimen", ")", ".", "Patients", "also", "received", "consolidation", ",", "maintenance", "therapy", ",", "and", "central", "nervous", "system", "prophylaxis", ".", "The", "trial", "accrued", "patients", "from", "August", "1996", "to", "October", "2004", ".", "RESULTS", "The", "median", "follow", "-", "up", "for", "survivors", "was", "7", "years", ",", "and", "the", "median", "patient", "age", "was", "43", "years", ".", "Responses", "were", "evaluated", "in", "164", "patients", ".", "The", "treatment", "arms", "were", "balanced", "in", "terms", "of", "pretreatment", "characteristics", ".", "The", "frequency", "of", "complete", "remission", "for", "the", "ALL-2", "regimen", "versus", "the", "L-20", "regimen", "was", "83", "%", "versus", "71", "%", "(", "P", "=", ".06", ")", ".", "More", "patients", "on", "the", "L-20", "arm", "failed", "with", "resistant", "disease", "(", "21", "%", "vs", "8", "%", ";", "P", "=", ".02", ")", ".", "Induction", "deaths", "were", "comparable", "at", "9", "%", "(", "ALL-2", ")", "versus", "7", "%", "(", "L-20", ")", ".", "The", "median", "survival", "was", "similar", ";", "and", ",", "at", "5", "years", ",", "the", "survival", "rate", "was", "33", "%", "alive", "on", "the", "ALL-2", "arm", "versus", "27", "%", "on", "the", "L-20", ".", "CONCLUSIONS", "Despite", "superior", "results", "of", "induction", "therapy", "with", "the", "ALL-2", "regimen", ",", "this", "treatment", "did", "not", "improve", "long", "-", "term", "outcomes", ".", "When", "coupled", "to", "the", "reported", "experience", "of", "other", "studies", "in", "adults", "with", "ALL", ",", "the", "results", "of", "this", "randomized", "trial", "raise", "the", "possibility", "that", "ultimate", "outcomes", "in", "adult", "ALL", "may", "be", "independent", "of", "the", "specific", "regimen", "chosen", ".", "Cancer", "2013", ".", "©", "2012", "American", "Cancer", "Society", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Age", "Outcome_Mortality", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]

adults is a Participant_Age, acute lymphoblastic leukemia is a Participant_Condition, vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both is a Intervention_Pharmacological, cytarabine is a Intervention_Pharmacological, mitoxantrone is a Intervention_Pharmacological, resistant disease is a Outcome_Physical, 4-drug induction ( the L-20 regimen ) . is a Intervention_Pharmacological, consolidation , maintenance therapy , and central nervous system prophylaxis is a Intervention_Pharmacological, median follow - up for survivors is a Outcome_Mortality, median patient age was 43 years is a Participant_Age, 164 is a Participant_Sample-size, frequency of complete remission is a Outcome_Physical, Induction deaths is a Outcome_Mortality, median survival is a Outcome_Mortality, survival rate is a Outcome_Mortality, long - term outcomes is a Outcome_Other

57808_task1

Sentence: Treatment of adults with acute lymphoblastic leukemia : do the specifics of the regimen matter ? : Results from a prospective randomized trial . BACKGROUND Induction therapy for adults with acute lymphoblastic leukemia ( ALL ) is similar across essentially all regimens , comprised of vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both . Given the lack of randomized data , to date , no regimen has emerged as standard . The authors previously evaluated cytarabine 3 g/m ( 2 ) daily for 5 days with mitoxantrone 80 mg/m ( 2 ) ( the ALL-2 regimen ) as a novel induction regimen . Compared with historic controls , the ALL-2 regimen was superior in terms of incidence of complete remission , failure with resistant disease , and activity in patients with Philadelphia chromosome ( Ph ) -positive ALL . METHODS The authors conducted a multicenter , prospective , randomized trial of the ALL-2 regimen compared with a standard 4-drug induction ( the L-20 regimen ) . Patients also received consolidation , maintenance therapy , and central nervous system prophylaxis . The trial accrued patients from August 1996 to October 2004 . RESULTS The median follow-up for survivors was 7 years , and the median patient age was 43 years . Responses were evaluated in 164 patients . The treatment arms were balanced in terms of pretreatment characteristics . The frequency of complete remission for the ALL-2 regimen versus the L-20 regimen was 83 % versus 71 % ( P = .06 ) . More patients on the L-20 arm failed with resistant disease ( 21 % vs 8 % ; P = .02 ) . Induction deaths were comparable at 9 % ( ALL-2 ) versus 7 % ( L-20 ) . The median survival was similar ; and , at 5 years , the survival rate was 33 % alive on the ALL-2 arm versus 27 % on the L-20 . CONCLUSIONS Despite superior results of induction therapy with the ALL-2 regimen , this treatment did not improve long-term outcomes . When coupled to the reported experience of other studies in adults with ALL , the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen . Cancer 2013 . © 2012 American Cancer Society . Instructions: please typing these entity words according to sentence: adults, acute lymphoblastic leukemia, vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both, cytarabine, mitoxantrone, resistant disease, 4-drug induction ( the L-20 regimen ) ., consolidation , maintenance therapy , and central nervous system prophylaxis, median follow - up for survivors, median patient age was 43 years, 164, frequency of complete remission, Induction deaths, median survival, survival rate, long - term outcomes Options: Intervention_Pharmacological, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Other

[ "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Treatment of adults with acute lymphoblastic leukemia : do the specifics of the regimen matter ? : Results from a prospective randomized trial . BACKGROUND Induction therapy for adults with acute lymphoblastic leukemia ( ALL ) is similar across essentially all regimens , comprised of vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both . Given the lack of randomized data , to date , no regimen has emerged as standard . The authors previously evaluated cytarabine 3 g/m ( 2 ) daily for 5 days with mitoxantrone 80 mg/m ( 2 ) ( the ALL-2 regimen ) as a novel induction regimen . Compared with historic controls , the ALL-2 regimen was superior in terms of incidence of complete remission , failure with resistant disease , and activity in patients with Philadelphia chromosome ( Ph ) -positive ALL . METHODS The authors conducted a multicenter , prospective , randomized trial of the ALL-2 regimen compared with a standard 4-drug induction ( the L-20 regimen ) . Patients also received consolidation , maintenance therapy , and central nervous system prophylaxis . The trial accrued patients from August 1996 to October 2004 . RESULTS The median follow-up for survivors was 7 years , and the median patient age was 43 years . Responses were evaluated in 164 patients . The treatment arms were balanced in terms of pretreatment characteristics . The frequency of complete remission for the ALL-2 regimen versus the L-20 regimen was 83 % versus 71 % ( P = .06 ) . More patients on the L-20 arm failed with resistant disease ( 21 % vs 8 % ; P = .02 ) . Induction deaths were comparable at 9 % ( ALL-2 ) versus 7 % ( L-20 ) . The median survival was similar ; and , at 5 years , the survival rate was 33 % alive on the ALL-2 arm versus 27 % on the L-20 . CONCLUSIONS Despite superior results of induction therapy with the ALL-2 regimen , this treatment did not improve long-term outcomes . When coupled to the reported experience of other studies in adults with ALL , the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen . Cancer 2013 . © 2012 American Cancer Society .

[ "Treatment", "of", "adults", "with", "acute", "lymphoblastic", "leukemia", ":", "do", "the", "specifics", "of", "the", "regimen", "matter", "?", ":", "Results", "from", "a", "prospective", "randomized", "trial", ".", "BACKGROUND", "Induction", "therapy", "for", "adults", "with", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "is", "similar", "across", "essentially", "all", "regimens", ",", "comprised", "of", "vincristine", ",", "corticosteroids", ",", "and", "anthracyclines", "intensified", "with", "cyclophosphamide", ",", "asparaginase", ",", "or", "both", ".", "Given", "the", "lack", "of", "randomized", "data", ",", "to", "date", ",", "no", "regimen", "has", "emerged", "as", "standard", ".", "The", "authors", "previously", "evaluated", "cytarabine", "3", "g", "/", "m", "(", "2", ")", "daily", "for", "5", "days", "with", "mitoxantrone", "80", "mg", "/", "m", "(", "2", ")", "(", "the", "ALL-2", "regimen", ")", "as", "a", "novel", "induction", "regimen", ".", "Compared", "with", "historic", "controls", ",", "the", "ALL-2", "regimen", "was", "superior", "in", "terms", "of", "incidence", "of", "complete", "remission", ",", "failure", "with", "resistant", "disease", ",", "and", "activity", "in", "patients", "with", "Philadelphia", "chromosome", "(", "Ph", ")", "-positive", "ALL", ".", "METHODS", "The", "authors", "conducted", "a", "multicenter", ",", "prospective", ",", "randomized", "trial", "of", "the", "ALL-2", "regimen", "compared", "with", "a", "standard", "4-drug", "induction", "(", "the", "L-20", "regimen", ")", ".", "Patients", "also", "received", "consolidation", ",", "maintenance", "therapy", ",", "and", "central", "nervous", "system", "prophylaxis", ".", "The", "trial", "accrued", "patients", "from", "August", "1996", "to", "October", "2004", ".", "RESULTS", "The", "median", "follow", "-", "up", "for", "survivors", "was", "7", "years", ",", "and", "the", "median", "patient", "age", "was", "43", "years", ".", "Responses", "were", "evaluated", "in", "164", "patients", ".", "The", "treatment", "arms", "were", "balanced", "in", "terms", "of", "pretreatment", "characteristics", ".", "The", "frequency", "of", "complete", "remission", "for", "the", "ALL-2", "regimen", "versus", "the", "L-20", "regimen", "was", "83", "%", "versus", "71", "%", "(", "P", "=", ".06", ")", ".", "More", "patients", "on", "the", "L-20", "arm", "failed", "with", "resistant", "disease", "(", "21", "%", "vs", "8", "%", ";", "P", "=", ".02", ")", ".", "Induction", "deaths", "were", "comparable", "at", "9", "%", "(", "ALL-2", ")", "versus", "7", "%", "(", "L-20", ")", ".", "The", "median", "survival", "was", "similar", ";", "and", ",", "at", "5", "years", ",", "the", "survival", "rate", "was", "33", "%", "alive", "on", "the", "ALL-2", "arm", "versus", "27", "%", "on", "the", "L-20", ".", "CONCLUSIONS", "Despite", "superior", "results", "of", "induction", "therapy", "with", "the", "ALL-2", "regimen", ",", "this", "treatment", "did", "not", "improve", "long", "-", "term", "outcomes", ".", "When", "coupled", "to", "the", "reported", "experience", "of", "other", "studies", "in", "adults", "with", "ALL", ",", "the", "results", "of", "this", "randomized", "trial", "raise", "the", "possibility", "that", "ultimate", "outcomes", "in", "adult", "ALL", "may", "be", "independent", "of", "the", "specific", "regimen", "chosen", ".", "Cancer", "2013", ".", "©", "2012", "American", "Cancer", "Society", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Age", "Outcome_Mortality", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]

adults, acute lymphoblastic leukemia, vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both, cytarabine, mitoxantrone, resistant disease, 4-drug induction ( the L-20 regimen ) ., consolidation , maintenance therapy , and central nervous system prophylaxis, median follow - up for survivors, median patient age was 43 years, 164, frequency of complete remission, Induction deaths, median survival, survival rate, long - term outcomes

57808_task2

Sentence: Treatment of adults with acute lymphoblastic leukemia : do the specifics of the regimen matter ? : Results from a prospective randomized trial . BACKGROUND Induction therapy for adults with acute lymphoblastic leukemia ( ALL ) is similar across essentially all regimens , comprised of vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both . Given the lack of randomized data , to date , no regimen has emerged as standard . The authors previously evaluated cytarabine 3 g/m ( 2 ) daily for 5 days with mitoxantrone 80 mg/m ( 2 ) ( the ALL-2 regimen ) as a novel induction regimen . Compared with historic controls , the ALL-2 regimen was superior in terms of incidence of complete remission , failure with resistant disease , and activity in patients with Philadelphia chromosome ( Ph ) -positive ALL . METHODS The authors conducted a multicenter , prospective , randomized trial of the ALL-2 regimen compared with a standard 4-drug induction ( the L-20 regimen ) . Patients also received consolidation , maintenance therapy , and central nervous system prophylaxis . The trial accrued patients from August 1996 to October 2004 . RESULTS The median follow-up for survivors was 7 years , and the median patient age was 43 years . Responses were evaluated in 164 patients . The treatment arms were balanced in terms of pretreatment characteristics . The frequency of complete remission for the ALL-2 regimen versus the L-20 regimen was 83 % versus 71 % ( P = .06 ) . More patients on the L-20 arm failed with resistant disease ( 21 % vs 8 % ; P = .02 ) . Induction deaths were comparable at 9 % ( ALL-2 ) versus 7 % ( L-20 ) . The median survival was similar ; and , at 5 years , the survival rate was 33 % alive on the ALL-2 arm versus 27 % on the L-20 . CONCLUSIONS Despite superior results of induction therapy with the ALL-2 regimen , this treatment did not improve long-term outcomes . When coupled to the reported experience of other studies in adults with ALL , the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen . Cancer 2013 . © 2012 American Cancer Society . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Treatment of adults with acute lymphoblastic leukemia : do the specifics of the regimen matter ? : Results from a prospective randomized trial . BACKGROUND Induction therapy for adults with acute lymphoblastic leukemia ( ALL ) is similar across essentially all regimens , comprised of vincristine , corticosteroids , and anthracyclines intensified with cyclophosphamide , asparaginase , or both . Given the lack of randomized data , to date , no regimen has emerged as standard . The authors previously evaluated cytarabine 3 g/m ( 2 ) daily for 5 days with mitoxantrone 80 mg/m ( 2 ) ( the ALL-2 regimen ) as a novel induction regimen . Compared with historic controls , the ALL-2 regimen was superior in terms of incidence of complete remission , failure with resistant disease , and activity in patients with Philadelphia chromosome ( Ph ) -positive ALL . METHODS The authors conducted a multicenter , prospective , randomized trial of the ALL-2 regimen compared with a standard 4-drug induction ( the L-20 regimen ) . Patients also received consolidation , maintenance therapy , and central nervous system prophylaxis . The trial accrued patients from August 1996 to October 2004 . RESULTS The median follow-up for survivors was 7 years , and the median patient age was 43 years . Responses were evaluated in 164 patients . The treatment arms were balanced in terms of pretreatment characteristics . The frequency of complete remission for the ALL-2 regimen versus the L-20 regimen was 83 % versus 71 % ( P = .06 ) . More patients on the L-20 arm failed with resistant disease ( 21 % vs 8 % ; P = .02 ) . Induction deaths were comparable at 9 % ( ALL-2 ) versus 7 % ( L-20 ) . The median survival was similar ; and , at 5 years , the survival rate was 33 % alive on the ALL-2 arm versus 27 % on the L-20 . CONCLUSIONS Despite superior results of induction therapy with the ALL-2 regimen , this treatment did not improve long-term outcomes . When coupled to the reported experience of other studies in adults with ALL , the results of this randomized trial raise the possibility that ultimate outcomes in adult ALL may be independent of the specific regimen chosen . Cancer 2013 . © 2012 American Cancer Society .

[ "Treatment", "of", "adults", "with", "acute", "lymphoblastic", "leukemia", ":", "do", "the", "specifics", "of", "the", "regimen", "matter", "?", ":", "Results", "from", "a", "prospective", "randomized", "trial", ".", "BACKGROUND", "Induction", "therapy", "for", "adults", "with", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "is", "similar", "across", "essentially", "all", "regimens", ",", "comprised", "of", "vincristine", ",", "corticosteroids", ",", "and", "anthracyclines", "intensified", "with", "cyclophosphamide", ",", "asparaginase", ",", "or", "both", ".", "Given", "the", "lack", "of", "randomized", "data", ",", "to", "date", ",", "no", "regimen", "has", "emerged", "as", "standard", ".", "The", "authors", "previously", "evaluated", "cytarabine", "3", "g", "/", "m", "(", "2", ")", "daily", "for", "5", "days", "with", "mitoxantrone", "80", "mg", "/", "m", "(", "2", ")", "(", "the", "ALL-2", "regimen", ")", "as", "a", "novel", "induction", "regimen", ".", "Compared", "with", "historic", "controls", ",", "the", "ALL-2", "regimen", "was", "superior", "in", "terms", "of", "incidence", "of", "complete", "remission", ",", "failure", "with", "resistant", "disease", ",", "and", "activity", "in", "patients", "with", "Philadelphia", "chromosome", "(", "Ph", ")", "-positive", "ALL", ".", "METHODS", "The", "authors", "conducted", "a", "multicenter", ",", "prospective", ",", "randomized", "trial", "of", "the", "ALL-2", "regimen", "compared", "with", "a", "standard", "4-drug", "induction", "(", "the", "L-20", "regimen", ")", ".", "Patients", "also", "received", "consolidation", ",", "maintenance", "therapy", ",", "and", "central", "nervous", "system", "prophylaxis", ".", "The", "trial", "accrued", "patients", "from", "August", "1996", "to", "October", "2004", ".", "RESULTS", "The", "median", "follow", "-", "up", "for", "survivors", "was", "7", "years", ",", "and", "the", "median", "patient", "age", "was", "43", "years", ".", "Responses", "were", "evaluated", "in", "164", "patients", ".", "The", "treatment", "arms", "were", "balanced", "in", "terms", "of", "pretreatment", "characteristics", ".", "The", "frequency", "of", "complete", "remission", "for", "the", "ALL-2", "regimen", "versus", "the", "L-20", "regimen", "was", "83", "%", "versus", "71", "%", "(", "P", "=", ".06", ")", ".", "More", "patients", "on", "the", "L-20", "arm", "failed", "with", "resistant", "disease", "(", "21", "%", "vs", "8", "%", ";", "P", "=", ".02", ")", ".", "Induction", "deaths", "were", "comparable", "at", "9", "%", "(", "ALL-2", ")", "versus", "7", "%", "(", "L-20", ")", ".", "The", "median", "survival", "was", "similar", ";", "and", ",", "at", "5", "years", ",", "the", "survival", "rate", "was", "33", "%", "alive", "on", "the", "ALL-2", "arm", "versus", "27", "%", "on", "the", "L-20", ".", "CONCLUSIONS", "Despite", "superior", "results", "of", "induction", "therapy", "with", "the", "ALL-2", "regimen", ",", "this", "treatment", "did", "not", "improve", "long", "-", "term", "outcomes", ".", "When", "coupled", "to", "the", "reported", "experience", "of", "other", "studies", "in", "adults", "with", "ALL", ",", "the", "results", "of", "this", "randomized", "trial", "raise", "the", "possibility", "that", "ultimate", "outcomes", "in", "adult", "ALL", "may", "be", "independent", "of", "the", "specific", "regimen", "chosen", ".", "Cancer", "2013", ".", "©", "2012", "American", "Cancer", "Society", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Participant_Age", "Outcome_Mortality", "Participant_Condition", "Outcome_Other", "Participant_Sample-size" ]

old is an umlsterm, female is an umlsterm, patient is an umlsterm, fractures is an umlsterm, minor is an umlsterm, trauma is an umlsterm, pelvis is an umlsterm, pseudoarthrosis is an umlsterm, simulated is an umlsterm, metastatic disease is an umlsterm, differential diagnosis is an umlsterm, fractures is an umlsterm

DerUnfallchirurg.91020656.eng.abstr_task0

Sentence: We report a case of a 64-year old female patient , who developed a total instability of the pelvic ring within one year as a result of increasing insufficiency fractures . A minor trauma of the pelvis was assumed to be the trigger of this process retrospectively . The radiographic appearance of the multiple pseudoarthrosis simulated a metastatic disease . The differential diagnosis and the typical pattern of sacral insufficiency fractures ( SIF ) are described . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

We report a case of a 64-year old female patient , who developed a total instability of the pelvic ring within one year as a result of increasing insufficiency fractures . A minor trauma of the pelvis was assumed to be the trigger of this process retrospectively . The radiographic appearance of the multiple pseudoarthrosis simulated a metastatic disease . The differential diagnosis and the typical pattern of sacral insufficiency fractures ( SIF ) are described .

[ "We", "report", "a", "case", "of", "a", "64-year", "old", "female", "patient", ",", "who", "developed", "a", "total", "instability", "of", "the", "pelvic", "ring", "within", "one", "year", "as", "a", "result", "of", "increasing", "insufficiency", "fractures", ".", "A", "minor", "trauma", "of", "the", "pelvis", "was", "assumed", "to", "be", "the", "trigger", "of", "this", "process", "retrospectively", ".", "The", "radiographic", "appearance", "of", "the", "multiple", "pseudoarthrosis", "simulated", "a", "metastatic", "disease", ".", "The", "differential", "diagnosis", "and", "the", "typical", "pattern", "of", "sacral", "insufficiency", "fractures", "(", "SIF", ")", "are", "described", "." ]

[ "umlsterm" ]

old is an umlsterm, female is an umlsterm, patient is an umlsterm, fractures is an umlsterm, minor is an umlsterm, trauma is an umlsterm, pelvis is an umlsterm, pseudoarthrosis is an umlsterm, simulated is an umlsterm, metastatic disease is an umlsterm, differential diagnosis is an umlsterm, fractures is an umlsterm

DerUnfallchirurg.91020656.eng.abstr_task1

Sentence: We report a case of a 64-year old female patient , who developed a total instability of the pelvic ring within one year as a result of increasing insufficiency fractures . A minor trauma of the pelvis was assumed to be the trigger of this process retrospectively . The radiographic appearance of the multiple pseudoarthrosis simulated a metastatic disease . The differential diagnosis and the typical pattern of sacral insufficiency fractures ( SIF ) are described . Instructions: please typing these entity words according to sentence: old, female, patient, fractures, minor, trauma, pelvis, pseudoarthrosis, simulated, metastatic disease, differential diagnosis, fractures Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

We report a case of a 64-year old female patient , who developed a total instability of the pelvic ring within one year as a result of increasing insufficiency fractures . A minor trauma of the pelvis was assumed to be the trigger of this process retrospectively . The radiographic appearance of the multiple pseudoarthrosis simulated a metastatic disease . The differential diagnosis and the typical pattern of sacral insufficiency fractures ( SIF ) are described .

[ "We", "report", "a", "case", "of", "a", "64-year", "old", "female", "patient", ",", "who", "developed", "a", "total", "instability", "of", "the", "pelvic", "ring", "within", "one", "year", "as", "a", "result", "of", "increasing", "insufficiency", "fractures", ".", "A", "minor", "trauma", "of", "the", "pelvis", "was", "assumed", "to", "be", "the", "trigger", "of", "this", "process", "retrospectively", ".", "The", "radiographic", "appearance", "of", "the", "multiple", "pseudoarthrosis", "simulated", "a", "metastatic", "disease", ".", "The", "differential", "diagnosis", "and", "the", "typical", "pattern", "of", "sacral", "insufficiency", "fractures", "(", "SIF", ")", "are", "described", "." ]

[ "umlsterm" ]

old, female, patient, fractures, minor, trauma, pelvis, pseudoarthrosis, simulated, metastatic disease, differential diagnosis, fractures

DerUnfallchirurg.91020656.eng.abstr_task2

Sentence: We report a case of a 64-year old female patient , who developed a total instability of the pelvic ring within one year as a result of increasing insufficiency fractures . A minor trauma of the pelvis was assumed to be the trigger of this process retrospectively . The radiographic appearance of the multiple pseudoarthrosis simulated a metastatic disease . The differential diagnosis and the typical pattern of sacral insufficiency fractures ( SIF ) are described . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

We report a case of a 64-year old female patient , who developed a total instability of the pelvic ring within one year as a result of increasing insufficiency fractures . A minor trauma of the pelvis was assumed to be the trigger of this process retrospectively . The radiographic appearance of the multiple pseudoarthrosis simulated a metastatic disease . The differential diagnosis and the typical pattern of sacral insufficiency fractures ( SIF ) are described .

[ "We", "report", "a", "case", "of", "a", "64-year", "old", "female", "patient", ",", "who", "developed", "a", "total", "instability", "of", "the", "pelvic", "ring", "within", "one", "year", "as", "a", "result", "of", "increasing", "insufficiency", "fractures", ".", "A", "minor", "trauma", "of", "the", "pelvis", "was", "assumed", "to", "be", "the", "trigger", "of", "this", "process", "retrospectively", ".", "The", "radiographic", "appearance", "of", "the", "multiple", "pseudoarthrosis", "simulated", "a", "metastatic", "disease", ".", "The", "differential", "diagnosis", "and", "the", "typical", "pattern", "of", "sacral", "insufficiency", "fractures", "(", "SIF", ")", "are", "described", "." ]

[ "umlsterm" ]

IgG is a Individual_protein, vinculin is a Individual_protein, talin is a Individual_protein, actin - binding protein is a Individual_protein

60_task0

Sentence: Although binding patterns of different sera were not identical, almost all sera caused IgG binding to platelet components of 87-90 kD, 140 kD (identified as vinculin) and 220-240 kD (tentatively identified as talin and actin-binding protein). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O" ]

Although binding patterns of different sera were not identical, almost all sera caused IgG binding to platelet components of 87-90 kD, 140 kD (identified as vinculin) and 220-240 kD (tentatively identified as talin and actin-binding protein).

[ "Although", "binding", "patterns", "of", "different", "sera", "were", "not", "identical", ",", "almost", "all", "sera", "caused", "IgG", "binding", "to", "platelet", "components", "of", "87", "-", "90", "kD", ",", "140", "kD", "(", "identified", "as", "vinculin", ")", "and", "220", "-", "240", "kD", "(", "tentatively", "identified", "as", "talin", "and", "actin", "-", "binding", "protein", ")", "." ]

[ "Individual_protein" ]

IgG is a Individual_protein, vinculin is a Individual_protein, talin is a Individual_protein, actin - binding protein is a Individual_protein

60_task1

Sentence: Although binding patterns of different sera were not identical, almost all sera caused IgG binding to platelet components of 87-90 kD, 140 kD (identified as vinculin) and 220-240 kD (tentatively identified as talin and actin-binding protein). Instructions: please typing these entity words according to sentence: IgG, vinculin, talin, actin - binding protein Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O" ]

Although binding patterns of different sera were not identical, almost all sera caused IgG binding to platelet components of 87-90 kD, 140 kD (identified as vinculin) and 220-240 kD (tentatively identified as talin and actin-binding protein).

[ "Although", "binding", "patterns", "of", "different", "sera", "were", "not", "identical", ",", "almost", "all", "sera", "caused", "IgG", "binding", "to", "platelet", "components", "of", "87", "-", "90", "kD", ",", "140", "kD", "(", "identified", "as", "vinculin", ")", "and", "220", "-", "240", "kD", "(", "tentatively", "identified", "as", "talin", "and", "actin", "-", "binding", "protein", ")", "." ]

[ "Individual_protein" ]

IgG, vinculin, talin, actin - binding protein

60_task2

Sentence: Although binding patterns of different sera were not identical, almost all sera caused IgG binding to platelet components of 87-90 kD, 140 kD (identified as vinculin) and 220-240 kD (tentatively identified as talin and actin-binding protein). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O" ]

Although binding patterns of different sera were not identical, almost all sera caused IgG binding to platelet components of 87-90 kD, 140 kD (identified as vinculin) and 220-240 kD (tentatively identified as talin and actin-binding protein).

[ "Although", "binding", "patterns", "of", "different", "sera", "were", "not", "identical", ",", "almost", "all", "sera", "caused", "IgG", "binding", "to", "platelet", "components", "of", "87", "-", "90", "kD", ",", "140", "kD", "(", "identified", "as", "vinculin", ")", "and", "220", "-", "240", "kD", "(", "tentatively", "identified", "as", "talin", "and", "actin", "-", "binding", "protein", ")", "." ]

[ "Individual_protein" ]

Rehabilitation outcomes is a Outcome_Physical, risk factors is a Outcome_Mental, psychological well - being is a Outcome_Mental, functional capacity is a Outcome_Mental, work resumption is a Outcome_Mental, post - percutaneous coronary interventions ( PCI ) is a Intervention_Educational, control ( standard care plus telephone follow - up is a Intervention_Control, post - PCI is a Intervention_Educational, serum cholesterol levels is a Outcome_Physical, exercise participation is a Outcome_Physical, body mass index ( BMI ) is a Outcome_Physical, returned to work is a Outcome_Mental, risk factor profiles and work resumption patterns is a Outcome_Other

6334_task0

Sentence: Rehabilitation outcomes following percutaneous coronary interventions ( PCI ) . This prospective study evaluated the effect of an individualized , comprehensive , home-based cardiac rehabilitation program combining exercise training with risk factor modification and psychosocial counseling on risk factors , psychological well-being , functional capacity , and work resumption in 99 post-percutaneous coronary interventions ( PCI ) patients randomized to control ( standard care plus telephone follow-up , n=49 ) or intervention ( individualized , comprehensive , home-based cardiac rehabilitation , n=50 ) groups . Data were collected at time 1 ( T ( 1 ) ) during hospital admission , time 2 ( T ( 2 ) ) approximately 2 months post-PCI , and time 3 ( T ( 3 ) ) approximately 12 months post-PCI . Results suggest that the allocation to an individualized , comprehensive , home-based cardiac rehabilitation program provided more advantageous outcomes . At both follow-ups , the intervention group showed within-group improvement in serum cholesterol levels ( P < 0.02 ; P < 0.01 ) and exercise participation ( P < 0.001 ; P < 0.001 ) with differences in exercise participation favoring the intervention group ( P < 0.01 ) at T ( 2 ) . Repeated measures ANOVA showed significant improvements over time in body mass index ( BMI ) ( P < 0.01 ) , psychological well-being ( P < 0.001 ) , and functional capacity ( P < 0.001 ) for both groups . More patients in the intervention group had returned to work at T ( 2 ) ( P < 0.001 ) and did so more quickly ( P < 0.01 ) . These findings suggest that an individualized , comprehensive , home-based cardiac rehabilitation program improves risk factor profiles and work resumption patterns for patients following PCI . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Control, Intervention_Educational, Outcome_Physical, Outcome_Other, Outcome_Mental

[ "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O" ]

Rehabilitation outcomes following percutaneous coronary interventions ( PCI ) . This prospective study evaluated the effect of an individualized , comprehensive , home-based cardiac rehabilitation program combining exercise training with risk factor modification and psychosocial counseling on risk factors , psychological well-being , functional capacity , and work resumption in 99 post-percutaneous coronary interventions ( PCI ) patients randomized to control ( standard care plus telephone follow-up , n=49 ) or intervention ( individualized , comprehensive , home-based cardiac rehabilitation , n=50 ) groups . Data were collected at time 1 ( T ( 1 ) ) during hospital admission , time 2 ( T ( 2 ) ) approximately 2 months post-PCI , and time 3 ( T ( 3 ) ) approximately 12 months post-PCI . Results suggest that the allocation to an individualized , comprehensive , home-based cardiac rehabilitation program provided more advantageous outcomes . At both follow-ups , the intervention group showed within-group improvement in serum cholesterol levels ( P < 0.02 ; P < 0.01 ) and exercise participation ( P < 0.001 ; P < 0.001 ) with differences in exercise participation favoring the intervention group ( P < 0.01 ) at T ( 2 ) . Repeated measures ANOVA showed significant improvements over time in body mass index ( BMI ) ( P < 0.01 ) , psychological well-being ( P < 0.001 ) , and functional capacity ( P < 0.001 ) for both groups . More patients in the intervention group had returned to work at T ( 2 ) ( P < 0.001 ) and did so more quickly ( P < 0.01 ) . These findings suggest that an individualized , comprehensive , home-based cardiac rehabilitation program improves risk factor profiles and work resumption patterns for patients following PCI .

[ "Rehabilitation", "outcomes", "following", "percutaneous", "coronary", "interventions", "(", "PCI", ")", ".", "This", "prospective", "study", "evaluated", "the", "effect", "of", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "combining", "exercise", "training", "with", "risk", "factor", "modification", "and", "psychosocial", "counseling", "on", "risk", "factors", ",", "psychological", "well", "-", "being", ",", "functional", "capacity", ",", "and", "work", "resumption", "in", "99", "post", "-", "percutaneous", "coronary", "interventions", "(", "PCI", ")", "patients", "randomized", "to", "control", "(", "standard", "care", "plus", "telephone", "follow", "-", "up", ",", "n=49", ")", "or", "intervention", "(", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", ",", "n=50", ")", "groups", ".", "Data", "were", "collected", "at", "time", "1", "(", "T", "(", "1", ")", ")", "during", "hospital", "admission", ",", "time", "2", "(", "T", "(", "2", ")", ")", "approximately", "2", "months", "post", "-", "PCI", ",", "and", "time", "3", "(", "T", "(", "3", ")", ")", "approximately", "12", "months", "post", "-", "PCI", ".", "Results", "suggest", "that", "the", "allocation", "to", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "provided", "more", "advantageous", "outcomes", ".", "At", "both", "follow", "-", "ups", ",", "the", "intervention", "group", "showed", "within", "-", "group", "improvement", "in", "serum", "cholesterol", "levels", "(", "P", "<", "0.02", ";", "P", "<", "0.01", ")", "and", "exercise", "participation", "(", "P", "<", "0.001", ";", "P", "<", "0.001", ")", "with", "differences", "in", "exercise", "participation", "favoring", "the", "intervention", "group", "(", "P", "<", "0.01", ")", "at", "T", "(", "2", ")", ".", "Repeated", "measures", "ANOVA", "showed", "significant", "improvements", "over", "time", "in", "body", "mass", "index", "(", "BMI", ")", "(", "P", "<", "0.01", ")", ",", "psychological", "well", "-", "being", "(", "P", "<", "0.001", ")", ",", "and", "functional", "capacity", "(", "P", "<", "0.001", ")", "for", "both", "groups", ".", "More", "patients", "in", "the", "intervention", "group", "had", "returned", "to", "work", "at", "T", "(", "2", ")", "(", "P", "<", "0.001", ")", "and", "did", "so", "more", "quickly", "(", "P", "<", "0.01", ")", ".", "These", "findings", "suggest", "that", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "improves", "risk", "factor", "profiles", "and", "work", "resumption", "patterns", "for", "patients", "following", "PCI", "." ]

[ "Outcome_Other", "Intervention_Educational", "Intervention_Control", "Outcome_Mental", "Outcome_Physical" ]

Rehabilitation outcomes is a Outcome_Physical, risk factors is a Outcome_Mental, psychological well - being is a Outcome_Mental, functional capacity is a Outcome_Mental, work resumption is a Outcome_Mental, post - percutaneous coronary interventions ( PCI ) is a Intervention_Educational, control ( standard care plus telephone follow - up is a Intervention_Control, post - PCI is a Intervention_Educational, serum cholesterol levels is a Outcome_Physical, exercise participation is a Outcome_Physical, body mass index ( BMI ) is a Outcome_Physical, returned to work is a Outcome_Mental, risk factor profiles and work resumption patterns is a Outcome_Other

6334_task1

Sentence: Rehabilitation outcomes following percutaneous coronary interventions ( PCI ) . This prospective study evaluated the effect of an individualized , comprehensive , home-based cardiac rehabilitation program combining exercise training with risk factor modification and psychosocial counseling on risk factors , psychological well-being , functional capacity , and work resumption in 99 post-percutaneous coronary interventions ( PCI ) patients randomized to control ( standard care plus telephone follow-up , n=49 ) or intervention ( individualized , comprehensive , home-based cardiac rehabilitation , n=50 ) groups . Data were collected at time 1 ( T ( 1 ) ) during hospital admission , time 2 ( T ( 2 ) ) approximately 2 months post-PCI , and time 3 ( T ( 3 ) ) approximately 12 months post-PCI . Results suggest that the allocation to an individualized , comprehensive , home-based cardiac rehabilitation program provided more advantageous outcomes . At both follow-ups , the intervention group showed within-group improvement in serum cholesterol levels ( P < 0.02 ; P < 0.01 ) and exercise participation ( P < 0.001 ; P < 0.001 ) with differences in exercise participation favoring the intervention group ( P < 0.01 ) at T ( 2 ) . Repeated measures ANOVA showed significant improvements over time in body mass index ( BMI ) ( P < 0.01 ) , psychological well-being ( P < 0.001 ) , and functional capacity ( P < 0.001 ) for both groups . More patients in the intervention group had returned to work at T ( 2 ) ( P < 0.001 ) and did so more quickly ( P < 0.01 ) . These findings suggest that an individualized , comprehensive , home-based cardiac rehabilitation program improves risk factor profiles and work resumption patterns for patients following PCI . Instructions: please typing these entity words according to sentence: Rehabilitation outcomes, risk factors, psychological well - being, functional capacity, work resumption, post - percutaneous coronary interventions ( PCI ), control ( standard care plus telephone follow - up, post - PCI, serum cholesterol levels, exercise participation, body mass index ( BMI ), returned to work, risk factor profiles and work resumption patterns Options: Intervention_Control, Intervention_Educational, Outcome_Physical, Outcome_Other, Outcome_Mental

[ "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O" ]

Rehabilitation outcomes following percutaneous coronary interventions ( PCI ) . This prospective study evaluated the effect of an individualized , comprehensive , home-based cardiac rehabilitation program combining exercise training with risk factor modification and psychosocial counseling on risk factors , psychological well-being , functional capacity , and work resumption in 99 post-percutaneous coronary interventions ( PCI ) patients randomized to control ( standard care plus telephone follow-up , n=49 ) or intervention ( individualized , comprehensive , home-based cardiac rehabilitation , n=50 ) groups . Data were collected at time 1 ( T ( 1 ) ) during hospital admission , time 2 ( T ( 2 ) ) approximately 2 months post-PCI , and time 3 ( T ( 3 ) ) approximately 12 months post-PCI . Results suggest that the allocation to an individualized , comprehensive , home-based cardiac rehabilitation program provided more advantageous outcomes . At both follow-ups , the intervention group showed within-group improvement in serum cholesterol levels ( P < 0.02 ; P < 0.01 ) and exercise participation ( P < 0.001 ; P < 0.001 ) with differences in exercise participation favoring the intervention group ( P < 0.01 ) at T ( 2 ) . Repeated measures ANOVA showed significant improvements over time in body mass index ( BMI ) ( P < 0.01 ) , psychological well-being ( P < 0.001 ) , and functional capacity ( P < 0.001 ) for both groups . More patients in the intervention group had returned to work at T ( 2 ) ( P < 0.001 ) and did so more quickly ( P < 0.01 ) . These findings suggest that an individualized , comprehensive , home-based cardiac rehabilitation program improves risk factor profiles and work resumption patterns for patients following PCI .

[ "Rehabilitation", "outcomes", "following", "percutaneous", "coronary", "interventions", "(", "PCI", ")", ".", "This", "prospective", "study", "evaluated", "the", "effect", "of", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "combining", "exercise", "training", "with", "risk", "factor", "modification", "and", "psychosocial", "counseling", "on", "risk", "factors", ",", "psychological", "well", "-", "being", ",", "functional", "capacity", ",", "and", "work", "resumption", "in", "99", "post", "-", "percutaneous", "coronary", "interventions", "(", "PCI", ")", "patients", "randomized", "to", "control", "(", "standard", "care", "plus", "telephone", "follow", "-", "up", ",", "n=49", ")", "or", "intervention", "(", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", ",", "n=50", ")", "groups", ".", "Data", "were", "collected", "at", "time", "1", "(", "T", "(", "1", ")", ")", "during", "hospital", "admission", ",", "time", "2", "(", "T", "(", "2", ")", ")", "approximately", "2", "months", "post", "-", "PCI", ",", "and", "time", "3", "(", "T", "(", "3", ")", ")", "approximately", "12", "months", "post", "-", "PCI", ".", "Results", "suggest", "that", "the", "allocation", "to", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "provided", "more", "advantageous", "outcomes", ".", "At", "both", "follow", "-", "ups", ",", "the", "intervention", "group", "showed", "within", "-", "group", "improvement", "in", "serum", "cholesterol", "levels", "(", "P", "<", "0.02", ";", "P", "<", "0.01", ")", "and", "exercise", "participation", "(", "P", "<", "0.001", ";", "P", "<", "0.001", ")", "with", "differences", "in", "exercise", "participation", "favoring", "the", "intervention", "group", "(", "P", "<", "0.01", ")", "at", "T", "(", "2", ")", ".", "Repeated", "measures", "ANOVA", "showed", "significant", "improvements", "over", "time", "in", "body", "mass", "index", "(", "BMI", ")", "(", "P", "<", "0.01", ")", ",", "psychological", "well", "-", "being", "(", "P", "<", "0.001", ")", ",", "and", "functional", "capacity", "(", "P", "<", "0.001", ")", "for", "both", "groups", ".", "More", "patients", "in", "the", "intervention", "group", "had", "returned", "to", "work", "at", "T", "(", "2", ")", "(", "P", "<", "0.001", ")", "and", "did", "so", "more", "quickly", "(", "P", "<", "0.01", ")", ".", "These", "findings", "suggest", "that", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "improves", "risk", "factor", "profiles", "and", "work", "resumption", "patterns", "for", "patients", "following", "PCI", "." ]

[ "Outcome_Other", "Intervention_Educational", "Intervention_Control", "Outcome_Mental", "Outcome_Physical" ]

Rehabilitation outcomes, risk factors, psychological well - being, functional capacity, work resumption, post - percutaneous coronary interventions ( PCI ), control ( standard care plus telephone follow - up, post - PCI, serum cholesterol levels, exercise participation, body mass index ( BMI ), returned to work, risk factor profiles and work resumption patterns

6334_task2

Sentence: Rehabilitation outcomes following percutaneous coronary interventions ( PCI ) . This prospective study evaluated the effect of an individualized , comprehensive , home-based cardiac rehabilitation program combining exercise training with risk factor modification and psychosocial counseling on risk factors , psychological well-being , functional capacity , and work resumption in 99 post-percutaneous coronary interventions ( PCI ) patients randomized to control ( standard care plus telephone follow-up , n=49 ) or intervention ( individualized , comprehensive , home-based cardiac rehabilitation , n=50 ) groups . Data were collected at time 1 ( T ( 1 ) ) during hospital admission , time 2 ( T ( 2 ) ) approximately 2 months post-PCI , and time 3 ( T ( 3 ) ) approximately 12 months post-PCI . Results suggest that the allocation to an individualized , comprehensive , home-based cardiac rehabilitation program provided more advantageous outcomes . At both follow-ups , the intervention group showed within-group improvement in serum cholesterol levels ( P < 0.02 ; P < 0.01 ) and exercise participation ( P < 0.001 ; P < 0.001 ) with differences in exercise participation favoring the intervention group ( P < 0.01 ) at T ( 2 ) . Repeated measures ANOVA showed significant improvements over time in body mass index ( BMI ) ( P < 0.01 ) , psychological well-being ( P < 0.001 ) , and functional capacity ( P < 0.001 ) for both groups . More patients in the intervention group had returned to work at T ( 2 ) ( P < 0.001 ) and did so more quickly ( P < 0.01 ) . These findings suggest that an individualized , comprehensive , home-based cardiac rehabilitation program improves risk factor profiles and work resumption patterns for patients following PCI . Instructions: please extract entity words from the input sentence

[ "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O" ]

Rehabilitation outcomes following percutaneous coronary interventions ( PCI ) . This prospective study evaluated the effect of an individualized , comprehensive , home-based cardiac rehabilitation program combining exercise training with risk factor modification and psychosocial counseling on risk factors , psychological well-being , functional capacity , and work resumption in 99 post-percutaneous coronary interventions ( PCI ) patients randomized to control ( standard care plus telephone follow-up , n=49 ) or intervention ( individualized , comprehensive , home-based cardiac rehabilitation , n=50 ) groups . Data were collected at time 1 ( T ( 1 ) ) during hospital admission , time 2 ( T ( 2 ) ) approximately 2 months post-PCI , and time 3 ( T ( 3 ) ) approximately 12 months post-PCI . Results suggest that the allocation to an individualized , comprehensive , home-based cardiac rehabilitation program provided more advantageous outcomes . At both follow-ups , the intervention group showed within-group improvement in serum cholesterol levels ( P < 0.02 ; P < 0.01 ) and exercise participation ( P < 0.001 ; P < 0.001 ) with differences in exercise participation favoring the intervention group ( P < 0.01 ) at T ( 2 ) . Repeated measures ANOVA showed significant improvements over time in body mass index ( BMI ) ( P < 0.01 ) , psychological well-being ( P < 0.001 ) , and functional capacity ( P < 0.001 ) for both groups . More patients in the intervention group had returned to work at T ( 2 ) ( P < 0.001 ) and did so more quickly ( P < 0.01 ) . These findings suggest that an individualized , comprehensive , home-based cardiac rehabilitation program improves risk factor profiles and work resumption patterns for patients following PCI .

[ "Rehabilitation", "outcomes", "following", "percutaneous", "coronary", "interventions", "(", "PCI", ")", ".", "This", "prospective", "study", "evaluated", "the", "effect", "of", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "combining", "exercise", "training", "with", "risk", "factor", "modification", "and", "psychosocial", "counseling", "on", "risk", "factors", ",", "psychological", "well", "-", "being", ",", "functional", "capacity", ",", "and", "work", "resumption", "in", "99", "post", "-", "percutaneous", "coronary", "interventions", "(", "PCI", ")", "patients", "randomized", "to", "control", "(", "standard", "care", "plus", "telephone", "follow", "-", "up", ",", "n=49", ")", "or", "intervention", "(", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", ",", "n=50", ")", "groups", ".", "Data", "were", "collected", "at", "time", "1", "(", "T", "(", "1", ")", ")", "during", "hospital", "admission", ",", "time", "2", "(", "T", "(", "2", ")", ")", "approximately", "2", "months", "post", "-", "PCI", ",", "and", "time", "3", "(", "T", "(", "3", ")", ")", "approximately", "12", "months", "post", "-", "PCI", ".", "Results", "suggest", "that", "the", "allocation", "to", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "provided", "more", "advantageous", "outcomes", ".", "At", "both", "follow", "-", "ups", ",", "the", "intervention", "group", "showed", "within", "-", "group", "improvement", "in", "serum", "cholesterol", "levels", "(", "P", "<", "0.02", ";", "P", "<", "0.01", ")", "and", "exercise", "participation", "(", "P", "<", "0.001", ";", "P", "<", "0.001", ")", "with", "differences", "in", "exercise", "participation", "favoring", "the", "intervention", "group", "(", "P", "<", "0.01", ")", "at", "T", "(", "2", ")", ".", "Repeated", "measures", "ANOVA", "showed", "significant", "improvements", "over", "time", "in", "body", "mass", "index", "(", "BMI", ")", "(", "P", "<", "0.01", ")", ",", "psychological", "well", "-", "being", "(", "P", "<", "0.001", ")", ",", "and", "functional", "capacity", "(", "P", "<", "0.001", ")", "for", "both", "groups", ".", "More", "patients", "in", "the", "intervention", "group", "had", "returned", "to", "work", "at", "T", "(", "2", ")", "(", "P", "<", "0.001", ")", "and", "did", "so", "more", "quickly", "(", "P", "<", "0.01", ")", ".", "These", "findings", "suggest", "that", "an", "individualized", ",", "comprehensive", ",", "home", "-", "based", "cardiac", "rehabilitation", "program", "improves", "risk", "factor", "profiles", "and", "work", "resumption", "patterns", "for", "patients", "following", "PCI", "." ]

[ "Outcome_Other", "Intervention_Educational", "Intervention_Control", "Outcome_Mental", "Outcome_Physical" ]

Kalksalzablagerungen is an umlsterm, licht- is an umlsterm, rasterelektronenmikroskopisch is an umlsterm, Natur is an umlsterm, Nadeln is an umlsterm, Natriumurats is an umlsterm, Wasser is an umlsterm, rasterelektronenmikroskopisch is an umlsterm, Kalzium is an umlsterm, Phosphor is an umlsterm, Fadengranulomen is an umlsterm, Geweben is an umlsterm, Knorpelarten is an umlsterm

ZfuerRheumatologie.00590240.ger.abstr_task0

Sentence: Verkalkungen von Gichttophi sind zwar ein bekanntes Ereignis , dennoch fehlen detaillierte Untersuchungsbefunde zur Zusammensetzung dieser sekundaeren Kalksalzablagerungen . Es sollte deshalb licht- und rasterelektronenmikroskopisch sowie roentgenmikroanalytisch die Natur solcher Verkalkungen geklaert werden . In ungefaerbten Schnittpraeparaten verkalkter Gichttophi herrschten die negativ doppelbrechenden Nadeln des Natriumurats vor , nach Inkubation in destilliertem Wasser waren sie verschwunden und lediglich plumpe unterschiedlich grosse positiv doppelbrechende Kristalle zurueckgeblieben ; ein gleichartiges Ergebnis wurde rasterelektronenmikroskopisch erhalten . Roentgenmikroanalytisch liessen hohe Zaehlraten fuer Kalzium und Phosphor auf die Anwesenheit von Kalziumpyrophosphat-Dihydrat schliessen . Das Auftreten von Kalziumpyrophosphatkristallen in Gichttophi und auch Fadengranulomen laesst die Schlussfolgerung zu , dass diese Kristalle nicht nur in artikulaeren Geweben im engeren Sinne oder verschiedenen Knorpelarten auftreten . Der biochemische Mechanismus , der zur Kristallbildung fuehrt , bleibt zwar unbekannt , es darf aber vermutet werden , dass die Verkalkung Folge einer vorausgegangenen Bindegewebsschaedigung ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Verkalkungen von Gichttophi sind zwar ein bekanntes Ereignis , dennoch fehlen detaillierte Untersuchungsbefunde zur Zusammensetzung dieser sekundaeren Kalksalzablagerungen . Es sollte deshalb licht- und rasterelektronenmikroskopisch sowie roentgenmikroanalytisch die Natur solcher Verkalkungen geklaert werden . In ungefaerbten Schnittpraeparaten verkalkter Gichttophi herrschten die negativ doppelbrechenden Nadeln des Natriumurats vor , nach Inkubation in destilliertem Wasser waren sie verschwunden und lediglich plumpe unterschiedlich grosse positiv doppelbrechende Kristalle zurueckgeblieben ; ein gleichartiges Ergebnis wurde rasterelektronenmikroskopisch erhalten . Roentgenmikroanalytisch liessen hohe Zaehlraten fuer Kalzium und Phosphor auf die Anwesenheit von Kalziumpyrophosphat-Dihydrat schliessen . Das Auftreten von Kalziumpyrophosphatkristallen in Gichttophi und auch Fadengranulomen laesst die Schlussfolgerung zu , dass diese Kristalle nicht nur in artikulaeren Geweben im engeren Sinne oder verschiedenen Knorpelarten auftreten . Der biochemische Mechanismus , der zur Kristallbildung fuehrt , bleibt zwar unbekannt , es darf aber vermutet werden , dass die Verkalkung Folge einer vorausgegangenen Bindegewebsschaedigung ist .

[ "Verkalkungen", "von", "Gichttophi", "sind", "zwar", "ein", "bekanntes", "Ereignis", ",", "dennoch", "fehlen", "detaillierte", "Untersuchungsbefunde", "zur", "Zusammensetzung", "dieser", "sekundaeren", "Kalksalzablagerungen", ".", "Es", "sollte", "deshalb", "licht-", "und", "rasterelektronenmikroskopisch", "sowie", "roentgenmikroanalytisch", "die", "Natur", "solcher", "Verkalkungen", "geklaert", "werden", ".", "In", "ungefaerbten", "Schnittpraeparaten", "verkalkter", "Gichttophi", "herrschten", "die", "negativ", "doppelbrechenden", "Nadeln", "des", "Natriumurats", "vor", ",", "nach", "Inkubation", "in", "destilliertem", "Wasser", "waren", "sie", "verschwunden", "und", "lediglich", "plumpe", "unterschiedlich", "grosse", "positiv", "doppelbrechende", "Kristalle", "zurueckgeblieben", ";", "ein", "gleichartiges", "Ergebnis", "wurde", "rasterelektronenmikroskopisch", "erhalten", ".", "Roentgenmikroanalytisch", "liessen", "hohe", "Zaehlraten", "fuer", "Kalzium", "und", "Phosphor", "auf", "die", "Anwesenheit", "von", "Kalziumpyrophosphat", "-", "Dihydrat", "schliessen", ".", "Das", "Auftreten", "von", "Kalziumpyrophosphatkristallen", "in", "Gichttophi", "und", "auch", "Fadengranulomen", "laesst", "die", "Schlussfolgerung", "zu", ",", "dass", "diese", "Kristalle", "nicht", "nur", "in", "artikulaeren", "Geweben", "im", "engeren", "Sinne", "oder", "verschiedenen", "Knorpelarten", "auftreten", ".", "Der", "biochemische", "Mechanismus", ",", "der", "zur", "Kristallbildung", "fuehrt", ",", "bleibt", "zwar", "unbekannt", ",", "es", "darf", "aber", "vermutet", "werden", ",", "dass", "die", "Verkalkung", "Folge", "einer", "vorausgegangenen", "Bindegewebsschaedigung", "ist", "." ]

[ "umlsterm" ]

Kalksalzablagerungen is an umlsterm, licht- is an umlsterm, rasterelektronenmikroskopisch is an umlsterm, Natur is an umlsterm, Nadeln is an umlsterm, Natriumurats is an umlsterm, Wasser is an umlsterm, rasterelektronenmikroskopisch is an umlsterm, Kalzium is an umlsterm, Phosphor is an umlsterm, Fadengranulomen is an umlsterm, Geweben is an umlsterm, Knorpelarten is an umlsterm

ZfuerRheumatologie.00590240.ger.abstr_task1

Sentence: Verkalkungen von Gichttophi sind zwar ein bekanntes Ereignis , dennoch fehlen detaillierte Untersuchungsbefunde zur Zusammensetzung dieser sekundaeren Kalksalzablagerungen . Es sollte deshalb licht- und rasterelektronenmikroskopisch sowie roentgenmikroanalytisch die Natur solcher Verkalkungen geklaert werden . In ungefaerbten Schnittpraeparaten verkalkter Gichttophi herrschten die negativ doppelbrechenden Nadeln des Natriumurats vor , nach Inkubation in destilliertem Wasser waren sie verschwunden und lediglich plumpe unterschiedlich grosse positiv doppelbrechende Kristalle zurueckgeblieben ; ein gleichartiges Ergebnis wurde rasterelektronenmikroskopisch erhalten . Roentgenmikroanalytisch liessen hohe Zaehlraten fuer Kalzium und Phosphor auf die Anwesenheit von Kalziumpyrophosphat-Dihydrat schliessen . Das Auftreten von Kalziumpyrophosphatkristallen in Gichttophi und auch Fadengranulomen laesst die Schlussfolgerung zu , dass diese Kristalle nicht nur in artikulaeren Geweben im engeren Sinne oder verschiedenen Knorpelarten auftreten . Der biochemische Mechanismus , der zur Kristallbildung fuehrt , bleibt zwar unbekannt , es darf aber vermutet werden , dass die Verkalkung Folge einer vorausgegangenen Bindegewebsschaedigung ist . Instructions: please typing these entity words according to sentence: Kalksalzablagerungen, licht-, rasterelektronenmikroskopisch, Natur, Nadeln, Natriumurats, Wasser, rasterelektronenmikroskopisch, Kalzium, Phosphor, Fadengranulomen, Geweben, Knorpelarten Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Verkalkungen von Gichttophi sind zwar ein bekanntes Ereignis , dennoch fehlen detaillierte Untersuchungsbefunde zur Zusammensetzung dieser sekundaeren Kalksalzablagerungen . Es sollte deshalb licht- und rasterelektronenmikroskopisch sowie roentgenmikroanalytisch die Natur solcher Verkalkungen geklaert werden . In ungefaerbten Schnittpraeparaten verkalkter Gichttophi herrschten die negativ doppelbrechenden Nadeln des Natriumurats vor , nach Inkubation in destilliertem Wasser waren sie verschwunden und lediglich plumpe unterschiedlich grosse positiv doppelbrechende Kristalle zurueckgeblieben ; ein gleichartiges Ergebnis wurde rasterelektronenmikroskopisch erhalten . Roentgenmikroanalytisch liessen hohe Zaehlraten fuer Kalzium und Phosphor auf die Anwesenheit von Kalziumpyrophosphat-Dihydrat schliessen . Das Auftreten von Kalziumpyrophosphatkristallen in Gichttophi und auch Fadengranulomen laesst die Schlussfolgerung zu , dass diese Kristalle nicht nur in artikulaeren Geweben im engeren Sinne oder verschiedenen Knorpelarten auftreten . Der biochemische Mechanismus , der zur Kristallbildung fuehrt , bleibt zwar unbekannt , es darf aber vermutet werden , dass die Verkalkung Folge einer vorausgegangenen Bindegewebsschaedigung ist .

[ "Verkalkungen", "von", "Gichttophi", "sind", "zwar", "ein", "bekanntes", "Ereignis", ",", "dennoch", "fehlen", "detaillierte", "Untersuchungsbefunde", "zur", "Zusammensetzung", "dieser", "sekundaeren", "Kalksalzablagerungen", ".", "Es", "sollte", "deshalb", "licht-", "und", "rasterelektronenmikroskopisch", "sowie", "roentgenmikroanalytisch", "die", "Natur", "solcher", "Verkalkungen", "geklaert", "werden", ".", "In", "ungefaerbten", "Schnittpraeparaten", "verkalkter", "Gichttophi", "herrschten", "die", "negativ", "doppelbrechenden", "Nadeln", "des", "Natriumurats", "vor", ",", "nach", "Inkubation", "in", "destilliertem", "Wasser", "waren", "sie", "verschwunden", "und", "lediglich", "plumpe", "unterschiedlich", "grosse", "positiv", "doppelbrechende", "Kristalle", "zurueckgeblieben", ";", "ein", "gleichartiges", "Ergebnis", "wurde", "rasterelektronenmikroskopisch", "erhalten", ".", "Roentgenmikroanalytisch", "liessen", "hohe", "Zaehlraten", "fuer", "Kalzium", "und", "Phosphor", "auf", "die", "Anwesenheit", "von", "Kalziumpyrophosphat", "-", "Dihydrat", "schliessen", ".", "Das", "Auftreten", "von", "Kalziumpyrophosphatkristallen", "in", "Gichttophi", "und", "auch", "Fadengranulomen", "laesst", "die", "Schlussfolgerung", "zu", ",", "dass", "diese", "Kristalle", "nicht", "nur", "in", "artikulaeren", "Geweben", "im", "engeren", "Sinne", "oder", "verschiedenen", "Knorpelarten", "auftreten", ".", "Der", "biochemische", "Mechanismus", ",", "der", "zur", "Kristallbildung", "fuehrt", ",", "bleibt", "zwar", "unbekannt", ",", "es", "darf", "aber", "vermutet", "werden", ",", "dass", "die", "Verkalkung", "Folge", "einer", "vorausgegangenen", "Bindegewebsschaedigung", "ist", "." ]

[ "umlsterm" ]

Kalksalzablagerungen, licht-, rasterelektronenmikroskopisch, Natur, Nadeln, Natriumurats, Wasser, rasterelektronenmikroskopisch, Kalzium, Phosphor, Fadengranulomen, Geweben, Knorpelarten

ZfuerRheumatologie.00590240.ger.abstr_task2

Sentence: Verkalkungen von Gichttophi sind zwar ein bekanntes Ereignis , dennoch fehlen detaillierte Untersuchungsbefunde zur Zusammensetzung dieser sekundaeren Kalksalzablagerungen . Es sollte deshalb licht- und rasterelektronenmikroskopisch sowie roentgenmikroanalytisch die Natur solcher Verkalkungen geklaert werden . In ungefaerbten Schnittpraeparaten verkalkter Gichttophi herrschten die negativ doppelbrechenden Nadeln des Natriumurats vor , nach Inkubation in destilliertem Wasser waren sie verschwunden und lediglich plumpe unterschiedlich grosse positiv doppelbrechende Kristalle zurueckgeblieben ; ein gleichartiges Ergebnis wurde rasterelektronenmikroskopisch erhalten . Roentgenmikroanalytisch liessen hohe Zaehlraten fuer Kalzium und Phosphor auf die Anwesenheit von Kalziumpyrophosphat-Dihydrat schliessen . Das Auftreten von Kalziumpyrophosphatkristallen in Gichttophi und auch Fadengranulomen laesst die Schlussfolgerung zu , dass diese Kristalle nicht nur in artikulaeren Geweben im engeren Sinne oder verschiedenen Knorpelarten auftreten . Der biochemische Mechanismus , der zur Kristallbildung fuehrt , bleibt zwar unbekannt , es darf aber vermutet werden , dass die Verkalkung Folge einer vorausgegangenen Bindegewebsschaedigung ist . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Verkalkungen von Gichttophi sind zwar ein bekanntes Ereignis , dennoch fehlen detaillierte Untersuchungsbefunde zur Zusammensetzung dieser sekundaeren Kalksalzablagerungen . Es sollte deshalb licht- und rasterelektronenmikroskopisch sowie roentgenmikroanalytisch die Natur solcher Verkalkungen geklaert werden . In ungefaerbten Schnittpraeparaten verkalkter Gichttophi herrschten die negativ doppelbrechenden Nadeln des Natriumurats vor , nach Inkubation in destilliertem Wasser waren sie verschwunden und lediglich plumpe unterschiedlich grosse positiv doppelbrechende Kristalle zurueckgeblieben ; ein gleichartiges Ergebnis wurde rasterelektronenmikroskopisch erhalten . Roentgenmikroanalytisch liessen hohe Zaehlraten fuer Kalzium und Phosphor auf die Anwesenheit von Kalziumpyrophosphat-Dihydrat schliessen . Das Auftreten von Kalziumpyrophosphatkristallen in Gichttophi und auch Fadengranulomen laesst die Schlussfolgerung zu , dass diese Kristalle nicht nur in artikulaeren Geweben im engeren Sinne oder verschiedenen Knorpelarten auftreten . Der biochemische Mechanismus , der zur Kristallbildung fuehrt , bleibt zwar unbekannt , es darf aber vermutet werden , dass die Verkalkung Folge einer vorausgegangenen Bindegewebsschaedigung ist .

[ "Verkalkungen", "von", "Gichttophi", "sind", "zwar", "ein", "bekanntes", "Ereignis", ",", "dennoch", "fehlen", "detaillierte", "Untersuchungsbefunde", "zur", "Zusammensetzung", "dieser", "sekundaeren", "Kalksalzablagerungen", ".", "Es", "sollte", "deshalb", "licht-", "und", "rasterelektronenmikroskopisch", "sowie", "roentgenmikroanalytisch", "die", "Natur", "solcher", "Verkalkungen", "geklaert", "werden", ".", "In", "ungefaerbten", "Schnittpraeparaten", "verkalkter", "Gichttophi", "herrschten", "die", "negativ", "doppelbrechenden", "Nadeln", "des", "Natriumurats", "vor", ",", "nach", "Inkubation", "in", "destilliertem", "Wasser", "waren", "sie", "verschwunden", "und", "lediglich", "plumpe", "unterschiedlich", "grosse", "positiv", "doppelbrechende", "Kristalle", "zurueckgeblieben", ";", "ein", "gleichartiges", "Ergebnis", "wurde", "rasterelektronenmikroskopisch", "erhalten", ".", "Roentgenmikroanalytisch", "liessen", "hohe", "Zaehlraten", "fuer", "Kalzium", "und", "Phosphor", "auf", "die", "Anwesenheit", "von", "Kalziumpyrophosphat", "-", "Dihydrat", "schliessen", ".", "Das", "Auftreten", "von", "Kalziumpyrophosphatkristallen", "in", "Gichttophi", "und", "auch", "Fadengranulomen", "laesst", "die", "Schlussfolgerung", "zu", ",", "dass", "diese", "Kristalle", "nicht", "nur", "in", "artikulaeren", "Geweben", "im", "engeren", "Sinne", "oder", "verschiedenen", "Knorpelarten", "auftreten", ".", "Der", "biochemische", "Mechanismus", ",", "der", "zur", "Kristallbildung", "fuehrt", ",", "bleibt", "zwar", "unbekannt", ",", "es", "darf", "aber", "vermutet", "werden", ",", "dass", "die", "Verkalkung", "Folge", "einer", "vorausgegangenen", "Bindegewebsschaedigung", "ist", "." ]

[ "umlsterm" ]

Tagesklinik is an umlsterm, Altenberatung is an umlsterm, Bundesregierung is an umlsterm, Stadt is an umlsterm, Allgemeinmedizin is an umlsterm, Altenhilfe is an umlsterm, psychischen Stoerung is an umlsterm, aelteren Menschen is an umlsterm, Pflegebeduerftigkeit is an umlsterm, Allgemeinkrankenhaeusern is an umlsterm, Patienten is an umlsterm, Erstdiagnose is an umlsterm, Altenhilfe is an umlsterm, Behandlung is an umlsterm

ZfuerGerontologie+Geriatrie.00330059.ger.abstr_task0

Sentence: Ziel der Evaluationsstudie , ueber deren ausgewaehlte Ergebnisse dieser Beitrag berichtet , ist es , die Auswirkungen eines Gerontopsychiatrischen Zentrums ( GZ : eine Kombination von ambulantem Dienst , Tagesklinik und Altenberatung ) auf den von der Expertenkommission der Bundesregierung geforderten und ausfuehrlich begruendeten Wandlungsprozess von intramuralen " ( stationaeren ) " zu extramuralen " ( tagesklinischen und klinisch-ambulanten , " i . w . hausgestuetzten regionalen Versorgungsstrukturen ) erstmalig einer empirischen Pruefung zu unterziehen . Auf der Basis umfangreicher Quer- und Laengsschnittdaten werden durch einen Vergleich der Versorgungsregion der Stadt Bielefeld ( ohne GZ ) mit der des Kreises Guetersloh ( mit GZ ) Veraenderungen in den regionalen Versorgungsteilstrukturen der Gerontopsychiatrie ( Subsystem A ) , der Allgemeinmedizin ( Subsystem B ) und der Altenhilfe ( Subsystem C ) analysiert . Die Untersuchung ergibt hinsichtlich Subsystem A , Dass ein GZ auf die intendierte Strukturform von intra- zu extramuraler Versorgung erheblichen Einfluss hat , ohne dabei seine Klientel nach Art und Schweregrad der psychischen Stoerung zu selegieren . Dabei erweist sich eine zugehende klinisch-ambulante , hausgestuetzte Versorgung bei funktionell psychisch gestoerten aelteren Menschen hinsichtlich der Entwicklung der Krankheitsschwere und des Umfangs der Hilfs- und Pflegebeduerftigkeit als besonders erfolgreich . Effekte des GZ auf das Subsystem B zeigen sich z . B. in den schon bald nach seiner Einrichtung sich entwickelnden Kooperationsbeziehungen zu den Allgemeinkrankenhaeusern der Versorgungsregion Guetersloh , in denen 2/5 ( ! ) aller gerontopsychiatrischen Patienten ( mit einer psychiatrischen Erstdiagnose nach ICD-9) behandelt werden . Ein Effekt des GZ auf das System der Altenhilfe ( Subsystem C ) findet moeglicherweise darin seine Ausdruck , dass in der Versorgungsregion Guetersloh die Heimeinweisungsrate nach klinisch-stationaerer Behandlung deutlich geringer als in der Bielefelder Kontrollregion ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ziel der Evaluationsstudie , ueber deren ausgewaehlte Ergebnisse dieser Beitrag berichtet , ist es , die Auswirkungen eines Gerontopsychiatrischen Zentrums ( GZ : eine Kombination von ambulantem Dienst , Tagesklinik und Altenberatung ) auf den von der Expertenkommission der Bundesregierung geforderten und ausfuehrlich begruendeten Wandlungsprozess von intramuralen " ( stationaeren ) " zu extramuralen " ( tagesklinischen und klinisch-ambulanten , " i . w . hausgestuetzten regionalen Versorgungsstrukturen ) erstmalig einer empirischen Pruefung zu unterziehen . Auf der Basis umfangreicher Quer- und Laengsschnittdaten werden durch einen Vergleich der Versorgungsregion der Stadt Bielefeld ( ohne GZ ) mit der des Kreises Guetersloh ( mit GZ ) Veraenderungen in den regionalen Versorgungsteilstrukturen der Gerontopsychiatrie ( Subsystem A ) , der Allgemeinmedizin ( Subsystem B ) und der Altenhilfe ( Subsystem C ) analysiert . Die Untersuchung ergibt hinsichtlich Subsystem A , Dass ein GZ auf die intendierte Strukturform von intra- zu extramuraler Versorgung erheblichen Einfluss hat , ohne dabei seine Klientel nach Art und Schweregrad der psychischen Stoerung zu selegieren . Dabei erweist sich eine zugehende klinisch-ambulante , hausgestuetzte Versorgung bei funktionell psychisch gestoerten aelteren Menschen hinsichtlich der Entwicklung der Krankheitsschwere und des Umfangs der Hilfs- und Pflegebeduerftigkeit als besonders erfolgreich . Effekte des GZ auf das Subsystem B zeigen sich z . B. in den schon bald nach seiner Einrichtung sich entwickelnden Kooperationsbeziehungen zu den Allgemeinkrankenhaeusern der Versorgungsregion Guetersloh , in denen 2/5 ( ! ) aller gerontopsychiatrischen Patienten ( mit einer psychiatrischen Erstdiagnose nach ICD-9) behandelt werden . Ein Effekt des GZ auf das System der Altenhilfe ( Subsystem C ) findet moeglicherweise darin seine Ausdruck , dass in der Versorgungsregion Guetersloh die Heimeinweisungsrate nach klinisch-stationaerer Behandlung deutlich geringer als in der Bielefelder Kontrollregion ist .

[ "Ziel", "der", "Evaluationsstudie", ",", "ueber", "deren", "ausgewaehlte", "Ergebnisse", "dieser", "Beitrag", "berichtet", ",", "ist", "es", ",", "die", "Auswirkungen", "eines", "Gerontopsychiatrischen", "Zentrums", "(", "GZ", ":", "eine", "Kombination", "von", "ambulantem", "Dienst", ",", "Tagesklinik", "und", "Altenberatung", ")", "auf", "den", "von", "der", "Expertenkommission", "der", "Bundesregierung", "geforderten", "und", "ausfuehrlich", "begruendeten", "Wandlungsprozess", "von", "intramuralen", "\"", "(", "stationaeren", ")", "\"", "zu", "extramuralen", "\"", "(", "tagesklinischen", "und", "klinisch", "-", "ambulanten", ",", "\"", "i", ".", "w", ".", "hausgestuetzten", "regionalen", "Versorgungsstrukturen", ")", "erstmalig", "einer", "empirischen", "Pruefung", "zu", "unterziehen", ".", "Auf", "der", "Basis", "umfangreicher", "Quer-", "und", "Laengsschnittdaten", "werden", "durch", "einen", "Vergleich", "der", "Versorgungsregion", "der", "Stadt", "Bielefeld", "(", "ohne", "GZ", ")", "mit", "der", "des", "Kreises", "Guetersloh", "(", "mit", "GZ", ")", "Veraenderungen", "in", "den", "regionalen", "Versorgungsteilstrukturen", "der", "Gerontopsychiatrie", "(", "Subsystem", "A", ")", ",", "der", "Allgemeinmedizin", "(", "Subsystem", "B", ")", "und", "der", "Altenhilfe", "(", "Subsystem", "C", ")", "analysiert", ".", "Die", "Untersuchung", "ergibt", "hinsichtlich", "Subsystem", "A", ",", "Dass", "ein", "GZ", "auf", "die", "intendierte", "Strukturform", "von", "intra-", "zu", "extramuraler", "Versorgung", "erheblichen", "Einfluss", "hat", ",", "ohne", "dabei", "seine", "Klientel", "nach", "Art", "und", "Schweregrad", "der", "psychischen", "Stoerung", "zu", "selegieren", ".", "Dabei", "erweist", "sich", "eine", "zugehende", "klinisch", "-", "ambulante", ",", "hausgestuetzte", "Versorgung", "bei", "funktionell", "psychisch", "gestoerten", "aelteren", "Menschen", "hinsichtlich", "der", "Entwicklung", "der", "Krankheitsschwere", "und", "des", "Umfangs", "der", "Hilfs-", "und", "Pflegebeduerftigkeit", "als", "besonders", "erfolgreich", ".", "Effekte", "des", "GZ", "auf", "das", "Subsystem", "B", "zeigen", "sich", "z", ".", "B.", "in", "den", "schon", "bald", "nach", "seiner", "Einrichtung", "sich", "entwickelnden", "Kooperationsbeziehungen", "zu", "den", "Allgemeinkrankenhaeusern", "der", "Versorgungsregion", "Guetersloh", ",", "in", "denen", "2/5", "(", "!", ")", "aller", "gerontopsychiatrischen", "Patienten", "(", "mit", "einer", "psychiatrischen", "Erstdiagnose", "nach", "ICD-9", ")", "behandelt", "werden", ".", "Ein", "Effekt", "des", "GZ", "auf", "das", "System", "der", "Altenhilfe", "(", "Subsystem", "C", ")", "findet", "moeglicherweise", "darin", "seine", "Ausdruck", ",", "dass", "in", "der", "Versorgungsregion", "Guetersloh", "die", "Heimeinweisungsrate", "nach", "klinisch", "-", "stationaerer", "Behandlung", "deutlich", "geringer", "als", "in", "der", "Bielefelder", "Kontrollregion", "ist", "." ]

[ "umlsterm" ]

Tagesklinik is an umlsterm, Altenberatung is an umlsterm, Bundesregierung is an umlsterm, Stadt is an umlsterm, Allgemeinmedizin is an umlsterm, Altenhilfe is an umlsterm, psychischen Stoerung is an umlsterm, aelteren Menschen is an umlsterm, Pflegebeduerftigkeit is an umlsterm, Allgemeinkrankenhaeusern is an umlsterm, Patienten is an umlsterm, Erstdiagnose is an umlsterm, Altenhilfe is an umlsterm, Behandlung is an umlsterm

ZfuerGerontologie+Geriatrie.00330059.ger.abstr_task1

Sentence: Ziel der Evaluationsstudie , ueber deren ausgewaehlte Ergebnisse dieser Beitrag berichtet , ist es , die Auswirkungen eines Gerontopsychiatrischen Zentrums ( GZ : eine Kombination von ambulantem Dienst , Tagesklinik und Altenberatung ) auf den von der Expertenkommission der Bundesregierung geforderten und ausfuehrlich begruendeten Wandlungsprozess von intramuralen " ( stationaeren ) " zu extramuralen " ( tagesklinischen und klinisch-ambulanten , " i . w . hausgestuetzten regionalen Versorgungsstrukturen ) erstmalig einer empirischen Pruefung zu unterziehen . Auf der Basis umfangreicher Quer- und Laengsschnittdaten werden durch einen Vergleich der Versorgungsregion der Stadt Bielefeld ( ohne GZ ) mit der des Kreises Guetersloh ( mit GZ ) Veraenderungen in den regionalen Versorgungsteilstrukturen der Gerontopsychiatrie ( Subsystem A ) , der Allgemeinmedizin ( Subsystem B ) und der Altenhilfe ( Subsystem C ) analysiert . Die Untersuchung ergibt hinsichtlich Subsystem A , Dass ein GZ auf die intendierte Strukturform von intra- zu extramuraler Versorgung erheblichen Einfluss hat , ohne dabei seine Klientel nach Art und Schweregrad der psychischen Stoerung zu selegieren . Dabei erweist sich eine zugehende klinisch-ambulante , hausgestuetzte Versorgung bei funktionell psychisch gestoerten aelteren Menschen hinsichtlich der Entwicklung der Krankheitsschwere und des Umfangs der Hilfs- und Pflegebeduerftigkeit als besonders erfolgreich . Effekte des GZ auf das Subsystem B zeigen sich z . B. in den schon bald nach seiner Einrichtung sich entwickelnden Kooperationsbeziehungen zu den Allgemeinkrankenhaeusern der Versorgungsregion Guetersloh , in denen 2/5 ( ! ) aller gerontopsychiatrischen Patienten ( mit einer psychiatrischen Erstdiagnose nach ICD-9) behandelt werden . Ein Effekt des GZ auf das System der Altenhilfe ( Subsystem C ) findet moeglicherweise darin seine Ausdruck , dass in der Versorgungsregion Guetersloh die Heimeinweisungsrate nach klinisch-stationaerer Behandlung deutlich geringer als in der Bielefelder Kontrollregion ist . Instructions: please typing these entity words according to sentence: Tagesklinik, Altenberatung, Bundesregierung, Stadt, Allgemeinmedizin, Altenhilfe, psychischen Stoerung, aelteren Menschen, Pflegebeduerftigkeit, Allgemeinkrankenhaeusern, Patienten, Erstdiagnose, Altenhilfe, Behandlung Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ziel der Evaluationsstudie , ueber deren ausgewaehlte Ergebnisse dieser Beitrag berichtet , ist es , die Auswirkungen eines Gerontopsychiatrischen Zentrums ( GZ : eine Kombination von ambulantem Dienst , Tagesklinik und Altenberatung ) auf den von der Expertenkommission der Bundesregierung geforderten und ausfuehrlich begruendeten Wandlungsprozess von intramuralen " ( stationaeren ) " zu extramuralen " ( tagesklinischen und klinisch-ambulanten , " i . w . hausgestuetzten regionalen Versorgungsstrukturen ) erstmalig einer empirischen Pruefung zu unterziehen . Auf der Basis umfangreicher Quer- und Laengsschnittdaten werden durch einen Vergleich der Versorgungsregion der Stadt Bielefeld ( ohne GZ ) mit der des Kreises Guetersloh ( mit GZ ) Veraenderungen in den regionalen Versorgungsteilstrukturen der Gerontopsychiatrie ( Subsystem A ) , der Allgemeinmedizin ( Subsystem B ) und der Altenhilfe ( Subsystem C ) analysiert . Die Untersuchung ergibt hinsichtlich Subsystem A , Dass ein GZ auf die intendierte Strukturform von intra- zu extramuraler Versorgung erheblichen Einfluss hat , ohne dabei seine Klientel nach Art und Schweregrad der psychischen Stoerung zu selegieren . Dabei erweist sich eine zugehende klinisch-ambulante , hausgestuetzte Versorgung bei funktionell psychisch gestoerten aelteren Menschen hinsichtlich der Entwicklung der Krankheitsschwere und des Umfangs der Hilfs- und Pflegebeduerftigkeit als besonders erfolgreich . Effekte des GZ auf das Subsystem B zeigen sich z . B. in den schon bald nach seiner Einrichtung sich entwickelnden Kooperationsbeziehungen zu den Allgemeinkrankenhaeusern der Versorgungsregion Guetersloh , in denen 2/5 ( ! ) aller gerontopsychiatrischen Patienten ( mit einer psychiatrischen Erstdiagnose nach ICD-9) behandelt werden . Ein Effekt des GZ auf das System der Altenhilfe ( Subsystem C ) findet moeglicherweise darin seine Ausdruck , dass in der Versorgungsregion Guetersloh die Heimeinweisungsrate nach klinisch-stationaerer Behandlung deutlich geringer als in der Bielefelder Kontrollregion ist .

[ "Ziel", "der", "Evaluationsstudie", ",", "ueber", "deren", "ausgewaehlte", "Ergebnisse", "dieser", "Beitrag", "berichtet", ",", "ist", "es", ",", "die", "Auswirkungen", "eines", "Gerontopsychiatrischen", "Zentrums", "(", "GZ", ":", "eine", "Kombination", "von", "ambulantem", "Dienst", ",", "Tagesklinik", "und", "Altenberatung", ")", "auf", "den", "von", "der", "Expertenkommission", "der", "Bundesregierung", "geforderten", "und", "ausfuehrlich", "begruendeten", "Wandlungsprozess", "von", "intramuralen", "\"", "(", "stationaeren", ")", "\"", "zu", "extramuralen", "\"", "(", "tagesklinischen", "und", "klinisch", "-", "ambulanten", ",", "\"", "i", ".", "w", ".", "hausgestuetzten", "regionalen", "Versorgungsstrukturen", ")", "erstmalig", "einer", "empirischen", "Pruefung", "zu", "unterziehen", ".", "Auf", "der", "Basis", "umfangreicher", "Quer-", "und", "Laengsschnittdaten", "werden", "durch", "einen", "Vergleich", "der", "Versorgungsregion", "der", "Stadt", "Bielefeld", "(", "ohne", "GZ", ")", "mit", "der", "des", "Kreises", "Guetersloh", "(", "mit", "GZ", ")", "Veraenderungen", "in", "den", "regionalen", "Versorgungsteilstrukturen", "der", "Gerontopsychiatrie", "(", "Subsystem", "A", ")", ",", "der", "Allgemeinmedizin", "(", "Subsystem", "B", ")", "und", "der", "Altenhilfe", "(", "Subsystem", "C", ")", "analysiert", ".", "Die", "Untersuchung", "ergibt", "hinsichtlich", "Subsystem", "A", ",", "Dass", "ein", "GZ", "auf", "die", "intendierte", "Strukturform", "von", "intra-", "zu", "extramuraler", "Versorgung", "erheblichen", "Einfluss", "hat", ",", "ohne", "dabei", "seine", "Klientel", "nach", "Art", "und", "Schweregrad", "der", "psychischen", "Stoerung", "zu", "selegieren", ".", "Dabei", "erweist", "sich", "eine", "zugehende", "klinisch", "-", "ambulante", ",", "hausgestuetzte", "Versorgung", "bei", "funktionell", "psychisch", "gestoerten", "aelteren", "Menschen", "hinsichtlich", "der", "Entwicklung", "der", "Krankheitsschwere", "und", "des", "Umfangs", "der", "Hilfs-", "und", "Pflegebeduerftigkeit", "als", "besonders", "erfolgreich", ".", "Effekte", "des", "GZ", "auf", "das", "Subsystem", "B", "zeigen", "sich", "z", ".", "B.", "in", "den", "schon", "bald", "nach", "seiner", "Einrichtung", "sich", "entwickelnden", "Kooperationsbeziehungen", "zu", "den", "Allgemeinkrankenhaeusern", "der", "Versorgungsregion", "Guetersloh", ",", "in", "denen", "2/5", "(", "!", ")", "aller", "gerontopsychiatrischen", "Patienten", "(", "mit", "einer", "psychiatrischen", "Erstdiagnose", "nach", "ICD-9", ")", "behandelt", "werden", ".", "Ein", "Effekt", "des", "GZ", "auf", "das", "System", "der", "Altenhilfe", "(", "Subsystem", "C", ")", "findet", "moeglicherweise", "darin", "seine", "Ausdruck", ",", "dass", "in", "der", "Versorgungsregion", "Guetersloh", "die", "Heimeinweisungsrate", "nach", "klinisch", "-", "stationaerer", "Behandlung", "deutlich", "geringer", "als", "in", "der", "Bielefelder", "Kontrollregion", "ist", "." ]

[ "umlsterm" ]

Tagesklinik, Altenberatung, Bundesregierung, Stadt, Allgemeinmedizin, Altenhilfe, psychischen Stoerung, aelteren Menschen, Pflegebeduerftigkeit, Allgemeinkrankenhaeusern, Patienten, Erstdiagnose, Altenhilfe, Behandlung

ZfuerGerontologie+Geriatrie.00330059.ger.abstr_task2

Sentence: Ziel der Evaluationsstudie , ueber deren ausgewaehlte Ergebnisse dieser Beitrag berichtet , ist es , die Auswirkungen eines Gerontopsychiatrischen Zentrums ( GZ : eine Kombination von ambulantem Dienst , Tagesklinik und Altenberatung ) auf den von der Expertenkommission der Bundesregierung geforderten und ausfuehrlich begruendeten Wandlungsprozess von intramuralen " ( stationaeren ) " zu extramuralen " ( tagesklinischen und klinisch-ambulanten , " i . w . hausgestuetzten regionalen Versorgungsstrukturen ) erstmalig einer empirischen Pruefung zu unterziehen . Auf der Basis umfangreicher Quer- und Laengsschnittdaten werden durch einen Vergleich der Versorgungsregion der Stadt Bielefeld ( ohne GZ ) mit der des Kreises Guetersloh ( mit GZ ) Veraenderungen in den regionalen Versorgungsteilstrukturen der Gerontopsychiatrie ( Subsystem A ) , der Allgemeinmedizin ( Subsystem B ) und der Altenhilfe ( Subsystem C ) analysiert . Die Untersuchung ergibt hinsichtlich Subsystem A , Dass ein GZ auf die intendierte Strukturform von intra- zu extramuraler Versorgung erheblichen Einfluss hat , ohne dabei seine Klientel nach Art und Schweregrad der psychischen Stoerung zu selegieren . Dabei erweist sich eine zugehende klinisch-ambulante , hausgestuetzte Versorgung bei funktionell psychisch gestoerten aelteren Menschen hinsichtlich der Entwicklung der Krankheitsschwere und des Umfangs der Hilfs- und Pflegebeduerftigkeit als besonders erfolgreich . Effekte des GZ auf das Subsystem B zeigen sich z . B. in den schon bald nach seiner Einrichtung sich entwickelnden Kooperationsbeziehungen zu den Allgemeinkrankenhaeusern der Versorgungsregion Guetersloh , in denen 2/5 ( ! ) aller gerontopsychiatrischen Patienten ( mit einer psychiatrischen Erstdiagnose nach ICD-9) behandelt werden . Ein Effekt des GZ auf das System der Altenhilfe ( Subsystem C ) findet moeglicherweise darin seine Ausdruck , dass in der Versorgungsregion Guetersloh die Heimeinweisungsrate nach klinisch-stationaerer Behandlung deutlich geringer als in der Bielefelder Kontrollregion ist . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ziel der Evaluationsstudie , ueber deren ausgewaehlte Ergebnisse dieser Beitrag berichtet , ist es , die Auswirkungen eines Gerontopsychiatrischen Zentrums ( GZ : eine Kombination von ambulantem Dienst , Tagesklinik und Altenberatung ) auf den von der Expertenkommission der Bundesregierung geforderten und ausfuehrlich begruendeten Wandlungsprozess von intramuralen " ( stationaeren ) " zu extramuralen " ( tagesklinischen und klinisch-ambulanten , " i . w . hausgestuetzten regionalen Versorgungsstrukturen ) erstmalig einer empirischen Pruefung zu unterziehen . Auf der Basis umfangreicher Quer- und Laengsschnittdaten werden durch einen Vergleich der Versorgungsregion der Stadt Bielefeld ( ohne GZ ) mit der des Kreises Guetersloh ( mit GZ ) Veraenderungen in den regionalen Versorgungsteilstrukturen der Gerontopsychiatrie ( Subsystem A ) , der Allgemeinmedizin ( Subsystem B ) und der Altenhilfe ( Subsystem C ) analysiert . Die Untersuchung ergibt hinsichtlich Subsystem A , Dass ein GZ auf die intendierte Strukturform von intra- zu extramuraler Versorgung erheblichen Einfluss hat , ohne dabei seine Klientel nach Art und Schweregrad der psychischen Stoerung zu selegieren . Dabei erweist sich eine zugehende klinisch-ambulante , hausgestuetzte Versorgung bei funktionell psychisch gestoerten aelteren Menschen hinsichtlich der Entwicklung der Krankheitsschwere und des Umfangs der Hilfs- und Pflegebeduerftigkeit als besonders erfolgreich . Effekte des GZ auf das Subsystem B zeigen sich z . B. in den schon bald nach seiner Einrichtung sich entwickelnden Kooperationsbeziehungen zu den Allgemeinkrankenhaeusern der Versorgungsregion Guetersloh , in denen 2/5 ( ! ) aller gerontopsychiatrischen Patienten ( mit einer psychiatrischen Erstdiagnose nach ICD-9) behandelt werden . Ein Effekt des GZ auf das System der Altenhilfe ( Subsystem C ) findet moeglicherweise darin seine Ausdruck , dass in der Versorgungsregion Guetersloh die Heimeinweisungsrate nach klinisch-stationaerer Behandlung deutlich geringer als in der Bielefelder Kontrollregion ist .

[ "Ziel", "der", "Evaluationsstudie", ",", "ueber", "deren", "ausgewaehlte", "Ergebnisse", "dieser", "Beitrag", "berichtet", ",", "ist", "es", ",", "die", "Auswirkungen", "eines", "Gerontopsychiatrischen", "Zentrums", "(", "GZ", ":", "eine", "Kombination", "von", "ambulantem", "Dienst", ",", "Tagesklinik", "und", "Altenberatung", ")", "auf", "den", "von", "der", "Expertenkommission", "der", "Bundesregierung", "geforderten", "und", "ausfuehrlich", "begruendeten", "Wandlungsprozess", "von", "intramuralen", "\"", "(", "stationaeren", ")", "\"", "zu", "extramuralen", "\"", "(", "tagesklinischen", "und", "klinisch", "-", "ambulanten", ",", "\"", "i", ".", "w", ".", "hausgestuetzten", "regionalen", "Versorgungsstrukturen", ")", "erstmalig", "einer", "empirischen", "Pruefung", "zu", "unterziehen", ".", "Auf", "der", "Basis", "umfangreicher", "Quer-", "und", "Laengsschnittdaten", "werden", "durch", "einen", "Vergleich", "der", "Versorgungsregion", "der", "Stadt", "Bielefeld", "(", "ohne", "GZ", ")", "mit", "der", "des", "Kreises", "Guetersloh", "(", "mit", "GZ", ")", "Veraenderungen", "in", "den", "regionalen", "Versorgungsteilstrukturen", "der", "Gerontopsychiatrie", "(", "Subsystem", "A", ")", ",", "der", "Allgemeinmedizin", "(", "Subsystem", "B", ")", "und", "der", "Altenhilfe", "(", "Subsystem", "C", ")", "analysiert", ".", "Die", "Untersuchung", "ergibt", "hinsichtlich", "Subsystem", "A", ",", "Dass", "ein", "GZ", "auf", "die", "intendierte", "Strukturform", "von", "intra-", "zu", "extramuraler", "Versorgung", "erheblichen", "Einfluss", "hat", ",", "ohne", "dabei", "seine", "Klientel", "nach", "Art", "und", "Schweregrad", "der", "psychischen", "Stoerung", "zu", "selegieren", ".", "Dabei", "erweist", "sich", "eine", "zugehende", "klinisch", "-", "ambulante", ",", "hausgestuetzte", "Versorgung", "bei", "funktionell", "psychisch", "gestoerten", "aelteren", "Menschen", "hinsichtlich", "der", "Entwicklung", "der", "Krankheitsschwere", "und", "des", "Umfangs", "der", "Hilfs-", "und", "Pflegebeduerftigkeit", "als", "besonders", "erfolgreich", ".", "Effekte", "des", "GZ", "auf", "das", "Subsystem", "B", "zeigen", "sich", "z", ".", "B.", "in", "den", "schon", "bald", "nach", "seiner", "Einrichtung", "sich", "entwickelnden", "Kooperationsbeziehungen", "zu", "den", "Allgemeinkrankenhaeusern", "der", "Versorgungsregion", "Guetersloh", ",", "in", "denen", "2/5", "(", "!", ")", "aller", "gerontopsychiatrischen", "Patienten", "(", "mit", "einer", "psychiatrischen", "Erstdiagnose", "nach", "ICD-9", ")", "behandelt", "werden", ".", "Ein", "Effekt", "des", "GZ", "auf", "das", "System", "der", "Altenhilfe", "(", "Subsystem", "C", ")", "findet", "moeglicherweise", "darin", "seine", "Ausdruck", ",", "dass", "in", "der", "Versorgungsregion", "Guetersloh", "die", "Heimeinweisungsrate", "nach", "klinisch", "-", "stationaerer", "Behandlung", "deutlich", "geringer", "als", "in", "der", "Bielefelder", "Kontrollregion", "ist", "." ]

[ "umlsterm" ]

RUNX1 is a Gene_or_gene_product, DNA is a Cellular_component, BCR - ABL+ leukemias is a Cancer, 21 is a Cellular_component, clonal is a Cell, imatinib is a Simple_chemical, chromosomal is a Cellular_component, RUNX1 is a Gene_or_gene_product, acute myeloblastic leukemias is a Cancer, AMLs is a Cancer, acute lymphoblastic leukemias is a Cancer, ALLs is a Cancer, chronic myelogenous leukemias is a Cancer, CMLs is a Cancer, BCR - ABL+ leukemias is a Cancer, chromosome 21 is a Cellular_component, myeloid blast crisis [ BC ] CML is a Cancer, chronic phase CML is a Cancer, DNA is a Cellular_component, RUNX1 is a Gene_or_gene_product, BCR - ABL+ ALLs is a Cancer, lymphoid BC CML is a Cancer, RUNX1 is a Gene_or_gene_product, 21 is a Cellular_component, chromosomal is a Cellular_component, RUNX1 is a Gene_or_gene_product, PRDM16 is a Gene_or_gene_product, chromosome 1p36 is a Cellular_component, patients is a Organism, myeloid BC CMLs is a Cancer, BCR - ABL+ ALL is a Cancer, patients is a Organism, RUNX1 is a Gene_or_gene_product, BCR is a Gene_or_gene_product, ABL is a Gene_or_gene_product, RUNX1 is a Gene_or_gene_product, CML is a Cancer, BCR - ABL+ ALL is a Cancer

104_task0

Sentence: RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cellular_component, Organism, Simple_chemical, Cancer, Gene_or_gene_product, Cell

[ "B-Gene_or_gene_product", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Organism", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O" ]

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL.

[ "RUNX1", "DNA", "-", "binding", "mutations", "and", "RUNX1-PRDM16", "cryptic", "fusions", "in", "BCR", "-", "ABL+", "leukemias", "are", "frequently", "associated", "with", "secondary", "trisomy", "21", "and", "may", "contribute", "to", "clonal", "evolution", "and", "imatinib", "resistance", ".", "\n", "Acquired", "molecular", "abnormalities", "(", "mutations", "or", "chromosomal", "translocations", ")", "of", "the", "RUNX1", "transcription", "factor", "gene", "are", "frequent", "in", "acute", "myeloblastic", "leukemias", "(", "AMLs", ")", "and", "in", "therapy", "-", "related", "myelodysplastic", "syndromes", ",", "but", "rarely", "in", "acute", "lymphoblastic", "leukemias", "(", "ALLs", ")", "and", "chronic", "myelogenous", "leukemias", "(", "CMLs", ")", ".", "Among", "18", "BCR", "-", "ABL+", "leukemias", "presenting", "acquired", "trisomy", "of", "chromosome", "21", ",", "we", "report", "a", "high", "frequency", "(", "33", "%", ")", "of", "recurrent", "point", "mutations", "(", "4", "in", "myeloid", "blast", "crisis", "[", "BC", "]", "CML", "and", "one", "in", "chronic", "phase", "CML", ")", "within", "the", "DNA", "-", "binding", "region", "of", "RUNX1", ".", "We", "did", "not", "found", "any", "mutation", "in", "de", "novo", "BCR", "-", "ABL+", "ALLs", "or", "lymphoid", "BC", "CML", ".", "Emergence", "of", "the", "RUNX1", "mutations", "was", "detected", "at", "diagnosis", "or", "before", "the", "acquisition", "of", "trisomy", "21", "during", "disease", "progression", ".", "In", "addition", ",", "we", "also", "report", "a", "high", "frequency", "of", "cryptic", "chromosomal", "RUNX1", "translocation", "to", "a", "novel", "recently", "described", "gene", "partner", ",", "PRDM16", "on", "chromosome", "1p36", ",", "for", "3", "(", "21.4", "%", ")", "of", "14", "investigated", "patients", ":", "2", "myeloid", "BC", "CMLs", "and", ",", "for", "the", "first", "time", ",", "1", "therapy", "-", "related", "BCR", "-", "ABL+", "ALL", ".", "Two", "patients", "presented", "both", "RUNX1", "mutations", "and", "RUNX1-PRDM16", "fusion", ".", "These", "events", "are", "associated", "with", "a", "short", "survival", "and", "support", "the", "concept", "of", "a", "cooperative", "effect", "of", "BCR", "-", "ABL", "with", "molecular", "RUNX1", "abnormalities", "on", "the", "differentiation", "arrest", "phenotype", "observed", "during", "progression", "of", "CML", "and", "in", "BCR", "-", "ABL+", "ALL", ".", "\n" ]

[ "Cancer", "Cellular_component", "Simple_chemical", "Organism", "Gene_or_gene_product", "Cell" ]

RUNX1 is a Gene_or_gene_product, DNA is a Cellular_component, BCR - ABL+ leukemias is a Cancer, 21 is a Cellular_component, clonal is a Cell, imatinib is a Simple_chemical, chromosomal is a Cellular_component, RUNX1 is a Gene_or_gene_product, acute myeloblastic leukemias is a Cancer, AMLs is a Cancer, acute lymphoblastic leukemias is a Cancer, ALLs is a Cancer, chronic myelogenous leukemias is a Cancer, CMLs is a Cancer, BCR - ABL+ leukemias is a Cancer, chromosome 21 is a Cellular_component, myeloid blast crisis [ BC ] CML is a Cancer, chronic phase CML is a Cancer, DNA is a Cellular_component, RUNX1 is a Gene_or_gene_product, BCR - ABL+ ALLs is a Cancer, lymphoid BC CML is a Cancer, RUNX1 is a Gene_or_gene_product, 21 is a Cellular_component, chromosomal is a Cellular_component, RUNX1 is a Gene_or_gene_product, PRDM16 is a Gene_or_gene_product, chromosome 1p36 is a Cellular_component, patients is a Organism, myeloid BC CMLs is a Cancer, BCR - ABL+ ALL is a Cancer, patients is a Organism, RUNX1 is a Gene_or_gene_product, BCR is a Gene_or_gene_product, ABL is a Gene_or_gene_product, RUNX1 is a Gene_or_gene_product, CML is a Cancer, BCR - ABL+ ALL is a Cancer

104_task1

Sentence: RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL. Instructions: please typing these entity words according to sentence: RUNX1, DNA, BCR - ABL+ leukemias, 21, clonal, imatinib, chromosomal, RUNX1, acute myeloblastic leukemias, AMLs, acute lymphoblastic leukemias, ALLs, chronic myelogenous leukemias, CMLs, BCR - ABL+ leukemias, chromosome 21, myeloid blast crisis [ BC ] CML, chronic phase CML, DNA, RUNX1, BCR - ABL+ ALLs, lymphoid BC CML, RUNX1, 21, chromosomal, RUNX1, PRDM16, chromosome 1p36, patients, myeloid BC CMLs, BCR - ABL+ ALL, patients, RUNX1, BCR, ABL, RUNX1, CML, BCR - ABL+ ALL Options: Cellular_component, Organism, Simple_chemical, Cancer, Gene_or_gene_product, Cell

[ "B-Gene_or_gene_product", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Organism", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O" ]

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL.

[ "RUNX1", "DNA", "-", "binding", "mutations", "and", "RUNX1-PRDM16", "cryptic", "fusions", "in", "BCR", "-", "ABL+", "leukemias", "are", "frequently", "associated", "with", "secondary", "trisomy", "21", "and", "may", "contribute", "to", "clonal", "evolution", "and", "imatinib", "resistance", ".", "\n", "Acquired", "molecular", "abnormalities", "(", "mutations", "or", "chromosomal", "translocations", ")", "of", "the", "RUNX1", "transcription", "factor", "gene", "are", "frequent", "in", "acute", "myeloblastic", "leukemias", "(", "AMLs", ")", "and", "in", "therapy", "-", "related", "myelodysplastic", "syndromes", ",", "but", "rarely", "in", "acute", "lymphoblastic", "leukemias", "(", "ALLs", ")", "and", "chronic", "myelogenous", "leukemias", "(", "CMLs", ")", ".", "Among", "18", "BCR", "-", "ABL+", "leukemias", "presenting", "acquired", "trisomy", "of", "chromosome", "21", ",", "we", "report", "a", "high", "frequency", "(", "33", "%", ")", "of", "recurrent", "point", "mutations", "(", "4", "in", "myeloid", "blast", "crisis", "[", "BC", "]", "CML", "and", "one", "in", "chronic", "phase", "CML", ")", "within", "the", "DNA", "-", "binding", "region", "of", "RUNX1", ".", "We", "did", "not", "found", "any", "mutation", "in", "de", "novo", "BCR", "-", "ABL+", "ALLs", "or", "lymphoid", "BC", "CML", ".", "Emergence", "of", "the", "RUNX1", "mutations", "was", "detected", "at", "diagnosis", "or", "before", "the", "acquisition", "of", "trisomy", "21", "during", "disease", "progression", ".", "In", "addition", ",", "we", "also", "report", "a", "high", "frequency", "of", "cryptic", "chromosomal", "RUNX1", "translocation", "to", "a", "novel", "recently", "described", "gene", "partner", ",", "PRDM16", "on", "chromosome", "1p36", ",", "for", "3", "(", "21.4", "%", ")", "of", "14", "investigated", "patients", ":", "2", "myeloid", "BC", "CMLs", "and", ",", "for", "the", "first", "time", ",", "1", "therapy", "-", "related", "BCR", "-", "ABL+", "ALL", ".", "Two", "patients", "presented", "both", "RUNX1", "mutations", "and", "RUNX1-PRDM16", "fusion", ".", "These", "events", "are", "associated", "with", "a", "short", "survival", "and", "support", "the", "concept", "of", "a", "cooperative", "effect", "of", "BCR", "-", "ABL", "with", "molecular", "RUNX1", "abnormalities", "on", "the", "differentiation", "arrest", "phenotype", "observed", "during", "progression", "of", "CML", "and", "in", "BCR", "-", "ABL+", "ALL", ".", "\n" ]

[ "Cancer", "Cellular_component", "Simple_chemical", "Organism", "Gene_or_gene_product", "Cell" ]

RUNX1, DNA, BCR - ABL+ leukemias, 21, clonal, imatinib, chromosomal, RUNX1, acute myeloblastic leukemias, AMLs, acute lymphoblastic leukemias, ALLs, chronic myelogenous leukemias, CMLs, BCR - ABL+ leukemias, chromosome 21, myeloid blast crisis [ BC ] CML, chronic phase CML, DNA, RUNX1, BCR - ABL+ ALLs, lymphoid BC CML, RUNX1, 21, chromosomal, RUNX1, PRDM16, chromosome 1p36, patients, myeloid BC CMLs, BCR - ABL+ ALL, patients, RUNX1, BCR, ABL, RUNX1, CML, BCR - ABL+ ALL

104_task2

Sentence: RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL. Instructions: please extract entity words from the input sentence

[ "B-Gene_or_gene_product", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Organism", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "I-Cancer", "O", "O" ]

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL.

[ "RUNX1", "DNA", "-", "binding", "mutations", "and", "RUNX1-PRDM16", "cryptic", "fusions", "in", "BCR", "-", "ABL+", "leukemias", "are", "frequently", "associated", "with", "secondary", "trisomy", "21", "and", "may", "contribute", "to", "clonal", "evolution", "and", "imatinib", "resistance", ".", "\n", "Acquired", "molecular", "abnormalities", "(", "mutations", "or", "chromosomal", "translocations", ")", "of", "the", "RUNX1", "transcription", "factor", "gene", "are", "frequent", "in", "acute", "myeloblastic", "leukemias", "(", "AMLs", ")", "and", "in", "therapy", "-", "related", "myelodysplastic", "syndromes", ",", "but", "rarely", "in", "acute", "lymphoblastic", "leukemias", "(", "ALLs", ")", "and", "chronic", "myelogenous", "leukemias", "(", "CMLs", ")", ".", "Among", "18", "BCR", "-", "ABL+", "leukemias", "presenting", "acquired", "trisomy", "of", "chromosome", "21", ",", "we", "report", "a", "high", "frequency", "(", "33", "%", ")", "of", "recurrent", "point", "mutations", "(", "4", "in", "myeloid", "blast", "crisis", "[", "BC", "]", "CML", "and", "one", "in", "chronic", "phase", "CML", ")", "within", "the", "DNA", "-", "binding", "region", "of", "RUNX1", ".", "We", "did", "not", "found", "any", "mutation", "in", "de", "novo", "BCR", "-", "ABL+", "ALLs", "or", "lymphoid", "BC", "CML", ".", "Emergence", "of", "the", "RUNX1", "mutations", "was", "detected", "at", "diagnosis", "or", "before", "the", "acquisition", "of", "trisomy", "21", "during", "disease", "progression", ".", "In", "addition", ",", "we", "also", "report", "a", "high", "frequency", "of", "cryptic", "chromosomal", "RUNX1", "translocation", "to", "a", "novel", "recently", "described", "gene", "partner", ",", "PRDM16", "on", "chromosome", "1p36", ",", "for", "3", "(", "21.4", "%", ")", "of", "14", "investigated", "patients", ":", "2", "myeloid", "BC", "CMLs", "and", ",", "for", "the", "first", "time", ",", "1", "therapy", "-", "related", "BCR", "-", "ABL+", "ALL", ".", "Two", "patients", "presented", "both", "RUNX1", "mutations", "and", "RUNX1-PRDM16", "fusion", ".", "These", "events", "are", "associated", "with", "a", "short", "survival", "and", "support", "the", "concept", "of", "a", "cooperative", "effect", "of", "BCR", "-", "ABL", "with", "molecular", "RUNX1", "abnormalities", "on", "the", "differentiation", "arrest", "phenotype", "observed", "during", "progression", "of", "CML", "and", "in", "BCR", "-", "ABL+", "ALL", ".", "\n" ]

[ "Cancer", "Cellular_component", "Simple_chemical", "Organism", "Gene_or_gene_product", "Cell" ]

Omega-3 fatty acids supplementation is a Intervention_Pharmacological, autism is a Participant_Condition, placebo - controlled is a Intervention_Control, . is a Outcome_Physical, neurodevelopmental disorders . is a Participant_Condition, 1.5 g / d of omega-3 fatty acids ( .84 g / d eicosapentaenoic acid is a Intervention_Pharmacological, .7 g / d docosahexaenoic acid ) supplementation is a Intervention_Pharmacological, 13 is a Participant_Sample-size, aged 5 to 17 years is a Participant_Age, severe tantrums , aggression , or self - injurious behavior is a Participant_Condition, Aberrant Behavior Checklist ( ABC ) is a Outcome_Mental, hyperactivity and stereotypy is a Outcome_Physical, adverse effects is a Outcome_Adverse-effects

27707_task0

Sentence: Omega-3 fatty acids supplementation in children with autism : a double-blind randomized , placebo-controlled pilot study . BACKGROUND There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders . METHODS We conducted a randomized , double-blind , placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids ( .84 g/d eicosapentaenoic acid , .7 g/d docosahexaenoic acid ) supplementation in 13 children ( aged 5 to 17 years ) with autistic disorders accompanied by severe tantrums , aggression , or self-injurious behavior . The outcome measure was the Aberrant Behavior Checklist ( ABC ) at 6 weeks . RESULTS We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy , each with a large effect size . Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity . No clinically relevant adverse effects were elicited in either group . CONCLUSIONS The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Mental

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Omega-3 fatty acids supplementation in children with autism : a double-blind randomized , placebo-controlled pilot study . BACKGROUND There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders . METHODS We conducted a randomized , double-blind , placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids ( .84 g/d eicosapentaenoic acid , .7 g/d docosahexaenoic acid ) supplementation in 13 children ( aged 5 to 17 years ) with autistic disorders accompanied by severe tantrums , aggression , or self-injurious behavior . The outcome measure was the Aberrant Behavior Checklist ( ABC ) at 6 weeks . RESULTS We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy , each with a large effect size . Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity . No clinically relevant adverse effects were elicited in either group . CONCLUSIONS The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism .

[ "Omega-3", "fatty", "acids", "supplementation", "in", "children", "with", "autism", ":", "a", "double", "-", "blind", "randomized", ",", "placebo", "-", "controlled", "pilot", "study", ".", "BACKGROUND", "There", "is", "increasing", "evidence", "that", "fatty", "acid", "deficiencies", "or", "imbalances", "may", "contribute", "to", "childhood", "neurodevelopmental", "disorders", ".", "METHODS", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "6-week", "pilot", "trial", "investigating", "the", "effects", "of", "1.5", "g", "/", "d", "of", "omega-3", "fatty", "acids", "(", ".84", "g", "/", "d", "eicosapentaenoic", "acid", ",", ".7", "g", "/", "d", "docosahexaenoic", "acid", ")", "supplementation", "in", "13", "children", "(", "aged", "5", "to", "17", "years", ")", "with", "autistic", "disorders", "accompanied", "by", "severe", "tantrums", ",", "aggression", ",", "or", "self", "-", "injurious", "behavior", ".", "The", "outcome", "measure", "was", "the", "Aberrant", "Behavior", "Checklist", "(", "ABC", ")", "at", "6", "weeks", ".", "RESULTS", "We", "observed", "an", "advantage", "of", "omega-3", "fatty", "acids", "compared", "with", "placebo", "for", "hyperactivity", "and", "stereotypy", ",", "each", "with", "a", "large", "effect", "size", ".", "Repeated", "-", "measures", "ANOVA", "indicated", "a", "trend", "toward", "superiority", "of", "omega-3", "fatty", "acids", "over", "placebo", "for", "hyperactivity", ".", "No", "clinically", "relevant", "adverse", "effects", "were", "elicited", "in", "either", "group", ".", "CONCLUSIONS", "The", "results", "of", "this", "study", "provide", "preliminary", "evidence", "that", "omega-3", "fatty", "acids", "may", "be", "an", "effective", "treatment", "for", "children", "with", "autism", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Mental", "Outcome_Physical", "Intervention_Control", "Participant_Age", "Outcome_Adverse-effects", "Outcome_Other", "Participant_Sample-size" ]

Omega-3 fatty acids supplementation is a Intervention_Pharmacological, autism is a Participant_Condition, placebo - controlled is a Intervention_Control, . is a Outcome_Physical, neurodevelopmental disorders . is a Participant_Condition, 1.5 g / d of omega-3 fatty acids ( .84 g / d eicosapentaenoic acid is a Intervention_Pharmacological, .7 g / d docosahexaenoic acid ) supplementation is a Intervention_Pharmacological, 13 is a Participant_Sample-size, aged 5 to 17 years is a Participant_Age, severe tantrums , aggression , or self - injurious behavior is a Participant_Condition, Aberrant Behavior Checklist ( ABC ) is a Outcome_Mental, hyperactivity and stereotypy is a Outcome_Physical, adverse effects is a Outcome_Adverse-effects

27707_task1

Sentence: Omega-3 fatty acids supplementation in children with autism : a double-blind randomized , placebo-controlled pilot study . BACKGROUND There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders . METHODS We conducted a randomized , double-blind , placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids ( .84 g/d eicosapentaenoic acid , .7 g/d docosahexaenoic acid ) supplementation in 13 children ( aged 5 to 17 years ) with autistic disorders accompanied by severe tantrums , aggression , or self-injurious behavior . The outcome measure was the Aberrant Behavior Checklist ( ABC ) at 6 weeks . RESULTS We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy , each with a large effect size . Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity . No clinically relevant adverse effects were elicited in either group . CONCLUSIONS The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism . Instructions: please typing these entity words according to sentence: Omega-3 fatty acids supplementation, autism, placebo - controlled, ., neurodevelopmental disorders ., 1.5 g / d of omega-3 fatty acids ( .84 g / d eicosapentaenoic acid, .7 g / d docosahexaenoic acid ) supplementation, 13, aged 5 to 17 years, severe tantrums , aggression , or self - injurious behavior, Aberrant Behavior Checklist ( ABC ), hyperactivity and stereotypy, adverse effects Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Age, Participant_Sample-size, Outcome_Mental

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Omega-3 fatty acids supplementation in children with autism : a double-blind randomized , placebo-controlled pilot study . BACKGROUND There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders . METHODS We conducted a randomized , double-blind , placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids ( .84 g/d eicosapentaenoic acid , .7 g/d docosahexaenoic acid ) supplementation in 13 children ( aged 5 to 17 years ) with autistic disorders accompanied by severe tantrums , aggression , or self-injurious behavior . The outcome measure was the Aberrant Behavior Checklist ( ABC ) at 6 weeks . RESULTS We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy , each with a large effect size . Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity . No clinically relevant adverse effects were elicited in either group . CONCLUSIONS The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism .

[ "Omega-3", "fatty", "acids", "supplementation", "in", "children", "with", "autism", ":", "a", "double", "-", "blind", "randomized", ",", "placebo", "-", "controlled", "pilot", "study", ".", "BACKGROUND", "There", "is", "increasing", "evidence", "that", "fatty", "acid", "deficiencies", "or", "imbalances", "may", "contribute", "to", "childhood", "neurodevelopmental", "disorders", ".", "METHODS", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "6-week", "pilot", "trial", "investigating", "the", "effects", "of", "1.5", "g", "/", "d", "of", "omega-3", "fatty", "acids", "(", ".84", "g", "/", "d", "eicosapentaenoic", "acid", ",", ".7", "g", "/", "d", "docosahexaenoic", "acid", ")", "supplementation", "in", "13", "children", "(", "aged", "5", "to", "17", "years", ")", "with", "autistic", "disorders", "accompanied", "by", "severe", "tantrums", ",", "aggression", ",", "or", "self", "-", "injurious", "behavior", ".", "The", "outcome", "measure", "was", "the", "Aberrant", "Behavior", "Checklist", "(", "ABC", ")", "at", "6", "weeks", ".", "RESULTS", "We", "observed", "an", "advantage", "of", "omega-3", "fatty", "acids", "compared", "with", "placebo", "for", "hyperactivity", "and", "stereotypy", ",", "each", "with", "a", "large", "effect", "size", ".", "Repeated", "-", "measures", "ANOVA", "indicated", "a", "trend", "toward", "superiority", "of", "omega-3", "fatty", "acids", "over", "placebo", "for", "hyperactivity", ".", "No", "clinically", "relevant", "adverse", "effects", "were", "elicited", "in", "either", "group", ".", "CONCLUSIONS", "The", "results", "of", "this", "study", "provide", "preliminary", "evidence", "that", "omega-3", "fatty", "acids", "may", "be", "an", "effective", "treatment", "for", "children", "with", "autism", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Mental", "Outcome_Physical", "Intervention_Control", "Participant_Age", "Outcome_Adverse-effects", "Outcome_Other", "Participant_Sample-size" ]

Omega-3 fatty acids supplementation, autism, placebo - controlled, ., neurodevelopmental disorders ., 1.5 g / d of omega-3 fatty acids ( .84 g / d eicosapentaenoic acid, .7 g / d docosahexaenoic acid ) supplementation, 13, aged 5 to 17 years, severe tantrums , aggression , or self - injurious behavior, Aberrant Behavior Checklist ( ABC ), hyperactivity and stereotypy, adverse effects

27707_task2

Sentence: Omega-3 fatty acids supplementation in children with autism : a double-blind randomized , placebo-controlled pilot study . BACKGROUND There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders . METHODS We conducted a randomized , double-blind , placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids ( .84 g/d eicosapentaenoic acid , .7 g/d docosahexaenoic acid ) supplementation in 13 children ( aged 5 to 17 years ) with autistic disorders accompanied by severe tantrums , aggression , or self-injurious behavior . The outcome measure was the Aberrant Behavior Checklist ( ABC ) at 6 weeks . RESULTS We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy , each with a large effect size . Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity . No clinically relevant adverse effects were elicited in either group . CONCLUSIONS The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Omega-3 fatty acids supplementation in children with autism : a double-blind randomized , placebo-controlled pilot study . BACKGROUND There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders . METHODS We conducted a randomized , double-blind , placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids ( .84 g/d eicosapentaenoic acid , .7 g/d docosahexaenoic acid ) supplementation in 13 children ( aged 5 to 17 years ) with autistic disorders accompanied by severe tantrums , aggression , or self-injurious behavior . The outcome measure was the Aberrant Behavior Checklist ( ABC ) at 6 weeks . RESULTS We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy , each with a large effect size . Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity . No clinically relevant adverse effects were elicited in either group . CONCLUSIONS The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism .

[ "Omega-3", "fatty", "acids", "supplementation", "in", "children", "with", "autism", ":", "a", "double", "-", "blind", "randomized", ",", "placebo", "-", "controlled", "pilot", "study", ".", "BACKGROUND", "There", "is", "increasing", "evidence", "that", "fatty", "acid", "deficiencies", "or", "imbalances", "may", "contribute", "to", "childhood", "neurodevelopmental", "disorders", ".", "METHODS", "We", "conducted", "a", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", "6-week", "pilot", "trial", "investigating", "the", "effects", "of", "1.5", "g", "/", "d", "of", "omega-3", "fatty", "acids", "(", ".84", "g", "/", "d", "eicosapentaenoic", "acid", ",", ".7", "g", "/", "d", "docosahexaenoic", "acid", ")", "supplementation", "in", "13", "children", "(", "aged", "5", "to", "17", "years", ")", "with", "autistic", "disorders", "accompanied", "by", "severe", "tantrums", ",", "aggression", ",", "or", "self", "-", "injurious", "behavior", ".", "The", "outcome", "measure", "was", "the", "Aberrant", "Behavior", "Checklist", "(", "ABC", ")", "at", "6", "weeks", ".", "RESULTS", "We", "observed", "an", "advantage", "of", "omega-3", "fatty", "acids", "compared", "with", "placebo", "for", "hyperactivity", "and", "stereotypy", ",", "each", "with", "a", "large", "effect", "size", ".", "Repeated", "-", "measures", "ANOVA", "indicated", "a", "trend", "toward", "superiority", "of", "omega-3", "fatty", "acids", "over", "placebo", "for", "hyperactivity", ".", "No", "clinically", "relevant", "adverse", "effects", "were", "elicited", "in", "either", "group", ".", "CONCLUSIONS", "The", "results", "of", "this", "study", "provide", "preliminary", "evidence", "that", "omega-3", "fatty", "acids", "may", "be", "an", "effective", "treatment", "for", "children", "with", "autism", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Mental", "Outcome_Physical", "Intervention_Control", "Participant_Age", "Outcome_Adverse-effects", "Outcome_Other", "Participant_Sample-size" ]

HLA - B is a protein, carbamazepine is a compound

DS.d532_task0

Sentence: Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy.

[ "Although", "the", "current", "studies", "associating", "particular", "genes", "and", "their", "variants", "with", "seizure", "control", "or", "adverse", "events", "have", "inherent", "weaknesses", "and", "have", "not", "provided", "unifying", "conclusions", ",", "several", "results", ",", "for", "example", "that", "Asian", "patients", "with", "a", "particular", "HLA", "allele", ",", "HLA", "-", "B", "*", "1502", ",", "are", "at", "a", "higher", "risk", "for", "Stevens", "-", "Johnson", "syndrome", "when", "using", "carbamazepine", ",", "are", "helpful", "to", "increase", "our", "knowledge", "how", "genetic", "variation", "affects", "the", "treatment", "of", "epilepsy", "." ]

[ "compound", "protein" ]

HLA - B is a protein, carbamazepine is a compound

DS.d532_task1

Sentence: Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy. Instructions: please typing these entity words according to sentence: HLA - B, carbamazepine Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy.

[ "Although", "the", "current", "studies", "associating", "particular", "genes", "and", "their", "variants", "with", "seizure", "control", "or", "adverse", "events", "have", "inherent", "weaknesses", "and", "have", "not", "provided", "unifying", "conclusions", ",", "several", "results", ",", "for", "example", "that", "Asian", "patients", "with", "a", "particular", "HLA", "allele", ",", "HLA", "-", "B", "*", "1502", ",", "are", "at", "a", "higher", "risk", "for", "Stevens", "-", "Johnson", "syndrome", "when", "using", "carbamazepine", ",", "are", "helpful", "to", "increase", "our", "knowledge", "how", "genetic", "variation", "affects", "the", "treatment", "of", "epilepsy", "." ]

[ "compound", "protein" ]

HLA - B, carbamazepine

DS.d532_task2

Sentence: Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Although the current studies associating particular genes and their variants with seizure control or adverse events have inherent weaknesses and have not provided unifying conclusions, several results, for example that Asian patients with a particular HLA allele, HLA-B *1502, are at a higher risk for Stevens-Johnson syndrome when using carbamazepine, are helpful to increase our knowledge how genetic variation affects the treatment of epilepsy.

[ "Although", "the", "current", "studies", "associating", "particular", "genes", "and", "their", "variants", "with", "seizure", "control", "or", "adverse", "events", "have", "inherent", "weaknesses", "and", "have", "not", "provided", "unifying", "conclusions", ",", "several", "results", ",", "for", "example", "that", "Asian", "patients", "with", "a", "particular", "HLA", "allele", ",", "HLA", "-", "B", "*", "1502", ",", "are", "at", "a", "higher", "risk", "for", "Stevens", "-", "Johnson", "syndrome", "when", "using", "carbamazepine", ",", "are", "helpful", "to", "increase", "our", "knowledge", "how", "genetic", "variation", "affects", "the", "treatment", "of", "epilepsy", "." ]

[ "compound", "protein" ]

nitric oxide is an umlsterm, clinical medicine is an umlsterm, use is an umlsterm, therapy is an umlsterm, intensive care is an umlsterm, patients is an umlsterm, respiratory distress syndrome is an umlsterm, interactions is an umlsterm, anaesthetic is an umlsterm, attention is an umlsterm, literature is an umlsterm, date is an umlsterm, need is an umlsterm, research is an umlsterm, review is an umlsterm, literature is an umlsterm, anaesthetics is an umlsterm, human body is an umlsterm

DerAnaesthesist.70460659.eng.abstr_task0

Sentence: Due to its important physiological and pathophysiological actions , the pluripotent signaling molecule nitric oxide ( NO ) is increasingly of interest in clinical medicine . Despite increasing use by anaesthetists in inhalational therapy for intensive care patients with respiratory distress syndrome , the potential interactions of anaesthetic agents and NO have thus far received little attention . The literature available to date on this topic is somewhat controversial , and highlights the need for additional research in this area . This review summarises the pertinent literature in this area for the anaesthetist and describes potential mechanisms by which anaesthetics may interfere with the synthesis and/or effects of NO in the human body . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Due to its important physiological and pathophysiological actions , the pluripotent signaling molecule nitric oxide ( NO ) is increasingly of interest in clinical medicine . Despite increasing use by anaesthetists in inhalational therapy for intensive care patients with respiratory distress syndrome , the potential interactions of anaesthetic agents and NO have thus far received little attention . The literature available to date on this topic is somewhat controversial , and highlights the need for additional research in this area . This review summarises the pertinent literature in this area for the anaesthetist and describes potential mechanisms by which anaesthetics may interfere with the synthesis and/or effects of NO in the human body .

[ "Due", "to", "its", "important", "physiological", "and", "pathophysiological", "actions", ",", "the", "pluripotent", "signaling", "molecule", "nitric", "oxide", "(", "NO", ")", "is", "increasingly", "of", "interest", "in", "clinical", "medicine", ".", "Despite", "increasing", "use", "by", "anaesthetists", "in", "inhalational", "therapy", "for", "intensive", "care", "patients", "with", "respiratory", "distress", "syndrome", ",", "the", "potential", "interactions", "of", "anaesthetic", "agents", "and", "NO", "have", "thus", "far", "received", "little", "attention", ".", "The", "literature", "available", "to", "date", "on", "this", "topic", "is", "somewhat", "controversial", ",", "and", "highlights", "the", "need", "for", "additional", "research", "in", "this", "area", ".", "This", "review", "summarises", "the", "pertinent", "literature", "in", "this", "area", "for", "the", "anaesthetist", "and", "describes", "potential", "mechanisms", "by", "which", "anaesthetics", "may", "interfere", "with", "the", "synthesis", "and", "/", "or", "effects", "of", "NO", "in", "the", "human", "body", "." ]

[ "umlsterm" ]

nitric oxide is an umlsterm, clinical medicine is an umlsterm, use is an umlsterm, therapy is an umlsterm, intensive care is an umlsterm, patients is an umlsterm, respiratory distress syndrome is an umlsterm, interactions is an umlsterm, anaesthetic is an umlsterm, attention is an umlsterm, literature is an umlsterm, date is an umlsterm, need is an umlsterm, research is an umlsterm, review is an umlsterm, literature is an umlsterm, anaesthetics is an umlsterm, human body is an umlsterm

DerAnaesthesist.70460659.eng.abstr_task1

Sentence: Due to its important physiological and pathophysiological actions , the pluripotent signaling molecule nitric oxide ( NO ) is increasingly of interest in clinical medicine . Despite increasing use by anaesthetists in inhalational therapy for intensive care patients with respiratory distress syndrome , the potential interactions of anaesthetic agents and NO have thus far received little attention . The literature available to date on this topic is somewhat controversial , and highlights the need for additional research in this area . This review summarises the pertinent literature in this area for the anaesthetist and describes potential mechanisms by which anaesthetics may interfere with the synthesis and/or effects of NO in the human body . Instructions: please typing these entity words according to sentence: nitric oxide, clinical medicine, use, therapy, intensive care, patients, respiratory distress syndrome, interactions, anaesthetic, attention, literature, date, need, research, review, literature, anaesthetics, human body Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Due to its important physiological and pathophysiological actions , the pluripotent signaling molecule nitric oxide ( NO ) is increasingly of interest in clinical medicine . Despite increasing use by anaesthetists in inhalational therapy for intensive care patients with respiratory distress syndrome , the potential interactions of anaesthetic agents and NO have thus far received little attention . The literature available to date on this topic is somewhat controversial , and highlights the need for additional research in this area . This review summarises the pertinent literature in this area for the anaesthetist and describes potential mechanisms by which anaesthetics may interfere with the synthesis and/or effects of NO in the human body .

[ "Due", "to", "its", "important", "physiological", "and", "pathophysiological", "actions", ",", "the", "pluripotent", "signaling", "molecule", "nitric", "oxide", "(", "NO", ")", "is", "increasingly", "of", "interest", "in", "clinical", "medicine", ".", "Despite", "increasing", "use", "by", "anaesthetists", "in", "inhalational", "therapy", "for", "intensive", "care", "patients", "with", "respiratory", "distress", "syndrome", ",", "the", "potential", "interactions", "of", "anaesthetic", "agents", "and", "NO", "have", "thus", "far", "received", "little", "attention", ".", "The", "literature", "available", "to", "date", "on", "this", "topic", "is", "somewhat", "controversial", ",", "and", "highlights", "the", "need", "for", "additional", "research", "in", "this", "area", ".", "This", "review", "summarises", "the", "pertinent", "literature", "in", "this", "area", "for", "the", "anaesthetist", "and", "describes", "potential", "mechanisms", "by", "which", "anaesthetics", "may", "interfere", "with", "the", "synthesis", "and", "/", "or", "effects", "of", "NO", "in", "the", "human", "body", "." ]

[ "umlsterm" ]

nitric oxide, clinical medicine, use, therapy, intensive care, patients, respiratory distress syndrome, interactions, anaesthetic, attention, literature, date, need, research, review, literature, anaesthetics, human body

DerAnaesthesist.70460659.eng.abstr_task2

Sentence: Due to its important physiological and pathophysiological actions , the pluripotent signaling molecule nitric oxide ( NO ) is increasingly of interest in clinical medicine . Despite increasing use by anaesthetists in inhalational therapy for intensive care patients with respiratory distress syndrome , the potential interactions of anaesthetic agents and NO have thus far received little attention . The literature available to date on this topic is somewhat controversial , and highlights the need for additional research in this area . This review summarises the pertinent literature in this area for the anaesthetist and describes potential mechanisms by which anaesthetics may interfere with the synthesis and/or effects of NO in the human body . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Due to its important physiological and pathophysiological actions , the pluripotent signaling molecule nitric oxide ( NO ) is increasingly of interest in clinical medicine . Despite increasing use by anaesthetists in inhalational therapy for intensive care patients with respiratory distress syndrome , the potential interactions of anaesthetic agents and NO have thus far received little attention . The literature available to date on this topic is somewhat controversial , and highlights the need for additional research in this area . This review summarises the pertinent literature in this area for the anaesthetist and describes potential mechanisms by which anaesthetics may interfere with the synthesis and/or effects of NO in the human body .

[ "Due", "to", "its", "important", "physiological", "and", "pathophysiological", "actions", ",", "the", "pluripotent", "signaling", "molecule", "nitric", "oxide", "(", "NO", ")", "is", "increasingly", "of", "interest", "in", "clinical", "medicine", ".", "Despite", "increasing", "use", "by", "anaesthetists", "in", "inhalational", "therapy", "for", "intensive", "care", "patients", "with", "respiratory", "distress", "syndrome", ",", "the", "potential", "interactions", "of", "anaesthetic", "agents", "and", "NO", "have", "thus", "far", "received", "little", "attention", ".", "The", "literature", "available", "to", "date", "on", "this", "topic", "is", "somewhat", "controversial", ",", "and", "highlights", "the", "need", "for", "additional", "research", "in", "this", "area", ".", "This", "review", "summarises", "the", "pertinent", "literature", "in", "this", "area", "for", "the", "anaesthetist", "and", "describes", "potential", "mechanisms", "by", "which", "anaesthetics", "may", "interfere", "with", "the", "synthesis", "and", "/", "or", "effects", "of", "NO", "in", "the", "human", "body", "." ]

[ "umlsterm" ]